<!DOCTYPE html>
<html lang="en-US" data-bt-theme="Industrial 1.3.1">
<head>

<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="robots" content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1">
<script type="06cd7e663a0e46d4271fe72d-text/javascript">if(navigator.userAgent.match(/MSIE|Internet Explorer/i)||navigator.userAgent.match(/Trident\/7\..*?rv:11/i)){var href=document.location.href;if(!href.match(/[?&]nowprocket/)){if(href.indexOf("?")==-1){if(href.indexOf("#")==-1){document.location.href=href+"?nowprocket=1"}else{document.location.href=href.replace("#","?nowprocket=1#")}}else{if(href.indexOf("#")==-1){document.location.href=href+"&nowprocket=1"}else{document.location.href=href.replace("#","&nowprocket=1#")}}}}</script><script type="06cd7e663a0e46d4271fe72d-text/javascript">class RocketLazyLoadScripts{constructor(e){this.triggerEvents=e,this.eventOptions={passive:!0},this.userEventListener=this.triggerListener.bind(this),this.delayedScripts={normal:[],async:[],defer:[]},this.allJQueries=[]}_addUserInteractionListener(e){this.triggerEvents.forEach((t=>window.addEventListener(t,e.userEventListener,e.eventOptions)))}_removeUserInteractionListener(e){this.triggerEvents.forEach((t=>window.removeEventListener(t,e.userEventListener,e.eventOptions)))}triggerListener(){this._removeUserInteractionListener(this),"loading"===document.readyState?document.addEventListener("DOMContentLoaded",this._loadEverythingNow.bind(this)):this._loadEverythingNow()}async _loadEverythingNow(){this._delayEventListeners(),this._delayJQueryReady(this),this._handleDocumentWrite(),this._registerAllDelayedScripts(),this._preloadAllScripts(),await this._loadScriptsFromList(this.delayedScripts.normal),await this._loadScriptsFromList(this.delayedScripts.defer),await this._loadScriptsFromList(this.delayedScripts.async),await this._triggerDOMContentLoaded(),await this._triggerWindowLoad(),window.dispatchEvent(new Event("rocket-allScriptsLoaded"))}_registerAllDelayedScripts(){document.querySelectorAll("script[type=rocketlazyloadscript]").forEach((e=>{e.hasAttribute("src")?e.hasAttribute("async")&&!1!==e.async?this.delayedScripts.async.push(e):e.hasAttribute("defer")&&!1!==e.defer||"module"===e.getAttribute("data-rocket-type")?this.delayedScripts.defer.push(e):this.delayedScripts.normal.push(e):this.delayedScripts.normal.push(e)}))}async _transformScript(e){return await this._requestAnimFrame(),new Promise((t=>{const n=document.createElement("script");let i;[...e.attributes].forEach((e=>{let t=e.nodeName;"type"!==t&&("data-rocket-type"===t&&(t="type",i=e.nodeValue),n.setAttribute(t,e.nodeValue))})),e.hasAttribute("src")&&this._isValidScriptType(i)?(n.addEventListener("load",t),n.addEventListener("error",t)):(n.text=e.text,t()),e.parentNode.replaceChild(n,e)}))}_isValidScriptType(e){return!e||""===e||"string"==typeof e&&["text/javascript","text/x-javascript","text/ecmascript","text/jscript","application/javascript","application/x-javascript","application/ecmascript","application/jscript","module"].includes(e.toLowerCase())}async _loadScriptsFromList(e){const t=e.shift();return t?(await this._transformScript(t),this._loadScriptsFromList(e)):Promise.resolve()}_preloadAllScripts(){var e=document.createDocumentFragment();[...this.delayedScripts.normal,...this.delayedScripts.defer,...this.delayedScripts.async].forEach((t=>{const n=t.getAttribute("src");if(n){const t=document.createElement("link");t.href=n,t.rel="preload",t.as="script",e.appendChild(t)}})),document.head.appendChild(e)}_delayEventListeners(){let e={};function t(t,n){!function(t){function n(n){return e[t].eventsToRewrite.indexOf(n)>=0?"rocket-"+n:n}e[t]||(e[t]={originalFunctions:{add:t.addEventListener,remove:t.removeEventListener},eventsToRewrite:[]},t.addEventListener=function(){arguments[0]=n(arguments[0]),e[t].originalFunctions.add.apply(t,arguments)},t.removeEventListener=function(){arguments[0]=n(arguments[0]),e[t].originalFunctions.remove.apply(t,arguments)})}(t),e[t].eventsToRewrite.push(n)}function n(e,t){let n=e[t];Object.defineProperty(e,t,{get:()=>n||function(){},set(i){e["rocket"+t]=n=i}})}t(document,"DOMContentLoaded"),t(window,"DOMContentLoaded"),t(window,"load"),t(window,"pageshow"),t(document,"readystatechange"),n(document,"onreadystatechange"),n(window,"onload"),n(window,"onpageshow")}_delayJQueryReady(e){let t=window.jQuery;Object.defineProperty(window,"jQuery",{get:()=>t,set(n){if(n&&n.fn&&!e.allJQueries.includes(n)){n.fn.ready=n.fn.init.prototype.ready=function(t){e.domReadyFired?t.bind(document)(n):document.addEventListener("rocket-DOMContentLoaded",(()=>t.bind(document)(n)))};const t=n.fn.on;n.fn.on=n.fn.init.prototype.on=function(){if(this[0]===window){function e(e){return e.split(" ").map((e=>"load"===e||0===e.indexOf("load.")?"rocket-jquery-load":e)).join(" ")}"string"==typeof arguments[0]||arguments[0]instanceof String?arguments[0]=e(arguments[0]):"object"==typeof arguments[0]&&Object.keys(arguments[0]).forEach((t=>{delete Object.assign(arguments[0],{[e(t)]:arguments[0][t]})[t]}))}return t.apply(this,arguments),this},e.allJQueries.push(n)}t=n}})}async _triggerDOMContentLoaded(){this.domReadyFired=!0,await this._requestAnimFrame(),document.dispatchEvent(new Event("rocket-DOMContentLoaded")),await this._requestAnimFrame(),window.dispatchEvent(new Event("rocket-DOMContentLoaded")),await this._requestAnimFrame(),document.dispatchEvent(new Event("rocket-readystatechange")),await this._requestAnimFrame(),document.rocketonreadystatechange&&document.rocketonreadystatechange()}async _triggerWindowLoad(){await this._requestAnimFrame(),window.dispatchEvent(new Event("rocket-load")),await this._requestAnimFrame(),window.rocketonload&&window.rocketonload(),await this._requestAnimFrame(),this.allJQueries.forEach((e=>e(window).trigger("rocket-jquery-load"))),window.dispatchEvent(new Event("rocket-pageshow")),await this._requestAnimFrame(),window.rocketonpageshow&&window.rocketonpageshow()}_handleDocumentWrite(){const e=new Map;document.write=document.writeln=function(t){const n=document.currentScript;n||console.error("WPRocket unable to document.write this: "+t);const i=document.createRange(),r=n.parentElement;let a=e.get(n);void 0===a&&(a=n.nextSibling,e.set(n,a));const o=document.createDocumentFragment();i.setStart(o,0),o.appendChild(i.createContextualFragment(t)),r.insertBefore(o,a)}}async _requestAnimFrame(){return new Promise((e=>requestAnimationFrame(e)))}static run(){const e=new RocketLazyLoadScripts(["keydown","mousemove","touchmove","touchstart","touchend","wheel"]);e._addUserInteractionListener(e)}}RocketLazyLoadScripts.run();
</script>
<title>Active pharmaceutical ingredients - Ikigai&reg; Corporation</title>
<link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CRoboto%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CRoboto%3A100%2C100italic%2C200%2C200italic%2C300%2C300italic%2C400%2C400italic%2C500%2C500italic%2C600%2C600italic%2C700%2C700italic%2C800%2C800italic%2C900%2C900italic%7CRoboto%20Slab%3A100%2C100italic%2C200%2C200italic%2C300%2C300italic%2C400%2C400italic%2C500%2C500italic%2C600%2C600italic%2C700%2C700italic%2C800%2C800italic%2C900%2C900italic&#038;subset=latin%2Clatin-ext&#038;display=swap">
<link rel="stylesheet" href="./../../../../wp-content/cache/min/1/94ef57cb2a7e04898d8df31f764bfef2.css" media="all" data-minify="1">
<meta name="description" content="API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA &amp; DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE &amp; INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES">
<link rel="canonical" href="./index.html">
<meta property="og:locale" content="en_US">
<meta property="og:type" content="article">
<meta property="og:title" content="Active pharmaceutical ingredients - Ikigai&reg; Corporation">
<meta property="og:description" content="API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA &amp; DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE &amp; INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES">
<meta property="og:url" content="./active-pharmaceutical-ingredients/">
<meta property="og:site_name" content="Ikigai&reg; Corporation">
<meta property="article:modified_time" content="2021-01-28T12:32:49+00:00">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:label1" content="Est. reading time">
<meta name="twitter:data1" content="1 minute">
<script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebSite","@id":"./#website","url":"./","name":"Ikigai&reg; Corporation","description":"Leading suppliers of API (active pharmaceutical ingredients)","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"./?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"./active-pharmaceutical-ingredients/#webpage","url":"./active-pharmaceutical-ingredients/","name":"Active pharmaceutical ingredients - Ikigai&reg; Corporation","isPartOf":{"@id":"./#website"},"datePublished":"2020-01-30T19:55:43+00:00","dateModified":"2021-01-28T12:32:49+00:00","description":"API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA & DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE & INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES","breadcrumb":{"@id":"./active-pharmaceutical-ingredients/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["./active-pharmaceutical-ingredients/"]}]},{"@type":"BreadcrumbList","@id":"./active-pharmaceutical-ingredients/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"./"},{"@type":"ListItem","position":2,"name":"Active pharmaceutical ingredients"}]}]}</script>

<link rel="dns-prefetch" href="https://use.fontawesome.com">
<link rel="dns-prefetch" href="https://fonts.googleapis.com">
<link href="https://fonts.gstatic.com" crossorigin rel="preconnect">
<style type="text/css">img.wp-smiley,
img.emoji {
	display: inline !important;
	border: none !important;
	box-shadow: none !important;
	height: 1em !important;
	width: 1em !important;
	margin: 0 .07em !important;
	vertical-align: -0.1em !important;
	background: none !important;
	padding: 0 !important;
}</style>

<style id="industrial-style-inline-css" type="text/css">select, input{font-family: Roboto;} input:not([type='checkbox']):not([type='radio']), textarea, select{ font-family: "Montserrat";} input:not([type='checkbox']):not([type='radio']):not([type='submit']):focus, textarea:focus{-webkit-box-shadow: 0 0 4px 0 #58a0d3; box-shadow: 0 0 4px 0 #58a0d3;} html a:hover, .btLightSkin a:hover, .btDarkSkin .btLightSkin a:hover, .btLightSkin .btDarkSkin .btLightSkin a:hover, .btDarkSkin a:hover, .btLightSkin .btDarkSkin a:hover, .btDarkSkin.btLightSkin .btDarkSkin a:hover{ color: #58a0d3;} .btLightSkin .btText a, .btDarkSkin .btLightSkin .btText a, .btLightSkin .btDarkSkin .btLightSkin .btText a, .btDarkSkin .btText a, .btLightSkin .btDarkSkin .btText a, .btDarkSkin.btLightSkin .btDarkSkin .btText a{color: #58a0d3;} body{font-family: "Roboto",Arial,sans-serif;} .btContentHolder cite{ font-family: Montserrat;} h1, h2, h3, h4, h5, h6{font-family: "Montserrat";} .btContentHolder table thead th{ background-color: #58a0d3; font-family: Montserrat;} .btAccentColorBackground{background-color: #58a0d3 !important;} .btAccentColorBackground .headline b.animate.animated{color: #1a86d3;} .btAccentColorBackground .btDash.bottomDash .dash:after{border-color: #1a86d3;} .btAccentDarkColorBackground{background-color: #2e7ab0 !important;} .btAccentDarkColorBackground .headline b.animate.animated{color: #1a86d3;} .btAccentVeryDarkColorBackground{background-color: #19425f !important;} .btAccentLightColorBackground{background-color: rgba(88,160,211,0.7) !important;} .btAlternateColorBackground{background-color: #1a86d3 !important;} .btAlternateDarkColorBackground{background-color: #125b8f !important;} .btAlternateVeryDarkColorBackground{background-color: #0c3e61 !important;} .btAlternateLightColorBackground{background-color: rgba(26,134,211,0.6) !important;} .btAccentDarkHeader .btPreloader .animation > div:first-child, .btLightAccentHeader .btPreloader .animation > div:first-child{ background-color: #2e7ab0;} .btPreloader .animation .preloaderLogo{height: 100px;} .mainHeader{ font-family: "Montserrat";} .btMenuVertical.btAccentDarkHeader .mainHeader, .btMenuVertical.btLightAccentHeader .mainHeader{background-color: #58a0d3;} .btMenuVertical.btLightAlternateHeader .mainHeader{background-color: #1a86d3;} .menuPort{font-family: "Montserrat";} .menuPort nav ul li a:hover{color: #58a0d3 !important;} .menuPort nav > ul > li > a{line-height: 100px;} .btTextLogo{ line-height: 100px;} .btLogoArea .logo img{height: 100px;} .btHorizontalMenuTrigger{ line-height: 100px;} .btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after{ background-color: #58a0d3;} .btAccentDarkHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btAccentDarkHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after, .btAccentLightHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btAccentLightHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after{background-color: #1a86d3;} .btMenuHorizontal .menuPort nav > ul > li > ul li.current-menu-ancestor > a, .btMenuHorizontal .menuPort nav > ul > li > ul li.current-menu-item > a{color: #58a0d3 !important;} body.btMenuHorizontal .subToggler{ line-height: 100px;} .btMenuHorizontal .topBarInMenu{ height: 100px;} .btLightSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btLightSkin.btAccentLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .topBar, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .topBar{background-color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .btBelowLogoArea:before, .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .topBar:before, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .btBelowLogoArea:before, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .topBar:before{ background-color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .topBar{background-color: #58a0d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btAccentDarkHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btAccentDarkHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #58a0d3;} .btAccentDarkHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #58a0d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btLightAccentHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btLightAccentHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #58a0d3;} .btLightAccentHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #58a0d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover{color: #58a0d3 !important;} .btLightAlternateHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btLightAlternateHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #1a86d3;} .btLightAlternateHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #1a86d3;} .btAccentDarkHeader.btMenuVertical > .menuPort .logo, .btLightAccentHeader.btMenuVertical > .menuPort .logo{background-color: #58a0d3;} .btLightAlternateHeader.btMenuVertical > .menuPort .logo{background-color: #1a86d3;} .btMenuVertical > .menuPort .btCloseVertical:before:hover{color: #58a0d3;} @media (min-width: 1200px){.btMenuVerticalOn .btVerticalMenuTrigger .btIco a:before{color: #58a0d3 !important;} }.btMenuHorizontal .topBarInLogoArea{ height: 100px;} .btMenuHorizontal .topBarInLogoArea .topBarInLogoAreaCell{border: 0 solid #58a0d3;} .btSearchInner.btFromTopBox{ background: #58a0d3;} .btSearchInner.btFromTopBox form button:hover:before{color: #58a0d3;} .btDarkSkin .btSiteFooter .port:before, .btLightSkin .btDarkSkin .btSiteFooter .port:before, .btDarkSkin.btLightSkin .btDarkSkin .btSiteFooter .port:before{background-color: #58a0d3;} .btMediaBox.btQuote, .btMediaBox.btLink{ background-color: #58a0d3;} .btArticleListItem .headline a:hover{color: #58a0d3;} .btCommentsBox .vcard .posted{ font-family: "Montserrat";} .btCommentsBox .commentTxt p.edit-link, .btCommentsBox .commentTxt p.reply{ font-family: "Montserrat";} .comment-respond .btnOutline button[type="submit"]{font-family: "Montserrat";} a#cancel-comment-reply-link:hover{color: #58a0d3;} .post-password-form input[type="submit"]{ background: #58a0d3; font-family: "Montserrat";} .btPagination{font-family: "Montserrat";} .btPagination .paging a:hover:after{border-color: #58a0d3;} span.btHighlight{ background-color: #58a0d3;} .btArticleCategories a:not(:first-child):before{ background-color: #58a0d3;} .btArticleMeta{font-family: "Montserrat";} body:not(.btNoDashInSidebar) .btBox > h4:after, body:not(.btNoDashInSidebar) .btCustomMenu > h4:after, body:not(.btNoDashInSidebar) .btTopBox > h4:after{ border-bottom: 3px solid #58a0d3;} .btBox ul li.current-menu-item > a, .btCustomMenu ul li.current-menu-item > a, .btTopBox ul li.current-menu-item > a{color: #58a0d3;} .btBox .ppTxt .header .headline a a:hover, .btCustomMenu .ppTxt .header .headline a a:hover, .btTopBox .ppTxt .header .headline a a:hover{color: #58a0d3;} .btBox p.posted, .btBox .quantity, .btCustomMenu p.posted, .btCustomMenu .quantity, .btTopBox p.posted, .btTopBox .quantity{ font-family: Montserrat;} .widget_calendar table caption{background: #58a0d3; font-family: "Montserrat";} .widget_rss li a.rsswidget{font-family: "Montserrat";} .fancy-select .trigger.open{color: #58a0d3;} .fancy-select ul.options li:hover{color: #58a0d3;} .widget_shopping_cart .total{ font-family: Montserrat;} .widget_shopping_cart .widget_shopping_cart_content .mini_cart_item .ppRemove a.remove{ background-color: #58a0d3;} .widget_shopping_cart .widget_shopping_cart_content .mini_cart_item .ppRemove a.remove:hover{background-color: #1a86d3;} .menuPort .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents, .topTools .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents, .topBarInLogoArea .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents{ background-color: #1a86d3; font: normal 10px/1 Montserrat;} .btMenuVertical .menuPort .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler, .btMenuVertical .topTools .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler, .btMenuVertical .topBarInLogoArea .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler{ background-color: #58a0d3;} .widget_recent_reviews{font-family: Montserrat;} .widget_price_filter .price_slider_wrapper .ui-slider .ui-slider-handle{ background-color: #58a0d3;} .btBox .tagcloud a, .btTags ul a{ background: #58a0d3; font-family: "Montserrat";} .btSidebar .btIconWidget:hover .btIconWidgetText, footer .btIconWidget:hover .btIconWidgetText{color: #58a0d3;} .btTopBox.widget_bt_text_image .widget_sp_image-description{ font-family: 'Roboto',arial,sans-serif;} .btMenuHorizontal .topTools .btIconWidget:hover, .btMenuHorizontal .topBarInMenu .btIconWidget:hover{color: #58a0d3;} .btMenuHorizontal .topTools .btAccentIconWidget, .btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #58a0d3;} .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #1a86d3;} .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget:hover, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal .topTools .btAccentIconWidget, .btLightAccentHeader.btMenuHorizontal .topTools .btAccentIconWidget, .btAccentLightHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget, .btLightAccentHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #1a86d3;} .btMenuHorizontal .topTools .btAccentIconWidget:hover, .btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{color: #1a86d3;} .btTopToolsInMenuArea.btLightAccentHeader.btMenuHorizontal .topTools .btAccentIconWidget:hover, .btTopToolsInMenuArea.btLightAccentHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{background-color: #58a0d3;} .btLightSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btLightSkin.btAccentLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #1a86d3;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #1a86d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #58a0d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #58a0d3;} .btSpecialHeaderIcon .btIco .btIcoHolder:before, .btSpecialHeaderIcon .btIconWidgetTitle, .btSpecialHeaderIcon .btIconWidgetText{color: #58a0d3 !important;} .btLightSkin .btBox .btSearch button:hover, .btDarkSkin .btLightSkin .btBox .btSearch button:hover, .btLightSkin .btDarkSkin .btLightSkin .btBox .btSearch button:hover, .btDarkSkin .btBox .btSearch button:hover, .btLightSkin .btDarkSkin .btBox .btSearch button:hover, .btDarkSkin.btLightSkin .btDarkSkin .btBox .btSearch button:hover, .btLightSkin form.woocommerce-product-search button:hover, .btDarkSkin .btLightSkin form.woocommerce-product-search button:hover, .btLightSkin .btDarkSkin .btLightSkin form.woocommerce-product-search button:hover, .btDarkSkin form.woocommerce-product-search button:hover, .btLightSkin .btDarkSkin form.woocommerce-product-search button:hover, .btDarkSkin.btLightSkin .btDarkSkin form.woocommerce-product-search button:hover{background: #58a0d3 !important; border-color: #58a0d3 !important;} .topTools .widget_search button, .topBarInMenu .widget_search button{ background: #58a0d3;} .topTools .widget_search button:before, .topBarInMenu .widget_search button:before{ color: #58a0d3;} .topTools .widget_search button:hover, .topBarInMenu .widget_search button:hover{background: #2e7ab0;} .btIcoFilledType.btIcoAccentColor.btIconHexagonShape.btIco .btIcoHolder .hex{fill: #58a0d3;} .btIcoFilledType.btIcoAlternateColor.btIconHexagonShape.btIco .btIcoHolder .hex{fill: #1a86d3;} .btIcoOutlineType.btIcoAccentColor.btIconHexagonShape.btIco .btIcoHolder .hex{ stroke: #58a0d3;} .btIcoOutlineType.btIcoAlternateColor.btIconHexagonShape.btIco .btIcoHolder .hex{ stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex{fill: #58a0d3; stroke: #58a0d3;} .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex{fill: #1a86d3; stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex{ stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex{ stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoFilledType .btIcoHolder svg .hex{ fill: #58a0d3;} .btIconHexagonShape .btIco.btIcoFilledType:hover .btIcoHolder svg .hex{stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoOutlineType .btIcoHolder svg .hex{stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoOutlineType:hover .btIcoHolder svg .hex{stroke: #58a0d3; fill: #58a0d3;} .btIco.btIcoFilledType.btIcoAccentColor .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAccentColor:hover .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1em #58a0d3 inset; box-shadow: 0 0 0 1em #58a0d3 inset;} .btIco.btIcoFilledType.btIcoAccentColor:hover .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAccentColor .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset; color: #58a0d3;} .btIco.btIcoFilledType.btIcoAlternateColor .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAlternateColor:hover .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1em #1a86d3 inset; box-shadow: 0 0 0 1em #1a86d3 inset;} .btIco.btIcoFilledType.btIcoAlternateColor:hover .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAlternateColor .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1px #1a86d3 inset; box-shadow: 0 0 0 1px #1a86d3 inset; color: #1a86d3;} .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before{color: #58a0d3;} .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before{color: #1a86d3;} .btIcoAccentColor span{color: #58a0d3;} .btIcoAlternateColor span{color: #1a86d3;} .btIcoDefaultColor:hover span{color: #58a0d3;} .btBtn{ font-family: "Montserrat";} .btnFilledStyle.btnAccentColor, .btnOutlineStyle.btnAccentColor:hover{background-color: #58a0d3; border: 2px solid #58a0d3;} .btnOutlineStyle.btnAccentColor, .btnFilledStyle.btnAccentColor:hover{ border: 2px solid #58a0d3; color: #58a0d3;} .btnOutlineStyle.btnAccentColor span, .btnFilledStyle.btnAccentColor:hover span, .btnOutlineStyle.btnAccentColor span:before, .btnFilledStyle.btnAccentColor:hover span:before, .btnOutlineStyle.btnAccentColor a, .btnFilledStyle.btnAccentColor:hover a, .btnOutlineStyle.btnAccentColor .btIco a:before, .btnFilledStyle.btnAccentColor:hover .btIco a:before, .btnOutlineStyle.btnAccentColor button, .btnFilledStyle.btnAccentColor:hover button{color: #58a0d3 !important;} .btnBorderlessStyle.btnAccentColor span, .btnBorderlessStyle.btnNormalColor:hover span, .btnBorderlessStyle.btnAccentColor span:before, .btnBorderlessStyle.btnNormalColor:hover span:before, .btnBorderlessStyle.btnAccentColor a, .btnBorderlessStyle.btnNormalColor:hover a, .btnBorderlessStyle.btnAccentColor .btIco a:before, .btnBorderlessStyle.btnNormalColor:hover .btIco a:before, .btnBorderlessStyle.btnAccentColor button, .btnBorderlessStyle.btnNormalColor:hover button{color: #58a0d3;} .btnFilledStyle.btnAlternateColor, .btnOutlineStyle.btnAlternateColor:hover{background-color: #1a86d3; border: 2px solid #1a86d3;} .btnOutlineStyle.btnAlternateColor, .btnFilledStyle.btnAlternateColor:hover{ border: 2px solid #1a86d3; color: #1a86d3;} .btnOutlineStyle.btnAlternateColor span, .btnFilledStyle.btnAlternateColor:hover span, .btnOutlineStyle.btnAlternateColor span:before, .btnFilledStyle.btnAlternateColor:hover span:before, .btnOutlineStyle.btnAlternateColor a, .btnFilledStyle.btnAlternateColor:hover a, .btnOutlineStyle.btnAlternateColor .btIco a:before, .btnFilledStyle.btnAlternateColor:hover .btIco a:before, .btnOutlineStyle.btnAlternateColor button, .btnFilledStyle.btnAlternateColor:hover button{color: #1a86d3 !important;} .btnBorderlessStyle.btnAlternateColor span, .btnBorderlessStyle.btnAlternateColor span:before, .btnBorderlessStyle.btnAlternateColor a, .btnBorderlessStyle.btnAlternateColor .btIco a:before, .btnBorderlessStyle.btnAlternateColor button{color: #1a86d3;} .btCounterHolder{font-family: "Montserrat";} .btCounterHolder .btCountdownHolder .days_text, .btCounterHolder .btCountdownHolder .hours_text, .btCounterHolder .btCountdownHolder .minutes_text, .btCounterHolder .btCountdownHolder .seconds_text{ font-family: Montserrat; color: #58a0d3;} .btProgressContent{font-family: "Montserrat";} .btProgressContent .btProgressAnim{ background-color: #58a0d3;} .btShowTitle{ border-left: 4px solid #58a0d3;} .btAccentColorBackground .btShowTitle{border-left: 4px solid #1a86d3;} .btPriceTable .btPriceTableHeader{background: #58a0d3;} .btPriceTableSticker{ font-family: "Montserrat";} .header .btSuperTitle{font-family: "Montserrat";} .header .btSubTitle{font-family: "Roboto";} .btDash.bottomDash .dash:after{ border-bottom: 4px solid #58a0d3;} .btDash.topDash .btSuperTitle:after, .btDash.topDash .btSuperTitle:before{ border-top: 1px solid #58a0d3;} .btNoMore{ font-family: Montserrat;} .btGridContent .header .btSuperTitle a:hover{color: #58a0d3;} .btCatFilter{ font-family: Montserrat;} .btCatFilter .btCatFilterItem:hover{color: #58a0d3;} .btCatFilter .btCatFilterItem.active{color: #58a0d3;} .nbs a .nbsItem .nbsDir{ font-family: "Montserrat";} .btLightSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin .btLightSkin .btSimpleArrows .nbs a:hover:before, .btLightSkin .btDarkSkin .btLightSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin .btSimpleArrows .nbs a:hover:before, .btLightSkin .btDarkSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin.btLightSkin .btDarkSkin .btSimpleArrows .nbs a:hover:before{color: #58a0d3 !important;} .neighboringArticles .nbs a .nbsItem .nbsDir{ font-family: 'Roboto',arial,sans-serif;} .neighboringArticles .nbs a:hover .nbsDir{color: #58a0d3;} .recentTweets small:before{ color: #58a0d3;} .btInfoBar .btInfoBarMeta p strong{color: #58a0d3;} .tabsHeader li{ font-family: "Montserrat";} .tabsVertical .tabAccordionTitle{ font-family: "Montserrat";} .btVisualizer{font-family: Montserrat;} form.wpcf7-form .wpcf7-submit{ background-color: #58a0d3;} .btAnimNav li.btAnimNavDot{ font-family: Montserrat;} .btAnimNav li.btAnimNavNext:hover, .btAnimNav li.btAnimNavPrev:hover{border-color: #58a0d3; color: #58a0d3;} .headline b.animate.animated{ color: #58a0d3;} .headline em.animate{ font-family: Roboto;} p.demo_store{ background-color: #58a0d3;} .woocommerce .woocommerce-info a: not(.button), .woocommerce .woocommerce-message a: not(.button), .woocommerce-page .woocommerce-info a: not(.button), .woocommerce-page .woocommerce-message a: not(.button){color: #58a0d3;} .woocommerce .woocommerce-message:before, .woocommerce .woocommerce-info:before, .woocommerce-page .woocommerce-message:before, .woocommerce-page .woocommerce-info:before{ color: #58a0d3;} .woocommerce a.button, .woocommerce input[type="submit"], .woocommerce button[type="submit"], .woocommerce input.button, .woocommerce input.alt:hover, .woocommerce a.button.alt:hover, .woocommerce .button.alt:hover, .woocommerce button.alt:hover, .woocommerce-page a.button, .woocommerce-page input[type="submit"], .woocommerce-page button[type="submit"], .woocommerce-page input.button, .woocommerce-page input.alt:hover, .woocommerce-page a.button.alt:hover, .woocommerce-page .button.alt:hover, .woocommerce-page button.alt:hover{ font-family: Montserrat;} .woocommerce a.button:hover, .woocommerce input[type="submit"]:hover, .woocommerce .button:hover, .woocommerce button:hover, .woocommerce input.alt, .woocommerce a.button.alt, .woocommerce .button.alt, .woocommerce button.alt, .woocommerce-page a.button:hover, .woocommerce-page input[type="submit"]:hover, .woocommerce-page .button:hover, .woocommerce-page button:hover, .woocommerce-page input.alt, .woocommerce-page a.button.alt, .woocommerce-page .button.alt, .woocommerce-page button.alt{ font-family: "Montserrat";} .woocommerce p.lost_password:before, .woocommerce-page p.lost_password:before{ color: #58a0d3;} .woocommerce form.login p.lost_password a:hover, .woocommerce-page form.login p.lost_password a:hover{color: #58a0d3;} .woocommerce .added:after, .woocommerce .loading:after, .woocommerce-page .added:after, .woocommerce-page .loading:after{ background-color: #58a0d3;} .woocommerce form .form-row .select2-container, .woocommerce-page form .form-row .select2-container{ font-family: "Montserrat";} .woocommerce div.product p.price, .woocommerce div.product span.price, .woocommerce-page div.product p.price, .woocommerce-page div.product span.price{ font-family: "Montserrat"; color: #58a0d3;} .woocommerce div.product .stock, .woocommerce-page div.product .stock{color: #58a0d3;} .woocommerce div.product a.reset_variations:hover, .woocommerce-page div.product a.reset_variations:hover{color: #58a0d3;} .woocommerce .added_to_cart, .woocommerce-page .added_to_cart{ font-family: Montserrat;} .woocommerce .products ul li.product .btPriceTableSticker, .woocommerce ul.products li.product .btPriceTableSticker, .woocommerce-page .products ul li.product .btPriceTableSticker, .woocommerce-page ul.products li.product .btPriceTableSticker{ background: #1a86d3;} .woocommerce .products ul li.product .price, .woocommerce ul.products li.product .price, .woocommerce-page .products ul li.product .price, .woocommerce-page ul.products li.product .price{ font-family: "Montserrat";} .woocommerce nav.woocommerce-pagination, .woocommerce-page nav.woocommerce-pagination{ font-family: "Montserrat";} .woocommerce nav.woocommerce-pagination ul li a:focus, .woocommerce nav.woocommerce-pagination ul li a:hover, .woocommerce nav.woocommerce-pagination ul li a.next, .woocommerce nav.woocommerce-pagination ul li a.prev, .woocommerce nav.woocommerce-pagination ul li span.current, .woocommerce-page nav.woocommerce-pagination ul li a:focus, .woocommerce-page nav.woocommerce-pagination ul li a:hover, .woocommerce-page nav.woocommerce-pagination ul li a.next, .woocommerce-page nav.woocommerce-pagination ul li a.prev, .woocommerce-page nav.woocommerce-pagination ul li span.current{background: #58a0d3;} .woocommerce .star-rating span:before, .woocommerce-page .star-rating span:before{ color: #58a0d3;} .woocommerce p.stars a[class^="star-"].active:after, .woocommerce p.stars a[class^="star-"]:hover:after, .woocommerce-page p.stars a[class^="star-"].active:after, .woocommerce-page p.stars a[class^="star-"]:hover:after{color: #58a0d3;} .woocommerce-cart table.cart td.product-remove a.remove{ color: #58a0d3; border: 1px solid #58a0d3;} .woocommerce-cart table.cart td.product-remove a.remove:hover{background-color: #58a0d3;} .woocommerce-cart .cart_totals .discount td{color: #58a0d3;} .woocommerce-account header.title .edit{ color: #58a0d3;} .woocommerce-account header.title .edit:before{ color: #58a0d3;} .btLightSkin.woocommerce-page .product .headline a:hover, .btDarkSkin .btLightSkin.woocommerce-page .product .headline a:hover, .btLightSkin .btDarkSkin .btLightSkin.woocommerce-page .product .headline a:hover, .btDarkSkin.woocommerce-page .product .headline a:hover, .btLightSkin .btDarkSkin.woocommerce-page .product .headline a:hover, .btDarkSkin.btLightSkin .btDarkSkin.woocommerce-page .product .headline a:hover{color: #58a0d3;} .btQuoteBooking .btTotalNextWrapper{ font-family: "Montserrat";} .btQuoteBooking .btContactNext{ border: #58a0d3 2px solid; color: #58a0d3;} .btQuoteBooking .btContactNext:hover, .btQuoteBooking .btContactNext:active{background-color: #58a0d3 !important;} .btQuoteBooking .btQuoteSwitch:hover{-webkit-box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btQuoteSwitch.on .btQuoteSwitchInner{ background: #58a0d3;} .btQuoteBooking .dd.ddcommon.borderRadiusTp .ddTitleText, .btQuoteBooking .dd.ddcommon.borderRadiusBtm .ddTitleText{ -webkit-box-shadow: 5px 0 0 #58a0d3 inset,0 2px 10px rgba(0,0,0,.2); box-shadow: 5px 0 0 #58a0d3 inset,0 2px 10px rgba(0,0,0,.2);} .btQuoteBooking .ui-slider .ui-slider-handle{ background: #58a0d3;} .btQuoteBooking .btQuoteBookingForm .btQuoteTotal{ background: #58a0d3;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea{border: 1px solid #58a0d3; -webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadius .ddTitleText{border: 1px solid #58a0d3; -webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input:hover, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea:hover{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadius:hover .ddTitleText{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input:focus, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea:focus{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadiusTp .ddTitleText{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btSubmitMessage{color: #58a0d3;} .btDatePicker .ui-datepicker-header{ background-color: #58a0d3;} .btQuoteBooking .btContactSubmit{font-family: "Montserrat"; background-color: #58a0d3; border: 1px solid #58a0d3;} .btQuoteBooking .btContactSubmit:hover{ color: #58a0d3;} .btPayPalButton:hover{-webkit-box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} #btSettingsPanel #btSettingsPanelToggler:before{ color: #58a0d3;} #btSettingsPanel h4{ background-color: #58a0d3;} #btSettingsPanel .btSettingsPanelRow.btAccentColorRow .trigger, #btSettingsPanel .btSettingsPanelRow.btAccentColorRow select{border-color: #58a0d3;} #btSettingsPanel .btSettingsPanelRow.btAlternateColorRow .trigger, #btSettingsPanel .btSettingsPanelRow.btAlternateColorRow select{border-color: #1a86d3;} .wp-block-button__link:hover{color: #58a0d3 !important;}
.tagcloud a { color: #ffffff; } .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget { background-color: #02b3f9; }</style>
<link rel="stylesheet" id="industrial-print-css" href="./../../../../wp-content/themes/industrial/print.css?ver=5.8" type="text/css" media="print">
<style id="elementor-frontend-inline-css" type="text/css">@font-face{font-family:eicons;src:url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.eot?5.10.0);src:url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.eot?5.10.0#iefix) format("embedded-opentype"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.woff2?5.10.0) format("woff2"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.woff?5.10.0) format("woff"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.ttf?5.10.0) format("truetype"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.svg?5.10.0#eicon) format("svg");font-weight:400;font-style:normal}</style>
<style id="font-awesome-official-v4shim-inline-css" type="text/css">@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.svg#fontawesome") format("svg");
}

@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.svg#fontawesome") format("svg");
}

@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.svg#fontawesome") format("svg");
unicode-range: U+F004-F005,U+F007,U+F017,U+F022,U+F024,U+F02E,U+F03E,U+F044,U+F057-F059,U+F06E,U+F070,U+F075,U+F07B-F07C,U+F080,U+F086,U+F089,U+F094,U+F09D,U+F0A0,U+F0A4-F0A7,U+F0C5,U+F0C7-F0C8,U+F0E0,U+F0EB,U+F0F3,U+F0F8,U+F0FE,U+F111,U+F118-F11A,U+F11C,U+F133,U+F144,U+F146,U+F14A,U+F14D-F14E,U+F150-F152,U+F15B-F15C,U+F164-F165,U+F185-F186,U+F191-F192,U+F1AD,U+F1C1-F1C9,U+F1CD,U+F1D8,U+F1E3,U+F1EA,U+F1F6,U+F1F9,U+F20A,U+F247-F249,U+F24D,U+F254-F25B,U+F25D,U+F267,U+F271-F274,U+F279,U+F28B,U+F28D,U+F2B5-F2B6,U+F2B9,U+F2BB,U+F2BD,U+F2C1-F2C2,U+F2D0,U+F2D2,U+F2DC,U+F2ED,U+F328,U+F358-F35B,U+F3A5,U+F3D1,U+F410,U+F4AD;
}</style>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/jquery/jquery.min.js?ver=3.6.0" id="jquery-core-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/jquery/jquery-migrate.min.js?ver=3.3.2" id="jquery-migrate-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/bold-page-builder/script_fe.js?ver=1620657753" id="bt_bb_fe-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_elements.js?ver=1620657753" id="bt_plugin_enqueue-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/jquery.cookie.js?ver=1620657753" id="jquery-cookie-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/html5shiv.min.js?ver=1" id="html5shiv-min-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/respond.min.js?ver=1" id="respond-min-js" defer></script>
<script  data-rocket-type="text/javascript" id="industrial-header-misc-js-before">
window.BoldThemesURI = "./wp-content/themes/industrial"; window.BoldThemesAJAXURL = "./wp-admin/admin-ajax.php";window.boldthemes_text = [];window.boldthemes_text.previous = 'previous';window.boldthemes_text.next = 'next';
</script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/header.misc.js?ver=1620657753" id="industrial-header-misc-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/sticky-header-effects-for-elementor/assets/js/she-header.js?ver=1620657753" id="she-header-js" defer></script>
<link rel="https://api.w.org/" href="./../../../../wp-json/index.html">
<link rel="alternate" type="application/json" href="./../../../../wp-json/wp/v2/pages/3408/index.html">
<meta name="generator" content="WordPress 5.8">
<link rel="shortlink" href="./../../../../index.html?p=3408">
<link rel="alternate" type="application/json+oembed" href="./../../../../wp-json/oembed/1.0/embed/index.html?url=https%3A%2F%2F%2Factive-pharmaceutical-ingredients%2F">
<link rel="alternate" type="text/xml+oembed" href="./../../../../wp-json/oembed/1.0/embed/index.html?url=https%3A%2F%2F%2Factive-pharmaceutical-ingredients%2F&#038;format=xml">
<script  data-rocket-type="text/javascript">
            ( function () {
                window.lae_fs = { can_use_premium_code: false};
            } )();
        </script>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Productivity.woff?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Development.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Construction.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/CraftEssential.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Pe-icon-7-stroke.woff?d7yf1v" crossorigin>
<link rel="icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-32x32.jpg" sizes="32x32">
<link rel="icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-192x192.jpg" sizes="192x192">
<link rel="apple-touch-icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-180x180.jpg">
<meta name="msapplication-TileImage" content="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-270x270.jpg">
<noscript><style id="rocket-lazyload-nojs-css">.rll-youtube-player, [data-lazy-src]{display:none !important;}</style></noscript>

<script  async src="https://www.googletagmanager.com/gtag/js?id=UA-124610061-1"></script>
<script >
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'UA-124610061-1');
	
</script>

<script  async src="https://www.googletagmanager.com/gtag/js?id=AW-634803173"></script>
<script >
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'AW-634803173');
</script>

<script >
  gtag('event', 'conversion', {'send_to': 'AW-634803173/aDeACK-KstABEOWn2a4C'});
</script>

<script >(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-KJ8SPBQ');</script>

<script async src="./../../../../cdn-cgi/bm/cv/669835187/api.js"></script>
</head>
<body class="page-template-default page page-id-3408 bt_bb_plugin_active bt_bb_fe_preview_toggle has-navmenu has-megamenu bodyPreloader btMenuLeftEnabled btMenuBelowLogo btStickyEnabled btHideHeadline btLightSkin btTopToolsInMenuArea btRemovePreloader btSoftRoundedButtons btLightAlternateHeader btNoSidebar cookies-not-set elementor-default elementor-kit-3445 elementor-page elementor-page-3408" data-autoplay="0">

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KJ8SPBQ" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>

<div class="btPageWrap" id="top">
<header class="mainHeader btClear gutter ">
<div class="port">
<div class="btLogoArea menuHolder btClear">
<span class="btVerticalMenuTrigger">&nbsp;<span class="btIco btIcoDefaultType"><a href="#" target="_self" data-ico-fa="&#xf0c9;" class="btIcoHolder"></a></span></span>
<span class="btHorizontalMenuTrigger">&nbsp;<span class="btIco btIcoDefaultType"><a href="#" target="_self" data-ico-fa="&#xf0c9;" class="btIcoHolder"></a></span></span>
<div class="logo">
<span>
<a href="./../../../../index.html"><img class="btMainLogo" data-hw="1" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ikigai&reg; Corporation" data-lazy-src="./../../../../wp-content/uploads/2020/05/logo-2.png"><noscript><img class="btMainLogo" data-hw="1" src="./../../../../wp-content/uploads/2020/05/logo-2.png" alt="Ikigai&reg; Corporation"></noscript>
<img class="btAltLogo" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ikigai&reg; Corporation" data-lazy-src="./../../../../wp-content/uploads/2018/10/cropped-imgonline-com-ua-Compressed-09lij2UbRT-com.jpg"><noscript><img class="btAltLogo" src="./../../../../wp-content/uploads/2018/10/cropped-imgonline-com-ua-Compressed-09lij2UbRT-com.jpg" alt="Ikigai&reg; Corporation"></noscript></a> </span>
</div>
<div class="topBarInLogoArea">
<div class="topBarInLogoAreaCell">
<span class="btIconWidget btAccentIconWidget btWidgetWithText"><span class="btIconWidgetIcon"><span class="btIco btIcoDefaultType btIcoDefaultColor"><span data-ico-pr="&#xf10f;" class="btIcoHolder"></span></span></span><span class="btIconWidgetContent"><span class="btIconWidgetTitle">Working hours:</span><span class="btIconWidgetText">Mon - Fri 9.00 - 18.00</span></span></span> </div>
</div>
</div>
<div class="btBelowLogoArea btClear"> <div class="menuPort">
<div class="topBarInMenu">
<div class="topBarInMenuCell">
<span id="time610e3a31c10e7" class="btIconWidget"><span class="btIconWidgetIcon"><span class="btIco btIcoDefaultType btIcoDefaultColor"><span data-ico-fa="&#xf017;" class="btIcoHolder"></span></span></span><span class="btIconWidgetContent"><span class="btIconWidgetTitle">Hong Kong time</span><span class="btIconWidgetText"></span></span></span><div class="btTopBox widget_search">
<h2 class="widgettitle">Search</h2>
<div class="btSearch">
<span class="btIco btIcoDefaultType btIcoDefaultColor"><a href="#" target="_self" data-ico-fa="&#xf002;" class="btIcoHolder" style="color:#fff"></a></span>
<div class="btSearchInner gutter" role="search">
<div class="btSearchInnerContent port">
 <form action="./index.html" method="get">
<div class="col-lg-12 form-control-group"><input type="text" id="elastic"placeholder="Looking for..."></div>
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/azithromycin/"style="
    color: #fff;
"><li class="hide">Azithromycin</li></a>
	<a href="./../../../../portfolio/doxycycline/"style="
    color: #fff;
"><li class="hide">Doxycycline</li></a>
	<a href="./../../../../portfolio/levofloxacin/"style="
    color: #fff;
"><li class="hide">Levofloxacin</li></a>
	<a href="./../../../../portfolio/metronidazole/"style="
    color: #fff;
"><li class="hide">Metronidazole</li></a>
	<a href="./../../../../portfolio/trimethoprim/"style="
    color: #fff;
"><li class="hide">Trimethoprim</li></a>
	<a href="./../../../../portfolio/sulfamethoxazole/"style="
    color: #fff;
"><li class="hide">Sulfamethoxazole</li></a>
	<a href="./../../../../portfolio/ciprofloxacin/"style="
    color: #fff;
"><li class="hide">Ciprofloxacin</li></a>
	<a href="./../../../../portfolio/cephalexin/"style="
    color: #fff;
"><li class="hide">Cephalexin</li></a>
	<a href="./../../../../portfolio/clindamycin/"style="
    color: #fff;
"><li class="hide">Clindamycin</li></a>
	<a href="./../../../../portfolio/clavulanic-acid/"style="
    color: #fff;
"><li class="hide">Clavulanic acid</li></a>



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/amoxicillin/"style="
    color: #fff;
"><li class="hide">Amoxicillin</li></a>
	<a href="./../../../../portfolio/boldenone-cypionate/"style="
    color: #fff;
"><li class="hide">Boldenone cypionate</li></a>
	<a href="./../../../../portfolio/boldenone-propionate/"style="
    color: #fff;
"><li class="hide">Boldenone propionate</li></a>
	<a href="./../../../../portfolio/boldenone-acetate/"style="
    color: #fff;
"><li class="hide">Boldenone acetate</li></a>
	<a href="./../../../../portfolio/boldenone-undecylenate/"style="
    color: #fff;
"><li class="hide">Boldenone undecylenate</li></a>
	<a href="./../../../../portfolio/boldenone/"style="
    color: #fff;
"><li class="hide">Boldenone</li></a>
	<a href="./../../../../portfolio/spironolactone/"style="
    color: #fff;
"><li class="hide">Spironolactone</li></a>
	<a href="./../../../../portfolio/11a-hydroxy-canrenone/"style="
    color: #fff;
"><li class="hide">11a Hydroxy Canrenone</li></a>
	<a href="./../../../../portfolio/canrenone/"style="
    color: #fff;
"><li class="hide">Canrenone</li></a>
	<a href="./../../../../portfolio/prednisolone-acetate/"style="
    color: #fff;
"><li class="hide">Prednisolone acetate</li></a>



</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/prednisolone/"style="
    color: #fff;
"><li class="hide">Prednisolone</li></a>
	<a href="./../../../../portfolio/anecortave-acetate/"style="
    color: #fff;
"><li class="hide">Anecortave acetate</li></a>
	<a href="./../../../../portfolio/prednisone-acetate/"style="
    color: #fff;
"><li class="hide">Prednisone acetate</li></a>
	<a href="./../../../../portfolio/prednisone/"style="
    color: #fff;
"><li class="hide">Prednisone</li></a>
	<a href="./../../../../portfolio/hydrocortisone-acetate/"style="
    color: #fff;
"><li class="hide">Hydrocortisone Acetate</li></a>
	<a href="./../../../../portfolio/hydrocortisone/"style="
    color: #fff;
"><li class="hide">Hydrocortisone</li></a>
	<a href="./../../../../portfolio/cortisone-acetate/"style="
    color: #fff;
"><li class="hide">Cortisone Acetate</li></a>
	<a href="./../../../../portfolio/cortisone/"style="
    color: #fff;
"><li class="hide">Cortisone</li></a>
	<a href="./../../../../portfolio/7-keto-dhea/"style="
    color: #fff;
"><li class="hide">7-Keto DHEA</li></a>
	<a href="./../../../../portfolio/androstanolone/"style="
    color: #fff;
"><li class="hide">Androstanolone</li></a>
	


</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/mestanolone/"style="
    color: #fff;
"><li class="hide">Mestanolone</li></a>
	<a href="./../../../../portfolio/epiandrosterone/"style="
    color: #fff;
"><li class="hide">Epiandrosterone</li></a>
	<a href="./../../../../portfolio/estradiol-valerate/"style="
    color: #fff;
"><li class="hide">Estradiol Valerate</li></a>
	<a href="./../../../../portfolio/estradiol-cypionate/"style="
    color: #fff;
"><li class="hide">Estradiol Cypionate</li></a>
	<a href="./../../../../portfolio/estradiol-enanthate/"style="
    color: #fff;
"><li class="hide">Estradiol Enanthate</li></a>
<a href="./../../../../portfolio/estradiol-benzoate/"style="
    color: #fff;
"><li class="hide">Estradiol Benzoate</li></a>
	<a href="./../../../../portfolio/estriol/"style="
    color: #fff;
"><li class="hide">Estriol</li></a>
	<a href="./../../../../portfolio/estradiol/"style="
    color: #fff;
"><li class="hide">Estradiol</li></a>
	<a href="./../../../../portfolio/estrone/"style="
    color: #fff;
"><li class="hide">Estrone</li></a>
	<a href="./../../../../portfolio/dehydronandrolone-acetate/"style="
    color: #fff;
"><li class="hide">Dehydronandrolone Acetate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/nandrolone-undecanoate/"style="
    color: #fff;
"><li class="hide">Nandrolone Undecanoate</li></a>
	<a href="./../../../../portfolio/nandrolone-cypionate/"style="
    color: #fff;
"><li class="hide">Nandrolone Cypionate</li></a>
	<a href="./../../../../portfolio/nandrolone-propionate/"style="
    color: #fff;
"><li class="hide">Pandrolone Propionate</li></a>
	<a href="./../../../../portfolio/nandrolone-phenylpropionate/"style="
    color: #fff;
"><li class="hide">Nandrolone Phenylpropionate</li></a>
	<a href="./../../../../portfolio/nandrolone-decanoate/"style="
    color: #fff;
"><li class="hide">Nandrolone Decanoate</li></a>
<a href="./../../../../portfolio/nandrolone-base-（19-nor-testosterone）/"style="
    color: #fff;
"><li class="hide">Nandrolone</li></a>
	<a href="./../../../../portfolio/drostanolone-enanthate/"style="
    color: #fff;
"><li class="hide">Drostanolone Enanthate</li></a>
	<a href="./../../../../portfolio/drostanolone-propionate/"style="
    color: #fff;
"><li class="hide">Drostanolone Propionate</li></a>
	<a href="./../../../../portfolio/metenolone-acetate/"style="
    color: #fff;
"><li class="hide">Metenolone Acetate</li></a>
	<a href="./../../../../portfolio/trenbolone-enanthate/"style="
    color: #fff;
"><li class="hide">Trenbolone Enanthate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/trenbolone-acetate/"style="
    color: #fff;
"><li class="hide">Trenbolone Acetate</li></a>
	<a href="./../../../../portfolio/fluoxymesterone/"style="
    color: #fff;
"><li class="hide">Fluoxymesterone</li></a>
	<a href="./../../../../portfolio/mesterolone/"style="
    color: #fff;
"><li class="hide">Mesterolone</li></a>
<a href="./../../../../portfolio/altrenogest//"style="
    color: #fff;
"><li class="hide">Altrenogest</li></a>
	<a href="./../../../../portfolio/exemestane/"style="
    color: #fff;
"><li class="hide">Exemestane</li></a>
	<a href="./../../../../portfolio/oxandrolone/"style="
    color: #fff;
"><li class="hide">Oxandrolone</li></a>
	<a href="./../../../../portfolio/methandienone/"style="
    color: #fff;
"><li class="hide">Methandienone</li></a>
	<a href="./../../../../portfolio/oxymetholone/"style="
    color: #fff;
"><li class="hide">Oxymetholone</li></a>
	<a href="./../../../../portfolio/stanozolol/"style="
    color: #fff;
"><li class="hide">Stanozolol</li></a>
	<a href="./../../../../portfolio/methenolone-enanthate/"style="
    color: #fff;
"><li class="hide">Methenolone Enanthate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/progesterone/"style="
    color: #fff;
"><li class="hide">Progesterone</li></a>
	<a href="./../../../../portfolio/20-formylpregn-4-en-3-one/"style="
    color: #fff;
"><li class="hide">20-Formylpregn-4-en-3-one</li></a>
	<a href="./../../../../portfolio/14-androstadienedioneadd/"style="
    color: #fff;
"><li class="hide">1,4-Androstadienedione(add)</li></a>
	<a href="./../../../../portfolio/4-androstenedione4-ad/"style="
    color: #fff;
"><li class="hide">4-Androstenedione (4-AD)</li></a>
	<a href="./../../../../portfolio/1-testosterone/"style="
    color: #fff;
"><li class="hide">1-Testosterone</li></a>
	<a href="./../../../../portfolio/methyl-1-testosterone/"style="
    color: #fff;
"><li class="hide">Methyl-1-Testosterone</li></a>
	<a href="./../../../../portfolio/testosterone-undecanoate/"style="
    color: #fff;
"><li class="hide">Testosterone Undecanoate</li></a>
	<a href="./../../../../portfolio/testosterone-isocaproate/"style="
    color: #fff;
"><li class="hide">Testosterone Isocaproate</li></a>
	<a href="./../../../../portfolio/testosterone-propionate/"style="
    color: #fff;
"><li class="hide">Testosterone Propionate</li></a>
	<a href="./../../../../portfolio/testosterone-phenylpropionate/"style="
    color: #fff;
"><li class="hide">Testosterone Phenylpropionate</li></a>



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/sitolactone/"style="
    color: #fff;
"><li class="hide">Sitolactone</li></a>
	<a href="./../../../../portfolio/testosterone-enanthate/"style="
    color: #fff;
"><li class="hide">Testosterone Enanthate</li></a>
	<a href="./../../../../portfolio/testosterone-decanoate/"style="
    color: #fff;
"><li class="hide">Testosterone Decanoate</li></a>
	<a href="./../../../../portfolio/testosterone-cypionate/"style="
    color: #fff;
"><li class="hide">Testosterone Cypionate</li></a>
	<a href="./../../../../portfolio/testosterone-acetate/"style="
    color: #fff;
"><li class="hide">Testosterone Acetate</li></a>
	<a href="./../../../../portfolio/methyltestosterone/"style="
    color: #fff;
"><li class="hide">Methyltestosterone</li></a>
	<a href="./../../../../portfolio/testosterone/"style="
    color: #fff;
"><li class="hide">Testosterone</li></a>
	<a href="./../../../../portfolio/magnesium-stearate/"style="
    color: #fff;
"><li class="hide">Magnesium Stearate</li></a>
	<a href="./../../../../portfolio/bis4-nitrophenylsulfane/"style="
    color: #fff;
"><li class="hide">Bis(4-nitrophenylsulfane)</li></a>
	<a href="./../../../../portfolio/n-benzhydrylpiperazine/"style="
    color: #fff;
"><li class="hide">N-Benzhydrylpiperazine</li></a>

	



</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	
<a href="./../../../../portfolio/zinc-stearate/"style="
    color: #fff;
"><li class="hide">Zinc stearate</li></a>
	<a href="./../../../../portfolio/sodium-starch-glycolate/"style="
    color: #fff;
"><li class="hide">Sodium starch glycolate</li></a>
	<a href="./../../../../portfolio/microcrystalline-cellulose/"style="
    color: #fff;
"><li class="hide">microcrystalline Cellulose</li></a>
	<a href="./../../../../portfolio/croscarmellose-sodium/"style="
    color: #fff;
"><li class="hide">CROSCARMELLOSE SODIUM</li></a>
	<a href="./../../../../portfolio/calcium-stearate/"style="
    color: #fff;
"><li class="hide">Calcium stearate</li></a>
	<a href="./../../../../portfolio/calcium-lactate/"style="
    color: #fff;
"><li class="hide">Calcium lactate</li></a>
	<a href="./../../../../portfolio/calcium-acetate/"style="
    color: #fff;
"><li class="hide">Calcium acetate</li></a>
	<a href="./../../../../portfolio/1-aminoindan/"style="
    color: #fff;
"><li class="hide">1-Aminoindan</li></a>
	<a href="./../../../../portfolio/44-sulfonylbisnitrobenzene/"style="
    color: #fff;
"><li class="hide">4,4′-sulfonylbis(nitrobenzene)</li></a>
	<a href="./../../../../portfolio/dehydroepiandrosterone-enanthate/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone Enanthate</li></a>




</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/11a17a-dihydroxyprogesterone/"style="
    color: #fff;
"><li class="hide">11a,17a-Dihydroxyprogesterone</li></a>
	<a href="./../../../../portfolio/17a-hydroxyprogesterone-hpg/"style="
    color: #fff;
"><li class="hide">17a-Hydroxyprogesterone (HPG)</li></a>
    <a href="./../../../../portfolio/dehydroepiandrosterone-acetate-prasterone-acetate/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone Acetate Prasterone Acetate</li></a>
	<a href="./../../../../portfolio/dehydroepiandrosterone-dheaprasterone/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone DHEA, Prasterone</li></a>
	<a href="./../../../../portfolio/trenbolone-cyclohexylmethylcarbonate/"style="
    color: #fff;
"><li class="hide">Trenbolone Cyclohexylmethylcarbonate</li></a>
	<a href="./../../../../portfolio/4-chlorodehydromethyltestosterone/"style="
    color: #fff;
"><li class="hide">4-Chlorodehydromethyltestosterone</li></a>
	<a href="./../../../../portfolio/21-hydroxy-20-methylpregn-4-en-3-one/"style="
    color: #fff;
"><li class="hide">21-Hydroxy-20-methylpregn-4-en-3-one</li></a>
	<a href="./../../../../portfolio/9a-hydroxy-4-androstenedione-（9a-ohad）/"style="
    color: #fff;
"><li class="hide">9a-Hydroxy-4-androstenedione（9a-OHAD)</li></a>
	<a href="./../../../../portfolio/44-difluorobenzhydrylpiperazine/"style="
    color: #fff;
"><li class="hide">4,4′-Difluorobenzhydrylpiperazine</li></a>
	<a href="./../../../../portfolio/ethyl-6-4-iodophenyl-1/"style="
    color: #fff;
"><li class="hide">Ethyl 6-(4-iodophenyl)-1-(4-methoxy phenyl)-7- oxo-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4- c]pyridine-3-carboxylate</li></a>
	



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
		<a href="./../../../../portfolio/ethyl-1-4-methoxyphenyl-7/"style="
    color: #fff;
"><li class="hide">Ethyl 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro1H-pyrazolo[3,4-c]pyridine-3-carboxylate</li></a>
		<a href="./../../../../portfolio/5-bromo-2-chloro4ethoxydiphenylmethane/"style="
    color: #fff;
"><li class="hide">5-Bromo-2-chloro4’ethoxydiphenylmethane</li></a>
	<a href="./../../../../portfolio/15-anhydro-1-c-4-chloro-3/"style="
    color: #fff;
"><li class="hide">1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-,2,3,4,6-tetraacetate, (1S)- D-Glucitol</li></a>
	<a href="./../../../../portfolio/2346-tetra-o-trimethylsilyl-s-d-glucolactone/"style="
    color: #fff;
"><li class="hide">2,3,4,6-tetra-O-trimethylsilyl-ß-D-glucolactone</li></a>
	<a href="./../../../../portfolio/carbamic-acid-n-1s2r/"style="
    color: #fff;
"><li class="hide">Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1- (phenylmethyl)propyl]-,1,1-dimethylethylester</li></a>
	<a href="./../../../../portfolio/10s-1011-dihydro-10-hydroxy/"style="
    color: #fff;
"><li class="hide">(10S)-10,11-Dihydro-10-hydroxy-5Hdibenz[b,f]azepine-5-carboxamide</li></a>
	<a href="./../../../../portfolio/1011-dihydro-10-hydroxy-5h/"style="
    color: #fff;
"><li class="hide">10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide</li></a>
	<a href="./../../../../portfolio/3-3-dichloro-1-4-iodophenyl-piperidin-2-one/"style="
    color: #fff;
"><li class="hide">3, 3-dichloro-1-(4-iodophenyl) piperidin-2-one</li></a>
	<a href="./../../../../portfolio/1-23-dichlorophenyl-piperazine/"style="
    color: #fff;
"><li class="hide">1-(2,3-Dichlorophenyl) Piperazine HCl</li></a>
	<a href="./../../../../portfolio/1e-n-hydroxy-5-methoxy-1/"style="
    color: #fff;
"><li class="hide">(1E)-N-Hydroxy-5-Methoxy-1-(4-Trifluoromethylphenyl)Pentan-1-Imine</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/2-bromo-4-benzyloxy-3-nitroacetophenone/"style="
    color: #fff;
"><li class="hide">2-Bromo-4′-benzyloxy-3′-nitroacetophenone</li></a>
	<a href="./../../../../portfolio/24-dihydro-4-4-4-4-methoxyphenyl-1/"style="
    color: #fff;
"><li class="hide">2,4-Dihydro-4-[4-[4-(4-methoxyphenyl)-1- piperazinyl]phenyl]-2-(1-methyl propyl)-3H-1,2,4-triazol-3-one</li></a>
	<a href="./../../../../portfolio/1-acetyl-4-4-hydroxyphenyl-piperazine/"style="
    color: #fff;
"><li class="hide">1-Acetyl-4-(4-hydroxyphenyl) piperazine</li></a>
	<a href="./../../../../portfolio/1r-2-2-4-nitrophenylethylamino-1/"style="
    color: #fff;
"><li class="hide">(1R)-2-{[2-(4-nitrophenyl)ethyl]amino}-1-phenylethanol</li></a>
	<a href="./../../../../portfolio/5-methylpyridin-21h-one-2-hydroxy-5/"style="
    color: #fff;
"><li class="hide">5-methylpyridin-2(1H)-one/2-Hydroxy-5- methylpyridine</li></a>
	<a href="./../../../../portfolio/dibenzo-b-f-1-4-thiazepin-1110h-one/"style="
    color: #fff;
"><li class="hide">Dibenzo [b, f] [1, 4] thiazepin- 11(10H)-one</li></a>
	<a href="./../../../../portfolio/4-4-5s-5-aminomethyl-2-oxo-13/"style="
    color: #fff;
"><li class="hide">4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride</li></a>
<a href="./../../../../portfolio/2-5s-2-oxo-3-4-3-oxomorpholin-4-yl/"style="
    color: #fff;
"><li class="hide">2-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione</li></a>
	<a href="./../../../../portfolio/2-3ar4s6r6as-6/"style="
    color: #fff;
"><li class="hide">2-(((3aR,4S,6R,6aS)-6-((5-amino-6-chlo ro-2-(propylthio)pyrimidin-4-yl)amino) -2,2-dimethyltetrahydro-3aH-cyclo penta[d][1,3]dioxol-4-yl)oxy)ethanol</li></a>
	<a href="./../../../../portfolio/1-acetamido-35-dimethyl-adamantane/"style="
    color: #fff;
"><li class="hide">1-Acetamido 3,5-dimethyl Adamantane*</li></a>
	



</ul></div> 

</form>
<div class="btSearchInnerClose"><span class="btIco "><a href="#" target="_self" data-ico-fa="&#xf00d;" class="btIcoHolder" style="color:#fff"></a></span></div>
</div>
</div>
</div>
</div> </div>
</div>
<nav>
<ul id="menu-primary-menu" class="menu">
<li id="menu-item-3253" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-3253"><a title="						" href="./../../../../index.html">Home</a></li>
<li id="menu-item-3403" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3403">
<a href="./../../../../about-us/index.html">About us</a><ul class="sub-menu">
<li id="menu-item-3399" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3399"><a href="./../../../../about-us/index.html#company_profile">Company Profile/ Who we are?</a></li>
<li id="menu-item-3400" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3400"><a href="./../../../../about-us/index.html#vision&#038;values">Vision &#038; Values</a></li>
<li id="menu-item-3401" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3401"><a href="./../../../../about-us/index.html#business_segment">Business Segments</a></li>
<li id="menu-item-3402" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3402"><a href="./../../../../about-us/index.html#geographic_spread">Geographic spread</a></li>
</ul>
</li>
<li id="menu-item-3459" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3459"><a href="./../../../../our-technology/index.html">Our Technology</a></li>
<li id="menu-item-3256" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-3256">
<a title="						" href="./../../../../services/index.html">Product Portfolio</a><ul class="sub-menu">
<li id="menu-item-3415" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-3408 current_page_item menu-item-3415"><a href="./../../../../active-pharmaceutical-ingredients/index.html" aria-current="page">Active pharmaceutical ingredients</a></li>
<li id="menu-item-3868" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3868"><a href="./../../../../pharmaceutical_intermediates/index.html">Pharmaceutical intermediates</a></li>
<li id="menu-item-3414" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3414"><a href="./../../../../pharmaceutical_excipients/index.html">Pharmaceutical excipients</a></li>
</ul>
</li>
<li id="menu-item-3872" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3872">
<a href="./../../../../policies/index.html">Policies</a><ul class="sub-menu">
<li id="menu-item-3497" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-privacy-policy menu-item-3497"><a href="./../../../../services/privacy-policy/index.html">Privacy Statement</a></li>
<li id="menu-item-3739" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3739"><a href="./../../../../services/ordering-details-terms-and-conditions/index.html">Ordering Details, Terms, and Conditions</a></li>
<li id="menu-item-3738" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3738"><a href="./../../../../services/browser-recommendation/index.html">Browser Recommendation</a></li>
<li id="menu-item-3737" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3737"><a href="./../../../../services/new-product-suggestion/index.html">New Product Suggestion</a></li>
</ul>
</li>
<li id="menu-item-3594" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3594"><a href="./../../../../services/partner_with_us/index.html">Partner with us</a></li>
<li id="menu-item-3494" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3494"><a href="./../../../../careers/index.html">Careers</a></li>
<li id="menu-item-4734" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4734"><a href="./../../../../library/index.html">Library</a></li>
<li id="menu-item-3438" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3438"><a href="./../../../../contact/index.html">Contact</a></li>
</ul> </nav>
</div>
</div>
</div>
</header>


<!--page-content-here-->
<div class="btContentWrap btClear" bis_skin_checked="1" style="padding-top: 61.4844px;">
<section class="boldSection bottomSemiSpaced btPageHeadline gutter  topSemiSpaced btTextLeft " data-parallax="0" data-parallax-offset="0"><div class="port" bis_skin_checked="1"><header class="header btClear large"><div class="btSuperTitle" bis_skin_checked="1"><span><div class="btBreadCrumbs" bis_skin_checked="1"><nav><ul><li><a href="/../../../../">Home</a></li><li>Category</li></ul></nav></div></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline">Articles Archives - Page 4 of 4 - Ikigai® Corporation</span></h2></div></header></div></section> <div class="btContentHolder" bis_skin_checked="1">
<div class="btContent" bis_skin_checked="1">
<article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5193 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g" class="avatar avatar-144 photo lazyloaded" height="144" width="144" srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" data-ll-status="loaded"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>12.01.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/01/12/effect-of-low-dose-spironolactone-on-resistant-hypertension-in-type-2-diabetes-mellitus-a-randomized-controlled-trial-in-a-sub-saharan-african-population/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/01/12/effect-of-low-dose-spironolactone-on-resistant-hypertension-in-type-2-diabetes-mellitus-a-randomized-controlled-trial-in-a-sub-saharan-african-population/">Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><ul class="c-author-list js-etal-collapsed js-no-scroll" data-etal="25" data-etal-small="3" data-test="authors-list" data-component-authors-activator="authors-list">
<li class="c-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Romance_Nguetse-Djoumessi" aria-pressed="false" aria-expanded="false">Romance Nguetse Djoumessi</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Jean_Jacques_N_-Noubiap" aria-pressed="false" aria-expanded="false">Jean Jacques N. Noubiap</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Francois_Folefack-Kaze" aria-pressed="false" aria-expanded="false">Francois Folefack Kaze</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Mickael-Essouma" aria-pressed="false" aria-expanded="false">Mickael Essouma</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Alain_Patrick-Menanga" aria-pressed="false" aria-expanded="false">Alain Patrick, Menanga</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Andre_Pascal-Kengne" aria-pressed="false" aria-expanded="false">Andre Pascal Kengne</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Jean_Claude-Mbanya" aria-pressed="false" aria-expanded="false">Jean Claude Mbanya</a>&nbsp;&amp;&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Eugene-Sobngwi" data-corresp-id="c1" aria-pressed="false" aria-expanded="false">Eugene Sobngwi</a></li>
</ul>
<h2 id="Abs1" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Abstract</h2>
<hr>
<p>&nbsp;</p>
<h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Background</h3>
<p>Low-dose spironolactone has been proven to be effective for resistant hypertension in the general population, but this has yet to be confirmed in type 2 diabetic (T2DM) patients. We assessed the efficacy of a low-dose spironolactone on resistant hypertension in a sub-Saharan African population of T2DM patients from Cameroon.</p>
<h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Methods</h3>
<p>This was a four-week single blinded randomized controlled trial in 17 subjects presenting with resistant hypertension in specialized diabetes care units in Cameroon. They were randomly assigned to treatment with a daily 25&nbsp;mg of spironolactone (n&nbsp;=&nbsp;9) or to an alternative antihypertensive regimen (n&nbsp;=&nbsp;8), on top of any ongoing regimen and prevailing lifestyle prescriptions. They were seen at the start of the treatment, then 2 and 4&nbsp;weeks later. The primary outcome was change in office and self-measured blood pressure (BP) during follow-up, and secondary outcomes were changes in serum potassium, sodium, and creatinine levels.</p>
<h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Results</h3>
<p>Compared with alternative treatment, low-dose spironolactone was associated with significant decrease in office systolic BP (−33 vs.&nbsp;−14&nbsp;mmHg;&nbsp;<i>p</i>&nbsp;=&nbsp;0.024), and in diastolic BP (−14 vs. −5&nbsp;mmHg;&nbsp;<i>p</i>&nbsp;=&nbsp;0.006). After 1&nbsp;month of spironolactone, all the patients were controlled based on BP below 130/80&nbsp;mmHg, with significant office BP reduction from 158&nbsp;±&nbsp;17/86&nbsp;±&nbsp;11 to 125&nbsp;±&nbsp;11/72&nbsp;±&nbsp;8, vs. 158&nbsp;±&nbsp;8/94&nbsp;±&nbsp;8 to 144&nbsp;±&nbsp;17/89&nbsp;±&nbsp;12&nbsp;mmHg in the alternative treatment group. There was no significant variation in sodium and creatinine levels in both groups, but a mild increase of potassium levels in the spironolactone group.</p>
<h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Interpretation</h3>
<p>Add-on low-dose spironolactone was effective in reducing BP to optimal levels in T2DM Cameroonian patients despite mild increase in serum potassium.</p>
<p><i>Trial registration</i>&nbsp;ClinicalTrials.gov Identifier&nbsp;<i>NCT02426099</i>.&nbsp;<i>Date of registration</i>&nbsp;April 2015</p>
<p>&nbsp;</p>
<h2 id="Sec1" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Background</h2>
<hr>
<p>&nbsp;</p>
<section aria-labelledby="Sec1" data-title="Background">
<div id="Sec1-section" class="c-article-section" bis_skin_checked="1">
<div id="Sec1-content" class="c-article-section__content" bis_skin_checked="1">
<p>Hypertension and diabetes have reached epidemic proportions worldwide, fuelling a burden of cardiovascular disease. It is estimated that at least 1 billion adults have hypertension globally, a figure that is projected to increase to 1.5 billion by 2025 [1]. The International Diabetes Federation (IDF) has estimated that the number of adults with diabetes in the world will increase by 55&nbsp;%, from 381.8 million in 2013 to 591.9 million in 2035 [2]. Hypertension is very frequent in diabetes patients. It affects up to 70&nbsp;% of individuals with diabetes and is approximately twice more common in individuals with diabetes than in those without [3]. Coexistence of diabetes and hypertension is associated with increased cardiovascular morbidity and mortality [4–6].</p>
<p>Blood pressure (BP) control is a huge challenge in diabetic patients, especially those of African ancestry. To date, there is a general consensus on angiotensin converting enzyme (ACE) inhibitors as first-line treatment for hypertension in diabetic subjects. Diuretics, B blockers and calcium channel blockers (CCB) can be added as second or third-line treatment to reach the target BP objectives. The choice of these drugs generally takes account of existing cofactors or indications [7]. More than 50&nbsp;% of diabetic patients with hypertension do not reach target BP control levels, sometimes in spite of double, triple, or even quadruple drug therapies [7]. This is partly due to resistant hypertension, defined as a failure of appropriate treatment with antihypertensive drugs from three or more classes, one of which a diuretic, to lower BP to the target level [8].</p>
<p>The prevalence of resistant hypertension is estimated at 10–15&nbsp;% in all patients treated with antihypertensive depending on definition and study population [9–12]. It is particularly prevalent in diabetes patients. The cause of resistant hypertension is in most cases multifactorial, including factors such as poor adherence, obesity, vascular stiffening, chronic renal disease as well as an underlying endocrine disease like primary aldosteronism; a condition present in 14&nbsp;% of type 2 diabetes mellitus (T2DM) patients with resistant hypertension [13]. In addition to its classic effects on sodium-water retention and excretion of potassium and magnesium, it has been proven that aldosterone has cardiovascular effects like myocardial fibrosis, cardiac arrhythmia and endothelial dysfunction [14–16]. During the last decade, studies like RALES (spironolactone) and EPHESUS (eplerenone) have provided reliable evidences on the efficacy of low doses of aldosterone antagonists in reducing the morbidity and mortality of severe heart failure and the control of resistant hypertension with low doses of spironolactone as add-on therapy [17,&nbsp;18]. However, there is still scarce data on the benefit of spironolactone in diabetic patients, especially those of African ancestry. To address this clinical issue, we conducted a pilot prospective randomized trial to evaluate the effect of low dose spironolactone on BP control in a group of T2DM Cameroonian patients with resistant hypertension.</p>
</div>
</div>
</section>
<section aria-labelledby="Sec2" data-title="Methods">
<div id="Sec2-section" class="c-article-section" bis_skin_checked="1">
<h2 id="Sec2" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Methods</h2>
<div id="Sec2-content" class="c-article-section__content" bis_skin_checked="1">
<h3 id="Sec3" class="c-article__sub-heading">Ethical considerations</h3>
<p>The study protocol was approved by the National Research Ethics Committee for Human Health of Cameroon (Ethical approval N° 077/CNE/SE/2012). Written informed consent was obtained from all participants. The study was conducted in accordance with the Helsinki Declaration.</p>
<h3 id="Sec4" class="c-article__sub-heading">Protocol and registration</h3>
<p>This project was retrospectively registered on ClinicalTrials.gov in April 2015.&nbsp;<i>NCT02426099</i>. A protocol was developed during the planning process.</p>
<h3 id="Sec5" class="c-article__sub-heading">Design</h3>
<p>It was a prospective randomized controlled single blinded trial conducted over a six-month period from October 2011 to March 2012. There was no change in protocol during the study.</p>
<h3 id="Sec6" class="c-article__sub-heading">Centers and patients</h3>
<p>The reference population comprised diabetic patients aged&nbsp;&lt;75&nbsp;years presenting with a resistant hypertension of unknown etiology at the outpatient clinics of the National Obesity Center and of the Diabetes Care and Education Center of the Yaoundé Central Hospital, as well as those participating in an ongoing study on glycated hemoglobin (HbA1c). Resistant hypertension was defined as an office BP value&nbsp;≥140/90&nbsp;mmHg and self-blood pressure measurement (SBPM)&nbsp;≥130/80&nbsp;mmHg under at least three antihypertensive drugs at optimal dosages for at least two months, including a diuretic [8]. From this population, those who consented were further excluded if they fulfilled any of the following criteria: T2DM with overt acute/chronic complications, serum potassium&nbsp;≥5.5&nbsp;mmol/l, estimated Glomerular Filtration Rate (eGFR) calculated using the Modification of Diet in Renal Disease formula&nbsp;≤30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>&nbsp;of body weight, absolute contraindication to any of the drug regimen of the trial, and current aldosterone antagonist treatment or cessation within the last 15&nbsp;months.</p>
<h3 id="Sec7" class="c-article__sub-heading">Randomization and blinding</h3>
<p>The experimental population was divided into two groups according to a restricted randomization method of blocks [19]. It consisted of drawing without replacement one out of two types of non-distinguishable counters from a non-transparent bag. Depending on the type of counter drawn, the subject was assigned to the spironolactone group or to the control group (taking an alternative drug regimen) by researchers who were aware of the type of counter presented. The alternative drug regimen included: candesartan, atenolol and alpha methyldopa; and the choice to administer each depended on the respective absolute/relative contraindications [20] applicable to the subject. As from the randomization day, subjects allocated to the spironolactone group received a daily 25&nbsp;mg tablet of spironolactone, whereas those from the control group received either a daily 100&nbsp;mg of atenolol, a daily 8&nbsp;mg of candesartan, or a daily 750&nbsp;mg of alpha methyldopa, all of these drugs added to their previous regimen, with unchanged diet. They were followed up during visits scheduled at the second and fourth weeks of treatment.</p>
<h3 id="Sec8" class="c-article__sub-heading">Outcomes measures</h3>
<p>A clinical examination was done and laboratory measurements carried out before the intervention (baseline) and at follow-up visits. Clinical examination included BP measurement (at baseline and during all follow-up visits), an electrocardiogram (ECG) and anthropometric parameters recorded at baseline. Biochemical measures included: serum sodium, serum potassium, serum creatinine, fasting capillary glycaemia, the lipid profile [including blood cholesterol, triglyceride, high density lipoprotein cholesterol (HDL), and low density lipoprotein cholesterol (LDL)], blood urea nitrogen (BUN) and proteinuria. All biochemical measurements were done at baseline and serum sodium, potassium and creatinine levels were checked again during visits.</p>
<p>Office BP and self-blood pressure measurement (SBPM) were considered at every visit. For office BP, three serial measurements taken 5&nbsp;min apart in the sitting position were obtained from the left arm placed at the level of the heart, using an automated sphygmomanometer Omron HEM-705 CP (Omron Corporation, Tokyo, Japan). The average of the second and third measurements was used for all analyses. The daytime SBPM considered was the mean of BP values self-recorded at home in the same condition than those applied in clinic three consecutive days prior to the visit, without health personnel. ECG was recorded using the CardiMax FX-7302 electrocardiograph (Fukuda DenShi, Tokyo, Japan). Weight was measured in light clothed subjects to the nearest 0.5&nbsp;kg with a mechanical scale; height was measured in the upright position to the nearest 0.5&nbsp;cm, and body mass index (BMI in kg/m<sup>2</sup>) was calculated as&nbsp;<span class="mathjax-tex"><span id="MathJax-Element-1-Frame" class="MathJax" style="box-sizing: inherit; display: inline; font-style: normal; font-weight: normal; line-height: normal; font-size: 18px; text-indent: 0px; text-align: left; text-transform: none; letter-spacing: normal; word-spacing: normal; overflow-wrap: normal; white-space: nowrap; float: none; direction: ltr; max-width: none; max-height: none; min-width: 0px; min-height: 0px; border: 0px; padding: 0px; margin: 0px; position: relative;" tabindex="0" role="presentation" data-mathml="<math xmlns=&quot;http://www.w3.org/1998/Math/MathML&quot;><mi>w</mi><mi>e</mi><mi>i</mi><mi>g</mi><mi>h</mi><mi>t</mi><mo stretchy=&quot;false&quot;>(</mo><mi>c</mi><mi>m</mi><mo stretchy=&quot;false&quot;>)</mo><mrow class=&quot;MJX-TeXAtom-ORD&quot;><mo>/</mo></mrow><mo stretchy=&quot;false&quot;>[</mo><mi>h</mi><mi>e</mi><mi>i</mi><mi>g</mi><mi>h</mi><mi>t</mi><mrow><mo>(</mo><mi>m</mi><mo>)</mo></mrow><mi>x</mi><mspace width=&quot;thinmathspace&quot; /><mi>h</mi><mi>e</mi><mi>i</mi><mi>g</mi><mi>h</mi><mi>t</mi><mrow><mo>(</mo><mi>m</mi><mo>)</mo></mrow><mo stretchy=&quot;false&quot;>]</mo></math>"><span id="MathJax-Span-1" class="math"><span id="MathJax-Span-2" class="mrow"><span id="MathJax-Span-3" class="mi">w</span><span id="MathJax-Span-4" class="mi">e</span><span id="MathJax-Span-5" class="mi">i</span><span id="MathJax-Span-6" class="mi">g</span><span id="MathJax-Span-7" class="mi">h</span><span id="MathJax-Span-8" class="mi">t</span><span id="MathJax-Span-9" class="mo">(</span><span id="MathJax-Span-10" class="mi">c</span><span id="MathJax-Span-11" class="mi">m</span><span id="MathJax-Span-12" class="mo">)</span><span id="MathJax-Span-13" class="texatom"><span id="MathJax-Span-14" class="mrow"><span id="MathJax-Span-15" class="mo">/</span></span></span><span id="MathJax-Span-16" class="mo">[</span><span id="MathJax-Span-17" class="mi">h</span><span id="MathJax-Span-18" class="mi">e</span><span id="MathJax-Span-19" class="mi">i</span><span id="MathJax-Span-20" class="mi">g</span><span id="MathJax-Span-21" class="mi">h</span><span id="MathJax-Span-22" class="mi">t</span><span id="MathJax-Span-23" class="mrow"><span id="MathJax-Span-24" class="mo">(</span><span id="MathJax-Span-25" class="mi">m</span><span id="MathJax-Span-26" class="mo">)</span></span><span id="MathJax-Span-27" class="mi">x</span><span id="MathJax-Span-29" class="mi">h</span><span id="MathJax-Span-30" class="mi">e</span><span id="MathJax-Span-31" class="mi">i</span><span id="MathJax-Span-32" class="mi">g</span><span id="MathJax-Span-33" class="mi">h</span><span id="MathJax-Span-34" class="mi">t</span><span id="MathJax-Span-35" class="mrow"><span id="MathJax-Span-36" class="mo">(</span><span id="MathJax-Span-37" class="mi">m</span><span id="MathJax-Span-38" class="mo">)</span></span><span id="MathJax-Span-39" class="mo">]</span></span></span><span class="MJX_Assistive_MathML" role="presentation">weight(cm)/[height(m)xheight(m)]</span></span></span>. Waist circumference was measured at the horizontal plane midway between the lower rib margin and the iliac crest with a measuring tape. Serum sodium, serum potassium, serum creatinine, BUN, serum triglyceride, serum cholesterol and serum HDL cholesterol were measured using standard colorimetric procedures. LDL cholesterol was calculated with the Friedwald’s formula [21]. Proteinuria was obtained by dipstix of spot urine, and considered positive for at least 1+. Fasting glycaemia was recorded using the Accu-Chek<sup>®</sup>&nbsp;Compact Plus glucometer (F. Hoffmann-La Roche AG, Basel, Switzerland). Unfortunately aldosterone was not measured in this study.</p>
<p>All drug information were checked at each visit by interviewing the participants and they were invited to phone the research team if any change was noticed in-between visits.</p>
<h3 id="Sec9" class="c-article__sub-heading">Statistical analysis</h3>
<p>We needed at least eight individuals in each group in order to detect with 80&nbsp;% power (ϕ) and 5&nbsp;% risk of error (α) a minimal relevant difference (δ) of 20 (SD 4) mmHg [22] for the systolic blood pressure (SBP) between the two groups, considering no dropout, based on the following formula [23]:</p>
<div id="Equa" class="c-article-equation" bis_skin_checked="1">
<div class="c-article-equation__content" bis_skin_checked="1">
<div class="MathJax_Display" bis_skin_checked="1"><span id="MathJax-Element-2-Frame" class="MathJax" style="box-sizing: inherit; display: block !important; font-style: normal; font-weight: normal; line-height: normal; font-size: 18px; text-indent: 0px; text-align: left; text-transform: none; letter-spacing: normal; word-spacing: normal; overflow-wrap: normal; white-space: nowrap; float: none; direction: ltr; max-width: 100%; max-height: none; min-width: 0px; min-height: 0px; border: 0px; padding: 0px; margin: 0px; overflow: auto hidden; position: relative;" tabindex="0" role="presentation" data-mathml="<math xmlns=&quot;http://www.w3.org/1998/Math/MathML&quot; display=&quot;block&quot;><mi>n</mi><mo>=</mo><msup><mrow><mo>[</mo><mrow class=&quot;MJX-TeXAtom-ORD&quot;><mfrac><mrow class=&quot;MJX-TeXAtom-ORD&quot;><mi>&amp;#x03C3;</mi><mrow><mo>(</mo><mrow class=&quot;MJX-TeXAtom-ORD&quot;><msub><mrow class=&quot;MJX-TeXAtom-ORD&quot;><mi mathvariant=&quot;normal&quot;>Z</mi></mrow><mrow class=&quot;MJX-TeXAtom-ORD&quot;><mrow class=&quot;MJX-TeXAtom-ORD&quot;><mn>1</mn><mfrac><mi>&amp;#x03B1;</mi><mn>2</mn></mfrac></mrow></mrow></msub><mo>+</mo><msub><mrow class=&quot;MJX-TeXAtom-ORD&quot;><mi mathvariant=&quot;normal&quot;>Z</mi></mrow><mrow class=&quot;MJX-TeXAtom-ORD&quot;><mrow class=&quot;MJX-TeXAtom-ORD&quot;><mtext fontfamily=&quot;Times&quot;>&amp;#x03C6;</mtext></mrow></mrow></msub></mrow><mo>)</mo></mrow></mrow><mi>&amp;#x03B4;</mi></mfrac></mrow><mo>]</mo></mrow><mrow class=&quot;MJX-TeXAtom-ORD&quot;><mn>2</mn></mrow></msup></math>"><span id="MathJax-Span-40" class="math"><span id="MathJax-Span-41" class="mrow"><span id="MathJax-Span-42" class="mi">n</span><span id="MathJax-Span-43" class="mo">=</span><span id="MathJax-Span-44" class="msubsup"><span id="MathJax-Span-45" class="mrow"><span id="MathJax-Span-46" class="mo">⎡⎣⎢</span><span id="MathJax-Span-47" class="texatom"><span id="MathJax-Span-48" class="mrow"><span id="MathJax-Span-49" class="mfrac"><span id="MathJax-Span-50" class="texatom"><span id="MathJax-Span-51" class="mrow"><span id="MathJax-Span-52" class="mi">σ</span><span id="MathJax-Span-53" class="mrow"><span id="MathJax-Span-54" class="mo">(</span><span id="MathJax-Span-55" class="texatom"><span id="MathJax-Span-56" class="mrow"><span id="MathJax-Span-57" class="msubsup"><span id="MathJax-Span-58" class="texatom"><span id="MathJax-Span-59" class="mrow"><span id="MathJax-Span-60" class="mi">Z</span></span></span><span id="MathJax-Span-61" class="texatom"><span id="MathJax-Span-62" class="mrow"><span id="MathJax-Span-63" class="texatom"><span id="MathJax-Span-64" class="mrow"><span id="MathJax-Span-65" class="mn">1</span><span id="MathJax-Span-66" class="mfrac"><span id="MathJax-Span-67" class="mi">α</span><span id="MathJax-Span-68" class="mn">2</span></span></span></span></span></span></span><span id="MathJax-Span-69" class="mo">+</span><span id="MathJax-Span-70" class="msubsup"><span id="MathJax-Span-71" class="texatom"><span id="MathJax-Span-72" class="mrow"><span id="MathJax-Span-73" class="mi">Z</span></span></span><span id="MathJax-Span-74" class="texatom"><span id="MathJax-Span-75" class="mrow"><span id="MathJax-Span-76" class="texatom"><span id="MathJax-Span-77" class="mrow"><span id="MathJax-Span-78" class="mtext">φ</span></span></span></span></span></span></span></span><span id="MathJax-Span-79" class="mo">)</span></span></span></span><span id="MathJax-Span-80" class="mi">δ</span></span></span></span><span id="MathJax-Span-81" class="mo">⎤⎦⎥</span></span><span id="MathJax-Span-82" class="texatom"><span id="MathJax-Span-83" class="mrow"><span id="MathJax-Span-84" class="mn">2</span></span></span></span></span></span><span class="MJX_Assistive_MathML MJX_Assistive_MathML_Block" role="presentation">n=[σ(Z1α2+Zφ)δ]2</span></span></div>
</div>
</div>
<p>Data were analyzed based on the intention to treat principle, using IBM SPSS for Windows, version 20.0 (IBM Corp., Armonk New York, USA). Continuous variables are expressed as means with standard deviation (SD), and categorical variables as count (percentage). Non parametric Mann–Whitney tests were used to compare continuous variables. A&nbsp;<i>p</i>&nbsp;value&nbsp;&lt;0.05 was considered statistically significant.</p>
</div>
</div>
<h2 id="Sec10" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Results</h2>
<hr>
</section>
<p>&nbsp;</p>
<p>Out of the 672 diabetic patients received at the enrolment centers between October 2011 and March 2012, 377 (56.1&nbsp;%) were hypertensive; of whom 49 (13&nbsp;%) had a diagnosis of resistant hypertension were screened for eligibility. After exclusion of ineligible subjects, 17 patients were definitively randomized. None of the participants left the trial, and all of them were included in the intention-to-treat analysis. There was a good compliance to treatment and no change in medications occurred during the follow up. The trial profile is outlined in Fig.&nbsp;1.</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="figure1" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13104-016-1987-5/MediaObjects/13104_2016_1987_Fig1_HTML.gif"><noscript><img src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13104-016-1987-5/MediaObjects/13104_2016_1987_Fig1_HTML.gif" alt="figure1" /></noscript></p>
<p>&nbsp;</p>
<p>As expected, the profile of participants was similar across the two trial arms at baseline. There were no sex differences between the two groups, although this has to be interpreted in the context of small numbers. The mean office SBP was 158&nbsp;mmHg in both groups. Mean serum potassium, sodium and creatinine levels were within normal ranges in both groups. All trial participants had chronic kidney disease (CKD) according to the KDIGO definition as the persistence for at least 3&nbsp;months of an estimated glomerular filtration rate below 60&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>&nbsp;[24]. Other characteristics are summarized in Table&nbsp;<a href="https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-016-1987-5#Tab1" data-track="click" data-track-label="link" data-track-action="table anchor">1</a>. Before the intervention, all trial participants were on treatment regimens comprising an ACE inhibitor, a diuretic and a calcium channel blocker. Besides this triple therapy, five subjects had a fourth drug, which was either alpha or beta-blockers; and the mean daily dosage was appropriate in both groups for each drug (data not shown).</p>
<p>&nbsp;</p>
<div class="c-article-table-container" bis_skin_checked="1">
<div class="c-article-table-border c-table-scroll-wrapper" bis_skin_checked="1">
<div class="c-table-scroll-wrapper__content c-table-scroll-wrapper__fade--transparent" data-component-scroll-wrapper="" bis_skin_checked="1">
<table class="data last-table">
<thead class="c-article-table-head">
<tr>
<th class="u-text-left ">Spironolactone (n&nbsp;=&nbsp;9)</th>
<th class="u-text-left ">Alternative drug regimen (n&nbsp;=&nbsp;8)</th>
<th class="u-text-left "><i>p</i>&nbsp;value</th>
</tr>
</thead>
<tbody>
<tr>
<td class="u-text-left " colspan="4">Sociodemographic and clinical characteristics</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Age (years)</td>
<td class="u-text-left ">64.6 (9.6)</td>
<td class="u-text-left ">61.0 (6.6)</td>
<td class="u-text-left ">0.15</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Sex (male/female)</td>
<td class="u-text-left ">3/6</td>
<td class="u-text-left ">5/3</td>
<td class="u-text-left ">0.34</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Smoking</td>
<td class="u-text-left ">0</td>
<td class="u-text-left ">0</td>
<td class="u-text-left ">–</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Alcoholic index (g/l)</td>
<td class="u-text-left ">0</td>
<td class="u-text-left ">0</td>
<td class="u-text-left ">–</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Body mass index (kg/m<sup>2</sup>)</td>
<td class="u-text-left ">30.3 (5.4)</td>
<td class="u-text-left ">30.5 (7.7)</td>
<td class="u-text-left ">0.95</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Waist circumference (cm)</td>
<td class="u-text-left ">104.8 (12.5)</td>
<td class="u-text-left ">102.7 (10.2)</td>
<td class="u-text-left ">0.74</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Office SBP<sup>a</sup>&nbsp;(mmHg)</td>
<td class="u-text-left ">158 (17)</td>
<td class="u-text-left ">158 (8)</td>
<td class="u-text-left ">0.96</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Office DBP<sup>a</sup>&nbsp;(mmHg)</td>
<td class="u-text-left ">86 (11)</td>
<td class="u-text-left ">94 (8)</td>
<td class="u-text-left ">0.08</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Office heart rate (beats/minute)</td>
<td class="u-text-left ">75 (12)</td>
<td class="u-text-left ">76 (1) 6</td>
<td class="u-text-left ">0.92</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Self-measured SBP (mmHg)</td>
<td class="u-text-left ">140 (9)</td>
<td class="u-text-left ">151 (15)</td>
<td class="u-text-left ">0.06</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Self-measured DBP (mmHg)</td>
<td class="u-text-left ">78 (8)</td>
<td class="u-text-left ">91 (15)</td>
<td class="u-text-left ">0.07</td>
</tr>
<tr>
<td class="u-text-left " colspan="4">Biological parameters</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Fasting glycaemia (g/l)</td>
<td class="u-text-left ">182.89 (105.45)</td>
<td class="u-text-left ">141.13 (56.36)</td>
<td class="u-text-left ">0.33</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Glycatedhaemoglobin (%)</td>
<td class="u-text-left ">8.45 (1.76)</td>
<td class="u-text-left ">8.64 (2.43)</td>
<td class="u-text-left ">0.88</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Blood urea nitrogen (g/l)</td>
<td class="u-text-left ">0.48 (0.01)</td>
<td class="u-text-left ">0.48 (0.04)</td>
<td class="u-text-left ">0.96</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Serum creatinine (mg/l)</td>
<td class="u-text-left ">15.63 (5.97)</td>
<td class="u-text-left ">12.45 (3.41)</td>
<td class="u-text-left ">0.20</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;eGFR (ml/min/1.73&nbsp;m<sup>2</sup>)</td>
<td class="u-text-left ">55.25 (23.76)</td>
<td class="u-text-left ">73.99 (27.96)</td>
<td class="u-text-left ">0.15</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Serum potassium (mmol/l)</td>
<td class="u-text-left ">4.02 (0.15)</td>
<td class="u-text-left ">4.01 (0.10)</td>
<td class="u-text-left ">0.88</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Serum sodium (mmol/l)</td>
<td class="u-text-left ">140.5 (0.5)</td>
<td class="u-text-left ">141.0(0.7)</td>
<td class="u-text-left ">0.11</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Serum total cholesterol (g/l)</td>
<td class="u-text-left ">1.71 (0.39)</td>
<td class="u-text-left ">2.21 (1.00)</td>
<td class="u-text-left ">0.43</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Serum HDL-C (g/l)</td>
<td class="u-text-left ">0.58 (0.09)</td>
<td class="u-text-left ">0.35 (0.10)</td>
<td class="u-text-left ">0.06</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Serum LDL-C (g/l)</td>
<td class="u-text-left ">0.88 (0.35)</td>
<td class="u-text-left ">1.54 (1.20)</td>
<td class="u-text-left ">0.43</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Serum triglyceride (g/l)</td>
<td class="u-text-left ">1.32 (0.98)</td>
<td class="u-text-left ">1.63 (1.43)</td>
<td class="u-text-left ">0.90</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Proteinuria (number of +)</td>
<td class="u-text-left ">1.11 (1.6)</td>
<td class="u-text-left ">1 (1.06)</td>
<td class="u-text-left ">0.84</td>
</tr>
<tr>
<td class="u-text-left " colspan="4">Complications</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;Chronic kidney disease</td>
<td class="u-text-left ">9 (100)</td>
<td class="u-text-left ">8 (100)</td>
<td class="u-text-left "></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="c-article-table-footer" bis_skin_checked="1">
<ol>
<li>Data are expressed as mean (standard deviations); no statistical difference was found for any of the parameters compared between the spironolactone and control groups; Alternative drug regimens include atenolol, candesartan and alpha methyldopa</li>
<li>Current smoking or ceased within the last 3&nbsp;years</li>
<li>Chronic kidney disease which is the only categorical variable is expressed in number (percentage)</li>
<li><i>SBP</i>&nbsp;systolic blood pressure;&nbsp;<i>DBP</i>&nbsp;diastolic blood pressure</li>
<li><i>eGFR</i>&nbsp;estimated glomerular filtration rate using the modification of diet in renal disease equation;&nbsp;<i>HDL-c</i>&nbsp;high density lipoprotein cholesterol;&nbsp;<i>LDL-c</i>&nbsp;low density lipoprotein cholesterol</li>
<li><sup>a</sup>&nbsp;Expressed as the average of the second and third measurements</li>
</ol>
</div>
<p>The mean change in office and self-measured systolic and diastolic BP at the end of the trial is presented in Table&nbsp;<a href="https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-016-1987-5#Tab2" data-track="click" data-track-label="link" data-track-action="table anchor">2</a>. The target BP was defined in this study by systolic (and diastolic) BP&nbsp;&lt;130&nbsp;mmHg (and 80&nbsp;mmHg) as recommended by the IDF up to 2012 [25]. Within the spironolactone group, there were significant reductions in systolic and diastolic office BP and in systolic SBPM. Their mean systolic and diastolic office BP decreased respectively from 158&nbsp;±&nbsp;17&nbsp;mmHg to 125&nbsp;±&nbsp;11&nbsp;mmHg (<i>p</i>&nbsp;=&nbsp;0.009) and from 86&nbsp;±&nbsp;11 to 72&nbsp;±&nbsp;8&nbsp;mmHg (<i>p</i>&nbsp;=&nbsp;0.009). Only one out of nine participants in the spironolactone group did not reach the target office BP (with BP&nbsp;=&nbsp;140/67&nbsp;mmHg 1&nbsp;month after); defined by systolic (and diastolic) BP&nbsp;&lt;140 (and 90&nbsp;mmHg). However, the target for SBPM, defined by systolic BP (and diastolic)&nbsp;&lt;135 (and 85&nbsp;mmHg) was reached after 1&nbsp;month for this patient, as all the participants in the spironolactone group. Comparing the two groups, the systolic and diastolic BP, both office-based and self-measured, decreased more in the spironolactone group than in the control group, with the systolic and diastolic office BP respectively decreasing by 33 vs. 14&nbsp;mmHg (<i>p</i>&nbsp;=&nbsp;0.024) and by 14 vs. 5&nbsp;mmHg (<i>p</i>&nbsp;=&nbsp;0.006). In the control group, the target BP was achieved neither for office BP [end-of-trial mean BP (mmHg)&nbsp;=&nbsp;144&nbsp;±&nbsp;17/89&nbsp;±&nbsp;12], nor for SBPM [end-of-trial mean BP (mmHg)&nbsp;=&nbsp;142&nbsp;±&nbsp;14/86&nbsp;±&nbsp;14]. Only two out of eight participants in the control group reached the target control BP levels.</p>
</div>
<div class="c-article-table-border c-table-scroll-wrapper" bis_skin_checked="1">
<div class="c-table-scroll-wrapper__content c-table-scroll-wrapper__fade--transparent" data-component-scroll-wrapper="" bis_skin_checked="1">
<table class="data last-table">
<thead class="c-article-table-head">
<tr>
<th class="u-text-left ">Spironolactone (n&nbsp;=&nbsp;9)</th>
<th class="u-text-left ">Alternative drug regimen (n&nbsp;=&nbsp;8)</th>
<th class="u-text-left "><i>P</i>&nbsp;value</th>
</tr>
</thead>
<tbody>
<tr>
<td class="u-text-left " colspan="4">Office blood pressure</td>
</tr>
<tr>
<td class="u-text-left " colspan="4">&nbsp;SBP(mmHg)</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;Before</td>
<td class="u-text-left ">158 (17)</td>
<td class="u-text-left ">158 (8)</td>
<td class="u-text-char ">0.96</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;After</td>
<td class="u-text-left ">125 (11)</td>
<td class="u-text-left ">144 (17)</td>
<td class="u-text-char ">0.02</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;<i>p</i>&nbsp;value</td>
<td class="u-text-left ">0.01</td>
<td class="u-text-left ">0.08</td>
<td class="u-text-left "></td>
</tr>
<tr>
<td class="u-text-left " colspan="4">&nbsp;DBP(mmHg)</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;Before</td>
<td class="u-text-left ">86 (11)</td>
<td class="u-text-left ">94 (8)</td>
<td class="u-text-char ">0.08</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;After</td>
<td class="u-text-left ">72 (8)</td>
<td class="u-text-left ">89 (12)</td>
<td class="u-text-char ">0.01</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;<i>p</i>&nbsp;value</td>
<td class="u-text-left ">0.01</td>
<td class="u-text-left ">0.02</td>
<td class="u-text-left "></td>
</tr>
<tr>
<td class="u-text-left " colspan="4">Self-blood pressure measurement</td>
</tr>
<tr>
<td class="u-text-left " colspan="4">&nbsp;SBP(mmHg)</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;Before</td>
<td class="u-text-left ">140 (9)</td>
<td class="u-text-left ">151 (15)</td>
<td class="u-text-char ">0.06</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;After</td>
<td class="u-text-left ">123 (10)</td>
<td class="u-text-left ">142 (14)</td>
<td class="u-text-char ">0.01</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;<i>p</i>&nbsp;value</td>
<td class="u-text-left ">0.02</td>
<td class="u-text-left ">0.02</td>
<td class="u-text-left "></td>
</tr>
<tr>
<td class="u-text-left " colspan="4">&nbsp;DBP(mmHg)</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;Before</td>
<td class="u-text-left ">78 (8)</td>
<td class="u-text-left ">91 (15)</td>
<td class="u-text-char ">0.07</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;After</td>
<td class="u-text-left ">73 (7)</td>
<td class="u-text-left ">86 (14)</td>
<td class="u-text-char ">0.04</td>
</tr>
<tr>
<td class="u-text-left ">&nbsp;&nbsp;<i>p</i>&nbsp;value</td>
<td class="u-text-left ">0.11</td>
<td class="u-text-left ">0.09</td>
<td class="u-text-left "></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="c-article-table-footer" bis_skin_checked="1">
<ol>
<li>Data are expressed as means (standard deviations)</li>
<li><i>SBP</i>&nbsp;systolic blood pressure;&nbsp;<i>DBP</i>&nbsp;diastolic blood pressure</li>
</ol>
<p>The mean serum potassium was mildly increased from 4.02 to 4.38&nbsp;mmol/L in the spironolactone group after 4&nbsp;weeks (Fig.&nbsp;2), the highest value being at 6.28&nbsp;mmol/l at the end of the trial. But the difference between the two study groups was not significant; an observation made also for serum sodium and creatinine levels (Fig.&nbsp;3). Adverse drug reactions were observed only in the spironolactone group at the end of the trial. These included: somnolence and asthenia in one patient (11.1&nbsp;%), and hyperkalemia (at 5.61 and 6.28&nbsp;mmol/l) in two other patients (22.2&nbsp;%) without clinical manifestations. However, these two patients had high initial potassium levels of 5.04&nbsp;mmol/L each. No unexpected adverse drug effect was noted.</p>
<h5 class="c-article-figure-title u-h1" data-test="top-caption">Fig.&nbsp;2</h5>
</div>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Fig.&nbsp;2" data-lazy-src="https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13104-016-1987-5/MediaObjects/13104_2016_1987_Fig2_HTML.gif"><noscript><img src="https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13104-016-1987-5/MediaObjects/13104_2016_1987_Fig2_HTML.gif" alt="Fig. 2" /></noscript></p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<h5 class="c-article-figure-title u-h1" data-test="top-caption">Fig.&nbsp;3</h5>
<p>&nbsp;</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Fig.&nbsp;3" data-lazy-src="https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13104-016-1987-5/MediaObjects/13104_2016_1987_Fig3_HTML.gif"><noscript><img src="https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13104-016-1987-5/MediaObjects/13104_2016_1987_Fig3_HTML.gif" alt="Fig. 3" /></noscript></p>
<p>&nbsp;</p>
<h2 id="Sec11" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Discussion</h2>
<hr>
<p>&nbsp;</p>
<p>Hypertensive patients with diabetes are at increased risk of developing diabetes-specific complications [26]. However, achieving and maintaining optimal BP control in this population remains a challenge [25,&nbsp;26]. Unlike in the general population where low-dose spironolactone has been shown to be effective for the treatment of resistant hypertension [27–29], little is known on its efficacy in people with diabetes in whom resistant hypertension tends to be highly prevalent and difficult to control. This evidence is much needed for patients of African ethnicity who have been found to be less responsive to the guidelines recommended first line antihypertensive drugs [ACEI or Angiotensin II Receptor Blocker (ARB)] in people with diabetes [25]. Thus, we conducted a randomized controlled trial to evaluate the effect of a low-dose spironolactone as add-on therapy on office and self-measured BP in a group of sub-Saharan African T2DM patients with resistant hypertension from Cameroon. After 1&nbsp;month of treatment, a daily 25&nbsp;mg of spironolactone was associated with a significant reduction of both office and SBPM, and high likelihood of reaching recommended target blood pressure, without significant change in serum sodium concentrations, and only a mild elevation of serum potassium levels.</p>
<p>Compared to the alternative drug regimen group, the spironolactone group exhibited a significant reduction of BP. The achieved reduction in their mean office BP (33/14&nbsp;mmHg) was higher than the 12/7&nbsp;mmHg reported by&nbsp;<i>Hase</i>&nbsp;et al. after treating 25 T2DM Japanese patients for 24&nbsp;weeks with similar dose of spironolactone [<a id="ref-link-section-d5949e2330" title="Hase M, Babazono T, Ujihara N, Uchigata Y. Comparison of spironolactone and trichlormethiazide as add-on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients. J Diabetes Invest. 2013;4(3):316–9. doi: 10.1111/jdi.12029 ." href="https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-016-1987-5#ref-CR30" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30">30</a>]. The more pronounced renal impairment in their population could account at least in part to this difference. Differing durations of follow-up is also another possible reason, which would suggest that perhaps, following our cohort beyond 4&nbsp;weeks could reveal some attenuation of the effect of spironolactone with time. It is of note however that, in Hase et al’s study [30], BP reduction was still significant 2&nbsp;years after the introduction of spironolactone.&nbsp;<i>Oxlund</i>&nbsp;et al. also reported significant reduction in office and ambulatory BP with a fixed daily dose of 25&nbsp;mg of spironolactone in 57 T2DM Danish patients after 16&nbsp;weeks of therapy [<a id="ref-link-section-d5949e2339" title="Oxlund CS, Jan Henriksen E, Tarnow L, Schousboe K, Gram J, Jacobsen A. Low dose spironolactone reduces blood pressure inpatients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31:2094–102." href="https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-016-1987-5#ref-CR31" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31">31</a>]. These results, together with ours, suggest the possible effectiveness of small-dose spironolactone in people with diabetes, unlike the general population or non-diabetic CKD patients in who higher doses are often needed to overcome resistant hypertension [29,&nbsp;32].</p>
<p>Unlike participants in our alternative drug regimen group, all those in the spironolactone group reached the target office BP of 130/80&nbsp;mmHg recommended by the IDF [25], with the exception one patient who reached the target diastolic, but not systolic BP. In the study conducted by&nbsp;<i>Oxlund</i>&nbsp;et al. [31], only 36&nbsp;% of patients receiving spironolactone reached the target BP. Although there is continuing debate about the target value of BP in T2DM patients, with some claims that the goal of 130/80&nbsp;mmHg is less realistic in older populations [26] like ours (mean age 64&nbsp;years), this target is associated with a reduced overall and cardiovascular mortality in T2DM patients [25], and still seems achievable.</p>
<p>Recent studies in animals and humans, have reported that spironolactone produces many other metabolic benefits (preventing dyslipidemia) and cardiovascular effects in T2DM, beside its known diuretic properties [15,&nbsp;16,&nbsp;29]. It reduces vascular stiffness and mediates vasodilation by increasing nitric oxide bioavailability and inhibiting the sympathetic system [33]. These last effects are likely more pronounced in resistant hypertension, where they translate into reduced pulse-wave velocity and systolic BP [29,&nbsp;34]. This can possibly explain the more pronounced action on systolic BP observed in our study. Alongside the above effects, spironolactone has many other beneficial effects in diabetic patients. In particular, it improves endothelial function, exerts antithrombogenic effects by blocking aldosterone, thereby mediating antithrombotic effects [34]. Furthermore, it reduces the risk of inflammatory cerebral, myocardial, and renal injury; and is associated with a reduced prevalence of arrhythmia, heart failure, sudden death and post myocardial infarction mortality [34]. It has been proven to reduce microalbuminuria [30]. Considering all these actions, spironolactone should perhaps not be conceived anymore as a simple antihypertensive drug, but also as a cardioprotective and nephroprotective drug suitable for diabetic patients, in the absence of other contraindications. Spironolactone probably has a place among the first-line antihypertensive drugs in diabetic patients regardless of whether they have resistant hypertension or not. Indeed, the “aldosterone escape” phenomenon characterized by an initial partially reversible decrease of aldosterone is well known with the use of ACEI agents, and makes aldosterone specific blockers such as spironolactone more effective [34].&nbsp;<i>Makhlough</i>&nbsp;et al. also proved that a low dose spironolactone used alone was as effective as spironolactone-losartan combination in improving on the diabetic nephropathy [35]. These arguments corroborate the fact that it is not an absolute necessity to combine spironolactone which mediates (with better results) all desired effects of ACEI/ARB with any of those drugs. Such associations are not even recommended [25], since they increase the risk of adverse drug reactions, including hyperkalemia [27,&nbsp;29–32,&nbsp;35].</p>
<p>Despite the safe dosage of spironolactone used in this study, we observed a mild increase in mean serum potassium levels in the spironolactone group. Even though severe hyperkalemia was noted in two subjects at the end of the study, this was likely driven by their high initial level of serum potassium level. Of note, all those patients had CKD, which is associated with high risk of hyperkalemia [32]. Furthermore, they were all on ACEI which can also increase serum potassium levels. The above suggest that caution should be exercised when prescribing spironolactone to diabetes patients with serum potassium in the upper end of the normal range, or who have concomitant conditions or are receiving treatments that can adversely increase potassium levels. Besides hyperkalemia, we did observe somnolence and asthenia in one patient (11.1&nbsp;%) in the spironolactone group at the end of the trial. These are known mild effects of the drug [36].</p>
<p>Our study is mostly limited by the small sample size, limiting our ability to generate stable estimates or to perform post hoc subgroups analyses. More adequately powered trials with extended follow-up are needed to draw definitive conclusions. Indeed, since hypertension is a chronic disease, the benefit of low-dose spironolactone in long term treatment of resistant hypertension still needs to be demonstrated.</p>
<p>&nbsp;</p>
<h2 id="Sec12" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Conclusions</h2>
<hr>
<p>&nbsp;</p>
<p>This trial has shown that a low-dose (25&nbsp;mg) of spironolactone as an add-on therapy for resistant hypertension among Black Africans with T2DM was associated with a significant reduction of the office and self-measured BP to optimal levels after 1&nbsp;month of treatment, without affecting sodium level, but with mild elevation of serum potassium.</p>
<p>&nbsp;</p>
<h2 id="abbreviations" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Abbreviations</h2>
<hr>
<p>&nbsp;</p>
<p><dfn>T2DM:</dfn></p>
<p>type 2 diabetes mellitus</p>
<p><dfn>IDF:</dfn></p>
<p>International Diabetes Federation</p>
<p><dfn>BP:</dfn></p>
<p>blood pressure</p>
<p><dfn>SBPM:</dfn></p>
<p>self-blood pressure measurement</p>
<p><dfn>PA:</dfn></p>
<p>primary aldoterolism</p>
<p><dfn>HbA1c:</dfn></p>
<p>glycated hemoglobin</p>
<p><dfn>eGFR:</dfn></p>
<p>estimated glomerular filtration rate</p>
<p><dfn>HDL:</dfn></p>
<p>high density lipoprotein</p>
<p><dfn>LDL:</dfn></p>
<p>low density lipoprotein</p>
<p><dfn>BUN:</dfn></p>
<p>blood urea nitrogen</p>
<p><dfn>BMI:</dfn></p>
<p>body mass index</p>
<p><dfn>CKD:</dfn></p>
<p>chronic kidney disease</p>
<p><dfn>ACEI:</dfn></p>
<p>angiotensin enzyme inhibitor</p>
<p><dfn>ARB:</dfn></p>
<p>angiotensin II receptor blocker</p>
<p>&nbsp;</p>
<h2 id="Bib1" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">References</h2>
<hr>
<p>&nbsp;</p>
<p>1.<br>
World Health Organization. A global brief on hypertension. 2013. http://www.apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf. Accessed 3 Apr 2013.</p>
<p>2.<br>
Federation ID. IDF Diabetes Atlas. 6th edn. Brussels: International Diabetes Federation. 2013.</p>
<p>3.<br>
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13.<br>
4.<br>
Ago RM, Singh PP, Nesto RW. Diabetes and hypertension. Nat Clin Pract Endocrinol Metab. 2007;3(10):667.<br>
5.<br>
Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053–9.<br>
6.<br>
Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Homan RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9.<br>
7.<br>
Patel BM, Mehta AA. The choice of anti-hypertensive agents in diabetic subjects. Diab Vasc Dis Res. 2013;10(50):385–96.<br>
8.<br>
Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012;14:7–12.<br>
9.<br>
Clark D 3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012;28:318–25.<br>
10.<br>
Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635–42.<br>
11.<br>
Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988–2008. Circulation. 2011;124:1046–58.<br>
12.<br>
Rios MT, Domingues-Sardina M, Ayala DE, Gomara S, Sineiro E, Pousa L, et al. Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Chronobiol Int. 2013;30:207–20.<br>
13.<br>
Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens. 2001;19:353–61.<br>
14.<br>
Gaillard RC. Aldostérone et cœur. Métab Horm Diabètes et Nutr. 2006;10(6):143–52.<br>
15.<br>
Goyal BR, Solanki N, Goyal RK, Mehta AA. Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. J Cardiovasc Pharmacol. 2009;54(6):502–9.<br>
16.<br>
Patel BM, Kakadiya J, Goyal RK, Mehta AA. Effect of spironolactone on cardiovascular complications associated with type-2 diabetes in rats. Exp Clin Endocrinol Diabetes. 2013;121(08):441–7.<br>
17.<br>
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators. N Engl J Med. 1999;341:709–17.<br>
18.<br>
Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS) investigators. N Engl J Med. 2003;348:1309–21.<br>
19.<br>
Organisation Mondiale de la santé. Méthodologie de la recherche dans le domaine de la santé. In: Guide de formation aux méthodes de la recherche scientifique.2e éd. Manille: OMS, 2003.<br>
20.<br>
Turner RC, Holman R, Stratton I, Cull C, Frighi V, Manley S, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type II diabetes: UKPDS38. BMJ. 1998;317:703–13.<br>
21.<br>
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.<br>
22.<br>
Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002;4:221–8.<br>
23.<br>
Levy PS, Lemeshow S. Sampling of populations: methods and applications. 3rd ed. New York: Wiley; 1999.<br>
24.<br>
/DIGO guidelines. Definition and classification. Kidney Int Suppl. 2013;3(1):19–62.<br>
25.<br>
International Diabetes Federation. Global guidelines for type 2 diabetes. 2012. http://www.idf.org. Accessed 15 Jan 2015.<br>
26.<br>
International Diabetes Federation. Managing older people with type 2 diabetes global guidelines. 2013. http://www.idf.org. Accessed 15 Jan 2015.<br>
27.<br>
Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15:333–9.<br>
28.<br>
Nishizaka MK, Zaman MA, Calhoun D. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(1):925–30.<br>
29.<br>
Vacklavick Jan, Sedlack R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) a randomized, double-blind placebo-controlled trial. Hypertens. 2011. doi:10.1161/hypertensionaha.111.169961.<br>
30.<br>
Hase M, Babazono T, Ujihara N, Uchigata Y. Comparison of spironolactone and trichlormethiazide as add-on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients. J Diabetes Invest. 2013;4(3):316–9. doi:10.1111/jdi.12029.<br>
31.<br>
Oxlund CS, Jan Henriksen E, Tarnow L, Schousboe K, Gram J, Jacobsen A. Low dose spironolactone reduces blood pressure inpatients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31:2094–102.<br>
32.<br>
Ni X, Zhang J, Zhang P, Wu F, Xia M, Ying G, et al. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. J Clin Hypertens. 2014;16(9):658–63.<br>
33.<br>
Schohn DC, Pelletier BC. Dose-related cardiovascular effects of spironolactone. Am J Cardiol. 1993;71:40A–5A.<br>
34.<br>
Struthers AD, Unger T. Physiology of aldosterone and pharmacology of aldosterone blockers. Eur Heat J. 2011;13(SB):B27–30.<br>
35.<br>
Makhlough A, Kashi Z, Akha O, Zamboni E, Yazdanicharati J. Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan. Nephro Urol Mon. 2014;6(1):e12148.<br>
36.<br>
Struthers AD. Aldosterone blockade in cardiovascular disease. Heart. 2004;90:1229–34.</p>
<p>&nbsp;</p>
<h2>Source</h2>
<hr>
<p>&nbsp;</p>
<p>https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-016-1987-5</p>
<div id="gtx-trans" style="position: absolute; left: 186px; top: 264.211px;" bis_skin_checked="1">
<div class="gtx-trans-icon" bis_skin_checked="1"></div>
</div>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/01/12/effect-of-low-dose-spironolactone-on-resistant-hypertension-in-type-2-diabetes-mellitus-a-randomized-controlled-trial-in-a-sub-saharan-african-population/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/01/12/effect-of-low-dose-spironolactone-on-resistant-hypertension-in-type-2-diabetes-mellitus-a-randomized-controlled-trial-in-a-sub-saharan-african-population/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5145 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>10.01.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/01/10/the-role-of-trimethoprim-sulfamethoxazole-in-the-treatment-of-infections-caused-by-carbapenem-resistant-enterobacteriaceae/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/01/10/the-role-of-trimethoprim-sulfamethoxazole-in-the-treatment-of-infections-caused-by-carbapenem-resistant-enterobacteriaceae/">The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p>Courtney L Luterbach, Ashley Boshe, Heather I Henderson, Eric Cober, Sandra S Richter, Robert A Salata, Robert C Kalayjian, Richard R Watkins, Andrea M Hujer, Kristine M Hujer, Susan D Rudin, T Nicholas Domitrovic, Yohei Doi, Keith S Kaye, Scott Evans, Vance G Fowler, Jr., Robert A Bonomo, David van Duin<br>
Open Forum Infectious Diseases, Volume 6, Issue 1, January 2019, ofy351, https://doi.org/10.1093/ofid/ofy351</p>
<h2 id="206233120" class="abstract-title">Abstract</h2>
<hr>
<p>&nbsp;</p>
<section class="abstract">
<p class="chapter-para">In the Consortium on Resistance Against Carbapenems in&nbsp;<em>Klebsiella</em>&nbsp;and other&nbsp;<em>Enterobacteriaceae</em>&nbsp;(CRACKLE), trimethoprim-sulfamethoxazole (TMP-SMX) had a limited role in the treatment of less severe carbapenem-resistant&nbsp;<em>Enterobacteriaceae</em>&nbsp;(CRE) infections, especially urinary tract infections. Of tested CRE, only 29% were susceptible to TMP-SMX. Development of resistance further limits the use of TMP-SMX in CRE infections.</p>
</section>
<div class="article-metadata-panel clearfix" bis_skin_checked="1">
<div class="kwd-group" bis_skin_checked="1"><a class="kwd-part kwd-main" data-keyword="&quot;antimicrobial resistance&quot;">Keyword: antimicrobial resistance</a>,&nbsp;<a class="kwd-part kwd-main" data-keyword="&quot;carbapenem-resistant Enterobacteriaceae&quot;">carbapenem-resistant&nbsp;<em>Enterobacteriaceae</em></a>,&nbsp;<a class="kwd-part kwd-main" data-keyword="&quot;Klebsiella pneumonia&quot;"><em>Klebsiella pneumonia</em></a>,&nbsp;<a class="kwd-part kwd-main" data-keyword="trimethoprim-sulfamethoxazole">trimethoprim-sulfamethoxazole</a>,&nbsp;<a class="kwd-part kwd-main" data-keyword="&quot;urinary tract infection&quot;">urinary tract infection</a></div>
<div class="related-topic-tags" bis_skin_checked="1"></div>
<div class="article-metadata-tocSections" bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<p class="chapter-para">The increase in carbapenem-resistant&nbsp;<em>Enterobacteriaceae</em>&nbsp;(CRE) infections is of great concern. CRE cause a broad range of infections in humans, including urinary tract, bloodstream, wound, and respiratory infections. Patients in hospitals, nursing homes, and other health care settings are at an increased risk of developing CRE infections due to weakened immune defenses, dysbiosis, and increased levels of exposure to antimicrobials and other patients harboring multidrug-resistant Gram-negative organisms [<a class="link link-ref link-reveal xref-bibr" data-open="CIT0001">1</a>]. In the first years of the CRE epidemic, treatment options were severely limited and included polymyxins, tigecycline, and aminoglycosides. Recently, ceftazidime-avibactam, meropenem-vaborbactam, and plazomicin have been added as possible treatment choices with superior outcomes and improved tolerability [<a class="link link-ref link-reveal xref-bibr" data-open="CIT0002">2</a>,&nbsp;<a class="link link-ref link-reveal xref-bibr" data-open="CIT0003">3</a>]. Other agents are in the development pipeline [<a class="link link-ref link-reveal xref-bibr" data-open="CIT0002">2</a>]. However, limited ability of laboratories to provide susceptibility testing, high costs, and reports of treatment-emergent resistance have hindered widespread use of new antibiotics [<a class="link link-ref link-reveal xref-bibr" data-open="CIT0004">4</a>].</p>
<p class="chapter-para">Therefore, resistance rates and use of trimethoprim-sulfamethoxazole (TMP-SMX) as a low-cost alternative treatment were evaluated in the Consortium on Resistance Against Carbapenems in&nbsp;<em>Klebsiella</em>&nbsp;and other&nbsp;<em>Enterobacteriaceae</em>&nbsp;(CRACKLE) [<a class="link link-ref link-reveal xref-bibr" data-open="CIT0005">5</a>].</p>
<p>&nbsp;</p>
</div>
<h2 id="206233128" class="section-title" data-legacy-id="s1">METHODS</h2>
<hr>
</div>
<p>&nbsp;</p>
<p>The CRACKLE-1 study has been previously described [<span id="jumplink-CIT0005" class="xrefLink"></span><a class="link link-ref link-reveal xref-bibr" data-open="CIT0005">5</a>]. Briefly, it is a multicenter, prospective observational study of hospitalized patients with CRE involving 18 hospitals located in the Great Lakes region and North Carolina. The 2012 criteria from the Centers for Disease Control and Prevention (CDC) were used to define CRE [<span id="jumplink-CIT0005" class="xrefLink"></span><a class="link link-ref link-reveal xref-bibr" data-open="CIT0005">5</a>]. A nested cohort was created to include unique patients at the time of their first infection caused by CRE and tested for susceptibility to TMP-SMX during the study period from December 24, 2011, until June 30, 2016. For available strains, detection of carbapenemase genes and repetitive extragenic palindromic (rep)–polymerase chain reaction (PCR) strain typing was performed as previously described [<span id="jumplink-CIT0005" class="xrefLink"></span><a class="link link-ref link-reveal xref-bibr" data-open="CIT0005">5</a>]. TMP-SMX in vitro resistance was determined in participating clinical microbiology laboratories and defined per Clinical and Laboratory Standards Institute guidelines as a minimum inhibitory concentration ≥4/76 µg/mL. Pitt Bacteremia score (PBS) and Charlson comorbidity score (CMS) were calculated as previously described [<span id="jumplink-CIT0005" class="xrefLink"></span><a class="link link-ref link-reveal xref-bibr" data-open="CIT0005">5</a>]. Antibiotics given within 7 days of the first positive CRE culture were evaluated. Antibiotics of interest were TMP-SMX, polymyxins, aminoglycosides, tigecycline, carbapenems, fosfomycin, and ceftazidime-avibactam. Statistical analyses were performed using R, version 3.5.0 (R Foundation for Statistical Computing) [<span id="jumplink-CIT0006" class="xrefLink"></span><a class="link link-ref link-reveal xref-bibr" data-open="CIT0006">6</a>].</p>
<p>&nbsp;</p>
<h2 id="206233132" class="section-title" data-legacy-id="s2">RESULTS</h2>
<hr>
<p>&nbsp;</p>
<p class="chapter-para">During the study period, 476 unique patients were infected with a CRE tested for susceptibility to TMP-SMX. Of these CRE, 138 (29%) were susceptible to TMP-SMX (<span id="jumplink-T1" class="xrefLink"></span><a class="link link-reveal link-table xref-fig" data-open="T1">Table 1</a>). The baseline characteristics of patients with CRE infection caused by a TMP-SMX-susceptible isolate were similar to those of patients with TMP-SMX-resistant CRE. Similarly, no differences were seen between the 2 groups in chronic comorbidities, acute illness, or infection types. Common infection types included urinary tract infection (UTI; 32%), bacteremia (24%), and pneumonia (22%). TMP-SMX-susceptible isolates were more likely to be non–<em>Klebsiella pneumoniae</em>&nbsp;CRE species. Overall, 255/276 (92%) of tested CRE were positive for at least 1 carbapenemase gene, which predominantly were&nbsp;<em>bla</em><sub>KPC-2</sub>&nbsp;(45%) and&nbsp;<em>bla</em><sub>KPC-3</sub> (45%).</p>
<div class="table-modal table-full-width-wrap" bis_skin_checked="1">
<div class="table-wrap table-wide" bis_skin_checked="1">
<div class="table-wrap-foot" bis_skin_checked="1">
<p>&nbsp;</p>
<div bis_skin_checked="1">
<p class="chapter-para">Table 1.</p>
</div>
</div>
</div>
</div>
<div class="table-full-width-wrap" bis_skin_checked="1">
<div class="table-wrap table-wide" bis_skin_checked="1">
<div id="T1" class="table-wrap-title" data-id="T1" bis_skin_checked="1">
<div class="caption" bis_skin_checked="1">
<p class="chapter-para">Characteristics of Patients Infected With Carbapenem-Resistant&nbsp;<em>Enterobacteriaceae</em>&nbsp;Compared by Susceptibility to Trimethoprim- Sulfamethoxazole</p>
</div>
<table>
<thead>
<tr>
<th>All</th>
<th>TMP-SMX Resistant</th>
<th>TMP-SMX Susceptible</th>
<th><em>P</em><sup>a</sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>476</td>
<td>338 (71)</td>
<td>138 (29)</td>
<td></td>
</tr>
<tr>
<td>Female sex</td>
<td>244 (51)</td>
<td>173 (51)</td>
<td>71 (51)</td>
<td>1.0</td>
</tr>
<tr>
<td>Age, median (IQR), y</td>
<td>65 (53–76)</td>
<td>65 (54–75)</td>
<td>64 (50–76)</td>
<td>.840</td>
</tr>
<tr>
<td>Charlson score, median (IQR)</td>
<td>3 (1–5)</td>
<td>3 (2–5)</td>
<td>3 (1–5)</td>
<td>.273</td>
</tr>
<tr>
<td>Pitt bacteremia score, median (IQR)</td>
<td>3 (1–4)</td>
<td>3 (1–4)</td>
<td>3 (2–4)</td>
<td>.605</td>
</tr>
<tr>
<td>Length of stay, median (IQR), d</td>
<td>13 (7–28)</td>
<td>13 (7–30)</td>
<td>13 (6–24)</td>
<td>.759</td>
</tr>
<tr>
<td>30-d hospital mortality</td>
<td>81 (17)</td>
<td>62 (18)</td>
<td>19 (14)</td>
<td>.282</td>
</tr>
<tr>
<td><em>Klebsiella pneumoniae</em></td>
<td>464 (97)</td>
<td>335 (99)</td>
<td>129 (93)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Carbapenemase present/tested<sup>b</sup></td>
<td>255/276 (92)</td>
<td>176/193 (91)</td>
<td>79/83 (95)</td>
<td>.326</td>
</tr>
<tr>
<td>Infection type</td>
<td></td>
<td></td>
<td></td>
<td>.695</td>
</tr>
<tr>
<td>Bacteremia</td>
<td>116 (24)</td>
<td>84 (25)</td>
<td>32 (23)</td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>105 (22)</td>
<td>76 (22)</td>
<td>29 (21)</td>
<td></td>
</tr>
<tr>
<td>Urinary tract</td>
<td>152 (32)</td>
<td>105 (31)</td>
<td>47 (34)</td>
<td></td>
</tr>
<tr>
<td>Wound</td>
<td>65 (14)</td>
<td>49 (15)</td>
<td>16 (12)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>38 (8)</td>
<td>24 (7)</td>
<td>14 (10)</td>
<td></td>
</tr>
</tbody>
</table>
</div>
<div bis_skin_checked="1">
<p class="chapter-para">Abbreviations: IQR, interquartile range; TMX-SMP, trimethoprim-sulfamethoxazole.</p>
</div>
<div bis_skin_checked="1">
<p class="chapter-para"><sup>a</sup>Compared by Fisher exact test for proportions, Pearson’s chi-squared test for distributions, and median test for medians.</p>
</div>
<div bis_skin_checked="1">
<p class="chapter-para"><sup>b</sup>Most common carbapenemase genes detected were&nbsp;<em>bla</em><sub>KPC-2</sub>&nbsp;(45%) and&nbsp;<em>bla</em><sub>KPC-3</sub>&nbsp;(45%).</p>
</div>
</div>
</div>
<p>&nbsp;</p>
<p class="chapter-para">In the group of patients with a TMP-SMX-susceptible isolate, 110/138 (80%) received at least 1 antibiotic of interest within 7 days of first positive culture. TMP-SMX was part of the treatment regimen in 22/110 (20%) patients and was used as monotherapy treatment in 12/110 (11%) patients. Other commonly used antibiotics in this group included carbapenems (45%), tigecycline (41%), aminoglycosides (36%), and colistin (21%). Among patients who received TMP-SMX monotherapy, 7 (58%) had UTIs, 3 (25%) had bacteremia, and 2 (17%) had other CRE infections; 11 (92%) were infected with CRKp, and 1 (8%) had an&nbsp;<em>Enterobacter</em>&nbsp;species. As compared with patients who received other therapy (n = 88), those treated with TMP-SMX monotherapy (n = 12) or a TMP-SMX-containing combination regimen (n = 10) had similar comorbid conditions (median Charlson score [interquartile range {IQR}], 3 [1–5] vs 2 [2–5] and 2.5 [1–6];&nbsp;<em>P</em>&nbsp;= .80) but were substantially less acutely ill (median Pitt bacteremia score [IQR], 4 [2–4] vs 2 [0–3] and 2 [2–3];&nbsp;<em>P</em>&nbsp;= .01). For TMP-SMX-susceptible CRE infections, all-cause 30-day in-hospital mortality in patients treated with TMP-SMX monotherapy or a TMP-SMX-containing combination regimen was similar to patients who did not receive TMP-SMX: 1/12 (8%), 0/10 (0%), and 17/88 (19%;&nbsp;<em>P</em>&nbsp;= .214).</p>
<p class="chapter-para">We evaluated subsequent resistance development in those patients who presented with initially susceptible TMP-SMX CRE and who later presented with another positive CRE culture. Resistance was observed in 3/4 patients (75%) treated with TMP-SMX who had a subsequent CRE culture at a later date. These 4 patients all received TMP-SMX monotherapy. None of the 10 patients who received TMP-SMX as part of combination therapy had subsequent CRE cultures. In 1 of 3 of these patients, the TMP-SMX-resistant isolate represented a different strain. In the other 2 patients, strain type by rep-PCR and carbapenemase type were identical in the TMP-SMX-susceptible index strain and the subsequent TMP-SMX-resistant strain. In comparison, subsequent TMP-SMX resistance was observed in 13/29 patients (45%) who were treated with other antibiotics (<em>P</em>&nbsp;= .335). Paired strains were available for 3/13 (23%) in this group, of which all were identical by rep-PCR and carbapenemase type.</p>
<p>&nbsp;</p>
<h2 id="206233142" class="section-title" data-legacy-id="s3">DISCUSSION</h2>
<hr>
<p>&nbsp;</p>
<p class="chapter-para">In this study, we investigated the use of TMP-SMX in the treatment of CRE infections in hospitalized patients. TMP-SMX has demonstrated activity against multiple&nbsp;<em>Enterobacteriaceae</em>&nbsp;species and in some cases may be one of the few remaining treatment options for bacteria resistant to other antibiotic classes. However, increasing global levels of antibiotic resistance to TMP-SMX has limited the broad use of this antibiotic. Overall, we found that more than two-thirds of tested CRE isolates were already resistant to TMP-SMX. Carbapenem-resistant&nbsp;<em>K. pneumoniae</em>&nbsp;(CRKp) makes up the majority of collected isolates in the CRACKLE-1 data set. In vitro susceptibility rates of CRKp to TMP-SMX reported in the literature are highly variable and dependent on region of the world, varying between 31% and 82% [<span id="jumplink-CIT0007 CIT0008 CIT0009" class="xrefLink"></span><a class="link link-ref link-reveal xref-bibr" data-open="CIT0007 CIT0008 CIT0009">7–9</a>].</p>
<p class="chapter-para">In our cohort, TMP-SMX was infrequently used, even in those patients with TMP-SMX-susceptible isolates. A case series from Rome describes 14 patients with KPC-producing CRKp infections treated with TMP-SMX, of whom 10 received monotherapy [<span id="jumplink-CIT0010" class="xrefLink"></span><a class="link link-ref link-reveal xref-bibr" data-open="CIT0010">10</a>]. In that report, clinical cure was achieved in 13/14 cases, and 1/14 patients died within 30 days. However, no controls were provided.</p>
<p class="chapter-para">In 3 of 4 patients who received TMP-SMX treatment during their initial CRE infection, subsequent CRE isolates were found to be resistant to TMP-SMX. Treatment-emergent resistance is an important issue for all antibiotics used in the treatment of CRE, including ceftazidime-avibactam and tigecycline [<span id="jumplink-CIT0004" class="xrefLink"></span><a class="link link-ref link-reveal xref-bibr" data-open="CIT0004">4</a>,&nbsp;<span id="jumplink-CIT0011" class="xrefLink"></span><a class="link link-ref link-reveal xref-bibr" data-open="CIT0011">11</a>].</p>
<p class="chapter-para">This study has a number of limitations. CRACKLE is an observational study; therefore, patients were not randomly assigned to different antibiotic treatments. Given the small sample size, we did not adjust for confounding by indication. We explicitly do not aim to provide comparative hypothesis testing analysis of TMP-SMX vs alternative treatments for CRE infections. However, we aim to provide guidance for clinicians by describing the experience with TMP-SMX as a therapeutic option in difficult-to-treat CRE infections.</p>
<p class="chapter-para">In summary, TMP-SMX resistance rates in CRE were high at baseline and increased after treatment. TMP-SMX was an infrequent treatment choice but may be used in highly selected, clinically stable patients with TMP-SMX-susceptible CRE in the urinary tract.</p>
<p class="chapter-para"><strong>Prior presentation.&nbsp;</strong>Preliminary results from this study were presented at ASM Microbe; June 1–5, 2017; New Orleans, LA.</p>
<p>&nbsp;</p>
<h2 id="206233158" class="backacknowledgements-title" data-legacy-id="ack1">Acknowledgments</h2>
<hr>
<p>&nbsp;</p>
<p class="chapter-para"><strong><em>Disclaimer. </em></strong>The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs.</p>
<p class="chapter-para"><strong><em>Financial support. </em></strong>This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award numbers UM1AI104681 and R21AI114508, by funding to D.V.D. and F.P. from the Clinical and Translational Science Collaborative of Cleveland, and by award number UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the NIH and NIH roadmap for Medical Research. V.G.F. was supported by the Mid-Career Mentoring Award K24-AI093969 from the NIH. In addition, research reported in this publication was supported in part by the National Institute of Allergy and Infectious Diseases of the NIH under award numbers R21AI114508 (D.v.D. and R.A.B.), R01AI100560 (R.A.B.), R01AI063517 (R.A.B.), and R01AI072219 (R.A.B.). This study was supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, award number 1I01BX001974 to R.A.B. from the Biomedical Laboratory Research &amp; Development Service of the VA Office of Research and Development, and the Geriatric Research Education and Clinical Center VISN 10 (R.A.B.). Further support came from the Research Program Committees of the Cleveland Clinic (D.V.D.) and an unrestricted research grant from the STERIS Corporation (D.V.D.). Y.D. was supported by research awards R01AI104895, R21AI123747, and R21AI135522 from the NIH. K.S.K. was supported by the National Institute of Allergy and Infectious Diseases (Division of Microbiology and Infectious Diseases protocol 10–0065 and R01AI119446-01).</p>
<p class="chapter-para"><strong><em>Potential conflicts of interest. </em></strong>S.S.R: research support from bioMerieux, BD Diagnostics, Roche, Hologic, Diasorin. Y.D.: grant support from Accelerate Diagnostics, NIH; advisory board: Tetraphase, Roche, Geom. K.K: consultant, grant investigator, speaker’s bureau, consulting fee, grant recipient, and speaker honorarium from Allergan; grant recipient, consultant for Merck; consultant for Xellia; consultant for Achaogen. R.R.W.: grant support from Allergan. R.A.B.: grant/research support from Achaogen, Allecra, Entasis, Merck, Roche, Shionogi, Wockhardt. V.G.F.: grant/research support from Advanced Liquid Logic, Cubist, Cerexa, MedImmune, Merck, NIH, Novartis, Pfizer, Theravance; paid consultant for Affinium, Baxter, Cerexa, Cubist, Debiopharm, Durata, Merck, Novartis, NovaDigm, The Medicines Company, MedImmune, Pfizer, Theravance, Trius; honoraria from Arpida, Astellas, Cubist, Inhibitex, Merck, Pfizer, Targanta, Theravance, Wyeth, Ortho-McNeil, Novartis, Vertex Pharmaceuticals; memberships in Merck Co-Chair V710 Vaccine. D.v.D.: advisory board for Actavis, Tetraphase, Sanofi-Pasteur, MedImmune, Astellas, Merck, Allergan, T2Biosystems, Roche, Achaogen, Neumedicine, Shionogi. Research funding from Scynexis and Steris Inc. No conflicts of interest: C.L.L., A.B., H.I.H., E.C., R.A.S., R.C.K., A.M.H., K.M.H., S.D.R., T.N.D., and S.E. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p>
<p>&nbsp;</p>
<h2 id="206233162" class="backreferences-title" data-legacy-id="rl1">References</h2>
<hr>
<p>&nbsp;</p>
<p>1. Nordmann P , Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis2009; 9:228–36.<br>
Google ScholarCrossrefPubMed<br>
2. Petty LA , Henig O, Patel TS, et al. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect Drug Resist2018; 11:1461–72.<br>
Google ScholarCrossrefPubMed<br>
3. van Duin D , Lok JJ, Earley M, et al. ; Antibacterial Resistance Leadership Group. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis2018; 66:163–71.<br>
Google ScholarCrossrefPubMed<br>
4. Shields RK , Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother2016; 61(3).<br>
Google Scholar<br>
5. van Duin D , Perez F, Rudin SD, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother2014; 58:4035–41.<br>
Google ScholarCrossrefPubMed<br>
6. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2018.<br>
Google Scholar<br>
7. Pouch SM , Kubin CJ, Satlin MJ, et al. Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients. Transpl Infect Dis2015; 17:800–9.<br>
Google ScholarCrossrefPubMed<br>
8. Lombardi F , Gaia P, Valaperta R, et al. Emergence of carbapenem-resistant Klebsiella pneumoniae: progressive spread and four-year period of observation in a cardiac surgery division. Biomed Res Int2015; 2015:871947.<br>
Google ScholarPubMed<br>
9. Shawky SM , Abdallah A, Khouly M. Antimicrobial activity of colistin and tigecycline against carbapenem-resistant Klebsiella pneumoniae clinical isolates in Alexandria, Egypt. Int J Curr Microbiol Appl Sci2015; 4:731–742.<br>
Google Scholar<br>
10. Murri R , Fiori B, Spanu T, et al. Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series. Infection2017; 45:209–13.<br>
Google ScholarCrossrefPubMed<br>
11. van Duin D , Cober ED, Richter SS, et al. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect2014; 20:O1117–20.<br>
Google ScholarCrossrefPubMed<br>
© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</p>
<p>&nbsp;</p>
<h2>Source</h2>
<hr>
<p>&nbsp;</p>
<p><a href="https://academic.oup.com/ofid/article/6/1/ofy351/5250079">https://academic.oup.com/ofid/article/6/1/ofy351/5250079</a></p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/01/10/the-role-of-trimethoprim-sulfamethoxazole-in-the-treatment-of-infections-caused-by-carbapenem-resistant-enterobacteriaceae/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/01/10/the-role-of-trimethoprim-sulfamethoxazole-in-the-treatment-of-infections-caused-by-carbapenem-resistant-enterobacteriaceae/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5138 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>06.01.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/01/06/trimethoprim-use-for-urinary-tract-infection-and-risk-of-adverse-outcomes-in-older-patients-cohort-study/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/01/06/trimethoprim-use-for-urinary-tract-infection-and-risk-of-adverse-outcomes-in-older-patients-cohort-study/">Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p><span class="highwire-cite-journal">BMJ</span>&nbsp;<span class="highwire-cite-published-year">2018</span>;&nbsp;<span class="highwire-cite-volume-issue">360</span>&nbsp;<span class="highwire-cite-doi">doi:&nbsp;https://doi.org/10.1136/bmj.k341</span>&nbsp;<span class="highwire-cite-date">(Published 09 February 2018)</span><span class="highwire-cite-article-as">Cite this as:&nbsp;<span class="italic">BMJ</span>&nbsp;2018;360:k341</span></p>
<ol id="contrib-group-1" class="contributor-list">
<li id="contrib-1" class="contributor"><span class="name">Elizabeth Crellin</span><span class="contrib-role">, research assistant</span>1,</li>
<li id="contrib-2" class="contributor"><span class="name">Kathryn E Mansfield</span><span class="contrib-role">, research fellow</span>1,</li>
<li id="contrib-3" class="contributor"><span class="name">Clémence Leyrat</span><span class="contrib-role">, research fellow</span>2,</li>
<li id="contrib-4" class="contributor"><span class="name">Dorothea Nitsch</span><span class="contrib-role">, professor</span>1,</li>
<li id="contrib-5" class="contributor"><span class="name">Ian J Douglas</span><span class="contrib-role">, associate professor</span>1,</li>
<li id="contrib-6" class="contributor"><span class="name">Adrian Root</span><span class="contrib-role">, research fellow</span>1,</li>
<li id="contrib-7" class="contributor"><span class="name">Elizabeth Williamson</span><span class="contrib-role">, associate professor</span>2,</li>
<li id="contrib-8" class="contributor"><span class="name">Liam Smeeth</span><span class="contrib-role">, professor</span>1,</li>
<li id="contrib-9" class="last"><span class="name">Laurie A Tomlinson</span><span class="contrib-role">, associate professor</span>1</li>
</ol>
<p>&nbsp;</p>
<h2 class="">Abstract</h2>
<hr>
<p>&nbsp;</p>
<div id="sec-1" class="subsection" bis_skin_checked="1">
<p id="p-2"><strong>Objective</strong>&nbsp;To determine if trimethoprim use for urinary tract infection (UTI) is associated with an increased risk of acute kidney injury, hyperkalaemia, or sudden death in the general population.</p>
</div>
<div id="sec-2" class="subsection" bis_skin_checked="1">
<p id="p-3"><strong>Design</strong>&nbsp;Cohort study.</p>
</div>
<div id="sec-3" class="subsection" bis_skin_checked="1">
<p id="p-4"><strong>Setting</strong>&nbsp;UK electronic primary care records from practices contributing to the Clinical Practice Research Datalink linked to the Hospital Episode Statistics database.</p>
</div>
<div id="sec-4" class="subsection" bis_skin_checked="1">
<p id="p-5"><strong>Participants</strong>&nbsp;Adults aged 65 and over with a prescription for trimethoprim, amoxicillin, cefalexin, ciprofloxacin, or nitrofurantoin prescribed up to three days after a primary care diagnosis of UTI between April 1997 and September 2015.</p>
</div>
<div id="sec-5" class="subsection" bis_skin_checked="1">
<p id="p-6"><strong>Main outcome measures</strong>&nbsp;The outcomes were acute kidney injury, hyperkalaemia, and death within 14 days of a UTI treated with antibiotics.</p>
</div>
<div id="sec-6" class="subsection" bis_skin_checked="1">
<p id="p-7"><strong>Results</strong>&nbsp;Among a cohort of 1 191 905 patients aged 65 and over, 178 238 individuals were identified with at least one UTI treated with antibiotics, comprising a total of 422 514 episodes of UTIs treated with antibiotics. The odds of acute kidney injury in the 14 days following antibiotic initiation were higher following trimethoprim (adjusted odds ratio 1.72, 95% confidence interval 1.31 to 2.24) and ciprofloxacin (1.48, 1.03 to 2.13) compared with amoxicillin. The odds of hyperkalaemia in the 14 days following antibiotic initiation were only higher following trimethoprim (2.27, 1.49 to 3.45) compared with amoxicillin. However, the odds of death within the 14 days following antibiotic initiation were not higher with trimethoprim than with amoxicillin: in the whole population the adjusted odds ratio was 0.90 (95% confidence interval 0.76 to 1.07) while among users of renin-angiotensin system blockers the odds of death within 14 days of antibiotic initiation was 1.12 (0.80 to 1.57). The results suggest that, for 1000 UTIs treated with antibiotics among people 65 and over, treatment with trimethoprim instead of amoxicillin would result in one to two additional cases of hyperkalaemia and two admissions with acute kidney injury, regardless of renin-angiotensin system blockade. However, for people taking renin-angiotensin system blockers and spironolactone treatment with trimethoprim instead of amoxicillin there were 18 additional cases of hyperkalaemia and 11 admissions with acute kidney injury.</p>
</div>
<div id="sec-7" class="subsection" bis_skin_checked="1">
<p id="p-8"><strong>Conclusion</strong> Trimethoprim is associated with a greater risk of acute kidney injury and hyperkalaemia compared with other antibiotics used to treat UTIs, but not a greater risk of death. The relative risk increase is similar across population groups, but the higher baseline risk among those taking renin-angiotensin system blockers and potassium-sparing diuretics translates into higher absolute risks of acute kidney injury and hyperkalaemia in these groups.</p>
</div>
<div class="row" bis_skin_checked="1">
<div class="left-content col-xs-12 col-sm-8 col-md-8 col-lg-8" bis_skin_checked="1">
<article>
<div class="panel-pane pane-highwire-article-citation" bis_skin_checked="1">
<div class="pane-content" bis_skin_checked="1">
<div id="node961049" class="highwire-article-citation highwire-citation-type-highwire-article" data-node-nid="961049" data-pisa="bmj;360/feb09_5/k341" data-pisa-master="bmj;bmj.k341" data-apath="/bmj/360/bmj.k341.atom" bis_skin_checked="1"><strong>Conclusion</strong> Trimethoprim is associated with a greater risk of acute kidney injury and hyperkalaemia compared with other antibiotics used to treat UTIs, but not a greater risk of death. The relative risk increase is similar across population groups, but the higher baseline risk among those taking renin-angiotensin system blockers and potassium-sparing diuretics translates into higher absolute risks of acute kidney injury and hyperkalaemia in these groups.</div>
<div data-node-nid="961049" data-pisa="bmj;360/feb09_5/k341" data-pisa-master="bmj;bmj.k341" data-apath="/bmj/360/bmj.k341.atom" bis_skin_checked="1"></div>
</div>
</div>
<div class="panel-pane pane-highwire-panel-tabs-container" bis_skin_checked="1">
<div class="pane-content" bis_skin_checked="1">
<div id="panels-ajax-tab-container-highwire_article_tabs" class="panels-ajax-tab-container" data-panels-ajax-tab-preloaded="jnl_bmj_tab_art" bis_skin_checked="1">
<div class="panels-ajax-tab-wrap-jnl_bmj_tab_art" bis_skin_checked="1">
<div class="panel-display panel-1col clearfix" bis_skin_checked="1">
<div class="panel-panel panel-col" bis_skin_checked="1">
<div bis_skin_checked="1">
<div class="panel-pane pane-highwire-markup" bis_skin_checked="1">
<div class="pane-content" bis_skin_checked="1">
<div class="highwire-markup" bis_skin_checked="1">
<div id="content-block-markup" data-highwire-cite-ref-tooltip-instance="highwire_reflinks_tooltip" bis_skin_checked="1">
<div class="article fulltext-view " bis_skin_checked="1">
<div id="abstract-1" class="section abstract" bis_skin_checked="1">
<h2 class="">Abstract</h2>
<div id="sec-1" class="subsection" bis_skin_checked="1">
<p id="p-2"><strong>Objective</strong>&nbsp;To determine if trimethoprim use for urinary tract infection (UTI) is associated with an increased risk of acute kidney injury, hyperkalaemia, or sudden death in the general population.</p>
</div>
<div id="sec-2" class="subsection" bis_skin_checked="1">
<p id="p-3"><strong>Design</strong>&nbsp;Cohort study.</p>
</div>
<div id="sec-3" class="subsection" bis_skin_checked="1">
<p id="p-4"><strong>Setting</strong>&nbsp;UK electronic primary care records from practices contributing to the Clinical Practice Research Datalink linked to the Hospital Episode Statistics database.</p>
</div>
<div id="sec-4" class="subsection" bis_skin_checked="1">
<p id="p-5"><strong>Participants</strong>&nbsp;Adults aged 65 and over with a prescription for trimethoprim, amoxicillin, cefalexin, ciprofloxacin, or nitrofurantoin prescribed up to three days after a primary care diagnosis of UTI between April 1997 and September 2015.</p>
</div>
<div id="sec-5" class="subsection" bis_skin_checked="1">
<p id="p-6"><strong>Main outcome measures</strong>&nbsp;The outcomes were acute kidney injury, hyperkalaemia, and death within 14 days of a UTI treated with antibiotics.</p>
</div>
<div id="sec-6" class="subsection" bis_skin_checked="1">
<p id="p-7"><strong>Results</strong>&nbsp;Among a cohort of 1 191 905 patients aged 65 and over, 178 238 individuals were identified with at least one UTI treated with antibiotics, comprising a total of 422 514 episodes of UTIs treated with antibiotics. The odds of acute kidney injury in the 14 days following antibiotic initiation were higher following trimethoprim (adjusted odds ratio 1.72, 95% confidence interval 1.31 to 2.24) and ciprofloxacin (1.48, 1.03 to 2.13) compared with amoxicillin. The odds of hyperkalaemia in the 14 days following antibiotic initiation were only higher following trimethoprim (2.27, 1.49 to 3.45) compared with amoxicillin. However, the odds of death within the 14 days following antibiotic initiation were not higher with trimethoprim than with amoxicillin: in the whole population the adjusted odds ratio was 0.90 (95% confidence interval 0.76 to 1.07) while among users of renin-angiotensin system blockers the odds of death within 14 days of antibiotic initiation was 1.12 (0.80 to 1.57). The results suggest that, for 1000 UTIs treated with antibiotics among people 65 and over, treatment with trimethoprim instead of amoxicillin would result in one to two additional cases of hyperkalaemia and two admissions with acute kidney injury, regardless of renin-angiotensin system blockade. However, for people taking renin-angiotensin system blockers and spironolactone treatment with trimethoprim instead of amoxicillin there were 18 additional cases of hyperkalaemia and 11 admissions with acute kidney injury.</p>
</div>
<div id="sec-7" class="subsection" bis_skin_checked="1">
<p id="p-8"><strong>Conclusion</strong>&nbsp;Trimethoprim is associated with a greater risk of acute kidney injury and hyperkalaemia compared with other antibiotics used to treat UTIs, but not a greater risk of death. The relative risk increase is similar across population groups, but the higher baseline risk among those taking renin-angiotensin system blockers and potassium-sparing diuretics translates into higher absolute risks of acute kidney injury and hyperkalaemia in these groups.</p>
</div>
</div>
<div id="sec-8" class="section intro" bis_skin_checked="1">
<h2 class="">Introduction</h2>
<hr>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</article>
</div>
</div>
<p>&nbsp;</p>
<p id="p-9">Co-trimoxazole is a combination antibiotic drug containing trimethoprim and sulfamethoxazole, prescribed for multiple indications and is the fourth most commonly prescribed antibiotic in the USA.<a id="xref-ref-1-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-1">1</a>&nbsp;Its use has been associated with an increased risk of sudden death among people taking renin-angiotensin system blockers.<a id="xref-ref-2-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-2">2</a><a id="xref-ref-3-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-3">3</a>&nbsp;This may be owing to acute kidney injury, a rapid deterioration in kidney function.<a id="xref-ref-4-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-4">4</a>&nbsp;Alternately, co-trimoxazole and trimethoprim alone have both been associated with an increased risk of an acute rise in potassium levels, hyperkalaemia, which can cause fatal cardiac arrhythmias.<a id="xref-ref-3-2" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-3">3</a><a id="xref-ref-5-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-5">5</a><a id="xref-ref-6-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-6">6</a><a id="xref-ref-7-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-7">7</a><a id="xref-ref-8-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-8">8</a></p>
<p id="p-10">Existing evidence has important limitations. It is not clear if the association between co-trimoxazole and adverse outcomes is owing to the sulfamethoxazole or the trimethoprim component. The observed association may be owing to confounding if the combination antibiotic was used for patients with more severe infections than the antibiotics it was compared with. Finally, existing evidence is primarily associated with specific groups of patients such as those taking renin-angiotensin system blockers. In the UK, co-trimoxazole is licensed for specific, uncommon indications and trimethoprim is more commonly used. However, there are efforts to reduce trimethoprim prescribing due to increasing antimicrobial resistance.<a id="xref-ref-9-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-9">9</a>&nbsp;In 2015 over 3.7 million prescriptions for trimethoprim were dispensed in England and it remains a first line option for treatment of uncomplicated urinary tract infections (UTIs).<a id="xref-ref-10-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-10">10</a>&nbsp;Despite this, whether trimethoprim alone is linked to sudden death both in the general population and in high risk groups is unknown.</p>
<p id="p-11">Our study therefore aimed to investigate the association between trimethoprim and acute kidney injury, hyperkalaemia, or sudden death in a cohort of patients aged 65 and over. To limit confounding by antibiotic indication we restricted our analysis to patients with an antibiotic prescription for the same indication (UTI) and examined the risk of adverse outcomes in patients prescribed trimethoprim and four comparison antibiotics (amoxicillin, cefalexin, ciprofloxacin, and nitrofurantoin). However, even when treatment is restricted to the same indication, different classes of antibiotic drugs are prescribed in slightly different clinical scenarios. For simple UTIs in adults, current UK guidelines recommend nitrofurantoin as the first line treatment (except for patients with poor renal function) and trimethoprim as a first line alternative where there is low risk of microbial resistance.<a id="xref-ref-11-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-11">11</a>&nbsp;Ciprofloxacin and cefalexin are not currently recommended treatments for simple UTIs (although ciprofloxacin is a first line option for pyelonephritis) but are used for patients with resistance to first line antibiotics. In addition, ciprofloxacin and cefalexin were used in practice as treatment for simple UTIs during the years covered by this study.<a id="xref-ref-12-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-12">12</a>&nbsp;We aimed to address the impact of these different usage patterns on the outcomes through adjustment for a range of comorbidities and sensitivity analyses.</p>
<p>&nbsp;</p>
<h2 class="">Methods</h2>
<hr>
<p>&nbsp;</p>
<div id="sec-10" class="subsection" bis_skin_checked="1">
<h3>Study design and setting</h3>
<p id="p-12">We undertook a cohort study using electronic clinical records from adults attending primary care practices contributing to the UK Clinical Practice Research Datalink (CPRD GOLD) and linked hospital record data from the Hospital Episode Statistics (HES) database. CPRD is a database of primary care electronic health record data from participating general practices, covering 7% of the UK population.<a id="xref-ref-13-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-13">13</a>&nbsp;Included patients are largely representative of the UK population in terms of age, sex, ethnicity, and body mass index.<a id="xref-ref-13-2" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-13">13</a><a id="xref-ref-14-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-14">14</a><a id="xref-ref-15-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-15">15</a>&nbsp;HES records cover all admissions for National Health Service (NHS) funded patients treated in either English NHS trusts or by independent providers.<a id="xref-ref-16-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-16">16</a>&nbsp;Seventy-five percent of English general practices included in CPRD are linked to HES data.<a id="xref-ref-13-3" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-13">13</a>&nbsp;The study period was from 1 April 1997 to 30 September 2015 (the period covered by HES data linkage to CPRD).</p>
</div>
<div id="sec-11" class="subsection" bis_skin_checked="1">
<h3>Participants, exposures, and outcomes</h3>
<p id="p-13">We identified all adults aged 65 years and over during the study period (April 1997 to September 2015). We chose an older population as this is a clinically important group at high risk of adverse health outcomes. In addition, they are more likely to be well monitored, enabling reliable recording of comorbidities and quantification of baseline renal function.</p>
<p id="p-14">Individuals were eligible for the study by receiving a prescription for an antibiotic for a urinary tract infection (UTI) after the latest of the following: 65th birthday; date practice reached CPRD quality control standards (to ensure data quality); or one year after practice registration date (to ensure that we had reliable measures of incident morbidity). Patients were no longer eligible to be included from the earliest of the following: date of death; left practice; or last data collection from practice. We excluded patients who developed end stage renal disease before they were eligible for inclusion.<a id="xref-ref-17-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-17">17</a></p>
<div id="sec-12" class="subsection" bis_skin_checked="1">
<h4>Exposures</h4>
<p id="p-15">The date of inclusion was the day of initiation for any of five antibiotic drugs (trimethoprim, amoxicillin, cefalexin, ciprofloxacin, and nitrofurantoin) recorded up to three days after a primary care morbidity code for uncomplicated UTI (ie, excluding more severe conditions such as pyelonephritis). We allowed a gap of three days between UTI diagnosis and treatment with an antibiotic to allow for delays between microbiological diagnosis and treatment. To ensure reliable measures of antibiotic exposure, we excluded any UTI episodes treated with antibiotics where two or more of the study antibiotics were prescribed on the same day. We excluded prescriptions for co-trimoxazole and did not include patients treated with co-amoxiclav in the amoxicillin comparison group as in the UK these drugs are prescribed for more severe or atypical UTIs. We also excluded any UTI episodes where a patient received one or more of the five study antibiotics in the 14 days before the UTI record to ensure that we were identifying the first consultation for an episode of UTI. Finally, we excluded any UTI episodes where a code for a non-UTI infection was recorded in the three days before antibiotic prescription.</p>
</div>
<div id="sec-13" class="subsection" bis_skin_checked="1">
<h4>Outcomes</h4>
<p id="p-16">We investigated the outcomes acute kidney injury, hyperkalaemia, and death recorded within 14 days of antibiotic initiation for UTI. Acute kidney injury was defined as hospital admission with acute kidney injury using ICD-10 (international classification of diseases, 10th revision) codes recorded in any diagnostic position of any inpatient episode starting within 14 days of antibiotic initiation.<a id="xref-ref-17-2" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-17">17</a><a id="xref-ref-18-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-18">18</a>&nbsp;Hyperkalaemia was identified in the 14 days after antibiotic initiation using morbidity coding in primary (Read codes) or secondary (ICD-10 codes) care, or a potassium level of 6 mmol/L or more recorded in primary care. Death was identified as the earliest record of death from Read codes in CPRD, CPRD defined death date, ICD-10 codes in HES, and the Office for National Statistics date of death.</p>
<p id="p-17">All morbidity code lists are available to download,<a id="xref-ref-19-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-19">19</a>&nbsp;and were either developed for use in other studies, or were developed in a consensus procedure by two authors with clinical experience in the NHS.</p>
</div>
</div>
<div id="sec-14" class="subsection" bis_skin_checked="1">
<h3>Covariates</h3>
<p id="p-18">Based on a priori knowledge, we considered the following variables as potential confounders of the relation between trimethoprim and acute kidney injury, hyperkalaemia, or sudden death: sex, age, calendar period, chronic comorbidities, history of renal or urological disease, baseline renal function, prescription for renin-angiotensin system blockers (including angiotensin converting enzyme inhibitors and angiotensin receptor blockers) or potassium-sparing diuretics, lifestyle factors (smoking, alcohol intake, and body mass index), ethnicity, and socioeconomic status. All covariates other than sex and ethnicity were updated over time.</p>
<p id="p-19">Age group was defined in the following bands at time of antibiotic initiation: 65–69; 70–74; 75–79; 80–84; and 85 and over.</p>
<p id="p-20">We included calendar period (1997–2000, 2001–04, 2005–08, 2009–11, and 2012–15) as a covariate to adjust for the many changes in clinical, diagnostic, and administrative practices over the study period that may influence the choice of antibiotic treatment for UTI, the measurement of renal function, and registration of outcomes.</p>
<p id="p-21">Chronic comorbidities included as confounders were diabetes mellitus, ischaemic heart disease, cardiac failure, arrhythmia, and hypertension, identified from both primary care and hospital data. Individuals were considered to have a specific comorbidity if they had a code recorded in their electronic health records before a UTI episode treated with antibiotics.</p>
<p id="p-22">Baseline renal function was defined using the most recent biochemical test results recorded in primary care at any time before each UTI treated with antibiotics. We used serum creatinine test results to calculate estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.<a id="xref-ref-20-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-20">20</a>&nbsp;We categorised estimated glomerular filtration rate into the following bands analogous to chronic kidney disease stages: 60 mL/min/1.73m<sup>2</sup>&nbsp;and over; 45–59 mL/min/1.73m<sup>2</sup>; 30–44 mL/min/1.73m<sup>2</sup>; and less than 30 mL/min/1.73m<sup>2</sup>. This created possible selection bias since those at greater risk of renal disease are more likely to have renal function measured. Therefore, we included an absent renal function category for those with no recorded serum creatinine test result before UTI treated with antibiotics.</p>
<p id="p-23">History of renal and urological disease were identified using primary care records and classified in the following categories: prostatic hypertrophy, renal calculi, urological malignancies, and renal structural anomalies. To identify historic diagnoses that may influence prescribing rather than a more immediate condition that may have caused the infection (and therefore potentially be on the causal pathway) we identified renal disease based on codes recorded more than a year before each UTI episode treated with antibiotics.</p>
<p id="p-24">Exposure to renin-angiotensin system blockers or potassium-sparing diuretics was defined using prescription data as a current prescription at the time of a UTI treated with antibiotics and categorised as neither a renin-angiotensin system blocker nor a potassium-sparing diuretic, either a renin-angiotensin system blocker or a potassium-sparing diuretic, or renin-angiotensin system blockers in combination with potassium-sparing diuretics. We calculated prescription duration using the quantity of medication prescribed and daily dose recorded; when these data were not available, we assumed the population median prescription duration of 28 days. We assumed exposure to medications started on the date of the prescription. We constructed continuous courses of therapy by allowing for a gap of 60 days between consecutive prescriptions. We therefore defined a current prescription when a UTI episode treated with antibiotics occurred during a continuous course of drug therapy.</p>
<p id="p-25">We used existing morbidity code lists and algorithms for ethnicity,14&nbsp;smoking status, alcohol intake, and body mass index.15&nbsp;A large proportion of ethnicity data were missing so we only adjusted for ethnicity as a covariate in sensitivity analyses.14&nbsp;Lifestyle covariates (smoking, alcohol intake, and body mass index) were defined using the closest primary care record to the date of antibiotic prescription. Socioeconomic status was defined using general practice level quintiles of index of multiple deprivation scores. The effects of lifestyle covariates and socioeconomic status were thought to be largely captured by comorbidity data; we therefore only adjusted for these covariates in sensitivity analyses.</p>
</div>
<div id="sec-15" class="subsection" bis_skin_checked="1">
<h3>Statistical analysis</h3>
<p id="p-26">We calculated odds ratios for each outcome (acute kidney injury, hyperkalaemia, and death) within 14 days of antibiotic initiation for a UTI comparing each antibiotic drug (trimethoprim, cefalexin, ciprofloxacin, and nitrofurantoin) to amoxicillin (as the reference category) adjusting for potential confounders using logistic regression. We used robust standard errors to account for clustering by general practice. Separately, we repeated the analyses using robust standard errors to account for clustering by patient to account for some patients contributing multiple UTI episodes to the analysis. We initially adjusted for sex and age only, and then fitted an adjusted model using sex, age, calendar period, chronic comorbidities, baseline renal function, history of renal or urological disease, and use of renin-angiotensin system blockers and potassium-sparing diuretics.</p>
</div>
<div id="sec-16" class="subsection" bis_skin_checked="1">
<h3>Sensitivity analyses</h3>
<p id="p-27">We tested the impact of our antibiotic exposure definition by repeating the main analysis after: defining exposure as antibiotic prescription on the same day as a record of a UTI morbidity code; excluding prescriptions for antibiotics where the patient received an antibiotic in the 28 days before index infection; and limiting the analysis to the first recorded UTI treated with antibiotics for each individual during eligible follow-up. We then tested the impact of defining more immediate outcomes by repeating the main analysis with all three outcomes defined within seven days (rather than 14 days) of index antibiotic initiation. We also repeated the main analysis additionally adjusting for lifestyle factors (smoking, alcohol intake, and body mass index) and socioeconomic status. We repeated the main analysis limiting to individuals who had ethnicity recorded in Clinical Practice Research Datalink (CPRD) or Hospital Episode Statistics (HES), and became eligible for study entry from 2006 when recording of ethnicity was rewarded in primary care leading to improvements in CPRD data completeness.<a id="xref-ref-14-4" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-14">14</a>&nbsp;We included ethnicity both in the equation used to calculate estimated glomerular filtration rate and as covariate in the analysis. Next, to more closely replicate previous studies,<a id="xref-ref-2-2" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-2">2</a><a id="xref-ref-3-3" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-3">3</a><a id="xref-ref-5-2" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-5">5</a><a id="xref-ref-21-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-21">21</a>&nbsp;we repeated the main analysis with the exposure defined as antibiotic prescription for any indication, and, separately, limiting to individuals who had a current prescription for a renin-angiotensin system blocker at the time of UTI treated with antibiotics examining death both at seven and 14 days. Finally , to ensure that we were comparing similar groups (to reduce confounding by indication), we examined the risks of all three outcomes after propensity score weighting (inverse probability of treatment weighting) of trimethoprim and amoxicillin users (full details in web appendix 1). In inverse probability of treatment weighting, patients are reweighted according to the inverse of their probability of receiving the treatment they actually received. The strength of inverse probability of treatment weighting compared with propensity score matching is that every patient is included in the analysis, whereas propensity score matching may lead to the exclusion of patients for which a good match cannot be found, therefore threatening the generalisability of the results.</p>
<p id="p-28">All data management and analyses were performed using Stata version 14 (StataCorp, Texas, USA).</p>
</div>
<div id="sec-17" class="subsection" bis_skin_checked="1">
<h3>Patient involvement</h3>
<p id="p-29">No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. We are not able to disseminate the results of the research directly to study participants because the data used were anonymised.</p>
</div>
<p>&nbsp;</p>
<h2 class="">Results</h2>
<hr>
<p>&nbsp;</p>
<h3>Study population</h3>
<p id="p-30">Figure 1&nbsp;shows that among a cohort of 1 191 905 patients aged 65 and over we identified 178 238 individuals with a least one urinary tract infection (UTI) treated with antibiotics, comprising a total of 422 514 episodes. Patients contributed a median of three UTIs treated with antibiotics (interquartile range 2–7) during a mean follow-up period of 9.1 (SD 5.0) years.&nbsp;<a id="xref-table-wrap-1-1" class="xref-table" href="https://www.bmj.com/content/360/bmj.k341#T1">Table 1</a>&nbsp;shows that of these UTIs, 5% (n=22 543) were treated with amoxicillin, 59% (251 193) with trimethoprim, 15% (64 885) with cefalexin, 5% (21 946) with ciprofloxacin, and 15% (61 947) with nitrofurantoin. There were a total of 1345 episodes of acute kidney injury, 648 episodes of hyperkalaemia, and 2214 deaths within 14 days of antibiotic initiation for a UTI. The majority of cases of hyperkalaemia were identified from primary care biochemical test results; 71% of all hyperkalaemia records within 14 days of a UTI treated with antibiotics were identified from test results, 18% were recorded using Read codes in primary care, and 11% from hospital records.</p>
<p>&nbsp;</p>
<p><img class="alignnone size-full wp-image-5139" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20604%20646'%3E%3C/svg%3E" alt="" width="604" height="646" data-lazy-srcset="/../../../../wp-content/uploads/2021/01/figure-1.jpg 604w, //ikigaicorporation.com/wp-content/uploads/2021/01/figure-1-320x342.jpg 320w" data-lazy-sizes="(max-width: 604px) 100vw, 604px" data-lazy-src="/../../../../wp-content/uploads/2021/01/figure-1.jpg"><noscript><img class="alignnone size-full wp-image-5139" src="/../../../../wp-content/uploads/2021/01/figure-1.jpg" alt="" width="604" height="646" srcset="/../../../../wp-content/uploads/2021/01/figure-1.jpg 604w, //ikigaicorporation.com/wp-content/uploads/2021/01/figure-1-320x342.jpg 320w" sizes="(max-width: 604px) 100vw, 604px" /></noscript></p>
<p><span class="fig-label">Fig 1</span></p>
<p id="p-31" class="first-child">Flow diagram</p>
<p><span class="table-label">Table 1</span></p>
<p id="p-32" class="first-child">Characteristics of the study population at time of antibiotic initiation for urinary tract infection for the whole study population and stratified by antibiotic drug. Values are numbers (percentages) unless stated otherwise</p>
<p>&nbsp;</p>
<p><a id="xref-table-wrap-1-2" class="xref-table" href="https://www.bmj.com/content/360/bmj.k341#T1">Table 1</a>&nbsp;shows the characteristics of patients at the time of antibiotic prescription for a UTI for the overall study population, and stratified by class of antibiotic prescribed. Amoxicillin or ciprofloxacin were more commonly used to treat UTIs in men and a slightly higher percentage of those prescribed amoxicillin were aged 85 and over. While the proportion of chronic comorbidities were broadly similar across the antibiotics, the patients prescribed trimethoprim had fewer comorbidities compared with amoxicillin. Individuals prescribed nitrofurantoin had better renal function (56% of UTIs treated with nitrofurantoin were in individuals with estimated glomerular filtration rate ≥60 mL/min/1.73m<sup>2</sup>, compared with 37% to 43% for other antibiotics). Ciprofloxacin was more likely to be prescribed for UTIs in patients with a history of prostatic hypertrophy or renal calculi (10% of patients prescribed ciprofloxacin had a history of prostatic hypertrophy compared with 5% to 6% for the other antibiotics, while 4% prescribed ciprofloxacin had a history of renal calculi compared with 2% to 3% for the other antibiotics).</p>
<p>&nbsp;</p>
<h3>Association of trimethoprim with acute kidney injury, hyperkalaemia, or death</h3>
<p id="p-35"><a id="xref-fig-2-1" class="xref-fig" href="https://www.bmj.com/content/360/bmj.k341#F2">Figure 2</a>&nbsp;shows the association between antibiotic prescription and all three adverse outcomes. In the 14 days after antibiotic initiation for a UTI, trimethoprim is associated with the highest odds of acute kidney injury (adjusted odds ratio 1.72, 95% confidence interval 1.31 to 2.24) and hyperkalaemia (2.27, 1.49 to 3.45) of all the antibiotics investigated. Ciprofloxacin was also associated with an increased odds of acute kidney injury (1.48, 1.03 to 2.13) but not of hyperkalaemia (1.17, 0.68 to 2.02). Cefalexin and nitrofurantoin were not associated with an increased odds of acute kidney injury or hyperkalaemia compared with amoxicillin. The odds of death within 14 days of antibiotic initiation for UTI were similar to amoxicillin for trimethoprim (0.90, 0.76 to 1.07) and the other antibiotics.</p>
<p><span class="fig-label">Fig 2</span></p>
<p id="p-36" class="first-child">Odds ratios (95% confidence intervals) comparing the odds of acute kidney injury, hyperkalaemia, and death in the 14 days following initiation of different antibiotic drugs for treatment of urinary tract infection</p>
<p>&nbsp;</p>
<div class="hero" bis_skin_checked="1">
<div class="panel-pane pane-bmj-article-open-access" bis_skin_checked="1">
<div class="pane-content" bis_skin_checked="1">
<div class="creative-commons" title="Creative Commons" bis_skin_checked="1"><span class="creative-commons-article"><span class="icon-cc">CC</span><span class="icon-by">BY</span><span class="icon-nc">NC</span>&nbsp;Open access</span></div>
</div>
</div>
</div>
<div class="row" bis_skin_checked="1">
<div class="left-content col-xs-12 col-sm-8 col-md-8 col-lg-8" bis_skin_checked="1">
<article>
<div class="panel-pane pane-highwire-article-citation" bis_skin_checked="1">
<div class="pane-content" bis_skin_checked="1">
<div id="node961049" class="highwire-article-citation highwire-citation-type-highwire-article" data-node-nid="961049" data-pisa="bmj;360/feb09_5/k341" data-pisa-master="bmj;bmj.k341" data-apath="/bmj/360/bmj.k341.atom" bis_skin_checked="1">
<p><cite class="highwire-cite highwire-citation-bmj-article-top"><span class="highwire-cite-article-type">Research</span></cite></p>
<h1 id="page-title" class="highwire-cite-title">Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study</h1>
<p><cite class="highwire-cite highwire-citation-bmj-article-top"><span class="highwire-cite-journal">BMJ</span>&nbsp;<span class="highwire-cite-published-year">2018</span>;&nbsp;<span class="highwire-cite-volume-issue">360</span>&nbsp;<span class="highwire-cite-doi">doi:&nbsp;<a href="https://doi.org/10.1136/bmj.k341">https://doi.org/10.1136/bmj.k341</a></span>&nbsp;<span class="highwire-cite-date">(Published 09 February 2018)</span><span class="highwire-cite-article-as">Cite this as:&nbsp;<span class="italic">BMJ</span>&nbsp;2018;360:k341</span></cite></p>
</div>
</div>
</div>
<div class="panel-separator" bis_skin_checked="1"></div>
<div class="panel-pane pane-highwire-panel-tabs pane-panels-ajax-tab-tabs panels-ajax-tabs-once-processed" bis_skin_checked="1">
<div class="pane-content" bis_skin_checked="1">
<ul class="tabs inline panels-ajax-tab">
<li class="first active"><a class="panels-ajax-tab-tab panels-ajax-tabs-once-processed panels-ajax-tabs-first-loaded hw-panels-ajax-tabs-once-processed" title="Article Tab - Article" href="https://www.bmj.com/content/360/bmj.k341" data-panel-name="jnl_bmj_tab_art" data-target-id="highwire_article_tabs" data-entity-context="node:961049" data-trigger="" data-url-enabled="1">Article</a></li>
<li><a class="panels-ajax-tab-tab panels-ajax-tabs-once-processed hw-panels-ajax-tabs-once-processed" title="Article Tab - Related Articles" href="https://www.bmj.com/content/360/bmj.k341/related" data-panel-name="jnl_bmj_tab_related_art" data-target-id="highwire_article_tabs" data-entity-context="node:961049" data-trigger="related" data-url-enabled="1">Related content</a></li>
<li><a class="panels-ajax-tab-tab panels-ajax-tabs-once-processed hw-panels-ajax-tabs-once-processed" title="Article Tab - Info &amp; Metrics" href="https://www.bmj.com/content/360/bmj.k341/article-info" data-panel-name="jnl_bmj_tab_info" data-target-id="highwire_article_tabs" data-entity-context="node:961049" data-trigger="article-info" data-url-enabled="1">Metrics</a></li>
<li><a class="panels-ajax-tab-tab panels-ajax-tabs-once-processed hw-panels-ajax-tabs-once-processed" title="BMJ Article Related Rapid Responses" href="https://www.bmj.com/content/360/bmj.k341/rapid-responses" data-panel-name="bmj_related_rapid_responses" data-target-id="highwire_article_tabs" data-entity-context="node:961049" data-trigger="rapid-responses" data-url-enabled="1">Responses</a></li>
<li><a class="panels-ajax-tab-tab panels-ajax-tabs-once-processed hw-panels-ajax-tabs-once-processed" title="Article Tab - Peer review" href="https://www.bmj.com/content/360/bmj.k341/peer-review" data-panel-name="jnl_bmj_tab_peer_review" data-target-id="highwire_article_tabs" data-entity-context="node:961049" data-trigger="peer-review" data-url-enabled="1">Peer review</a></li>
</ul>
</div>
</div>
<div class="panel-separator" bis_skin_checked="1"></div>
<div class="panel-pane pane-highwire-panel-tabs-container" bis_skin_checked="1">
<div class="pane-content" bis_skin_checked="1">
<div id="panels-ajax-tab-container-highwire_article_tabs" class="panels-ajax-tab-container" data-panels-ajax-tab-preloaded="jnl_bmj_tab_art" bis_skin_checked="1">
<div class="panels-ajax-tab-wrap-jnl_bmj_tab_art" bis_skin_checked="1">
<div class="panel-display panel-1col clearfix" bis_skin_checked="1">
<div class="panel-panel panel-col" bis_skin_checked="1">
<div bis_skin_checked="1">
<div class="panel-pane pane-highwire-markup" bis_skin_checked="1">
<div class="pane-content" bis_skin_checked="1">
<div class="highwire-markup" bis_skin_checked="1">
<div id="content-block-markup" data-highwire-cite-ref-tooltip-instance="highwire_reflinks_tooltip" bis_skin_checked="1">
<div class="article fulltext-view " bis_skin_checked="1">
<div class="contributors jquery-once-2-processed" bis_skin_checked="1">
<ol id="contrib-group-1" class="contributor-list">
<li id="contrib-1" class="contributor"><span class="name">Elizabeth Crellin</span><span class="contrib-role">, research assistant</span><a id="xref-aff-1-1" class="xref-aff bmjAuthorAffiliatesMarkupProcessor-processed" href="https://www.bmj.com/content/360/bmj.k341#aff-1">1</a>,</li>
<li id="contrib-2" class="contributor"><span class="name">Kathryn E Mansfield</span><span class="contrib-role">, research fellow</span><a id="xref-aff-1-2" class="xref-aff bmjAuthorAffiliatesMarkupProcessor-processed" href="https://www.bmj.com/content/360/bmj.k341#aff-1">1</a>,</li>
<li id="contrib-3" class="contributor"><span class="name">Clémence Leyrat</span><span class="contrib-role">, research fellow</span><a id="xref-aff-2-1" class="xref-aff bmjAuthorAffiliatesMarkupProcessor-processed" href="https://www.bmj.com/content/360/bmj.k341#aff-2">2</a>,</li>
<li id="contrib-4" class="contributor"><span class="name">Dorothea Nitsch</span><span class="contrib-role">, professor</span><a id="xref-aff-1-3" class="xref-aff bmjAuthorAffiliatesMarkupProcessor-processed" href="https://www.bmj.com/content/360/bmj.k341#aff-1">1</a>,</li>
<li id="contrib-5" class="contributor"><span class="name">Ian J Douglas</span><span class="contrib-role">, associate professor</span><a id="xref-aff-1-4" class="xref-aff bmjAuthorAffiliatesMarkupProcessor-processed" href="https://www.bmj.com/content/360/bmj.k341#aff-1">1</a>,</li>
<li id="contrib-6" class="contributor"><span class="name">Adrian Root</span><span class="contrib-role">, research fellow</span><a id="xref-aff-1-5" class="xref-aff bmjAuthorAffiliatesMarkupProcessor-processed" href="https://www.bmj.com/content/360/bmj.k341#aff-1">1</a>,</li>
<li id="contrib-7" class="contributor"><span class="name">Elizabeth Williamson</span><span class="contrib-role">, associate professor</span><a id="xref-aff-2-2" class="xref-aff bmjAuthorAffiliatesMarkupProcessor-processed" href="https://www.bmj.com/content/360/bmj.k341#aff-2">2</a>,</li>
<li id="contrib-8" class="contributor"><span class="name">Liam Smeeth</span><span class="contrib-role">, professor</span><a id="xref-aff-1-6" class="xref-aff bmjAuthorAffiliatesMarkupProcessor-processed" href="https://www.bmj.com/content/360/bmj.k341#aff-1">1</a>,</li>
<li id="contrib-9" class="last"><span class="name">Laurie A Tomlinson</span><span class="contrib-role">, associate professor</span><a id="xref-aff-1-7" class="xref-aff bmjAuthorAffiliatesMarkupProcessor-processed" href="https://www.bmj.com/content/360/bmj.k341#aff-1">1</a></li>
</ol>
<p><a class="view-more" href="https://www.bmj.com/content/360/bmj.k341#">Author affiliations</a></p>
<ol class="corresp-list">
<li id="corresp-1" class="corresp">Correspondence to: K Mansfield&nbsp;<span class="em-link"><span class="em-addr"><a href="mailto:kathryn.mansfield@lshtm.ac.uk">kathryn.mansfield@lshtm.ac.uk</a></span></span></li>
</ol>
<ul class="history-list">
<li class="accepted"><span class="accepted-label">Accepted&nbsp;</span>16 January 2018</li>
</ul>
</div>
<div id="abstract-1" class="section abstract" bis_skin_checked="1">
<h2 class="">Abstract</h2>
<div id="sec-1" class="subsection" bis_skin_checked="1">
<p id="p-2"><strong>Objective</strong>&nbsp;To determine if trimethoprim use for urinary tract infection (UTI) is associated with an increased risk of acute kidney injury, hyperkalaemia, or sudden death in the general population.</p>
</div>
<div id="sec-2" class="subsection" bis_skin_checked="1">
<p id="p-3"><strong>Design</strong>&nbsp;Cohort study.</p>
</div>
<div id="sec-3" class="subsection" bis_skin_checked="1">
<p id="p-4"><strong>Setting</strong>&nbsp;UK electronic primary care records from practices contributing to the Clinical Practice Research Datalink linked to the Hospital Episode Statistics database.</p>
</div>
<div id="sec-4" class="subsection" bis_skin_checked="1">
<p id="p-5"><strong>Participants</strong>&nbsp;Adults aged 65 and over with a prescription for trimethoprim, amoxicillin, cefalexin, ciprofloxacin, or nitrofurantoin prescribed up to three days after a primary care diagnosis of UTI between April 1997 and September 2015.</p>
</div>
<div id="sec-5" class="subsection" bis_skin_checked="1">
<p id="p-6"><strong>Main outcome measures</strong>&nbsp;The outcomes were acute kidney injury, hyperkalaemia, and death within 14 days of a UTI treated with antibiotics.</p>
</div>
<div id="sec-6" class="subsection" bis_skin_checked="1">
<p id="p-7"><strong>Results</strong>&nbsp;Among a cohort of 1 191 905 patients aged 65 and over, 178 238 individuals were identified with at least one UTI treated with antibiotics, comprising a total of 422 514 episodes of UTIs treated with antibiotics. The odds of acute kidney injury in the 14 days following antibiotic initiation were higher following trimethoprim (adjusted odds ratio 1.72, 95% confidence interval 1.31 to 2.24) and ciprofloxacin (1.48, 1.03 to 2.13) compared with amoxicillin. The odds of hyperkalaemia in the 14 days following antibiotic initiation were only higher following trimethoprim (2.27, 1.49 to 3.45) compared with amoxicillin. However, the odds of death within the 14 days following antibiotic initiation were not higher with trimethoprim than with amoxicillin: in the whole population the adjusted odds ratio was 0.90 (95% confidence interval 0.76 to 1.07) while among users of renin-angiotensin system blockers the odds of death within 14 days of antibiotic initiation was 1.12 (0.80 to 1.57). The results suggest that, for 1000 UTIs treated with antibiotics among people 65 and over, treatment with trimethoprim instead of amoxicillin would result in one to two additional cases of hyperkalaemia and two admissions with acute kidney injury, regardless of renin-angiotensin system blockade. However, for people taking renin-angiotensin system blockers and spironolactone treatment with trimethoprim instead of amoxicillin there were 18 additional cases of hyperkalaemia and 11 admissions with acute kidney injury.</p>
</div>
<div id="sec-7" class="subsection" bis_skin_checked="1">
<p id="p-8"><strong>Conclusion</strong>&nbsp;Trimethoprim is associated with a greater risk of acute kidney injury and hyperkalaemia compared with other antibiotics used to treat UTIs, but not a greater risk of death. The relative risk increase is similar across population groups, but the higher baseline risk among those taking renin-angiotensin system blockers and potassium-sparing diuretics translates into higher absolute risks of acute kidney injury and hyperkalaemia in these groups.</p>
</div>
</div>
<div id="sec-8" class="section intro" bis_skin_checked="1">
<h2 class="">Introduction</h2>
<p id="p-9">Co-trimoxazole is a combination antibiotic drug containing trimethoprim and sulfamethoxazole, prescribed for multiple indications and is the fourth most commonly prescribed antibiotic in the USA.<a id="xref-ref-1-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-1">1</a>&nbsp;Its use has been associated with an increased risk of sudden death among people taking renin-angiotensin system blockers.<a id="xref-ref-2-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-2">2</a>3&nbsp;This may be owing to acute kidney injury, a rapid deterioration in kidney function.<a id="xref-ref-4-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-4">4</a>&nbsp;Alternately, co-trimoxazole and trimethoprim alone have both been associated with an increased risk of an acute rise in potassium levels, hyperkalaemia, which can cause fatal cardiac arrhythmias.35678</p>
<p id="p-10">Existing evidence has important limitations. It is not clear if the association between co-trimoxazole and adverse outcomes is owing to the sulfamethoxazole or the trimethoprim component. The observed association may be owing to confounding if the combination antibiotic was used for patients with more severe infections than the antibiotics it was compared with. Finally, existing evidence is primarily associated with specific groups of patients such as those taking renin-angiotensin system blockers. In the UK, co-trimoxazole is licensed for specific, uncommon indications and trimethoprim is more commonly used. However, there are efforts to reduce trimethoprim prescribing due to increasing antimicrobial resistance.<a id="xref-ref-9-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-9">9</a>&nbsp;In 2015 over 3.7 million prescriptions for trimethoprim were dispensed in England and it remains a first line option for treatment of uncomplicated urinary tract infections (UTIs).<a id="xref-ref-10-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-10">10</a>&nbsp;Despite this, whether trimethoprim alone is linked to sudden death both in the general population and in high risk groups is unknown.</p>
<p id="p-11">Our study therefore aimed to investigate the association between trimethoprim and acute kidney injury, hyperkalaemia, or sudden death in a cohort of patients aged 65 and over. To limit confounding by antibiotic indication we restricted our analysis to patients with an antibiotic prescription for the same indication (UTI) and examined the risk of adverse outcomes in patients prescribed trimethoprim and four comparison antibiotics (amoxicillin, cefalexin, ciprofloxacin, and nitrofurantoin). However, even when treatment is restricted to the same indication, different classes of antibiotic drugs are prescribed in slightly different clinical scenarios. For simple UTIs in adults, current UK guidelines recommend nitrofurantoin as the first line treatment (except for patients with poor renal function) and trimethoprim as a first line alternative where there is low risk of microbial resistance.<a id="xref-ref-11-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-11">11</a>&nbsp;Ciprofloxacin and cefalexin are not currently recommended treatments for simple UTIs (although ciprofloxacin is a first line option for pyelonephritis) but are used for patients with resistance to first line antibiotics. In addition, ciprofloxacin and cefalexin were used in practice as treatment for simple UTIs during the years covered by this study.<a id="xref-ref-12-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-12">12</a>&nbsp;We aimed to address the impact of these different usage patterns on the outcomes through adjustment for a range of comorbidities and sensitivity analyses.</p>
</div>
<div id="sec-9" class="section methods" bis_skin_checked="1">
<h2 class="">Methods</h2>
<div id="sec-10" class="subsection" bis_skin_checked="1">
<h3>Study design and setting</h3>
<p id="p-12">We undertook a cohort study using electronic clinical records from adults attending primary care practices contributing to the UK Clinical Practice Research Datalink (CPRD GOLD) and linked hospital record data from the Hospital Episode Statistics (HES) database. CPRD is a database of primary care electronic health record data from participating general practices, covering 7% of the UK population.13&nbsp;Included patients are largely representative of the UK population in terms of age, sex, ethnicity, and body mass index.131415&nbsp;HES records cover all admissions for National Health Service (NHS) funded patients treated in either English NHS trusts or by independent providers.16&nbsp;Seventy-five percent of English general practices included in CPRD are linked to HES data.13&nbsp;The study period was from 1 April 1997 to 30 September 2015 (the period covered by HES data linkage to CPRD).</p>
</div>
<div id="sec-11" class="subsection" bis_skin_checked="1">
<h3>Participants, exposures, and outcomes</h3>
<p id="p-13">We identified all adults aged 65 years and over during the study period (April 1997 to September 2015). We chose an older population as this is a clinically important group at high risk of adverse health outcomes. In addition, they are more likely to be well monitored, enabling reliable recording of comorbidities and quantification of baseline renal function.</p>
<p id="p-14">Individuals were eligible for the study by receiving a prescription for an antibiotic for a urinary tract infection (UTI) after the latest of the following: 65th birthday; date practice reached CPRD quality control standards (to ensure data quality); or one year after practice registration date (to ensure that we had reliable measures of incident morbidity). Patients were no longer eligible to be included from the earliest of the following: date of death; left practice; or last data collection from practice. We excluded patients who developed end stage renal disease before they were eligible for inclusion.17</p>
<div id="sec-12" class="subsection" bis_skin_checked="1">
<h4>Exposures</h4>
<p id="p-15">The date of inclusion was the day of initiation for any of five antibiotic drugs (trimethoprim, amoxicillin, cefalexin, ciprofloxacin, and nitrofurantoin) recorded up to three days after a primary care morbidity code for uncomplicated UTI (ie, excluding more severe conditions such as pyelonephritis). We allowed a gap of three days between UTI diagnosis and treatment with an antibiotic to allow for delays between microbiological diagnosis and treatment. To ensure reliable measures of antibiotic exposure, we excluded any UTI episodes treated with antibiotics where two or more of the study antibiotics were prescribed on the same day. We excluded prescriptions for co-trimoxazole and did not include patients treated with co-amoxiclav in the amoxicillin comparison group as in the UK these drugs are prescribed for more severe or atypical UTIs. We also excluded any UTI episodes where a patient received one or more of the five study antibiotics in the 14 days before the UTI record to ensure that we were identifying the first consultation for an episode of UTI. Finally, we excluded any UTI episodes where a code for a non-UTI infection was recorded in the three days before antibiotic prescription.</p>
</div>
<div id="sec-13" class="subsection" bis_skin_checked="1">
<h4>Outcomes</h4>
<p id="p-16">We investigated the outcomes acute kidney injury, hyperkalaemia, and death recorded within 14 days of antibiotic initiation for UTI. Acute kidney injury was defined as hospital admission with acute kidney injury using ICD-10 (international classification of diseases, 10th revision) codes recorded in any diagnostic position of any inpatient episode starting within 14 days of antibiotic initiation.1718&nbsp;Hyperkalaemia was identified in the 14 days after antibiotic initiation using morbidity coding in primary (Read codes) or secondary (ICD-10 codes) care, or a potassium level of 6 mmol/L or more recorded in primary care. Death was identified as the earliest record of death from Read codes in CPRD, CPRD defined death date, ICD-10 codes in HES, and the Office for National Statistics date of death.</p>
<p id="p-17">All morbidity code lists are available to download,19&nbsp;and were either developed for use in other studies, or were developed in a consensus procedure by two authors with clinical experience in the NHS.</p>
</div>
</div>
<div id="sec-14" class="subsection" bis_skin_checked="1">
<h3>Covariates</h3>
<p id="p-18">Based on a priori knowledge, we considered the following variables as potential confounders of the relation between trimethoprim and acute kidney injury, hyperkalaemia, or sudden death: sex, age, calendar period, chronic comorbidities, history of renal or urological disease, baseline renal function, prescription for renin-angiotensin system blockers (including angiotensin converting enzyme inhibitors and angiotensin receptor blockers) or potassium-sparing diuretics, lifestyle factors (smoking, alcohol intake, and body mass index), ethnicity, and socioeconomic status. All covariates other than sex and ethnicity were updated over time.</p>
<p id="p-19">Age group was defined in the following bands at time of antibiotic initiation: 65–69; 70–74; 75–79; 80–84; and 85 and over.</p>
<p id="p-20">We included calendar period (1997–2000, 2001–04, 2005–08, 2009–11, and 2012–15) as a covariate to adjust for the many changes in clinical, diagnostic, and administrative practices over the study period that may influence the choice of antibiotic treatment for UTI, the measurement of renal function, and registration of outcomes.</p>
<p id="p-21">Chronic comorbidities included as confounders were diabetes mellitus, ischaemic heart disease, cardiac failure, arrhythmia, and hypertension, identified from both primary care and hospital data. Individuals were considered to have a specific comorbidity if they had a code recorded in their electronic health records before a UTI episode treated with antibiotics.</p>
<p id="p-22">Baseline renal function was defined using the most recent biochemical test results recorded in primary care at any time before each UTI treated with antibiotics. We used serum creatinine test results to calculate estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.20&nbsp;We categorised estimated glomerular filtration rate into the following bands analogous to chronic kidney disease stages: 60 mL/min/1.73m<sup>2</sup>&nbsp;and over; 45–59 mL/min/1.73m<sup>2</sup>; 30–44 mL/min/1.73m<sup>2</sup>; and less than 30 mL/min/1.73m<sup>2</sup>. This created possible selection bias since those at greater risk of renal disease are more likely to have renal function measured. Therefore, we included an absent renal function category for those with no recorded serum creatinine test result before UTI treated with antibiotics.</p>
<p id="p-23">History of renal and urological disease were identified using primary care records and classified in the following categories: prostatic hypertrophy, renal calculi, urological malignancies, and renal structural anomalies. To identify historic diagnoses that may influence prescribing rather than a more immediate condition that may have caused the infection (and therefore potentially be on the causal pathway) we identified renal disease based on codes recorded more than a year before each UTI episode treated with antibiotics.</p>
<p id="p-24">Exposure to renin-angiotensin system blockers or potassium-sparing diuretics was defined using prescription data as a current prescription at the time of a UTI treated with antibiotics and categorised as neither a renin-angiotensin system blocker nor a potassium-sparing diuretic, either a renin-angiotensin system blocker or a potassium-sparing diuretic, or renin-angiotensin system blockers in combination with potassium-sparing diuretics. We calculated prescription duration using the quantity of medication prescribed and daily dose recorded; when these data were not available, we assumed the population median prescription duration of 28 days. We assumed exposure to medications started on the date of the prescription. We constructed continuous courses of therapy by allowing for a gap of 60 days between consecutive prescriptions. We therefore defined a current prescription when a UTI episode treated with antibiotics occurred during a continuous course of drug therapy.</p>
<p id="p-25">We used existing morbidity code lists and algorithms for ethnicity,<a id="xref-ref-14-2" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-14">14</a>&nbsp;smoking status, alcohol intake, and body mass index.15&nbsp;A large proportion of ethnicity data were missing so we only adjusted for ethnicity as a covariate in sensitivity analyses.14&nbsp;Lifestyle covariates (smoking, alcohol intake, and body mass index) were defined using the closest primary care record to the date of antibiotic prescription. Socioeconomic status was defined using general practice level quintiles of index of multiple deprivation scores. The effects of lifestyle covariates and socioeconomic status were thought to be largely captured by comorbidity data; we therefore only adjusted for these covariates in sensitivity analyses.</p>
</div>
<div id="sec-15" class="subsection" bis_skin_checked="1">
<h3>Statistical analysis</h3>
<p id="p-26">We calculated odds ratios for each outcome (acute kidney injury, hyperkalaemia, and death) within 14 days of antibiotic initiation for a UTI comparing each antibiotic drug (trimethoprim, cefalexin, ciprofloxacin, and nitrofurantoin) to amoxicillin (as the reference category) adjusting for potential confounders using logistic regression. We used robust standard errors to account for clustering by general practice. Separately, we repeated the analyses using robust standard errors to account for clustering by patient to account for some patients contributing multiple UTI episodes to the analysis. We initially adjusted for sex and age only, and then fitted an adjusted model using sex, age, calendar period, chronic comorbidities, baseline renal function, history of renal or urological disease, and use of renin-angiotensin system blockers and potassium-sparing diuretics.</p>
</div>
<div id="sec-16" class="subsection" bis_skin_checked="1">
<h3>Sensitivity analyses</h3>
<p id="p-27">We tested the impact of our antibiotic exposure definition by repeating the main analysis after: defining exposure as antibiotic prescription on the same day as a record of a UTI morbidity code; excluding prescriptions for antibiotics where the patient received an antibiotic in the 28 days before index infection; and limiting the analysis to the first recorded UTI treated with antibiotics for each individual during eligible follow-up. We then tested the impact of defining more immediate outcomes by repeating the main analysis with all three outcomes defined within seven days (rather than 14 days) of index antibiotic initiation. We also repeated the main analysis additionally adjusting for lifestyle factors (smoking, alcohol intake, and body mass index) and socioeconomic status. We repeated the main analysis limiting to individuals who had ethnicity recorded in Clinical Practice Research Datalink (CPRD) or Hospital Episode Statistics (HES), and became eligible for study entry from 2006 when recording of ethnicity was rewarded in primary care leading to improvements in CPRD data completeness.14&nbsp;We included ethnicity both in the equation used to calculate estimated glomerular filtration rate and as covariate in the analysis. Next, to more closely replicate previous studies,23521&nbsp;we repeated the main analysis with the exposure defined as antibiotic prescription for any indication, and, separately, limiting to individuals who had a current prescription for a renin-angiotensin system blocker at the time of UTI treated with antibiotics examining death both at seven and 14 days. Finally , to ensure that we were comparing similar groups (to reduce confounding by indication), we examined the risks of all three outcomes after propensity score weighting (inverse probability of treatment weighting) of trimethoprim and amoxicillin users (full details in web appendix 1). In inverse probability of treatment weighting, patients are reweighted according to the inverse of their probability of receiving the treatment they actually received. The strength of inverse probability of treatment weighting compared with propensity score matching is that every patient is included in the analysis, whereas propensity score matching may lead to the exclusion of patients for which a good match cannot be found, therefore threatening the generalisability of the results.</p>
<p id="p-28">All data management and analyses were performed using Stata version 14 (StataCorp, Texas, USA).</p>
</div>
<div id="sec-17" class="subsection" bis_skin_checked="1">
<h3>Patient involvement</h3>
<p id="p-29">No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. We are not able to disseminate the results of the research directly to study participants because the data used were anonymised.</p>
</div>
</div>
<div id="sec-18" class="section results" bis_skin_checked="1">
<h2 class="">Results</h2>
<div id="sec-19" class="subsection" bis_skin_checked="1">
<h3>Study population</h3>
<p id="p-30"><a id="xref-fig-1-1" class="xref-fig" href="https://www.bmj.com/content/360/bmj.k341#F1">Figure 1</a>&nbsp;shows that among a cohort of 1 191 905 patients aged 65 and over we identified 178 238 individuals with a least one urinary tract infection (UTI) treated with antibiotics, comprising a total of 422 514 episodes. Patients contributed a median of three UTIs treated with antibiotics (interquartile range 2–7) during a mean follow-up period of 9.1 (SD 5.0) years.&nbsp;<a id="xref-table-wrap-1-1" class="xref-table" href="https://www.bmj.com/content/360/bmj.k341#T1">Table 1</a>&nbsp;shows that of these UTIs, 5% (n=22 543) were treated with amoxicillin, 59% (251 193) with trimethoprim, 15% (64 885) with cefalexin, 5% (21 946) with ciprofloxacin, and 15% (61 947) with nitrofurantoin. There were a total of 1345 episodes of acute kidney injury, 648 episodes of hyperkalaemia, and 2214 deaths within 14 days of antibiotic initiation for a UTI. The majority of cases of hyperkalaemia were identified from primary care biochemical test results; 71% of all hyperkalaemia records within 14 days of a UTI treated with antibiotics were identified from test results, 18% were recorded using Read codes in primary care, and 11% from hospital records.</p>
<div id="F1" class="fig pos-float type-figure odd" bis_skin_checked="1">
<div class="fig-inline" bis_skin_checked="1">
<div class="highwire-figure" bis_skin_checked="1">
<div class="fig-inline-img-wrapper" bis_skin_checked="1">
<div class="fig-inline-img" bis_skin_checked="1"><a class="colorbox fragment-images colorbox-load init-colorbox-processed cboxElement" style="box-sizing: border-box; background: transparent; color: #2a6ebb; text-decoration: none; margin: 0px; padding: 0px; border: 0px; font-style: inherit; font-variant: inherit; font-weight: inherit; font-stretch: inherit; line-height: inherit; font-family: inherit; font-size: 16px; vertical-align: baseline; word-break: break-all;" title="Flow diagram" href="https://www.bmj.com/content/bmj/360/bmj.k341/F1.large.jpg?width=800&amp;height=600" rel="gallery-fragment-images" data-figure-caption="<div class=&quot;highwire-markup&quot;><div class=&quot;fig-caption&quot; xmlns:xhtml=&quot;http://www.w3.org/1999/xhtml&quot;><span class=&quot;fig-label&quot;>Fig 1</span> <p id=&quot;p-31&quot; class=&quot;first-child&quot;>Flow diagram</p><div class=&quot;sb-div caption-clear&quot;></div></div></div>" bis_size="{&quot;x&quot;:30,&quot;y&quot;:68460,&quot;w&quot;:300,&quot;h&quot;:19,&quot;abs_x&quot;:30,&quot;abs_y&quot;:68460}"><img class="fragment-image" title="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Fig 1" data-original-title="" data-lazy-src="https://www.bmj.com/content/bmj/360/bmj.k341/F1.medium.gif" bis_size="{&quot;x&quot;:30,&quot;y&quot;:68325,&quot;w&quot;:300,&quot;h&quot;:150,&quot;abs_x&quot;:30,&quot;abs_y&quot;:68325}" bis_id="bn_d3yl5jje9e63d858osou85"><noscript><img class="fragment-image" title="" src="https://www.bmj.com/content/bmj/360/bmj.k341/F1.medium.gif" alt="Fig 1" data-original-title="" /></noscript></a></div>
</div>
<div class="fig-caption" bis_skin_checked="1">
<p><span class="fig-label">Fig 1</span></p>
<p id="p-31" class="first-child">Flow diagram</p>
</div>
</div>
</div>
<div class="fig-caption" bis_skin_checked="1"></div>
</div>
<div id="T1" class="table pos-float" bis_skin_checked="1">
<div class="table" bis_skin_checked="1">
<div class="table-caption" bis_skin_checked="1">
<p><span class="table-label">Table 1</span></p>
<p id="p-32" class="first-child">Characteristics of the study population at time of antibiotic initiation for urinary tract infection for the whole study population and stratified by antibiotic drug. Values are numbers (percentages) unless stated otherwise</p>
<div class="sb-div caption-clear" bis_skin_checked="1"></div>
</div>
</div>
<div bis_skin_checked="1"></div>
</div>
<p id="p-34">Table 1&nbsp;shows the characteristics of patients at the time of antibiotic prescription for a UTI for the overall study population, and stratified by class of antibiotic prescribed. Amoxicillin or ciprofloxacin were more commonly used to treat UTIs in men and a slightly higher percentage of those prescribed amoxicillin were aged 85 and over. While the proportion of chronic comorbidities were broadly similar across the antibiotics, the patients prescribed trimethoprim had fewer comorbidities compared with amoxicillin. Individuals prescribed nitrofurantoin had better renal function (56% of UTIs treated with nitrofurantoin were in individuals with estimated glomerular filtration rate ≥60 mL/min/1.73m<sup>2</sup>, compared with 37% to 43% for other antibiotics). Ciprofloxacin was more likely to be prescribed for UTIs in patients with a history of prostatic hypertrophy or renal calculi (10% of patients prescribed ciprofloxacin had a history of prostatic hypertrophy compared with 5% to 6% for the other antibiotics, while 4% prescribed ciprofloxacin had a history of renal calculi compared with 2% to 3% for the other antibiotics).</p>
</div>
<div id="sec-20" class="subsection" bis_skin_checked="1">
<h3>Association of trimethoprim with acute kidney injury, hyperkalaemia, or death</h3>
<p id="p-35"><a id="xref-fig-2-1" class="xref-fig" href="https://www.bmj.com/content/360/bmj.k341#F2">Figure 2</a>&nbsp;shows the association between antibiotic prescription and all three adverse outcomes. In the 14 days after antibiotic initiation for a UTI, trimethoprim is associated with the highest odds of acute kidney injury (adjusted odds ratio 1.72, 95% confidence interval 1.31 to 2.24) and hyperkalaemia (2.27, 1.49 to 3.45) of all the antibiotics investigated. Ciprofloxacin was also associated with an increased odds of acute kidney injury (1.48, 1.03 to 2.13) but not of hyperkalaemia (1.17, 0.68 to 2.02). Cefalexin and nitrofurantoin were not associated with an increased odds of acute kidney injury or hyperkalaemia compared with amoxicillin. The odds of death within 14 days of antibiotic initiation for UTI were similar to amoxicillin for trimethoprim (0.90, 0.76 to 1.07) and the other antibiotics.</p>
<div id="F2" class="fig pos-float type-figure odd" bis_skin_checked="1">
<div class="fig-inline" bis_skin_checked="1">
<div class="highwire-figure" bis_skin_checked="1">
<div class="fig-inline-img-wrapper" bis_skin_checked="1">
<div class="fig-inline-img" bis_skin_checked="1"><a class="colorbox fragment-images colorbox-load init-colorbox-processed cboxElement" style="box-sizing: border-box; background: transparent; color: #2a6ebb; text-decoration: none; margin: 0px; padding: 0px; border: 0px; font-style: inherit; font-variant: inherit; font-weight: inherit; font-stretch: inherit; line-height: inherit; font-family: inherit; font-size: 16px; vertical-align: baseline; word-break: break-all;" title="Odds ratios (95% confidence intervals) comparing the odds of acute kidney injury, hyperkalaemia, and death in the 14 days following initiation of different antibiotic drugs for treatment of urinary tract infection " href="https://www.bmj.com/content/bmj/360/bmj.k341/F2.large.jpg?width=800&amp;height=600" rel="gallery-fragment-images" data-figure-caption="<div class=&quot;highwire-markup&quot;><div class=&quot;fig-caption&quot; xmlns:xhtml=&quot;http://www.w3.org/1999/xhtml&quot;></div></div>" bis_size="{&quot;x&quot;:30,&quot;y&quot;:70190,&quot;w&quot;:300,&quot;h&quot;:19,&quot;abs_x&quot;:30,&quot;abs_y&quot;:70190}"><img class="fragment-image" title="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Fig 2" data-original-title="" data-lazy-src="https://www.bmj.com/content/bmj/360/bmj.k341/F2.medium.gif" bis_size="{&quot;x&quot;:30,&quot;y&quot;:70055,&quot;w&quot;:300,&quot;h&quot;:150,&quot;abs_x&quot;:30,&quot;abs_y&quot;:70055}" bis_id="bn_jidt72e352gny4qluu3jky"><noscript><img class="fragment-image" title="" src="https://www.bmj.com/content/bmj/360/bmj.k341/F2.medium.gif" alt="Fig 2" data-original-title="" /></noscript></a></div>
</div>
<div class="fig-caption" bis_skin_checked="1">
<p><span class="fig-label">Fig 2</span></p>
<p id="p-36" class="first-child">Odds ratios (95% confidence intervals) comparing the odds of acute kidney injury, hyperkalemia, and death in the 14 days following initiation of different antibiotic drugs for treatment of urinary tract infection</p>
<h3>Sensitivity analyses</h3>
<p id="p-37">We saw minimal differences in the odds ratios for acute kidney injury, hyperkalaemia, or sudden death comparing trimethoprim, cefalexin, ciprofloxacin, or nitrofurantoin with amoxicillin after the majority of sensitivity analyses, or after additionally adjusting for lifestyle factors, ethnicity, and socioeconomic status (web appendix 1). Repeating the main analysis excluding patients without known baseline renal function made minimal differences to the results (web appendix 1). Redefining exposure as antibiotic prescription for any indication (rather than only for a UTI) increased the observed effect size of the association between trimethoprim and acute kidney injury: the odds ratio comparing trimethoprim with amoxicillin increased from 1.72 to 2.36 (95% confidence interval 2.22 to 2.51). There were minimal changes in the sizes of the association with hyperkalaemia and death. When the analysis was restricted to users of renin-angiotensin system blockers at the time of a UTI (as opposed to adjusting for these drugs as covariates), the risk of acute kidney injury and hyperkalaemia after trimethoprim use were similar to the main analysis; adjusted odds ratio of 1.92 (1.29 to 2.87) for acute kidney injury and 2.22 (1.34 to 3.68) for hyperkalaemia. While the point estimate for death comparing trimethoprim with amoxicillin among users of renin-angiotensin system blockers was higher than among the whole population, confidence intervals were wide; within 14 days adjusted odds ratio for death was 1.12 (0.80 to 1.57). To enable comparison with other studies we counted the number of people prescribed renin-angiotensin system blockers who died with codes specifically suggestive of sudden death (I46, R96, R98, and R99) in the 14 days after antibiotic initiation. However, this included only six people so we were unable to analyse this outcome.</p>
<p id="p-38">Finally, analyses using multivariable regression and inverse probability treatment weighting approaches comparing trimethoprim with amoxicillin users (prescribed for a UTI) were consistent with those from the main analysis (web appendix 1).</p>
</div>
</div>
</div>
</div>
</div>
<div id="sec-21" class="subsection" bis_skin_checked="1">
<h2 class="">Discussion</h2>
<div id="sec-22" class="section discussion" bis_skin_checked="1">
<p id="p-39">Our results show that in older patients in the general population, regardless of use of renin-angiotensin system blockers or potassium-sparing diuretics, treatment with trimethoprim for a urinary tract infection (UTI) is associated with a 72% increase in the odds of acute kidney injury and a greater than doubling of the odds of hyperkalaemia compared with amoxicillin. We also show that ciprofloxacin is associated with a 48% increase in the odds of acute kidney injury compared with amoxicillin. In contrast, no antibiotic was associated with increased risk of death within 14 days compared with amoxicillin. The relative risks of acute kidney injury, hyperkalaemia, and death were similar in the general population and among those prescribed renin-angiotensin system blockers after trimethoprim use for a UTI.</p>
<div id="sec-23" class="subsection" bis_skin_checked="1">
<h3>Strengths and weaknesses of this study</h3>
<p id="p-40">This is the first study to quantify the association of trimethoprim with these outcomes, for an unselected general population cohort after a UTI. Our study used a large number of routine, prospectively collected clinical records from a UK general practice database that is broadly representative of the UK population.13&nbsp;Our results are therefore generalisable to all patients aged 65 and over, in contrast to previous research restricted to select populations (eg, patients taking renin-angiotensin system blockers and potassium-sparing diuretics).2321&nbsp;We have investigated the risk of adverse outcomes after taking antibiotics prescribed for a UTI, thereby reducing the confounding by indication that has limited previous research.234521&nbsp;As we investigated the effect of trimethoprim alone, we can be clear about the likely causative agent compared with research on the combination product co-trimoxazole.</p>
<p id="p-41">However, there are some important limitations. While we attempted to capture only simple UTIs (defined using primary care morbidity coding, but not excluding those with a history of more complex urological pathology) in our main analysis, we may have included patients with underlying urinary tract disorders, or other infections. Since different classes of antibiotic drugs are prescribed for different clinical scenarios, some degree of confounding by indication is unavoidable. However, we were able to reduce confounding by robustly defining and adjusting for variables that may have influenced the choice of antibiotic drug prescribed such as baseline renal function. As trimethoprim was less frequently prescribed for patients with urological pathology, this would likely have led to underestimating the odds of adverse outcomes, particularly acute kidney injury, for trimethoprim compared with the true result. Similarly, clinicians may have been cautious in prescribing trimethoprim to those at highest risk of acute kidney injury and hyperkalaemia, again leading to an underestimation of the true risk of adverse outcomes, particularly for those taking renin-angiotensin system blockers. However, the strongest evidence of adverse outcomes in association with trimethoprim use for those taking renin-angiotensin system blockers was only published towards the end of the period of this study.<a id="xref-ref-2-5" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-2">2</a><a id="xref-ref-21-4" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-21">21</a></p>
<p id="p-42">Our assessment of antibiotic exposure was based on prescriptions alone and patients may not have collected or taken their medicine. This may have led to differential misclassification owing to the severity of the infection, with resulting over or under estimation of the true effect size. However, we have attempted to mitigate for this by limiting the study to simple UTIs and adjusting, in particular, for history of renal or urological disease.</p>
<p id="p-43">We may also have misclassified the outcomes. Trimethoprim reduces tubular secretion of creatinine causing apparent renal impairment, although glomerular filtration rate does not fall.<a id="xref-ref-22-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-22">22</a>&nbsp;Lack of awareness of this physiological effect may have led clinicians to incorrectly diagnose acute kidney injury among the trimethoprim treated group, particularly given the current focus on creatinine based definitions of acute kidney injury. However, our definition of acute kidney injury relied on clinical coding of hospital admissions. In general, this leads to under ascertainment compared with analyses of serial creatinine tests but disproportionately captures more severe acute kidney injury.<a id="xref-ref-23-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-23">23</a>&nbsp;In addition, the increased risk of acute kidney injury dated back to 2001-04, before creatinine based definitions of acute kidney injury were in common use. It is also possible that there was a bias towards testing for or recording acute kidney injury or hyperkalaemia among patients taking trimethoprim if clinicians were aware of a potential association which would have led to an overestimation of the true risk of adverse outcomes.</p>
</div>
<div id="sec-24" class="subsection" bis_skin_checked="1">
<h3>Results in context</h3>
<p id="p-44">Multiple historic case reports and case series have implicated co-trimoxazole as a cause of reduced renal function,824&nbsp;interstitial nephritis,2526&nbsp;or acute tubular necrosis.27&nbsp;Among patients receiving co-trimoxazole in hospital, 6% developed a creatinine based definition of acute kidney injury that was attributed to the antibiotics.4&nbsp;However, we believe our study to be the first to show and quantify an association between trimethoprim alone and acute kidney injury in the general population. This is an important distinction as the sulphonamide antibiotics (including sulfamethoxazole) have been long recognised to be associated with a substantial risk of acute renal impairment, which could have been assumed to be causal.28&nbsp;Our finding of an association of ciprofloxacin with acute kidney injury is similar to another population based study that showed that users of fluoroquinolones had a 2.18-fold (95% confidence interval 1.74 to 2.73) higher rate of acute kidney injury.29&nbsp;However, ciprofloxacin is recommended for treatment of pyelonephritis, so an association with acute kidney injury may be due to confounding by severity of infection.</p>
<p id="p-45">An association between both co-trimoxazole, or trimethoprim alone, with hyperkalaemia is well reported, particularly in association with renin-angiotensin system blockers.<a id="xref-ref-3-6" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-3">3</a><a id="xref-ref-7-2" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-7">7</a><a id="xref-ref-8-3" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-8">8</a><a id="xref-ref-30-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-30">30</a><a id="xref-ref-31-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-31">31</a><a id="xref-ref-32-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-32">32</a><a id="xref-ref-33-1" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-33">33</a>&nbsp;Our results suggest that, regardless of other drug use (renin-angiotensin system blockers or potassium-sparing diuretics), trimethoprim (but not ciprofloxacin), is associated with a more than doubling of the odds of hyperkalaemia. There is an additional increase in the odds of hyperkalaemia after a UTI for those prescribed renin-angiotensin system blockers, and greater than sixfold increase in association with concomitant use of a potassium-sparing diuretic, regardless of antibiotic choice. Our findings are in keeping with those of a Canadian nested case-control study of older patients taking renin-angiotensin system blockers that identified a nearly sevenfold increased risk of hospital admission for hyperkalaemia with co-trimoxazole compared with other antibiotic drugs.<a id="xref-ref-3-7" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-3">3</a></p>
<p id="p-46">This cohort covers the years 1997-2015, and we have shown a progressive increase in the odds of developing hyperkalaemia and acute kidney injury after a UTI in more recent years. The increase in hyperkalaemia may be due to an increased rate of blood testing in primary care (particularly among groups at risk of high potassium levels, such as patients with diabetes or chronic kidney disease) or improved automatic recording of test results in general practice records. The marked increase in acute kidney injury over time as defined by Hospital Episode Statistics (HES) coding is well established and likely to be predominantly related to increased clinical focus and the adoption of consensus definitions defined by changes in creatinine levels.3435&nbsp;By adjusting for calendar period we aimed to minimise the influence of these secular trends on our results.</p>
<p id="p-47">In contrast to previous studies, we did not identify an increased risk of death from any cause in users of trimethoprim. The two previous papers that identified an increased risk of sudden death among users of renin-angiotensin system blockade taking co-trimoxazole, used a case-control design with cases defined by sudden death, among residents of Ontario over 18 years of follow-up.221&nbsp;They were therefore well powered for this outcome. We chose all cause death as a prespecified analysis owing to lack of power for cause specific death, since we restricted the cohort to patients with a UTI to address issues of confounding by indication for antibiotic choice that had limited previous research. In addition, since our cohort was not restricted to users of renin-angiotensin system blockers, the overall risk of sudden death was likely to be lower in our study. However, acknowledging these limitations, our findings of an odds ratio of death (comparing trimethoprim with amoxicillin) within seven days of a UTI of 1.51 (95% confidence interval 0.87 to 2.65) among users of renin-angiotensin system blockers are consistent with those of Fralick et al (adjusted odds ratio 1.38, 95% confidence interval 1.09 to 1.76).<a id="xref-ref-2-7" class="xref-bibr" href="https://www.bmj.com/content/360/bmj.k341#ref-2">2</a>&nbsp;However, our study also had greater ability to adjust for detailed characteristics, such as estimated glomerular filtration rate before UTI, which are likely to have reduced residual confounding. While we cannot exclude a small increase in the odds of sudden death after trimethoprim use among users of renin-angiotensin system blockers, we have found no evidence of an association between trimethoprim use and death in the whole population of older adults, and sudden death is a rare outcome (1.1% (6 in 542) of total deaths within 14 days of antibiotic initiation among users of renin-angiotensin system blockers).</p>
</div>
<div id="sec-25" class="subsection" bis_skin_checked="1">
<h3>Clinical implications</h3>
<p id="p-48">Recent national prescribing guidance recommends nitrofurantoin as the first line choice for treating UTIs in adults, with trimethoprim an equivalent choice for those with low risk of antimicrobial resistance, meaning that trimethoprim will continue to be commonly prescribed.10&nbsp;Current British National Formulary prescribing guidelines for trimethoprim mention an unquantified risk of hyperkalaemia (but not acute kidney injury), and a possible increase in risk if given with angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-receptor antagonists, and spironolactone.36&nbsp;Given the different rates of outcomes within subgroups of the population, it is useful to consider absolute and relative risk together by calculating the excess number of events attributable to trimethoprim treatment, although our very strict definition of a UTI means that these estimates should be treated with caution. As an example, our results suggest that for 1000 UTI episodes treated with antibiotics in those aged 65 and over not taking renin-angiotensin system blockers, treatment with trimethoprim, instead of amoxicillin, would result in one additional case of hyperkalaemia and two of acute kidney injury. Among those taking either renin-angiotensin system blockers or potassium-sparing diuretics the figures would be very similar; two additional cases of both hyperkalaemia and acute kidney injury. However, treatment with both renin-angiotensin system blockers and potassium-sparing diuretics would result in 18 additional cases of hyperkalaemia and 11 of acute kidney injury.</p>
<p id="p-49">A small increased absolute risk of a rare outcome (such as in the general population) from trimethoprim may be acceptable when set against a need for multiple treatment options for patients with allergy to other antibiotics or bacterial resistance patterns. While acute kidney injury and hyperkalaemia may result in avoidable morbidity and hospital admission, it is reassuring that we have not identified an increased risk of death, suggesting that there is appropriate response to these outcomes. Our results show that trimethoprim continues to be prescribed to people at high risk of adverse outcomes including patients with advanced renal impairment and those taking renin-angiotensin system blockers with potassium-sparing diuretics. For groups at high risk of acute kidney injury and hyperkalaemia, other antibiotics should be considered, but, if this is not possible, monitoring of renal function and potassium levels should be performed, in line with the existing summary of product characteristics for trimethoprim.</p>
</div>
<div id="sec-26" class="subsection" bis_skin_checked="1">
<h3>Conclusion</h3>
<p id="p-50">Our results show that trimethoprim is associated with greater risk of acute kidney injury and hyperkalaemia compared with other antibiotic drugs for a UTI, among the general population aged 65 and over, and not just those treated with renin-angiotensin system blockers. However, this is not associated with an increased risk of death.</p>
<div id="boxed-text-1" class="4" bis_skin_checked="1">
<div id="sec-27" class="subsection" bis_skin_checked="1">
<h4>What is already known on this topic</h4>
<ul id="list-1" class="list-simple ">
<li id="list-item-1">
<p id="p-51">Co-trimoxazole (a combination antibiotic drug containing trimethoprim and sulfamethoxazole) has been associated with an increased risk of sudden death, which may be mediated by increased serum potassium</p>
</li>
<li id="list-item-2">
<p id="p-52">Previous research is limited to specific patient groups (eg, patients taking renin-angiotensin system blockers) and is limited by possible confounding by type and severity of infection</p>
</li>
<li id="list-item-3">
<p id="p-53">It is not known if the risks for trimethoprim are similar to those for co-trimoxazole</p>
</li>
</ul>
</div>
<div id="sec-28" class="subsection" bis_skin_checked="1">
<h4>What this study adds</h4>
<ul id="list-2" class="list-simple ">
<li id="list-item-4">
<p id="p-54">Compared with amoxicillin, the risk of acute kidney injury and hyperkalaemia increased in the two weeks after taking trimethoprim for a UTI</p>
</li>
<li id="list-item-5">
<p id="p-55">The risk of sudden death was not higher among patients prescribed trimethoprim compared with amoxicillin</p>
</li>
<li id="list-item-6">
<p id="p-56">Trimethoprim is associated with a greater risk of acute kidney injury and hyperkalaemia compared with other antibiotic drugs for a UTI among the general population as well as those taking renin-angiotensin system blockers</p>
</li>
</ul>
</div>
</div>
</div>
</div>
<div id="ack-1" class="section ack" bis_skin_checked="1">
<h2>Acknowledgments</h2>
<p id="p-57">This paper is dedicated to the memory of Dr Adrian Root, a much-loved colleague and friend. With natural frequencies we will remember him.</p>
</div>
</div>
<h2>Footnotes</h2>
<hr>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</article>
</div>
</div>
<div id="fn-group-1" class="section fn-group" bis_skin_checked="1">
<ul>
<li id="fn-1" class="fn-participating-researchers">
<p id="p-58">Contributors: LAT had the original idea for the study. All authors were involved in the study design. EC and KEM contributed equally to this paper. EC undertook the data management and primary analysis, and wrote early drafts of the manuscript. KM supervised each stage of data management and preliminary analyses, and wrote the first complete manuscript draft. CL undertook the inverse probability of treatment weighting analysis. All authors contributed to further drafts and approved the final manuscript. All authors had full access to the data in the study. EC and KEM are the guarantors.</p>
</li>
<li id="fn-2" class="fn-financial-disclosure">
<p id="p-59">Funding: LAT and KEM were funded by a Wellcome Trust intermediate clinical fellowship (101143/Z/13/Z). LS and EC were supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (098504/Z/12/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
</li>
<li id="fn-3" class="fn-conflict">
<p id="p-60">Competing interests: All authors have completed the Unified Competing Interest form at&nbsp;<a href="http://www.icmje.org/coi_disclosure.pdf">www.icmje.org/coi_disclosure.pdf</a>&nbsp;(available on request from the corresponding author) and declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.</p>
</li>
<li id="fn-4" class="fn-other">
<p id="p-61">Ethical approval: This study was approved by the London School of Hygiene and Tropical Medicine Research Ethics Committee (reference 12014) and by the Clinical Practice Research Datalink independent scientific advisory committee (ISAC protocol number: 16_087R).</p>
</li>
<li id="fn-5" class="fn-other">
<p id="p-62">Data sharing: No additional data are available.</p>
</li>
<li id="fn-6" class="fn-other">
<p id="p-63">Transparency: The manuscripts guarantors (EC and KEM) affirm that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.</p>
</li>
</ul>
</div>
<div id="license-1" class="license" bis_skin_checked="1">
<p id="p-1">This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See:&nbsp;<a href="https://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
<p>&nbsp;</p>
</div>
<h2>References</h2>
<p>1. ↵Center for Disease Dynamics Economics and Policy. Human use of antibiotics. In: The state of the world’s antibiotics 2015. https://cddep.org/wp-content/uploads/2017/06/swa_edits_9.16.pdf<br>
2. ↵Fralick M, Macdonald EM, Gomes T, et al., Canadian Drug Safety and Effectiveness Research Network. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ2014;349:g6196.. doi:doi:10.1136/bmj.g6196pmid:25359996Abstract/FREE Full TextGoogle Scholar<br>
3. ↵Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med2010;170:1045-9. doi:doi:10.1001/archinternmed.2010.142pmid:20585070CrossRefPubMedWeb of ScienceGoogle Scholar<br>
4. ↵Fraser TN, Avellaneda AA, Graviss EA, Musher DM. Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother2012;67:1271-7.. doi:doi:10.1093/jac/dks030pmid:22351681CrossRefPubMedWeb of ScienceGoogle Scholar<br>
5. ↵Alappan R, Buller GK, Perazella MA. Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem?Am J Nephrol1999;19:389-94.. doi:doi:10.1159/000013483pmid:10393376CrossRefPubMedWeb of ScienceGoogle Scholar<br>
6. ↵Michel A, Martín-Pérez M, Ruigómez A, García Rodríguez LA. Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. Eur J Heart Fail2015;17:205-13.. doi:doi:10.1002/ejhf.226pmid:25581138CrossRefPubMedGoogle Scholar<br>
7. ↵Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. BMJ2011;343:d5228-5228.. doi:doi:10.1136/bmj.d5228pmid:21911446Abstract/FREE Full TextGoogle Scholar<br>
8. ↵Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. Ann Pharmacother2013;47:1618-26.. doi:doi:10.1177/1060028013509973pmid:24259630CrossRefPubMedGoogle Scholar<br>
9. ↵NHS England/Commissioning Strategy/Contracts and Incentives. Technical Guidance Annex B Information on Quality Premium. 2017. https://www.england.nhs.uk/wp-content/uploads/2015/12/ann-b-qual-prem.pdf<br>
10. ↵Public Health England. Managment of infection guidance for primary care – Summary tables. 2017. https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care<br>
11. ↵Scottish Intercollegiate Guidelines Network. Scottish Intercollegiate Guidelines Network (SIGN). Management of suspected bacterial urinary tract infection in adults. 2012. http://www.sign.ac.uk<br>
12. ↵Butler CC, Dunstan F, Heginbothom M, et al. Containing antibiotic resistance: decreased antibiotic-resistant coliform urinary tract infections with reduction in antibiotic prescribing by general practices. Br J Gen Pract2007;57:785-92.pmid:17925135Abstract/FREE Full TextGoogle Scholar<br>
13. ↵Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol2015;44:827-36.. doi:doi:10.1093/ije/dyv098pmid:26050254CrossRefPubMedGoogle Scholar<br>
14. ↵Mathur R, Bhaskaran K, Chaturvedi N, et al. Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health (Oxf)2014;36:684-92.. doi:doi:10.1093/pubmed/fdt116pmid:24323951CrossRefPubMedGoogle Scholar<br>
15. ↵Bhaskaran K, Forbes HJ, Douglas I, Leon DA, Smeeth L. Representativeness and optimal use of body mass index (BMI) in the UK Clinical Practice Research Datalink (CPRD). BMJ Open2013;3:e003389.. doi:doi:10.1136/bmjopen-2013-003389pmid:24038008Abstract/FREE Full TextGoogle Scholar<br>
16. ↵HSCIC. Hospital Episode Statistics. http://content.digital.nhs.uk/hes (accessed 25 Jun2015).<br>
17. ↵Mansfield KE, Nitsch D, Smeeth L, Bhaskaran K, Tomlinson LA. Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study. BMJ Open2016;6:e012690.. doi:doi:10.1136/bmjopen-2016-012690pmid:28003286Abstract/FREE Full TextGoogle Scholar<br>
18. ↵Tomlinson LA, Riding AM, Payne RA, et al. The accuracy of diagnostic coding for acute kidney injury in England – a single centre study. BMC Nephrol2013;14:58.. doi:doi:10.1186/1471-2369-14-58pmid:23496869CrossRefPubMedGoogle Scholar<br>
19. ↵London School of Hygiene &amp; Tropical Medicine. Code lists for “Adverse outcomes following trimethoprim for urinary tract infection in patients over 65: a cohort study”. http://datacompass.lshtm.ac.uk/502/<br>
20. ↵Levey AS, Stevens LA, Schmid CH, et al., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med2009;150:604-12. doi:doi:10.7326/0003-4819-150-9-200905050-00006pmid:19414839CrossRefPubMedWeb of ScienceGoogle Scholar<br>
21. ↵Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim–sulfamethoxazole and risk of sudden death among patients taking spironolactone. C Can Med Assoc J 2015;187:1-6.http://www.cmaj.ca/content/early/2015/02/02/cmaj.140816<br>
22. ↵Naderer O, Nafziger AN, Bertino JS Jr.. Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. Antimicrob Agents Chemother1997;41:2466-70.pmid:9371351Abstract/FREE Full TextGoogle Scholar<br>
23. ↵Sawhney S, Fluck N, Marks A, et al. Acute kidney injury-how does automated detection perform?Nephrol Dial Transplant2015;30:1853-61.. doi:doi:10.1093/ndt/gfv094pmid:25925702CrossRefPubMedGoogle Scholar<br>
24. ↵Trollfors B, Wahl M, Alestig K. Co-trimoxazole, creatinine and renal function. J Infect1980;2:221-6. http://www.sciencedirect.com/science/article/pii/S016344538090626X. doi:doi:10.1016/S0163-4453(80)90626-Xpmid:6821086CrossRefPubMedWeb of ScienceGoogle Scholar<br>
25. ↵Saltissi D, Pusey CD, Rainford DJ. Recurrent acute renal failure due to antibiotic-induced interstitial nephritis. Br Med J1979;1:1182-3.. doi:doi:10.1136/bmj.1.6172.1182-apmid:445001FREE Full TextGoogle Scholar<br>
26. ↵Smith EJ, Light JA, Filo RS, Yum MN. Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients. JAMA1980;244:360-1.. doi:doi:10.1001/jama.1980.03310040042025pmid:6993701CrossRefPubMedWeb of ScienceGoogle Scholar<br>
27. ↵Rudra T, Webb DB, Evans AG. Acute tubular necrosis following co-trimoxazole therapy. Nephron1989;53:85-6. doi:doi:10.1159/000185711pmid:2528700CrossRefPubMedWeb of ScienceGoogle Scholar<br>
28. ↵Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med2008;36(Suppl):S216-23.. doi:doi:10.1097/CCM.0b013e318168e375pmid:18382197CrossRefPubMedWeb of ScienceGoogle Scholar<br>
29. ↵Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JA. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ2013;185:E475-82.. doi:doi:10.1503/cmaj.121730pmid:23734036Abstract/FREE Full TextGoogle Scholar<br>
30. ↵Higashioka K, Niiro H, Yoshida K, et al. Renal Insufficiency in Concert with Renin-angiotensin-aldosterone Inhibition Is a Major Risk Factor for Hyperkalemia Associated with Low-dose Trimethoprim-sulfamethoxazole in Adults. Intern Med2016;55:467-71.. doi:doi:10.2169/internalmedicine.55.5697pmid:26935365CrossRefPubMedGoogle Scholar<br>
31. ↵Chan WY, Clark AB, Wilson AM, Loke YK, TIPAC investigators. The effect of co-trimoxazole on serum potassium concentration: safety evaluation of a randomized controlled trial. Br J Clin Pharmacol2017;83:1808-14. doi:doi:10.1111/bcp.13263.pmid:28192629CrossRefPubMedGoogle Scholar<br>
32. ↵Mihm LB, Rathbun RC, Resman-Targoff BH. Hyperkalemia associated with high-dose trimethoprim-sulfamethoxazole in a patient with the acquired immunodeficiency syndrome. Pharmacotherapy1995;15:793-7.pmid:8602391PubMedGoogle Scholar<br>
33. ↵Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. Drug Saf2000;22:227-36.. doi:doi:10.2165/00002018-200022030-00006pmid:10738846CrossRefPubMedWeb of ScienceGoogle Scholar<br>
34. ↵Siew ED, Davenport A. The growth of acute kidney injury: a rising tide or just closer attention to detail?Kidney Int2015;87:46-61.. doi:doi:10.1038/ki.2014.293pmid:25229340CrossRefPubMedGoogle Scholar<br>
35. ↵Kolhe NV, Muirhead AW, Wilkes SR, Fluck RJ, Taal MW. The epidemiology of hospitalised acute kidney injury not requiring dialysis in England from 1998 to 2013: retrospective analysis of hospital episode statistics. Int J Clin Pract2016;70:330-9.. doi:doi:10.1111/ijcp.12774pmid:26799821CrossRefPubMedGoogle Scholar<br>
36. ↵Joint Formulary Committee. British National Formulary (BNF) 72. BMJ Publishing Group Ltd and Royal Pharmaceutical Society 2016. https://www.bnf.org/products/bnf-online/</p>
<p>&nbsp;</p>
<h2>Source</h2>
<hr>
<p>&nbsp;</p>
<p><a href="https://www.bmj.com/content/360/bmj.k341">https://www.bmj.com/content/360/bmj.k341</a></p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/01/06/trimethoprim-use-for-urinary-tract-infection-and-risk-of-adverse-outcomes-in-older-patients-cohort-study/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/01/06/trimethoprim-use-for-urinary-tract-infection-and-risk-of-adverse-outcomes-in-older-patients-cohort-study/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5168 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>05.01.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/01/05/amoxicillin-clavulanic-acid-for-the-treatment-of-odontogenic-infections-a-randomised-study-comparing-efficacy-and-tolerability-versus-clindamycin/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/01/05/amoxicillin-clavulanic-acid-for-the-treatment-of-odontogenic-infections-a-randomised-study-comparing-efficacy-and-tolerability-versus-clindamycin/">Amoxicillin/Clavulanic Acid for the Treatment of Odontogenic Infections: A Randomised Study Comparing Efficacy and Tolerability versus Clindamycin</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p><span class="">Archiel Launch Tancawan,<sup>1</sup>&nbsp;</span><span class="">Maria Noemi Pato,<sup>2</sup>&nbsp;</span><span class="">Khamiza Zainol Abidin,<sup>3</sup>&nbsp;</span><span class="">A. S. Mohd Asari,<sup>4</sup>&nbsp;</span><span class="">Tran Xuan Thong,<sup>5</sup>&nbsp;</span><span class=""><b>Puja Kochhar</b>,<sup>6</sup>&nbsp;</span><span class="">Chandra Muganurmath,<sup>7</sup>&nbsp;</span><span class="">Monique Twynholm,<sup>8</sup>&nbsp;and&nbsp;</span><span class="">Keith Barker<sup>9</sup></span></p>
<p>&nbsp;</p>
<h4 id="abstract" class="header">Abstract</h4>
<hr>
<p>&nbsp;</p>
<p><i>Background</i>. Treatment of odontogenic infections includes surgical drainage and adjunctive antibiotics. This study was designed to generate efficacy and safety data to support twice daily dosing of amoxicillin/clavulanic acid compared to clindamycin in odontogenic infections.&nbsp;<i>Methods</i>. This was a phase IV, randomised, observer blind study; 472 subjects were randomised to receive amoxicillin/clavulanic acid (875 mg/125 mg BID, n=235 ) or clindamycin (150 mg QID, n=235) for 5 or 7 days based on clinical response. The primary endpoint was percentage of subjects achieving clinical success (composite measure of pain, swelling, fever, and additional antimicrobial therapy required) at the end of treatment. <i>Results</i>. The upper limit of two-sided 95% confidence interval for the treatment difference between the study arms (7.7%) was within protocol specified noninferiority margin of 10%, thus demonstrating noninferiority of amoxicillin/clavulanic acid to clindamycin. Secondary efficacy results showed a higher clinical success rate at Day 5 in the amoxicillin/clavulanic acid arm. Most adverse events (raised liver enzymes, diarrhoea, and headache) were similar across both arms and were of mild to moderate intensity.&nbsp;<i>Conclusion</i>. Amoxicillin/clavulanic acid was comparable to clindamycin in achieving clinical success (88.2% versus 89.7%) in acute odontogenic infections and the safety profile was consistent with the known side effects of both drugs.&nbsp;<i>Trial Registration</i>. This trial is registered with Clinicaltrials.gov identifier:&nbsp;NCT02141217.</p>
<h4 id="introduction">1. Introduction</h4>
<hr>
<p>&nbsp;</p>
<p>Odontogenic infections are one of the most prevalent diseases worldwide and the principal reason for seeking dental care. Dental prescriptions account for nearly 7% to 11% of all common antibiotic prescriptions [<a class="refAnchor">1</a>]. The commonest emergency odontogenic infections are periapical abscess (25%), pericoronitis (11%), and periodontal abscess (7%) [<a class="refAnchor">2</a>].</p>
<p>Odontogenic infections are mostly polymicrobial and frequently encountered odontopathogens are<i>&nbsp;Streptococci</i>&nbsp;spp.,<i>&nbsp;Corynebacterium</i>&nbsp;spp. and<i>&nbsp;Staphylococcus</i>&nbsp;spp.,<i>&nbsp;Prevotella</i>&nbsp;spp.,<i>&nbsp;Porphyromonas</i>&nbsp;spp.,<i>&nbsp;Fusobacterium</i>&nbsp;spp., and<i>&nbsp;Bacteroides</i>&nbsp;spp. [<a class="refAnchor">2</a>,&nbsp;<a class="refAnchor">3</a>]. Therapeutic success in odontogenic infections is determined by the control of infection by surgical debridement and/or antimicrobial therapy which is indicated when there are clear signs of systemic involvement such as pyrexia or lymphadenopathy [<a class="refAnchor">2</a>]. The polymicrobial nature of odontogenic infections necessitates the use of antibiotics active against both aerobic and anaerobic bacteria [<a class="refAnchor">4</a>]. The antibiotics most commonly prescribed for acute dental abscesses are amoxicillin, penicillin, metronidazole, and erythromycin with clindamycin as an alternative in individuals allergic to the beta-lactam antibiotics [<a class="refAnchor">3</a>].</p>
<p>Recently, published evidence suggests that penicillin and amoxicillin are being rendered increasingly less effective because of beta-lactamase producing bacteria. More than half of the Gram-negative anaerobic bacilli (including<i>&nbsp;Prevotella</i>,<i>&nbsp;Porphyromonas</i>,<i>&nbsp;Bacteroides</i>, and<i>&nbsp;Fusobacterium</i>&nbsp;spp.) are capable of producing beta-lactamase leading to treatment failures in dental infections [<a class="refAnchor">5</a>]. Studies have revealed the presence of beta-lactamase producing species in 74–88% of patients with periodontitis [<a class="refAnchor">4</a>]. Addition of a beta-lactamase inhibitor such as clavulanic acid to amoxicillin (Augmentin) confers resistance to beta-lactamases thereby extending the antibiotic spectrum to anaerobes such as<i>&nbsp;Prevotella</i>&nbsp;spp. and<i>&nbsp;Bacteroides</i>&nbsp;spp. anaerobes and to<i>&nbsp;Staphylococcus</i>&nbsp;spp. [<a class="refAnchor">4</a>]. Efficacy of amoxicillin/clavulanic acid in the treatment of acute periapical abscess has been established in several studies [<a class="refAnchor">2</a>,&nbsp;<a class="refAnchor">4</a>].</p>
<p>Clindamycin is a broad-spectrum antibiotic with activity against aerobic, anaerobic bacteria including coverage against beta-lactamase producing pathogens [<a class="refAnchor">6</a>]. Clinical trials have demonstrated the efficacy of clindamycin in treating odontogenic infections [<a class="refAnchor">7</a>–<a class="refAnchor">11</a>]. Use of clindamycin in dental infections is based on careful patient selection in view of reported cases of pseudomembranous colitis (a rare but serious consequence of clindamycin).</p>
<p>Despite published evidence evaluating different oral formulations of amoxicillin/clavulanic acid in dental infections, there is limited published data on the use of twice daily dosing of 875/125 mg in odontogenic infections. Available evidence suggests that twice daily dosing with 875/125 mg amoxicillin/clavulanic acid results in a successful clinical outcome, better patient compliance, and less gastrointestinal upset, due to a reduction in the dose of clavulanic acid [<a class="refAnchor">1</a>]. The aim of the current study was to assess the clinical efficacy and safety of amoxicillin/clavulanic acid 875/125 mg twice daily versus clindamycin 150 mg four times daily, for 5 or 7 days in dental infections.</p>
<h4 id="methods">2. Methods</h4>
<hr>
<p>&nbsp;</p>
<h5 id="sec2.1">2.1. Study Design</h5>
<p>AUG117044 was a phase IV, randomised, parallel group, comparative, observer blind study to evaluate efficacy, safety, and tolerability of amoxicillin/clavulanic acid (875 mg/125 mg) and clindamycin (150 mg) in the treatment of acute odontogenic infection with or without abscess. The study was conducted in fifteen centres across four countries with four centres each in Malaysia, Philippines, and Vietnam and three in Thailand.</p>
<p>The study protocol, the informed consent, and other information that required preapproval were reviewed and approved by a national, regional, or investigational centre ethics committee or institutional review board, in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) and applicable country-specific requirements. Written informed consent was obtained from each subject prior to the performance of any study-specific procedures. The study was conducted in accordance with ICH GCP and all applicable subject privacy requirements and the ethical principles that are outlined in the Declaration of Helsinki 2008.</p>
<p>A total of 472 subjects were randomised in a 1 : 1 ratio in each of the treatment arms. The study included a one-day screening period followed by a treatment period of five days that could be extended to seven days based on clinical response. Standard surgical intervention for odontogenic infection was permitted only before commencing study treatment. Eligible subjects were randomized on the day of their screening visit or within a day of screening. Efficacy and safety evaluations were performed on Day 2, Day 5, and/or Day 7 (based on treatment duration) (Figure&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/fig1/" target="_blank" rel="noopener">1</a>). Study treatment included amoxicillin/clavulanic acid (875 mg/125 mg) administered twice daily or clindamycin (150 mg) administered four times daily along with meals for 5 or 7 days. Clinical efficacy (cure (cure was defined as complete resolution of signs and symptoms of infection present at baseline such that no additional antimicrobial therapy was required), improvement (improvement was defined as resolution of fever (if present at baseline) and &gt;70% reduction in swelling and pain and improvement in other signs and symptoms such that no additional antimicrobial therapy was required), and failure (failure was defined as inability to improve the signs and symptoms of infection after seven days of therapy so that additional antimicrobial therapy was required)) of the study treatment was assessed based on the response shown by the subjects on the Visual Analogue Scale (VAS) scores of pain and swelling. Since these clinical efficacy parameters were based on symptomatic relief, an optimal study design would have been a double blind design. However, the different dosage regimens and formulations of the study drugs presented practical challenges for a double blind design. Based on these considerations, the study was designed to be an observer blind study with the investigator remaining blinded throughout the study period. An unblinded study team member was appointed for the study for drug dispensing and drug accountability and was also present during the clinic visits to ensure that the investigators remained blinded to treatment assignment. Adherence to the study design requirements was essential and no protocol waivers or exemptions were allowed during the study. This study did not require an independent data safety monitoring board and no interim analysis was performed.</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://static-01.hindawi.com/articles/ijd/volume-2015/472470/figures/472470.fig.001.svgz"><noscript><img src="https://static-01.hindawi.com/articles/ijd/volume-2015/472470/figures/472470.fig.001.svgz" /></noscript></p>
<p>&nbsp;</p>
<div class="floats-partial-caption" bis_skin_checked="1"><span class="caption-text">Figure 1</span><a class="caption-partial-url" title="full view" href="https://www.hindawi.com/journals/ijd/2015/472470/fig1/" target="_blank" rel="noopener" aria-label="full view">&nbsp;</a></div>
<div class="floats-partial-caption-text" bis_skin_checked="1">
<div bis_skin_checked="1">Study schema. Note: the study had a 1-day screening period (Day 1 to Day 0) during which eligibility was assessed and laboratory tests were performed. Randomisation occurred within 24 hours of screening at baseline (Day 0). Further visits (Day 2, Day 5, and Day 7) were calculated from the baseline/randomisation visit (Day 0).</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h5 id="sec2.2">2.2. Study Population</h5>
<p>Inclusion criteria: the study enrolled subjects ≥18 years of age with a diagnosis of acute odontogenic infections (periapical abscess, acute periodontitis, and pericoronitis) that required antibiotic therapy. Radiographic evidence of odontogenic infection and dental pain on mastication were mandatory diagnostic criteria for enrollment. Exclusion criteria: subjects presenting with complicated odontogenic infections (such as osteomyelitis, dentocutaneous and dentoalveolar fistula, and facial-space swelling) or odontogenic infections secondary to traumatic injury or requiring hospitalisation, aggressive intravenous antimicrobial therapy, or local application of antimicrobials for the treatment of odontogenic infection were excluded. Further, patients with other key exclusion criteria such as conditions prone to infective endocarditis and those treated with systemic antibiotics within two weeks before the study of drug administration or injectable long acting antibiotics administered four weeks prior to study of drug administration were also excluded from study.</p>
<h5 id="sec2.3">2.3. Study Variables</h5>
<p>The primary objective of the study was the comparison of clinical efficacy of amoxicillin/clavulanic acid with clindamycin in subjects with acute odontogenic infection with or without abscess. This efficacy endpoint was based on the percentage of subjects achieving clinical success (cure or improvement) at the end of treatment (Day 5 or 7). The secondary endpoints of the study included percentage of subjects achieving clinical success at Day 5 and change in the VAS score for pain and swelling from baseline to Days 2, 5, and 7. Safety assessments included monitoring of adverse events (AEs) and serious adverse events (SAEs) from the start of study treatment until the end of study treatment. The antibiotic susceptibility of bacterial isolates obtained from pus specimens was recorded at baseline.</p>
<h5 id="sec2.4">2.4. Statistical Analysis</h5>
<p>A sample size of 205 evaluable subjects in each of the treatment arms provided 90% power to assess noninferiority for the primary endpoint. This was based on a noninferiority margin of 10%, assuming clinical success response rate in the comparator arm (clindamycin 150 mg) of 90% and a one-sided&nbsp;%. Considering a 15% drop-out rate, a final sample size of 236 subjects in each study group was chosen. Thus total randomised subjects in the study were 472 for a 1 : 1 treatment allocation in each study group to get at least 205 evaluable subjects in each arm.</p>
<p>The per-protocol (PP) population was a subset of Intent-to-Treat (ITT) population that had a postbaseline clinical success response assessment and did not report major protocol deviation(s). However, those subjects who discontinued from the study without any postbaseline assessment and where the reason for discontinuation was documented as “Lack of Efficacy” or “Treatment Failure” were included in the PP population with clinical success outcome treated as “Clinical Failure.” For noninferiority analysis, the PP population using observed case (OC) method was treated as the primary dataset. The assessment of noninferiority for clinical success response was based on two-sided 95% confidence interval (CI); the upper limit of two-sided 95% CI of the difference of proportion between the two treatments of less than 0.10 (10%) was set to conclude the noninferiority between the treatment arms. The analysis of the Intent-to-Treat-Efficacy (ITT-E) population (all randomised subjects with at least one postbaseline assessment of clinical success response) using the OC dataset was provided as a sensitivity analysis for the primary endpoint and was also used to evaluate secondary endpoints. The ITT population (all randomised subjects who received at least one dose of study medication) was the safety dataset for the study.</p>
<p>The investigator’s judgment was considered decisive for the assessment of clinical improvement in a subject. In the event that the main signs and symptoms were cured or improved (complete resolution of fever and &gt;70% reduction in swelling and pain) and there was “no change” or “worsening from baseline” in other signs and symptoms (such as increased leucocyte count/tooth mobility/lymphadenopathy), the investigator’s opinion was sought as to whether additional antimicrobial therapy was required. Subjects that required no additional antimicrobial therapy per the investigators judgment were considered a “success” while those requiring additional antimicrobials were deemed as “failures.” The analysis based on the investigator’s judgment of clinical success or failure was considered as the primary analysis for testing of noninferiority between the treatment groups and the analysis excluding the investigator’s assessment for clinical success was presented as supportive analysis.</p>
<p>For sensitivity analysis, all subjects with an assessment of cure or improvement (complete resolution of fever, &gt;70% reduction in swelling and pain) but with “no change” or “worsening from baseline” in other signs and symptoms (increased leucocyte count/tooth mobility/lymphadenopathy) were considered as “Clinical Failures” irrespective of the clinical judgment of investigator.</p>
<p>Clinical laboratory assessments were summarized on ITT population using OC approach for missing values. Liver function tests (LFTs) values were summarised after values were normalised. Any LFT parameter which was out of reference range for that particular laboratory was considered an adverse event (AE). However, AST, ALT, and alkaline phosphatase values &gt;3 × upper limit of reference range (ULRR) and total bilirubin &gt;1.5 × ULRR were considered to be of potential clinical concern (PCC) as defined by sponsor.</p>
</div>
<p>&nbsp;</p>
<h4 id="results">3. Results</h4>
<hr>
<p>&nbsp;</p>
<h5 id="sec3.1">3.1. Participants</h5>
<p>A total of 510 subjects were screened for a planned enrollment of 472 subjects. Amongst the 472 randomised subjects, 235 (46.1%) subjects were randomised to the amoxicillin/clavulanic acid arm and 237 (46.5%) to the clindamycin arm. However, a total of 236 subjects received amoxicillin/clavulanic acid and 235 subjects received clindamycin (one subject randomised to the amoxicillin/clavulanic acid arm did not receive any study drug and two subjects randomised to the clindamycin arm incorrectly received amoxicillin/clavulanic acid). A similar proportion of enrolled subjects completed the study in both the treatment arms (223 (94.9%) in the amoxicillin/clavulanic acid arm and 229 (96.6%) in the clindamycin arm). A total of 11 (4.7%) subjects in the amoxicillin/clavulanic acid arm and 8 (3.4%) subjects in the clindamycin arm discontinued before study completion and the main reasons for discontinuations were as follows: AEs (one and two in amoxicillin/clavulanic acid and clindamycin arms, resp.), protocol noncompliance (one and four in amoxicillin/clavulanic acid and clindamycin arms, resp.), and meeting the withdrawal criteria (nine and two in amoxicillin/clavulanic acid and clindamycin arms, resp.).</p>
<h5 id="sec3.2">3.2. Baseline Characteristics</h5>
<p>Subjects recruited in the study were South East Asian in origin with similar age and sex distribution across both treatment arms. Periapical abscess was the predominant odontogenic infection across both arms (56.8% and 54.9% subjects in the amoxicillin/clavulanic acid and clindamycin arms, resp.). There was no significant difference in baseline characteristics such as pain, swelling, radiographic evidence of dental infection, and medical history/preexisting conditions between the treatment arms (Table&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/tab1/" target="_blank" rel="noopener">1</a>).</p>
<p>&nbsp;</p>
<p><img class="alignnone size-medium wp-image-5169" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20640%20835'%3E%3C/svg%3E" alt="" width="640" height="835" data-lazy-srcset="/../../../../wp-content/uploads/2021/01/tabl1-640x835.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/tabl1-320x417.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/tabl1.jpg 667w" data-lazy-sizes="(max-width: 640px) 100vw, 640px" data-lazy-src="/../../../../wp-content/uploads/2021/01/tabl1-640x835.jpg"><noscript><img class="alignnone size-medium wp-image-5169" src="/../../../../wp-content/uploads/2021/01/tabl1-640x835.jpg" alt="" width="640" height="835" srcset="/../../../../wp-content/uploads/2021/01/tabl1-640x835.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/tabl1-320x417.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/tabl1.jpg 667w" sizes="(max-width: 640px) 100vw, 640px" /></noscript></p>
<p>&nbsp;</p>
<h5 id="sec3.3">3.3. Primary Efficacy Results</h5>
<p>The primary efficacy analysis using the PP population demonstrated that the clinical efficacy of amoxicillin/clavulanic acid was noninferior to clindamycin, since the upper limit of two-sided 95% CI was within the protocol specified noninferiority margin of 10%.</p>
<p>The percentage of subjects achieving clinical success using the primary analysis population was 88.2% (95% CI: 83.0%, 92.2%) in the amoxicillin/clavulanic acid arm and 89.7% (95% CI: 84.6%, 93.5%) in the clindamycin arm. The treatment difference between the treatment arms was 1.5% (95% CI: −4.7%, 7.7%) using Miettinen and Nurminen method, 1.5% (95% CI: −4.9%, 8.0%) using Farrington and Manning method, and 1.5% (95% CI: −4.5%, 7.6%) using a two-sample proportion test. Since the upper limit of the two-sided 95% CI for between-group percentages differences was less than the prespecified noninferiority margin of 10%, noninferiority of amoxicillin/clavulanic acid to clindamycin with respect to clinical success was demonstrated. This result was also corroborated by sensitivity analysis using the ITT-E population (Table&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/tab2/" target="_blank" rel="noopener">2</a>).</p>
<div class="floats-full-page-caption" bis_skin_checked="1">Primary efficacy endpoint: clinical success outcome at the end of the study.</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab2" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="6">
<hr>
</td>
</tr>
<tr class="thead">
<td rowspan="2" align="left">Population</td>
<td rowspan="2" align="center">Clindamycin [% (95% CI)]</td>
<td rowspan="2" align="center">Amoxicillin/clavulanic acid [% (95% CI)]</td>
<td colspan="3" align="center">Treatment difference</td>
</tr>
<tr class="thead">
<td align="center">Miettinen and Nurminen method (primary) [% (95% CI)]</td>
<td align="center">Farrington and Manning method [% (95% CI)]</td>
<td align="center">Two-sample proportion test [% (95% CI)]</td>
</tr>
<tr>
<td class="thead-hr" colspan="6">
<hr>
</td>
</tr>
<tr>
<td align="left">PP</td>
<td align="center">89.7%<br>
(84.6%, 93.5%)</td>
<td align="center">88.2% (83.0%, 92.2%)</td>
<td align="center">1.5% ( 95 CI: −4.7%, 7.7%)</td>
<td align="center">1.5%<br>
(−4.9%, 8.0%)</td>
<td align="center">1.5% (−4.5%, 7.6%)</td>
</tr>
<tr>
<td colspan="6" align="center">
<hr>
</td>
</tr>
<tr>
<td align="left">ITT-E</td>
<td align="center">86.4%<br>
(81.3%, 90.5%)</td>
<td align="center">85.5% (80.3%, 89.8%)</td>
<td align="center">0.9% (−5.5%, 7.3%)</td>
<td align="center">0.9%<br>
(−5.6%, 7.4%)</td>
<td align="center">0.9% (−5.5%, 7.2%)</td>
</tr>
<tr>
<td colspan="6" align="center">
<hr>
</td>
</tr>
<tr>
<td align="left">ITT (randomised treatment arm)</td>
<td align="center">85.7%<br>
(80.5%, 89.9%)</td>
<td align="center">83.3% (77.9%, 87.9%)</td>
<td align="center">2.3% (−4.3%, 9.0%)</td>
<td align="center">2.3%<br>
(−4.4%, 9.0%)</td>
<td align="center">2.3% (−4.2%, 8.9%)<p></p>
<p>&nbsp;</p></td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<h5 id="sec3.4">3.4. Secondary Efficacy Results</h5>
<p>A slightly higher percentage of subjects achieved clinical success in the amoxicillin/clavulanic acid arm by Day 5 [76.8% (95% CI: 70.7%, 82.2%)] than the clindamycin arm [69.1% (95% CI 62.7%, 75.0%)] possibly indicating a faster response in subjects receiving amoxicillin/clavulanic acid arm as compared to subjects who received clindamycin.</p>
<p>The least square mean change in the VAS score for pain (using ITT-E dataset with OC approach) was maximum at Day 7 (6.38 and 6.34 in the amoxicillin/clavulanic acid and clindamycin arms, resp.) compared to Day 5 (5.49 and 5.38 in the treatment arms, resp.) and Day 2 (3.34 and 3.07, resp.) and it was similar between the treatment arms at each time point. Similar results were also noted for swelling (Table&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/tab3/" target="_blank" rel="noopener">3</a>). A summary of VAS by visit and treatment arms demonstrated that higher mean percentage reduction in pain by Day 2 was achieved in the amoxicillin/clavulanic acid arm (49.5%) compared with (45.6%) the clindamycin arm. Similarly, a higher mean percentage reduction in swelling by Day 2 was achieved in the amoxicillin/clavulanic acid arm (43.6%) compared with the clindamycin arm (39.6%).</p>
<p>&nbsp;</p>
<p><img class="alignnone size-medium wp-image-5170" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20640%20451'%3E%3C/svg%3E" alt="" width="640" height="451" data-lazy-srcset="/../../../../wp-content/uploads/2021/01/tabl3-640x451.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/tabl3-1024x721.jpg 1024w, //ikigaicorporation.com/wp-content/uploads/2021/01/tabl3-320x225.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/tabl3.jpg 1058w" data-lazy-sizes="(max-width: 640px) 100vw, 640px" data-lazy-src="/../../../../wp-content/uploads/2021/01/tabl3-640x451.jpg"><noscript><img class="alignnone size-medium wp-image-5170" src="/../../../../wp-content/uploads/2021/01/tabl3-640x451.jpg" alt="" width="640" height="451" srcset="/../../../../wp-content/uploads/2021/01/tabl3-640x451.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/tabl3-1024x721.jpg 1024w, //ikigaicorporation.com/wp-content/uploads/2021/01/tabl3-320x225.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/tabl3.jpg 1058w" sizes="(max-width: 640px) 100vw, 640px" /></noscript></p>
<h5 id="sec3.5">3.5. Microbiological Results</h5>
<p>Pus specimens were obtained in 58 subjects who consented to microbiological sampling including two who were screen failures (25 in the amoxicillin/clavulanic acid arm and 31 in the clindamycin arm; the 2 screen failures were excluded). A total of 61 isolates were obtained from 56 samples, 26 in the amoxicillin/clavulanic acid arm and 35 in the clindamycin arm. Organisms isolated in both the treatment arms were similar and predominantly viridans streptococci group ((n=24) including<i>&nbsp;Streptococcus oralis</i>,<i>&nbsp;Streptococcus mitis</i>, and<i>&nbsp;Streptococcus parasanguinis</i>),<i>&nbsp;Enterobacter</i> spp. (n=10),<i>&nbsp;Klebsiella</i> spp. (n=9),<i>&nbsp;Pseudomonas</i> spp. (n=7), and<i>&nbsp;Staphylococcus</i> spp. (n=5). CLSI breakpoints are not uniformly available for all isolates for both study drugs which posed a challenge in providing meaningful interpretation of susceptibility data.</p>
<h5 id="sec3.6">3.6. Safety Results</h5>
<p>A total of 243 treatment emergent AEs (TEAEs) were reported in 123 subjects in the amoxicillin/clavulanic acid arm and 236 events were reported in 124 subjects in the clindamycin arm. The most frequently observed TEAEs with frequency ≥3% were abdominal discomfort, raised liver enzymes (AST, ALT, and bilirubin), diarrhoea, dizziness, headache, increased appetite, and somnolence (Table&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/tab4/" target="_blank" rel="noopener">4</a>). Generally the incidence of TEAEs was similar between treatment arms, except for diarrhoea and headache which were reported in slightly more patients in the clindamycin arm. Most AEs were of mild to moderate intensity. The incidence of drug related TEAEs in both the treatment arms was similar (165 AEs reported in 93 (39.4%) subjects and 171 AEs reported in 97 (41.3%) subjects in the amoxicillin/clavulanic acid and clindamycin arms, resp.). The most frequently reported drug related TEAEs were gastrointestinal disorders including abdominal discomfort, diarrhoea, nausea and vomiting, abnormal LFTs, increased appetite, somnolence, dizziness, and headache<i>.</i>&nbsp;Most of the related TEAEs were mild to moderate in intensity except for six events of severe intensity. These were elevated ALT, headache, and vomiting reported in the amoxicillin/clavulanic acid arm and burning sensation, hypertension, and hypersomnia in the clindamycin arm. All events had resolved by the end of the study except hypersomnia. A total of 89 subjects in the amoxicillin/clavulanic acid arm and 76 subjects in the clindamycin arm had AEs that remained ongoing at the end of the study. Increased LFT was the predominant ongoing AE and was present in 46 subjects in the amoxicillin/clavulanic acid arm and 40 subjects in clindamycin arm, respectively. The probable reason for the ongoing AEs could be the short duration of the study (7 to 8 days) and the lack of a planned follow-up visit after study treatment. No subjects in the study showed shift in ALT and AST from normal at baseline (with respect to local laboratory reference range) to PCC range (as defined in statistical analysis section) at end of the study whereas three subjects each in both the study arms showed shift in total bilirubin to PCC range at the end of the study. However, since these subjects only had increased bilirubin with no increase in ALT or AST, these were not of clinical concern. Four subjects in the clindamycin arm with high LFT parameter (one subject each for ALT and AST and two subjects for total bilirubin) at baseline remained in the PCC range at the end of the study (Figure&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/fig2/" target="_blank" rel="noopener">2</a>). No events of SAE or death were reported in the study.</p></td>
</tr>
</tbody>
</table>
</div>
<p>&nbsp;</p>
<div class="floats-full-page-caption" bis_skin_checked="1">Summary of commonly observed treatment emergent AEs (≥3% in either of the arms).</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab4" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="3">
<hr>
</td>
</tr>
<tr class="thead">
<td align="left">MedDRA preferred term</td>
<td align="center">Amoxicillin/clavulanic acid<br>
(N=236)</td>
<td align="center">Clindamycin<br>
(N=235)</td>
</tr>
<tr>
<td class="thead-hr" colspan="3">
<hr>
</td>
</tr>
<tr>
<td align="left">Total number of treatment emergent AEs</td>
<td align="center">243</td>
<td align="center">236</td>
</tr>
<tr>
<td align="left">Subjects who experienced at least one AE</td>
<td align="center">123 (52.1%)</td>
<td align="center">124 (52.8%)</td>
</tr>
<tr>
<td align="left">Abdominal discomfort</td>
<td align="center">11 (4.7%)</td>
<td align="center">7 (3.0%)</td>
</tr>
<tr>
<td align="left">Alanine aminotransferase increased</td>
<td align="center">26 (11.0%)</td>
<td align="center">24 (10.2%)</td>
</tr>
<tr>
<td align="left">Aspartate aminotransferase increased</td>
<td align="center">24 (10.2%)</td>
<td align="center">20 (8.5%)</td>
</tr>
<tr>
<td align="left">Blood bilirubin increased</td>
<td align="center">12 (5.1%)</td>
<td align="center">13 (5.5%)</td>
</tr>
<tr>
<td align="left">Diarrhoea</td>
<td align="center">19 (8.1%)</td>
<td align="center">28 (11.9%)</td>
</tr>
<tr>
<td align="left">Dizziness</td>
<td align="center">18 (7.6%)</td>
<td align="center">14 (6.0%)</td>
</tr>
<tr>
<td align="left">Headache</td>
<td align="center">8 (3.4%)</td>
<td align="center">14 (6.0%)</td>
</tr>
<tr>
<td align="left">Increased appetite</td>
<td align="center">20 (8.5%)</td>
<td align="center">15 (6.4%)</td>
</tr>
<tr>
<td align="left">Nausea</td>
<td align="center">7 (3.0%)</td>
<td align="center">4 (1.7%)</td>
</tr>
<tr>
<td align="left">Somnolence</td>
<td align="center">19 (8.1%)</td>
<td align="center">17 (7.2%)</td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://static-01.hindawi.com/articles/ijd/volume-2015/472470/figures/472470.fig.002.svgz"><noscript><img src="https://static-01.hindawi.com/articles/ijd/volume-2015/472470/figures/472470.fig.002.svgz" /></noscript></p>
<p>&nbsp;</p>
<div class="floats-partial-caption" bis_skin_checked="1"><span class="caption-text">Figure 2</span><a class="caption-partial-url" title="full view" href="https://www.hindawi.com/journals/ijd/2015/472470/fig2/" target="_blank" rel="noopener" aria-label="full view">&nbsp;</a></div>
<div class="floats-partial-caption-text" bis_skin_checked="1">
<div bis_skin_checked="1">Scatter plot of LFT with respect to baseline and end of study by treatment. Normalised value = laboratory value/upper limit of normal reference range of the respective local laboratory.</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h4 id="discussion">4. Discussion</h4>
<hr>
</div>
<p>&nbsp;</p>
<p>The primary treatment in acute odontogenic infections is surgical drainage while antibiotics are an adjunct in patients showing signs of systemic involvement [<a class="refAnchor">12</a>]. The polymicrobial component of odontogenic infection necessitates the use of antibiotics that are active against both aerobic and anaerobic bacteria and therefore are recommended [<a class="refAnchor">4</a>]. The current study was aimed at comparing the clinical efficacy of amoxicillin/clavulanic acid (875 mg/125 mg) to clindamycin (150 mg) in subjects with acute odontogenic infections.</p>
<p>Amoxicillin/clavulanic acid (875 mg/125 mg) was administered twice daily for 5–7 days and was found to be noninferior or “comparable” to clindamycin (150 mg) administered four times daily. The overall clinical success seen with amoxicillin/clavulanic acid in the study (88.2% (95% CI: 83.0%, 92.2%)) was similar to results seen in other published studies. Success rates of 87% with amoxicillin/clavulanic acid 1 g twice daily and 96% with amoxicillin/clavulanic acid 625 mg thrice daily have been previously reported in other studies [<a class="refAnchor">13</a>,&nbsp;<a class="refAnchor">14</a>]. A higher percentage of pain and swelling reduction (49.5% and 43.6%) was achieved in the amoxicillin/clavulanic acid arm compared to the clindamycin arm (45.6% and 39.6%) after two days of treatment. In a similar study aimed at demonstrating possible differences in the severity of symptoms after the use of amoxicillin and amoxicillin/clavulanic acid in dental ailments, pain was found to be less acute with amoxicillin/clavulanic acid [<a class="refAnchor">15</a>]. Thus, these results indicate that amoxicillin/clavulanic acid given twice daily for the treatment of odontogenic infection serves as an appropriate treatment option with the potential advantage of an early clinical response.</p>
<p>Safety of the subjects, assessed throughout the study, showed that the overall incidences of TEAEs were similar across both the treatment arms. These were mainly events such as abdominal discomfort, diarrhoea, and raised liver enzymes. As per the available safety information of amoxicillin/clavulanic acid 875/125 mg, nausea and diarrhoea are commonly reported events [<a class="refAnchor">16</a>]. Diarrhoea was seen in 8.1% of subjects in amoxicillin/clavulanic acid arm (compared to 11.9% in the clindamycin arm) and this is consistent with the known pharmacological effects of the drug and with the global prescribing information. Raised liver enzymes are a known but uncommon side effect (≥1/1,000 to &lt;1/100) of amoxicillin/clavulanic acid. In the current study, a total of 34 subjects (14.4%) in the amoxicillin/clavulanic acid arm had raised liver enzymes posttreatment compared to 33 subjects (14.04%) in the clindamycin arm that were assessed by the investigator as related to the study drug. However, most of these events were of mild to moderate intensity and none of the subjects were considered to have any LFT values that were of clinical concern. Pseudomembranous colitis is a rare but serious side effect of both clindamycin and amoxicillin-clavulanic acid. However, literature evidence suggests that the incidence is particularly low when these antibiotics are given in outpatient care settings (6.7 cases/100,000 antibiotic exposures). In dental infections there is not much difference in the incidence of<i>&nbsp;C. difficile</i>&nbsp;colitis between the two drugs [<a class="refAnchor">6</a>]. In the current study there were no cases of pseudomembranous colitis with either of the study drugs. There were no SAEs or deaths reported in this study.</p>
<p>One of the main limitations of the study was the use of an outcome measure based on a subjective score (VAS score) to assess pain and swelling to derive the composite clinical outcome. However, to overcome the subjectivity of the VAS score and to reflect real world practice, only subjects demonstrating &gt;70% reduction in pain and swelling were considered for calculating clinical success response. Another limitation was not having a planned follow-up visit for the subjects after the end of the study visits. As a result, ongoing AEs typically key laboratory parameters such as liver enzymes could not be followed until resolution; however, most were mild and transient in nature.</p>
<p>&nbsp;</p>
<h4 id="conclusions">5. Conclusions</h4>
<hr>
<p>&nbsp;</p>
<p>Amoxicillin/clavulanic acid (875 mg/125 mg) administered twice daily was found to be comparable to clindamycin (150 mg) administered four times daily in achieving clinical success in acute odontogenic infections with or without abscess. It was also found to be well tolerated with a safety profile consistent with the known pharmacologic effects of amoxicillin/clavulanic acid and with that described in the global prescribing information.</p>
<h4 id="conflict-of-interests">Conflict of Interests</h4>
<p>Archiel Launch Tancawan, Maria Noemi Pato, Khamiza Zainol Abidin, A. S. Mohd Asari, and Tran Xuan Thong declare no conflict of interests regarding the publication of this paper. Puja Kochhar, Chandra Muganurmath, Monique Twynholm, and Keith Barker are employees of GlaxoSmithKline and hold stocks/shares in GlaxoSmithKline. Archiel Launch Tancawan, Maria Noemi Pato, Khamiza Zainol Abidin, A. S. Mohd Asari, and Tran Xuan Thong were principal investigators in AUG117044 study.</p>
<p>&nbsp;</p>
<h4 id="acknowledgments">Acknowledgments</h4>
<hr>
<p>&nbsp;</p>
<p>Nooraini Bt Osman (Putrajaya Dental Clinic, Malaysia), Christopher Vincent (Selayang Hospital, Malaysia), Haidee Daphnee Digma (Southern Philippines Medical Center, Philippines), Margarita Oasin (Rizal Medical Center, Philippines), Ngo Thi Quynh Lan (University of Medicine and Pharmacy, Vietnam), Huynh Dai Hai (Odonto-Maxillo-Facial Hospital, Vietnam), Dao Thi Dung (Vietnam-Cuba Friendship, Hanoi), Tanakrit Noppakunwijai (Tanarat Fort Hospital, Thailand), Prisana Pripatnanont (Prince of Songkla University, Thailand), and Nipon Chaisrisookumporn (Lampang Regional Hospital, Thailand) were principal investigators. Gandhali Paranjape and Kavitha Rangappa (DiagnoSearch Life Sciences Pvt. Ltd.) were responsible for editorial assistance; Boshi Mohala (GlaxoSmithKline) was responsible for safety review; Jie Ding (GlaxoSmithKline) and Varsha Parulekar (DiagnoSearch Life Sciences Pvt. Ltd.) were responsible for statistical support. Study was funded by GlaxoSmithKline Pharmaceuticals Ltd. and editorial assistance was provided by DiagnoSearch Life Sciences Pvt. Ltd.</p>
<p>&nbsp;</p>
<h4 id="references" class="references">References</h4>
<hr>
<p>&nbsp;</p>
<ol>
<li id="B1">N. S. Dar-Odeh, O. Abu-Hammad, M. K. Al-Omiri, A. S. Khraisat, and A. A. Shehabi, “Antibiotic prescribing practices by dentists: a review,”&nbsp;<i>Therapeutics and Clinical Risk Management</i>, vol. 6, pp. 301–306, 2010.</li>
<li id="B2">R. López-Píriz, L. Aguilar, and M. J. Giménez, “Management of odontogenic infection of pulpal and periodontal origin,”&nbsp;<i>Medicina Oral, Patología Oral y Cirugía Bucal</i>, vol. 12, no. 2, pp. E154–E159, 2007.</li>
<li id="B3">D. Robertson and A. J. Smith, “The microbiology of the acute dental abscess,”&nbsp;<i>Journal of Medical Microbiology</i>, vol. 58, no. 2, pp. 155–162, 2009.</li>
<li id="B4">A. B. Martínez, J. M. A. Urízar, A. B. Fenoll et al., “Consensus statement on antimicrobial treatment of odontogenic bacterial infections,”&nbsp;<i>Medicina Oral, Patologia Oral y Cirugia Bucal</i>, vol. 9, no. 5, pp. 363–376, 2004.</li>
<li id="B5">I. Brook, E. H. Frazier, and M. E. Gher, “Aerobic and anaerobic microbiology of periapical abscess,”&nbsp;<i>Oral Microbiology and Immunology</i>, vol. 6, no. 2, pp. 123–125, 1991.</li>
<li id="B6">I. Brook, M. A. O. Lewis, G. K. B. Sándor, M. Jeffcoat, L. P. Samaranayake, and J. V. Rojas, “Clindamycin in dentistry: more than just effective prophylaxis for endocarditis?”&nbsp;<i>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology</i>, vol. 100, no. 5, pp. 550–558, 2005.</li>
<li id="B7">C. Walker and J. Gordon, “The effect of clindamycin on the microbiota associated with refractory periodontitis,”&nbsp;<i>Journal of Periodontology</i>, vol. 61, no. 11, pp. 692–698, 1990.</li>
<li id="B8">W. C. Gilmore, N. V. Jacobus, S. L. Gorbach, H. C. Doku, and F. P. Tally, “A prospective double-blind evaluation of penicillin versus clindamycin in the treatment of odontogenic infections,”&nbsp;<i>Journal of Oral and Maxillofacial Surgery</i>, vol. 46, no. 12, pp. 1065–1070, 1988.</li>
<li id="B9">L. Von Konow, P. A. Kondell, C. E. Nord, and A. Heimdahl, “Clindamycin versus phenoxymethylpenicillin in the treatment of acute orofacial infections,”&nbsp;<i>European Journal of Clinical Microbiology and Infectious Diseases</i>, vol. 11, no. 12, pp. 1129–1135, 1992.</li>
<li id="B10">S. Mangundjaja and K. Hardjawinata, “Clindamycin versus ampicillin in the treatment of odontogenic infections,”&nbsp;<i>Clinical Therapeutics</i>, vol. 12, no. 3, pp. 242–249, 1990.</li>
<li id="B11">J. Gordon, C. Walker, C. Hovliaras, and S. Socransky, “Efficacy of clindamycin hydrochloride in refractory periodontitis: 24-month results,”&nbsp;<i>Journal of Periodontology</i>, vol. 61, no. 11, pp. 686–691, 1990.</li>
<li id="B12">S. J. Ellison, “An outcome audit of three day antimicrobial prescribing for the acute dentoalveolar abscess,”&nbsp;<i>British Dental Journal</i>, vol. 211, no. 12, pp. 591–594, 2011.</li>
<li id="B13">B. J. Al-Selivany, N. A. Al-Derzi, and S. Y. Agha, “Dental infections: clinical and microbiological evaluation of responsiveness to twice daily amoxicillin-clavulanic acid (amoxiclave),”&nbsp;<i>Jordan Medical Journal</i>, vol. 44, no. 3, pp. 305–312, 2010.</li>
<li id="B14">C. F. Adriaenssen, “Comparison of the efficacy, safety and tolerability of azithromycin and co-amoxiclav in the treatment of acute periapical abscesses,”&nbsp;<i>Journal of International Medical Research</i>, vol. 26, no. 5, pp. 257–265, 1998.</li>
<li id="B15">N. Sulejmanagić, H. Sulejmanagić, Z. Ljutović, D. Salihagić, and M. Sijercić, “Combined application of amoxicillin and clavulanic acid after oral surgical interventions,”&nbsp;<i>Bosnian Journal of Basic Medical Sciences</i>, vol. 5, no. 1, pp. 61–68, 2005.</li>
<li id="B16">AUGMENTIN 875/125MG, “Amoxicillin/clavulanic acid,” Product Information, 2013.</li>
</ol>
<p>&nbsp;</p>
<h2>Source:</h2>
<p>https://www.hindawi.com/journals/ijd/2015/472470/</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/01/05/amoxicillin-clavulanic-acid-for-the-treatment-of-odontogenic-infections-a-randomised-study-comparing-efficacy-and-tolerability-versus-clindamycin/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/01/05/amoxicillin-clavulanic-acid-for-the-treatment-of-odontogenic-infections-a-randomised-study-comparing-efficacy-and-tolerability-versus-clindamycin/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5136 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>02.01.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/01/02/pharmacokinetic-aspects-of-levofloxacin/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/01/02/pharmacokinetic-aspects-of-levofloxacin/">Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><div class="wi-authors" bis_skin_checked="1">
<div class="al-authors-list" bis_skin_checked="1"><span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">Mario Furlanut</a><span class="delimiter">,</span></span>&nbsp;<span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">Loris Brollo</a><span class="delimiter">,</span></span>&nbsp;<span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">Emilio Lugatti</a><span class="delimiter">,</span></span>&nbsp;<span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">Elena Di Qual</a><span class="delimiter">,</span></span>&nbsp;<span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">Flavio Dolcet</a><span class="delimiter">,</span></span>&nbsp;<span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">Giovanni Talmassons</a><span class="delimiter">,</span></span>&nbsp;<span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">Federico Pea</a></span></div>
</div>
<div class="pub-history-wrap clearfix" bis_skin_checked="1">
<div class="pub-history-row clearfix" bis_skin_checked="1">
<div class="ww-citation-primary" bis_skin_checked="1"><em>Journal of Antimicrobial Chemotherapy</em>, Volume 51, Issue 1, January 2003, Pages 101–106,&nbsp;https://doi.org/10.1093/jac/dkg035</div>
</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="13499224" class="abstract-title">Abstract</h2>
<hr>
</div>
<p>&nbsp;</p>
<p>Levofloxacin is considered an effective antibiotic in the treatment of community-acquired lower respiratory tract infections (LRTIs). A study was carried out on 17 in-patients to assess the pharmacokinetics of a 500 mg once-daily switch intravenous (iv)/oral regimen of levofloxacin in the treatment of LRTI patients. Blood samples were collected under steady-state conditions at appropriate intervals. Levofloxacin plasma concentrations were analysed by means of HPLC and pharmacokinetic parameters were estimated using the WinNonlin pharmacokinetic software package. A lower clearance of levofloxacin (&lt;2 mL/min/kg), conditioning both a longer elimination half-life (∼9 h) and a larger AUC<sub>0–</sub><sub>τ</sub>&nbsp;(∼80 mg/L·h), was observed for both routes in our patients than in healthy volunteers. These differences may be explained considering that levofloxacin is excreted mainly as unchanged drug by the renal route, and most of our patients (71%) were very elderly subjects whose renal function physiologically declines with age. The almost complete (≥99%) absolute oral bioavailability suggests that a comparable exposure to the iv regimen may be achieved after oral administration. The overall clinical success rate was 94.1%.</p>
<p>&nbsp;</p>
<div class="kwd-group" bis_skin_checked="1"><a class="kwd-part kwd-main" data-keyword="&quot;Keywords: levofloxacin, oral bioavailability, switch therapy, elderly&quot;">Keywords: levofloxacin, oral bioavailability, switch therapy, elderly</a></div>
<div class="article-metadata-tocSections" bis_skin_checked="1">
<div class="article-metadata-tocSections-title" bis_skin_checked="1">Issue Section: Original Articles</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="13499228" class="section-title">Introduction</h2>
<hr>
</div>
<p>&nbsp;</p>
<p class="chapter-para">Levofloxacin is characterized by rapid bactericidal activity and a broad antimicrobial spectrum, which make it an attractive agent for the treatment of community-acquired lower respiratory tract infections (LRTIs).<span id="jumplink-DKG035C1" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C1">1</a><sup>–</sup><span id="jumplink-DKG035C5" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C5">5</a>&nbsp;Unlike earlier fluoroquinolones, levofloxacin is active not only against many Gram-negative aerobic species (i.e.&nbsp;<em>Moraxella catharralis</em>,&nbsp;<em>Haemophilus influenzae</em>&nbsp;and Enterobacteriaceae),<span id="jumplink-DKG035C6" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C6">6</a>&nbsp;but also against the major Gram-positive aerobic microorganisms implicated in LRTIs, namely&nbsp;<em>Streptococcus pneumoniae</em>&nbsp;(including penicillin-resistant strains)<span id="jumplink-DKG035C7" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C7">7</a>&nbsp;and methicillin-susceptible&nbsp;<em>Staphylococcus aureus</em>&nbsp;(MSSA).<span id="jumplink-DKG035C1" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C1">1</a><sup>,</sup><span id="jumplink-DKG035C6" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C6">6</a>&nbsp;A population pharmacokinetic study in healthy volunteers showed that oral levofloxacin may achieve a higher level in the epithelial lining fluid than in plasma (1.16-fold), this exposure guaranteeing optimal efficacy against the extracellular pathogens involved in LRTIs.<span id="jumplink-DKG035C8" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C8">8</a>&nbsp;Moreover, thanks to its ability to penetrate the plasma membrane of eukaryotic cells, levofloxacin also exhibits a valid activity against intracellular pathogens responsible for atypical pneumonia, namely&nbsp;<em>Mycoplasma pneumoniae</em>,&nbsp;<em>Legionella pneumophila</em>&nbsp;and&nbsp;<em>Chlamydia pneumoniae</em>.<span id="jumplink-DKG035C9" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C9">9</a><sup>–</sup><span id="jumplink-DKG035C11" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C11">11</a></p>
<p class="chapter-para">In a randomized prospective multicentre trial, File&nbsp;<em>et al.</em><span id="jumplink-DKG035C12" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C12">12</a>&nbsp;showed that intravenous (iv) and/or oral levofloxacin 500 mg once daily for 7–14 days was more effective than iv ceftriaxone 1–2 g once or twice daily and/or oral cefuroxime axetil 500 mg twice daily ± oral erythromycin 0.5–1 g four times a day in the treatment of 590 patients with community-acquired pneumonia (96% versus 90% clinical success). Likewise, a 500 mg once-daily dose of levofloxacin was shown to be effective in the treatment of both acute exacerbation of chronic bronchitis<span id="jumplink-DKG035C13" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C13">13</a>&nbsp;and community-acquired pneumonia sustained by macrolide-resistant&nbsp;<em>S. pneumoniae</em>.<span id="jumplink-DKG035C14" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C14">14</a></p>
<p class="chapter-para">On this basis, levofloxacin may be considered an effective alternative choice to the β-lactam plus macrolide combination in the empirical treatment of community-acquired LRTIs especially when an intracellular pathogen may be involved or when a high rate of penicillin- or macrolide-resistant&nbsp;<em>S. pneumoniae</em>&nbsp;or an allergy to β-lactams may be the concern.<span id="jumplink-DKG035C15" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C15">15</a><sup>–</sup><span id="jumplink-DKG035C18" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C18">18</a></p>
<p class="chapter-para">Since levofloxacin may be administered either parenterally or orally, a sequential timely conversion from iv to oral therapy may be adopted for enabling both a cost-effective treatment of infections and an early hospital discharge.<span id="jumplink-DKG035C19" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C19">19</a></p>
<p class="chapter-para">The primary objective of our study was to assess the pharmacokinetic appropriateness and the interindividual variability of a standard switch iv/oral regimen of levofloxacin 500 mg once daily frequently used in routine clinical practice for the treatment of patients with LRTIs.</p>
<p>&nbsp;</p>
<h2 id="13499234" class="section-title">Patients and methods</h2>
<hr>
<p>&nbsp;</p>
<h3 id="13499235" class="section-title">Study entry criteria</h3>
<p class="chapter-para">This study was carried out on a cohort of 17 in-patients (10 male and seven female) empirically treated for LRTIs (community-acquired pneumonia or acute exacerbation of chronic bronchitis) at the Division of Pneumology, SM Misericordia Hospital, Udine, Italy. All the patients were treated with a standard levofloxacin regimen, irrespective of their body weight, sex and age, for a variable duration according to the clinical status: 500 mg iv once daily administered as a 1 h intermittent infusion for 4–9 days followed by 500 mg oral once daily until the end of the therapy (total duration of therapy being 9–17 days). Patients’ characteristics are depicted in Table&nbsp;<span id="jumplink-DKG035TB1" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035TB1">1</a>. No patient presented with major renal or hepatic impairment.</p>
<p class="chapter-para">The aetiological agents were assessed by cultures of sputum and, whenever isolated, their&nbsp;<em>in vitro</em>&nbsp;susceptibility to levofloxacin was tested. The MIC was determined according to NCCLS methods.</p>
<p>&nbsp;</p>
<h3 id="13499238" class="section-title">Study design</h3>
<p class="chapter-para">The pharmacokinetic evaluations of levofloxacin were carried out after having obtained an informed consent from each patient. Criteria for inclusion in the study were: age ≥ 18 years, serum creatinine &lt; 1.5 mg/dL, antimicrobial monotherapy with levofloxacin.</p>
<p class="chapter-para">The iv and oral pharmacokinetic evaluations were carried out under steady-state conditions, that is after at least 48 h of unmodified treatment by each route of administration. To avoid potential interactions,<span id="jumplink-DKG035C20" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C20">20</a><sup>,</sup><span id="jumplink-DKG035C21" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C21">21</a>&nbsp;patients were fasted overnight before and for 3 h after levofloxacin morning administration and no antacid drugs were co-administered during the study period. Many of the patients were co-treated with other drugs, none of which had a known influence on levofloxacin pharmacokinetics. Blood samples were collected each time by direct venal puncture: before and 0, 0.25, 0.5, 1, 2, 4, 6, 8 and 11 h after the 1 h iv infusion; before and 0.5, 1, 1.5, 2, 4, 6, 8 and 12 h after the oral administration. All the samples were frozen at –80°C until assayed.</p>
<h3 id="13499241" class="section-title">HPLC analysis</h3>
<p class="chapter-para">Levofloxacin plasma concentrations were analysed by means of an HPLC method validated in our laboratory, as previously described.<span id="jumplink-DKG035C22" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C22">22</a><sup>,</sup><span id="jumplink-DKG035C23" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C23">23</a>&nbsp;This method was not stereospecific for levofloxacin in the presence of ofloxacin; however, since levofloxacin has been shown to be stereochemically stable and not to convert into ofloxacin&nbsp;<em>in vivo</em>, this did not interfere with the assay.<span id="jumplink-DKG035C24" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C24">24</a><sup>,</sup><span id="jumplink-DKG035C25" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C25">25</a>&nbsp;Intra- and inter-assay coefficients of variation (CV) were always &lt;10%. The lower limit of detection was 0.1 mg/L.</p>
<h3 id="13499243" class="section-title">Pharmacokinetic evaluations</h3>
<p class="chapter-para">Individual patient’s concentration-versus-time data obtained were estimated by a two-compartment open model with first-order elimination using the WinNonlin pharmacokinetic software package (Pharsight Corporation, Mountain View, CA, USA). The pharmacokinetic parameters assessed after iv administration included: steady-state maximum plasma concentration (<em>C</em><sub>max ss</sub>), volume of distribution at the steady-state (<em>V</em><sub>ss</sub>), distribution half-life (<em>t</em><sub>1/2</sub>α), elimination half-life (<em>t</em><sub>1/2</sub>β), total body clearance (CL) and area under the plasma concentration–time curve during the observational period (AUC<sub>0–</sub><sub>τ</sub>). The pharmacokinetic parameters explored after oral administration included:&nbsp;<em>C</em><sub>max ss</sub>, time to reach maximum plasma concentration (<em>T</em><sub>max</sub>),&nbsp;<em>V</em><sub>ss</sub>, absorption half-life (<em>t</em><sub>1/2</sub><em>k</em><sub>a</sub>),&nbsp;<em>t</em><sub>1/2</sub>α,&nbsp;<em>t</em><sub>1/2</sub>β, CL and AUC<sub>0–</sub><sub>τ</sub>. The absolute oral bioavailability (<em>F</em><sub>os</sub>) was determined by means of the following formula: [AUC<sub>po (0–</sub><sub>τ</sub><sub>)</sub>/AUC<sub>iv (0–</sub><sub>τ</sub><sub>)</sub>]×100.</p>
<p class="chapter-para">Since patients received standard levofloxacin dosages, to avoid bias due to interindividual differences in body weight, the dose-related pharmacokinetic parameters (<em>C</em><sub>max ss</sub>&nbsp;and AUC<sub>0–</sub><sub>τ</sub>) were also normalized with respect to levofloxacin dose per kg, and consequently to a dose of 1 mg/kg levofloxacin every 24 h.</p>
<h3 id="13499246" class="section-title">Assessment of clinical efficacy</h3>
<p class="chapter-para">The clinical efficacy of the antimicrobial therapy was defined as follows. Cure was defined as complete resolution of clinically significant signs and symptoms of LRTI at the end of therapy; improvement was defined as partial resolution of clinically significant signs and symptoms of LRTI at the end of therapy; failure was defined as the need for a change in therapy during treatment because of the persistence or worsening of clinical symptoms of LRTI. Cure and improvement were considered as successful responses.</p>
<h3 id="13499248" class="section-title">Statistical analysis</h3>
<p class="chapter-para">According to normal or non-normal distribution, the findings were expressed as mean ± standard deviation (<span class="small-caps">S.D.</span>) or median and range, respectively. Statistical analysis was carried out by&nbsp;<em>t</em>-test for paired data and/or Mann–Whitney Rank Sum Test as appropriate using SigmaStat (Jandel Scientific, GmbH, Erkrath, Germany). A statistically significant difference was defined as&nbsp;<em>P</em>&nbsp;&lt; 0.05.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<h2 id="13499250" class="section-title">Results</h2>
<hr>
<p>&nbsp;</p>
<h3 id="13499251" class="section-title">Patients’ characteristics and microbiology</h3>
<p class="chapter-para">Among the 17 patients included in the study, admission diagnosis was acute exacerbation of chronic bronchitis in 10 cases and pneumonia in seven cases. Despite appropriate microbial investigations, only five of these 17 LRTI patients (29%) had a microbiologically confirmed bacterial aetiology. The infection was monomicrobial in three cases (<em>Enterococcus</em>&nbsp;spp.,&nbsp;<em>Pseudomonas aeruginosa</em>, methicillin-susceptible&nbsp;<em>S. aureus</em>) and polymicrobial in two cases (<em>Enterobacter aerogenes</em>,&nbsp;<em>H. influenzae</em>&nbsp;and&nbsp;<em>S. pneumoniae</em>&nbsp;in one case;&nbsp;<em>H. influenzae</em>&nbsp;and&nbsp;<em>Klebsiella pneumoniae</em>&nbsp;in the other case).</p>
<p class="chapter-para">All of these isolates were shown to be sensitive&nbsp;<em>in vitro</em>&nbsp;to levofloxacin (MIC &lt; 1 mg/L).</p>
<h3 id="13499254" class="section-title">Pharmacokinetic analysis</h3>
<p class="chapter-para">Mean (± standard deviation,&nbsp;<span class="small-caps">S.D.</span>) levofloxacin plasma concentration-versus-time profiles after both iv and oral administration are shown in Figure&nbsp;<span id="jumplink-DKG035F1" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035F1">1</a>. Average levofloxacin&nbsp;<em>C</em><sub>max</sub><sub>ss</sub>&nbsp;was 10.71 mg/L immediately after the 1 h iv infusion and 7.93 mg/L at 1.23 h after oral administration, respectively. Levofloxacin pharmacokinetic parameters are summarized in Table&nbsp;<span id="jumplink-DKG035TB2" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035TB2">2</a>.</p>
<p class="chapter-para">Moderate linear relationships between estimated creatinine clearance, on the one hand, and either levofloxacin CL (Figure&nbsp;<span id="jumplink-DKG035F2" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035F2">2</a>) or dose-normalized AUC<sub>0–</sub><sub>τ</sub>&nbsp;(Figure&nbsp;<span id="jumplink-DKG035F3" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035F3">3</a>), on the other hand, were observed.</p>
<p class="chapter-para">Dose-normalized data showed that for each mg/kg of levofloxacin, the mean dose-normalized&nbsp;<em>C</em><sub>max ss</sub>&nbsp;reached was 1.46 and 1.22 mg/L, whereas the mean fractional AUC<sub>0–</sub><sub>τ</sub>&nbsp;guaranteed was 10.18 and 11.62 mg/L·h, for the iv and oral route, respectively.</p>
<h3 id="13499258" class="section-title">Outcome of therapy</h3>
<p class="chapter-para"><em>Clinical outcome</em>. Median length of levofloxacin therapy was 5 and 6 days for iv and oral treatment, respectively. At the end of levofloxacin therapy, the overall clinical success rate was 94.1%, since 76.4% (13/17) of cases were cured, whereas 17.6% of cases (3/17) were improved. In the remaining 5.9% of cases (1/17), the therapy failed and, consequently led to a persistence of clinical symptoms of LRTI; a change in the antimicrobial chemotherapy (ceftazidime plus ciprofloxacin plus amikacin) was required.</p>
<h2 id="13499260" class="section-title">Discussion</h2>
<hr>
<p>&nbsp;</p>
<p class="chapter-para">Our study compared the steady-state pharmacokinetic profile of a standard levofloxacin 500 mg once-daily regimen during a switch iv/oral therapy and assessed clinical outcome in LRTI patients.</p>
<p class="chapter-para">Although our pharmacokinetic data were generally similar to those observed by other authors,<span id="jumplink-DKG035C25" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C25">25</a><sup>–</sup><span id="jumplink-DKG035C27" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C27">27</a>&nbsp;a lower clearance, conditioning both a longer elimination half-life and a larger AUC, was observed after both administration routes in our patients than in healthy volunteers.<span id="jumplink-DKG035C25" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C25">25</a><sup>–</sup><span id="jumplink-DKG035C27" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C27">27</a>&nbsp;These differences may be explained considering that levofloxacin is mainly excreted as unchanged drug by the kidney, and most of our patients were very elderly subjects (12/17 aged &gt;71 years) whose renal function had physiologically declined with age, as definitely demonstrated by Cockcroft &amp; Gault.<span id="jumplink-DKG035C28" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C28">28</a>&nbsp;Tanigawara&nbsp;<em>et al</em>.<span id="jumplink-DKG035C29" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C29">29</a>&nbsp;in a premarketing population pharmacokinetic study found that the elderly exhibited a 32% reduction in levofloxacin clearance as a consequence of a lower creatinine clearance. Likewise, Chien&nbsp;<em>et al.</em><span id="jumplink-DKG035C30" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C30">30</a>&nbsp;showed that levofloxacin clearance after administration of a single 500 mg oral dose was significantly lower in elderly than in young volunteers (1.68 versus 2.49 mL/min/kg) mainly due to major differences in renal function. According to this hypothesis, a moderate linear relationship between levofloxacin clearance and creatinine clearance after both iv and oral administration was also found in our study.</p>
<p class="chapter-para">As a consequence of this reduced clearance, total body exposure to levofloxacin (AUC<sub>0–</sub><sub>τ</sub>) was ∼1.5-fold larger in our patients than in young healthy volunteers,<span id="jumplink-DKG035C25" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C25">25</a><sup>–</sup><span id="jumplink-DKG035C27" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C27">27</a>&nbsp;but it was comparable to Chien’s findings in elderly volunteers.<span id="jumplink-DKG035C30" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C30">30</a></p>
<p class="chapter-para">Normalized data showed that a wide interindividual variability for&nbsp;<em>C</em><sub>max</sub>&nbsp;and AUC<sub>0–</sub><sub>τ</sub>&nbsp;persists irrespective of patient body weight (coefficient of variations between 25% and 41%). This is in agreement with other authors’ findings showing that interindividual variation in levofloxacin pharmacokinetics may largely be related to the estimated creatinine clearance either in patients with serious community-acquired infection<span id="jumplink-DKG035C31" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C31">31</a>&nbsp;or in ICU patients with early onset ventilator-associated pneumonia.<span id="jumplink-DKG035C23" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C23">23</a>&nbsp;In particular, in a population pharmacokinetic study, Preston&nbsp;<em>et al</em>.<span id="jumplink-DKG035C31" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C31">31</a>&nbsp;showed that the most important covariate influencing the clearance of levofloxacin in 272 patients with community-acquired infection was the estimated creatinine clearance.</p>
<p class="chapter-para">Although iv levofloxacin should be considered the optimal route for initial empirical therapy in hospitalized patients with serious LRTIs, the oral route may represent both an effective and cost saving regimen in appropriately selected patients, namely from the commencement in mild to moderate LRTI outpatients or as a continuation therapy. An oral 500 mg once-daily levofloxacin regimen should be considered a valid therapeutic approach for LRTIs in malabsorption-free patients, since it provides an effective treatment at lower costs.<span id="jumplink-DKG035C19" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C19">19</a>&nbsp;However, other less expensive treatments based on β-lactams (i.e. cefuroxime) and macrolides (i.e. clarithromycin) may also represent a valid alternative for the sequential iv/oral therapy of LRTIs, especially when a risk factor for fluoroquinolone use exists (i.e. neurological disorders).</p>
<p class="chapter-para">The almost complete (≥99%) absolute oral bioavailability and the mean oral&nbsp;<em>C</em><sub>max ss</sub>&nbsp;quite similar to that observed immediately after the 1 h iv infusion (7.93 versus 10.71 mg/L) suggest that a comparable exposure to the iv regimen may be achieved after oral administration of levofloxacin. The &gt;100% average oral bioavailability (114%) suggests that a larger exposure for the oral than for the iv route might have occurred in some cases. Actually, since this was a within-patient study and the same dosage was administered for both routes, these results might have represented a hard-to-explain finding. However, it has to be considered that Chien&nbsp;<em>et al.</em>,<span id="jumplink-DKG035C26" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C26">26</a>&nbsp;in a cross-over 500 mg iv versus oral single dose study assessing levofloxacin pharmacokinetics in 23 healthy volunteers, showed that the oral bioavailability of levofloxacin was of a similar extent (103 ± 10%). Moreover, in our patients the trend for a larger exposure after the oral route may be partially explained by the fact that a slight reduction in renal function was observed in some patients during the oral assessment. As a consequence, a mean 12% lower levofloxacin clearance (1.65 versus 1.87 mL/min/kg) leading to an ∼1.15-fold longer average elimination half-life of levofloxacin (9.81 versus 8.77 h) was observed after oral compared with iv administration. In any case, no statistically significant difference between mean AUCs (both for absolute and normalized data) was observed after oral and iv administration of levofloxacin.</p>
<p class="chapter-para">A successful clinical response was obtained in all but one patient (94%), in agreement with other authors’ findings showing that iv/oral therapy with levofloxacin 500 mg once daily was very effective (96% clinical success) in treating community-acquired pneumonia.<span id="jumplink-DKG035C12" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C12">12</a>&nbsp;Whereas the median duration of therapy was in line with many guidelines for LRTIs,<span id="jumplink-DKG035C15" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C15">15</a><sup>–</sup><span id="jumplink-DKG035C17" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C17">17</a>&nbsp;in two cases it was decided to prolong treatment for 14 and 17 days, respectively, due to the severity of illness.</p>
<p class="chapter-para">In conclusion, the switch iv/oral levofloxacin 500 mg once-daily therapy represents a valid approach in the treatment of LRTIs. The concentration-dependent pharmacodynamic bactericidal activity combined with the sufficiently long elimination half-life of levofloxacin justifies the once- a-day administration in patients with community-acquired LRTIs.</p>
<p>&nbsp;</p>
<h2 id="13499269" class="section-title">Acknowledgments</h2>
<hr>
<p>&nbsp;</p>
<p class="chapter-para">We would like to thank Dr Orietta Coletti for her valuable help and Mrs Eliana Di Terlizzi for her technical assistance. Aspects of this work were partially presented in abstract form at the Fourth European Congress of Chemotherapy and Infection, Paris, France, 4–7 May 2002.</p>
<div bis_skin_checked="1">
<p><span class="fn"><span class="label fn-label"><span class="end-note-link" data-fn-id="FN1">*</span></span></span></p>
<p class="chapter-para">Corresponding author. Tel/Fax: +39-0432-559833; E-mail:&nbsp;<a href="mailto:federico.pea@med.uniud.it">federico.pea@med.uniud.it</a></p>
</div>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure 1. Mean (±s.d.) steady-state levofloxacin plasma concentration–time profiles following iv and oral administration of 500 mg once daily during sequential therapy in LRTI patients (n = 17)." data-lazy-src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/1/10.1093/jac/dkg035/2/m_dkg035f1.gif?Expires=1611400684&amp;Signature=fYXuWcAR-feyfhxjCJAE1nkoh-evP3ey~g1mwSdYKtX-01dmBtbrNFhUF04Nj6KvZwQcLDULQRSETAMJ~MTWkRjK6TOLUqSIEIvfNJJtxVDRnfiRgwHJZ48YJ4NIybIII8UpXEYRV1TDDPH-SYs5o3MAn8J5wjJUqgE0xfjgZO1umixKHoq2YAUKtXfaCLsqtcYeFYd9CMYAKB53cJwdo34Zbr-Z1QjhFriHS4rq4uS7G95p-m2wMv3vMf5qcAU8eym765wNIFj1GuDPUDeK5sLK9-7ciJDYo89kUUYbB7BvujtggokN8bbEgYpi6IcpbEKh9sihqDldtEZitsvwaQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"><noscript><img src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/1/10.1093/jac/dkg035/2/m_dkg035f1.gif?Expires=1611400684&amp;Signature=fYXuWcAR-feyfhxjCJAE1nkoh-evP3ey~g1mwSdYKtX-01dmBtbrNFhUF04Nj6KvZwQcLDULQRSETAMJ~MTWkRjK6TOLUqSIEIvfNJJtxVDRnfiRgwHJZ48YJ4NIybIII8UpXEYRV1TDDPH-SYs5o3MAn8J5wjJUqgE0xfjgZO1umixKHoq2YAUKtXfaCLsqtcYeFYd9CMYAKB53cJwdo34Zbr-Z1QjhFriHS4rq4uS7G95p-m2wMv3vMf5qcAU8eym765wNIFj1GuDPUDeK5sLK9-7ciJDYo89kUUYbB7BvujtggokN8bbEgYpi6IcpbEKh9sihqDldtEZitsvwaQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Figure 1. Mean (±s.d.) steady-state levofloxacin plasma concentration–time profiles following iv and oral administration of 500 mg once daily during sequential therapy in LRTI patients (n = 17)." /></noscript></p>
<p><strong>Figure 1.</strong> Mean (±<span class="small-caps">S.D.</span>) steady-state levofloxacin plasma concentration–time profiles following iv and oral administration of 500 mg once daily during sequential therapy in LRTI patients (<em>n</em>&nbsp;= 17).</p>
<p>&nbsp;</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure 2. Relationship between steady-state levofloxacin plasma clearance (CL) and estimated creatinine clearance (CLCR) by means of the Cockcroft and Gault formula.28" data-lazy-src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/1/10.1093/jac/dkg035/2/m_dkg035f2.gif?Expires=1611400684&amp;Signature=jNW-QUOmz1ZPMclbg3uljdsS4EOcFE1VUxUiR7JqTBJCN0E2idrrFHWVJT50bNfw~hJg1CIQUBaJf~g2j-TOaVrkGSZFjXhnj1X3gSFHEjH6-gXRSS2WCcO2-FTfAXwfE6NK7qdI~pF3ie9ehDNUWB9uZMQliwMck8cRiDE1YIfDjtWafZQ1xRalVPYktPcoUQhGxLoZG0cgDLw07FwbSIVSyv691Trj9AXhvy8HYJ2xoL3KiHcgRQa-8ryQaeSebRKpnhbi6me-lCf-7~kow9kONPecPEzLtnrkUaCOQlsyPbvOl~fx2OgIyYwRDtz-~O~AGWjAULeqdT7JALt5OA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"><noscript><img src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/1/10.1093/jac/dkg035/2/m_dkg035f2.gif?Expires=1611400684&amp;Signature=jNW-QUOmz1ZPMclbg3uljdsS4EOcFE1VUxUiR7JqTBJCN0E2idrrFHWVJT50bNfw~hJg1CIQUBaJf~g2j-TOaVrkGSZFjXhnj1X3gSFHEjH6-gXRSS2WCcO2-FTfAXwfE6NK7qdI~pF3ie9ehDNUWB9uZMQliwMck8cRiDE1YIfDjtWafZQ1xRalVPYktPcoUQhGxLoZG0cgDLw07FwbSIVSyv691Trj9AXhvy8HYJ2xoL3KiHcgRQa-8ryQaeSebRKpnhbi6me-lCf-7~kow9kONPecPEzLtnrkUaCOQlsyPbvOl~fx2OgIyYwRDtz-~O~AGWjAULeqdT7JALt5OA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Figure 2. Relationship between steady-state levofloxacin plasma clearance (CL) and estimated creatinine clearance (CLCR) by means of the Cockcroft and Gault formula.28" /></noscript></p>
<p><strong>Figure 2.</strong> Relationship between steady-state levofloxacin plasma clearance (CL) and estimated creatinine clearance (CL<sub>CR</sub>) by means of the Cockcroft and Gault formula.<span id="jumplink-DKG035C28" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C28">28</a></p>
<p>&nbsp;</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure 3. Relationship between steady-state dose-normalized levofloxacin area under the concentration–time curve (AUC0–τ) and estimated creatinine clearance (CLCR) by means of the Cockcroft and Gault formula.28" data-lazy-src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/1/10.1093/jac/dkg035/2/m_dkg035f3.gif?Expires=1611400684&amp;Signature=NxQSBoRa6SOYAkhyjqOK6qFoQo0Yy67OAzeFRMPr7a44RueR1R9PBx1x8RINjnoiclSnxu7WzHGVy8o6jLKKfKDQl0pGVF2-Yuy1tkZlJVwa7~f9G5vbvamsc5Mwtj11yKLCvGPoUCzeNZ2p3OnUrPeugVmaAWkRdF2pNk~kSiD28kcKwN8zW~XbmfL-MhFYAAOz8Z420Z2ue2zM7LwX-E3FLKR1R1IEXJpQirDSGk8cTSVQltzkPAk79gsAT9AQhGFEwqVsScvVctTVQsKmM92Nvnrhn2sU8csOlNtvLSuumux5s36sn8odcn9LlgHF~YRv9JXLhu7StAy9Xmvpkg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"><noscript><img src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/1/10.1093/jac/dkg035/2/m_dkg035f3.gif?Expires=1611400684&amp;Signature=NxQSBoRa6SOYAkhyjqOK6qFoQo0Yy67OAzeFRMPr7a44RueR1R9PBx1x8RINjnoiclSnxu7WzHGVy8o6jLKKfKDQl0pGVF2-Yuy1tkZlJVwa7~f9G5vbvamsc5Mwtj11yKLCvGPoUCzeNZ2p3OnUrPeugVmaAWkRdF2pNk~kSiD28kcKwN8zW~XbmfL-MhFYAAOz8Z420Z2ue2zM7LwX-E3FLKR1R1IEXJpQirDSGk8cTSVQltzkPAk79gsAT9AQhGFEwqVsScvVctTVQsKmM92Nvnrhn2sU8csOlNtvLSuumux5s36sn8odcn9LlgHF~YRv9JXLhu7StAy9Xmvpkg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Figure 3. Relationship between steady-state dose-normalized levofloxacin area under the concentration–time curve (AUC0–τ) and estimated creatinine clearance (CLCR) by means of the Cockcroft and Gault formula.28" /></noscript></p>
<p><strong>Figure 3.</strong> Relationship between steady-state dose-normalized levofloxacin area under the concentration–time curve (AUC<sub>0–</sub><sub>τ</sub>) and estimated creatinine clearance (CL<sub>CR</sub>) by means of the Cockcroft and Gault formula.<span id="jumplink-DKG035C28" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG035C28">28</a></p>
<p>&nbsp;</p>
<div id="DKG035TB1" class="table-wrap-title" data-id="DKG035TB1" bis_skin_checked="1">
<p><span class="label"><strong>Table 1.</strong></span></p>
<div class="caption" bis_skin_checked="1">
<p class="chapter-para"> Patient characteristics at baseline</p>
</div>
</div>
<div class="table-overflow" bis_skin_checked="1">
<table>
<tbody>
<tr>
<td>Parameter</td>
<td>Mean ±&nbsp;<span class="small-caps">S.D.</span></td>
</tr>
<tr>
<td>Age (years)</td>
<td>70 ± 13</td>
</tr>
<tr>
<td>Gender</td>
<td>10 M/7 F</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>71 ± 15</td>
</tr>
<tr>
<td>SGOT (IU/L)</td>
<td>31 ± 20</td>
</tr>
<tr>
<td>SGPT (IU/L)</td>
<td>51 ± 35</td>
</tr>
<tr>
<td>SCr (mg/dL)</td>
<td> 0.98 ± 0.26</td>
</tr>
<tr>
<td>CL<sub>CR</sub>&nbsp;(mL/min/kg)</td>
<td> 1.03 ± 0.40</td>
</tr>
</tbody>
</table>
</div>
<div class="table-wrap-foot" bis_skin_checked="1">
<p class="chapter-para">CL<sub>CR</sub>, estimated creatinine clearance by means of the Cockcroft and Gault formula;<a class="link link-ref link-reveal xref-default" data-open="DKG035C28">28</a>&nbsp;SCr, serum creatinine (normal range = 0.6–1.4 mg/dL); SGOT, serum glutamic oxalacetic transaminase (normal range = 10–45 IU/L); SGPT, serum glutamic pyruvic transaminase (normal range = 10–40 IU/L).</p>
</div>
<p>&nbsp;</p>
<div id="DKG035TB2" class="table-wrap-title" data-id="DKG035TB2" bis_skin_checked="1">
<p><span class="label"><strong>Table 2.</strong></span></p>
<div class="caption" bis_skin_checked="1">
<p class="chapter-para"> Mean ±&nbsp;<span class="small-caps">S.D.</span>&nbsp;steady-state levofloxacin pharmacokinetic parameters after iv and oral administration of 500 mg once daily during sequential therapy in 17 patients with LRTIs</p>
</div>
</div>
<div class="table-overflow" bis_skin_checked="1">
<table>
<tbody>
<tr>
<td></td>
<td colspan="2">Route of administration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parameter</td>
<td>iv</td>
<td>oral</td>
<td></td>
<td><em>P</em>&nbsp;value</td>
</tr>
<tr>
<td>Dose&nbsp;<sub>0–</sub><sub>τ</sub>&nbsp;(mg/kg/24 h)</td>
<td> 7.46 ± 1.97</td>
<td>7.46 ± 1.97</td>
<td></td>
<td>1.000</td>
</tr>
<tr>
<td><em>C</em><sub>max ss</sub>&nbsp;(mg/L)</td>
<td>10.71 ± 3.30</td>
<td>7.93 ± 3.44</td>
<td></td>
<td>0.022</td>
</tr>
<tr>
<td><em>T</em><sub>max</sub>&nbsp;(h)</td>
<td>NA</td>
<td>1.23 ± 0.71</td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td><em>V</em><sub>ss</sub>&nbsp;(L/kg)</td>
<td> 1.24 ± 0.22</td>
<td>1.23 ± 0.24</td>
<td></td>
<td>0.938</td>
</tr>
<tr>
<td><em>t</em><sub>1/2</sub><em>k</em><sub>a</sub>&nbsp;(h)</td>
<td>NA</td>
<td>0.29 ± 0.16</td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td><em>t</em><sub>1/2</sub>α (h)</td>
<td> 0.27 ± 0.20</td>
<td>0.59 ± 0.29</td>
<td></td>
<td>0.001</td>
</tr>
<tr>
<td><em>t</em><sub>1/2</sub>β (h)</td>
<td> 8.77 ± 3.52</td>
<td>9.81 ± 4.61</td>
<td></td>
<td>0.469</td>
</tr>
<tr>
<td>CL (mL/min/kg)</td>
<td> 1.87 ± 0.79</td>
<td>1.65 ± 0.65</td>
<td></td>
<td>0.324</td>
</tr>
<tr>
<td>AUC<sub>0–</sub><sub>τ</sub>&nbsp;(mg/L·h)</td>
<td>74.97 ± 29.29</td>
<td>85.60 ± 38.21</td>
<td></td>
<td>0.346</td>
</tr>
<tr>
<td><em>F</em><sub>os</sub>&nbsp;(%)</td>
<td>NA</td>
<td>114 ± 19</td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>Dose-normalized&nbsp;<em>C</em><sub>max ss&nbsp;</sub>(mg/L per mg/kg)</td>
<td> 1.46 ± 0.36</td>
<td>1.22 ± 0.35</td>
<td></td>
<td>0.037</td>
</tr>
<tr>
<td>Dose-normalized AUC<sub>0–</sub><sub>τ</sub>&nbsp;(mg/L·h per mg/kg)</td>
<td>10.18 ± 4.19</td>
<td>11.62 ± 5.17</td>
<td></td>
<td>0.395</td>
</tr>
</tbody>
</table>
</div>
<div class="table-wrap-foot" bis_skin_checked="1">
<p class="chapter-para">AUC<sub>0–</sub><sub>τ</sub>&nbsp;= area under the plasma concentration–time curve during the observation period; CL = total body clearance;&nbsp;<em>C</em><sub>max ss</sub>&nbsp;= steady-state peak plasma concentration; Dose<sub>0–</sub><sub>τ</sub>&nbsp;= amount of dose every 24 h;&nbsp;<em>F</em><sub>os</sub>&nbsp;= percentage absolute oral bioavailability; NA = not applicable;&nbsp;<em>t</em><sub>1/2</sub>α = distribution half-life;&nbsp;<em>t</em><sub>1/2</sub>β = elimination half-life;&nbsp;<em>t</em><sub>1/2</sub><em>k</em><sub>a</sub>, absorption half-life;&nbsp;<em>T</em><sub>max</sub>, time to reach&nbsp;<em>C</em><sub>max</sub>;&nbsp;<em>V</em><sub>ss</sub>, volume of distribution at the steady-state.</p>
</div>
<p>&nbsp;</p>
<p>References<br>
1. Langtry, H. D. &amp; Lamb, H. M. (1998). Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 56, 487–515.<br>
2. Norrby, S. R. (2001). Optimal treatment strategies for acute exacerbations of chronic bronchitis: high-risk patients. Chemotherapy 47, 47–52.<br>
3. Carbon, C. (2001). Optimal treatment strategies for community-acquired pneumonia: high-risk patients (geriatric and with comorbidity). Chemotherapy 47, 19–25.<br>
4. File, T. M., Jr (2001). Optimal treatment strategies for community-acquired pneumonia: non-responders to conventional regimens. Chemotherapy 47, 11–8.<br>
5. Shah, P. M. (2000). The use of levofloxacin in the treatment of respiratory tract infection. Journal of Chemotherapy 12, 27–31.<br>
6. Yamane, N., Jones, R. N., Frei, R., Hoban, D. J., Pignatari, A. C. &amp; Marco, F. (1994). Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. Journal of Chemotherapy 6, 83–91.<br>
7. Jones, R. N. &amp; Pfaller, M. A. (2000). In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Clinical Infectious Diseases 31, S16–23.<br>
8. Drusano, G. L., Preston, S. L., Gotfried, M. H., Danziger, L. H. &amp; Rodvold, K. A. (2002). Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation. Antimicrobial Agents and Chemotherapy 46, 586–9.<br>
9. Jonas, D., Engels, I., Friedhoff, C., Spitzmuller, B., Daschner, F. D. &amp; Frank, U. (2001). Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. Journal of Antimicrobial Chemotherapy 47, 147–52.<br>
10. Hammerschlag, M. R. &amp; Roblin, P. M. (2000). Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 44, 1409.<br>
11. Critchley, I. A., Jones, M. E., Heinze, P. D., Hubbard, D., Engler, H. D., Evangelista, A. T. et al. (2002). In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clinical Microbiology and Infection 8, 214–21.<br>
12. File, T. M., Jr, Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R. et al. (1997). A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 41, 1965–72.<br>
13. Masterton, R. G. &amp; Burley, C. J. (2001). Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. International Journal of Antimicrobial Agents 18, 503–12.<br>
14. Fogarty, C. M., Greenberg, R. N., Dunbar, L., Player, R., Marrie, T. J., Kojak, C. M. et al. (2001). Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. Clinical Therapeutics 23, 425–39.<br>
15. Bartlett, J. G., Dowell, S. F., Mandell, L. A., File, T. M., Jr, Musher, D. M. &amp; Fine, M. J. (2000). Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clinical Infectious Diseases 31, 347–82.<br>
16. Mandell, L. A., Marrie, T. J., Grossman, R. F., Chow, A. W. &amp; Hyland, R. H. (2000). Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clinical Infectious Diseases 31, 383–421.<br>
17. Niederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D. et al. (2001). Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. American Journal of Respiratory and Critical Care Medicine 163, 1730–54.<br>
18. Zhanel, G. G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A. S., Embil, J. et al. (2002). A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62, 13–59.<br>
19. Milkovich, G. (2001). Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience. Pharmacotherapy 21, 83S–88S.<br>
20. Lee, L. J., Hafkin, B., Lee, I. D., Hoh, J. &amp; Dix, R. (1997). Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Antimicrobial Agents and Chemotherapy 41, 2196–200.<br>
21. Pea, F. &amp; Furlanut, M. (2001). Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clinical Pharmacokinetics 40, 833–68.<br>
22. Scotton, P. G., Pea, F., Giobbia, M., Baraldo, M., Vaglia, A. &amp; Furlanut, M. (2001). Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis. Clinical Infectious Diseases 33, e109–11.<br>
23. Pea, F., Di Qual, E., Cusenza, A., Brollo, L., Baldassarre, M. &amp; Furlanut, M. (2002). Pharmacokinetics and pharmacodynamics of levofloxacin 500 mg bid IV in ICU patients with early-onset ventilator-associated pneumonia. Clinical Pharmacokinetics, in press.<br>
24. Verho, M., Malerczyk, V., Damm, D. &amp; Lehr, K. H. (1996). Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. Drug Metabolism and Drug Interaction 13, 57–67.<br>
25. Fish, D. N. &amp; Chow, A. T. (1997). The clinical pharmacokinetics of levofloxacin. Clinical Pharmacokinetics 32, 101–19.<br>
26. Chien, S. C., Rogge, M. C., Gisclon, L. G., Curtin, C., Wong, F., Natarajan, J. et al. (1997). Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrobial Agents and Chemotherapy 41, 2256–60.<br>
27. Lubasch, A., Keller, I., Borner, K., Koeppe, P. &amp; Lode, H. (2000). Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrobial Agents and Chemotherapy 44, 2600–3.<br>
28. Cockcroft, D. W. &amp; Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16, 31–41.<br>
29. Tanigawara, Y., Nomura, H., Kagimoto, N., Okumura, K. &amp; Hori, R. (1995). Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Biological and Pharmaceutical Bulletin 18, 315–20.<br>
30. Chien, S. C., Chow, A. T., Natarajan, J., Williams, R. R., Wong, F. A., Rogge, M. C. et al. (1997). Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrobial Agents and Chemotherapy 41, 1562–5.<br>
31. Preston, S. L., Drusano, G. L., Berman, A. L., Fowler, C. L., Chow, A. T., Dornseif, B. et al. (1998). Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrobial Agents and Chemotherapy 42, 1098–104.</p>
<h3>Source</h3>
<hr>
<p><a href="https://academic.oup.com/jac/article/51/1/101/771178">https://academic.oup.com/jac/article/51/1/101/771178</a></p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/01/02/pharmacokinetic-aspects-of-levofloxacin/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/01/02/pharmacokinetic-aspects-of-levofloxacin/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5126 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>31.12.2020</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2020/12/31/levofloxacin-insights-into-antibiotic-resistance-and-product-quality/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2020/12/31/levofloxacin-insights-into-antibiotic-resistance-and-product-quality/">Levofloxacin: Insights Into Antibiotic Resistance and Product Quality</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p>Ensieh Izadi<sup>1</sup>, Gull Afshan<sup>2</sup>, Rahul P. Patel<sup>1</sup>, Venkatesan M. Rao<sup>3</sup>, Kai Bin Liew<sup>4</sup>, Meor Mohd Redzuan Meor Mohd Affandi<sup>5</sup>, Nurolaini Kifli<sup>6</sup>, Amal Suleiman<sup>7</sup>, Kah Seng Lee<sup>4</sup>,&nbsp;Md. Moklesur R. Sarker<sup>8</sup>,&nbsp;Syed Tabish Zaidi<sup>1,9</sup>&nbsp;and&nbsp;Long Chiau Ming<sup>1,6</sup></p>
<div class="JournalAbstract" bis_skin_checked="1">
<ul class="notes">
<li><sup>1</sup>Division of Pharmacy, School of Medicine, University of Tasmania, Hobart, TAS, Australia</li>
<li><sup>2</sup>Department of Pulmonary Medicine, Liaquat National Hospital and Medical College, Karachi, Pakistan</li>
<li><sup>3</sup>Faculty of Pharmacy, SEGi University, Kota Damansara, Malaysia</li>
<li><sup>4</sup>Faculty of Pharmacy, Cyberjaya University College of Medical Sciences, Cyberjaya, Malaysia</li>
<li><sup>5</sup>Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Malaysia</li>
<li><sup>6</sup>PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei Darussalam</li>
<li><sup>7</sup>College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al Kharj, Saudi Arabia</li>
<li><sup>8</sup>Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh</li>
<li><sup>9</sup>School of Healthcare, University of Leeds, Leeds, United Kingdom</li>
</ul>
<p>Counterfeit and substandard medicines are recognized as one of serious threats to public health. The product quality of antibacterial medicine will compromise patients’ recovery and increase the chance of antibacterial resistance. The review aims to provide a summary of low quality levofloxacin issues and the risk factors as well as suggesting the aspects of product quality that need to be regulated strictly. Quality of the active ingredient, levofloxacin, has an important role to contribute to successful therapy. The poor quality of raw material, directly and indirectly, causes treatment failure as the presence of insufficient dose, mislabeled content, and poor dissolution characteristics can lead to lower bioavailability. Identifying and reporting these factors can potentially help in improving the quality of drug marketed in various developing countries and may also reduce the incidences of treatment failure. Dissolution test is used for testing the dissolution profiles and the rate of drug release from solid formulation such as oral formulations, thus providing information regarding the in vivo performance of a formulation and its bioequivalence. On the other hand, quality-testing procedures are used for comparing the quality of products.</p>
<div class="clear" bis_skin_checked="1"></div>
</div>
<div class="JournalFullText" bis_skin_checked="1">
<h2>Introduction</h2>
<hr>
</div>
<p class="mb15">Nowadays, treatment failure of infectious diseases is one of the major healthcare issues especially in developing countries (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B41">Lee et al., 2015</a>). Respiratory tract infection (RTI) is one of the main microbial infections in developing countries that causes about 4–5 million deaths per year among children (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B44">Liu et al., 2014</a>). For instance, pneumonia is an inflammation of air sacs in lungs and one of common RTI that may cause hospitalization and mortality (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B41">Lee et al., 2015</a>;&nbsp;<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B16">Crispian, 2016</a>). Although the emergence of antibiotic therapy and vaccines in the twentieth century increased the survival rate among these patients, however, it was still reported that pneumonia caused a high incidence of death rate among geriatrics and children especially in the developing countries (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B9">Basnet et al., 2015</a>). There are resistance cases reported on first-line antibiotics such as penicillin and macrolides for the treatment of pneumonia. Quinolone class is considered as one of the empirical treatments of the infection (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B21">Endimiani et al., 2005</a>). However, the rising of quinolone resistance cases is alarming in North and South American countries in the year 2000 (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B33">Kays et al., 2002</a>).&nbsp;<i>Haemophilus influenzae</i>&nbsp;is one of common organisms which can cause RTI, and there are few studies reported the quinolone-resistant of&nbsp;<i>H. influenzae</i>&nbsp;(Bastida et al., 2003). There are few studies suggesting that poor quality and substandard drugs are a major contributor to antibiotic resistance in RTIs in developing countries (Conway et al., 2013;&nbsp;Currie et al., 2014;&nbsp;Basnet et al., 2015). This draws the attention of regulatory authority to look into the aspect of poor quality medicines which were reported in many developing countries. It is reported that a significant percentage of generic drugs fails to meet the innovator specifications in Latin America (Nightingale, 2005).</p>
<p class="mb0">Drug quality has a key role to deliver successful treatments. It is important to achieve the required minimum inhibitory concentration (MIC) in order to cure an infection (Miller et al., 2005). High quality antibiotics are essential in treatment of serious common RTIs while poor quality antibiotic therapy may increase morbidity and mortality rates (Khasawneh et al., 2014). Hence, the aim of this review is to summarize low quality levofloxacin tablet issue and suggest aspects of product quality that need to be strengthen and regulated strictly.</p>
<p>&nbsp;</p>
<h2>Levofloxacin Resistance</h2>
<hr>
<p>&nbsp;</p>
<p>Previous studies conducted in South Korea, Canada, USA, and Spain show the correlation between fluoroquinolone administration and resistance (Kays et al., 2002). The resistance of microbes toward some fluoroquinolones products have been reported in the treatment of hospital acquired infections (Torloni et al., 2016).&nbsp;Kays et al. (2002)&nbsp;have claimed that levofloxacin susceptibility in pneumonia infection had reduced as utilization of levofloxacin prescription increased. Meanwhile,&nbsp;Davidson et al. (2002)&nbsp;reported treatment failure in&nbsp;<i>Streptococcus pneumoniae</i>&nbsp;in three different cases after fluoroquinolone administration. Fluoroquinolone resistance is reported in some developing countries such as China and Thailand with 3% non-susceptibility to levofloxacin while the fluoroquinolone resistance against&nbsp;<i>S. pneumonia</i>&nbsp;is below 1% in the United States from 1987 to 1998 (Sahm et al., 2000;&nbsp;Hu et al., 2011). Although, the results in the United States may be related to different prescribing behaviors or fundamental characteristics of the selected pathogens, but&nbsp;<i>S. pneumonia</i>&nbsp;is still capable of resistance development in fluoroquinolone therapy (Sahm et al., 2000;&nbsp;Davidson et al., 2002).&nbsp;Seok et al. (2018)&nbsp;have stated evidence for non-susceptibility to levofloxacin due to prior usage of antibiotics within 3 months, and it is recommended to restrict unnecessary fluoroquinolone prescriptions. Also,&nbsp;Ayukekbong et al. (2017)&nbsp;have presented multiple factors contributing to the problem of antimicrobial resistance due to unnecessary antibiotic prescriptions, especially in developing countries. Available evidence suggests that non-susceptibility to levofloxacin is an ongoing problem.</p>
<p>&nbsp;</p>
<h2>Poor Quality Drug Products</h2>
<hr>
<p>&nbsp;</p>
<p class="mb15">Poor quality drug product is a major global healthcare issues (Sarpong and Miller, 2014). There are studies suggesting that antibacterial drugs mainly antimalarial, antiviral, and antibiotics are among the poor quality drug products reported in developing countries (Nsimba, 2008;&nbsp;Melo et al., 2014). Poor quality drug product is defined as drug product which the drug content does not follow the provided standards such as chemical stability, bioavailability, and purity in drugs (Almuzaini et al., 2013). Poor quality drug product can be sub-classified into substandard drugs product and counterfeit drug product (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B51">Newton et al., 2010</a>). Substandard drug products are medicines produced by an authorized manufacturer which do not follow designated standard quality standings. On the other hand, counterfeit medicines are defined as “deliberately and fraudulently mislabeled with respect to identity and/or source” whether with the right or falsified ingredients or with the forged labeling. Substandard/counterfeit medicines are not usually bioequivalent due to differences in bioavailability as a result of pharmacokinetics (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B30">Johansson et al., 2010</a>).</p>
<p class="mb15">Moreover, some poor quality drugs do not have good&nbsp;<i>in vivo</i>&nbsp;dissolution in the gastrointestinal tract leading to incomplete absorption; hence, therapeutic levels in blood cannot be achieved (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B30">Johansson et al., 2010</a>). The MIC is not achieved when the drug plasma concentration is below expectation which leads to therapy failure and antibiotic resistance (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B4">Almuzaini et al., 2013</a>).</p>
<p class="mb0"><a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#T1">Table 1</a>&nbsp;shows the relevant studies which reported the substandard/counterfeit drugs. These studies claim that there are many substandard or counterfeit drugs available in developing counties (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B52">Nightingale, 2005</a>;&nbsp;<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B27">Hosseini et al., 2011</a>;&nbsp;<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B11">Bate et al., 2013</a>;&nbsp;<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B38">Khurelbat et al., 2014</a>;&nbsp;<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B39">Lalani et al., 2015</a>).</p>
<p>&nbsp;</p>
<div class="Imageheaders" bis_skin_checked="1">TABLE 1</div>
<div bis_skin_checked="1">
<figure id="attachment_5127" aria-describedby="caption-attachment-5127" style="width: 640px" class="wp-caption alignnone"><img class="size-medium wp-image-5127" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20640%20439'%3E%3C/svg%3E" alt="" width="640" height="439" data-lazy-srcset="/../../../../wp-content/uploads/2020/12/table1-640x439.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2020/12/table1-320x220.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2020/12/table1.jpg 772w" data-lazy-sizes="(max-width: 640px) 100vw, 640px" data-lazy-src="/../../../../wp-content/uploads/2020/12/table1-640x439.jpg"><noscript><img class="size-medium wp-image-5127" src="/../../../../wp-content/uploads/2020/12/table1-640x439.jpg" alt="" width="640" height="439" srcset="/../../../../wp-content/uploads/2020/12/table1-640x439.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2020/12/table1-320x220.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2020/12/table1.jpg 772w" sizes="(max-width: 640px) 100vw, 640px" /></noscript><figcaption id="caption-attachment-5127" class="wp-caption-text">Counterfeit and substandard medicines are recognized as one of serious threats to public health.</figcaption></figure>
</div>
<div class="FigureDesc" bis_skin_checked="1">
<p><strong>Table 1</strong>&nbsp;The percentage of substandard, counterfeit, and unregistered levofloxacin available in the market of different countries.</p>
</div>
<p>In addition, many studies have confirmed that substandard or counterfeit drugs caused side effects such as allergies because of impurity, toxicity, or a high percentage of the active agent (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B69">Tipke et al., 2008</a>;&nbsp;<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B72">Wang et al., 2015</a>). Substandard drugs may lead to potential side effects and death as the higher or lower amount of drug than the labeled one is delivered (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B13">Boyd et al., 2009</a>;&nbsp;<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B67">Tamargo et al., 2015</a>;&nbsp;<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B72">Wang et al., 2015</a>).</p>
<p>&nbsp;</p>
<h2>Aspects of Product Quality</h2>
<hr>
<p>&nbsp;</p>
<p>It is important that the generic pharmaceutical manufacturers ensure the production of quality products which help to reduce the therapy failure and antibiotic resistance. Several aspects of product quality is discussed in this review—namely, dissolution study and bioequivalence, quality control of product, quality control test and stability of drug product, post-marketing surveillance (PMS), effect of storage, and poor quality control during manufacturing.</p>
<p>&nbsp;</p>
<h2>Dissolution Study and Bioequivalence</h2>
<hr>
<p>&nbsp;</p>
<p class="mb15">A generic drug is defined as a product which has the same active ingredients as the innovator medicine but with different inactive agents or excipients (Nitzki-George, 2004). Generic drug products are cheaper than the innovator drug products due to the initial saving of research and development expenses for new drugs, so they are highly preferred in the society especially by low income patients (Dunne et al., 2013).</p>
<p class="mb15">One of the ways to show drug quality of generic product is through bioequivalence study. Bioequivalence study is required to ensure that the generic medicine product is equivalent with the innovator medicine product in terms of pharmacokinetics requirement as maximal serum concentration and area under the curve (drug concentration against time) (Johansson et al., 2010). Hence, FDA uses a bioequivalent approach to assess generic drugs (Paveliu et al., 2011). A bioequivalent is considered if the two drugs in comparison have less than 20% difference in the pharmacokinetics parameters (Paveliu et al., 2011). Thus, generic drug manufacturers are required to prove that rate and extent of drug absorption into the bloodstream is comparable to the amount from a brand name product (Davit et al., 2009).</p>
<p class="mb0">Although, both generic and innovator drugs are susceptible to be falsified, but generic medications are easier to be manipulated (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B25">Gibson, 2005</a>). In most cases, samples of generic drugs are as safe and effective as branded one, but still some problems may occur (Kesselheim et al., 2008). Treatment failures have been reported in different cases, such that in one case, symptoms were improved after replacing the prescribed generic levofloxacin with Tavanic (Innovator product) without the presence of any adverse effect (Gallelli et al., 2013). The issue was identified as the excipients of the generic product is different (Tamargo et al., 2015). Although the active content that helps to control may be the same, the filler material, color, or binder used may be different (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B67">Tamargo et al., 2015</a>). The problem may occur when the active agent is not sufficient or the inactive content has impurity or contamination that can have a great impact on bioavailability, metabolism, and elimination (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B67">Tamargo et al., 2015</a>).</p>
<p>&nbsp;</p>
<h2>Quality Control and Stability of Drug Product</h2>
<hr>
<p>&nbsp;</p>
<p class="mb15">Pharmaceutical industries need to adhere and comply with the good manufacturing practice (GMP) to guarantee the products safety, efficacy, and quality (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B43">Li et al., 2015</a>). Nowadays, export or occasional drug use among the country of production is also subjected to compliance with GMP requirements and regulations by manufacturer (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B1">Abdellah et al., 2015</a>). Compliance with the requirements and regulation of GMP is considered as an essential and vital aim for quality assurance and ultimately the profitability of the pharmaceutical industry (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B70">Tomic et al., 2010</a>).</p>
<p class="mb15">Analysis of raw materials, substances, and intermediate products are important tasks in pharmaceutical manufacturing and quality control. Pharmacopeia is used as a reference for chemical, physical, and microbiological tests (Kaul et al., 2016). The manufacturers are responsible to not just produce a final product, but they are also obliged to look into the post-production drug product stability issues (Lambert and Conway, 2003;&nbsp;Wang et al., 2015;&nbsp;Kaul et al., 2016). U.S. Pharmacopeia (USP) is one of commonly available pharmacopeia to control quality of raw materials, components, packaging, and final products (Panchagnula et al., 2006;&nbsp;Kaul et al., 2016).</p>
<p class="mb15">Innovator (brand name) and generic medicines use the same API, but they may contain diverse inactive agents while they still need to follow quality standards of innovator drug (Al Ameri et al., 2012). Quality control is essential for detecting the substandard drugs containing inactive substance, impurities, and toxic substances (Almuzaini et al., 2013;&nbsp;Fadeyi et al., 2015). Substandard drugs can be detected using the quality-testing protocols such as USP which is also defined by the World Health Organization and International Pharmacopeias (Kayumba et al., 2004;&nbsp;Maezawa et al., 2013).</p>
<p class="mb0">The drug product should contain an equal amount of active pharmaceutical ingredient (API) as stated in the product claim (Zaid et al., 2013). According to WHO’s definition, an API is a material or combination of materials that are used in the pharmaceutical products as an active compound with a direct effect in treatment (World Health Organization, 2011;&nbsp;World Health Organization, 2016). The compatibility between API and excipients is important to ensure stability of the API in the dosage form. A stable API will deliver the claimed effect within the shelf life of the product. A crucial role of excipient in drug formulation requires the regulatory approval to avoid toxic or poor quality medicines that may lead to treatment failure (Baldrick, 2000).</p>
<p>&nbsp;</p>
<h3>Effect of Storage Conditions on Drug Stability</h3>
<hr>
<p>&nbsp;</p>
<p>Storage is one factor that may affect the quality of a drug (Kayumba et al., 2004). The storage under tropical conditions was reported by&nbsp;Kayumba et al. (2004)&nbsp;as the main problem of the instability of some formulations of drugs collected in Tanzania, and it was suggested to drug regulatory authorities to develop a quality assurance system to control poor quality drugs. Another study by&nbsp;Nogueira et al. (2011)&nbsp;claims that storage has an essential role in the stability of the drug after production, and poor drug samples were found in poor drug storage conditions in 75% relative humidity and 40°C.</p>
<p>&nbsp;</p>
<h3>Poor Quality Control During Manufacturing</h3>
<hr>
<p>&nbsp;</p>
<p>Quality control framework based on established pharmacopeia techniques is essential to ensure product quality (Losada-Urzáiz et al., 2015). Moreover, lack of quality control due to irresponsibility and corruption increase the percentage of supplying counterfeit drugs in the market which lead to serious public health issues (Zavras et al., 2016). One of the main reasons for quality problems in developing or low income countries is lack of PMS and regulation (Taylor et al., 2001). The financial issue may increase the percentage of treatment failure and resistance due to poor quality or counterfeit drugs in developing countries (Taylor et al., 2001;&nbsp;Nsimba, 2008). Nevertheless, the number of cases of substandard or poor quality drugs are significant in low income and developing countries which can be related to limited financial support in health care, PMS, and pharmaceutical manufacturing (Taylor et al., 2001;&nbsp;Tipke et al., 2008;&nbsp;Conway et al., 2013;&nbsp;Karunamoorthi, 2014;&nbsp;Fadeyi et al., 2015).</p>
<p>&nbsp;</p>
<h3>Control Measures to Reduce Low Quality Drugs</h3>
<hr>
<p>&nbsp;</p>
<p>Low quality medicine produced during pharmaceutical manufacturing can be detected using drug dissolution studies (Wang et al., 2015). The most effective way to reduce the low quality drugs in the market is strictly prohibiting entry of counterfeit drugs into the market (Losada-Urzáiz et al., 2015). The other way to ensure both innovator and generic drugs are following standards and regulations is clearly expressed to the manufacturers that the specific pharmacopoeial techniques need to be complied (Losada-Urzáiz et al., 2015). Bioequivalence study is a must to ensure that the generic product is equivalent with the innovator product.</p>
<p>&nbsp;</p>
<h2>Case Study: Levofloxacin</h2>
<p class="mb15">Levofloxacin is a broad spectrum antibiotic which belongs to the third generation of quinolones group (Scoper, 2008). It prevents DNA replication in bacteria leading to bacterial cell death, and it is mainly used as a second-line therapy of lungs infection (Noreddin and Elkhatib, 2010). This drug is considered as an important antibiotic in case of microorganism that is resistant to other class of antibacterial agents such as beta-lactam antibiotics; hence, its quality is critical in effective treatment (Kayumba et al., 2004;&nbsp;Endimiani et al., 2005).</p>
<p class="mb15">Levofloxacin is chosen as the model drug for a common empirical treatment of pneumonia caused by Gram-negative bacteria such as&nbsp;<i>H. influenza</i>&nbsp;as well as Gram-positive bacteria such as&nbsp;<i>S. pneumoniae</i>&nbsp;(Kays et al., 2002).</p>
<p class="mb15">Levofloxacin has high oral bioavailability with rapid bactericidal activity; hence, it is considered for the treatment of choice for severe pneumonia (Boyd et al., 2009;&nbsp;Maezawa et al., 2013). Although, levofloxacin is one of the most widely prescribed agents for the pneumonia treatment but the number of treatment failure incidences have been recently increased with levofloxacin therapy (Kays et al., 2002;&nbsp;Bastida et al., 2003;&nbsp;Endimiani et al., 2005;&nbsp;Boyd et al., 2009). The possible risk factors suggested for the treatment failure of levofloxacin are poor quality medicines and drug resistance (Davidson et al., 2002). Death in pneumonia due to levofloxacin treatment failure has been reported in North America as four patients in Canada and one patient in the USA in 2000–2001 (Davidson et al., 2002;&nbsp;Kays et al., 2002). Pneumonia can be caused by virus, bacteria, or fungi, and it is commonly categorized as community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) (Abrahamian et al., 2008). The CAP is caused by&nbsp;<i>Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae</i>, and respiratory viruses (Abrahamian et al., 2008;&nbsp;Johansson et al., 2010). On the other hand, HAP occurs after 48 h of hospital admission by&nbsp;<i>Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa</i>, and&nbsp;<i>Staphylococcus aureus</i>, including methicillin-resistant&nbsp;<i>S. aureus</i>&nbsp;(MRSA) (Imran et al., 2016). The treatment is chosen on the basis of different categories and the causative organisms (Imran et al., 2016). The main treatment of pneumonia is antibiotics while sometimes the patients need to be admitted to the hospital to monitor their progression (Bradley et al., 2014). In addition, approving a specific microbial etiology is important in empirical treatment of pneumonia to minimize the risk of exposed side effects and antibiotic resistance (Leekha et al., 2011). There are different types of antibiotics used for treatment of pneumonia especially in CAP which is the most common pneumonia and may cause serious infections globally (Abrahamian et al., 2008). Although, the particular antibiotic for management of CAP is given based on severity of infections or etiology (pathology) while combination of beta-lactam (amoxicillin) and macrolides (azithromycin) or antipneumococcal fluoroquinolone are the preferred empirical treatment (Mandell et al., 2007).</p>
<p class="mb15">Therapeutic window is the range between the amount of the drug that gives the desired effect and the drug may be ineffective or toxic if the drug therapeutic index is below or above the range, respectively (Tamargo et al., 2015). Treatment failure may occur by various factors such as an inadequate antibiotic coverage and concentration, deficient diagnosis, or resistance (Sánchez García, 2009). Poor quality antibacterial may lead to drug resistance or severe side effects if the therapeutic window of levofloxacin is not achieved (Boyd et al., 2009;&nbsp;Tamargo et al., 2015). Therefore, if the dose is lower than the standard window, the drug is not effective, and it may increase resistance; on the other hand, if above the MIC range, then it may cause toxicity and adverse reaction (Tamargo et al., 2015). Additionally, levofloxacin is a broad spectrum antibiotic which is susceptible to cause resistance of normal flora; hence, substandard drugs may increase the risk of resistance significantly (Kays et al., 2002;&nbsp;Bastida et al., 2003).</p>
<p class="mb0">Poor quality antibacterial product may lead to drug resistance, severe side effects, and death; hence, it has a critical role in the treatment and public health (Melo et al., 2014). There are many factors causing resistance, such as irrational and excessive use caused by wrong prescribing and poor quality of medicine (Melo et al., 2014).&nbsp;Table 2&nbsp;shows the relevant studies reported levofloxacin resistance to&nbsp;<i>H. influenza, S. pneumoniae</i>, and&nbsp;<i>S. aureus</i>&nbsp;species in different pneumonia. Even though, the site of infections and treatments are different from each other, but it shows levofloxacin resistance have occurred (Ho et al., 2001;&nbsp;Davidson et al., 2002;&nbsp;Kays et al., 2002;&nbsp;Bastida et al., 2003;&nbsp;Endimiani et al., 2005). Thus, it is evident that levofloxacin resistance is one of the main reasons behind treatment failure of pneumonia (Endimiani et al., 2005). Therefore, public awareness about low quality medicine can be created through the reported resistant susceptibility and quality of levofloxacin (Talan et al., 2016).</p>
<p>&nbsp;</p>
<p>TABLE 2</p>
<figure id="attachment_5128" aria-describedby="caption-attachment-5128" style="width: 640px" class="wp-caption alignnone"><img class="size-medium wp-image-5128" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20640%20227'%3E%3C/svg%3E" alt="" width="640" height="227" data-lazy-srcset="/../../../../wp-content/uploads/2020/12/table2-640x227.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2020/12/table2-320x114.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2020/12/table2.jpg 772w" data-lazy-sizes="(max-width: 640px) 100vw, 640px" data-lazy-src="/../../../../wp-content/uploads/2020/12/table2-640x227.jpg"><noscript><img class="size-medium wp-image-5128" src="/../../../../wp-content/uploads/2020/12/table2-640x227.jpg" alt="" width="640" height="227" srcset="/../../../../wp-content/uploads/2020/12/table2-640x227.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2020/12/table2-320x114.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2020/12/table2.jpg 772w" sizes="(max-width: 640px) 100vw, 640px" /></noscript><figcaption id="caption-attachment-5128" class="wp-caption-text">Counterfeit and substandard medicines are recognized as one of serious threats to public health.</figcaption></figure>
<p>&nbsp;</p>
<h3>Dissolution Testing of Levofloxacin Tablets</h3>
<hr>
<p>&nbsp;</p>
<p class="mb15">Quality control tests used to identify substandard drugs and control the quality of drugs are colorimetric, dissolution, chromatography, and spectrometry procedures (Almuzaini et al., 2013;&nbsp;Maezawa et al., 2013). Dissolution test provides the data of&nbsp;<i>in vitro</i>&nbsp;performance of the drug and prediction for its bioequivalence (Anand et al., 2011). Hence, it is used to estimate the concentration of API and also drug quality (Anand et al., 2011). The dissolution rate consists of drug release by dissolving of solid form in an API into the fluid to determine the stability and physical changes (Kayumba et al., 2004;&nbsp;Nogueira et al., 2011). Drug dissolution test is an essential factor to identify the quality of drugs especially in oral administration as it provides the process of drug release from its solid formulation, and it can discriminate the substandard and low quality products (<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#B40">Lambert and Conway, 2003</a>;&nbsp;Al Ameri et al., 2012;&nbsp;Khadka et al., 2014).</p>
<p class="mb0">Dissolution test is required to be applied under&nbsp;<i>in vitro</i>&nbsp;conditions to compare the drug release of active ingredient from a solid form into solution and its bioavailability during a defined time (Frick et al., 1998). Previous studies on dissolution of levofloxacin have shown little variation in levofloxacin tablets tested in different countries.&nbsp;<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full#T3">Table 3</a>&nbsp;shows the various dissolution studies of levofloxacin tablets conducted in various countries.</p>
<p>&nbsp;</p>
<p>TABLE 3</p>
<figure id="attachment_5129" aria-describedby="caption-attachment-5129" style="width: 640px" class="wp-caption alignnone"><img class="size-medium wp-image-5129" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20640%20104'%3E%3C/svg%3E" alt="" width="640" height="104" data-lazy-srcset="/../../../../wp-content/uploads/2020/12/table3-640x104.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2020/12/table3-1280x208.jpg 1280w, //ikigaicorporation.com/wp-content/uploads/2020/12/table3-1024x166.jpg 1024w, //ikigaicorporation.com/wp-content/uploads/2020/12/table3-320x52.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2020/12/table3.jpg 1460w" data-lazy-sizes="(max-width: 640px) 100vw, 640px" data-lazy-src="/../../../../wp-content/uploads/2020/12/table3-640x104.jpg"><noscript><img class="size-medium wp-image-5129" src="/../../../../wp-content/uploads/2020/12/table3-640x104.jpg" alt="" width="640" height="104" srcset="/../../../../wp-content/uploads/2020/12/table3-640x104.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2020/12/table3-1280x208.jpg 1280w, //ikigaicorporation.com/wp-content/uploads/2020/12/table3-1024x166.jpg 1024w, //ikigaicorporation.com/wp-content/uploads/2020/12/table3-320x52.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2020/12/table3.jpg 1460w" sizes="(max-width: 640px) 100vw, 640px" /></noscript><figcaption id="caption-attachment-5129" class="wp-caption-text">Counterfeit and substandard medicines are recognized as one of serious threats to public health.</figcaption></figure>
<p>&nbsp;</p>
<p>It is observed that certain generic brands in Japan, Taiwan, Pakistan, and India showed difference in dissolution profile when compared with the innovator product. There is only one study by&nbsp;Bano et al. (2011)&nbsp;comparing few generic brands of levofloxacin tablet does not show significant difference in dissolution profile. The result of this study shows that the different&nbsp;<i>in vitro</i>&nbsp;activity may have a direct effect on the&nbsp;<i>in vivo</i>&nbsp;activities and demonstrate the predictive capability of the former (Sun et al., 2016).</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<h2>Conclusions</h2>
<hr>
<p>&nbsp;</p>
<p>Current evidences from various researchers have indicated that poor quality of levofloxacin tablets could be an important factor causing resistance of levofloxacin. Clinical efficacy of this broad spectrum antibiotic relies on the quality of the levofloxacin tablet in term of in vivo release and dissolution inside the gastrointestinal tract. As poor performances of quality control tests of levofloxacin tablets have been reported in developing countries, more PMS to ensure quality of levofloxacin tablets are required to prevent therapy failure and antibiotic resistance.</p>
<p>&nbsp;</p>
<h2>Author Contributions</h2>
<hr>
<p>&nbsp;</p>
<p>RP, SZ and LM conceived the concept; EI, VMR, RP, MS, SZ and LM wrote the initial draft; KBL, AS, NK MM, KSL and GA revised the paper. All authors contributed toward finalizing the manuscript and agreed to be accountable for all aspects of the work.</p>
<p>&nbsp;</p>
<h2>Conflict of Interest Statement</h2>
<hr>
<p>&nbsp;</p>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>&nbsp;</p>
<h2>References</h2>
<hr>
<p>&nbsp;</p>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1">Abdellah, A., Noordin, M. I., Wan Ismail, W. A. (2015). Importance and globalization status of good manufacturing practice (GMP) requirements for pharmaceutical excipients.&nbsp;<i>Saudi Pharm. J.</i>&nbsp;23 (1), 9–13. doi: 10.1016/j.jsps.2013.06.003</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=25685037" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1016/j.jsps.2013.06.003" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=A.+Abdellah&amp;author=M.%20I.+Noordin&amp;author=W.%20A.+Wan%20Ismail&amp;publication_year=2015&amp;title=Importance%20and%20globalization%20status%20of%20good%20manufacturing%20practice%20%28GMP%29%20requirements%20for%20pharmaceutical%20excipients&amp;journal=Saudi+Pharm.+J.&amp;volume=23&amp;pages=9" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B2" name="B2"></a>Abrahamian, F. M., Deblieux, P. M., Emerman, C. L., Kollef, M. H., Kupersmith, E., Leeper, K. V., Jr., et al. (2008). Health care-associated pneumonia: identification and initial management in the ED.&nbsp;<i>Am. J. Emerg. Med.</i>&nbsp;26 (6 Suppl), 1–11. doi: 10.1016/j.ajem.2008.03.015</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/j.ajem.2008.03.015" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=F.%20M.+Abrahamian&amp;author=P.%20M.+Deblieux&amp;author=C.%20L.+Emerman&amp;author=M.%20H.+Kollef&amp;author=E.+Kupersmith&amp;author=K.%20V.+Leeper+Jr.&amp;publication_year=2008&amp;title=Health%20care-associated%20pneumonia%3A%20identification%20and%20initial%20management%20in%20the%20ED&amp;journal=Am.+J.+Emerg.+Med.&amp;volume=26&amp;pages=1" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B3" name="B3"></a>Al Ameri, M. N., Nayuni, N., Anil Kumar, K. G., Perrett, D., Tucker, A., Johnston, A. (2012). The differences between the branded and generic medicines using solid dosage forms: in-vitro dissolution testing.&nbsp;<i>Results Pharma. Sci.</i>&nbsp;2, 1–8. doi: 10.1016/j.rinphs.2011.12.001</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=25755988" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1016/j.rinphs.2011.12.001" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=M.%20N.+Al%20Ameri&amp;author=N.+Nayuni&amp;author=K.%20G.+Anil%20Kumar&amp;author=D.+Perrett&amp;author=A.+Tucker&amp;author=A.+Johnston&amp;publication_year=2012&amp;title=The%20differences%20between%20the%20branded%20and%20generic%20medicines%20using%20solid%20dosage%20forms%3A%20in-vitro%20dissolution%20testing&amp;journal=Results+Pharma.+Sci.&amp;volume=2&amp;pages=1" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B4" name="B4"></a>Almuzaini, T., Choonara, I., Sammons, H. (2013). Substandard and counterfeit medicines: a systematic review of the literature.&nbsp;<i>BMJ Open</i>&nbsp;3 (8), e002923. doi: 10.1136/bmjopen-2013-002923</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=23955188" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1136/bmjopen-2013-002923" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=T.+Almuzaini&amp;author=I.+Choonara&amp;author=H.+Sammons&amp;publication_year=2013&amp;title=Substandard%20and%20counterfeit%20medicines%3A%20a%20systematic%20review%20of%20the%20literature&amp;journal=BMJ+Open&amp;volume=3&amp;pages=e002923" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B5" name="B5"></a>Anand, O., Yu, L. X., Conner, D. P., Davit, B. M. (2011). Dissolution testing for generic drugs: an FDA perspective.&nbsp;<i>AAPS J.</i>&nbsp;13 (3), 328–335. doi: 10.1208/s12248-011-9272-y</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=21479700" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1208/s12248-011-9272-y" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=O.+Anand&amp;author=L.%20X.+Yu&amp;author=D.%20P.+Conner&amp;author=B.%20M.+Davit&amp;publication_year=2011&amp;title=Dissolution%20testing%20for%20generic%20drugs%3A%20an%20FDA%20perspective&amp;journal=AAPS+J.&amp;volume=13&amp;pages=328" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B6" name="B6"></a>Ayukekbong, J. A., Ntemgwa, M., Atabe, A. N. (2017). The threat of antimicrobial resistance in developing countries: causes and control strategies.&nbsp;<i>Antimicrob. Resist. Infect. Control</i>&nbsp;6 (1), 47. doi: 10.1186/s13756-017-0208-x</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=28515903" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1186/s13756-017-0208-x" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=J.%20A.+Ayukekbong&amp;author=M.+Ntemgwa&amp;author=A.%20N.+Atabe&amp;publication_year=2017&amp;title=The%20threat%20of%20antimicrobial%20resistance%20in%20developing%20countries%3A%20causes%20and%20control%20strategies&amp;journal=Antimicrob.+Resist.+Infect.+Control&amp;volume=6&amp;pages=47" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B7" name="B7"></a>Baldrick, P. (2000). Pharmaceutical excipient development: the need for preclinical guidance.&nbsp;<i>Regul. Toxicol. Pharmacol.</i>&nbsp;32 (2), 210–218. doi: 10.1006/rtph.2000.1421</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=11067777" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1006/rtph.2000.1421" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=P.+Baldrick&amp;publication_year=2000&amp;title=Pharmaceutical%20excipient%20development%3A%20the%20need%20for%20preclinical%20guidance&amp;journal=Regul.+Toxicol.+Pharmacol.&amp;volume=32&amp;pages=210" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B8" name="B8"></a>Bano, R., Gauhar, S., Naqvi, S. B. S., Mahmood, S. (2011). Pharmaceutical evaluation of different brands of levofloxacin tablets (250mg) available in local market of karachi (pakistan).&nbsp;<i>Int. J. Curr. Pharm. Res.</i>&nbsp;3 (1), 15–22.</p>
<p class="ReferencesCopy2"><a href="https://scholar.google.com/scholar_lookup?author=R.+Bano&amp;author=S.+Gauhar&amp;author=S.%20B.%20S.+Naqvi&amp;author=S.+Mahmood&amp;publication_year=2011&amp;title=Pharmaceutical%20evaluation%20of%20different%20brands%20of%20levofloxacin%20tablets%20%28250mg%29%20available%20in%20local%20market%20of%20karachi%20%28pakistan%29&amp;journal=Int.+J.+Curr.+Pharm.+Res.&amp;volume=3&amp;pages=15" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B9" name="B9"></a>Basnet, S., Sharma, A., Mathisen, M., Shrestha, P. S., Ghimire, R. K., Shrestha, D. M., et al. (2015). Predictors of duration and treatment failure of severe pneumonia in hospitalized young nepalese children.&nbsp;<i>PLoS One</i>&nbsp;10 (3), e0122052. doi: 10.1371/journal.pone.0122052</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=25798907" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1371/journal.pone.0122052" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=S.+Basnet&amp;author=A.+Sharma&amp;author=M.+Mathisen&amp;author=P.%20S.+Shrestha&amp;author=R.%20K.+Ghimire&amp;author=D.%20M.+Shrestha&amp;publication_year=2015&amp;title=Predictors%20of%20duration%20and%20treatment%20failure%20of%20severe%20pneumonia%20in%20hospitalized%20young%20nepalese%20children&amp;journal=PLoS+One&amp;volume=10&amp;" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B10" name="B10"></a>Bastida, T., Perez-Vazquez, M., Campos, J., Cortes-Lletget, M. C., Roman, F., Tubau, F., et al. (2003). Levofloxacin treatment failure in haemophilus influenzae pneumonia.&nbsp;<i>Emerg. Infect. Dis.</i>&nbsp;9 (11), 1475–1478. doi: 10.3201/eid0911.030176</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=14718097" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.3201/eid0911.030176" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=T.+Bastida&amp;author=M.+Perez-Vazquez&amp;author=J.+Campos&amp;author=M.%20C.+Cortes-Lletget&amp;author=F.+Roman&amp;author=F.+Tubau&amp;publication_year=2003&amp;title=Levofloxacin%20treatment%20failure%20in%20haemophilus%20influenzae%20pneumonia&amp;journal=Emerg.+Infect.+Dis.&amp;volume=9&amp;pages=1475" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B11" name="B11"></a>Bate, R., Jensen, P., Hess, K., Mooney, L., Milligan, J. (2013). Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis.&nbsp;<i>Int. J. Tuberc. Lung Dis.</i>&nbsp;17 (3), 308–311. doi: 10.5588/ijtld.12.0355</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=23321423" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.5588/ijtld.12.0355" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=R.+Bate&amp;author=P.+Jensen&amp;author=K.+Hess&amp;author=L.+Mooney&amp;author=J.+Milligan&amp;publication_year=2013&amp;title=Substandard%20and%20falsified%20anti-tuberculosis%20drugs%3A%20a%20preliminary%20field%20analysis&amp;journal=Int.+J.+Tuberc.+Lung+Dis.&amp;volume=17&amp;pages=308" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B12" name="B12"></a>Bhavanam, P. R., Lekkala, V. K., Maddirala, P., Reddy, S. N., Sai Krishna, A. (2011). Formulation and evaluation of levofloxacin using different types and concentrations of superdisintegrants.&nbsp;<i>Pharm. Sci. Res.</i>&nbsp;100 (5), 1628–1636.</p>
<p class="ReferencesCopy2"><a href="https://scholar.google.com/scholar_lookup?author=P.%20R.+Bhavanam&amp;author=V.%20K.+Lekkala&amp;author=P.+Maddirala&amp;author=S.%20N.+Reddy&amp;author=A.+Sai%20Krishna&amp;publication_year=2011&amp;title=Formulation%20and%20evaluation%20of%20levofloxacin%20using%20different%20types%20and%20concentrations%20of%20superdisintegrants&amp;journal=Pharm.+Sci.+Res.&amp;volume=100&amp;pages=1628" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B13" name="B13"></a>Boyd, L. B., Maynard, M. J., Morgan-Linnell, S. K., Horton, L. B., Sucgang, R., Hamill, R. J., et al. (2009). Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant escherichia coli clinical isolates.&nbsp;<i>Antimicrob. Agents Chemother.</i>&nbsp;53 (10), 229–234. doi: 10.1128/AAC.00722-08</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=18838594" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1128/AAC.00722-08" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=L.%20B.+Boyd&amp;author=M.%20J.+Maynard&amp;author=S.%20K.+Morgan-Linnell&amp;author=L.%20B.+Horton&amp;author=R.+Sucgang&amp;author=R.%20J.+Hamill&amp;publication_year=2009&amp;title=Relationships%20among%20ciprofloxacin%2C%20gatifloxacin%2C%20levofloxacin%2C%20and%20norfloxacin%20MICs%20for%20fluoroquinolone-resistant%20escherichia%20coli%20clinical%20isolates&amp;journal=Antimicrob.+Agents+Chemother.&amp;volume=53&amp;pages=229" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B14" name="B14"></a>Bradley, B. D., Howie, S. R., Chan, T. C., Cheng, Y. L. (2014). Estimating oxygen needs for childhood pneumonia in developing country health systems: a new model for expecting the unexpected.&nbsp;<i>PLoS One</i>&nbsp;9 (2), e89872. doi: 10.1371/journal.pone.0089872</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=24587089" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1371/journal.pone.0089872" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=B.%20D.+Bradley&amp;author=S.%20R.+Howie&amp;author=T.%20C.+Chan&amp;author=Y.%20L.+Cheng&amp;publication_year=2014&amp;title=Estimating%20oxygen%20needs%20for%20childhood%20pneumonia%20in%20developing%20country%20health%20systems%3A%20a%20new%20model%20for%20expecting%20the%20unexpected&amp;journal=PLoS+One&amp;volume=9&amp;" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B15" name="B15"></a>Conway, J., Bero, L., Ondari, C., Wasan, K. M. (2013). Review of the quality of pediatric medications in developing countries.&nbsp;<i>J. Pharm. Sci.</i>&nbsp;102 (5), 1419–1433. doi: 10.1002/jps.23474</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=23450511" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1002/jps.23474" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=J.+Conway&amp;author=L.+Bero&amp;author=C.+Ondari&amp;author=K.%20M.+Wasan&amp;publication_year=2013&amp;title=Review%20of%20the%20quality%20of%20pediatric%20medications%20in%20developing%20countries&amp;journal=J.+Pharm.+Sci.&amp;volume=102&amp;pages=1419" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B16" name="B16"></a>Crispian, S. (2016). “Pneumonia,” in&nbsp;<i>Scully’s handbook of medical problems in dentistry.</i>&nbsp;(London, United Kingdom: Elsevier Health Sciences), 293.</p>
<p class="ReferencesCopy2"><a href="https://scholar.google.com/scholar_lookup?author=S.+Crispian&amp;publication_year=2016&amp;title=Pneumonia&amp;book=Scully%E2%80%99s+handbook+of+medical+problems+in+dentistry.&amp;pages=293" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B17" name="B17"></a>Currie, C. J., Berni, E., Jenkins-Jones, S., Poole, C. D., Ouwens, M., Driessen, S., et al. (2014). Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis.&nbsp;<i>BMJ</i>&nbsp;349, g5493. doi: 10.1136/bmj.g5493</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=25249162" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1136/bmj.g5493" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=C.%20J.+Currie&amp;author=E.+Berni&amp;author=S.+Jenkins-Jones&amp;author=C.%20D.+Poole&amp;author=M.+Ouwens&amp;author=S.+Driessen&amp;publication_year=2014&amp;title=Antibiotic%20treatment%20failure%20in%20four%20common%20infections%20in%20UK%20primary%20care%201991-2012%3A%20longitudinal%20analysis&amp;journal=BMJ&amp;volume=349&amp;" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B18" name="B18"></a>Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., Azavedo, J. C. S., Kibsey, P., et al. (2002). Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.&nbsp;<i>N. Engl. J. Med.</i>&nbsp;346 (10), 747–750. doi: 10.1056/NEJMoa012122</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=11882730" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1056/NEJMoa012122" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=R.+Davidson&amp;author=R.+Cavalcanti&amp;author=J.%20L.+Brunton&amp;author=D.%20J.+Bast&amp;author=J.%20C.%20S.+Azavedo&amp;author=P.+Kibsey&amp;publication_year=2002&amp;title=Resistance%20to%20levofloxacin%20and%20failure%20of%20treatment%20of%20pneumococcal%20pneumonia&amp;journal=N.+Engl.+J.+Med.&amp;volume=346&amp;pages=747" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B19" name="B19"></a>Davit, B. M., Nwakama, P. E., Buehler, G. J., Conner, D. P., Haidar, S. H., Patel, D. T., et al. (2009). Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the united states food and drug administration.&nbsp;<i>Ann. Pharmacother.</i>&nbsp;43 (10), 1583–1597. doi: 10.1345/aph.1M141</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=19776300" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1345/aph.1M141" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=B.%20M.+Davit&amp;author=P.%20E.+Nwakama&amp;author=G.%20J.+Buehler&amp;author=D.%20P.+Conner&amp;author=S.%20H.+Haidar&amp;author=D.%20T.+Patel&amp;publication_year=2009&amp;title=Comparing%20generic%20and%20innovator%20drugs%3A%20a%20review%20of%2012%20years%20of%20bioequivalence%20data%20from%20the%20united%20states%20food%20and%20drug%20administration&amp;journal=Ann.+Pharmacother.&amp;volume=43&amp;pages=1583" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B20" name="B20"></a>Dunne, S., Shannon, B., Dunne, C., Cullen, W. (2013). A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.&nbsp;<i>BMC Pharmacol. Toxicol.</i>&nbsp;14, 1. doi: 10.1186/2050-6511-14-1</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=23289757" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1186/2050-6511-14-1" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=S.+Dunne&amp;author=B.+Shannon&amp;author=C.+Dunne&amp;author=W.+Cullen&amp;publication_year=2013&amp;title=A%20review%20of%20the%20differences%20and%20similarities%20between%20generic%20drugs%20and%20their%20originator%20counterparts%2C%20including%20economic%20benefits%20associated%20with%20usage%20of%20generic%20medicines%2C%20using%20Ireland%20as%20a%20case%20study&amp;journal=BMC+Pharmacol.+Toxicol.&amp;volume=14&amp;pages=1" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B21" name="B21"></a>Endimiani, A., Brigante, G., Bettaccini, A. A., Luzzaro, F., Grossi, P., Toniolo, A. Q. (2005). Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.&nbsp;<i>BMC Infect. Dis.</i>&nbsp;5, 106. doi: 10.1186/1471-2334-5-106</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=16307682" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1186/1471-2334-5-106" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=A.+Endimiani&amp;author=G.+Brigante&amp;author=A.%20A.+Bettaccini&amp;author=F.+Luzzaro&amp;author=P.+Grossi&amp;author=A.%20Q.+Toniolo&amp;publication_year=2005&amp;title=Failure%20of%20levofloxacin%20treatment%20in%20community-acquired%20pneumococcal%20pneumonia&amp;journal=BMC+Infect.+Dis.&amp;volume=5&amp;pages=106" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B22" name="B22"></a>Fadeyi, I., Lalani, M., Mailk, N., Van Wyk, A., Kaur, H. (2015). Quality of the antibiotics–amoxicillin and co-trimoxazole from Ghana, Nigeria, and the United Kingdom.&nbsp;<i>Am. J. Trop. Med. Hyg.</i>&nbsp;92 (6 Suppl), 87–94. doi: 10.4269/ajtmh.14-0539</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=25897067" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.4269/ajtmh.14-0539" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=I.+Fadeyi&amp;author=M.+Lalani&amp;author=N.+Mailk&amp;author=A.+Van%20Wyk&amp;author=H.+Kaur&amp;publication_year=2015&amp;title=Quality%20of%20the%20antibiotics%E2%80%93amoxicillin%20and%20co-trimoxazole%20from%20Ghana%2C%20Nigeria%2C%20and%20the%20United%20Kingdom&amp;journal=Am.+J.+Trop.+Med.+Hyg.&amp;volume=92&amp;pages=87" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B23" name="B23"></a>Frick, A., Moller, H., Wirbitzki, E. (1998). Biopharmaceutical characterization of oral immediate release drug products. in vitro/<i>in vivo</i>&nbsp;comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin.&nbsp;<i>Eur. J. Pharm. Biopharm.</i>&nbsp;46 (3), 305–311. doi: 10.1016/S0939-6411(98)00041-1</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=9885303" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1016/S0939-6411(98)00041-1" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=A.+Frick&amp;author=H.+Moller&amp;author=E.+Wirbitzki&amp;publication_year=1998&amp;title=Biopharmaceutical%20characterization%20of%20oral%20immediate%20release%20drug%20products.%20in%20vitro%2Fin%20vivo%20comparison%20of%20phenoxymethylpenicillin%20potassium%2C%20glimepiride%20and%20levofloxacin&amp;journal=Eur.+J.+Pharm.+Biopharm.&amp;volume=46&amp;pages=305" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B24" name="B24"></a>Gallelli, L., Palleria, C., De Vuono, A., Mumoli, L., Vasapollo, P., Piro, B., et al. (2013). Safety and efficacy of generic drugs with respect to brand formulation.&nbsp;<i>J. Pharmacol. Pharmacother.</i>&nbsp;4 (Suppl 1), S110–S114. doi: 10.4103/0976-500X.120972</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=24347975" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.4103/0976-500X.120972" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=L.+Gallelli&amp;author=C.+Palleria&amp;author=A.+De%20Vuono&amp;author=L.+Mumoli&amp;author=P.+Vasapollo&amp;author=B.+Piro&amp;publication_year=2013&amp;title=Safety%20and%20efficacy%20of%20generic%20drugs%20with%20respect%20to%20brand%20formulation&amp;journal=J.+Pharmacol.+Pharmacother.&amp;volume=4&amp;pages=S110" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B25" name="B25"></a>Gibson, L. (2005). Adverse reaction reports may be vulnerable to manipulation.&nbsp;<i>BMJ</i>&nbsp;330 (7503), 1287. doi: 10.1136/bmj.330.7503.1287</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=15933346" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1136/bmj.330.7503.1287" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=L.+Gibson&amp;publication_year=2005&amp;title=Adverse%20reaction%20reports%20may%20be%20vulnerable%20to%20manipulation&amp;journal=BMJ&amp;volume=330&amp;pages=1287" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B26" name="B26"></a>Ho, P. L., Yung, R. W., Tsang, D. N., Que, T. L., Ho, M., Seto, W. H., et al. (2001). Increasing resistance of streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.&nbsp;<i>J. Antimicrob. Chemother.</i>&nbsp;48 (5), 659–665. doi: 10.1093/jac/48.5.659</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=11679555" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1093/jac/48.5.659" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=P.%20L.+Ho&amp;author=R.%20W.+Yung&amp;author=D.%20N.+Tsang&amp;author=T.%20L.+Que&amp;author=M.+Ho&amp;author=W.%20H.+Seto&amp;publication_year=2001&amp;title=Increasing%20resistance%20of%20streptococcus%20pneumoniae%20to%20fluoroquinolones%3A%20results%20of%20a%20Hong%20Kong%20multicentre%20study%20in%202000&amp;journal=J.+Antimicrob.+Chemother.&amp;volume=48&amp;pages=659" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B27" name="B27"></a>Hosseini, S. A., Darbooy, S., Tehrani Banihashemi, S. A., Naseri, S. M., Dinarvand, R. (2011). Counterfeit medicines: report of a cross-sectional retrospective study in Iran.&nbsp;<i>Public Health</i>&nbsp;125 (3), 165–171. doi: 10.1016/j.puhe.2010.11.015</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=21397286" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1016/j.puhe.2010.11.015" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=S.%20A.+Hosseini&amp;author=S.+Darbooy&amp;author=S.%20A.+Tehrani%20Banihashemi&amp;author=S.%20M.+Naseri&amp;author=R.+Dinarvand&amp;publication_year=2011&amp;title=Counterfeit%20medicines%3A%20report%20of%20a%20cross-sectional%20retrospective%20study%20in%20Iran&amp;journal=Public+Health&amp;volume=125&amp;pages=165" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B28" name="B28"></a>Hu, Y., Mathema, B., Wang, W., Kreiswirth, B., Jiang, W., Xu, B. (2011). Population-based investigation of fluoroquinolones resistant tuberculosis in rural eastern China.&nbsp;<i>Tuberculosis (Edinb)</i>&nbsp;91 (3), 238–243. doi: 10.1016/j.tube.2011.03.001</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=21450523" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1016/j.tube.2011.03.001" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=Y.+Hu&amp;author=B.+Mathema&amp;author=W.+Wang&amp;author=B.+Kreiswirth&amp;author=W.+Jiang&amp;author=B.+Xu&amp;publication_year=2011&amp;title=Population-based%20investigation%20of%20fluoroquinolones%20resistant%20tuberculosis%20in%20rural%20eastern%20China&amp;journal=Tuberculosis+(Edinb)&amp;volume=91&amp;pages=238" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B29" name="B29"></a>Imran, M., Amjad, A., Haidri, F. R. (2016). Frequency of hospital acquired pneumonia and its microbiological etiology in medical intensive care unit.&nbsp;<i>Pak. J. Med. Sci.</i>&nbsp;32 (4), 823–826. doi: 10.12669/pjms.324.8942</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=27648021" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.12669/pjms.324.8942" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=M.+Imran&amp;author=A.+Amjad&amp;author=F.%20R.+Haidri&amp;publication_year=2016&amp;title=Frequency%20of%20hospital%20acquired%20pneumonia%20and%20its%20microbiological%20etiology%20in%20medical%20intensive%20care%20unit&amp;journal=Pak.+J.+Med.+Sci.&amp;volume=32&amp;pages=823" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B30" name="B30"></a>Johansson, N., Kalin, M., Tiveljung-Lindell, A., Giske, C. G., Hedlund, J. (2010). Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods.&nbsp;<i>Clin. Infect. Dis.</i>&nbsp;50 (2), 202–209. doi: 10.1086/648678</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=20014950" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1086/648678" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=N.+Johansson&amp;author=M.+Kalin&amp;author=A.+Tiveljung-Lindell&amp;author=C.%20G.+Giske&amp;author=J.+Hedlund&amp;publication_year=2010&amp;title=Etiology%20of%20community-acquired%20pneumonia%3A%20increased%20microbiological%20yield%20with%20new%20diagnostic%20methods&amp;journal=Clin.+Infect.+Dis.&amp;volume=50&amp;pages=202" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B31" name="B31"></a>Karunamoorthi, K. (2014). The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence.&nbsp;<i>Malar. J.</i>&nbsp;13, 209. doi: 10.1186/1475-2875-13-209</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=24888370" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1186/1475-2875-13-209" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=K.+Karunamoorthi&amp;publication_year=2014&amp;title=The%20counterfeit%20anti-malarial%20is%20a%20crime%20against%20humanity%3A%20a%20systematic%20review%20of%20the%20scientific%20evidence&amp;journal=Malar.+J.&amp;volume=13&amp;pages=209" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B32" name="B32"></a>Kaul, S., Zimmer, J., Dehus, O., Costanzo, A., Daas, A., Buchheit, K. H., et al. (2016). Standardization of allergen products: 3. validation of candidate european pharmacopoeia standard methods for quantification of major birch allergen bet v 1.&nbsp;<i>Allergy</i>. 7 (10), 1414–1424. doi: 10.1111/all.12898</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1111/all.12898" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=S.+Kaul&amp;author=J.+Zimmer&amp;author=O.+Dehus&amp;author=A.+Costanzo&amp;author=A.+Daas&amp;author=K.%20H.+Buchheit&amp;publication_year=2016&amp;title=Standardization%20of%20allergen%20products%3A%203.%20validation%20of%20candidate%20european%20pharmacopoeia%20standard%20methods%20for%20quantification%20of%20major%20birch%20allergen%20bet%20v%201&amp;journal=Allergy&amp;volume=7&amp;pages=1414" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B33" name="B33"></a>Kays, M. B., Smith, D. W., Wack, M. E., Denys, G. A. (2002). Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.&nbsp;<i>Pharmacother.</i>&nbsp;22 (3), 395–399. doi: 10.1592/phco.22.5.395.33185</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1592/phco.22.5.395.33185" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=M.%20B.+Kays&amp;author=D.%20W.+Smith&amp;author=M.%20E.+Wack&amp;author=G.%20A.+Denys&amp;publication_year=2002&amp;title=Levofloxacin%20treatment%20failure%20in%20a%20patient%20with%20fluoroquinolone-resistant%20Streptococcus%20pneumoniae%20pneumonia&amp;journal=Pharmacother.&amp;volume=22&amp;pages=395" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B34" name="B34"></a>Kayumba, P. C., Risha, P. G., Shewiyo, D., Msami, A., Masuki, G., Ameye, D., et al. (2004). The quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and Tanzania: influence of tropical storage conditions on&nbsp;<i>in vitro</i>&nbsp;dissolution.&nbsp;<i>J. Clin. Pharm. Ther.</i>&nbsp;29 (4), 331–338. doi: 10.1111/j.1365-2710.2004.00568.x</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=15271100" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1111/j.1365-2710.2004.00568.x" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=P.%20C.+Kayumba&amp;author=P.%20G.+Risha&amp;author=D.+Shewiyo&amp;author=A.+Msami&amp;author=G.+Masuki&amp;author=D.+Ameye&amp;publication_year=2004&amp;title=The%20quality%20of%20essential%20antimicrobial%20and%20antimalarial%20drugs%20marketed%20in%20Rwanda%20and%20Tanzania%3A%20influence%20of%20tropical%20storage%20conditions%20on%20in%20vitro%20dissolution&amp;journal=J.+Clin.+Pharm.+Ther.&amp;volume=29&amp;pages=331" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B35" name="B35"></a>Kesselheim, A. S., Misono, A. S., Lee, J. L., Stedman, M. R., Brookhart, M. A., Choudhry, N. K., et al. (2008). Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.&nbsp;<i>JAMA</i>&nbsp;300 (21), 2514–2526. doi: 10.1001/jama.2008.758</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=19050195" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1001/jama.2008.758" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=A.%20S.+Kesselheim&amp;author=A.%20S.+Misono&amp;author=J.%20L.+Lee&amp;author=M.%20R.+Stedman&amp;author=M.%20A.+Brookhart&amp;author=N.%20K.+Choudhry&amp;publication_year=2008&amp;title=Clinical%20equivalence%20of%20generic%20and%20brand-name%20drugs%20used%20in%20cardiovascular%20disease%3A%20a%20systematic%20review%20and%20meta-analysis&amp;journal=JAMA&amp;volume=300&amp;pages=2514" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B36" name="B36"></a>Khadka, P., Ro, J., Kim, H., Kim, I., Kim, J.T., Kim, H., et al. (2014). Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability.&nbsp;<i>Asian J. Pharm. Sci.</i>&nbsp;9 (6), 304–316. doi: 10.1016/j.ajps.2014.05.005</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/j.ajps.2014.05.005" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=P.+Khadka&amp;author=J.+Ro&amp;author=H.+Kim&amp;author=I.+Kim&amp;author=J.T.+Kim&amp;author=H.+Kim&amp;publication_year=2014&amp;title=Pharmaceutical%20particle%20technologies%3A%20an%20approach%20to%20improve%20drug%20solubility%2C%20dissolution%20and%20bioavailability&amp;journal=Asian+J.+Pharm.+Sci.&amp;volume=9&amp;pages=304" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B37" name="B37"></a>Khasawneh, F. A., Karim, A., Mahmood, T., Ahmed, S., Jaffri, S. F., Tate, M. E., et al. (2014). Antibiotic de-escalation in bacteremic urinary tract infections: potential opportunities and effect on outcome.&nbsp;<i>Infect.</i>&nbsp;42 (5), 829–834. doi: 10.1007/s15010-014-0639-8</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1007/s15010-014-0639-8" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=F.%20A.+Khasawneh&amp;author=A.+Karim&amp;author=T.+Mahmood&amp;author=S.+Ahmed&amp;author=S.%20F.+Jaffri&amp;author=M.%20E.+Tate&amp;publication_year=2014&amp;title=Antibiotic%20de-escalation%20in%20bacteremic%20urinary%20tract%20infections%3A%20potential%20opportunities%20and%20effect%20on%20outcome&amp;journal=Infect.&amp;volume=42&amp;pages=829" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B38" name="B38"></a>Khurelbat, D., Dorj, G., Bayarsaikhan, E., Chimedsuren, M., Sanjjav, T., Morimoto, T., et al. (2014). Prevalence estimates of substandard drugs in Mongolia using a random sample survey.&nbsp;<i>Springerplus</i>&nbsp;3, 709. doi: 10.1186/2193-1801-3-709</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=25525570" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1186/2193-1801-3-709" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=D.+Khurelbat&amp;author=G.+Dorj&amp;author=E.+Bayarsaikhan&amp;author=M.+Chimedsuren&amp;author=T.+Sanjjav&amp;author=T.+Morimoto&amp;publication_year=2014&amp;title=Prevalence%20estimates%20of%20substandard%20drugs%20in%20Mongolia%20using%20a%20random%20sample%20survey&amp;journal=Springerplus&amp;volume=3&amp;pages=709" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B39" name="B39"></a>Lalani, M., Kaur, H., Mohammed, N., Mailk, N., van Wyk, A., Jan, S., et al. (2015). Substandard antimalarials available in Afghanistan: a case for assessing the quality of drugs in resource poor settings.&nbsp;<i>Am. J. Trop. Med. Hyg.</i>&nbsp;92 (6 Suppl), 51–58. doi: 10.4269/ajtmh.14-0394</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=25897070" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.4269/ajtmh.14-0394" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=M.+Lalani&amp;author=H.+Kaur&amp;author=N.+Mohammed&amp;author=N.+Mailk&amp;author=A.+van%20Wyk&amp;author=S.+Jan&amp;publication_year=2015&amp;title=Substandard%20antimalarials%20available%20in%20Afghanistan%3A%20a%20case%20for%20assessing%20the%20quality%20of%20drugs%20in%20resource%20poor%20settings&amp;journal=Am.+J.+Trop.+Med.+Hyg.&amp;volume=92&amp;pages=51" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B40" name="B40"></a>Lambert, P. A., Conway, B. R. (2003). Pharmaceutical quality of ceftriaxone generic drug products compared with rocephin.&nbsp;<i>J. Chemother.</i>&nbsp;15 (4), 357–368. doi: 10.1179/joc.2003.15.4.357</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=12962364" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1179/joc.2003.15.4.357" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=P.%20A.+Lambert&amp;author=B.%20R.+Conway&amp;publication_year=2003&amp;title=Pharmaceutical%20quality%20of%20ceftriaxone%20generic%20drug%20products%20compared%20with%20rocephin&amp;journal=J.+Chemother.&amp;volume=15&amp;pages=357" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B41" name="B41"></a>Lee, M. T., Lee, S. H., Chang, S. S., Chan, Y. L., Pang, L., Hsu, S. M., et al. (2015). Comparative treatment failure rates of respiratory fluoroquinolones or beta-lactam + macrolide versus beta-lactam alone in the treatment for community-acquired pneumonia in adult outpatients: an analysis of a nationally representative claims database.&nbsp;<i>Medicine (Baltimore)</i>&nbsp;94 (39), 1–8. doi: 10.1097/MD.0000000000001662</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1097/MD.0000000000001662" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=M.%20T.+Lee&amp;author=S.%20H.+Lee&amp;author=S.%20S.+Chang&amp;author=Y.%20L.+Chan&amp;author=L.+Pang&amp;author=S.%20M.+Hsu&amp;publication_year=2015&amp;title=Comparative%20treatment%20failure%20rates%20of%20respiratory%20fluoroquinolones%20or%20beta-lactam%20%2B%20macrolide%20versus%20beta-lactam%20alone%20in%20the%20treatment%20for%20community-acquired%20pneumonia%20in%20adult%20outpatients%3A%20an%20analysis%20of%20a%20nationally%20representative%20claims%20database&amp;journal=Medicine+(Baltimore)&amp;volume=94&amp;pages=1" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B42" name="B42"></a>Leekha, S., Terrell, C. L., Edson, R. S. (2011). General principles of antimicrobial therapy.&nbsp;<i>Mayo Clin. Proc.</i>&nbsp;86 (2), 156–167. doi: 10.4065/mcp.2010.0639</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=21282489" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.4065/mcp.2010.0639" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=S.+Leekha&amp;author=C.%20L.+Terrell&amp;author=R.%20S.+Edson&amp;publication_year=2011&amp;title=General%20principles%20of%20antimicrobial%20therapy&amp;journal=Mayo+Clin.+Proc.&amp;volume=86&amp;pages=156" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B43" name="B43"></a>Li, T. W., Tu, P. W., Liu, L. L., Wu, S. I. (2015). Assurance of medical device quality with quality management system: an analysis of good manufacturing practice implementation in Taiwan.&nbsp;<i>Biomed Res. Int.</i>&nbsp;2015, 670420. doi: 10.1155/2015/670420</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=26075255" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1155/2015/670420" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=T.%20W.+Li&amp;author=P.%20W.+Tu&amp;author=L.%20L.+Liu&amp;author=S.%20I.+Wu&amp;publication_year=2015&amp;title=Assurance%20of%20medical%20device%20quality%20with%20quality%20management%20system%3A%20an%20analysis%20of%20good%20manufacturing%20practice%20implementation%20in%20Taiwan&amp;journal=Biomed+Res.+Int.&amp;volume=2015&amp;pages=670420" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B44" name="B44"></a>Liu, W. K., Liu, Q., Chen, D. H., Liang, H. X., Chen, X. K., Chen, M. X., et al. (2014). Epidemiology of acute respiratory infections in children in Guangzhou: a three-year study.&nbsp;<i>PLoS One</i>&nbsp;9 (5), e96674. doi: 10.1371/journal.pone.0096674</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=24797911" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1371/journal.pone.0096674" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=W.%20K.+Liu&amp;author=Q.+Liu&amp;author=D.%20H.+Chen&amp;author=H.%20X.+Liang&amp;author=X.%20K.+Chen&amp;author=M.%20X.+Chen&amp;publication_year=2014&amp;title=Epidemiology%20of%20acute%20respiratory%20infections%20in%20children%20in%20Guangzhou%3A%20a%20three-year%20study&amp;journal=PLoS+One&amp;volume=9&amp;" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B45" name="B45"></a>Losada-Urzáiz, F., González-Gaya, C., Sebastián-Pérez, M.A. (2015). Metrological regulations for quality control equipment calibration in pharmaceutical industry.&nbsp;<i>Procedia Eng.</i>&nbsp;132 (2), 811–815. doi: 10.1016/j.proeng.2015.12.564</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/j.proeng.2015.12.564" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=F.+Losada-Urz%C3%A1iz&amp;author=C.+Gonz%C3%A1lez-Gaya&amp;author=M.A.+Sebasti%C3%A1n-P%C3%A9rez&amp;publication_year=2015&amp;title=Metrological%20regulations%20for%20quality%20control%20equipment%20calibration%20in%20pharmaceutical%20industry&amp;journal=Procedia+Eng.&amp;volume=132&amp;pages=811" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B46" name="B46"></a>Maezawa, K., Yajima, R., Terajima, T., Kizu, J., Hori, S. (2013). Dissolution profile of 24 levofloxacin (100 mg) tablets.&nbsp;<i>J. Infect. Chemother.</i>&nbsp;19 (5), 996–998. doi: 10.1007/s10156-012-0530-4</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=23380968" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1007/s10156-012-0530-4" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=K.+Maezawa&amp;author=R.+Yajima&amp;author=T.+Terajima&amp;author=J.+Kizu&amp;author=S.+Hori&amp;publication_year=2013&amp;title=Dissolution%20profile%20of%2024%20levofloxacin%20%28100%20mg%29%20tablets&amp;journal=J.+Infect.+Chemother.&amp;volume=19&amp;pages=996" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B47" name="B47"></a>Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., et al. (2007). Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults.&nbsp;<i>Clin. Infect. Dis.</i>&nbsp;44 (2), 27–72. doi: 10.1086/511159</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1086/511159" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=L.%20A.+Mandell&amp;author=R.%20G.+Wunderink&amp;author=A.+Anzueto&amp;author=J.%20G.+Bartlett&amp;author=G.%20D.+Campbell&amp;author=N.%20C.+Dean&amp;publication_year=2007&amp;title=Infectious%20diseases%20society%20of%20america%2Famerican%20thoracic%20society%20consensus%20guidelines%20on%20the%20management%20of%20community-acquired%20pneumonia%20in%20adults&amp;journal=Clin.+Infect.+Dis.&amp;volume=44&amp;pages=27" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B48" name="B48"></a>Melo, V. V., Costa, M. S., Soares, A. Q. (2014). Quality of prescription of high-alert medication and patient safety in pediatric emergency.&nbsp;<i>Farm. Hosp.</i>&nbsp;38 (1), 9–17. doi: 10.7399/FH.2014.38.1.1097</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=24483854" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.7399/FH.2014.38.1.1097" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=V.%20V.+Melo&amp;author=M.%20S.+Costa&amp;author=A.%20Q.+Soares&amp;publication_year=2014&amp;title=Quality%20of%20prescription%20of%20high-alert%20medication%20and%20patient%20safety%20in%20pediatric%20emergency&amp;journal=Farm.+Hosp.&amp;volume=38&amp;pages=9" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B49" name="B49"></a>Miller, R. A., Walker, R. D., Carson, J., Coles, M., Coyne, R., Dalsgaard, I., et al. (2005). Standardization of a broth microdilution susceptibility testing method to determine minimum inhibitory concentrations of aquatic bacteria.&nbsp;<i>Dis. Aquat. Organ.</i>&nbsp;64 (3), 211–222. doi: 10.3354/dao064211</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=15997819" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.3354/dao064211" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=R.%20A.+Miller&amp;author=R.%20D.+Walker&amp;author=J.+Carson&amp;author=M.+Coles&amp;author=R.+Coyne&amp;author=I.+Dalsgaard&amp;publication_year=2005&amp;title=Standardization%20of%20a%20broth%20microdilution%20susceptibility%20testing%20method%20to%20determine%20minimum%20inhibitory%20concentrations%20of%20aquatic%20bacteria&amp;journal=Dis.+Aquat.+Organ.&amp;volume=64&amp;pages=211" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B50" name="B50"></a>Nazir, S. U. R., Nadeem, M., Malik, A., Irshad, K. N., Amer, M., Asjad, H. M. (2013). Formulation and&nbsp;<i>in-vitro</i>&nbsp;evaluation of levofloxacin tablets by using superdisintegrants.&nbsp;<i>Am. J. Res. Commun.</i>&nbsp;1 (4), 193–199.</p>
<p class="ReferencesCopy2"><a href="https://scholar.google.com/scholar_lookup?author=S.%20U.%20R.+Nazir&amp;author=M.+Nadeem&amp;author=A.+Malik&amp;author=K.%20N.+Irshad&amp;author=M.+Amer&amp;author=H.%20M.+Asjad&amp;publication_year=2013&amp;title=Formulation%20and%20in-vitro%20evaluation%20of%20levofloxacin%20tablets%20by%20using%20superdisintegrants&amp;journal=Am.+J.+Res.+Commun.&amp;volume=1&amp;pages=193" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B51" name="B51"></a>Newton, P. N., Green, M. D., Fernandez, F. M. (2010). Impact of poor-quality medicines in the ‘developing’ world.&nbsp;<i>Trends Pharmacol. Sci.</i>&nbsp;31 (3), 99–101. doi: 10.1016/j.tips.2009.11.005</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=20117849" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1016/j.tips.2009.11.005" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=P.%20N.+Newton&amp;author=M.%20D.+Green&amp;author=F.%20M.+Fernandez&amp;publication_year=2010&amp;title=Impact%20of%20poor-quality%20medicines%20in%20the%20%E2%80%98developing%E2%80%99%20world&amp;journal=Trends+Pharmacol.+Sci.&amp;volume=31&amp;pages=99" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B52" name="B52"></a>Nightingale, C. H. (2005). A survey of the quality of generic clarithromycin products from 18 countries.&nbsp;<i>Clin. Drug Investig.</i>&nbsp;25 (2), 135–152. doi: 10.2165/00044011-200525020-00006</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=17523763" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.2165/00044011-200525020-00006" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=C.%20H.+Nightingale&amp;publication_year=2005&amp;title=A%20survey%20of%20the%20quality%20of%20generic%20clarithromycin%20products%20from%2018%20countries&amp;journal=Clin.+Drug+Investig.&amp;volume=25&amp;pages=135" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B53" name="B53"></a>Nitzki-George, D. (2004). “Getting the terminology straight,” in&nbsp;<i>Generic Alternatives to Prescription Drugs</i>. Ed. Rosenberf, C. (North Bergen: Basic Health Publication), 5.</p>
<p class="ReferencesCopy2"><a href="https://scholar.google.com/scholar_lookup?author=D.+Nitzki-George&amp;publication_year=2004&amp;title=Getting%20the%20terminology%20straight&amp;book=Generic+Alternatives+to+Prescription+Drugs&amp;pages=5" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B54" name="B54"></a>Nogueira, F. H., Moreira-Campos, L. M., Santos, R. L., Pianetti, G. A. (2011). Quality of essential drugs in tropical countries: evaluation of antimalarial drugs in the brazilian health system.&nbsp;<i>Rev. Soc. Bras. Med. Trop.</i>&nbsp;44 (5), 582–586. doi: 10.1590/S0037-86822011000500010</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=22031073" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1590/S0037-86822011000500010" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=F.%20H.+Nogueira&amp;author=L.%20M.+Moreira-Campos&amp;author=R.%20L.+Santos&amp;author=G.%20A.+Pianetti&amp;publication_year=2011&amp;title=Quality%20of%20essential%20drugs%20in%20tropical%20countries%3A%20evaluation%20of%20antimalarial%20drugs%20in%20the%20brazilian%20health%20system&amp;journal=Rev.+Soc.+Bras.+Med.+Trop.&amp;volume=44&amp;pages=582" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B55" name="B55"></a>Noreddin, A. M., Elkhatib, W. F. (2010). Levofloxacin in the treatment of community-acquired pneumonia.&nbsp;<i>Expert Rev. Anti Infect. Ther.</i>&nbsp;8 (5), 505–514. doi: 10.1586/eri.10.35</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=20455679" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1586/eri.10.35" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=A.%20M.+Noreddin&amp;author=W.%20F.+Elkhatib&amp;publication_year=2010&amp;title=Levofloxacin%20in%20the%20treatment%20of%20community-acquired%20pneumonia&amp;journal=Expert+Rev.+Anti+Infect.+Ther.&amp;volume=8&amp;pages=505" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B56" name="B56"></a>Nsimba, S. E. (2008). Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy.&nbsp;<i>East Afr. J. Public Health</i>&nbsp;5 (3), 205–210. doi: 10.4314/eajph.v5i3.39004</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=19374325" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.4314/eajph.v5i3.39004" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=S.%20E.+Nsimba&amp;publication_year=2008&amp;title=Problems%20associated%20with%20substandard%20and%20counterfeit%20drugs%20in%20developing%20countries%3A%20a%20review%20article%20on%20global%20implications%20of%20counterfeit%20drugs%20in%20the%20era%20of%20antiretroviral%20%28ARVs%29%20drugs%20in%20a%20free%20market%20economy&amp;journal=East+Afr.+J.+Public+Health&amp;volume=5&amp;pages=205" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B57" name="B57"></a>Panchagnula, R., Kumar Bajpai, A., Agrawal, S., Ashokraj, Y. (2006). Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.&nbsp;<i>Pharmazie</i>&nbsp;61 (10), 851–854.</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=17069424" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=R.+Panchagnula&amp;author=A.+Kumar%20Bajpai&amp;author=S.+Agrawal&amp;author=Y.+Ashokraj&amp;publication_year=2006&amp;title=Dissolution%20testing%20of%20marketed%20rifampicin%20containing%20fixed%20dose%20combination%20formulations%20using%20a%20new%20discriminative%20media%3A%20a%20post%20marketing%20retrospective%20study&amp;journal=Pharmazie&amp;volume=61&amp;pages=851" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B58" name="B58"></a>Paveliu, M. S., Bengea, S., Paveliu, F. S. (2011). Generic substitution issues: brand-generic substitution, generic-generic substitution, and generic substitution of narrow therapeutic index (NTI)/critical dose drugs.&nbsp;<i>Maedica (Buchar)</i>&nbsp;6 (1), 52–58.</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=21977191" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=M.%20S.+Paveliu&amp;author=S.+Bengea&amp;author=F.%20S.+Paveliu&amp;publication_year=2011&amp;title=Generic%20substitution%20issues%3A%20brand-generic%20substitution%2C%20generic-generic%20substitution%2C%20and%20generic%20substitution%20of%20narrow%20therapeutic%20index%20%28NTI%29%2Fcritical%20dose%20drugs&amp;journal=Maedica+(Buchar)&amp;volume=6&amp;pages=52" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B59" name="B59"></a>Rizvi, M., Nisa, Z. U., Ahmed, M., Naqvi, B., Abbas, A., Sabah, A. (2014). Comparision of&nbsp;<i>in vitro</i>&nbsp;antibacterial activity of cefoperazone and levofloxacin against different clinical isolates.&nbsp;<i>Int. J. Allied Med. Sci. Clin. Res.</i>&nbsp;2 (1), 74–78.</p>
<p class="ReferencesCopy2"><a href="https://scholar.google.com/scholar_lookup?author=M.+Rizvi&amp;author=Z.%20U.+Nisa&amp;author=M.+Ahmed&amp;author=B.+Naqvi&amp;author=A.+Abbas&amp;author=A.+Sabah&amp;publication_year=2014&amp;title=Comparision%20of%20in%20vitro%20antibacterial%20activity%20of%20cefoperazone%20and%20levofloxacin%20against%20different%20clinical%20isolates&amp;journal=Int.+J.+Allied+Med.+Sci.+Clin.+Res.&amp;volume=2&amp;pages=74" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B60" name="B60"></a>Sahm, D. F., Peterson, D. E., Critchley, I. A., Thornsberry, C. (2000). Analysis of ciprofloxacin activity against streptococcus pneumoniae after 10 years of use in the United States.&nbsp;<i>Antimicrob. Agents Chemother.</i>&nbsp;44 (9), 2521–2524. doi: 10.1128/AAC.44.9.2521-2524.2000</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=10952606" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1128/AAC.44.9.2521-2524.2000" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=D.%20F.+Sahm&amp;author=D.%20E.+Peterson&amp;author=I.%20A.+Critchley&amp;author=C.+Thornsberry&amp;publication_year=2000&amp;title=Analysis%20of%20ciprofloxacin%20activity%20against%20streptococcus%20pneumoniae%20after%2010%20years%20of%20use%20in%20the%20United%20States&amp;journal=Antimicrob.+Agents+Chemother.&amp;volume=44&amp;pages=2521" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B61" name="B61"></a>Sánchez García, M. (2009). Early antibiotic treatment failure.&nbsp;<i>Int. J. Antimicrob. Agents</i>&nbsp;34 (3), 14–19. doi: 10.1016/S0924-8579(09)70552-7</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/S0924-8579(09)70552-7" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=M.+S%C3%A1nchez%20Garc%C3%ADa&amp;publication_year=2009&amp;title=Early%20antibiotic%20treatment%20failure&amp;journal=Int.+J.+Antimicrob.+Agents&amp;volume=34&amp;pages=14" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B62" name="B62"></a>Sarpong, E. M., Miller, G. E. (2014). Narrow- and broad-spectrum antibiotic use among U.S. children.&nbsp;<i>Health Serv. Res.</i>&nbsp;50 (3), 830–846. doi: 10.1111/1475-6773.12260</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=25424240" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1111/1475-6773.12260" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=E.%20M.+Sarpong&amp;author=G.%20E.+Miller&amp;publication_year=2014&amp;title=Narrow-%20and%20broad-spectrum%20antibiotic%20use%20among%20U.S.%20children&amp;journal=Health+Serv.+Res.&amp;volume=50&amp;pages=830" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B63" name="B63"></a>Seok, H., Kang, C. I., Huh, K., Cho, S. Y., Ha, Y. E., Chung, D. R., et al. (2018). Risk factors for community-onset pneumonia caused by levofloxacin-nonsusceptible streptococcus pneumoniae.&nbsp;<i>Microb. Drug Resist</i>. doi: 10.1089/mdr.2017.0416</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1089/mdr.2017.0416" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=H.+Seok&amp;author=C.%20I.+Kang&amp;author=K.+Huh&amp;author=S.%20Y.+Cho&amp;author=Y.%20E.+Ha&amp;author=D.%20R.+Chung&amp;publication_year=2018&amp;title=Risk%20factors%20for%20community-onset%20pneumonia%20caused%20by%20levofloxacin-nonsusceptible%20streptococcus%20pneumoniae&amp;journal=Microb.+Drug+Resist&amp;" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B64" name="B64"></a>Scoper, S. V. (2008). Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.&nbsp;<i>Adv. Ther.</i>&nbsp;25 (10), 979–994. doi: 10.1007/s12325-008-0107-x</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=18836691" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1007/s12325-008-0107-x" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=S.%20V.+Scoper&amp;publication_year=2008&amp;title=Review%20of%20third-and%20fourth-generation%20fluoroquinolones%20in%20ophthalmology%3A%20in-vitro%20and%20in-vivo%20efficacy&amp;journal=Adv.+Ther.&amp;volume=25&amp;pages=979" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B65" name="B65"></a>Sun, H. Y., Liao, H. W., Sheng, M. H., Tai, H. M., Kuo, C. H., Sheng, W. H. (2016). Bioequivalence and&nbsp;<i>in vitro</i>&nbsp;antimicrobial activity between generic and brand-name levofloxacin.&nbsp;<i>Diagn. Microbiol. Infect. Dis.</i>&nbsp;85 (3), 347–351. doi: 10.1016/j.diagmicrobio.2016.04.015</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=27181716" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1016/j.diagmicrobio.2016.04.015" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=H.%20Y.+Sun&amp;author=H.%20W.+Liao&amp;author=M.%20H.+Sheng&amp;author=H.%20M.+Tai&amp;author=C.%20H.+Kuo&amp;author=W.%20H.+Sheng&amp;publication_year=2016&amp;title=Bioequivalence%20and%20in%20vitro%20antimicrobial%20activity%20between%20generic%20and%20brand-name%20levofloxacin&amp;journal=Diagn.+Microbiol.+Infect.+Dis.&amp;volume=85&amp;pages=347" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B66" name="B66"></a>Talan, D. A., Takhar, S. S., Krishnadasan, A., Abrahamian, F. M., Mower, W. R., Moran, G. J., et al. (2016). Fluoroquinolone-resistant and extended-spectrum beta-lactamase-producing escherichia coli infections in patients with pyelonephritis, United States.&nbsp;<i>Emerg. Infect. Dis.</i>&nbsp;22 (9), 1594–1603. doi: 10.3201/eid2209.160148</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.3201/eid2209.160148" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=D.%20A.+Talan&amp;author=S.%20S.+Takhar&amp;author=A.+Krishnadasan&amp;author=F.%20M.+Abrahamian&amp;author=W.%20R.+Mower&amp;author=G.%20J.+Moran&amp;publication_year=2016&amp;title=Fluoroquinolone-resistant%20and%20extended-spectrum%20beta-lactamase-producing%20escherichia%20coli%20infections%20in%20patients%20with%20pyelonephritis%2C%20United%20States&amp;journal=Emerg.+Infect.+Dis.&amp;volume=22&amp;pages=1594" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B67" name="B67"></a>Tamargo, J., LeHeuzey, J. Y., Mabo, P. (2015). Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide.&nbsp;<i>Eur. J. Clin. Pharmacol.</i>&nbsp;71 (5), 549–567. doi: 10.1007/s00228-015-1832-0</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=25870032" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1007/s00228-015-1832-0" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=J.+Tamargo&amp;author=J.%20Y.+LeHeuzey&amp;author=P.+Mabo&amp;publication_year=2015&amp;title=Narrow%20therapeutic%20index%20drugs%3A%20a%20clinical%20pharmacological%20consideration%20to%20flecainide&amp;journal=Eur.+J.+Clin.+Pharmacol.&amp;volume=71&amp;pages=549" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B68" name="B68"></a>Taylor, R. B., Shakoor, O., Behrens, R. H., Everard, M., Low, A. S., Wangboonskul, J., et al. (2001). Pharmacopoeial quality of drugs supplied by Nigerian pharmacies.&nbsp;<i>Lancet</i>&nbsp;357 (9272), 1933–1936. doi: 10.1016/S0140-6736(00)05065-0</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=11425415" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1016/S0140-6736(00)05065-0" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=R.%20B.+Taylor&amp;author=O.+Shakoor&amp;author=R.%20H.+Behrens&amp;author=M.+Everard&amp;author=A.%20S.+Low&amp;author=J.+Wangboonskul&amp;publication_year=2001&amp;title=Pharmacopoeial%20quality%20of%20drugs%20supplied%20by%20Nigerian%20pharmacies&amp;journal=Lancet&amp;volume=357&amp;pages=1933" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B69" name="B69"></a>Tipke, M., Diallo, S., Coulibaly, B., Storzinger, D., Hoppe-Tichy, T., Sie, A., et al. (2008). Substandard anti-malarial drugs in Burkina Faso.&nbsp;<i>Malar. J.</i>&nbsp;7, 95. doi: 10.1186/1475-2875-7-95</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=18505584" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1186/1475-2875-7-95" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=M.+Tipke&amp;author=S.+Diallo&amp;author=B.+Coulibaly&amp;author=D.+Storzinger&amp;author=T.+Hoppe-Tichy&amp;author=A.+Sie&amp;publication_year=2008&amp;title=Substandard%20anti-malarial%20drugs%20in%20Burkina%20Faso&amp;journal=Malar.+J.&amp;volume=7&amp;pages=95" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B70" name="B70"></a>Tomic, S., Filipovic Sucic, A., Ilic Martinac, A. (2010). Good manufacturing practice: the role of local manufacturers and competent authorities.&nbsp;<i>Arh. Hig. Rada Toksikol.</i>&nbsp;61 (4), 425–436. doi: 10.2478/10004-1254-61-2010-2035</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=21183434" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.2478/10004-1254-61-2010-2035" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=S.+Tomic&amp;author=A.+Filipovic%20Sucic&amp;author=A.+Ilic%20Martinac&amp;publication_year=2010&amp;title=Good%20manufacturing%20practice%3A%20the%20role%20of%20local%20manufacturers%20and%20competent%20authorities&amp;journal=Arh.+Hig.+Rada+Toksikol.&amp;volume=61&amp;pages=425" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B71" name="B71"></a>Torloni, M. R., Gomes Freitas, C., Kartoglu, U. H., Metin Gulmezoglu, A., Widmer, M. (2016). Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature.&nbsp;<i>BJOG</i>. 123 (13), 2076–2208 doi: 10.1111/1471-0528.13998</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=27006180" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1111/1471-0528.13998" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=M.%20R.+Torloni&amp;author=C.+Gomes%20Freitas&amp;author=U.%20H.+Kartoglu&amp;author=A.+Metin%20Gulmezoglu&amp;author=M.+Widmer&amp;publication_year=2016&amp;title=Quality%20of%20oxytocin%20available%20in%20low-%20and%20middle-income%20countries%3A%20a%20systematic%20review%20of%20the%20literature&amp;journal=BJOG&amp;volume=123&amp;pages=2076" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B72" name="B72"></a>Wang, T., Hoag, S. W., Eng, M. L., Polli, J., Pandit, N. (2015). Quality of antiretroviral and opportunistic infection medications dispensed from developing countries and internet pharmacies.&nbsp;<i>J. Clin. Pharm. Ther.</i>&nbsp;40 (1), 68–75. doi: 10.1111/jcpt.12226</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=25381836" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1111/jcpt.12226" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=T.+Wang&amp;author=S.%20W.+Hoag&amp;author=M.%20L.+Eng&amp;author=J.+Polli&amp;author=N.+Pandit&amp;publication_year=2015&amp;title=Quality%20of%20antiretroviral%20and%20opportunistic%20infection%20medications%20dispensed%20from%20developing%20countries%20and%20internet%20pharmacies&amp;journal=J.+Clin.+Pharm.+Ther.&amp;volume=40&amp;pages=68" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B73" name="B73"></a>World Health Organization. (2011). Definition of active pharmaceutical ingredient. Geneva: WHO.</p>
<p class="ReferencesCopy2"><a href="https://scholar.google.com/scholar_lookup?author=World%20Health%20Organization&amp;publication_year=2011&amp;title=Definition%20of%20active%20pharmaceutical%20ingredient&amp;" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B74" name="B74"></a>World Health Organization. (2016).&nbsp;<i>Substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) medical products</i>. Stockholm: World Health Organization. Retrieved from&nbsp;<a href="http://www.who.int/mediacentre/factsheets/fs275/en/">http://www.who.int/mediacentre/factsheets/fs275/en/#</a>.</p>
<p class="ReferencesCopy2"><a href="https://scholar.google.com/scholar_lookup?author=World%20Health%20Organization&amp;publication_year=2016&amp;journal=Substandard,+spurious,+falsely+labelled,+falsified+and+counterfeit+(SSFFC)+medical+products&amp;" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1"><a id="B75" name="B75"></a>Zaid, A. N., Al-Ramahi, R. J., Ghoush, A. A., Qaddumi, A., Zaaror, Y. A., (2013). Weight and content uniformity of lorazepam half-tablets: a study of correlation of a low drug content product.&nbsp;<i>Saudi Pharm. J.</i>&nbsp;21 (1), 71–75. doi: 10.1016/j.jsps.2011.12.009</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=23960821" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1016/j.jsps.2011.12.009" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=A.%20N.+Zaid&amp;author=R.%20J.+Al-Ramahi&amp;author=A.%20A.+Ghoush&amp;author=A.+Qaddumi&amp;author=Y.%20A.+Zaaror&amp;publication_year=2013&amp;title=Weight%20and%20content%20uniformity%20of%20lorazepam%20half-tablets%3A%20a%20study%20of%20correlation%20of%20a%20low%20drug%20content%20product&amp;journal=Saudi+Pharm.+J.&amp;volume=21&amp;pages=71" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<div class="References" bis_skin_checked="1">
<p class="ReferencesCopy1">Zavras, D., Zavras, A. I., Kyriopoulos, I. I., Kyriopoulos, J. (2016). Economic crisis, austerity and unmet healthcare needs: the case of Greece.&nbsp;<i>BMC Health Serv. Res.</i>&nbsp;16 (1), 309. doi: 10.1186/s12913-016-1557-5</p>
<p class="ReferencesCopy2"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=27460938" target="_blank" rel="noopener">PubMed Abstract</a>&nbsp;|&nbsp;<a href="https://doi.org/10.1186/s12913-016-1557-5" target="_blank" rel="noopener">CrossRef Full Text</a>&nbsp;|&nbsp;<a href="https://scholar.google.com/scholar_lookup?author=D.+Zavras&amp;author=A.%20I.+Zavras&amp;author=I.%20I.+Kyriopoulos&amp;author=J.+Kyriopoulos&amp;publication_year=2016&amp;title=Economic%20crisis%2C%20austerity%20and%20unmet%20healthcare%20needs%3A%20the%20case%20of%20Greece&amp;journal=BMC+Health+Serv.+Res.&amp;volume=16&amp;pages=309" target="_blank" rel="noopener">Google Scholar</a></p>
</div>
<p>&nbsp;</p>
<p>Keywords:&nbsp;counterfeit, post marketing surveillance, regulatory requirement, fluroquinolone resistance, quality medicine</p>
<p>Citation:&nbsp;Izadi E, Afshan G, Patel RP, Rao VM, Liew KB, Meor Mohd Affandi MMR, Kifli N, Suleiman A, Lee KS, Sarker MMR, Zaidi ST and Ming LC (2019) Levofloxacin: Insights Into Antibiotic Resistance and Product Quality.&nbsp;<i>Front. Pharmacol.</i>&nbsp;10:881. doi: 10.3389/fphar.2019.00881</p>
<p id="timestamps">Received:&nbsp;13 January 2019;&nbsp;Accepted:&nbsp;15 July 2019;<br>
Published:&nbsp;14 August 2019.</p>
<div bis_skin_checked="1">
<p>Edited by:</p>
<p><a href="https://loop.frontiersin.org/people/19028">Francisco J. DeAbajo</a>, University of Alcalá, Spain</p>
</div>
<div bis_skin_checked="1">
<p>Reviewed by:</p>
<p><a href="https://loop.frontiersin.org/people/554651">Syed Sarim Imam</a>, Glocal University, India<br>
<a href="https://loop.frontiersin.org/people/429450">Mele Antonietta</a>, University of Bari Aldo Moro, Italy</p>
</div>
<p>Copyright&nbsp;© 2019 Izadi, Afshan, Patel, Rao, Liew, Meor Mohd Affandi, Kifli, Suleiman, Lee, Sarker, Zaidi and Ming. This is an open-access article distributed under the terms of the&nbsp;<a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" rel="license noopener">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p>*Correspondence:&nbsp;L. C. Ming,&nbsp;<a href="mailto:ming.long@bath.edu">ming.long@bath.edu</a></p>
<p>&nbsp;</p>
<h2>Source</h2>
<hr>
<p>&nbsp;</p>
<p>https://www.frontiersin.org/articles/10.3389/fphar.2019.00881/full</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2020/12/31/levofloxacin-insights-into-antibiotic-resistance-and-product-quality/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2020/12/31/levofloxacin-insights-into-antibiotic-resistance-and-product-quality/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5116 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>28.12.2020</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2020/12/28/doxycycline-treatment-of-high-risk-covid-19-positive-patients-with-comorbid-pulmonary-disease/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2020/12/28/doxycycline-treatment-of-high-risk-covid-19-positive-patients-with-comorbid-pulmonary-disease/">Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><div class="authorLayer" bis_skin_checked="1">
<div class="header" bis_skin_checked="1">
<div class="hlFld-Title" bis_skin_checked="1">
<div class="publicationContentTitle" bis_skin_checked="1">
<div class="hlFld-Title" bis_skin_checked="1">
<div class="publicationContentTitle" bis_skin_checked="1"></div>
</div>
<div class="publicationContentAuthors" bis_skin_checked="1">
<div class="author-container js__articleAuthorContainer" data-max-authors="5" data-authorname-selector=".contribDegrees > .entryAuthor" data-author-container-selector=".NLM_contrib-group" bis_skin_checked="1">
<div class="authors" bis_skin_checked="1">
<div class="hlFld-ContribAuthor" bis_skin_checked="1">
<p><span class="contribDegrees">Paul A. Yates,&nbsp;</span><span class="contribDegrees">Steven A. Newman,&nbsp;</span><span class="contribDegrees">Lauren J. Oshry,&nbsp;</span></p>
<div class="expandable-author" bis_skin_checked="1"><span class="contribDegrees">Robert H. Glassman</span>,&nbsp;<span class="contribDegrees">Ashton M. Leone</span>,&nbsp;<span class="contribDegrees">Elias Reichel<a href="https://orcid.org/0000-0001-9523-9046" target="_blank" rel="noopener noreferrer" bis_size="{&quot;x&quot;:30,&quot;y&quot;:165594,&quot;w&quot;:300,&quot;h&quot;:16,&quot;abs_x&quot;:30,&quot;abs_y&quot;:165594}"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://journals.sagepub.com/templates/jsp/images/orcid.png" bis_size="{&quot;x&quot;:30,&quot;y&quot;:165457,&quot;w&quot;:300,&quot;h&quot;:150,&quot;abs_x&quot;:30,&quot;abs_y&quot;:165457}" bis_id="bn_oasabqnrjlvifxsd2ae416"><noscript><img src="https://journals.sagepub.com/templates/jsp/images/orcid.png" /></noscript></a></span></div>
</div>
</div>
</div>
</div>
<p><span class="publicationContentEpubDate dates"><b>First Published&nbsp;</b>September 1, 2020&nbsp;</span><span class="ArticleType">Case Report</span></p>
<div class="articleMetaDrop publicationContentDropZone publicationContentDropZone1" data-pb-dropzone="articleMetaDropZone1" bis_skin_checked="1">
<div id="66028d4c-d8fb-4855-92bd-8d3e954d6d44" class="widget doiWidget none widget-none widget-compact-all" bis_skin_checked="1">
<div class="wrapped " bis_skin_checked="1">
<div class="widget-body body body-none body-compact-all" bis_skin_checked="1">
<div class="doiWidgetContainer" bis_skin_checked="1"><a class="doiWidgetLink" href="https://doi.org/10.1177%2F1753466620951053" rel="noopener">https://doi.org/10.1177/1753466620951053</a></div>
<div bis_skin_checked="1"></div>
</div>
<div bis_skin_checked="1">
<h4>Article Information</h4>
<div class="Article information" bis_skin_checked="1">
<div bis_skin_checked="1">Volume: 14</div>
<div class="published-dates" bis_skin_checked="1"><b>Article first published online:</b>&nbsp;September 1, 2020;&nbsp;<b>Issue published:</b>&nbsp;January 1, 2020<br>
Received: June 24, 2020; Accepted: July 07, 2020</div>
<div class="copyRight" bis_skin_checked="1"></div>
</div>
<div class="Authors information" bis_skin_checked="1">
<div class="author name" bis_skin_checked="1">
<div class="hlFld-ContribAuthor" bis_skin_checked="1">
<div class="contribDegrees with-aff" bis_skin_checked="1">
<p><strong>Paul A. Yates</strong></p>
<div class="artice-info-affiliation" bis_skin_checked="1">Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA</div>
<p><span class="role">Conceptualization</span><span class="role">Investigation</span><span class="role">Methodology</span><span class="role">Project administration</span><span class="role">Writing original draft</span><span class="role">Writing review editing</span></p>
</div>
<div class="contribDegrees with-aff" bis_skin_checked="1">
<p><strong>Steven A. Newman</strong></p>
<div class="artice-info-affiliation" bis_skin_checked="1">Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA</div>
<p><span class="role">Data curation</span><span class="role">Investigation</span><span class="role">Writing original draft</span></p>
</div>
<div class="contribDegrees with-aff" bis_skin_checked="1">
<p><strong>Lauren J. Oshry</strong></p>
<div class="artice-info-affiliation" bis_skin_checked="1">Department of Medicine, Boston University School of Medicine, Boston, MA, USA</div>
<p><span class="role">Conceptualization</span><span class="role">Data curation</span><span class="role">Formal analysis</span><span class="role">Investigation</span><span class="role">Methodology</span><span class="role">Writing original draft</span><span class="role">Writing review editing</span></p>
</div>
<div class="contribDegrees with-aff" bis_skin_checked="1">
<p><strong>Robert H. Glassman</strong></p>
<div class="artice-info-affiliation" bis_skin_checked="1">Department of Medicine, Weill Cornell Medicine, New York, NY, USA</div>
<p><span class="role">Data curation</span><span class="role">Investigation</span><span class="role">Validation</span><span class="role">Writing original draft</span></p>
</div>
<div class="contribDegrees with-aff" bis_skin_checked="1">
<p><strong>Ashton M. Leone</strong></p>
<div class="artice-info-affiliation" bis_skin_checked="1">Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA</div>
<p><span class="role">Data curation</span><span class="role">Investigation</span><span class="role">Project administration. </span><span class="role">Writing original draft</span></p>
</div>
<div class="contribDegrees with-aff" bis_skin_checked="1">
<p><strong>Elias Reichel</strong></p>
<div class="artice-info-affiliation" bis_skin_checked="1">Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111, USA</div>
<p><span class="role">Conceptualization</span><span class="role">Data curation format</span><span class="role">&nbsp;analysis</span><span class="role">Investigation</span><span class="role">Methodology</span><span class="role">Project administration writing</span><span class="role"> original draft writing</span><span class="role">&nbsp;review editing</span></p>
</div>
<div class="artice-notes" bis_skin_checked="1"><strong>Corresponding Author:</strong><br>
<a class="email" href="mailto:reichelconsulting@gmail.com">reichelconsulting@gmail.com</a></div>
<div class="credit_roles" bis_skin_checked="1">
<div class="credit-title" bis_skin_checked="1"><strong>Author Contributions:</strong></div>
<div class="contributor_role" bis_skin_checked="1">Paul A. Yates: Conceptualization; Investigation; Methodology; Project administration; Writing original draft; Writing review editing</div>
<div class="contributor_role" bis_skin_checked="1">Steven A. Newman: Data curation; Investigation; Writing original draft</div>
<div class="contributor_role" bis_skin_checked="1">Lauren J. Oshry: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Writing original draft; Writing review editing</div>
<div class="contributor_role" bis_skin_checked="1">Robert H. Glassman: Data curation; Investigation; Validation; Writing original draft</div>
<div class="contributor_role" bis_skin_checked="1">Ashton M. Leone: Data curation; Investigation; Project administration; Writing original draft</div>
<div class="contributor_role" bis_skin_checked="1">Elias Reichel: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Writing original draft; Writing review editing</div>
</div>
</div>
</div>
</div>
<div class="publicationContentLicenseTagging" bis_skin_checked="1">https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<a href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</a>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<a href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</a>).</div>
<p>&nbsp;</p>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="articleMetaDrop publicationContentDropZone publicationContentDropZone1" data-pb-dropzone="articleMetaDropZone1" bis_skin_checked="1">
<div id="80078b98-037a-4dab-b149-628ef0ecefc6" class="widget layout-one-column none widget-none widget-compact-all" bis_skin_checked="1">
<div class="wrapped " bis_skin_checked="1">
<div class="widget-body body body-none body-compact-all" bis_skin_checked="1">
<div class="pb-columns row-fluid" bis_skin_checked="1">
<div class="width_1_1" bis_skin_checked="1">
<div data-pb-dropzone="center" bis_skin_checked="1">
<div id="de1d8314-cfbd-4c21-ae0c-fd75561d30c2" class="widget layout-inline-content none badgeBar widget-none widget-compact-all" bis_skin_checked="1">
<div class="wrapped " bis_skin_checked="1">
<div class="widget-body body body-none body-compact-all" bis_skin_checked="1">
<div class="inline-dropzone" data-pb-dropzone="content" bis_skin_checked="1">
<div id="b271a0d4-9500-4879-a880-60e90df38c35" class="widget sageConditionalDisplayWidget none pull-right widget-none widget-compact-all" bis_skin_checked="1">
<div class="wrapped " bis_skin_checked="1">
<div class="widget-body body body-none body-compact-all" bis_skin_checked="1">
<div data-pb-dropzone="conditional" bis_skin_checked="1">
<h2 class="sectionHeading">Abstract</h2>
<hr>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="widget-body body body-none body-compact-all" bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<p>Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive.</p>
<p>Antiviral drugs such as remdesivir may be of some benefit but are reserved for severe cases given limited availability and potential toxicity. Repurposing of safer, established medications that may have antiviral activity is a possible approach for treatment of earlier-stage disease. Tetracycline and its derivatives (e.g. doxycycline and minocycline) are nontraditional antibiotics with a well-established safety profile, potential efficacy against viral pathogens such as dengue fever and chikungunya, and may regulate pathways important in initial infection, replication, and systemic response to SARS-CoV-2. We present a series of four high-risk, symptomatic, COVID-19<sup>+</sup>&nbsp;patients, with known pulmonary disease, treated with doxycycline with subsequent rapid clinical improvement. No safety issues were noted with use of doxycycline.</p>
<p>Doxycycline is an attractive candidate as a repurposed drug in the treatment of COVID-19 infection, with an established safety profile, strong preclinical rationale, and compelling initial clinical experience described here.</p>
<p><i>The reviews of this paper are available via the supplemental material section.</i></p>
</div>
<p><b>Keywords&nbsp;</b>COVID-19,&nbsp;doxycycline,&nbsp;pulmonary disease,&nbsp;SARS-CoV-2,&nbsp;therapeutic</p>
<p>&nbsp;</p>
<h2 class="sectionHeading">Introduction</h2>
<hr>
<p>SARS-CoV-2 is a newly emerged coronavirus for which there are limited therapeutic options and no available vaccine.<sup><a id="focusIdbibr1-1753466620951053209" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr1-1753466620951053" data-ref-text="1" data-reflink="bibr1-1753466620951053" data-referenceslink="1 Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) treatment guidelines, https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html (Accessed 21 May 2020).">1</a></sup>&nbsp;Patients who test positive are advised to self-quarantine, with supportive care including rest and fluid intake.<sup><a id="focusIdbibr1-1753466620951053210" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr1-1753466620951053" data-ref-text="1" data-reflink="bibr1-1753466620951053" data-referenceslink="1 Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) treatment guidelines, https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html (Accessed 21 May 2020).">1</a></sup>&nbsp;Hospitalization is indicated for severe disease and may be considered for patients with moderate disease with high-risk features, including immunocompromised states (e.g. cancer treatment, chronic lung disease, diabetes, severe obesity).<sup><a id="focusIdbibr1-1753466620951053211" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr1-1753466620951053" data-ref-text="1" data-reflink="bibr1-1753466620951053" data-referenceslink="1 Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) treatment guidelines, https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html (Accessed 21 May 2020).">1</a></sup>&nbsp;Mortality in patients with lung cancer and COVID-19 infection is high; 33% in a recently reported international series.<sup><a id="focusIdbibr2-1753466620951053212" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr2-1753466620951053" data-ref-text="2" data-reflink="bibr2-1753466620951053" data-referenceslink="2 Garassino M. TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): first results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies. Presented at the American Association for Cancer Research Annual Virtual Meeting, 20–22 July 2020, Philadelphia, PA.">2</a></sup></p>
<p>There is significant interest in repurposing existing, approved medications for treatment of COVID-19. Tetracycline and its derivatives (e.g. doxycycline) may offer a rational and safe treatment for COVID-19<sup>+</sup>&nbsp;patients. Doxycycline is commonly dosed at 100 mg twice daily to treat bacterial infections and dermatologic conditions (e.g. acne vulgaris and rosacea).<sup><a id="focusIdbibr3-1753466620951053213" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr3-1753466620951053" data-ref-text="3" data-reflink="bibr3-1753466620951053" data-referenceslink="3 Griffin MO, Fricovsky E, Ceballos G, et al. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299: C539–C548.">3</a></sup>&nbsp;Tetracyclines have both antiviral and anti-inflammatory properties that may ameliorate the response to viral infection.<sup><a id="focusIdbibr3-1753466620951053214" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr3-1753466620951053" data-ref-text="3" data-reflink="bibr3-1753466620951053" data-referenceslink="3 Griffin MO, Fricovsky E, Ceballos G, et al. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299: C539–C548.">3</a><a id="focusIdbibr4-1753466620951053215" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr4-1753466620951053" data-ref-text="" data-reflink="bibr4-1753466620951053" data-referenceslink="4 Fredeking TM, Zavala-Castro JE, González-Martínez P, et al. Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Pat Antiinfect Drug Discov 2015; 10: 51–58."></a><a id="focusIdbibr5-1753466620951053216" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr5-1753466620951053" data-ref-text="" data-reflink="bibr5-1753466620951053" data-referenceslink="5 Rothan HA, Bahrani H, Mohamed Z, et al. A combination of doxycycline and ribavirin alleviated chikungunya infection. PLoS One 2015; 10: e0126360."></a>–<a id="focusIdbibr6-1753466620951053217" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr6-1753466620951053" data-ref-text="6" data-reflink="bibr6-1753466620951053" data-referenceslink="6 Malek AE, Granwehr BP, Kontoyiannis DP. Doxycycline as a potential partner of COVID-19 therapies. IDCases 2020; 21: e00864.">6</a></sup>&nbsp;Clinical studies indicate efficacy of doxycycline against dengue and chikungunya viral infections.<sup><a id="focusIdbibr4-1753466620951053218" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr4-1753466620951053" data-ref-text="4" data-reflink="bibr4-1753466620951053" data-referenceslink="4 Fredeking TM, Zavala-Castro JE, González-Martínez P, et al. Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Pat Antiinfect Drug Discov 2015; 10: 51–58.">4</a>,<a id="focusIdbibr5-1753466620951053219" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr5-1753466620951053" data-ref-text="5" data-reflink="bibr5-1753466620951053" data-referenceslink="5 Rothan HA, Bahrani H, Mohamed Z, et al. A combination of doxycycline and ribavirin alleviated chikungunya infection. PLoS One 2015; 10: e0126360.">5</a></sup>&nbsp;In addition, doxycycline may affect several pathways regulating viral replication.<sup><a id="focusIdbibr7-1753466620951053220" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr7-1753466620951053" data-ref-text="7" data-reflink="bibr7-1753466620951053" data-referenceslink="7 Kumar N, Xin Z-T, Liang Y, et al. NF-kappaB signaling differentially regulates influenza virus RNA synthesis. J Virol 2008; 82: 9880–9889.">7</a><a id="focusIdbibr8-1753466620951053221" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr8-1753466620951053" data-ref-text="" data-reflink="bibr8-1753466620951053" data-referenceslink="8 Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY) 2020; 12: 6511–6517."></a>–<a id="focusIdbibr9-1753466620951053222" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr9-1753466620951053" data-ref-text="9" data-reflink="bibr9-1753466620951053" data-referenceslink="9 Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020; 10: 766–788.">9</a></sup>&nbsp;These pleiotropic features of tetracyclines likely result from actions on nontraditional, antibiotic molecular pathways.<sup><a id="focusIdbibr3-1753466620951053223" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr3-1753466620951053" data-ref-text="3" data-reflink="bibr3-1753466620951053" data-referenceslink="3 Griffin MO, Fricovsky E, Ceballos G, et al. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299: C539–C548.">3</a></sup></p>
<p>Doxycycline has several potential mechanisms of action through which it may prevent or ameliorate the effects of COVID-19 infection. Doxycycline is well known to inhibit metalloproteinases (MMPs), in particular MMP-9, which is likely required for initial viral entry into the cell.<sup><a id="focusIdbibr3-1753466620951053224" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr3-1753466620951053" data-ref-text="3" data-reflink="bibr3-1753466620951053" data-referenceslink="3 Griffin MO, Fricovsky E, Ceballos G, et al. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299: C539–C548.">3</a></sup>&nbsp;Doxycycline inhibits interleukin (IL)-6, with both IL-6 and MMPs key regulators of the ‘cytokine storm’ often associated with severe viral pneumonitis.<sup><a id="focusIdbibr10-1753466620951053225" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr10-1753466620951053" data-ref-text="10" data-reflink="bibr10-1753466620951053" data-referenceslink="10 Kong MYF, Whitley RJ, Peng N, et al. Matrix metalloproteinase-9 mediates RSV infection in vitro and in vivo. Viruses 2015; 7: 4230–4253.">10</a><a id="focusIdbibr11-1753466620951053226" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr11-1753466620951053" data-ref-text="" data-reflink="bibr11-1753466620951053" data-referenceslink="11 Phillips JM, Gallagher T, Weiss SR. Neurovirulent murine coronavirus JHM.SD uses cellular zinc metalloproteases for virus entry and cell-cell fusion. J Virol 2017; 91: e01564-16."></a>–<a id="focusIdbibr12-1753466620951053227" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr12-1753466620951053" data-ref-text="12" data-reflink="bibr12-1753466620951053" data-referenceslink="12 Conforti C, Giuffrida R, Zalaudek I, et al. Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak. Dermatol Ther 2020: e13437.">12</a></sup>&nbsp;Doxycycline is an established ionophore, helping transport zinc intracellularly, with increased cellular concentrations of zinc shown&nbsp;<i>in vitro</i>&nbsp;to inhibit coronavirus replication.<sup><a id="focusIdbibr3-1753466620951053228" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr3-1753466620951053" data-ref-text="3" data-reflink="bibr3-1753466620951053" data-referenceslink="3 Griffin MO, Fricovsky E, Ceballos G, et al. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299: C539–C548.">3</a>,<a id="focusIdbibr13-1753466620951053229" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr13-1753466620951053" data-ref-text="13" data-reflink="bibr13-1753466620951053" data-referenceslink="13 te Velthuis AJW, van den Worm SHE, Sims AC, et al. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010; 6: e1001176.">13</a></sup>&nbsp;Doxycycline inhibits nuclear factor (NF)-κB<sup><a id="focusIdbibr3-1753466620951053230" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr3-1753466620951053" data-ref-text="3" data-reflink="bibr3-1753466620951053" data-referenceslink="3 Griffin MO, Fricovsky E, Ceballos G, et al. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299: C539–C548.">3</a>,<a id="focusIdbibr14-1753466620951053231" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr14-1753466620951053" data-ref-text="14" data-reflink="bibr14-1753466620951053" data-referenceslink="14 Santa-Cecília FV, Socias B, Ouidja MO, et al. Doxycycline suppresses microglial activation by inhibiting the p38 MAPK and NF-kB signaling pathways. Neurotox Res 2016; 29: 447–459.">14</a></sup>, which may lower risk of viral entry due to direct inhibition of DPP4 cell surface receptor<sup><a id="focusIdbibr15-1753466620951053232" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr15-1753466620951053" data-ref-text="15" data-reflink="bibr15-1753466620951053" data-referenceslink="15 Choi B, Lee S, Kim S-M, et al. Dipeptidyl peptidase-4 induces aortic valve calcification by inhibiting insulin-like growth factor-1 signaling in valvular interstitial cells. Circulation 2017; 135: 1935–1950.">15</a></sup>&nbsp;and diminish a hyperactive immune response following infection. Nonantimicrobial, low-dose doxycycline has been found&nbsp;<i>in vivo</i>&nbsp;to inhibit expression of CD147/EMMPRIN,<sup><a id="focusIdbibr16-1753466620951053233" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr16-1753466620951053" data-ref-text="16" data-reflink="bibr16-1753466620951053" data-referenceslink="16 Emingil G, Atilla G, Sorsa T, et al. The effect of adjunctive subantimicrobial dose doxycycline therapy on GCF EMMPRIN levels in chronic periodontitis. J Periodontol 2008; 79: 469–476.">16</a></sup>&nbsp;which may be necessary for SARS-CoV-2 entry into T lymphocytes.<sup><a id="focusIdbibr16-1753466620951053234" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr16-1753466620951053" data-ref-text="16" data-reflink="bibr16-1753466620951053" data-referenceslink="16 Emingil G, Atilla G, Sorsa T, et al. The effect of adjunctive subantimicrobial dose doxycycline therapy on GCF EMMPRIN levels in chronic periodontitis. J Periodontol 2008; 79: 469–476.">16</a>,<a id="focusIdbibr17-1753466620951053235" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr17-1753466620951053" data-ref-text="17" data-reflink="bibr17-1753466620951053" data-referenceslink="17 Wang X, Xu W, Hu G, et al. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. Epub ahead of print 7 April 2020. DOI: 10.1038/s41423-020-0424-9.">17</a></sup>&nbsp;Structural analysis demonstrates that doxycycline has the potential to inhibit papain-like proteinase (PLpro) and 3C-like main protease (3CLpro), viral proteins both essential to viral replication and lifecycle.<sup><a id="focusIdbibr9-1753466620951053236" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr9-1753466620951053" data-ref-text="9" data-reflink="bibr9-1753466620951053" data-referenceslink="9 Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020; 10: 766–788.">9</a></sup></p>
<p>In view of the above considerations, we report a series of four patients with COVID-19 infection and known high-risk pulmonary disease who were placed on standard doses of doxycycline for a course between 5 and 14 days. Patients were initiated on therapy with doxycycline after discussion of potential risks and benefits and after informed consent was obtained. There was no concomitant use of any other antibiotics, antiviral agents, antimalarial drugs, zinc, or any supplements postulated to be beneficial in therapy for SARS-CoV-2 in these four patients.</p>
<div id="section2-1753466620951053" class="NLM_sec NLM_sec_level_2" bis_skin_checked="1">
<div class="head-b" bis_skin_checked="1">
<h3>Case 1</h3>
</div>
<p>A 48-year-old black woman, never smoker, with stage IV epidermal growth factor receptor (EGFR) mutated adenocarcinoma of lung, diagnosed in August 2018, was treated with osimertinib since November 2018 with response in all sites of disease. Other medications included loperamide and doxycycline, as needed for EGFR inhibitor-related diarrhea and rash, respectively. She worked as a nursing assistant. On 6 April 2020 she reported fever of 101° F, headache, anorexia and anosmia. On examination: temperature 101° F, pulse 102, blood pressure 115/71, O<sub>2</sub>&nbsp;sat 98% on room air. She was noted to have mild cough with normal respiratory effort. Laboratory tests revealed white blood cell count of 2.7, with lymphopenia, similar to prior recent determinations; C-reactive protein (CRP) 10.6 (0–5 mg/l), creatine kinase (CK) 2996 (46–179 U/l), troponin &lt;0.006 (negative), aspartate aminotransferase 105 (13–39 U/l), creatinine 1.3 (05–1.1) mg/dl. Chest X-ray showed chronic stable right retrocardiac midlung opacities with no new focal consolidation or effusion. The following day her swab returned positive for SARS-CoV-2. As she had declined hospitalization, she was instructed to discontinue osimertinib but to start doxycycline initially 200 mg followed by 100 mg daily for 5 days. She noted improvement in all symptoms within 5 days.</p>
</div>
<div id="section3-1753466620951053" class="NLM_sec NLM_sec_level_2" bis_skin_checked="1">
<div class="head-b" bis_skin_checked="1">
<h3>Case 2</h3>
</div>
<p>A 71-year-old white male physician with a 9 year history of pulmonary sarcoidosis, treated with intermittent steroids, noted new intermittent cough and one episode of diarrhea in early April 2020. Nasopharyngeal swab was positive for SARS-CoV-2. No additional evaluation was performed. The patient was started on doxycycline 100 mg orally twice a day and self-monitored pulse oximetry at home. Revisit to the emergency department was prompted by transient drop in oxygen saturation to 88% on day six. His temperature was 100.4° F, chest X-ray showed evidence of his chronic lower lung changes attributed to sarcoidosis, O<sub>2</sub>&nbsp;sat was 96%. The patient returned home without supplemental oxygen and remained on doxycycline for 10 days. Fever resolved and he remained asymptomatic. After 3 weeks retesting was negative for SARS-CoV-2 and he returned to work.</p>
</div>
<div id="section4-1753466620951053" class="NLM_sec NLM_sec_level_2" bis_skin_checked="1">
<div class="head-b" bis_skin_checked="1">
<h3>Case 3</h3>
</div>
<p>A 40-year-old Asian woman, never smoker, with stage IV EGFR mutated lung adenocarcinoma, on osimertinib since 13 June 2018, also treated with stereotactic radiation to right lower lobe primary lesion in July 2019, presented to an urgent care clinic with 4 days of anosmia, mild cough, and mild dyspnea. She worked as a personal care assistant for elderly patients at home. Nasopharyngeal swab testing was positive for SARS-CoV-2 RNA. The patient continued to take osimertinib and doxycycline 100 mg twice daily (previously prescribed for EGFR-I related rash). Symptoms improved within 1 week. Repeat nasopharyngeal swab testing on 9 May 2020 was negative for SARS-CoV-2 RNA.</p>
</div>
<div id="section5-1753466620951053" class="NLM_sec NLM_sec_level_2" bis_skin_checked="1">
<div class="head-b" bis_skin_checked="1">
<h3>Case 4</h3>
</div>
<p>An 88-year-old white man, with several comorbidities including sick sinus syndrome, cardiovascular disease, lacunar strokes, mild obstructive lung disease, and chronic indwelling bladder catheter, was admitted from a Veterans Nursing Home with fever to 102° F, severe dry cough, weakness, and dyspnea. Chest X-ray showed bilateral diffuse infiltrates. Laboratory tests were notable for nasopharyngeal swab positive for SARS-CoV-2 RNA, CRP 11, mild hypoxia with O<sub>2</sub>&nbsp;sat 89–92%. Ceftriaxone, azithromycin and 2 liters of nasal prong O<sub>2</sub>&nbsp;were begun. His initial hospital course showed progression of his pulmonary symptomatology with decreasing O<sub>2</sub>&nbsp;saturation requiring 4 liters of nasal prong O<sub>2</sub>&nbsp;by day 3, with CRP increase to 13. On day 4 ceftriaxone was discontinued and azithromycin was replaced with doxycycline 100 mg twice daily. His pulmonary course quickly improved alongside decreasing CRP. By day 8, he no longer required oxygen and his CRP was 1.0. He never received any antiviral, IL-6 antibody, nor convalescent plasma. He was discharged on day 28 after his lung infiltrates resolved on chest X-ray after 14 days of doxycycline therapy.</p>
</div>
<p>&nbsp;</p>
<h2 class="sectionHeading">Discussion</h2>
<hr>
<p>&nbsp;</p>
<p>These reported cases are the first to provide a correlative relationship between doxycycline and potential reduction of severity of symptoms in COVID-19<sup>+</sup>&nbsp;patients. It is difficult to establish a definitive causal link between use of doxycycline and accelerated recovery or decreased morbidity from SARS-CoV-2 infection in a small case series. We believe this study provides a rationale for initiating larger controlled trials evaluating the use of doxycycline in COVID-19<sup>+</sup>&nbsp;patients.</p>
<p>The patients we report had a number of high-risk features, predictive of severe disease and increased risk of mortality. Patients one and four had advanced lung cancer on treatment, a group for whom mortality rates with COVID-19 infection is in excess of 33%.<sup><a id="focusIdbibr2-1753466620951053238" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr2-1753466620951053" data-ref-text="2" data-reflink="bibr2-1753466620951053" data-referenceslink="2 Garassino M. TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): first results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies. Presented at the American Association for Cancer Research Annual Virtual Meeting, 20–22 July 2020, Philadelphia, PA.">2</a></sup>&nbsp;Elevated inflammatory markers, including CRP, transaminases, and CK (as in cases 1 and 4) are also associated with worse outcomes.<sup><a id="focusIdbibr18-1753466620951053239" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr18-1753466620951053" data-ref-text="18" data-reflink="bibr18-1753466620951053" data-referenceslink="18 Chen W, Zheng KI, Liu S, et al. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob 2020; 19: 18.">18</a></sup>&nbsp;Advanced age and diffuse bilateral infiltrates (case 4), are also predictors of high morbidity and mortality.<sup><a id="focusIdbibr19-1753466620951053240" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr19-1753466620951053" data-ref-text="19" data-reflink="bibr19-1753466620951053" data-referenceslink="19 Du R-H, Liang L-R, Yang C-Q, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020; 55: 2000524.">19</a></sup>&nbsp;Case 4 demonstrated a temporal relationship between administration of doxycycline and clinical improvement, after several days of worsening on azithromycin. Patients with active pulmonary sarcoidosis, as in case 2, are also at greater risk of complications from COVID-19 due to immunologic dysfunction and dysregulation.<sup><a id="focusIdbibr20-1753466620951053241" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr20-1753466620951053" data-ref-text="20" data-reflink="bibr20-1753466620951053" data-referenceslink="20 Sweiss NJ, Korsten P, Syed HJ, et al. When the game changes: guidance to adjust sarcoidosis management during the COVID-19 pandemic. Chest. Epub ahead of print 29 April 2020. DOI: 10.1016/j.chest.2020.04.033.">20</a></sup>&nbsp;The described patients were at a significant increased risk from COVID-19 morbidity and mortality. All improved, with one showing resolution of bilateral pulmonary infiltrates. None progressed to severe disease.</p>
<p>A standard antimicrobial dose of doxycycline (100 mg twice daily or daily) was administered to the four patients in this case series. Doxycycline is unique among the many tetracycline derivatives, in that it has a clear dosing split between its cellular cytotoxic/antimicrobial effects (&gt;100 mg) and its potential anti-inflammatory/antiviral/pro-ionophoric effects (40 mg).<sup><a id="focusIdbibr3-1753466620951053242" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr3-1753466620951053" data-ref-text="3" data-reflink="bibr3-1753466620951053" data-referenceslink="3 Griffin MO, Fricovsky E, Ceballos G, et al. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299: C539–C548.">3</a>,<a id="focusIdbibr4-1753466620951053243" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr4-1753466620951053" data-ref-text="4" data-reflink="bibr4-1753466620951053" data-referenceslink="4 Fredeking TM, Zavala-Castro JE, González-Martínez P, et al. Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Pat Antiinfect Drug Discov 2015; 10: 51–58.">4</a>,<a id="focusIdbibr7-1753466620951053244" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr7-1753466620951053" data-ref-text="7" data-reflink="bibr7-1753466620951053" data-referenceslink="7 Kumar N, Xin Z-T, Liang Y, et al. NF-kappaB signaling differentially regulates influenza virus RNA synthesis. J Virol 2008; 82: 9880–9889.">7</a>,<a id="focusIdbibr8-1753466620951053245" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr8-1753466620951053" data-ref-text="8" data-reflink="bibr8-1753466620951053" data-referenceslink="8 Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY) 2020; 12: 6511–6517.">8</a>,<a id="focusIdbibr12-1753466620951053246" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr12-1753466620951053" data-ref-text="12" data-reflink="bibr12-1753466620951053" data-referenceslink="12 Conforti C, Giuffrida R, Zalaudek I, et al. Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak. Dermatol Ther 2020: e13437.">12</a></sup>&nbsp;This may be an important consideration for low-dose doxycycline (20 mg twice daily) as a potential prophylactic treatment against COVID-19 infection.</p>
<p>Potential efficacy of doxycycline against COVID-19 may be due to pleiotropic effects against the general pathways involved in viral infection, replication, and associated over-exuberant inflammatory response, with associated angiogenic effects.<sup><a id="focusIdbibr3-1753466620951053247" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr3-1753466620951053" data-ref-text="3" data-reflink="bibr3-1753466620951053" data-referenceslink="3 Griffin MO, Fricovsky E, Ceballos G, et al. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299: C539–C548.">3</a></sup>&nbsp;Doxycycline has no known direct specificity for inhibition of SARS-CoV-2. Doxycycline likely has activity against known coreceptors DPP4/CD26, through demonstrated inhibition of NF-κB,<sup><a id="focusIdbibr14-1753466620951053248" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr14-1753466620951053" data-ref-text="14" data-reflink="bibr14-1753466620951053" data-referenceslink="14 Santa-Cecília FV, Socias B, Ouidja MO, et al. Doxycycline suppresses microglial activation by inhibiting the p38 MAPK and NF-kB signaling pathways. Neurotox Res 2016; 29: 447–459.">14</a>,<a id="focusIdbibr15-1753466620951053249" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr15-1753466620951053" data-ref-text="15" data-reflink="bibr15-1753466620951053" data-referenceslink="15 Choi B, Lee S, Kim S-M, et al. Dipeptidyl peptidase-4 induces aortic valve calcification by inhibiting insulin-like growth factor-1 signaling in valvular interstitial cells. Circulation 2017; 135: 1935–1950.">15</a></sup>&nbsp;and coreceptor CD147/EMMPRIN, necessary for entry of SARS-CoV into T lymphocytes, even at submicrobial doses.<sup><a id="focusIdbibr16-1753466620951053250" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr16-1753466620951053" data-ref-text="16" data-reflink="bibr16-1753466620951053" data-referenceslink="16 Emingil G, Atilla G, Sorsa T, et al. The effect of adjunctive subantimicrobial dose doxycycline therapy on GCF EMMPRIN levels in chronic periodontitis. J Periodontol 2008; 79: 469–476.">16</a>,<a id="focusIdbibr17-1753466620951053251" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr17-1753466620951053" data-ref-text="17" data-reflink="bibr17-1753466620951053" data-referenceslink="17 Wang X, Xu W, Hu G, et al. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. Epub ahead of print 7 April 2020. DOI: 10.1038/s41423-020-0424-9.">17</a></sup>&nbsp;DPP4 appears to have a binding site for NF-κB and inhibition of NF-κB decreases DPP4 expression.<sup><a id="focusIdbibr15-1753466620951053252" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr15-1753466620951053" data-ref-text="15" data-reflink="bibr15-1753466620951053" data-referenceslink="15 Choi B, Lee S, Kim S-M, et al. Dipeptidyl peptidase-4 induces aortic valve calcification by inhibiting insulin-like growth factor-1 signaling in valvular interstitial cells. Circulation 2017; 135: 1935–1950.">15</a></sup>&nbsp;DPP4 demonstrates increased expression in older patients and those with diabetes or pulmonary disease, and may account in part for increased morbidity and mortality to COVID-19.<sup><a id="focusIdbibr8-1753466620951053253" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr8-1753466620951053" data-ref-text="8" data-reflink="bibr8-1753466620951053" data-referenceslink="8 Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY) 2020; 12: 6511–6517.">8</a></sup>&nbsp;Finally, MMP-9 also appears to be required for the virus to traverse the cell wall for infection.<sup><a id="focusIdbibr10-1753466620951053254" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr10-1753466620951053" data-ref-text="10" data-reflink="bibr10-1753466620951053" data-referenceslink="10 Kong MYF, Whitley RJ, Peng N, et al. Matrix metalloproteinase-9 mediates RSV infection in vitro and in vivo. Viruses 2015; 7: 4230–4253.">10</a>,<a id="focusIdbibr11-1753466620951053255" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr11-1753466620951053" data-ref-text="11" data-reflink="bibr11-1753466620951053" data-referenceslink="11 Phillips JM, Gallagher T, Weiss SR. Neurovirulent murine coronavirus JHM.SD uses cellular zinc metalloproteases for virus entry and cell-cell fusion. J Virol 2017; 91: e01564-16.">11</a></sup></p>
<p>Once COVID-19 has infected the cell, structural analysis indicates doxycycline may be able to bind to PLpro, which is responsible for proteolytic cleavage of the replicase polyprotein that releases nonstructural proteins 1, 2 and 3 (Nsp1, Nsp2 and Nsp3), essential for viral replication.<sup><a id="focusIdbibr9-1753466620951053256" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr9-1753466620951053" data-ref-text="9" data-reflink="bibr9-1753466620951053" data-referenceslink="9 Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020; 10: 766–788.">9</a></sup>&nbsp;It is similarly predicted to bind to 3CLpro or Nsp5, which is cleaved from the polyproteins, causing further cleavage of Nsp4-16, mediating maturation of Nsps essential in the virus lifecycle.<sup><a id="focusIdbibr9-1753466620951053257" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr9-1753466620951053" data-ref-text="9" data-reflink="bibr9-1753466620951053" data-referenceslink="9 Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020; 10: 766–788.">9</a></sup>&nbsp;Doxycycline is an ionophore that binds divalent cations (including zinc) to facilitate cell membrane transport, and thereby increase zinc concentration in the cell.<sup><a id="focusIdbibr3-1753466620951053258" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr3-1753466620951053" data-ref-text="3" data-reflink="bibr3-1753466620951053" data-referenceslink="3 Griffin MO, Fricovsky E, Ceballos G, et al. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299: C539–C548.">3</a>,<a id="focusIdbibr13-1753466620951053259" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr13-1753466620951053" data-ref-text="13" data-reflink="bibr13-1753466620951053" data-referenceslink="13 te Velthuis AJW, van den Worm SHE, Sims AC, et al. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010; 6: e1001176.">13</a></sup>&nbsp;Elevated zinc has an inhibitory effect on the replication of SARS-CoV-2.<sup><a id="focusIdbibr13-1753466620951053260" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr13-1753466620951053" data-ref-text="13" data-reflink="bibr13-1753466620951053" data-referenceslink="13 te Velthuis AJW, van den Worm SHE, Sims AC, et al. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010; 6: e1001176.">13</a></sup>&nbsp;The presumed mechanisms are through inhibition of proper processing of replicase proteins and RNA-dependent RNA polymerase (RdRp) activity.<sup><a id="focusIdbibr13-1753466620951053261" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr13-1753466620951053" data-ref-text="13" data-reflink="bibr13-1753466620951053" data-referenceslink="13 te Velthuis AJW, van den Worm SHE, Sims AC, et al. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010; 6: e1001176.">13</a></sup></p>
<p>Lastly, doxycycline may help prevent the ‘cytokine storm’ following COVID-19 infection presumed to be due to hyperactivity of the immune response to SARS-CoV-2. A primary driver of the anti-inflammatory activity of doxycycline is secondary to its direct inhibition of NF-κB.<sup><a id="focusIdbibr14-1753466620951053262" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr14-1753466620951053" data-ref-text="14" data-reflink="bibr14-1753466620951053" data-referenceslink="14 Santa-Cecília FV, Socias B, Ouidja MO, et al. Doxycycline suppresses microglial activation by inhibiting the p38 MAPK and NF-kB signaling pathways. Neurotox Res 2016; 29: 447–459.">14</a></sup>&nbsp;NF-κB directly regulates IL-6 expression, which is a key driver of the cytokine storm.<sup><a id="focusIdbibr21-1753466620951053263" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr21-1753466620951053" data-ref-text="21" data-reflink="bibr21-1753466620951053" data-referenceslink="21 Brasier AR. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 2010; 86: 211–218.">21</a></sup>&nbsp;Doxycycline may also precipitate apoptosis of senescent epithelial cells,<sup><a id="focusIdbibr8-1753466620951053264" class="ref showRefEvent2" role="button" href="https://journals.sagepub.com/doi/full/10.1177/1753466620951053#" data-rid="bibr8-1753466620951053" data-ref-text="8" data-reflink="bibr8-1753466620951053" data-referenceslink="8 Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY) 2020; 12: 6511–6517.">8</a></sup>&nbsp;which have known increased expression of DPP4/CD26, likely exhibiting increased viral replication in these cells which leads to induction of the cytokine storm.</p>
<p>&nbsp;</p>
<h2 class="sectionHeading">Conclusion</h2>
<hr>
<p>&nbsp;</p>
<p>In summary, we present reports of four patients at high risk for morbidity and mortality from SARS-CoV-2 infection who experienced improvement and/or mild clinical course in association with doxycycline. Despite the safety of doxycycline, we would not recommend general use of this medication for treatment of COVID-19<sup>+</sup>&nbsp;patients, except under direct physician guidance and monitoring. A larger randomized controlled trial should be considered.</p>
<p>&nbsp;</p>
<p><span class="fn-label">Author contribution(s)</span><br>
<b>Paul A. Yates:</b>&nbsp;Conceptualization; Investigation; Methodology; Project administration; Writing-original draft; Writing-review &amp; editing.</p>
<p><b>Steven A. Newman:</b>&nbsp;Data curation; Investigation; Writing-original draft.</p>
<p><b>Lauren J. Oshry:</b>&nbsp;Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Writing-original draft; Writing-review &amp; editing.</p>
<p><b>Robert H. Glassman:</b>&nbsp;Data curation; Investigation; Validation; Writing-original draft.</p>
<p><b>Ashton M. Leone:</b>&nbsp;Data curation; Investigation; Project administration; Writing-original draft.</p>
<p><b>Elias Reichel:</b>&nbsp;Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Writing-original draft; Writing-review &amp; editing.</p>
<p><span class="fn-label">Conflict of interest statement</span><br>
The authors declare that there is no conflict of interest.</p>
<p><span class="fn-label">Funding</span><br>
The authors received no financial support for the research, authorship, and/or publication of this article.</p>
<p><span class="fn-label">ORCID iD</span><br>
Elias Reichel&nbsp;<span class="NLM_inline-graphic"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="" data-lazy-src="https://journals.sagepub.com/na101/home/literatum/publisher/sage/journals/content/tara/2020/tara_14/1753466620951053/20200901/images/medium/10.1177_1753466620951053-img1.png"><noscript><img src="https://journals.sagepub.com/na101/home/literatum/publisher/sage/journals/content/tara/2020/tara_14/1753466620951053/20200901/images/medium/10.1177_1753466620951053-img1.png" alt="" /></noscript></span>&nbsp;<a class="ext-link" href="https://orcid.org/0000-0001-9523-9046" target="_blank" rel="noopener">https://orcid.org/0000-0001-9523-9046</a></p>
<p><span class="fn-label">Supplemental material</span><br>
The reviews of this paper are available via the supplemental material section.</p>
<p>&nbsp;</p>
<div class="sectionInfo" bis_skin_checked="1">
<h2 class="sectionHeading">References</h2>
<hr>
</div>
<table class="references" border="0">
<tbody>
<tr id="bibr1-1753466620951053">
<td class="refnumber">1.</td>
<td valign="top">Centers for Disease Control and Prevention. Coronavirus disease&nbsp;<span class="NLM_year">2019</span>&nbsp;<span class="NLM_article-title">(COVID-19) treatment guidelines</span>,&nbsp;<a class="ext-link" href="https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html" target="_blank" rel="noopener">https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html</a>&nbsp;(Accessed 21 May 2020).<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2019&amp;author=Centers+for+Disease+Control+and+Prevention.+Coronavirus+disease&amp;title=%28COVID-19%29+treatment+guidelines">Google Scholar</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr2-1753466620951053">
<td class="refnumber">2.</td>
<td valign="top">Garassino, M. TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): first results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies.&nbsp;<span class="NLM_article-title">Presented at the American Association for Cancer Research Annual Virtual Meeting</span>,&nbsp;<span class="NLM_day">20–22</span>&nbsp;<span class="NLM_month">July</span>&nbsp;<span class="NLM_year">2020</span>,&nbsp;<span class="NLM_publisher-loc">Philadelphia, PA</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2020&amp;author=M.+Garassino&amp;title=TERAVOLT+%28Thoracic+cancERs+international+coVid+19+cOLlaboraTion%29%3A+first+results+of+a+global+collaboration+to+address+the+impact+of+COVID-19+in+patients+with+thoracic+malignancies">Google Scholar</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr3-1753466620951053">
<td class="refnumber">3.</td>
<td valign="top">Griffin, MO, Fricovsky, E, Ceballos, G,&nbsp;<span class="NLM_etal">et al</span>. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties .&nbsp;<span class="NLM_article-title">Review of the literature</span>. Am J Physiol Cell Physiol&nbsp;<span class="NLM_year">2010</span>; 299:&nbsp;<span class="NLM_fpage">C539</span>–<span class="NLM_lpage">C548</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2010&amp;pages=C539-C548&amp;author=MO+Griffin&amp;author=E+Fricovsky&amp;author=G+Ceballos&amp;title=Am+J+Physiol+Cell+Physiol">Google Scholar</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr4-1753466620951053">
<td class="refnumber">4.</td>
<td valign="top">Fredeking, TM, Zavala-Castro, JE, González-Martínez, P,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels</span>. Recent Pat Antiinfect Drug Discov&nbsp;<span class="NLM_year">2015</span>; 10:&nbsp;<span class="NLM_fpage">51</span>–<span class="NLM_lpage">58</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=10&amp;publication_year=2015&amp;pages=51-58&amp;author=TM+Fredeking&amp;author=JE+Zavala-Castro&amp;author=P+Gonz%C3%A1lez-Mart%C3%ADnez&amp;title=Dengue+patients+treated+with+doxycycline+showed+lower+mortality+associated+to+a+reduction+in+IL-6+and+TNF+levels">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr4-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.2174%2F1574891X10666150410153839">Crossref</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr4-1753466620951053&amp;dbid=8&amp;doi=10.1177%2F1753466620951053&amp;key=25858261">Medline</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr5-1753466620951053">
<td class="refnumber">5.</td>
<td valign="top">Rothan, HA, Bahrani, H, Mohamed, Z,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">A combination of doxycycline and ribavirin alleviated chikungunya infection</span>. PLoS One&nbsp;<span class="NLM_year">2015</span>; 10: e0126360.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=10&amp;publication_year=2015&amp;author=HA+Rothan&amp;author=H+Bahrani&amp;author=Z+Mohamed&amp;title=A+combination+of+doxycycline+and+ribavirin+alleviated+chikungunya+infection">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr5-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1371%2Fjournal.pone.0126360">Crossref</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr6-1753466620951053">
<td class="refnumber">6.</td>
<td valign="top">Malek, AE, Granwehr, BP, Kontoyiannis, DP.&nbsp;<span class="NLM_article-title">Doxycycline as a potential partner of COVID-19 therapies</span>. IDCases&nbsp;<span class="NLM_year">2020</span>; 21: e00864.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=21&amp;publication_year=2020&amp;author=AE+Malek&amp;author=BP+Granwehr&amp;author=DP+Kontoyiannis&amp;title=Doxycycline+as+a+potential+partner+of+COVID-19+therapies">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr6-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1016%2Fj.idcr.2020.e00864">Crossref</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr7-1753466620951053">
<td class="refnumber">7.</td>
<td valign="top">Kumar, N, Xin, Z-T, Liang, Y,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">NF-kappaB signaling differentially regulates influenza virus RNA synthesis</span>. J Virol&nbsp;<span class="NLM_year">2008</span>; 82:&nbsp;<span class="NLM_fpage">9880</span>–<span class="NLM_lpage">9889</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=82&amp;publication_year=2008&amp;pages=9880-9889&amp;author=N+Kumar&amp;author=Z-T+Xin&amp;author=Y+Liang&amp;title=NF-kappaB+signaling+differentially+regulates+influenza+virus+RNA+synthesis">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr7-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1128%2FJVI.00909-08">Crossref</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr7-1753466620951053&amp;dbid=8&amp;doi=10.1177%2F1753466620951053&amp;key=18701591">Medline</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr7-1753466620951053&amp;dbid=128&amp;doi=10.1177%2F1753466620951053&amp;key=000260109100008">ISI</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr8-1753466620951053">
<td class="refnumber">8.</td>
<td valign="top">Sargiacomo, C, Sotgia, F, Lisanti, MP.&nbsp;<span class="NLM_article-title">COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?</span>&nbsp;Aging (Albany NY)&nbsp;<span class="NLM_year">2020</span>; 12:&nbsp;<span class="NLM_fpage">6511</span>–<span class="NLM_lpage">6517</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=12&amp;publication_year=2020&amp;pages=6511-6517&amp;author=C+Sargiacomo&amp;author=F+Sotgia&amp;author=MP+Lisanti&amp;title=COVID-19+and+chronological+aging%3A+senolytics+and+other+anti-aging+drugs+for+the+treatment+or+prevention+of+corona+virus+infection%3F">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr8-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.18632%2Faging.103001">Crossref</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr8-1753466620951053&amp;dbid=8&amp;doi=10.1177%2F1753466620951053&amp;key=32229706">Medline</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr9-1753466620951053">
<td class="refnumber">9.</td>
<td valign="top">Wu, C, Liu, Y, Yang, Y,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</span>. Acta Pharm Sin B&nbsp;<span class="NLM_year">2020</span>; 10:&nbsp;<span class="NLM_fpage">766</span>–<span class="NLM_lpage">788</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=10&amp;publication_year=2020&amp;pages=766-788&amp;author=C+Wu&amp;author=Y+Liu&amp;author=Y+Yang&amp;title=Analysis+of+therapeutic+targets+for+SARS-CoV-2+and+discovery+of+potential+drugs+by+computational+methods">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr9-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1016%2Fj.apsb.2020.02.008">Crossref</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr9-1753466620951053&amp;dbid=8&amp;doi=10.1177%2F1753466620951053&amp;key=32292689">Medline</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr10-1753466620951053">
<td class="refnumber">10.</td>
<td valign="top">Kong, MYF, Whitley, RJ, Peng, N,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">Matrix metalloproteinase-9 mediates RSV infection in vitro and in vivo</span>. Viruses&nbsp;<span class="NLM_year">2015</span>; 7:&nbsp;<span class="NLM_fpage">4230</span>–<span class="NLM_lpage">4253</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=7&amp;publication_year=2015&amp;pages=4230-4253&amp;author=MYF+Kong&amp;author=RJ+Whitley&amp;author=N+Peng&amp;title=Matrix+metalloproteinase-9+mediates+RSV+infection+in+vitro+and+in+vivo">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr10-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.3390%2Fv7082817">Crossref</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr10-1753466620951053&amp;dbid=8&amp;doi=10.1177%2F1753466620951053&amp;key=26264019">Medline</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr11-1753466620951053">
<td class="refnumber">11.</td>
<td valign="top">Phillips, JM, Gallagher, T, Weiss, SR.&nbsp;<span class="NLM_article-title">Neurovirulent murine coronavirus JHM.SD uses cellular zinc metalloproteases for virus entry and cell-cell fusion</span>. J Virol&nbsp;<span class="NLM_year">2017</span>; 91: e01564-16.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=91&amp;publication_year=2017&amp;author=JM+Phillips&amp;author=T+Gallagher&amp;author=SR+Weiss&amp;title=Neurovirulent+murine+coronavirus+JHM.SD+uses+cellular+zinc+metalloproteases+for+virus+entry+and+cell-cell+fusion">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr11-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1128%2FJVI.01564-16">Crossref</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr12-1753466620951053">
<td class="refnumber">12.</td>
<td valign="top">Conforti, C, Giuffrida, R, Zalaudek, I,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak</span>. Dermatol Ther 2020: e13437.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar?hl=en&amp;q=%0AConforti+C%2C+Giuffrida+R%2C+Zalaudek+I%2C+et+al.+Doxycycline%2C+a+widely+used+antibiotic+in+dermatology+with+a+possible+anti-inflammatory+action+against+IL-6+in+COVID-19+outbreak.+Dermatol+Ther+2020%3A+e13437.">Google Scholar</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr13-1753466620951053">
<td class="refnumber">13.</td>
<td valign="top">te Velthuis, AJW, van den Worm, SHE, Sims, AC,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture</span>. PLoS Pathog&nbsp;<span class="NLM_year">2010</span>; 6: e1001176.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=6&amp;publication_year=2010&amp;author=AJW+te+Velthuis&amp;author=SHE+van+den+Worm&amp;author=AC+Sims&amp;title=Zn2%2B+inhibits+coronavirus+and+arterivirus+RNA+polymerase+activity+in+vitro+and+zinc+ionophores+block+the+replication+of+these+viruses+in+cell+culture">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr13-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1371%2Fjournal.ppat.1001176">Crossref</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr13-1753466620951053&amp;dbid=8&amp;doi=10.1177%2F1753466620951053&amp;key=21079686">Medline</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr14-1753466620951053">
<td class="refnumber">14.</td>
<td valign="top">Santa-Cecília, FV, Socias, B, Ouidja, MO,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">Doxycycline suppresses microglial activation by inhibiting the p38 MAPK and NF-kB signaling pathways</span>. Neurotox Res&nbsp;<span class="NLM_year">2016</span>; 29:&nbsp;<span class="NLM_fpage">447</span>–<span class="NLM_lpage">459</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=29&amp;publication_year=2016&amp;pages=447-459&amp;author=FV+Santa-Cec%C3%ADlia&amp;author=B+Socias&amp;author=MO+Ouidja&amp;title=Doxycycline+suppresses+microglial+activation+by+inhibiting+the+p38+MAPK+and+NF-kB+signaling+pathways">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr14-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1007%2Fs12640-015-9592-2">Crossref</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr14-1753466620951053&amp;dbid=8&amp;doi=10.1177%2F1753466620951053&amp;key=26745968">Medline</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr15-1753466620951053">
<td class="refnumber">15.</td>
<td valign="top">Choi, B, Lee, S, Kim, S-M,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">Dipeptidyl peptidase-4 induces aortic valve calcification by inhibiting insulin-like growth factor-1 signaling in valvular interstitial cells</span>. Circulation&nbsp;<span class="NLM_year">2017</span>; 135:&nbsp;<span class="NLM_fpage">1935</span>–<span class="NLM_lpage">1950</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=135&amp;publication_year=2017&amp;pages=1935-1950&amp;author=B+Choi&amp;author=S+Lee&amp;author=S-M+Kim&amp;title=Dipeptidyl+peptidase-4+induces+aortic+valve+calcification+by+inhibiting+insulin-like+growth+factor-1+signaling+in+valvular+interstitial+cells">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr15-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1161%2FCIRCULATIONAHA.116.024270">Crossref</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr15-1753466620951053&amp;dbid=8&amp;doi=10.1177%2F1753466620951053&amp;key=28179397">Medline</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr16-1753466620951053">
<td class="refnumber">16.</td>
<td valign="top">Emingil, G, Atilla, G, Sorsa, T,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">The effect of adjunctive subantimicrobial dose doxycycline therapy on GCF EMMPRIN levels in chronic periodontitis</span>. J Periodontol&nbsp;<span class="NLM_year">2008</span>; 79:&nbsp;<span class="NLM_fpage">469</span>–<span class="NLM_lpage">476</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=79&amp;publication_year=2008&amp;pages=469-476&amp;author=G+Emingil&amp;author=G+Atilla&amp;author=T+Sorsa&amp;title=The+effect+of+adjunctive+subantimicrobial+dose+doxycycline+therapy+on+GCF+EMMPRIN+levels+in+chronic+periodontitis">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr16-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1902%2Fjop.2008.070165">Crossref</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr16-1753466620951053&amp;dbid=8&amp;doi=10.1177%2F1753466620951053&amp;key=18315429">Medline</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr16-1753466620951053&amp;dbid=128&amp;doi=10.1177%2F1753466620951053&amp;key=000253923700011">ISI</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr17-1753466620951053">
<td class="refnumber">17.</td>
<td valign="top">Wang, X, Xu, W, Hu, G,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion</span>. Cell Mol Immunol. Epub ahead of print 7 April 2020. DOI:&nbsp;<a class="meta__doi" href="https://doi.org/10.1038/s41423-020-0424-9" target="_blank" rel="noopener">10.1038/s41423-020-0424-9</a>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar?hl=en&amp;q=%0AWang+X%2C+Xu+W%2C+Hu+G%2C+et+al.+SARS-CoV-2+infects+T+lymphocytes+through+its+spike+protein-mediated+membrane+fusion.+Cell+Mol+Immunol.+Epub+ahead+of+print+7+April+2020.+DOI%3A+10.1038%2Fs41423-020-0424-9.">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr17-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1038%2Fs41423-020-0424-9">Crossref</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr18-1753466620951053">
<td class="refnumber">18.</td>
<td valign="top">Chen, W, Zheng, KI, Liu, S,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">Plasma CRP level is positively associated with the severity of COVID-19</span>. Ann Clin Microbiol Antimicrob&nbsp;<span class="NLM_year">2020</span>; 19:&nbsp;<span class="NLM_fpage">18</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=19&amp;publication_year=2020&amp;pages=18&amp;author=W+Chen&amp;author=KI+Zheng&amp;author=S+Liu&amp;title=Plasma+CRP+level+is+positively+associated+with+the+severity+of+COVID-19">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr18-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1186%2Fs12941-020-00362-2">Crossref</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr18-1753466620951053&amp;dbid=8&amp;doi=10.1177%2F1753466620951053&amp;key=32414383">Medline</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr19-1753466620951053">
<td class="refnumber">19.</td>
<td valign="top">Du, R-H, Liang, L-R, Yang, C-Q,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study</span>. Eur Respir J&nbsp;<span class="NLM_year">2020</span>; 55: 2000524.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=55&amp;publication_year=2020&amp;author=R-H+Du&amp;author=L-R+Liang&amp;author=C-Q+Yang&amp;title=Predictors+of+mortality+for+patients+with+COVID-19+pneumonia+caused+by+SARS-CoV-2%3A+a+prospective+cohort+study">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr19-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1183%2F13993003.00524-2020">Crossref</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr20-1753466620951053">
<td class="refnumber">20.</td>
<td valign="top">Sweiss, NJ, Korsten, P, Syed, HJ,&nbsp;<span class="NLM_etal">et al</span>.&nbsp;<span class="NLM_article-title">When the game changes: guidance to adjust sarcoidosis management during the COVID-19 pandemic</span>. Chest. Epub ahead of print 29 April 2020. DOI:&nbsp;<a class="meta__doi" href="https://doi.org/10.1016/j.chest.2020.04.033" target="_blank" rel="noopener">10.1016/j.chest.2020.04.033</a>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar?hl=en&amp;q=%0ASweiss+NJ%2C+Korsten+P%2C+Syed+HJ%2C+et+al.+When+the+game+changes%3A+guidance+to+adjust+sarcoidosis+management+during+the+COVID-19+pandemic.+Chest.+Epub+ahead+of+print+29+April+2020.+DOI%3A+10.1016%2Fj.chest.2020.04.033.">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr20-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1016%2Fj.chest.2020.04.033">Crossref</a></span><p></p>
<hr aria-hidden="true">
</td>
</tr>
<tr id="bibr21-1753466620951053">
<td class="refnumber">21.</td>
<td valign="top">Brasier, AR .&nbsp;<span class="NLM_article-title">The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation</span>. Cardiovasc Res&nbsp;<span class="NLM_year">2010</span>; 86:&nbsp;<span class="NLM_fpage">211</span>–<span class="NLM_lpage">218</span>.<br>
<span class="ref-google"><a class="google-scholar" href="https://scholar.google.com/scholar_lookup?hl=en&amp;volume=86&amp;publication_year=2010&amp;pages=211-218&amp;author=AR+Brasier&amp;title=The+nuclear+factor-kappaB-interleukin-6+signalling+pathway+mediating+vascular+inflammation">Google Scholar</a></span><span class="ref-xLink">&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr21-1753466620951053&amp;dbid=16&amp;doi=10.1177%2F1753466620951053&amp;key=10.1093%2Fcvr%2Fcvq076">Crossref</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr21-1753466620951053&amp;dbid=8&amp;doi=10.1177%2F1753466620951053&amp;key=20202975">Medline</a>&nbsp;|&nbsp;<a href="https://journals.sagepub.com/servlet/linkout?suffix=bibr21-1753466620951053&amp;dbid=128&amp;doi=10.1177%2F1753466620951053&amp;key=000276996300006">ISI</a></span>&nbsp;</td>
</tr>
</tbody>
</table>
<h2>Source</h2>
<hr>
<p>&nbsp;</p>
<p>https://journals.sagepub.com/doi/full/10.1177/1753466620951053</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2020/12/28/doxycycline-treatment-of-high-risk-covid-19-positive-patients-with-comorbid-pulmonary-disease/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2020/12/28/doxycycline-treatment-of-high-risk-covid-19-positive-patients-with-comorbid-pulmonary-disease/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5113 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>24.12.2020</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2020/12/24/doxycycline-reduces-osteopenia-in-female-rats/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2020/12/24/doxycycline-reduces-osteopenia-in-female-rats/">Doxycycline reduces osteopenia in female rats</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><ul class="c-author-list js-etal-collapsed js-no-scroll" data-etal="25" data-etal-small="3" data-test="authors-list" data-component-authors-activator="authors-list">
<li class="c-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Fellipe_A__T_-Figueiredo" aria-pressed="false" aria-expanded="false">Fellipe A. T. de Figueiredo</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Roberta_C_-Shimano" aria-pressed="false" aria-expanded="false">Roberta C. Shimano</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Edilson-Ervolino" aria-pressed="false" aria-expanded="false">Edilson Ervolino</a>, <a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Dimitrius_L_-Pitol" aria-pressed="false" aria-expanded="false">Dimitrius L. Pitol</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Raquel_F_-Gerlach" aria-pressed="false" aria-expanded="false">Raquel F. Gerlach</a>&nbsp;&amp;&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Joao_Paulo_M_-Issa" data-corresp-id="c1" aria-pressed="false" aria-expanded="false">Joao Paulo M. Issa</a></li>
</ul>
<p>&nbsp;</p>
<h3>ABSTRACT</h3>
<hr>
<p>&nbsp;</p>
<p>Doxycycline, a member of the tetracycline family, is a drug used as an antibiotic (dosage of 100 mg/day) and as an anti-inflammatory drug on the dosage of 20 mg twice a day, this use has Matrix Metalloproteinases (MMP) inhibitor action. Doxycycline is a calcium chelator and therefore interferes in bone remodeling. The main objective of this study was to evaluate the action of the drug doxycycline in the control of osteopenia. Sixty three Wistars rats were divided into 9 groups with n = 7 each, as follow: the control group with doxycycline 10 mg/kg/day (C10), control with doxycycline 30 mg/kg/day (C30) and control (C), ovariectomized group with doxycycline 10 mg/kg/day (OVX10), ovariectomized with doxycycline 30 mg/kg/day (OVX30), and ovariectomized with water (OVX), sedentary group with 10 mg/kg/day (Se10), sedentary with doxycycline 30 mg/kg/day (Se30), and sedentary group with water (Se). Left femoral bone was used for bone densitometry, right femoral bone for histological analysis. The right tibia was intended for chemical quantifications, the total serum was used for cholesterol and calcium quantification. The length of the left femoral bone was measured after the densitometry analysis. Statistical analysis was performed using multivariate general linear model (ANOVA two factors with Bonferroni adjustment) and the TRAP analysis was subjected to normality test and then were subjected to nonparametric test, both with p &lt; 0.05 significance. Statistically significant differences were found, with better results for the groups exposed to the medication (10 and 30 mg/kg/day): Se vs. Se10 and Se vs. Se30 for BMC, quantification of magnesium, amount of cancellous bone in the distal portion; OVX vs. OVX10 for BMC, BMD and calcium in serum; OVX vs. OVX10 and OVX30 for quantification in proximal and distal portion of cancellous bone; Se vs. Se30 and OVX vs. OVX30 for immunostaining for TRAP, all results with minimum of p ≤ 0.05. Doxycycline had a deleterious effect on control groups and positive action for bone organization on female rats affected by bilateral ovariectomy-induced osteopenia and sedentary lifestyle.</p>
<p>&nbsp;</p>
<section aria-labelledby="Sec1" data-title="Introduction" data-gtm-vis-first-on-screen-10482319_393="208252" data-gtm-vis-total-visible-time-10482319_393="10000" data-gtm-vis-first-on-screen-10482319_401="208252" data-gtm-vis-total-visible-time-10482319_401="10000" data-gtm-vis-has-fired-10482319_393="1" data-gtm-vis-has-fired-10482319_401="1">
<div id="Sec1-section" class="c-article-section" bis_skin_checked="1">
<h2 id="Sec1" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Introduction</h2>
<hr>
</div>
</section>
<section aria-labelledby="Sec2" data-title="The Role of Doxycycline" data-gtm-vis-first-on-screen-10482319_393="208302" data-gtm-vis-total-visible-time-10482319_393="10000" data-gtm-vis-first-on-screen-10482319_401="208302" data-gtm-vis-total-visible-time-10482319_401="10000" data-gtm-vis-has-fired-10482319_393="1" data-gtm-vis-has-fired-10482319_401="1">
<div id="Sec2-section" class="c-article-section" bis_skin_checked="1">
<h3 id="Sec2" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">The Role of Doxycycline</h3>
<hr>
</div>
</section>
<p>&nbsp;</p>
<p>Doxycycline is a member of the tetracycline family, a drug used as an antibiotic (dosage of 100 mg/day) and as matrix Metalloproteinases (MMPs) inhibitor (dosage of 20 mg twice a day), which use has an anti-inflammatory effect. The molecule of tetracycline is defined as naphthacene carboxamide ring system<sup><a id="ref-link-section-d4412e415" title="Sapadin, A. N. &amp; Fleischmajer, R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54, 258–265, https://doi.org/10.1016/j.jaad.2005.10.004 (2006)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR1" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1">1</a></sup>, Doxycycline differs structurally from the tetracycline molecule in the modifications of substituent at positions 5 and 6 of the ring system, which make it more lipid soluble and could be presented in the anhydrous form (Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig1" data-track="click" data-track-label="link" data-track-action="figure anchor">1</a>)<sup><a id="ref-link-section-d4412e422" title="Valentín, S., Morales, A., Sánchez, J. L. &amp; Rivera, A. Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol 2, 129–140 (2009)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR2" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2">2</a></sup>. Doxycycline on this low-dose is considered for the treatment of chronic periodontitis<sup><a id="ref-link-section-d4412e426" title="Golub, L. M. et al. Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. Journal of clinical periodontology 28, 146–156 (2001)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR3" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3">3</a></sup>&nbsp;and chronic inflammation in the skin<sup><a id="ref-link-section-d4412e430" title="Tan, K. R., Magill, A. J., Parise, M. E. &amp; Arguin, P. M. Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis. The American Journal of Tropical Medicine and Hygiene 84, 517–531, https://doi.org/10.4269/ajtmh.2011.10-0285 (2011)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR4" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4">4</a></sup>. For these uses doxycycline in “subdoses” (Subantimicrobial dose doxycycline or SDD) was approved in 1998 by the Food and Drug Administration (FDA) in the USA and also by the regulatory agencies of Canada and Europe. These formulations of doxycycline are named Periostat and Oracea (in the US) and the use can be done continuously for 9 months. This dose does not induce microbial resistance<sup><a id="ref-link-section-d4412e435" title="Thomas, J., Walker, C. &amp; Bradshaw, M. Long-Term Use of Subantimicrobial Dose Doxycycline Does Not Lead to Changes in Antimicrobial Susceptibility. Journal of Periodontology 71, 1472–1483, https://doi.org/10.1902/jop.2000.71.9.1472 (2000)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR5" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5">5</a></sup>.</p>
<p><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Figure 1</b></p>
<div class="c-article-section__figure-content" bis_skin_checked="1">
<div class="c-article-section__figure-item" bis_skin_checked="1"><picture><source data-lazy-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig1_HTML.png?as=webp" type="image/webp"><img class="rds_hl_nofollow" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20685%20340'%3E%3C/svg%3E" alt="figure1" width="685" height="340" aria-describedby="figure-1-desc" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig1_HTML.png"><noscript><img class="rds_hl_nofollow" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig1_HTML.png" alt="figure1" width="685" height="340" aria-describedby="figure-1-desc" /></noscript></picture></div>
<div id="figure-1-desc" class="c-article-section__figure-description" data-test="bottom-caption" bis_skin_checked="1">
<p>Representation of the chemical structure of Doxycycline.</p>
</div>
</div>
<p>&nbsp;</p>
<p>&nbsp;</p>
<h3 id="Sec3" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Doxycycline and Bone Interactions</h3>
<hr>
<p>&nbsp;</p>
<p>Doxycycline interacts with bone and teeth, accumulating on these tissues during their mineralization (teeth and bone) and during the physiologic remodeling (bone)<sup><a id="ref-link-section-d4412e464" title="Wallner, H. J. &amp; Schmiedel, A. Blood serum levels in mother and child after oral administration of doxycycline ante partum (author’s transl). MMW, Munchener medizinische Wochenschrift 117, 349–352 (1975)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR6" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6">6</a></sup>. In bone metastasis from breast cancer and prostate cancer, doxycycline has a curious role on the bone remodeling inducing the bone formation<sup><a id="ref-link-section-d4412e468" title="Duivenvoorden, W. C. et al. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer research 62, 1588–1591 (2002)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR7" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7">7</a></sup>&nbsp;and inhibiting the MMP associated to this tumor<sup><a id="ref-link-section-d4412e472" title="Saikali, Z. &amp; Singh, G. Doxycycline and other tetracyclines in the treatment of bone metastasis. Anti-cancer drugs 14, 773–778, https://doi.org/10.1097/01.cad.0000099002.92896.cf (2003)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR8" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8">8</a></sup>. SDD of this medication is related to reduction of serum biomarker of bone resorption and related to the increase of biomarker of bone formation<sup><a id="ref-link-section-d4412e476" title="Golub, L. M. et al. Doxycycline Effects on Serum Bone Biomarkers in Post-menopausal Women. Journal of Dental Research 89, 644–649, https://doi.org/10.1177/0022034510363367 (2010)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR9" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9">9</a></sup>&nbsp;in postmenopausal osteopenic women with 2 years follow-up. These interaction with the bone are not related to the antimicrobial interaction (SDD), but doxycycline can act as inhibitory inflammatory medication of the bone resorption<sup><a id="ref-link-section-d4412e480" title="Bezerra, M. M., Brito, G. A. C., Ribeiro, R. A. &amp; Rocha, F. A. C. Low-dose doxycycline prevents inflammatory bone resorption in rats. Brazilian Journal of Medical and Biological Research 35, 613–616 (2002)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR10" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10">10</a></sup>.</p>
<p>&nbsp;</p>
<h3 id="Sec4" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Osteoporosis, Public Health and Induction of Osteopenia</h3>
<hr>
<p>&nbsp;</p>
<p>Osteoporosis is a classical disorder of elderlies, responsible for increased risk of bone fractures<sup><a id="ref-link-section-d4412e492" title="Riggs, B. L. &amp; Melton, L. J. III Involutional osteoporosis. The New England journal of medicine 314, 1676–1686, https://doi.org/10.1056/nejm198606263142605 (1986)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR11" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11">11</a></sup>, characterized as an increase of skeletal fragility<sup><a id="ref-link-section-d4412e496" title="Turner, C. H. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 13, 97–104, https://doi.org/10.1007/s001980200000 (2002)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR12" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12">12</a></sup>. Osteopenia is defined as “low bone mass” and it is a warning for the future osteoporosis. Exercises and a better quality of life might prevent the fracture of the bones affects by this low mass<sup><a id="ref-link-section-d4412e500" title="NIH. Osteoporosis, https://www.nia.nih.gov/health/osteoporosis (2019)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR13" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13">13</a></sup>.</p>
<p>The incidence of fractures due to osteoporosis is increasing and it also increases the costs of public health to treat this disorder<sup><a id="ref-link-section-d4412e507" title="Ross, P. D., Genant, H. K., Davis, J. W., Miller, P. D. &amp; Wasnich, R. D. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 3, 120–126 (1993)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR14" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14">14</a>,<a id="ref-link-section-d4412e510" title="Bandeira, F. &amp; Carvalho, E. Fd Prevalência de osteoporose e fraturas vertebrais em mulheres na pós-menopausa atendidas em serviços de referência. Revista Brasileira de Epidemiologia 10, 86–98 (2007)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR15" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15">15</a></sup>. This information is important because it has been shown in study that during the youth practicing physical exercises and balanced diet are crucial for prevention of osteoporosis. Also during childhood and adolescence, it is essential for the increase of bone density and bone growth in humans<sup><a id="ref-link-section-d4412e514" title="Malina, R. M., Bouchard, C. &amp; Bar-Or, O. Growth, Maturation, and Physical Activity. (Human Kinetics, 2004)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR16" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16">16</a></sup>.</p>
<p>Bone remodeling depends on a balance between bone resorption and bone formation<sup><a id="ref-link-section-d4412e521" title="Matsuo, K. Cross-talk among bone cells. Current opinion in nephrology and hypertension 18, 292–297, https://doi.org/10.1097/MNH.0b013e32832b75f1 (2009)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR17" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17">17</a></sup>. Considering the high prevalence of osteoporosis in many populations, researchers have proposed animal models for osteopenia induction. One of them is the ovariectomy-induced menopause that mimics the increase in osteoclastic activity which exceeds the osteoblastic activity, resulting an induction of osteoporosis<sup><a id="ref-link-section-d4412e525" title="Teitelbaum, S. L. Bone Resorption by Osteoclasts. Science (New York, N.Y.) 289, 1504–1508, https://doi.org/10.1126/science.289.5484.1504 (2000)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR18" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18">18</a></sup>. Rats are the animal model used for this purpose<sup><a id="ref-link-section-d4412e529" title="Jee, W. S. &amp; Yao, W. Overview: animal models of osteopenia and osteoporosis. J Musculoskelet Neuronal Interact 1, 193–207 (2001)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR19" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19">19</a></sup>&nbsp;because they supply enough sample for statistical purposes, easy feed and location. Different research groups worked with this type of osteopenia induction in Wistar rats<sup><a id="ref-link-section-d4412e533" title="Shimano, A. C., Volpon, J. B. &amp; Lima, R. S. Ação do Treinamento Físico Antes e Após a Instalação da Osteopenia de Ratas Ovariectomizadas. (Faculdade de Medicina de Ribeirão Preto/USP., 2008)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR20" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">20</a>,<a id="ref-link-section-d4412e533_1" title="Shimano, R. C. et al. Biomechanical and microstructural benefits of physical exercise associated with risedronate in bones of ovariectomized rats. Microsc Res Tech 77, 431–438, https://doi.org/10.1002/jemt.22363 (2014)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR21" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">21</a>,<a id="ref-link-section-d4412e533_2" title="Issa, J. P. M. et al. The effect of simvastatin treatment on bone repair of femoral fracture in animal model. Growth Factors 33, 139–148, https://doi.org/10.3109/08977194.2015.1011270 (2015)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR22" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">22</a>,<a id="ref-link-section-d4412e533_3" title="Monteiro, L. O. et al. Effect of treatment with simvastatin on bone microarchitecture of the femoral head in an osteoporosis animal model. Microscopy Research and Technique 79, 684–690, https://doi.org/10.1002/jemt.22682 (2016)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR23" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">23</a>,<a id="ref-link-section-d4412e536" title="Macedo, A. P. et al. Influence of treadmill training on bone structure under osteometabolic alteration in rats subjected to high-fat diet. Scandinavian Journal of Medicine &amp; Science in Sports 27, 167–176, https://doi.org/10.1111/sms.12650 (2017)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR24" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24">24</a></sup>.</p>
<p>&nbsp;</p>
<h3 id="Sec5" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Sedentarism and Osteopenia</h3>
<hr>
<p>&nbsp;</p>
<p>Nowadays young people and children are being “victims” of modern life sedentarism and obesity<sup><a id="ref-link-section-d4412e548" title="Wang, Y., Monteiro, C. &amp; Popkin, B. M. Trends of obesity and underweight in older children and adolescents in the United States, Brazil, China, and Russia. The American journal of clinical nutrition 75, 971–977 (2002)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR25" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25">25</a>,<a id="ref-link-section-d4412e551" title="Duncan, S. et al. Modifiable risk factors for overweight and obesity in children and adolescents from Sao Paulo, Brazil. BMC Public Health 11, 585 (2011)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR26" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26">26</a></sup>, exactly during this time of life, prevention of chronic diseases of adult life needs to be initiated (high blood pressure, dyslipidemias, diabetes mellitus)<sup><a id="ref-link-section-d4412e555" title="Malina, R. M., Bouchard, C. &amp; Bar-Or, O. Growth, Maturation, and Physical Activity. (Human Kinetics, 2004)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR16" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16">16</a>,<a id="ref-link-section-d4412e558" title="Fernandes, R. A. et al. Prevalence of dyslipidemia in individuals physically active during childhood, adolescence and adult age. Arq Bras Cardiol 97, 317–323 (2011)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR27" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27">27</a></sup>. Moreover, it is pointed out that the practice of exercises in the youth, when the bones are more malleable, promotes better bone quality in the future<sup><a id="ref-link-section-d4412e562" title="Bass, S. et al. Exercise before puberty may confer residual benefits in bone density in adulthood: studies in active prepubertal and retired female gymnasts. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 13, 500–507, https://doi.org/10.1359/jbmr.1998.13.3.500 (1998)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR28" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">28</a>,<a id="ref-link-section-d4412e562_1" title="Morris, F. L., Naughton, G. A., Gibbs, J. L., Carlson, J. S. &amp; Wark, J. D. Prospective ten-month exercise intervention in premenarcheal girls: positive effects on bone and lean mass. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 12, 1453–1462, https://doi.org/10.1359/jbmr.1997.12.9.1453 (1997)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR29" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">29</a>,<a id="ref-link-section-d4412e562_2" title="Kontulainen, S. et al. Good maintenance of exercise-induced bone gain with decreased training of female tennis and squash players: a prospective 5-year follow-up study of young and old starters and controls. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 16, 195–201, https://doi.org/10.1359/jbmr.2001.16.2.195 (2001)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR30" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">30</a>,<a id="ref-link-section-d4412e565" title="MacKelvie, K. J., Khan, K. M., Petit, M. A., Janssen, P. A. &amp; McKay, H. A. A school-based exercise intervention elicits substantial bone health benefits: a 2-year randomized controlled trial in girls. Pediatrics 112, e447 (2003)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR31" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31">31</a></sup>. According to NiA (National institute of age, NIH, USA), weight training, walking, hiking, jogging, climbing stairs, tennis, and dancing can prevent the fractures of bones affected by this low bone mass. Karlsson and collaborators studied about football players who have left their profession for over 20 years, demonstrating a residual protective effect on bone quality after the long time without performing intense exercises<sup><a id="ref-link-section-d4412e569" title="Karlsson, M. K. et al. Exercise during growth and bone mineral density and fractures in old age. Lancet (London, England) 355, 469–470 (2000)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR32" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32">32</a></sup>, characterizing that sports at early age contribute to a better quality of life in elderly phase.</p>
<p>A calcium deficient diet, common on sedentary diets, also induces osteopenia as demonstrated by a meta-analysis Specker (1996), who presented a result showing that a sedentary lifestyle (no exercise) combined with a calcium-poor diet worsens the picture of osteopenia, as shown by data obtained from bone densitometry<sup><a id="ref-link-section-d4412e576" title="Specker, B. L. Evidence for an interaction between calcium intake and physical activity on changes in bone mineral density. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 11, 1539–1544, https://doi.org/10.1002/jbmr.5650111022 (1996)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR33" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33">33</a></sup>.</p>
<p>With all of this important knowledge of osteopenia and it is relation with the drug doxycycline, the main objective of this study was to evaluate the action of the drug doxycycline in the control of osteopenia induced by bilateral ovariectomy and sedentary lifestyle in Wistar female rats.</p>
<p>&nbsp;</p>
<h3 id="Sec6" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Materials and Methods</h3>
<hr>
<p>&nbsp;</p>
<p>This study was approved by the Ethics Committee on use of animals in research of the University of Sao Paulo: School of dentistry of Ribeirao Preto (in Portuguese CEUA/FORP-USP) under the Protocol of 2013.1.1528.58.5 in confirmation to all the methods and guidelines of CONCEA (National guideline of animal use on experimentation from Brazil), which follow the international parameters on use and handling of animals. Sixty three (63) female Wistar rats with 45 days of life (or 100 g) were obtained from the campus of the University of São Paulo, Ribeirao Preto and stayed at the School of Dentistry of Ribeirao Preto for ambiance for 30 days until methodological procedure. Experimental procedures of groups were started with 75 days of age (or 150 g), this age has been considered as day1 of experimental time (Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig2" data-track="click" data-track-label="link" data-track-action="figure anchor">2</a>). Wistar females reached sexual maturity at this age and it is known that bone maturity is acquired only by 10 months of age (or 300 days of life)<sup><a id="ref-link-section-d4412e595" title="Jee, W. S. &amp; Yao, W. Overview: animal models of osteopenia and osteoporosis. J Musculoskelet Neuronal Interact 1, 193–207 (2001)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR19" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19">19</a></sup>. The doxycycline administration starts on day 90 of treatment (or 165 days of life) and it was administered for 60 days until the induction of death.</p>
<p>&nbsp;</p>
<p><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Figure 2</b></p>
<div class="c-article-section__figure-content" bis_skin_checked="1">
<div class="c-article-section__figure-item" bis_skin_checked="1"><picture><source data-lazy-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig2_HTML.png?as=webp" type="image/webp"><img class="rds_hl_nofollow" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20685%20293'%3E%3C/svg%3E" alt="figure2" width="685" height="293" aria-describedby="figure-2-desc" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig2_HTML.png"><noscript><img class="rds_hl_nofollow" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig2_HTML.png" alt="figure2" width="685" height="293" aria-describedby="figure-2-desc" /></noscript></picture></div>
<div id="figure-2-desc" class="c-article-section__figure-description" data-test="bottom-caption" bis_skin_checked="1">
<p>Flow chart with the interventions on present work.</p>
</div>
</div>
<p>&nbsp;</p>
<h3 id="Sec7" class="c-article__sub-heading c-article__sub-heading--divider">As for the division of the groups</h3>
<p>Control group with Doxycycline 10 mg/kg/day (C10), Control with Doxycycline 30 mg/kg/day (C30), and Control (C), Ovariectomizated Group with Doxycycline 10 mg/kg/day (OVX10), Ovariectomizated with Doxycycline 30 mg/kg/day (OVX30) and Ovariectomizated with water (OVX), Sedentary group with 10 mg/kg/day (Se10), Sedentary group with 30 mg/kg/day (Se30) and Sedentary group with Water (Se).</p>
<h3 id="Sec8" class="c-article__sub-heading c-article__sub-heading--divider">Procedure of ovariectomy</h3>
<p>The animals were anesthetized with Xylazine and Ketamine in concentration 10 mg/kg and 100 mg/kg, respectively, followed by trichotomy and the skin were prepared with antiseptic. A caudal midline incision was made from the umbilicus to the pelvis and the ovarian horn was exteriorized between the bottom of costal edge and the top of the pelvis. Shortly thereafter the evisceration of the ovary horn was executed followed by ovary ligation for containing the bleeding. The same procedure was performed on the opposite side to the excision to excise both ovaries<sup><a id="ref-link-section-d4412e631" title="Shimano, A. C., Volpon, J. B. &amp; Lima, R. S. Ação do Treinamento Físico Antes e Após a Instalação da Osteopenia de Ratas Ovariectomizadas. (Faculdade de Medicina de Ribeirão Preto/USP., 2008)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR20" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20">20</a>,<a id="ref-link-section-d4412e634" title="Issa, J. P. M. et al. The effect of simvastatin treatment on bone repair of femoral fracture in animal model. Growth Factors 33, 139–148, https://doi.org/10.3109/08977194.2015.1011270 (2015)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR22" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22">22</a>,<a id="ref-link-section-d4412e637" title="Monteiro, L. O. et al. Effect of treatment with simvastatin on bone microarchitecture of the femoral head in an osteoporosis animal model. Microscopy Research and Technique 79, 684–690, https://doi.org/10.1002/jemt.22682 (2016)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR23" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23">23</a></sup>. After the surgical procedure, the application of antibiotics was performed (Veterinary pentabiotic, Zoetis, Parsippany-Troy Hills, New Jersey, USA) once a day for a period of 48 hours after the surgery. The osteopenia was induced for 90 days after the surgical procedure, once significant findings occurring through this time of experiment<sup><a id="ref-link-section-d4412e641" title="Wronski, T. J., Cintron, M. &amp; Dann, L. M. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int 43, 179–183 (1988)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR34" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34">34</a>,<a id="ref-link-section-d4412e644" title="Wronski, T. J., Dann, L. M., Scott, K. S. &amp; Cintron, M. Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 45, 360–366 (1989)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR35" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35">35</a></sup>. Then the groups received doxycycline (Bioquanti, compounding pharmacy, Ribeirao Preto, SP, Brazil) at 2 concentrations for 60 days.</p>
<h3 id="Sec9" class="c-article__sub-heading c-article__sub-heading--divider">Procedures for the sedentary groups</h3>
<p>Females of this group were divided in individual cages with 30cmx20cmx16cm with superior grid, limiting their movements for 90 days to mimic a sedentary lifestyle<sup><a id="ref-link-section-d4412e656" title="Macedo, A. P. et al. Influence of treadmill training on bone structure under osteometabolic alteration in rats subjected to high-fat diet. Scandinavian Journal of Medicine &amp; Science in Sports 27, 167–176, https://doi.org/10.1111/sms.12650 (2017)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR24" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24">24</a>,<a id="ref-link-section-d4412e659" title="Tschop, M. &amp; Heiman, M. L. Rodent obesity models: an overview. Exp Clin Endocrinol Diabetes 109, 307–319, https://doi.org/10.1055/s-2001-17297 (2001)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR36" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36">36</a>,<a id="ref-link-section-d4412e662" title="Oliveira Milani, J. G. P., Matheus, J. P. C., Gomide, L. B., Volpon, J. B. &amp; Shimano, A. C. Biomechanical Effects of Immobilization and Rehabilitation on the Skeletal Muscle of Trained and Sedentary Rats. Annals of Biomedical Engineering 36, 1641–1648, https://doi.org/10.1007/s10439-008-9542-8 (2008)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR37" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37">37</a></sup>. Then the Se10 and Se30 groups received the medicine for 60 days. The low locomotion induction of osteopenia (Sedentary lifestyle induction on rats) is used not as a method of disuse, but a method of restriction of movement, that culminates on osteopenia.</p>
<h3 id="Sec10" class="c-article__sub-heading c-article__sub-heading--divider">Administration of doxycycline</h3>
<p>After the 90 days, doxycycline was administered for 60 days (for comparison between groups) in drinking water<sup><a id="ref-link-section-d4412e675" title="Issa, J. P. M. et al. The effect of simvastatin treatment on bone repair of femoral fracture in animal model. Growth Factors 33, 139–148, https://doi.org/10.3109/08977194.2015.1011270 (2015)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR22" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22">22</a></sup>, serviced according to a daily chart daily chart of total body weight (Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig3" data-track="click" data-track-label="link" data-track-action="figure anchor">3</a>) and based on how much the rats drank water, with all duly noted and monitored. The two chosen doses were based on previously published studies<sup><a id="ref-link-section-d4412e682" title="Castro, M. M. et al. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. Nitric Oxide 26, 162–168, https://doi.org/10.1016/j.niox.2012.01.009 (2012)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR38" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">38</a>,<a id="ref-link-section-d4412e682_1" title="Briest, W. et al. Significance of matrix metalloproteinases in norepinephrine-induced remodelling of rat hearts. Cardiovasc Res 57, 379–387 (2003)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR39" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">39</a>,<a id="ref-link-section-d4412e682_2" title="Guimaraes, D. A. et al. Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. Basic Clin Pharmacol Toxicol 108, 318–325, https://doi.org/10.1111/j.1742-7843.2010.00656.x (2011)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR40" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">40</a>,<a id="ref-link-section-d4412e685" title="Tharappel, J. C. et al. Doxycycline shows dose-dependent changes in hernia repair strength after mesh repair. Surg Endosc 30, 2016–2021, https://doi.org/10.1007/s00464-015-4434-0 (2016)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR41" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41">41</a></sup>, their application were assed because of it is safe use for 60 days and for the mimetics aspect with the SDD use in humans for 2 years.</p>
<p>&nbsp;</p>
<p><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Figure 3</b></p>
<div class="c-article-section__figure-content" bis_skin_checked="1">
<div class="c-article-section__figure-item" bis_skin_checked="1"><picture><source data-lazy-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig3_HTML.png?as=webp" type="image/webp"><img class="rds_hl_nofollow" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20685%20520'%3E%3C/svg%3E" alt="figure3" width="685" height="520" aria-describedby="figure-3-desc" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig3_HTML.png"><noscript><img class="rds_hl_nofollow" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig3_HTML.png" alt="figure3" width="685" height="520" aria-describedby="figure-3-desc" /></noscript></picture></div>
<div id="figure-3-desc" class="c-article-section__figure-description" data-test="bottom-caption" bis_skin_checked="1">
<p>Graph of the weights of the rats from day of experiment until the day of induction of death (20th week).</p>
</div>
</div>
<p>At the end of the experiment, the animals were euthanized by an overdose of anesthetic (xylazine at 30 mg/kg and ketamine at 150 mg/kg) followed by CO<sub>2</sub>&nbsp;inhalation. The bones were removed and cleaned of soft tissue for the subsequent analyses.</p>
<h3 id="Sec11" class="c-article__sub-heading c-article__sub-heading--divider">Sampling and analysis</h3>
<p>The left femoral bone samples were intended for bone densitometry and samples of right femoral bone were intended for histological analysis. It has been used samples of right tibia for chemical quantification of calcium, magnesium, zinc and phosphorus. The total weight of the rats was assessed in precision scales. The left femur (dry by an oven at 37 degrees Celsius) was weighted in laboratory precision scale BioPrecisa FA2104N (Curitiba, PR, Brazil) and the length of the femoral bones were measured with the aid of a digital caliper (MTX group, Guarulhos, Sao Paulo, Brazil) that measured the bones in your long axis. The blood serum was used for measurement of calcium and total cholesterol.</p>
<h3 id="Sec12" class="c-article__sub-heading c-article__sub-heading--divider">Quantification of calcium and cholesterol in serum</h3>
<p>The whole blood of animals was obtained by cardiac puncture. Tubes containing the whole blood were centrifuged (800 × <i>g</i>, 6 min) to obtain serum<sup><a id="ref-link-section-d4412e730" title="Amaral, J. H. et al. The Relationship between Blood and Serum Lead Levels in Peripartum Women and their Respective Umbilical Cords. Basic &amp; Clinical Pharmacology &amp; Toxicology 107, 971–975, https://doi.org/10.1111/j.1742-7843.2010.00616.x (2010)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR42" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42">42</a>,<a id="ref-link-section-d4412e733" title="Rezende, V. B., Amaral, J. H., Gerlach, R. F., Barbosa, F. Jr. &amp; Tanus-Santos, J. E. Should we measure serum or plasma lead concentrations? J Trace Elem Med Biol 24, 147–151, https://doi.org/10.1016/j.jtemb.2010.01.008 (2010)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR43" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43">43</a></sup>. Syringes and needles were previously decontaminated in nitric acid 3%<sup><a id="ref-link-section-d4412e737" title="de Figueiredo, F. A. et al. Reduced bone and body mass in young male rats exposed to lead. Biomed Res Int 2014, 571065, https://doi.org/10.1155/2014/571065 (2014)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR44" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44">44</a></sup>.</p>
<p>For calcium measurement, the catalyst of phosphorus (phosphate binder on medical activities<sup><a id="ref-link-section-d4412e744" title="Behets, G. J., Verberckmoes, S. C., D’Haese, P. C. &amp; De Broe, M. E. Lanthanum carbonate: a new phosphate binder. Current opinion in nephrology and hypertension 13, 403–409 (2004)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR45" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">45</a>,<a id="ref-link-section-d4412e744_1" title="Sprague, S. M. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Current medical research and opinion 23, 3167–3175, https://doi.org/10.1185/030079907x242719 (2007)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR46" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">46</a>,<a id="ref-link-section-d4412e747" title="Chan, S. et al. Phosphate binders in patients with chronic kidney disease. Australian prescriber 40, 10–14, https://doi.org/10.18773/austprescr.2017.002 (2017)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR47" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47">47</a></sup>) content of sample was the lanthanum that separate this typical interference of this sample in this kind of analysis<sup><a id="ref-link-section-d4412e751" title="Trudeau, D. L. &amp; Freier, E. F. Determination of calcium in urine and serum by atomic absorption spectrophotometry (AAS). Clinical chemistry 13, 101–114 (1967)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR48" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48">48</a></sup>. Lanthanum was placed on ratio of 0.5% of the total volume thinned and the samples were analyzed in a flame atomic absorption (Perkin Elmer AAS400, Norwalk, USA).</p>
<p>Quantification of total cholesterol was perform using the Cholesterol Liquiform Kit (Labtest Diagnóstica, Lagoa Santa, MG, Brazil) in a colorimetric plate adapted for the BioTek μQuant (BioTek, Winooski, VT, USA) equipment. The method used for this measurement was “End-point Colorimetric Assay – 500 nm”.</p>
<h3 id="Sec13" class="c-article__sub-heading c-article__sub-heading--divider">Bone densitometry</h3>
<p>The left femora were submitted to densitometric analysis using “dual-energy” x-ray densitometer equipment, Alpha, Lunar DPX ® (Lunar, Madison, WI, United States) installed at the School of Medicine of Ribeirao Preto. Adapted for measurement small animals with the PIXImus software (Lunar, Madison, WI, United States)<sup><a id="ref-link-section-d4412e766" title="Shimano, R. C. et al. Effects of high-impact exercise on the physical properties of bones of ovariectomized rats fed to a high-protein diet. Scandinavian Journal of Medicine &amp; Science in Sports 28, 1523–1531, https://doi.org/10.1111/sms.13058 (2018)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR49" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49">49</a>,<a id="ref-link-section-d4412e769" title="Yanagihara, G. R. et al. Influence of high-fat diet on bone tissue: An experimental study in growing rats. The journal of nutrition, health &amp; aging 21, 1337–1343, https://doi.org/10.1007/s12603-017-0871-x (2017)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR50" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50">50</a></sup>. The image acquisition is proceeded with the femurs (distal portion of the femur) position with ROI of 9 mm² (Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig4" data-track="click" data-track-label="link" data-track-action="figure anchor">4</a>), immersed in a depth of 2 cm of deionized water (simulating soft tissues) and the following options have been selected: Type 1 Appendicular Bone; high resolution mode; 76 kVp; 150 μA; Collimation; standard 40 mm × 20 mm areas.</p>
<p>&nbsp;</p>
<p><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Figure 4</b></p>
<div class="c-article-section__figure-content" bis_skin_checked="1">
<div class="c-article-section__figure-item" bis_skin_checked="1"><picture><source data-lazy-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig4_HTML.png?as=webp" type="image/webp"><img class="rds_hl_nofollow" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20685%201189'%3E%3C/svg%3E" alt="figure4" width="685" height="1189" aria-describedby="figure-4-desc" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig4_HTML.png"><noscript><img class="rds_hl_nofollow" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig4_HTML.png" alt="figure4" width="685" height="1189" aria-describedby="figure-4-desc" /></noscript></picture></div>
<div id="figure-4-desc" class="c-article-section__figure-description" data-test="bottom-caption" bis_skin_checked="1">
<p>Photograph of a femur bone used on the present work showing the area of interest for the densitometric analysis (Square symbol on the photograph) and the anatomical points distinguishing the area of interest.</p>
</div>
<p>Bone mass content (BMC) and bone mineral density (BMD) were obtained.</p>
<h3 id="Sec14" class="c-article__sub-heading c-article__sub-heading--divider">Chemical analyses of calcium, magnesium and zinc in the bones</h3>
<p>All materials used in the analysis were decontaminated in distillated nitric acid. To perform the analytical test a bi-distillated acid was diluted with deionized water ultrapure to reach 3% of acid on solution. Bone was dried in Chapel of laminar flow, to prevent the deposition of dust<sup><a id="ref-link-section-d4412e804" title="de Figueiredo, F. A. et al. Reduced bone and body mass in young male rats exposed to lead. Biomed Res Int 2014, 571065, https://doi.org/10.1155/2014/571065 (2014)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR44" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44">44</a></sup>. All this was done to avoid contamination of specimens.</p>
<p>The right tibias were submerged in half on bi-distilled nitric acid 3% for 1 minute<sup><a id="ref-link-section-d4412e811" title="Sawan, R. M. et al. Fluoride increases lead concentrations in whole blood and in calcified tissues from lead-exposed rats. Toxicology 271, 21–26, https://doi.org/10.1016/j.tox.2010.02.002 (2010)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR51" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 51">51</a></sup>, then the bone was withdraw and the solution were submitted to chemical analysis. The biopsy was performed to make the results measurable on the calibration curve.</p>
<h3 id="Sec15" class="c-article__sub-heading c-article__sub-heading--divider">Immunohistochemistry analysis by TRAP</h3>
<p>The immunohistochemical analysis was performed by a certified morphologist and blind to the treatment. A semi-quantitative analysis was carried using a histological section of each animal, in the original increase of 200X. The pattern of immunolabeling was assigned a score. The criterion adopted for the establishment of the scores was based and modified from those established by Faria&nbsp;<i>et al</i>.<sup><a id="ref-link-section-d4412e826" title="Faria, P. E. et al. Immunohistochemical, tomographic and histological study on onlay iliac grafts remodeling. Clinical oral implants research 19, 393–401, https://doi.org/10.1111/j.1600-0501.2007.01485.x (2008)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR52" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 52">52</a></sup>, where: 0 SCORE = absence of immunolabeling; 1 = low SCORE ± standard; 2 = moderate SCORE ± standard; 3 = high SCORE ± standard (Table&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Tab1" data-track="click" data-track-label="link" data-track-action="table anchor">1</a>&nbsp;and Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig5" data-track="click" data-track-label="link" data-track-action="figure anchor">5</a>).</p>
</div>
<p>&nbsp;</p>
<p><b id="Fig5" class="c-article-section__figure-caption" data-test="figure-caption-text">Figure 5</b></p>
<div class="c-article-section__figure-content" bis_skin_checked="1">
<div class="c-article-section__figure-item" bis_skin_checked="1"><picture><source data-lazy-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig5_HTML.png?as=webp" type="image/webp"><img class="rds_hl_nofollow" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20685%201042'%3E%3C/svg%3E" alt="figure5" width="685" height="1042" aria-describedby="figure-5-desc" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig5_HTML.png"><noscript><img class="rds_hl_nofollow" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig5_HTML.png" alt="figure5" width="685" height="1042" aria-describedby="figure-5-desc" /></noscript></picture></div>
<div id="figure-5-desc" class="c-article-section__figure-description" data-test="bottom-caption" bis_skin_checked="1">
<p>Immunolabeling for TRAP. (<b>A</b>–<b>R</b>) Photomicrography’s showing the immunolabeling standard for TRAP in groups C (<b>A</b>,<b>D</b>), C10 (<b>B</b>,<b>E</b>), C30 (<b>C</b>,<b>F</b>), OVX (<b>G</b>,<b>J</b>), OVX10 (<b>H</b>,<b>K</b>), OVX30 (<b>I</b>,<b>L</b>), Se(<b>M</b>,<b>P</b>), Se10 (<b>N</b>,<b>Q</b>), Se30 (<b>O</b>,<b>R</b>). Symbols: Red arrows: Immunolabeling cells, and rectangles: increases in the areas listed. Counter-staining: Harris Hematoxylin. Increase: (<b>A</b>–<b>C</b>), (<b>G</b>–<b>I</b>), (<b>M</b>–<b>O</b>) 400x of magnification; (<b>D</b>–<b>F</b>), (<b>J</b>–<b>L</b>), (<b>P</b>–<b>R</b>) 1000x of magnification.</p>
</div>
</div>
<p>&nbsp;</p>
<h3 id="Sec16" class="c-article__sub-heading c-article__sub-heading--divider">Analysis of bone by masson trichrome and picrosirius-red staining</h3>
<p>The quantitative analysis of the histological glasses allows to evaluate the bone microarchitecture in the proximal and distal epiphysis areas by Masson trichrome staining<sup><a id="ref-link-section-d4412e1277" title="Issa, J. P. M. et al. The effect of simvastatin treatment on bone repair of femoral fracture in animal model. Growth Factors 33, 139–148, https://doi.org/10.3109/08977194.2015.1011270 (2015)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR22" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22">22</a>,<a id="ref-link-section-d4412e1280" title="Monteiro, L. O. et al. Effect of treatment with simvastatin on bone microarchitecture of the femoral head in an osteoporosis animal model. Microscopy Research and Technique 79, 684–690, https://doi.org/10.1002/jemt.22682 (2016)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR23" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23">23</a></sup>. Picrosirius-red staining allows to quantify the total collagen on the histological glasses. It was used a light microscope Axioimager Z2 Zeiss (Carl Zeiss, Oberkochen, Germany) coupled to a digital camera, aided by a DELL Precision T3500 workstation (DELL, São Paulo, Brazil). The digital images obtained from the Masson trichrome staining were analyzed by the software AxioVision 4.8 (Carl Zeiss, Oberkochen, Germany) on 25x of magnification. The quantification of total collagen obtained from picrosirius-red staining was obtained on magnification of 40x and was analyzed by ImageJ program (NIH, USA) using the plugins needed for this achievement. For quantitative analysis were focused the area of 30 mm² of the cancellous bone region (withdraw the growth plate), a distal and proximal acquisitions (Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig6" data-track="click" data-track-label="link" data-track-action="figure anchor">6</a>), histological sections with 5 µm of thickness stained by Masson trichrome were analyzed by quantitative and qualitative analysis between the groups and were discussed below in the section “Results”<sup><a id="ref-link-section-d4412e1287" title="Dempster, D. W. et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 28, 2–17, https://doi.org/10.1002/jbmr.1805 (2013)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR53" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 53">53</a></sup>&nbsp;(Figs&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;and&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig8" data-track="click" data-track-label="link" data-track-action="figure anchor">8</a>).</p>
<p><b id="Fig6" class="c-article-section__figure-caption" data-test="figure-caption-text">Figure 6</b></p>
<div class="c-article-section__figure-content" bis_skin_checked="1">
<div class="c-article-section__figure-item" bis_skin_checked="1"><picture><source data-lazy-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig6_HTML.png?as=webp" type="image/webp"><img class="rds_hl_nofollow" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20685%201166'%3E%3C/svg%3E" alt="figure6" width="685" height="1166" aria-describedby="figure-6-desc" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig6_HTML.png"><noscript><img class="rds_hl_nofollow" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig6_HTML.png" alt="figure6" width="685" height="1166" aria-describedby="figure-6-desc" /></noscript></picture></div>
<div id="figure-6-desc" class="c-article-section__figure-description" data-test="bottom-caption" bis_skin_checked="1">
<p>Photograph of a femur bone used on the present work showing the area of interest used for the quantification of cancellous bone (Square symbols on the photograph).</p>
</div>
</div>
<div id="figure-7" class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" data-title="Figure 7" data-gtm-vis-first-on-screen-10482319_399="555201" data-gtm-vis-total-visible-time-10482319_399="10000" data-gtm-vis-has-fired-10482319_399="1" bis_skin_checked="1">
<figure><figcaption><b id="Fig7" class="c-article-section__figure-caption" data-test="figure-caption-text">Figure 7</b></figcaption><div class="c-article-section__figure-content" bis_skin_checked="1">
<div class="c-article-section__figure-item" bis_skin_checked="1"><a class="c-article-section__figure-link rds_hl_nofollow" href="https://www.nature.com/articles/s41598-019-51702-y/figures/7" rel="nofollow" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure"><picture><source data-lazy-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig7_HTML.png?as=webp" type="image/webp"><img class="rds_hl_nofollow" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20685%20518'%3E%3C/svg%3E" alt="figure7" width="685" height="518" aria-describedby="figure-7-desc" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig7_HTML.png"><noscript><img class="rds_hl_nofollow" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig7_HTML.png" alt="figure7" width="685" height="518" aria-describedby="figure-7-desc" /></noscript></picture></a></div>
<div id="figure-7-desc" class="c-article-section__figure-description" data-test="bottom-caption" bis_skin_checked="1">
<p>Histological photomicrograph of femur bone at distal portion, demonstrating the cancellous bone (Cn), growth plate (Gp) and cortical bone (Ct). Staining: Masson trichrome: 25x of magnification.</p>
</div>
</div>
<div class="u-text-right u-hide-print" bis_skin_checked="1"><a class="c-article__pill-button rds_hl_nofollow" href="https://www.nature.com/articles/s41598-019-51702-y/figures/7" rel="nofollow" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" data-track-dest="link:Figure7 Full size image">Full size image</a></div>
</figure>
</div>
<div id="figure-8" class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" data-title="Figure 8" data-gtm-vis-first-on-screen-10482319_399="554835" data-gtm-vis-total-visible-time-10482319_399="6200" data-gtm-vis-polling-id-10482319_399="5999" data-gtm-vis-recent-on-screen-10482319_399="992231" bis_skin_checked="1">
<figure><figcaption><b id="Fig8" class="c-article-section__figure-caption" data-test="figure-caption-text">Figure 8</b></figcaption><div class="c-article-section__figure-content" bis_skin_checked="1">
<div class="c-article-section__figure-item" bis_skin_checked="1"><picture><source data-lazy-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig8_HTML.png?as=webp" type="image/webp"><img class="rds_hl_nofollow" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20685%20517'%3E%3C/svg%3E" alt="figure8" width="685" height="517" aria-describedby="figure-8-desc" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig8_HTML.png"><noscript><img class="rds_hl_nofollow" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51702-y/MediaObjects/41598_2019_51702_Fig8_HTML.png" alt="figure8" width="685" height="517" aria-describedby="figure-8-desc" /></noscript></picture></div>
<div id="figure-8-desc" class="c-article-section__figure-description" data-test="bottom-caption" bis_skin_checked="1">
<p>Histological photomicrograph of femur bone at proximal portion, demonstrating the cancellous bone (Cn), growth plate (Gp) and cortical bone (Ct). Staining: Masson trichrome: 25x of magnification.</p>
</div>
</div>
</figure>
</div>
<h3 id="Sec17" class="c-article__sub-heading c-article__sub-heading--divider">Analysis of the samples</h3>
<p>Densitometry results were demonstrated in mg/mm<sup>2</sup>&nbsp;for BMD and Milligram (mg) for BMC with the x-rays focusing on 9 mm<sup>2</sup>&nbsp;on distal portion of femoral bone. Quantification data from calcium, magnesium and zinc were expressed in milligram per gram (mg/g). Quantification of cancellous bone was expressed on Pixels². Measures of total weight of animals were expressed in grams (g). Femur length was shown in centimeters (cm) and the bone weight was demonstrated in milligrams (mg). Serum samples were subjected to measurements of the quantity of total calcium and total cholesterol, these data were expressed in milligram per deciliter (mg/dL).</p>
<h3 id="Sec18" class="c-article__sub-heading c-article__sub-heading--divider">Statistical analysis</h3>
<p>The software used for statistical analysis was SPSS 20.0 (IBM, New York, NY, USA) and the samples were submitted to the general linear model test, and all comparisons were submitted to Bonferroni adjustment<sup><a id="ref-link-section-d4412e1369" title="Macedo, A. P. et al. Influence of treadmill training on bone structure under osteometabolic alteration in rats subjected to high-fat diet. Scandinavian Journal of Medicine &amp; Science in Sports 27, 167–176, https://doi.org/10.1111/sms.12650 (2017)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR24" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24">24</a>,<a id="ref-link-section-d4412e1372" title="Shimano, R. C. et al. Effects of high-impact exercise on the physical properties of bones of ovariectomized rats fed to a high-protein diet. Scandinavian Journal of Medicine &amp; Science in Sports 28, 1523–1531, https://doi.org/10.1111/sms.13058 (2018)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR49" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49">49</a></sup>. Analysis of TRAP were subjected to normality test and then it was subjected to nonparametric test with Kruskal Wallis as analysis of variance, with a post-test of Dunn that was held to specify these differences. The results were considered different when p ≤ 0.05.</p>
<p>&nbsp;</p>
<h2 id="Sec19" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Results</h2>
<hr>
<p>&nbsp;</p>
<p>The results represented on the Table&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Tab2" data-track="click" data-track-label="link" data-track-action="table anchor">2</a>&nbsp;have the first column with the analysis made. The other 3 columns have the results mean (standard deviation) and the fourth column have the p value with the differences points as “<sup>a</sup>” and “<sup>b</sup>” corresponding to the line of the analysis.</p>
<p>&nbsp;</p>
<h3 id="Sec20" class="c-article__sub-heading">Preclinical findings</h3>
<p>Twenty eight percent of the rats from Se group (because they were isolated in individual cages) presented eruptions on skin at the final week of the study, as a result of absence hygiene, motivated by the absence of contact with other animal of the same species. Due to this, it was managed a daily treatment with rifamycin (Rifocina Spray, Sanovi Aventis, Sao Paulo, Brazil) until the induction of death and it was guaranteed that the use of this medicine did not influence on the results of this study, according to studies of bone repair where it look for infections prevention of the surgical region<sup><a id="ref-link-section-d4412e2538" title="Freitas, S. H. D. et al. Tomographic imaging of fragmented cortical bone heteroimplant and methylmethacrylate in segmental bone defect of rabbit tibia. Acta Cirurgica Brasileira 29, 794–800 (2014)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR54" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 54">54</a></sup>. All the animals were on good health and well treated before the palliative treatment with rifamycin.</p>
<h3 id="Sec21" class="c-article__sub-heading">Quantitative analysis</h3>
<p>Quantification of cancellous bone by Masson trichrome was expressed in Pixel<sup>2</sup> <sup><a id="ref-link-section-d4412e2552" title="Issa, J. P. M. et al. The effect of simvastatin treatment on bone repair of femoral fracture in animal model. Growth Factors 33, 139–148, https://doi.org/10.3109/08977194.2015.1011270 (2015)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR22" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22">22</a>,<a id="ref-link-section-d4412e2555" title="Monteiro, L. O. et al. Effect of treatment with simvastatin on bone microarchitecture of the femoral head in an osteoporosis animal model. Microscopy Research and Technique 79, 684–690, https://doi.org/10.1002/jemt.22682 (2016)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR23" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23">23</a></sup>, quantification by picrosirius was expressed as percentage of total collagen (%)<sup><a id="ref-link-section-d4412e2559" title="Pereira, B. F. et al. Effects of biodegradable detergents in morphological parameters of liver in two neotropical fish species (Prochilodus lineatus and Astyanax altiparanae). Microscopy. Research 2, 39 (2014)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR55" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 55">55</a></sup>&nbsp;and immunolabeling for TRAP was expressed by Scores<sup><a id="ref-link-section-d4412e2563" title="Shimano, R. C. et al. Biomechanical and microstructural benefits of physical exercise associated with risedronate in bones of ovariectomized rats. Microsc Res Tech 77, 431–438, https://doi.org/10.1002/jemt.22363 (2014)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR21" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21">21</a></sup>.</p>
<p>The immunohistochemical technique for TRAP (Tartrate-resistant acid phosphatase) showed high specificity in detecting such protein. This specificity indicates an immunolabeling of osteoclastic activity<sup><a id="ref-link-section-d4412e2570" title="Habermann, B., Eberhardt, C., Feld, M., Zichner, L. &amp; Kurth, A. A. Tartrate-resistant acid phosphatase 5b (TRAP 5b) as a marker of osteoclast activity in the early phase after cementless total hip replacement. Acta Orthop 78, 221–225, https://doi.org/10.1080/17453670710013717 (2007)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR56" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 56">56</a></sup>, which was proven by the total absence of markup in the negative control reaction. Immunoreactive cells showed a brownish staining confined exclusively to the cytoplasm. The differences found was Se&nbsp;<i>vs</i>. Se30 and OVX&nbsp;<i>vs</i>. OVX30 with p &lt; 0.00001, been lower osteoclast expression on OVX30 and Se30, compared to control OVX and Se, data shown on Table&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Tab1" data-track="click" data-track-label="link" data-track-action="table anchor">1</a>.</p>
<p>Table&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Tab2" data-track="click" data-track-label="link" data-track-action="table anchor">2</a>&nbsp;shows the values of the averages with their respective standard deviations in parentheses and followed by the p value when there are significant differences, showing a comparison between groups.</p>
<p>BMC demonstrated that the control C vs. C10 (p = 0.018) and C&nbsp;<i>vs</i>. C30 (p &lt; 0.0001) had statistically significant differences, been higher values of BMC attributed to the control C. In the OVX group, OVX&nbsp;<i>vs</i>. OVX10 (p = 0.044) had significant differences. The group Se&nbsp;<i>vs</i>. Se10 (p &lt; 0.0001) and Se&nbsp;<i>vs</i>. Se30 (p &lt; 0.001) had significant differences with higher values attributed to the groups treated with doxycycline.</p>
<p>BMD for OVX group showed the following difference, OVX&nbsp;<i>vs</i>. OVX10 (p = 0.031). Sedentary group presented Se&nbsp;<i>vs</i>. Se10 (p &lt; 0.001) and Se vs. Se30 (p &lt; 0.001) with higher values attributed to the groups treated with doxycycline. No difference was found between C, C10 and C30.</p>
<p>For calcium quantification on periosteal surface of distal half of tibia bone biopsy, it was observed in the control group C&nbsp;<i>vs</i>. C10 (p &lt; 0.001) and C&nbsp;<i>vs</i>. C30 (p &lt; 0.001) had statistically significant differences with higher values of calcium concentration on the control C. Groups OVX and Se had no statistically significant, but have a tendency of increase of this alkaline earth metal on the groups exposed to doxycycline.</p>
<p>For magnesium and zinc measurements on periosteal surface of distal half of tibia bone biopsy, control group C&nbsp;<i>vs</i>. C10 (p &lt; 0.001) and C&nbsp;<i>vs</i>. C30 (p &lt; 0.001) had statistically significant differences with higher values of magnesium and zinc concentration on the control C. In the OVX group was not obtained significant differences on both analysis, but for quantification of magnesium on the Se group, it was observed differences when it compares the Groups Se&nbsp;<i>vs</i>. Se30 (p &lt; 0.001) and Se&nbsp;<i>vs</i>. Se10 (p = 0.007) with higher values on the groups exposed to the doxycycline (Se10 and Se30).</p>
<p>Quantification of calcium on serum of control and sedentary groups, no significant differences were found, but for OVX group it was observed that OVX&nbsp;<i>vs</i>. OVX30 (p = 0.013) had statistically significant differences with higher concentration of calcium on serum on the group OVX30 and a tendency of increase dose-dependent of doxycycline medication on this particular group.</p>
<p>Quantification of cancellous bone by Masson trichrome on proximal portion of femur bone had OVX&nbsp;<i>vs</i>. OVX10 (p = 0.04) and OVX&nbsp;<i>vs</i>. OVX30 (p = 0.05) with statistical differences with an increase of cancellous bone on the groups treated with doxycycline.</p>
<p>Quantification of cancellous bone by Masson trichrome in distal portion of femur bone region had for the control group (C)&nbsp;<i>vs</i>. C30 (p = 0.036) significant differences. Ovariectomized group had OVX&nbsp;<i>vs</i>. OVX10 (p &lt; 0.01) and OVX&nbsp;<i>vs</i>. OVX30 (p = 0.03) significant differences. Sedentarism group presented the following statistical differences, Se&nbsp;<i>vs</i>. Se10 (p = 0.05) and Se&nbsp;<i>vs</i>. Se30 (p = 0.02). All the results of cancellous bone on distal portion of the bone showed that doxycycline took by control group were no beneficial, so the C has higher values than C30, but when the disease is established, the medication showed higher values for Se10 and S30 and OVX10 and OVX30 in comparison to it is controls.</p>
<p>On the other hand, for total weight of the rats before death induction, total cholesterol, quantification of collagen by picrosirius, total length of femurs and femoral weight, no differences were found.</p>
<h3 id="Sec22" class="c-article__sub-heading">Qualitative analysis for histology</h3>
<h4 id="Sec23" class="c-article__sub-heading c-article__sub-heading--small">Trichrome of masson</h4>
<p>Histological photomicrographs stained by Trichrome of Masson are represented at distal portion – Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;and proximal portion – Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig8" data-track="click" data-track-label="link" data-track-action="figure anchor">8</a>. The cancellous bone (Cn), growth plate (Gp) and the cortical bone (Ct) are indicated in both figures.</p>
<p>The letters in the upper left corner are referred to the experimental groups of this work Group C: control without doxycycline or any treatments; Group C10: Doxycycline 10 mg/kg induced; Group C30: Doxycycline 30 mg/kg induced; Group Se: Sedentary control; Se10 Group: Sedentary 10 mg/kg/day; Se30 Group: sedentary lifestyle 30 mg/kg/day; OVX Group: control Ovariectomized; OVX10 Group: Ovariectomy 10 mg/kg/day and OVX30 Group: Ovariectomy 30 mg/kg/day.</p>
<p>Figures&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;and&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig8" data-track="click" data-track-label="link" data-track-action="figure anchor">8</a>&nbsp;shows histological images of cancellous bone with the thickness of 5 µm on the area of 30 mm², the presented results was expressed in Pixel<sup>2</sup> <sup><a id="ref-link-section-d4412e2707" title="Issa, J. P. M. et al. The effect of simvastatin treatment on bone repair of femoral fracture in animal model. Growth Factors 33, 139–148, https://doi.org/10.3109/08977194.2015.1011270 (2015)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR22" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22">22</a>,<a id="ref-link-section-d4412e2710" title="Monteiro, L. O. et al. Effect of treatment with simvastatin on bone microarchitecture of the femoral head in an osteoporosis animal model. Microscopy Research and Technique 79, 684–690, https://doi.org/10.1002/jemt.22682 (2016)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR23" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23">23</a></sup>&nbsp;by the software AxioVision 4.8 (Carl Zeiss, Oberkochen, Germany) which distingue the cancellous bone from cortical bone and the growth plate portion, using the spectrum of color to delimitated the area of interest.</p>
<p>Figure&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7C</a>&nbsp;presented a mineralized normal bone tissue with cancellous bone distributed uniformly (Cn) and the growth plate across the distal portion of the bone as normal and uniform mode (Gp). Figure&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;-C10 had a mineralized bone tissue with the same distributions, however to a lesser amount of cancellous bone when comparing with the bone tissue of Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7C</a>&nbsp;as the cancellous bone (Cn) appeared slightly more spaced. Growth plate (Gp) showed ticker aspect in this section. Figure&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;C30 had the presence of a mineralized bone tissue with slight decreases in bone quality. This fact may be caused by the reduced amount of cancellous bone (Cn) and wide space distance between cancellous tissue contrasting with the control (Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7C</a>).</p>
<p>Figure&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;-Se showed the presence of a bone tissue affected by a degenerative disease caused by sedentary Wistar rats induced in females. Cancellous bone (Cn) showed a large spacing between themselves and the growth plates (Gp) altered more their thicknesses. Figure&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;-Se10 showed a great improvement of the cancellous bone tissue (Cn) combined with an irregularity presented in growth plate (Gp) demonstrating that doxycycline is able to change the growth plate morphology. Figure&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;-Se30 demonstrated a large amount of cancellous bone tissue (Cn) and a change more evident in the growth plate (Gp).</p>
<p>Figure&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;-OVX had the presence of a bone tissue affected by a degenerative disease caused by bilateral ovariectomy in female Wistar rats, with spacing of cancellous bone (Cn) and thick growth plate (Gp) (Yao&nbsp;<i>et al</i>., 2006). Figure<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;-OVX10 and -OVX30 had been an increase in the number of cancellous bone and a decrease in the changes in growth plate thickness (Gp).</p>
<p>Figure&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig8" data-track="click" data-track-label="link" data-track-action="figure anchor">8</a>&nbsp;(proximal femur) showed no significant differences in cancellous bone (Cn), in exception for OVX group. It was found changes in growth plate (Gp) on samples of rats exposed to Doxycycline for 60 days (Figures-C10, C30, Se10, Se30 and OVX30 and this growth plate was absent completely in Figure-OVX10). According to statistical differences found in Table&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Tab2" data-track="click" data-track-label="link" data-track-action="table anchor">2</a>, OVX vs. OVX10 p = 0.04 and OVX vs. OVX30 p = 0.05 had statistically significant.</p>
<h4 id="Sec24" class="c-article__sub-heading c-article__sub-heading--small">Pricrosirius-red</h4>
<p>Data obtained from samples submitted to picrosirius red staining (data not shown) did not shown statistical differences on total collagen (Table&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Tab2" data-track="click" data-track-label="link" data-track-action="table anchor">2</a>). It suggests that the doses were not enough for changing the total amount of total collagen on bone, but it well known that the inhibition of collagenase is one of the actions of doxycycline<sup><a id="ref-link-section-d4412e2777" title="Golub, L. M. et al. Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. Journal of periodontal research 19, 651–655 (1984)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR57" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">57</a>,<a id="ref-link-section-d4412e2777_1" title="Belo, V. A. et al. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clinical biochemistry 42, 984–990, https://doi.org/10.1016/j.clinbiochem.2009.03.025 (2009)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR58" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">58</a>,<a id="ref-link-section-d4412e2780" title="Castro, M. M., Tanus-Santos, J. E. &amp; Gerlach, R. F. Matrix metalloproteinases: Targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacological research 64, 567–572, https://doi.org/10.1016/j.phrs.2011.04.002 (2011)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR59" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 59">59</a></sup>. This fact did not result in changes on the quantification of total collagen at this work.</p>
<p>&nbsp;</p>
<h2 id="Sec25" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Discussion</h2>
<hr>
<p>&nbsp;</p>
<p>Data of immunolabeling for TRAP showed semi-quantitative differences, with higher immunostaining identification for control group compared to the exposed to doxycycline 10 mg/kg/day and 30 mg/kg/day, demonstrating that the doxycycline in these two doses inhibited osteoclast action in this study. This type of inhibition had been described in previous&nbsp;<i>in vitro</i>&nbsp;studies<sup><a id="ref-link-section-d4412e2797" title="Zhang, C., Tang, T. T., Ren, W. P., Zhang, X. L. &amp; Dai, K. R. Inhibiting wear particles-induced osteolysis with doxycycline. Acta Pharmacol Sin 28, 1603–1610, https://doi.org/10.1111/j.1745-7254.2007.00638.x (2007)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR60" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 60">60</a>,<a id="ref-link-section-d4412e2800" title="Zhou, X., Zhang, P., Zhang, C., An, B. &amp; Zhu, Z. A. Tetracyclines Inhibit Rat Osteoclast Formation and Activity In Vitro and Affect Bone Turnover in Young Rats In Vivo. Calcified Tissue International 86, 163–171, https://doi.org/10.1007/s00223-009-9328-5 (2010)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR61" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 61">61</a></sup>.</p>
<p>Figure&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig1" data-track="click" data-track-label="link" data-track-action="figure anchor">1</a>– shows the molecule of doxycycline<sup><a id="ref-link-section-d4412e2810" title="Babu, E. et al. Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol 88, 69–76 (2002)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR62" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 62">62</a>,<a id="ref-link-section-d4412e2813" title="Griffin, M. O., Fricovsky, E., Ceballos, G. &amp; Villarreal, F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. American Journal of Physiology - Cell Physiology 299, C539–C548, https://doi.org/10.1152/ajpcell.00047.2010 (2010)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR63" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 63">63</a></sup>&nbsp;in the anhydrous form (Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig1" data-track="click" data-track-label="link" data-track-action="figure anchor">1</a>). The lower portion of the molecule doxycycline is capable of bivalent metal binding<sup><a id="ref-link-section-d4412e2820" title="Sapadin, A. N. &amp; Fleischmajer, R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54, 258–265, https://doi.org/10.1016/j.jaad.2005.10.004 (2006)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR1" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1">1</a></sup>. A study affirmed that in the presence of Zn<sup>2+</sup>&nbsp;ions, there is the occurrence of competition for the catalytic site of MMP-7 connected prior to Ca<sup>2+</sup>&nbsp;Ion, thus inhibiting activity of MMP-7<sup><a id="ref-link-section-d4412e2829" title="García, R. A. et al. Molecular Interactions between Matrilysin and the Matrix Metalloproteinase Inhibitor Doxycycline Investigated by Deuterium Exchange Mass Spectrometry. Molecular Pharmacology 67, 1128–1136, https://doi.org/10.1124/mol.104.006346 (2005)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR64" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 64">64</a></sup>, although it is known that tetracyclines are chelators of Zn<sup>2+</sup>&nbsp;ions<sup><a id="ref-link-section-d4412e2835" title="Peterson, J. T. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 9, 63–79, https://doi.org/10.1023/B:HREV.0000011395.11179.af (2004)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR65" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 65">65</a></sup>, the actual mechanism of inhibition of MMPs are not yet clear.</p>
<p>Tetracyclines have 4 aromatic rings (Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig1" data-track="click" data-track-label="link" data-track-action="figure anchor">1</a>) and also have characteristic of chelating bivalent metal in physiological conditions, forming chelate complexes<sup><a id="ref-link-section-d4412e2845" title="Palm, G. J. et al. Specific binding of divalent metal ions to tetracycline and to the Tet repressor/tetracycline complex. J Biol Inorg Chem 13, 1097–1110, https://doi.org/10.1007/s00775-008-0395-2 (2008)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR66" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 66">66</a></sup>. In this study, the authors tested the association (calculating the equilibrium constants of association) between several divalent metals and tetracycline, considering the following metals: Mg, Ca, Sr, Ba, Mn, Fe, Co, Ni, Cu, Zn and Cd. The constant of association varied in 3 orders of magnitude, and the results show that under physiological conditions, the metals with higher-to-low affinity for tetracycline are first order Ba, Sr, Cd, followed by the second order Ca, Mg, Cu, Mn and Zn. Only the third order Fe, Ni and Co had lower affinity than zinc (about 5 times less). However, since the physiological levels of calcium are at the millimolar level, which is the metal that is connected to tetracycline. Other divalent metals are in much lower concentrations<sup><a id="ref-link-section-d4412e2849" title="Palm, G. J. et al. Specific binding of divalent metal ions to tetracycline and to the Tet repressor/tetracycline complex. J Biol Inorg Chem 13, 1097–1110, https://doi.org/10.1007/s00775-008-0395-2 (2008)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR66" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 66">66</a></sup>.</p>
<p>In addition, tetracyclines inhibit MMP-13 and this type of MMP is intrinsically related to the biology of growth plate of the bones. The type X collagen is find in smaller quantities in MMP-13 knockout mice and the lack of expression of this type of collagen are related to the dwarfism and is related to changes in activities of chondrocytes<sup><a id="ref-link-section-d4412e2856" title="Ionescu, A. et al. FoxA family members are crucial regulators of the hypertrophic chondrocyte differentiation program. Developmental Cell 22, 927–939, https://doi.org/10.1016/j.devcel.2012.03.011 (2012)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR67" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67">67</a></sup>. It is known that the hypertrophic chondrocyte is responsible for three actions on bone: 60% of bone growth, 30% of the mineral deposition in the bone and 10% of cellular proliferation<sup><a id="ref-link-section-d4412e2860" title="Wilsman, N. J., Farnum, C. E., Leiferman, E. M., Fry, M. &amp; Barreto, C. Differential growth by growth plates as a function of multiple parameters of chondrocytic kinetics. Journal of orthopaedic research: official publication of the Orthopaedic Research Society 14, 927–936, https://doi.org/10.1002/jor.1100140613 (1996)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR68" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 68">68</a></sup>.</p>
<p>MMP-2 was first isolated from bone, and it is very important for normal bone maintenance<sup><a id="ref-link-section-d4412e2868" title="Nagase, H. &amp; Woessner, J. F. Jr. Matrix metalloproteinases. The Journal of biological chemistry 274, 21491–21494 (1999)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR69" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 69">69</a></sup>. Lack of activity of MMP-14 (MT1-MMP) induces dwarfism, osteopenia, arthritis, and connective tissue disease<sup><a id="ref-link-section-d4412e2872" title="Holmbeck, K. et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81–92 (1999)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR70" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 70">70</a></sup>. Therefore, the use of doxycycline would also inhibit MT1-MMP and other MMPs<sup><a id="ref-link-section-d4412e2876" title="Stechmiller, J., Cowan, L. &amp; Schultz, G. The Role of Doxycycline as a Matrix Metalloproteinase Inhibitor for the Treatment of Chronic Wounds. Biological Research For Nursing 11, 336–344, https://doi.org/10.1177/1099800409346333 (2010)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR71" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 71">71</a></sup>, since this drug is not selective.</p>
<p>Morphological analysis showed a clear improvement on the quality of cancellous bone accordingly to histological analyses (Figs&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;and&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig8" data-track="click" data-track-label="link" data-track-action="figure anchor">8</a>). Data from distal portion of the femur bone in Wistar rats with osteopenia induced exposed to two doses of doxycycline (Se10, Se30, OVX10 and OVX30), permits to infer that this medicine is able to improve the quality of the bone structure compared to the control groups (C, Se and OVX). This finding was described in Table&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Tab2" data-track="click" data-track-label="link" data-track-action="table anchor">2</a>&nbsp;and Fig.&nbsp;<a href="https://www.nature.com/articles/s41598-019-51702-y#Fig7" data-track="click" data-track-label="link" data-track-action="figure anchor">7</a>&nbsp;and is supported by another study using orthodontic tooth movement in mice<sup><a id="ref-link-section-d4412e2895" title="Mavragani, M., Brudvik, P. &amp; Selvig, K. A. Orthodontically induced root and alveolar bone resorption: inhibitory effect of systemic doxycycline administration in rats. European Journal of Orthodontics 27, 215–225, https://doi.org/10.1093/ejo/cji015 (2005)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR72" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 72">72</a></sup>. On this related study there was a smaller dental root resorption in rats subjected to Doxycycline for 7, 10 and 14 days of orthodontic treatment and on orthodontic movement it was found lesser amount for TRAP immunostaining at the group exposed to Doxycycline during tooth movement<sup><a id="ref-link-section-d4412e2900" title="Mavragani, M., Brudvik, P. &amp; Selvig, K. A. Orthodontically induced root and alveolar bone resorption: inhibitory effect of systemic doxycycline administration in rats. European Journal of Orthodontics 27, 215–225, https://doi.org/10.1093/ejo/cji015 (2005)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR72" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 72">72</a></sup>. Gomes and Fernandes concluded an&nbsp;<i>in vitro</i>&nbsp;study that doxycycline and minocycline promoted human osteoblastic cells proliferation and this leaded to a later mineralization, which allowed to consider that doxycycline may induce bone mineralization<sup><a id="ref-link-section-d4412e2907" title="Gomes, P. S. &amp; Fernandes, M. H. Effect of therapeutic levels of doxycycline and minocycline in the proliferation and differentiation of human bone marrow osteoblastic cells. Archives of oral biology 52, 251–259, https://doi.org/10.1016/j.archoralbio.2006.10.005 (2007)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR73" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 73">73</a></sup>&nbsp;and less bone resorption<sup><a id="ref-link-section-d4412e2911" title="Mavragani, M., Brudvik, P. &amp; Selvig, K. A. Orthodontically induced root and alveolar bone resorption: inhibitory effect of systemic doxycycline administration in rats. European Journal of Orthodontics 27, 215–225, https://doi.org/10.1093/ejo/cji015 (2005)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR72" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 72">72</a></sup>. Considering this kind of dental intervention it is well sedimented in the literature that orthodontic movement induces an inflammatory reaction, which is considered a normal side effect for orthodontic practice<sup><a id="ref-link-section-d4412e2915" style="vertical-align: baseline; background-color: transparent; text-decoration: none; color: #006699; box-sizing: inherit; overflow-wrap: break-word; word-break: break-word;" title="Rygh, P. Orthodontic root resorption studied by electron microscopy. Angle Orthod 47, 1–16, doi:10.1043/0003-3219(1977)047<0001:orrsbe>2.0.co;2 (1977)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR74" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 74">74</a></sup>.</p>
<p>Limirio and collaborators showed that doxycycline 10% associate to alendronate 1% increase the time of bone neoformation on 7 and 15 days on rats with femur osteotomy. Their findings suggests that doxycycline associated to alendronate on the defect suppress the osteoclasts and had less bone neoformated on 7 days<sup><a id="ref-link-section-d4412e2922" title="Limirio, P. H. et al. The Effect of Local Delivery Doxycycline and Alendronate on Bone Repair. AAPS PharmSciTech 17, 872–877, https://doi.org/10.1208/s12249-015-0411-0 (2016)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR75" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 75">75</a></sup>, this data corroborate to our findings on controls groups (C, C10 and C30), which doxycycline SDD have a negative rule on the physiological bone. But long-term treatment (60 days) of SDD on physiological bone, without osteopenia, was never tested. Normally the doxycycline is studied for bone repair or alveolar repair<sup><a id="ref-link-section-d4412e2926" title="Gomes, K. D. N., Alves, A. P. N. N., Dutra, P. G. P. &amp; Viana, G. S. B. Doxycycline induces bone repair and changes in Wnt signalling. International Journal Of Oral Science 9, 158, https://doi.org/10.1038/ijos.2017.28 (2017)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR76" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 76">76</a></sup>&nbsp;with positive results, but never tested on long-term SDD on long bones.</p>
<p>Another study performed in dogs, showed that doxycycline is able to reduce bone loss caused by endodontic peri radicular surgery<sup><a id="ref-link-section-d4412e2933" title="Cummings, G. R. &amp; Torabinejad, M. Effect of Systemic Doxycycline on Alveolar Bone Loss after Periradicular Surgery. Journal of endodontics 26, 325–327, https://doi.org/10.1097/00004770-200006000-00004 (2000)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR77" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 77">77</a></sup>. However, another study showed that doxycycline does not improved the quantity and quality of tissue repair on bone in Wistar rats subjected to dental extraction and subsequently treated for 7 days on doxycycline and erythromycin<sup><a id="ref-link-section-d4412e2937" title="Shahabooei, M. et al. A histomorphometric study of the effect of doxycycline and erythromycin on bone formation in dental alveolar socket of rat. Adv Biomed Res 4, 71, https://doi.org/10.4103/2277-9175.153895 (2015)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR78" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 78">78</a></sup>. This fact may be comprehended in this previous cited work, explaining that the rats were subjected to a short period of treatment with doxycycline (7 days) and the quantification was injured because of this short time of treatment.</p>
<p>In this present research, doxycycline inhibited osteoclastic bone action<sup><a id="ref-link-section-d4412e2944" title="Gomes, K. D. N., Alves, A. P. N. N., Dutra, P. G. P. &amp; Viana, G. S. B. Doxycycline induces bone repair and changes in Wnt signalling. International Journal Of Oral Science 9, 158, https://doi.org/10.1038/ijos.2017.28 (2017)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR76" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 76">76</a></sup>, and therefore this drug was beneficial for bone under conditions of high osteoclastic activity. However, under normal physiological conditions, it is not beneficial for bone. It is worth pointing out that doxycycline can increase osteoblast action, perhaps by modifying the unbalance caused by osteoporosis where it had an increase in the action of osteoclasts cells, and a decrease in the action of osteoblasts cells<sup><a id="ref-link-section-d4412e2948" title="Teitelbaum, S. L. Bone Resorption by Osteoclasts. Science (New York, N.Y.) 289, 1504–1508, https://doi.org/10.1126/science.289.5484.1504 (2000)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR18" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18">18</a>,<a id="ref-link-section-d4412e2951" title="Gomes, K. D. N., Alves, A. P. N. N., Dutra, P. G. P. &amp; Viana, G. S. B. Doxycycline induces bone repair and changes in Wnt signalling. International Journal Of Oral Science 9, 158, https://doi.org/10.1038/ijos.2017.28 (2017)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR76" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 76">76</a></sup>. Apparently looking for this topic at current literature and results contained in this present work, we can summarize that doxycycline decreases osteoclastic action<sup><a id="ref-link-section-d4412e2955" title="Zhang, C., Tang, T. T., Ren, W. P., Zhang, X. L. &amp; Dai, K. R. Inhibiting wear particles-induced osteolysis with doxycycline. Acta Pharmacol Sin 28, 1603–1610, https://doi.org/10.1111/j.1745-7254.2007.00638.x (2007)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR60" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 60">60</a>,<a id="ref-link-section-d4412e2958" title="Zhou, X., Zhang, P., Zhang, C., An, B. &amp; Zhu, Z. A. Tetracyclines Inhibit Rat Osteoclast Formation and Activity In Vitro and Affect Bone Turnover in Young Rats In Vivo. Calcified Tissue International 86, 163–171, https://doi.org/10.1007/s00223-009-9328-5 (2010)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR61" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 61">61</a>,<a id="ref-link-section-d4412e2961" title="Gomes, K. D. N., Alves, A. P. N. N., Dutra, P. G. P. &amp; Viana, G. S. B. Doxycycline induces bone repair and changes in Wnt signalling. International Journal Of Oral Science 9, 158, https://doi.org/10.1038/ijos.2017.28 (2017)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR76" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 76">76</a></sup>&nbsp;and increases osteoblast action<sup><a id="ref-link-section-d4412e2965" title="Gomes, P. S. &amp; Fernandes, M. H. Effect of therapeutic levels of doxycycline and minocycline in the proliferation and differentiation of human bone marrow osteoblastic cells. Archives of oral biology 52, 251–259, https://doi.org/10.1016/j.archoralbio.2006.10.005 (2007)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR73" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 73">73</a>,<a id="ref-link-section-d4412e2968" title="Gomes, K. D. N., Alves, A. P. N. N., Dutra, P. G. P. &amp; Viana, G. S. B. Doxycycline induces bone repair and changes in Wnt signalling. International Journal Of Oral Science 9, 158, https://doi.org/10.1038/ijos.2017.28 (2017)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR76" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 76">76</a></sup>. However, it is not known how this “re-balance” happens, further studies are needed to prove that.</p>
<p>It is well known that doxycycline chelates divalent metals<sup><a id="ref-link-section-d4412e2975" title="Palm, G. J. et al. Specific binding of divalent metal ions to tetracycline and to the Tet repressor/tetracycline complex. J Biol Inorg Chem 13, 1097–1110, https://doi.org/10.1007/s00775-008-0395-2 (2008)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR66" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 66">66</a></sup>&nbsp;and this interaction between doxycycline and divalent metal calcium is important for the health of bone tissue, as in the study of Weaver and colleagues sought to measure bone quality via the urinary excretion of Calcium isotopes. The authors used an isotope of tetracycline to make this measurement and with that, the authors could measure almost immediately the differences after induction of osteopenia by ovariectomy<sup><a id="ref-link-section-d4412e2979" title="Weaver, C. et al. (3)H-tetracycline as a proxy for (41)Ca for measuring dietary perturbations of bone resorption. Nuclear instruments &amp; methods in physics research. Section B. Beam interactions with materials and atoms 259, 790–795, https://doi.org/10.1016/j.nimb.2007.02.004 (2007)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR79" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 79">79</a></sup>.</p>
<p>There are several questionings about the fact that doxycycline being an antibiotic and does not present an increase of microbial resistance. In humans, the dose of 20 mg/kg/day does not presented increased subgingival flora<sup><a id="ref-link-section-d4412e2987" title="Walker, C. et al. Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiologic results. J Periodontol 78, 1590–1601, https://doi.org/10.1902/jop.2007.070015 (2007)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR80" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 80">80</a></sup>&nbsp;and it is used as metalloproteinase inhibitor for treatment of periodontitis<sup><a id="ref-link-section-d4412e2991" title="Thomas, J., Walker, C. &amp; Bradshaw, M. Long-Term Use of Subantimicrobial Dose Doxycycline Does Not Lead to Changes in Antimicrobial Susceptibility. Journal of Periodontology 71, 1472–1483, https://doi.org/10.1902/jop.2000.71.9.1472 (2000)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR5" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5">5</a>,<a id="ref-link-section-d4412e2994" title="Golub, L. M. et al. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. Journal of clinical periodontology 22, 100–109 (1995)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR81" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 81">81</a></sup>. Furthermore, the use of doxycycline at this dose has already been proven not antimicrobial (SDD), not affecting the skin floras<sup><a id="ref-link-section-d4412e2998" title="Skidmore, R. et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 139, 459–464, https://doi.org/10.1001/archderm.139.4.459 (2003)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR82" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 82">82</a></sup>. As the tetracyclines, minocycline and doxycycline, are widely used for antimicrobial purpose (skin problems) at SDD<sup><a id="ref-link-section-d4412e3002" title="Cohen, P. R. &amp; Grossman, M. E. Management of cutaneous lesions associated with an emerging epidemic: community-acquired methicillin-resistant Staphylococcus aureus skin infections. J Am Acad Dermatol 51, 132–135, https://doi.org/10.1016/j.jaad.2004.03.010 (2004)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR83" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">83</a>,<a id="ref-link-section-d4412e3002_1" title="Del Rosso, J. Q. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. Cutis 74, 118–122 (2004)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR84" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">84</a>,<a id="ref-link-section-d4412e3002_2" title="Pelle, M. T., Crawford, G. H. &amp; James, W. D. Rosacea: II. Therapy. J Am Acad Dermatol 51, 499–512; quiz 513–494, https://doi.org/10.1016/j.jaad.2004.03.033 (2004)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR85" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">85</a>,<a id="ref-link-section-d4412e3002_3" title="Cohen, P. R. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol 8, 259–270 (2007)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR86" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">86</a>,<a id="ref-link-section-d4412e3002_4" title="Elston, D. M. Community-acquired methicillin-resistant Staphylococcus aureus. J Am Acad Dermatol 56, 1–16; quiz 17–20, https://doi.org/10.1016/j.jaad.2006.04.018 (2007)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR87" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref">87</a>,<a id="ref-link-section-d4412e3005" title="Bhambri, S. &amp; Kim, G. Use of Oral Doxycycline for Community-acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA) Infections. The. Journal of Clinical and Aesthetic Dermatology 2, 45–50 (2009)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR88" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 88">88</a></sup>.</p>
<p>Data shows that the amount of calcium present in serum seemed to had contributed positively for bone increase (with an increase in serum calcium of samples from the OVX10 and OVX30 groups compared with OVX). Densitometric and histological findings corroborate with the clinical improvement of bone quality. Calcium homeostasis is a mechanism closely regulated in our body<sup><a id="ref-link-section-d4412e3012" title="Boden, S. D. &amp; Kaplan, F. S. Calcium homeostasis. Orthop Clin North Am 21, 31–42 (1990)." href="https://www.nature.com/articles/s41598-019-51702-y#ref-CR89" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 89">89</a></sup>, so, further studies are needed to determine whether doxycycline really changes serum calcium and whether those changes reflect bone changes or induce bone changes. It is tempting to say that doxycycline can carry calcium to the bone in osteoporotic rats. The same affirmation is not true with controls, in which doxycycline had deleterious effects.</p>
<p>In conclusion, SDDs for a long time (sixty days) in 2 models of osteopenia (hormone-dependent and sedentarism-induced) in female rats had positive effects on bone, particularly well characterized the decrease in osteoclastic activity. On the control groups doxycycline were mostly deleterious, with exception the quantification of cancellous bone with a slight increase of collagen quantification on proximal portion of the femur. Osteopenic animals also showed increased densitometric data in bone analyses in femurs, and a higher quality of cancellous bone was observed in the osteopenic groups that received doxycycline. According to the results of this study, doxycycline had a high therapeutic potential for the long-term treatment of osteopenia.</p>
<p>&nbsp;</p>
<h2 id="Bib1" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">References</h2>
<hr>
<p>&nbsp;</p>
<p><span class="c-article-references__counter">1.</span></p>
<p id="ref-CR1" class="c-article-references__text">Sapadin, A. N. &amp; Fleischmajer, R. Tetracyclines: nonantibiotic properties and their clinical implications.&nbsp;<i>J Am Acad Dermatol</i>&nbsp;<b>54</b>, 258–265,&nbsp;<a href="https://doi.org/10.1016/j.jaad.2005.10.004">https://doi.org/10.1016/j.jaad.2005.10.004</a>&nbsp;(2006).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16443056" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 1 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.jaad.2005.10.004" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 1">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Tetracyclines%3A%20nonantibiotic%20properties%20and%20their%20clinical%20implications&amp;journal=J%20Am%20Acad%20Dermatol&amp;doi=10.1016%2Fj.jaad.2005.10.004&amp;volume=54&amp;pages=258-265&amp;publication_year=2006&amp;author=Sapadin%2CAN&amp;author=Fleischmajer%2CR" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 1 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">2.</span></p>
<p id="ref-CR2" class="c-article-references__text">Valentín, S., Morales, A., Sánchez, J. L. &amp; Rivera, A. Safety and efficacy of doxycycline in the treatment of rosacea.&nbsp;<i>Clin Cosmet Investig Dermatol</i>&nbsp;<b>2</b>, 129–140 (2009).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21436975" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 2 on PubMed">PubMed</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047926" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 2 on PubMed Central">PubMed Central</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Safety%20and%20efficacy%20of%20doxycycline%20in%20the%20treatment%20of%20rosacea&amp;journal=Clin%20Cosmet%20Investig%20Dermatol&amp;volume=2&amp;pages=129-140&amp;publication_year=2009&amp;author=Valent%C3%ADn%2CS&amp;author=Morales%2CA&amp;author=S%C3%A1nchez%2CJL&amp;author=Rivera%2CA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 2 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">3.</span></p>
<p id="ref-CR3" class="c-article-references__text">Golub, L. M.&nbsp;<i>et al</i>. Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis.&nbsp;<i>Journal of clinical periodontology</i>&nbsp;<b>28</b>, 146–156 (2001).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD3MXovFeisQ%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 3 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11168739" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 3 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1034%2Fj.1600-051x.2001.028002146.x" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 3">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Adjunctive%20treatment%20with%20subantimicrobial%20doses%20of%20doxycycline%3A%20effects%20on%20gingival%20fluid%20collagenase%20activity%20and%20attachment%20loss%20in%20adult%20periodontitis&amp;journal=Journal%20of%20clinical%20periodontology&amp;volume=28&amp;pages=146-156&amp;publication_year=2001&amp;author=Golub%2CLM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 3 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">4.</span></p>
<p id="ref-CR4" class="c-article-references__text">Tan, K. R., Magill, A. J., Parise, M. E. &amp; Arguin, P. M. Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis.&nbsp;<i>The American Journal of Tropical Medicine and Hygiene</i>&nbsp;<b>84</b>, 517–531,&nbsp;<a href="https://doi.org/10.4269/ajtmh.2011.10-0285">https://doi.org/10.4269/ajtmh.2011.10-0285</a>&nbsp;(2011).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21460003" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 4 on PubMed">PubMed</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062442" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 4 on PubMed Central">PubMed Central</a>&nbsp;<a href="https://doi.org/10.4269%2Fajtmh.2011.10-0285" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 4">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Doxycycline%20for%20Malaria%20Chemoprophylaxis%20and%20Treatment%3A%20Report%20from%20the%20CDC%20Expert%20Meeting%20on%20Malaria%20Chemoprophylaxis&amp;journal=The%20American%20Journal%20of%20Tropical%20Medicine%20and%20Hygiene&amp;doi=10.4269%2Fajtmh.2011.10-0285&amp;volume=84&amp;pages=517-531&amp;publication_year=2011&amp;author=Tan%2CKR&amp;author=Magill%2CAJ&amp;author=Parise%2CME&amp;author=Arguin%2CPM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 4 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">5.</span></p>
<p id="ref-CR5" class="c-article-references__text">Thomas, J., Walker, C. &amp; Bradshaw, M. Long-Term Use of Subantimicrobial Dose Doxycycline Does Not Lead to Changes in Antimicrobial Susceptibility.&nbsp;<i>Journal of Periodontology</i>&nbsp;<b>71</b>, 1472–1483,&nbsp;<a href="https://doi.org/10.1902/jop.2000.71.9.1472">https://doi.org/10.1902/jop.2000.71.9.1472</a>&nbsp;(2000).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD3cXnt12rs74%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 5 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11022778" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 5 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1902%2Fjop.2000.71.9.1472" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 5">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Long-Term%20Use%20of%20Subantimicrobial%20Dose%20Doxycycline%20Does%20Not%20Lead%20to%20Changes%20in%20Antimicrobial%20Susceptibility&amp;journal=Journal%20of%20Periodontology&amp;doi=10.1902%2Fjop.2000.71.9.1472&amp;volume=71&amp;pages=1472-1483&amp;publication_year=2000&amp;author=Thomas%2CJ&amp;author=Walker%2CC&amp;author=Bradshaw%2CM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 5 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">6.</span></p>
<p id="ref-CR6" class="c-article-references__text">Wallner, H. J. &amp; Schmiedel, A. Blood serum levels in mother and child after oral administration of doxycycline ante partum (author’s transl).&nbsp;<i>MMW, Munchener medizinische Wochenschrift</i>&nbsp;<b>117</b>, 349–352 (1975).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADyaE2MXktVShsLw%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 6 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=804643" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 6 on PubMed">PubMed</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Blood%20serum%20levels%20in%20mother%20and%20child%20after%20oral%20administration%20of%20doxycycline%20ante%20partum%20%28author%E2%80%99s%20transl%29&amp;journal=MMW%2C%20Munchener%20medizinische%20Wochenschrift&amp;volume=117&amp;pages=349-352&amp;publication_year=1975&amp;author=Wallner%2CHJ&amp;author=Schmiedel%2CA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 6 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">7.</span></p>
<p id="ref-CR7" class="c-article-references__text">Duivenvoorden, W. C.&nbsp;<i>et al</i>. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer.&nbsp;<i>Cancer research</i>&nbsp;<b>62</b>, 1588–1591 (2002).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD38XisVSis7g%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 7 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11912125" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 7 on PubMed">PubMed</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Doxycycline%20decreases%20tumor%20burden%20in%20a%20bone%20metastasis%20model%20of%20human%20breast%20cancer&amp;journal=Cancer%20research&amp;volume=62&amp;pages=1588-1591&amp;publication_year=2002&amp;author=Duivenvoorden%2CWC" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 7 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">8.</span></p>
<p id="ref-CR8" class="c-article-references__text">Saikali, Z. &amp; Singh, G. Doxycycline and other tetracyclines in the treatment of bone metastasis.&nbsp;<i>Anti-cancer drugs</i>&nbsp;<b>14</b>, 773–778,&nbsp;<a href="https://doi.org/10.1097/01.cad.0000099002.92896.cf">https://doi.org/10.1097/01.cad.0000099002.92896.cf</a>&nbsp;(2003).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD3sXos1Wgt7w%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 8 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14597870" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 8 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1097%2F01.cad.0000099002.92896.cf" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 8">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Doxycycline%20and%20other%20tetracyclines%20in%20the%20treatment%20of%20bone%20metastasis&amp;journal=Anti-cancer%20drugs&amp;doi=10.1097%2F01.cad.0000099002.92896.cf&amp;volume=14&amp;pages=773-778&amp;publication_year=2003&amp;author=Saikali%2CZ&amp;author=Singh%2CG" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 8 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">9.</span></p>
<p id="ref-CR9" class="c-article-references__text">Golub, L. M.&nbsp;<i>et al</i>. Doxycycline Effects on Serum Bone Biomarkers in Post-menopausal Women.&nbsp;<i>Journal of Dental Research</i>&nbsp;<b>89</b>, 644–649,&nbsp;<a href="https://doi.org/10.1177/0022034510363367">https://doi.org/10.1177/0022034510363367</a>&nbsp;(2010).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC3cXnvFKltrc%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 9 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20348487" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 9 on PubMed">PubMed</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967045" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 9 on PubMed Central">PubMed Central</a>&nbsp;<a href="https://doi.org/10.1177%2F0022034510363367" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 9">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Doxycycline%20Effects%20on%20Serum%20Bone%20Biomarkers%20in%20Post-menopausal%20Women&amp;journal=Journal%20of%20Dental%20Research&amp;doi=10.1177%2F0022034510363367&amp;volume=89&amp;pages=644-649&amp;publication_year=2010&amp;author=Golub%2CLM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 9 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">10.</span></p>
<p id="ref-CR10" class="c-article-references__text">Bezerra, M. M., Brito, G. A. C., Ribeiro, R. A. &amp; Rocha, F. A. C. Low-dose doxycycline prevents inflammatory bone resorption in rats.&nbsp;<i>Brazilian Journal of Medical and Biological Research</i>&nbsp;<b>35</b>, 613–616 (2002).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD38XltFSiu78%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 10 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12011948" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 10 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1590%2FS0100-879X2002000500015" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 10">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Low-dose%20doxycycline%20prevents%20inflammatory%20bone%20resorption%20in%20rats&amp;journal=Brazilian%20Journal%20of%20Medical%20and%20Biological%20Research&amp;volume=35&amp;pages=613-616&amp;publication_year=2002&amp;author=Bezerra%2CMM&amp;author=Brito%2CGAC&amp;author=Ribeiro%2CRA&amp;author=Rocha%2CFAC" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 10 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">11.</span></p>
<p id="ref-CR11" class="c-article-references__text">Riggs, B. L. &amp; Melton, L. J. III Involutional osteoporosis.&nbsp;<i>The New England journal of medicine</i>&nbsp;<b>314</b>, 1676–1686,&nbsp;<a href="https://doi.org/10.1056/nejm198606263142605">https://doi.org/10.1056/nejm198606263142605</a>&nbsp;(1986).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADyaL283jtVOntw%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 11 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=3520321" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 11 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1056%2Fnejm198606263142605" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 11">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Involutional%20osteoporosis&amp;journal=The%20New%20England%20journal%20of%20medicine&amp;doi=10.1056%2Fnejm198606263142605&amp;volume=314&amp;pages=1676-1686&amp;publication_year=1986&amp;author=Riggs%2CBL&amp;author=Melton%2CLJ" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 11 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">12.</span></p>
<p id="ref-CR12" class="c-article-references__text">Turner, C. H. Biomechanics of bone: determinants of skeletal fragility and bone quality.&nbsp;<i>Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</i>&nbsp;<b>13</b>, 97–104,&nbsp;<a href="https://doi.org/10.1007/s001980200000">https://doi.org/10.1007/s001980200000</a>&nbsp;(2002).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADC%252BD387ntlaguw%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 12 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1007%2Fs001980200000" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 12">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Biomechanics%20of%20bone%3A%20determinants%20of%20skeletal%20fragility%20and%20bone%20quality&amp;journal=Osteoporosis%20international%3A%20a%20journal%20established%20as%20result%20of%20cooperation%20between%20the%20European%20Foundation%20for%20Osteoporosis%20and%20the%20National%20Osteoporosis%20Foundation%20of%20the%20USA&amp;doi=10.1007%2Fs001980200000&amp;volume=13&amp;pages=97-104&amp;publication_year=2002&amp;author=Turner%2CCH" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 12 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">13.</span></p>
<p id="ref-CR13" class="c-article-references__text">NIH. Osteoporosis,&nbsp;<a href="https://www.nia.nih.gov/health/osteoporosis">https://www.nia.nih.gov/health/osteoporosis</a>&nbsp;(2019).</p>
<p><span class="c-article-references__counter">14.</span></p>
<p id="ref-CR14" class="c-article-references__text">Ross, P. D., Genant, H. K., Davis, J. W., Miller, P. D. &amp; Wasnich, R. D. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women.&nbsp;<i>Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</i>&nbsp;<b>3</b>, 120–126 (1993).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADyaK3s3ksVGhuw%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 14 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1007%2FBF01623272" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 14">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Predicting%20vertebral%20fracture%20incidence%20from%20prevalent%20fractures%20and%20bone%20density%20among%20non-black%2C%20osteoporotic%20women&amp;journal=Osteoporosis%20international%3A%20a%20journal%20established%20as%20result%20of%20cooperation%20between%20the%20European%20Foundation%20for%20Osteoporosis%20and%20the%20National%20Osteoporosis%20Foundation%20of%20the%20USA&amp;volume=3&amp;pages=120-126&amp;publication_year=1993&amp;author=Ross%2CPD&amp;author=Genant%2CHK&amp;author=Davis%2CJW&amp;author=Miller%2CPD&amp;author=Wasnich%2CRD" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 14 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">15.</span></p>
<p id="ref-CR15" class="c-article-references__text">Bandeira, F. &amp; Carvalho, E. Fd Prevalência de osteoporose e fraturas vertebrais em mulheres na pós-menopausa atendidas em serviços de referência.&nbsp;<i>Revista Brasileira de Epidemiologia</i>&nbsp;<b>10</b>, 86–98 (2007).</p>
<p class="c-article-references__links u-hide-print"><a href="https://doi.org/10.1590%2FS1415-790X2007000100010" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 15">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Preval%C3%AAncia%20de%20osteoporose%20e%20fraturas%20vertebrais%20em%20mulheres%20na%20p%C3%B3s-menopausa%20atendidas%20em%20servi%C3%A7os%20de%20refer%C3%AAncia&amp;journal=Revista%20Brasileira%20de%20Epidemiologia&amp;volume=10&amp;pages=86-98&amp;publication_year=2007&amp;author=Bandeira%2CF&amp;author=Carvalho%2CEFd" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 15 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">16.</span></p>
<p id="ref-CR16" class="c-article-references__text">Malina, R. M., Bouchard, C. &amp; Bar-Or, O.&nbsp;<i>Growth, Maturation, and Physical Activity</i>. (Human Kinetics, 2004).</p>
<p><span class="c-article-references__counter">17.</span></p>
<p id="ref-CR17" class="c-article-references__text">Matsuo, K. Cross-talk among bone cells.&nbsp;<i>Current opinion in nephrology and hypertension</i>&nbsp;<b>18</b>, 292–297,&nbsp;<a href="https://doi.org/10.1097/MNH.0b013e32832b75f1">https://doi.org/10.1097/MNH.0b013e32832b75f1</a>&nbsp;(2009).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD1MXnsFyhsbY%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 17 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19395964" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 17 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1097%2FMNH.0b013e32832b75f1" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 17">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Cross-talk%20among%20bone%20cells&amp;journal=Current%20opinion%20in%20nephrology%20and%20hypertension&amp;doi=10.1097%2FMNH.0b013e32832b75f1&amp;volume=18&amp;pages=292-297&amp;publication_year=2009&amp;author=Matsuo%2CK" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 17 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">18.</span></p>
<p id="ref-CR18" class="c-article-references__text">Teitelbaum, S. L. Bone Resorption by Osteoclasts.&nbsp;<i>Science (New York, N.Y.)</i>&nbsp;<b>289</b>, 1504–1508,&nbsp;<a href="https://doi.org/10.1126/science.289.5484.1504">https://doi.org/10.1126/science.289.5484.1504</a>&nbsp;(2000).</p>
<p class="c-article-references__links u-hide-print"><a href="http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&amp;bibcode=2000Sci...289.1504T" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 18 on ADS">ADS</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD3cXmt1KgsLk%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 18 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1126%2Fscience.289.5484.1504" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 18">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Bone%20Resorption%20by%20Osteoclasts&amp;journal=Science%20%28New%20York%2C%20N.Y.%29&amp;doi=10.1126%2Fscience.289.5484.1504&amp;volume=289&amp;pages=1504-1508&amp;publication_year=2000&amp;author=Teitelbaum%2CSL" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 18 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">19.</span></p>
<p id="ref-CR19" class="c-article-references__text">Jee, W. S. &amp; Yao, W. Overview: animal models of osteopenia and osteoporosis.&nbsp;<i>J Musculoskelet Neuronal Interact</i>&nbsp;<b>1</b>, 193–207 (2001).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADC%252BD2M7islGgug%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 19 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15758493" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 19 on PubMed">PubMed</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Overview%3A%20animal%20models%20of%20osteopenia%20and%20osteoporosis&amp;journal=J%20Musculoskelet%20Neuronal%20Interact&amp;volume=1&amp;pages=193-207&amp;publication_year=2001&amp;author=Jee%2CWS&amp;author=Yao%2CW" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 19 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">20.</span></p>
<p id="ref-CR20" class="c-article-references__text">Shimano, A. C., Volpon, J. B. &amp; Lima, R. S.&nbsp;<i>Ação do Treinamento Físico Antes e Após a Instalação da Osteopenia de Ratas Ovariectomizadas</i>. (Faculdade de Medicina de Ribeirão Preto/USP., 2008).</p>
<p><span class="c-article-references__counter">21.</span></p>
<p id="ref-CR21" class="c-article-references__text">Shimano, R. C.&nbsp;<i>et al</i>. Biomechanical and microstructural benefits of physical exercise associated with risedronate in bones of ovariectomized rats.&nbsp;<i>Microsc Res Tech</i>&nbsp;<b>77</b>, 431–438,&nbsp;<a href="https://doi.org/10.1002/jemt.22363">https://doi.org/10.1002/jemt.22363</a>&nbsp;(2014).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC2cXosFahs7k%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 21 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24692117" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 21 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1002%2Fjemt.22363" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 21">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Biomechanical%20and%20microstructural%20benefits%20of%20physical%20exercise%20associated%20with%20risedronate%20in%20bones%20of%20ovariectomized%20rats&amp;journal=Microsc%20Res%20Tech&amp;doi=10.1002%2Fjemt.22363&amp;volume=77&amp;pages=431-438&amp;publication_year=2014&amp;author=Shimano%2CRC" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 21 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">22.</span></p>
<p id="ref-CR22" class="c-article-references__text">Issa, J. P. M.&nbsp;<i>et al</i>. The effect of simvastatin treatment on bone repair of femoral fracture in animal model.&nbsp;<i>Growth Factors</i>&nbsp;<b>33</b>, 139–148,&nbsp;<a href="https://doi.org/10.3109/08977194.2015.1011270">https://doi.org/10.3109/08977194.2015.1011270</a>&nbsp;(2015).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC2MXotlCgtL0%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 22 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25798995" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 22 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.3109%2F08977194.2015.1011270" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 22">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=The%20effect%20of%20simvastatin%20treatment%20on%20bone%20repair%20of%20femoral%20fracture%20in%20animal%20model&amp;journal=Growth%20Factors&amp;doi=10.3109%2F08977194.2015.1011270&amp;volume=33&amp;pages=139-148&amp;publication_year=2015&amp;author=Issa%2CJPM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 22 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">23.</span></p>
<p id="ref-CR23" class="c-article-references__text">Monteiro, L. O.&nbsp;<i>et al</i>. Effect of treatment with simvastatin on bone microarchitecture of the femoral head in an osteoporosis animal model.&nbsp;<i>Microscopy Research and Technique</i>&nbsp;<b>79</b>, 684–690,&nbsp;<a href="https://doi.org/10.1002/jemt.22682">https://doi.org/10.1002/jemt.22682</a>&nbsp;(2016).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC28XhtFOhurvP" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 23 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27186631" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 23 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1002%2Fjemt.22682" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 23">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20treatment%20with%20simvastatin%20on%20bone%20microarchitecture%20of%20the%20femoral%20head%20in%20an%20osteoporosis%20animal%20model&amp;journal=Microscopy%20Research%20and%20Technique&amp;doi=10.1002%2Fjemt.22682&amp;volume=79&amp;pages=684-690&amp;publication_year=2016&amp;author=Monteiro%2CLO" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 23 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">24.</span></p>
<p id="ref-CR24" class="c-article-references__text">Macedo, A. P.&nbsp;<i>et al</i>. Influence of treadmill training on bone structure under osteometabolic alteration in rats subjected to high-fat diet.&nbsp;<i>Scandinavian Journal of Medicine &amp; Science in Sports</i>&nbsp;<b>27</b>, 167–176,&nbsp;<a href="https://doi.org/10.1111/sms.12650">https://doi.org/10.1111/sms.12650</a>&nbsp;(2017).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADC%252BC28jlt1WjtQ%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 24 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1111%2Fsms.12650" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 24">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Influence%20of%20treadmill%20training%20on%20bone%20structure%20under%20osteometabolic%20alteration%20in%20rats%20subjected%20to%20high-fat%20diet&amp;journal=Scandinavian%20Journal%20of%20Medicine%20%26%20Science%20in%20Sports&amp;doi=10.1111%2Fsms.12650&amp;volume=27&amp;pages=167-176&amp;publication_year=2017&amp;author=Macedo%2CAP" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 24 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">25.</span></p>
<p id="ref-CR25" class="c-article-references__text">Wang, Y., Monteiro, C. &amp; Popkin, B. M. Trends of obesity and underweight in older children and adolescents in the United States, Brazil, China, and Russia.&nbsp;<i>The American journal of clinical nutrition</i>&nbsp;<b>75</b>, 971–977 (2002).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD38XktlSmsbw%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 25 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12036801" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 25 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1093%2Fajcn%2F75.6.971" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 25">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Trends%20of%20obesity%20and%20underweight%20in%20older%20children%20and%20adolescents%20in%20the%20United%20States%2C%20Brazil%2C%20China%2C%20and%20Russia&amp;journal=The%20American%20journal%20of%20clinical%20nutrition&amp;volume=75&amp;pages=971-977&amp;publication_year=2002&amp;author=Wang%2CY&amp;author=Monteiro%2CC&amp;author=Popkin%2CBM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 25 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">26.</span></p>
<p id="ref-CR26" class="c-article-references__text">Duncan, S.&nbsp;<i>et al</i>. Modifiable risk factors for overweight and obesity in children and adolescents from Sao Paulo, Brazil.&nbsp;<i>BMC Public Health</i>&nbsp;<b>11</b>, 585 (2011).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21781313" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 26 on PubMed">PubMed</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154175" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 26 on PubMed Central">PubMed Central</a>&nbsp;<a href="https://doi.org/10.1186%2F1471-2458-11-585" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 26">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Modifiable%20risk%20factors%20for%20overweight%20and%20obesity%20in%20children%20and%20adolescents%20from%20Sao%20Paulo%2C%20Brazil&amp;journal=BMC%20Public%20Health&amp;volume=11&amp;publication_year=2011&amp;author=Duncan%2CS" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 26 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">27.</span></p>
<p id="ref-CR27" class="c-article-references__text">Fernandes, R. A.&nbsp;<i>et al</i>. Prevalence of dyslipidemia in individuals physically active during childhood, adolescence and adult age.&nbsp;<i>Arq Bras Cardiol</i>&nbsp;<b>97</b>, 317–323 (2011).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21830000" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 27 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1590%2FS0066-782X2011005000083" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 27">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Prevalence%20of%20dyslipidemia%20in%20individuals%20physically%20active%20during%20childhood%2C%20adolescence%20and%20adult%20age&amp;journal=Arq%20Bras%20Cardiol&amp;volume=97&amp;pages=317-323&amp;publication_year=2011&amp;author=Fernandes%2CRA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 27 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">28.</span></p>
<p id="ref-CR28" class="c-article-references__text">Bass, S.&nbsp;<i>et al</i>. Exercise before puberty may confer residual benefits in bone density in adulthood: studies in active prepubertal and retired female gymnasts.&nbsp;<i>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research</i>&nbsp;<b>13</b>, 500–507,&nbsp;<a href="https://doi.org/10.1359/jbmr.1998.13.3.500">https://doi.org/10.1359/jbmr.1998.13.3.500</a>&nbsp;(1998).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADyaK1c7osValsQ%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 28 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1359%2Fjbmr.1998.13.3.500" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 28">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Exercise%20before%20puberty%20may%20confer%20residual%20benefits%20in%20bone%20density%20in%20adulthood%3A%20studies%20in%20active%20prepubertal%20and%20retired%20female%20gymnasts&amp;journal=Journal%20of%20bone%20and%20mineral%20research%3A%20the%20official%20journal%20of%20the%20American%20Society%20for%20Bone%20and%20Mineral%20Research&amp;doi=10.1359%2Fjbmr.1998.13.3.500&amp;volume=13&amp;pages=500-507&amp;publication_year=1998&amp;author=Bass%2CS" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 28 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">29.</span></p>
<p id="ref-CR29" class="c-article-references__text">Morris, F. L., Naughton, G. A., Gibbs, J. L., Carlson, J. S. &amp; Wark, J. D. Prospective ten-month exercise intervention in premenarcheal girls: positive effects on bone and lean mass.&nbsp;<i>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research</i>&nbsp;<b>12</b>, 1453–1462,&nbsp;<a href="https://doi.org/10.1359/jbmr.1997.12.9.1453">https://doi.org/10.1359/jbmr.1997.12.9.1453</a>&nbsp;(1997).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADyaK2svjt1yrsA%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 29 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1359%2Fjbmr.1997.12.9.1453" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 29">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Prospective%20ten-month%20exercise%20intervention%20in%20premenarcheal%20girls%3A%20positive%20effects%20on%20bone%20and%20lean%20mass&amp;journal=Journal%20of%20bone%20and%20mineral%20research%3A%20the%20official%20journal%20of%20the%20American%20Society%20for%20Bone%20and%20Mineral%20Research&amp;doi=10.1359%2Fjbmr.1997.12.9.1453&amp;volume=12&amp;pages=1453-1462&amp;publication_year=1997&amp;author=Morris%2CFL&amp;author=Naughton%2CGA&amp;author=Gibbs%2CJL&amp;author=Carlson%2CJS&amp;author=Wark%2CJD" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 29 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">30.</span></p>
<p id="ref-CR30" class="c-article-references__text">Kontulainen, S.&nbsp;<i>et al</i>. Good maintenance of exercise-induced bone gain with decreased training of female tennis and squash players: a prospective 5-year follow-up study of young and old starters and controls.&nbsp;<i>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research</i>&nbsp;<b>16</b>, 195–201,&nbsp;<a href="https://doi.org/10.1359/jbmr.2001.16.2.195">https://doi.org/10.1359/jbmr.2001.16.2.195</a>&nbsp;(2001).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADC%252BD3M3ht1WnsA%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 30 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1359%2Fjbmr.2001.16.2.195" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 30">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Good%20maintenance%20of%20exercise-induced%20bone%20gain%20with%20decreased%20training%20of%20female%20tennis%20and%20squash%20players%3A%20a%20prospective%205-year%20follow-up%20study%20of%20young%20and%20old%20starters%20and%20controls&amp;journal=Journal%20of%20bone%20and%20mineral%20research%3A%20the%20official%20journal%20of%20the%20American%20Society%20for%20Bone%20and%20Mineral%20Research&amp;doi=10.1359%2Fjbmr.2001.16.2.195&amp;volume=16&amp;pages=195-201&amp;publication_year=2001&amp;author=Kontulainen%2CS" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 30 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">31.</span></p>
<p id="ref-CR31" class="c-article-references__text">MacKelvie, K. J., Khan, K. M., Petit, M. A., Janssen, P. A. &amp; McKay, H. A. A school-based exercise intervention elicits substantial bone health benefits: a 2-year randomized controlled trial in girls.&nbsp;<i>Pediatrics</i>&nbsp;<b>112</b>, e447 (2003).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14654643" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 31 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1542%2Fpeds.112.6.e447" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 31">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=A%20school-based%20exercise%20intervention%20elicits%20substantial%20bone%20health%20benefits%3A%20a%202-year%20randomized%20controlled%20trial%20in%20girls&amp;journal=Pediatrics&amp;volume=112&amp;publication_year=2003&amp;author=MacKelvie%2CKJ&amp;author=Khan%2CKM&amp;author=Petit%2CMA&amp;author=Janssen%2CPA&amp;author=McKay%2CHA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 31 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">32.</span></p>
<p id="ref-CR32" class="c-article-references__text">Karlsson, M. K.&nbsp;<i>et al</i>. Exercise during growth and bone mineral density and fractures in old age.&nbsp;<i>Lancet (London, England)</i>&nbsp;<b>355</b>, 469–470 (2000).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADC%252BD3c3pslyhuw%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 32 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1016%2FS0140-6736%2800%2982020-6" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 32">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Exercise%20during%20growth%20and%20bone%20mineral%20density%20and%20fractures%20in%20old%20age&amp;journal=Lancet%20%28London%2C%20England%29&amp;volume=355&amp;pages=469-470&amp;publication_year=2000&amp;author=Karlsson%2CMK" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 32 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">33.</span></p>
<p id="ref-CR33" class="c-article-references__text">Specker, B. L. Evidence for an interaction between calcium intake and physical activity on changes in bone mineral density.&nbsp;<i>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research</i>&nbsp;<b>11</b>, 1539–1544,&nbsp;<a href="https://doi.org/10.1002/jbmr.5650111022">https://doi.org/10.1002/jbmr.5650111022</a>&nbsp;(1996).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADyaK28XmsValtbs%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 33 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1002%2Fjbmr.5650111022" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 33">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Evidence%20for%20an%20interaction%20between%20calcium%20intake%20and%20physical%20activity%20on%20changes%20in%20bone%20mineral%20density&amp;journal=Journal%20of%20bone%20and%20mineral%20research%3A%20the%20official%20journal%20of%20the%20American%20Society%20for%20Bone%20and%20Mineral%20Research&amp;doi=10.1002%2Fjbmr.5650111022&amp;volume=11&amp;pages=1539-1544&amp;publication_year=1996&amp;author=Specker%2CBL" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 33 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">34.</span></p>
<p id="ref-CR34" class="c-article-references__text">Wronski, T. J., Cintron, M. &amp; Dann, L. M. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats.&nbsp;<i>Calcif Tissue Int</i>&nbsp;<b>43</b>, 179–183 (1988).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADyaL1M%252FislyjtQ%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 34 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=3141020" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 34 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1007%2FBF02571317" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 34">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Temporal%20relationship%20between%20bone%20loss%20and%20increased%20bone%20turnover%20in%20ovariectomized%20rats&amp;journal=Calcif%20Tissue%20Int&amp;volume=43&amp;pages=179-183&amp;publication_year=1988&amp;author=Wronski%2CTJ&amp;author=Cintron%2CM&amp;author=Dann%2CLM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 34 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">35.</span></p>
<p id="ref-CR35" class="c-article-references__text">Wronski, T. J., Dann, L. M., Scott, K. S. &amp; Cintron, M. Long-term effects of ovariectomy and aging on the rat skeleton.&nbsp;<i>Calcif Tissue Int</i>&nbsp;<b>45</b>, 360–366 (1989).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADyaK3c%252FivFKkug%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 35 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2509027" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 35 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1007%2FBF02556007" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 35">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Long-term%20effects%20of%20ovariectomy%20and%20aging%20on%20the%20rat%20skeleton&amp;journal=Calcif%20Tissue%20Int&amp;volume=45&amp;pages=360-366&amp;publication_year=1989&amp;author=Wronski%2CTJ&amp;author=Dann%2CLM&amp;author=Scott%2CKS&amp;author=Cintron%2CM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 35 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">36.</span></p>
<p id="ref-CR36" class="c-article-references__text">Tschop, M. &amp; Heiman, M. L. Rodent obesity models: an overview.&nbsp;<i>Exp Clin Endocrinol Diabetes</i>&nbsp;<b>109</b>, 307–319,&nbsp;<a href="https://doi.org/10.1055/s-2001-17297">https://doi.org/10.1055/s-2001-17297</a>&nbsp;(2001).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD3MXnsVersrw%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 36 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11571668" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 36 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1055%2Fs-2001-17297" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 36">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Rodent%20obesity%20models%3A%20an%20overview&amp;journal=Exp%20Clin%20Endocrinol%20Diabetes&amp;doi=10.1055%2Fs-2001-17297&amp;volume=109&amp;pages=307-319&amp;publication_year=2001&amp;author=Tschop%2CM&amp;author=Heiman%2CML" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 36 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">37.</span></p>
<p id="ref-CR37" class="c-article-references__text">Oliveira Milani, J. G. P., Matheus, J. P. C., Gomide, L. B., Volpon, J. B. &amp; Shimano, A. C. Biomechanical Effects of Immobilization and Rehabilitation on the Skeletal Muscle of Trained and Sedentary Rats.&nbsp;<i>Annals of Biomedical Engineering</i>&nbsp;<b>36</b>, 1641–1648,&nbsp;<a href="https://doi.org/10.1007/s10439-008-9542-8">https://doi.org/10.1007/s10439-008-9542-8</a>&nbsp;(2008).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18683054" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 37 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1007%2Fs10439-008-9542-8" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 37">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Biomechanical%20Effects%20of%20Immobilization%20and%20Rehabilitation%20on%20the%20Skeletal%20Muscle%20of%20Trained%20and%20Sedentary%20Rats&amp;journal=Annals%20of%20Biomedical%20Engineering&amp;doi=10.1007%2Fs10439-008-9542-8&amp;volume=36&amp;pages=1641-1648&amp;publication_year=2008&amp;author=Oliveira%20Milani%2CJGP&amp;author=Matheus%2CJPC&amp;author=Gomide%2CLB&amp;author=Volpon%2CJB&amp;author=Shimano%2CAC" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 37 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">38.</span></p>
<p id="ref-CR38" class="c-article-references__text">Castro, M. M.&nbsp;<i>et al</i>. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability.&nbsp;<i>Nitric Oxide</i>&nbsp;<b>26</b>, 162–168,&nbsp;<a href="https://doi.org/10.1016/j.niox.2012.01.009">https://doi.org/10.1016/j.niox.2012.01.009</a>&nbsp;(2012).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC38XisFOqtL8%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 38 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22327038" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 38 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.niox.2012.01.009" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 38">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Doxycycline%20ameliorates%202K-1C%20hypertension-induced%20vascular%20dysfunction%20in%20rats%20by%20attenuating%20oxidative%20stress%20and%20improving%20nitric%20oxide%20bioavailability&amp;journal=Nitric%20Oxide&amp;doi=10.1016%2Fj.niox.2012.01.009&amp;volume=26&amp;pages=162-168&amp;publication_year=2012&amp;author=Castro%2CMM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 38 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">39.</span></p>
<p id="ref-CR39" class="c-article-references__text">Briest, W.&nbsp;<i>et al</i>. Significance of matrix metalloproteinases in norepinephrine-induced remodelling of rat hearts.&nbsp;<i>Cardiovasc Res</i>&nbsp;<b>57</b>, 379–387 (2003).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD3sXptFCgtA%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 39 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12566110" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 39 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2FS0008-6363%2802%2900700-9" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 39">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Significance%20of%20matrix%20metalloproteinases%20in%20norepinephrine-induced%20remodelling%20of%20rat%20hearts&amp;journal=Cardiovasc%20Res&amp;volume=57&amp;pages=379-387&amp;publication_year=2003&amp;author=Briest%2CW" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 39 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">40.</span></p>
<p id="ref-CR40" class="c-article-references__text">Guimaraes, D. A.&nbsp;<i>et al</i>. Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension.&nbsp;<i>Basic Clin Pharmacol Toxicol</i>&nbsp;<b>108</b>, 318–325,&nbsp;<a href="https://doi.org/10.1111/j.1742-7843.2010.00656.x">https://doi.org/10.1111/j.1742-7843.2010.00656.x</a>&nbsp;(2011).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC3MXls1OrsL0%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 40 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21176109" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 40 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1111%2Fj.1742-7843.2010.00656.x" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 40">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Doxycycline%20dose-dependently%20inhibits%20MMP-2-mediated%20vascular%20changes%20in%202K1C%20hypertension&amp;journal=Basic%20Clin%20Pharmacol%20Toxicol&amp;doi=10.1111%2Fj.1742-7843.2010.00656.x&amp;volume=108&amp;pages=318-325&amp;publication_year=2011&amp;author=Guimaraes%2CDA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 40 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">41.</span></p>
<p id="ref-CR41" class="c-article-references__text">Tharappel, J. C.&nbsp;<i>et al</i>. Doxycycline shows dose-dependent changes in hernia repair strength after mesh repair.&nbsp;<i>Surg Endosc</i>&nbsp;<b>30</b>, 2016–2021,&nbsp;<a href="https://doi.org/10.1007/s00464-015-4434-0">https://doi.org/10.1007/s00464-015-4434-0</a>&nbsp;(2016).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26264696" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 41 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1007%2Fs00464-015-4434-0" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 41">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Doxycycline%20shows%20dose-dependent%20changes%20in%20hernia%20repair%20strength%20after%20mesh%20repair&amp;journal=Surg%20Endosc&amp;doi=10.1007%2Fs00464-015-4434-0&amp;volume=30&amp;pages=2016-2021&amp;publication_year=2016&amp;author=Tharappel%2CJC" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 41 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">42.</span></p>
<p id="ref-CR42" class="c-article-references__text">Amaral, J. H.&nbsp;<i>et al</i>. The Relationship between Blood and Serum Lead Levels in Peripartum Women and their Respective Umbilical Cords.&nbsp;<i>Basic &amp; Clinical Pharmacology &amp; Toxicology</i>&nbsp;<b>107</b>, 971–975,&nbsp;<a href="https://doi.org/10.1111/j.1742-7843.2010.00616.x">https://doi.org/10.1111/j.1742-7843.2010.00616.x</a>&nbsp;(2010).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC3cXhsFWhsrzN" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 42 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1111%2Fj.1742-7843.2010.00616.x" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 42">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=The%20Relationship%20between%20Blood%20and%20Serum%20Lead%20Levels%20in%20Peripartum%20Women%20and%20their%20Respective%20Umbilical%20Cords&amp;journal=Basic%20%26%20Clinical%20Pharmacology%20%26%20Toxicology&amp;doi=10.1111%2Fj.1742-7843.2010.00616.x&amp;volume=107&amp;pages=971-975&amp;publication_year=2010&amp;author=Amaral%2CJH" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 42 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">43.</span></p>
<p id="ref-CR43" class="c-article-references__text">Rezende, V. B., Amaral, J. H., Gerlach, R. F., Barbosa, F. Jr. &amp; Tanus-Santos, J. E. Should we measure serum or plasma lead concentrations?&nbsp;<i>J Trace Elem Med Biol</i>&nbsp;<b>24</b>, 147–151,&nbsp;<a href="https://doi.org/10.1016/j.jtemb.2010.01.008">https://doi.org/10.1016/j.jtemb.2010.01.008</a>&nbsp;(2010).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC3cXpsVGgt74%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 43 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20569924" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 43 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.jtemb.2010.01.008" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 43">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Should%20we%20measure%20serum%20or%20plasma%20lead%20concentrations%3F&amp;journal=J%20Trace%20Elem%20Med%20Biol&amp;doi=10.1016%2Fj.jtemb.2010.01.008&amp;volume=24&amp;pages=147-151&amp;publication_year=2010&amp;author=Rezende%2CVB&amp;author=Amaral%2CJH&amp;author=Gerlach%2CRF&amp;author=Barbosa%2CF&amp;author=Tanus-Santos%2CJE" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 43 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">44.</span></p>
<p id="ref-CR44" class="c-article-references__text">de Figueiredo, F. A.&nbsp;<i>et al</i>. Reduced bone and body mass in young male rats exposed to lead.&nbsp;<i>Biomed Res Int</i>&nbsp;<b>2014</b>, 571065,&nbsp;<a href="https://doi.org/10.1155/2014/571065">https://doi.org/10.1155/2014/571065</a>&nbsp;(2014).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24800241" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 44 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1155%2F2014%2F571065" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 44">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Reduced%20bone%20and%20body%20mass%20in%20young%20male%20rats%20exposed%20to%20lead&amp;journal=Biomed%20Res%20Int&amp;doi=10.1155%2F2014%2F571065&amp;volume=2014&amp;publication_year=2014&amp;author=Figueiredo%2CFA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 44 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">45.</span></p>
<p id="ref-CR45" class="c-article-references__text">Behets, G. J., Verberckmoes, S. C., D’Haese, P. C. &amp; De Broe, M. E. Lanthanum carbonate: a new phosphate binder.&nbsp;<i>Current opinion in nephrology and hypertension</i>&nbsp;<b>13</b>, 403–409 (2004).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD2cXmsVKqtr4%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 45 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15199290" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 45 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1097%2F01.mnh.0000133973.86816.e9" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 45">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Lanthanum%20carbonate%3A%20a%20new%20phosphate%20binder&amp;journal=Current%20opinion%20in%20nephrology%20and%20hypertension&amp;volume=13&amp;pages=403-409&amp;publication_year=2004&amp;author=Behets%2CGJ&amp;author=Verberckmoes%2CSC&amp;author=D%E2%80%99Haese%2CPC&amp;author=Broe%2CME" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 45 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">46.</span></p>
<p id="ref-CR46" class="c-article-references__text">Sprague, S. M. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.&nbsp;<i>Current medical research and opinion</i>&nbsp;<b>23</b>, 3167–3175,&nbsp;<a href="https://doi.org/10.1185/030079907x242719">https://doi.org/10.1185/030079907×242719</a>&nbsp;(2007).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD1cXhslOktrk%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 46 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17991307" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 46 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1185%2F030079907x242719" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 46">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=A%20comparative%20review%20of%20the%20efficacy%20and%20safety%20of%20established%20phosphate%20binders%3A%20calcium%2C%20sevelamer%2C%20and%20lanthanum%20carbonate&amp;journal=Current%20medical%20research%20and%20opinion&amp;doi=10.1185%2F030079907x242719&amp;volume=23&amp;pages=3167-3175&amp;publication_year=2007&amp;author=Sprague%2CSM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 46 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">47.</span></p>
<p id="ref-CR47" class="c-article-references__text">Chan, S.&nbsp;<i>et al</i>. Phosphate binders in patients with chronic kidney disease.&nbsp;<i>Australian prescriber</i>&nbsp;<b>40</b>, 10–14,&nbsp;<a href="https://doi.org/10.18773/austprescr.2017.002">https://doi.org/10.18773/austprescr.2017.002</a>&nbsp;(2017).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28246429" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 47 on PubMed">PubMed</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313253" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 47 on PubMed Central">PubMed Central</a>&nbsp;<a href="https://doi.org/10.18773%2Faustprescr.2017.002" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 47">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Phosphate%20binders%20in%20patients%20with%20chronic%20kidney%20disease&amp;journal=Australian%20prescriber&amp;doi=10.18773%2Faustprescr.2017.002&amp;volume=40&amp;pages=10-14&amp;publication_year=2017&amp;author=Chan%2CS" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 47 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">48.</span></p>
<p id="ref-CR48" class="c-article-references__text">Trudeau, D. L. &amp; Freier, E. F. Determination of calcium in urine and serum by atomic absorption spectrophotometry (AAS).&nbsp;<i>Clinical chemistry</i>&nbsp;<b>13</b>, 101–114 (1967).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADyaF2sXntlWnsg%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 48 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=4959769" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 48 on PubMed">PubMed</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Determination%20of%20calcium%20in%20urine%20and%20serum%20by%20atomic%20absorption%20spectrophotometry%20%28AAS%29&amp;journal=Clinical%20chemistry&amp;volume=13&amp;pages=101-114&amp;publication_year=1967&amp;author=Trudeau%2CDL&amp;author=Freier%2CEF" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 48 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">49.</span></p>
<p id="ref-CR49" class="c-article-references__text">Shimano, R. C.&nbsp;<i>et al</i>. Effects of high-impact exercise on the physical properties of bones of ovariectomized rats fed to a high-protein diet.&nbsp;<i>Scandinavian Journal of Medicine &amp; Science in Sports</i>&nbsp;<b>28</b>, 1523–1531,&nbsp;<a href="https://doi.org/10.1111/sms.13058">https://doi.org/10.1111/sms.13058</a>&nbsp;(2018).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADC%252BC1MvhvFSqtg%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 49 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1111%2Fsms.13058" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 49">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Effects%20of%20high-impact%20exercise%20on%20the%20physical%20properties%20of%20bones%20of%20ovariectomized%20rats%20fed%20to%20a%20high-protein%20diet&amp;journal=Scandinavian%20Journal%20of%20Medicine%20%26%20Science%20in%20Sports&amp;doi=10.1111%2Fsms.13058&amp;volume=28&amp;pages=1523-1531&amp;publication_year=2018&amp;author=Shimano%2CRC" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 49 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">50.</span></p>
<p id="ref-CR50" class="c-article-references__text">Yanagihara, G. R.&nbsp;<i>et al</i>. Influence of high-fat diet on bone tissue: An experimental study in growing rats.&nbsp;<i>The journal of nutrition, health &amp; aging</i>&nbsp;<b>21</b>, 1337–1343,&nbsp;<a href="https://doi.org/10.1007/s12603-017-0871-x">https://doi.org/10.1007/s12603-017-0871-x</a>&nbsp;(2017).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC2sXht12ksLc%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 50 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1007%2Fs12603-017-0871-x" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 50">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Influence%20of%20high-fat%20diet%20on%20bone%20tissue%3A%20An%20experimental%20study%20in%20growing%20rats&amp;journal=The%20journal%20of%20nutrition%2C%20health%20%26%20aging&amp;doi=10.1007%2Fs12603-017-0871-x&amp;volume=21&amp;pages=1337-1343&amp;publication_year=2017&amp;author=Yanagihara%2CGR" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 50 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">51.</span></p>
<p id="ref-CR51" class="c-article-references__text">Sawan, R. M.&nbsp;<i>et al</i>. Fluoride increases lead concentrations in whole blood and in calcified tissues from lead-exposed rats.&nbsp;<i>Toxicology</i>&nbsp;<b>271</b>, 21–26,&nbsp;<a href="https://doi.org/10.1016/j.tox.2010.02.002">https://doi.org/10.1016/j.tox.2010.02.002</a>&nbsp;(2010).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC3cXks1WjtL0%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 51 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20188782" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 51 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.tox.2010.02.002" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 51">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Fluoride%20increases%20lead%20concentrations%20in%20whole%20blood%20and%20in%20calcified%20tissues%20from%20lead-exposed%20rats&amp;journal=Toxicology&amp;doi=10.1016%2Fj.tox.2010.02.002&amp;volume=271&amp;pages=21-26&amp;publication_year=2010&amp;author=Sawan%2CRM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 51 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">52.</span></p>
<p id="ref-CR52" class="c-article-references__text">Faria, P. E.&nbsp;<i>et al</i>. Immunohistochemical, tomographic and histological study on onlay iliac grafts remodeling.&nbsp;<i>Clinical oral implants research</i>&nbsp;<b>19</b>, 393–401,&nbsp;<a href="https://doi.org/10.1111/j.1600-0501.2007.01485.x">https://doi.org/10.1111/j.1600-0501.2007.01485.x</a>&nbsp;(2008).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18324960" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 52 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1111%2Fj.1600-0501.2007.01485.x" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 52">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Immunohistochemical%2C%20tomographic%20and%20histological%20study%20on%20onlay%20iliac%20grafts%20remodeling&amp;journal=Clinical%20oral%20implants%20research&amp;doi=10.1111%2Fj.1600-0501.2007.01485.x&amp;volume=19&amp;pages=393-401&amp;publication_year=2008&amp;author=Faria%2CPE" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 52 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">53.</span></p>
<p id="ref-CR53" class="c-article-references__text">Dempster, D. W.&nbsp;<i>et al</i>. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee.&nbsp;<i>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research</i>&nbsp;<b>28</b>, 2–17,&nbsp;<a href="https://doi.org/10.1002/jbmr.1805">https://doi.org/10.1002/jbmr.1805</a>&nbsp;(2013).</p>
<p class="c-article-references__links u-hide-print"><a href="https://doi.org/10.1002%2Fjbmr.1805" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 53">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Standardized%20nomenclature%2C%20symbols%2C%20and%20units%20for%20bone%20histomorphometry%3A%20a%202012%20update%20of%20the%20report%20of%20the%20ASBMR%20Histomorphometry%20Nomenclature%20Committee&amp;journal=Journal%20of%20bone%20and%20mineral%20research%3A%20the%20official%20journal%20of%20the%20American%20Society%20for%20Bone%20and%20Mineral%20Research&amp;doi=10.1002%2Fjbmr.1805&amp;volume=28&amp;pages=2-17&amp;publication_year=2013&amp;author=Dempster%2CDW" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 53 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">54.</span></p>
<p id="ref-CR54" class="c-article-references__text">Freitas, S. H. D.&nbsp;<i>et al</i>. Tomographic imaging of fragmented cortical bone heteroimplant and methylmethacrylate in segmental bone defect of rabbit tibia.&nbsp;<i>Acta Cirurgica Brasileira</i>&nbsp;<b>29</b>, 794–800 (2014).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25517492" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 54 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1590%2FS0102-86502014001900005" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 54">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Tomographic%20imaging%20of%20fragmented%20cortical%20bone%20heteroimplant%20and%20methylmethacrylate%20in%20segmental%20bone%20defect%20of%20rabbit%20tibia&amp;journal=Acta%20Cirurgica%20Brasileira&amp;volume=29&amp;pages=794-800&amp;publication_year=2014&amp;author=Freitas%2CSHD" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 54 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">55.</span></p>
<p id="ref-CR55" class="c-article-references__text">Pereira, B. F.&nbsp;<i>et al</i>. Effects of biodegradable detergents in morphological parameters of liver in two neotropical fish species (Prochilodus lineatus and Astyanax altiparanae). Microscopy.&nbsp;<i>Research</i>&nbsp;<b>2</b>, 39 (2014).</p>
<p class="c-article-references__links u-hide-print"><a href="https://scholar.google.com/scholar_lookup?&amp;title=Effects%20of%20biodegradable%20detergents%20in%20morphological%20parameters%20of%20liver%20in%20two%20neotropical%20fish%20species%20%28Prochilodus%20lineatus%20and%20Astyanax%20altiparanae%29.%20Microscopy&amp;journal=Research&amp;volume=2&amp;publication_year=2014&amp;author=Pereira%2CBF" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 55 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">56.</span></p>
<p id="ref-CR56" class="c-article-references__text">Habermann, B., Eberhardt, C., Feld, M., Zichner, L. &amp; Kurth, A. A. Tartrate-resistant acid phosphatase 5b (TRAP 5b) as a marker of osteoclast activity in the early phase after cementless total hip replacement.&nbsp;<i>Acta Orthop</i>&nbsp;<b>78</b>, 221–225,&nbsp;<a href="https://doi.org/10.1080/17453670710013717">https://doi.org/10.1080/17453670710013717</a>&nbsp;(2007).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17464610" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 56 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1080%2F17453670710013717" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 56">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Tartrate-resistant%20acid%20phosphatase%205b%20%28TRAP%205b%29%20as%20a%20marker%20of%20osteoclast%20activity%20in%20the%20early%20phase%20after%20cementless%20total%20hip%20replacement&amp;journal=Acta%20Orthop&amp;doi=10.1080%2F17453670710013717&amp;volume=78&amp;pages=221-225&amp;publication_year=2007&amp;author=Habermann%2CB&amp;author=Eberhardt%2CC&amp;author=Feld%2CM&amp;author=Zichner%2CL&amp;author=Kurth%2CAA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 56 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">57.</span></p>
<p id="ref-CR57" class="c-article-references__text">Golub, L. M.&nbsp;<i>et al</i>. Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease.&nbsp;<i>Journal of periodontal research</i>&nbsp;<b>19</b>, 651–655 (1984).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADyaL2MXhtVKhu70%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 57 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=6098638" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 57 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1111%2Fj.1600-0765.1984.tb01334.x" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 57">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Tetracyclines%20inhibit%20tissue%20collagenase%20activity.%20A%20new%20mechanism%20in%20the%20treatment%20of%20periodontal%20disease&amp;journal=Journal%20of%20periodontal%20research&amp;volume=19&amp;pages=651-655&amp;publication_year=1984&amp;author=Golub%2CLM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 57 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">58.</span></p>
<p id="ref-CR58" class="c-article-references__text">Belo, V. A.&nbsp;<i>et al</i>. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.&nbsp;<i>Clinical biochemistry</i>&nbsp;<b>42</b>, 984–990,&nbsp;<a href="https://doi.org/10.1016/j.clinbiochem.2009.03.025">https://doi.org/10.1016/j.clinbiochem.2009.03.025</a>&nbsp;(2009).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD1MXnt1emt7k%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 58 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19358835" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 58 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.clinbiochem.2009.03.025" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 58">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Assessment%20of%20matrix%20metalloproteinase%20%28MMP%29-2%2C%20MMP-8%2C%20MMP-9%2C%20and%20their%20inhibitors%2C%20the%20tissue%20inhibitors%20of%20metalloproteinase%20%28TIMP%29-1%20and%20TIMP-2%20in%20obese%20children%20and%20adolescents&amp;journal=Clinical%20biochemistry&amp;doi=10.1016%2Fj.clinbiochem.2009.03.025&amp;volume=42&amp;pages=984-990&amp;publication_year=2009&amp;author=Belo%2CVA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 58 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">59.</span></p>
<p id="ref-CR59" class="c-article-references__text">Castro, M. M., Tanus-Santos, J. E. &amp; Gerlach, R. F. Matrix metalloproteinases: Targets for doxycycline to prevent the vascular alterations of hypertension.&nbsp;<i>Pharmacological research</i>&nbsp;<b>64</b>, 567–572,&nbsp;<a href="https://doi.org/10.1016/j.phrs.2011.04.002">https://doi.org/10.1016/j.phrs.2011.04.002</a>&nbsp;(2011).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC3MXhtlChs73I" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 59 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21514386" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 59 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.phrs.2011.04.002" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 59">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Matrix%20metalloproteinases%3A%20Targets%20for%20doxycycline%20to%20prevent%20the%20vascular%20alterations%20of%20hypertension&amp;journal=Pharmacological%20research&amp;doi=10.1016%2Fj.phrs.2011.04.002&amp;volume=64&amp;pages=567-572&amp;publication_year=2011&amp;author=Castro%2CMM&amp;author=Tanus-Santos%2CJE&amp;author=Gerlach%2CRF" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 59 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">60.</span></p>
<p id="ref-CR60" class="c-article-references__text">Zhang, C., Tang, T. T., Ren, W. P., Zhang, X. L. &amp; Dai, K. R. Inhibiting wear particles-induced osteolysis with doxycycline.&nbsp;<i>Acta Pharmacol Sin</i>&nbsp;<b>28</b>, 1603–1610,&nbsp;<a href="https://doi.org/10.1111/j.1745-7254.2007.00638.x">https://doi.org/10.1111/j.1745-7254.2007.00638.x</a>&nbsp;(2007).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD2sXhtFKjtr3J" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 60 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17883947" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 60 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1111%2Fj.1745-7254.2007.00638.x" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 60">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Inhibiting%20wear%20particles-induced%20osteolysis%20with%20doxycycline&amp;journal=Acta%20Pharmacol%20Sin&amp;doi=10.1111%2Fj.1745-7254.2007.00638.x&amp;volume=28&amp;pages=1603-1610&amp;publication_year=2007&amp;author=Zhang%2CC&amp;author=Tang%2CTT&amp;author=Ren%2CWP&amp;author=Zhang%2CXL&amp;author=Dai%2CKR" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 60 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">61.</span></p>
<p id="ref-CR61" class="c-article-references__text">Zhou, X., Zhang, P., Zhang, C., An, B. &amp; Zhu, Z. A. Tetracyclines Inhibit Rat Osteoclast Formation and Activity&nbsp;<i>In Vitro</i>&nbsp;and Affect Bone Turnover in Young Rats&nbsp;<i>In Vivo</i>.&nbsp;<i>Calcified Tissue International</i>&nbsp;<b>86</b>, 163–171,&nbsp;<a href="https://doi.org/10.1007/s00223-009-9328-5">https://doi.org/10.1007/s00223-009-9328-5</a>&nbsp;(2010).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC3cXovVamtA%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 61 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20033141" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 61 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1007%2Fs00223-009-9328-5" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 61">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Tetracyclines%20Inhibit%20Rat%20Osteoclast%20Formation%20and%20Activity%20In%20Vitro%20and%20Affect%20Bone%20Turnover%20in%20Young%20Rats%20In%20Vivo&amp;journal=Calcified%20Tissue%20International&amp;doi=10.1007%2Fs00223-009-9328-5&amp;volume=86&amp;pages=163-171&amp;publication_year=2010&amp;author=Zhou%2CX&amp;author=Zhang%2CP&amp;author=Zhang%2CC&amp;author=An%2CB&amp;author=Zhu%2CZA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 61 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">62.</span></p>
<p id="ref-CR62" class="c-article-references__text">Babu, E.&nbsp;<i>et al</i>. Human organic anion transporters mediate the transport of tetracycline.&nbsp;<i>Jpn J Pharmacol</i>&nbsp;<b>88</b>, 69–76 (2002).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD38XpsFamuw%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 62 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11855680" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 62 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1254%2Fjjp.88.69" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 62">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Human%20organic%20anion%20transporters%20mediate%20the%20transport%20of%20tetracycline&amp;journal=Jpn%20J%20Pharmacol&amp;volume=88&amp;pages=69-76&amp;publication_year=2002&amp;author=Babu%2CE" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 62 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">63.</span></p>
<p id="ref-CR63" class="c-article-references__text">Griffin, M. O., Fricovsky, E., Ceballos, G. &amp; Villarreal, F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature.&nbsp;<i>American Journal of Physiology – Cell Physiology</i>&nbsp;<b>299</b>, C539–C548,&nbsp;<a href="https://doi.org/10.1152/ajpcell.00047.2010">https://doi.org/10.1152/ajpcell.00047.2010</a>&nbsp;(2010).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC3cXht1Wgu7rI" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 63 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20592239" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 63 on PubMed">PubMed</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944325" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 63 on PubMed Central">PubMed Central</a>&nbsp;<a href="https://doi.org/10.1152%2Fajpcell.00047.2010" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 63">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Tetracyclines%3A%20a%20pleitropic%20family%20of%20compounds%20with%20promising%20therapeutic%20properties.%20Review%20of%20the%20literature&amp;journal=American%20Journal%20of%20Physiology%20-%20Cell%20Physiology&amp;doi=10.1152%2Fajpcell.00047.2010&amp;volume=299&amp;pages=C539-C548&amp;publication_year=2010&amp;author=Griffin%2CMO&amp;author=Fricovsky%2CE&amp;author=Ceballos%2CG&amp;author=Villarreal%2CF" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 63 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">64.</span></p>
<p id="ref-CR64" class="c-article-references__text">García, R. A.&nbsp;<i>et al</i>. Molecular Interactions between Matrilysin and the Matrix Metalloproteinase Inhibitor Doxycycline Investigated by Deuterium Exchange Mass Spectrometry.&nbsp;<i>Molecular Pharmacology</i>&nbsp;<b>67</b>, 1128–1136,&nbsp;<a href="https://doi.org/10.1124/mol.104.006346">https://doi.org/10.1124/mol.104.006346</a>&nbsp;(2005).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD2MXjtFWms78%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 64 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15665254" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 64 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1124%2Fmol.104.006346" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 64">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Molecular%20Interactions%20between%20Matrilysin%20and%20the%20Matrix%20Metalloproteinase%20Inhibitor%20Doxycycline%20Investigated%20by%20Deuterium%20Exchange%20Mass%20Spectrometry&amp;journal=Molecular%20Pharmacology&amp;doi=10.1124%2Fmol.104.006346&amp;volume=67&amp;pages=1128-1136&amp;publication_year=2005&amp;author=Garc%C3%ADa%2CRA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 64 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">65.</span></p>
<p id="ref-CR65" class="c-article-references__text">Peterson, J. T. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.&nbsp;<i>Heart Fail Rev</i>&nbsp;<b>9</b>, 63–79,&nbsp;<a href="https://doi.org/10.1023/B:HREV.0000011395.11179.af">https://doi.org/10.1023/B:HREV.0000011395.11179.af</a>&nbsp;(2004).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD2cXisVegug%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 65 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14739769" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 65 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1023%2FB%3AHREV.0000011395.11179.af" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 65">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Matrix%20metalloproteinase%20inhibitor%20development%20and%20the%20remodeling%20of%20drug%20discovery&amp;journal=Heart%20Fail%20Rev&amp;doi=10.1023%2FB%3AHREV.0000011395.11179.af&amp;volume=9&amp;pages=63-79&amp;publication_year=2004&amp;author=Peterson%2CJT" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 65 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">66.</span></p>
<p id="ref-CR66" class="c-article-references__text">Palm, G. J.&nbsp;<i>et al</i>. Specific binding of divalent metal ions to tetracycline and to the Tet repressor/tetracycline complex.&nbsp;<i>J Biol Inorg Chem</i>&nbsp;<b>13</b>, 1097–1110,&nbsp;<a href="https://doi.org/10.1007/s00775-008-0395-2">https://doi.org/10.1007/s00775-008-0395-2</a>&nbsp;(2008).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD1cXhtFOqsLrO" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 66 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18548290" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 66 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1007%2Fs00775-008-0395-2" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 66">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Specific%20binding%20of%20divalent%20metal%20ions%20to%20tetracycline%20and%20to%20the%20Tet%20repressor%2Ftetracycline%20complex&amp;journal=J%20Biol%20Inorg%20Chem&amp;doi=10.1007%2Fs00775-008-0395-2&amp;volume=13&amp;pages=1097-1110&amp;publication_year=2008&amp;author=Palm%2CGJ" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 66 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">67.</span></p>
<p id="ref-CR67" class="c-article-references__text">Ionescu, A.&nbsp;<i>et al</i>. FoxA family members are crucial regulators of the hypertrophic chondrocyte differentiation program.&nbsp;<i>Developmental Cell</i>&nbsp;<b>22</b>, 927–939,&nbsp;<a href="https://doi.org/10.1016/j.devcel.2012.03.011">https://doi.org/10.1016/j.devcel.2012.03.011</a>&nbsp;(2012).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC38Xntlaqs7w%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 67 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22595668" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 67 on PubMed">PubMed</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356573" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 67 on PubMed Central">PubMed Central</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.devcel.2012.03.011" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 67">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=FoxA%20family%20members%20are%20crucial%20regulators%20of%20the%20hypertrophic%20chondrocyte%20differentiation%20program&amp;journal=Developmental%20Cell&amp;doi=10.1016%2Fj.devcel.2012.03.011&amp;volume=22&amp;pages=927-939&amp;publication_year=2012&amp;author=Ionescu%2CA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 67 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">68.</span></p>
<p id="ref-CR68" class="c-article-references__text">Wilsman, N. J., Farnum, C. E., Leiferman, E. M., Fry, M. &amp; Barreto, C. Differential growth by growth plates as a function of multiple parameters of chondrocytic kinetics.&nbsp;<i>Journal of orthopaedic research: official publication of the Orthopaedic Research Society</i>&nbsp;<b>14</b>, 927–936,&nbsp;<a href="https://doi.org/10.1002/jor.1100140613">https://doi.org/10.1002/jor.1100140613</a>&nbsp;(1996).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADyaK2s7js1Omuw%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 68 on CAS">CAS</a>&nbsp;<a href="https://doi.org/10.1002%2Fjor.1100140613" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 68">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Differential%20growth%20by%20growth%20plates%20as%20a%20function%20of%20multiple%20parameters%20of%20chondrocytic%20kinetics&amp;journal=Journal%20of%20orthopaedic%20research%3A%20official%20publication%20of%20the%20Orthopaedic%20Research%20Society&amp;doi=10.1002%2Fjor.1100140613&amp;volume=14&amp;pages=927-936&amp;publication_year=1996&amp;author=Wilsman%2CNJ&amp;author=Farnum%2CCE&amp;author=Leiferman%2CEM&amp;author=Fry%2CM&amp;author=Barreto%2CC" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 68 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">69.</span></p>
<p id="ref-CR69" class="c-article-references__text">Nagase, H. &amp; Woessner, J. F. Jr. Matrix metalloproteinases.&nbsp;<i>The Journal of biological chemistry</i>&nbsp;<b>274</b>, 21491–21494 (1999).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADyaK1MXltVynu7s%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 69 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10419448" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 69 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1074%2Fjbc.274.31.21491" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 69">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Matrix%20metalloproteinases&amp;journal=The%20Journal%20of%20biological%20chemistry&amp;volume=274&amp;pages=21491-21494&amp;publication_year=1999&amp;author=Nagase%2CH&amp;author=Woessner%2CJF" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 69 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">70.</span></p>
<p id="ref-CR70" class="c-article-references__text">Holmbeck, K.&nbsp;<i>et al</i>. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.&nbsp;<i>Cell</i>&nbsp;<b>99</b>, 81–92 (1999).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADyaK1MXmsleqs7c%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 70 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10520996" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 70 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2FS0092-8674%2800%2980064-1" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 70">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=MT1-MMP-deficient%20mice%20develop%20dwarfism%2C%20osteopenia%2C%20arthritis%2C%20and%20connective%20tissue%20disease%20due%20to%20inadequate%20collagen%20turnover&amp;journal=Cell&amp;volume=99&amp;pages=81-92&amp;publication_year=1999&amp;author=Holmbeck%2CK" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 70 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">71.</span></p>
<p id="ref-CR71" class="c-article-references__text">Stechmiller, J., Cowan, L. &amp; Schultz, G. The Role of Doxycycline as a Matrix Metalloproteinase Inhibitor for the Treatment of Chronic Wounds.&nbsp;<i>Biological Research For Nursing</i>&nbsp;<b>11</b>, 336–344,&nbsp;<a href="https://doi.org/10.1177/1099800409346333">https://doi.org/10.1177/1099800409346333</a>&nbsp;(2010).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC3cXlt1yjtr4%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 71 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20031955" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 71 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1177%2F1099800409346333" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 71">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=The%20Role%20of%20Doxycycline%20as%20a%20Matrix%20Metalloproteinase%20Inhibitor%20for%20the%20Treatment%20of%20Chronic%20Wounds&amp;journal=Biological%20Research%20For%20Nursing&amp;doi=10.1177%2F1099800409346333&amp;volume=11&amp;pages=336-344&amp;publication_year=2010&amp;author=Stechmiller%2CJ&amp;author=Cowan%2CL&amp;author=Schultz%2CG" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 71 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">72.</span></p>
<p id="ref-CR72" class="c-article-references__text">Mavragani, M., Brudvik, P. &amp; Selvig, K. A. Orthodontically induced root and alveolar bone resorption: inhibitory effect of systemic doxycycline administration in rats.&nbsp;<i>European Journal of Orthodontics</i>&nbsp;<b>27</b>, 215–225,&nbsp;<a href="https://doi.org/10.1093/ejo/cji015">https://doi.org/10.1093/ejo/cji015</a>&nbsp;(2005).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15947219" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 72 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1093%2Fejo%2Fcji015" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 72">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Orthodontically%20induced%20root%20and%20alveolar%20bone%20resorption%3A%20inhibitory%20effect%20of%20systemic%20doxycycline%20administration%20in%20rats&amp;journal=European%20Journal%20of%20Orthodontics&amp;doi=10.1093%2Fejo%2Fcji015&amp;volume=27&amp;pages=215-225&amp;publication_year=2005&amp;author=Mavragani%2CM&amp;author=Brudvik%2CP&amp;author=Selvig%2CKA" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 72 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">73.</span></p>
<p id="ref-CR73" class="c-article-references__text">Gomes, P. S. &amp; Fernandes, M. H. Effect of therapeutic levels of doxycycline and minocycline in the proliferation and differentiation of human bone marrow osteoblastic cells.&nbsp;<i>Archives of oral biology</i>&nbsp;<b>52</b>, 251–259,&nbsp;<a href="https://doi.org/10.1016/j.archoralbio.2006.10.005">https://doi.org/10.1016/j.archoralbio.2006.10.005</a>&nbsp;(2007).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD2sXntlKgtw%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 73 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17141175" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 73 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.archoralbio.2006.10.005" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 73">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20therapeutic%20levels%20of%20doxycycline%20and%20minocycline%20in%20the%20proliferation%20and%20differentiation%20of%20human%20bone%20marrow%20osteoblastic%20cells&amp;journal=Archives%20of%20oral%20biology&amp;doi=10.1016%2Fj.archoralbio.2006.10.005&amp;volume=52&amp;pages=251-259&amp;publication_year=2007&amp;author=Gomes%2CPS&amp;author=Fernandes%2CMH" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 73 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">74.</span></p>
<p id="ref-CR74" class="c-article-references__text">Rygh, P. Orthodontic root resorption studied by electron microscopy.&nbsp;<i>Angle Orthod</i>&nbsp;<b>47</b>, 1–16, doi:10.1043/0003-3219(1977)047&lt;0001:orrsbe&gt;2.0.co;2 (1977).</p>
<p><span class="c-article-references__counter">75.</span></p>
<p id="ref-CR75" class="c-article-references__text">Limirio, P. H.&nbsp;<i>et al</i>. The Effect of Local Delivery Doxycycline and Alendronate on Bone Repair.&nbsp;<i>AAPS PharmSciTech</i>&nbsp;<b>17</b>, 872–877,&nbsp;<a href="https://doi.org/10.1208/s12249-015-0411-0">https://doi.org/10.1208/s12249-015-0411-0</a>&nbsp;(2016).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC2MXhsFagu7nN" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 75 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26381914" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 75 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1208%2Fs12249-015-0411-0" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 75">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=The%20Effect%20of%20Local%20Delivery%20Doxycycline%20and%20Alendronate%20on%20Bone%20Repair&amp;journal=AAPS%20PharmSciTech&amp;doi=10.1208%2Fs12249-015-0411-0&amp;volume=17&amp;pages=872-877&amp;publication_year=2016&amp;author=Limirio%2CPH" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 75 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">76.</span></p>
<p id="ref-CR76" class="c-article-references__text">Gomes, K. D. N., Alves, A. P. N. N., Dutra, P. G. P. &amp; Viana, G. S. B. Doxycycline induces bone repair and changes in Wnt signalling.&nbsp;<i>International Journal Of Oral Science</i>&nbsp;<b>9</b>, 158,&nbsp;<a href="https://doi.org/10.1038/ijos.2017.28">https://doi.org/10.1038/ijos.2017.28</a>&nbsp;(2017).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC1cXotV2mug%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 76 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28960195" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 76 on PubMed">PubMed</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709545" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 76 on PubMed Central">PubMed Central</a>&nbsp;<a href="https://doi.org/10.1038%2Fijos.2017.28" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 76">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Doxycycline%20induces%20bone%20repair%20and%20changes%20in%20Wnt%20signalling&amp;journal=International%20Journal%20Of%20Oral%20Science&amp;doi=10.1038%2Fijos.2017.28&amp;volume=9&amp;publication_year=2017&amp;author=Gomes%2CKDN&amp;author=Alves%2CAPNN&amp;author=Dutra%2CPGP&amp;author=Viana%2CGSB" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 76 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">77.</span></p>
<p id="ref-CR77" class="c-article-references__text">Cummings, G. R. &amp; Torabinejad, M. Effect of Systemic Doxycycline on Alveolar Bone Loss after Periradicular Surgery.&nbsp;<i>Journal of endodontics</i>&nbsp;<b>26</b>, 325–327,&nbsp;<a href="https://doi.org/10.1097/00004770-200006000-00004">https://doi.org/10.1097/00004770-200006000-00004</a>&nbsp;(2000).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADC%252BD3M7jt1arsA%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 77 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11199747" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 77 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1097%2F00004770-200006000-00004" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 77">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20Systemic%20Doxycycline%20on%20Alveolar%20Bone%20Loss%20after%20Periradicular%20Surgery&amp;journal=Journal%20of%20endodontics&amp;doi=10.1097%2F00004770-200006000-00004&amp;volume=26&amp;pages=325-327&amp;publication_year=2000&amp;author=Cummings%2CGR&amp;author=Torabinejad%2CM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 77 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">78.</span></p>
<p id="ref-CR78" class="c-article-references__text">Shahabooei, M.&nbsp;<i>et al</i>. A histomorphometric study of the effect of doxycycline and erythromycin on bone formation in dental alveolar socket of rat.&nbsp;<i>Adv Biomed Res</i>&nbsp;<b>4</b>, 71,&nbsp;<a href="https://doi.org/10.4103/2277-9175.153895">https://doi.org/10.4103/2277-9175.153895</a>&nbsp;(2015).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BC2MXmtFagsL4%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 78 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25878996" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 78 on PubMed">PubMed</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386208" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 78 on PubMed Central">PubMed Central</a>&nbsp;<a href="https://doi.org/10.4103%2F2277-9175.153895" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 78">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=A%20histomorphometric%20study%20of%20the%20effect%20of%20doxycycline%20and%20erythromycin%20on%20bone%20formation%20in%20dental%20alveolar%20socket%20of%20rat&amp;journal=Adv%20Biomed%20Res&amp;doi=10.4103%2F2277-9175.153895&amp;volume=4&amp;publication_year=2015&amp;author=Shahabooei%2CM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 78 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">79.</span></p>
<p id="ref-CR79" class="c-article-references__text">Weaver, C.&nbsp;<i>et al</i>. (3)H-tetracycline as a proxy for (41)Ca for measuring dietary perturbations of bone resorption. Nuclear instruments &amp; methods in physics research. Section B.&nbsp;<i>Beam interactions with materials and atoms</i>&nbsp;<b>259</b>, 790–795,&nbsp;<a href="https://doi.org/10.1016/j.nimb.2007.02.004">https://doi.org/10.1016/j.nimb.2007.02.004</a>&nbsp;(2007).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD2sXlsFKjtr4%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 79 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19498951" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 79 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.nimb.2007.02.004" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 79">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=%283%29H-tetracycline%20as%20a%20proxy%20for%20%2841%29Ca%20for%20measuring%20dietary%20perturbations%20of%20bone%20resorption.%20Nuclear%20instruments%20%26%20methods%20in%20physics%20research.%20Section%20B&amp;journal=Beam%20interactions%20with%20materials%20and%20atoms&amp;doi=10.1016%2Fj.nimb.2007.02.004&amp;volume=259&amp;pages=790-795&amp;publication_year=2007&amp;author=Weaver%2CC" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 79 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">80.</span></p>
<p id="ref-CR80" class="c-article-references__text">Walker, C.&nbsp;<i>et al</i>. Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiologic results.&nbsp;<i>J Periodontol</i>&nbsp;<b>78</b>, 1590–1601,&nbsp;<a href="https://doi.org/10.1902/jop.2007.070015">https://doi.org/10.1902/jop.2007.070015</a>&nbsp;(2007).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD2sXhtFanurnE" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 80 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17668979" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 80 on PubMed">PubMed</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2041927" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 80 on PubMed Central">PubMed Central</a>&nbsp;<a href="https://doi.org/10.1902%2Fjop.2007.070015" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 80">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Subantimicrobial%20dose%20doxycycline%20effects%20on%20osteopenic%20bone%20loss%3A%20microbiologic%20results&amp;journal=J%20Periodontol&amp;doi=10.1902%2Fjop.2007.070015&amp;volume=78&amp;pages=1590-1601&amp;publication_year=2007&amp;author=Walker%2CC" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 80 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">81.</span></p>
<p id="ref-CR81" class="c-article-references__text">Golub, L. M.&nbsp;<i>et al</i>. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva.&nbsp;<i>Journal of clinical periodontology</i>&nbsp;<b>22</b>, 100–109 (1995).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADyaK2MXltlCisr0%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 81 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=7775665" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 81 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1111%2Fj.1600-051X.1995.tb00120.x" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 81">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Doxycycline%20inhibits%20neutrophil%20%28PMN%29-type%20matrix%20metalloproteinases%20in%20human%20adult%20periodontitis%20gingiva&amp;journal=Journal%20of%20clinical%20periodontology&amp;volume=22&amp;pages=100-109&amp;publication_year=1995&amp;author=Golub%2CLM" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 81 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">82.</span></p>
<p id="ref-CR82" class="c-article-references__text">Skidmore, R.&nbsp;<i>et al</i>. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne.&nbsp;<i>Arch Dermatol</i>&nbsp;<b>139</b>, 459–464,&nbsp;<a href="https://doi.org/10.1001/archderm.139.4.459">https://doi.org/10.1001/archderm.139.4.459</a>&nbsp;(2003).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ACAS%3A528%3ADC%252BD3sXjsVOmt7Y%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 82 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12707093" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 82 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1001%2Farchderm.139.4.459" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 82">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Effects%20of%20subantimicrobial-dose%20doxycycline%20in%20the%20treatment%20of%20moderate%20acne&amp;journal=Arch%20Dermatol&amp;doi=10.1001%2Farchderm.139.4.459&amp;volume=139&amp;pages=459-464&amp;publication_year=2003&amp;author=Skidmore%2CR" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 82 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">83.</span></p>
<p id="ref-CR83" class="c-article-references__text">Cohen, P. R. &amp; Grossman, M. E. Management of cutaneous lesions associated with an emerging epidemic: community-acquired methicillin-resistant Staphylococcus aureus skin infections.&nbsp;<i>J Am Acad Dermatol</i>&nbsp;<b>51</b>, 132–135,&nbsp;<a href="https://doi.org/10.1016/j.jaad.2004.03.010">https://doi.org/10.1016/j.jaad.2004.03.010</a>&nbsp;(2004).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15243539" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 83 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.jaad.2004.03.010" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 83">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Management%20of%20cutaneous%20lesions%20associated%20with%20an%20emerging%20epidemic%3A%20community-acquired%20methicillin-resistant%20Staphylococcus%20aureus%20skin%20infections&amp;journal=J%20Am%20Acad%20Dermatol&amp;doi=10.1016%2Fj.jaad.2004.03.010&amp;volume=51&amp;pages=132-135&amp;publication_year=2004&amp;author=Cohen%2CPR&amp;author=Grossman%2CME" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 83 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">84.</span></p>
<p id="ref-CR84" class="c-article-references__text">Del Rosso, J. Q. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines.&nbsp;<i>Cutis</i>&nbsp;<b>74</b>, 118–122 (2004).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15379364" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 84 on PubMed">PubMed</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=A%20status%20report%20on%20the%20use%20of%20subantimicrobial-dose%20doxycycline%3A%20a%20review%20of%20the%20biologic%20and%20antimicrobial%20effects%20of%20the%20tetracyclines&amp;journal=Cutis&amp;volume=74&amp;pages=118-122&amp;publication_year=2004&amp;author=Rosso%2CJQ" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 84 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">85.</span></p>
<p id="ref-CR85" class="c-article-references__text">Pelle, M. T., Crawford, G. H. &amp; James, W. D. Rosacea: II. Therapy.&nbsp;<i>J Am Acad Dermatol</i>&nbsp;<b>51</b>, 499–512; quiz 513–494,&nbsp;<a href="https://doi.org/10.1016/j.jaad.2004.03.033">https://doi.org/10.1016/j.jaad.2004.03.033</a>&nbsp;(2004).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15389184" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 85 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.jaad.2004.03.033" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 85">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Rosacea%3A%20II.%20Therapy&amp;journal=Journal%20of%20the%20American%20Academy%20of%20Dermatology&amp;volume=51&amp;issue=4&amp;pages=499-512&amp;publication_year=2004&amp;author=Pelle%2CMichelle%20T.&amp;author=Crawford%2CGlen%20H.&amp;author=James%2CWilliam%20D." data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 85 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">86.</span></p>
<p id="ref-CR86" class="c-article-references__text">Cohen, P. R. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners.&nbsp;<i>Am J Clin Dermatol</i>&nbsp;<b>8</b>, 259–270 (2007).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17902728" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 86 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.2165%2F00128071-200708050-00001" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 86">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Community-acquired%20methicillin-resistant%20Staphylococcus%20aureus%20skin%20infections%3A%20implications%20for%20patients%20and%20practitioners&amp;journal=Am%20J%20Clin%20Dermatol&amp;volume=8&amp;pages=259-270&amp;publication_year=2007&amp;author=Cohen%2CPR" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 86 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">87.</span></p>
<p id="ref-CR87" class="c-article-references__text">Elston, D. M. Community-acquired methicillin-resistant Staphylococcus aureus.&nbsp;<i>J Am Acad Dermatol</i>&nbsp;<b>56</b>, 1–16; quiz 17–20,&nbsp;<a href="https://doi.org/10.1016/j.jaad.2006.04.018">https://doi.org/10.1016/j.jaad.2006.04.018</a>&nbsp;(2007).</p>
<p class="c-article-references__links u-hide-print"><a href="http://www.ams.org/mathscinet-getitem?mr=469131" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 87 on MathSciNet">MathSciNet</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17190619" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 87 on PubMed">PubMed</a>&nbsp;<a href="https://doi.org/10.1016%2Fj.jaad.2006.04.018" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 87">Article</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Community-acquired%20methicillin-resistant%20Staphylococcus%20aureus&amp;journal=Journal%20of%20the%20American%20Academy%20of%20Dermatology&amp;volume=56&amp;issue=1&amp;pages=1-16&amp;publication_year=2007&amp;author=Elston%2CDirk%20M." data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 87 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">88.</span></p>
<p id="ref-CR88" class="c-article-references__text">Bhambri, S. &amp; Kim, G. Use of Oral Doxycycline for Community-acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA) Infections. The.&nbsp;<i>Journal of Clinical and Aesthetic Dermatology</i>&nbsp;<b>2</b>, 45–50 (2009).</p>
<p class="c-article-references__links u-hide-print"><a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20729939" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 88 on PubMed">PubMed</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Use%20of%20Oral%20Doxycycline%20for%20Community-acquired%20Methicillin-resistant%20Staphylococcus%20aureus%20%28CA-MRSA%29%20Infections.%20The&amp;journal=Journal%20of%20Clinical%20and%20Aesthetic%20Dermatology&amp;volume=2&amp;pages=45-50&amp;publication_year=2009&amp;author=Bhambri%2CS&amp;author=Kim%2CG" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 88 on Google Scholar">Google Scholar</a></p>
<p><span class="c-article-references__counter">89.</span></p>
<p id="ref-CR89" class="c-article-references__text">Boden, S. D. &amp; Kaplan, F. S. Calcium homeostasis.&nbsp;<i>Orthop Clin North Am</i>&nbsp;<b>21</b>, 31–42 (1990).</p>
<p class="c-article-references__links u-hide-print"><a href="https://www.nature.com/articles/cas-redirect/1%3ASTN%3A280%3ADyaK3c7hsV2nug%253D%253D" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 89 on CAS">CAS</a>&nbsp;<a class="rds_hl_nofollow" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2404236" rel="nofollow" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="View reference 89 on PubMed">PubMed</a>&nbsp;<a href="https://scholar.google.com/scholar_lookup?&amp;title=Calcium%20homeostasis&amp;journal=Orthop%20Clin%20North%20Am&amp;volume=21&amp;pages=31-42&amp;publication_year=1990&amp;author=Boden%2CSD&amp;author=Kaplan%2CFS" data-track="click" data-track-action="outbound reference" data-track-label="link" aria-label="Search for reference 89 on Google Scholar">Google Scholar</a></p>
<p>&nbsp;</p>
<h3>Source</h3>
<hr>
<p>&nbsp;</p>
<p>https://www.nature.com/articles/s41598-019-51702-y</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2020/12/24/doxycycline-reduces-osteopenia-in-female-rats/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2020/12/24/doxycycline-reduces-osteopenia-in-female-rats/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-4985 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>27.07.2020</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2020/07/27/effect-of-estradiol-cypionate-on-estrus-expression-and-pregnancy-in-timed-artificially-inseminated-beef-cows/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2020/07/27/effect-of-estradiol-cypionate-on-estrus-expression-and-pregnancy-in-timed-artificially-inseminated-beef-cows/">Effect of estradiol cypionate on estrus expression and pregnancy in timed artificially inseminated beef cows</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p><span class="content"><span class="text given-name">Luiz Francisco Machado</span><span class="text surname">Pfeifer</span><span id="baff0001" class="author-ref"><sup>a</sup></span></span><span class="content"><span class="text given-name">Elizângela Mírian</span><span class="text surname">Moreira</span><span id="baff0001" class="author-ref"><sup>a</sup></span><span id="baff0006" class="author-ref"><sup>f</sup></span></span><a class="author size-m workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#!" name="bau0003"><span class="content"><span class="text given-name">George M</span></span></a><span class="content"><span class="text given-name">oreira</span></span><span class="content"><span class="text surname">da Silva</span><span id="baff0001" class="author-ref"><sup>a</sup></span><span id="baff0002" class="author-ref"><sup>b</sup></span></span><span class="content"><span class="text given-name">Vanessa Lemos</span><span class="text surname">de Souza</span><span id="baff0001" class="author-ref"><sup>a</sup></span><span id="baff0002" class="author-ref"><sup>b</sup></span></span><span class="content"><span class="text given-name">Vanessa Rachele Ribeiro</span><span class="text surname">Nunes</span><span id="baff0001" class="author-ref"><sup>a</sup></span></span><span class="content"><span class="text given-name">Jéssica de Souza</span><span class="text surname">Andrade</span><span id="baff0001" class="author-ref"><sup>a</sup></span><span id="baff0003" class="author-ref"><sup>c</sup></span></span><span class="content"><span class="text given-name">Paulo Marcos Araújo</span></span><span class="content"><span class="text surname">Neve</span></span><a class="author size-m workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#!" name="bau0007"><span class="content"><span class="text surname">s</span><span id="baff0001" class="author-ref"><sup>a</sup></span><span id="baff0004" class="author-ref"><sup>d</sup></span></span></a><span class="content"><span class="text given-name">Rogerio</span><span class="text surname">Ferreira</span><span id="baff0005" class="author-ref"><sup>e</sup></span></span></p>
<dl class="affiliation">
<dt>
<dl class="affiliation">
<dt><span style="font-size: xx-small;"><sup>a</sup></span></dt>
<dd><span style="font-size: xx-small;">Embrapa, Brazilian Agricultural Research Corporation, Porto Velho, RO, Brazil</span></dd>
</dl>
<dl class="affiliation">
<dt><span style="font-size: xx-small;"><sup>b</sup></span></dt>
<dd><span style="font-size: xx-small;">UNIR, Universidade Federal de Rondônia, Programa de Pós-Graduação em Desenvolvimento Regional e Meio Ambiente, Porto Velho, RO, Brazil</span></dd>
</dl>
<dl class="affiliation">
<dt><span style="font-size: xx-small;"><sup>c</sup></span></dt>
<dd><span style="font-size: xx-small;">Bionorte, Programa de Pós-Graduação em Biodiversidade e Biotecnologia, Porto Velho, RO, Brazil</span></dd>
</dl>
<dl class="affiliation">
<dt><span style="font-size: xx-small;"><sup>d</sup></span></dt>
<dd><span style="font-size: xx-small;">UNIR, Universidade Federal de Rondônia, Programa de Pós-Graduação em Ciências Ambientais, Rolim de Moura, RO, Brazil</span></dd>
</dl>
<dl class="affiliation">
<dt><span style="font-size: xx-small;"><sup>e</sup></span></dt>
<dd><span style="font-size: xx-small;">UDESC, Universidade do Estado de Santa Catarina, Chapecó, SC, Brazil</span></dd>
</dl>
<dl class="affiliation">
<dt><span style="font-size: xx-small;"><sup>f</sup></span></dt>
<dd><span style="font-size: xx-small;">FAPERO, Fundação de Amparo à Pesquisa de Rondônia, Porto Velho, RO, Brazil</span></dd>
</dl>
</dt>
</dl>
<h2>ABSTRACT</h2>
<hr>
<p>&nbsp;</p>
<p>Several studies have shown that cows displaying estrus before timed artificial insemination (TAI) are more likely to become pregnant. However, the most frequently used ovulation-inducing agents by South American beef operations, estradiol esters, may artificially induce estrus in treated cows. The hypotheses tested in the present study were: 1) estradiol cypionate (EC) treatment will induce estrus in ovariectomized cows, and 2) cows that exhibit estrus following administration of EC and eCG will have lower P/AI compared to those that do not receive EC. In Experiment 1, 14 ovariectomized cows were used in a cross-over design with an interval of 30 d between replicates. On Day 0, all cows received 2 mg of estradiol benzoate and a CIDR device and 12.5 mg of Dinoprost (PGF2α analogue) on Day 7. On Day 9, the CIDR devices were removed and cows were placed at random into one of two experimental groups and administered either 0.5 mL of canola oil (Control, CTL group, n = 14) or 1 mg of EC (EC group, n = 14). Estrotect estrus detection patches were used and cows were observed 4 times daily to determine the occurrence of estrus. More EC-treated cows showed estrus (12/14, 85.7%) than canola oil-treated cows (0/14; P &lt; 0,001). The interval from EC treatment to estrus was 46 ± 3.7 h. In Experiment 2, 804 postpartum Nelore cows were treated as in Experiment 1, except that all cows received 300 IU of equine chorionic gonadotrophin at CIDR removal, and were randomly divided into 3 groups: 1) EC group (n = 269) received 1 mg i.m. of EC on Day 9; 2) EC-GnRH group (n = 269) received EC on Day 9, and were inseminated on observation of estrus, while those not showing estrus received GnRH on Day 11; and, 3) EstrusGnRH group (n = 266) did not receive EC on Day 9 and were inseminated on observation of estrus. Those in Groups 2 and 3 that did not show estrus received GnRH on Day 11 at the time of TAI. The proportion of cows showing estrus was greater (P &lt; 0.0001) in EC (68.7%, 185/269) and EC-GnRH (57.2%; 154/269) groups than in the Estrus-GnRH group (35.7%, 95/266). However, no difference in P/AI was observed among the groups (P = 0.87). These results show that EC will induce estrus in ovariectomized cows, and that EC treatment increased the proportion of intact cows exhibiting estrus in a TAI protocol without reducing P/AI.</p>
<section id="sec0001">
<h3 class="u-h3 u-margin-l-top u-margin-xs-bottom">1.&nbsp;Introduction</h3>
<hr>
<p>&nbsp;</p>
<p id="para0004">Estradiol and progesterone-based protocols are commonly used in South American beef operations to synchronize follicular wave emergence and ovulation for timed artificial insemination (TAI;&nbsp;Sa&nbsp;Filho et&nbsp;al., 2009; Sa&nbsp;Filho&nbsp;et&nbsp;al., 2011). In such protocols, ovulations are usually induced with a low dose of estradiol ester concurrently with a progesterone device removal or 24&nbsp;h later (Bo&nbsp;et&nbsp;al., 2003). Previous studies have demonstrated the efficacy of estradiol cypionate (EC) at the time of progesterone device removal to induce ovulation and to minimize the animal handling (Colazo&nbsp;et&nbsp;al., 2003;&nbsp;Ayres&nbsp;et&nbsp;al., 2008).</p>
<p id="para0005">The occurrence of estrus after progesterone device removal and prior to TAI results in greater pregnancy per AI (P/AI; Sa&nbsp;Filho&nbsp;et&nbsp;al., 2010;&nbsp;Pfeifer&nbsp;et&nbsp;al., 2018;&nbsp;Nogueira&nbsp;et&nbsp;al., 2019). Cows that displayed estrus were 3.3 times more likely to become pregnant than those not detected in estrus (Sa&nbsp;Filho&nbsp;et&nbsp;al., 2010). However, estradiol esters have been shown to induce behavioral estrus. In an earlier study, nulliparous, ovariectomized cattle showed sexual behaviors typical of estrus after estradiol administration (Katz&nbsp;et&nbsp;al., 1980). In addition, in TAI programs greater P/AI have been reported for cows that display estrus than those that did not (Richardson&nbsp;et&nbsp;al., 2016). In this regard, fertility of cows that did not show estrus between progesterone insert removal and TAI was improved by delaying AI by 24&nbsp;h (Thomas&nbsp;et&nbsp;al., 2014) or by administering GnRH concurrent with TAI in females that failed to express estrus (Thomas&nbsp;et&nbsp;al., 2014;&nbsp;Bishop&nbsp;et&nbsp;al., 2017). Similarly, the use of GnRH concurrent with TAI in Nelore cows raised under tropical conditions increased P/AI in those that did not display estrus (Sa&nbsp;Filho&nbsp;et&nbsp;al., 2011;&nbsp;Rodrigues&nbsp;et&nbsp;al., 2019). In addition, under circumstances with high incidence of anestrus, typically observed in grazing, suckled beef herds in Brazil, the efficacy of these treatments have been shown to be compromised (Sa&nbsp;Filho et&nbsp;al., 2013). Thus, equine chorionic gonadotropin (eCG) has been included in TAI protocols aiming to stimulate the ovarian follicular growth and, consequently, improving ovulation and P/AI (Baruselli&nbsp;et&nbsp;al., 2012).</p>
<p id="para0006">Based on these considerations, it was hypothesized that eCG-treated cows showing estrus without EC are more likely to become pregnant than eCG+EC-treated cows. The objectives of this study were to determine whether EC will induce estrus in ovariectomized cows, and to determine the effect of EC on expression of estrus and P/AI in ovary-intact cows subjected to TAI protocols which included the addition of eCG treatment. The hypotheses were that EC will induce estrus in ovariectomized cows, and, that cows that exhibit estrus following EC administration will have lower P/AI compared to those that do not receive EC.</p>
</section>
<section id="sec0002">
<h3 class="u-h3 u-margin-l-top u-margin-xs-bottom">2.&nbsp;Materials and methods</h3>
<hr>
<p>&nbsp;</p>
<p id="para0007">The Committee for Ethics in Animal Experimentation from Embrapa, the Brazilian Agricultural Research Corporation, approved all of the procedures performed in the experiments described in this manuscript (Protocol 04/2017).</p>
<section id="sec0003">
<h4 id="cesectitle0006" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.1.&nbsp;Experiment 1</h4>
<p id="para0008">This study was performed at the experimental research farm of Embrapa Rondônia (08,<sup>0</sup>48′12″S, 63,<sup>0</sup>50′56″W).</p>
<p id="para0009">Fourteen ovariectomized crossbred cows, 3–7 years old, 450–650&nbsp;kg in body weight, and with a 3–4 of body condition score (BCS; range 1–5, where 1&nbsp;=&nbsp;emaciated and 5&nbsp;=&nbsp;obese; (<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#bib0013" name="bbib0013">Lowman&nbsp;et&nbsp;al., 1976</a>)) were used. Cows were kept in an outdoor grazing system (<em>Brachiaria brizantha</em>&nbsp;pasture) with ad libitum access to mineral, salt and water.</p>
<p id="para0010">All cows were submitted to a TAI protocol and received an intravaginal progesterone-releasing device (1.9&nbsp;g progesterone, CIDR®, Pfizer Animal Health, São Paulo, Brazil) plus 2&nbsp;mg of estradiol benzoate (Gonadiol®, Zoetis, São Paulo, Brazil) i.m. on Day 0. On Day 7, cows received 12.5&nbsp;mg i.m. of Dinoprost (PGF<sub>2</sub>α-analogue, Lutalyse®, Zoetis, São Paulo,Brazil). On Day 9, the CIDR devices were removed and cows were randomly assigned to two treatment groups to receive: 1) 0.5&nbsp;mL of canola oil (Control Group,&nbsp;<em>n</em>&nbsp;=&nbsp;14) i.m., or 2) 1&nbsp;mg i.m. of estradiol cypionate (EC Group,&nbsp;<em>n</em>&nbsp;=&nbsp;14; E.C.P®, Pfizer Animal Health, São Paulo, Brazil). A 2&nbsp;×&nbsp;2 cross-over design in which all cows received both treatments was used. The interval between replicates was 1 month.</p>
<p id="para0011">Estrus detection aids (Estrotect®, Rockway Inc., Spring Valley, WI, USA) were placed on all cows on Day 9. Cows were observed for Estrotect® activation four times daily, from Days 9 to 13.</p>
</section>
<section id="sec0004">
<h4 id="cesectitle0007" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.2.&nbsp;Experiment 2</h4>
<p id="para0012">This experiment was performed on a commercial farm in the northern region of Brazil (08,<sup>0</sup>48′12″S, 63,<sup>0</sup>50′56″W). In this experiment, 804 Nelore cows, 40 to 60 days postpartum with a BCS ranging from 2.5 to 3.5 were enrolled. The cows were maintained on a grazing system (<em>Brachiaria brizantha</em>) with ad libitum access to mineral, salt and water.</p>
<p id="para0013">Cows were submitted to the same TAI protocol as in Experiment 1. However, on Day 9 when CIDR® devices were removed, all cows received 300 IU i.m. of equine chorionic gonadotrophin (eCG, Novormon®, Zoetis, São Paulo, Brazil). All cows were painted with a chalk marker in the sacrococcigeal region to identify cows that showed estrus, and were randomly assigned to one of three treatments groups: 1) EC group (<em>n</em>&nbsp;=&nbsp;269); cows received 1&nbsp;mg i.m. of EC on Day 9 (ECP®, Pfizer Animal Health, São Paulo, Brazil) and were TAI on Day 11; 2) EC-GnRH group (<em>n</em>&nbsp;=&nbsp;269); cows received 1&nbsp;mg i.m. of EC on Day 9 and cows that did not display estrus between CIDR® removal and TAI on Day 11 received GnRH (10.5&nbsp;µg i.m. of buserelin acetate, Gonaxal®, Biogenesis Bagó, Buenos Aires, Argentina) at that time; and 3) Estrus-GnRH group (<em>n</em>&nbsp;=&nbsp;266); cows did not receive EC on Day 9, and cows that did not display estrus between CIDR® removal and TAI on Day 11 received GnRH at that time. On Day 11, estrus was evaluated at the time of TAI, and deemed to have occurred in cows without a tail-head chalk mark. A single inseminator performed all inseminations, and semen straws from five bulls of proven fertility were equally distributed among the three treatment groups.</p>
<p id="para0014">Ultrasound examinations were performed at TAI in a subset (<em>n</em>&nbsp;=&nbsp;138) in order to measure the diameter of the pre-ovulatory follicle (POF), and at 30 days post-TAI to assess pregnancy status in all cows. Visualization of the embryonic vesicle and detection of the embryo were the positive criteria for determining pregnancy status.</p>
</section>
<section id="sec0005">
<h4 id="cesectitle0008" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.3.&nbsp;Statistical analyses</h4>
<p id="para0015">All statistical analyses were performed using SAS software. The statistical model included the effects of treatment, bull, body condition score (BCS) and parity. The variables bull, BCS, and parity had no significant effect on the model and were excluded from it. The diameter of the ovulatory follicle was analyzed using analysis of variance (PROC GLIMMIX) and means were compared among groups using Tukey’s test. Proportions with dichotomous outcomes (yes or no), such as estrus detection and P/AI, were analyzed using Chi-squared tests. The relationship between the diameter of the POF at TAI on the probability of cows displaying estrus was determined. Logistic regression curves were created using the coefficients provided by the interactive data analysis from SAS and the formula&nbsp;<em>y</em>&nbsp;=&nbsp;exp(α<em>x</em>&nbsp;+&nbsp;<em>b</em>)/[1&nbsp;+&nbsp;<em>exp</em>(α<em>x</em>&nbsp;+&nbsp;<em>b</em>)]. The results are expressed as means ± SEM or as percentages. In all analyses, differences were considered significant when&nbsp;<em>P</em>&nbsp;≤&nbsp;0.05, whereas 0.05 &lt;&nbsp;<em>P</em>&nbsp;≤&nbsp;0.10 were considered tendencies.</p>
</section>
<div bis_skin_checked="1">
<section id="sec0006">
<h3 class="u-h3 u-margin-l-top u-margin-xs-bottom">3.&nbsp;Results</h3>
<hr>
<section id="sec0007">
<h6></h6>
<h6 id="cesectitle0010" class="u-h4 u-margin-m-top u-margin-xs-bottom">3.1.&nbsp;Experiment 1</h6>
<div bis_skin_checked="1">
<p id="para0016">The estrus responses in Experiment 1 are summarized in&nbsp;Table&nbsp;1. The number of ovariectomized cows showing estrus was greater in the EC group than in the canola oil group (<em>P</em>&nbsp;&lt; 0.001). In those showing estrus in the EC group, the mean interval from CIDR® device removal was 46&nbsp;±&nbsp;3.7&nbsp;h.</p>
<div id="tbl0001" class="tables colsep-0 frame-topbot rowsep-0" bis_skin_checked="1">
<p id="spara003"><span class="label">Table 1</span>.&nbsp;Estrus responses of ovariectomized cows treated with 1&nbsp;mg of EC or 0.5&nbsp;mL of canola oil (Control) after exposure to progesterone devices.</p>
<div class="groups" bis_skin_checked="1">
<table>
<thead>
<tr class="rowsep-1">
<th id="en0001" class="align-left valign-top" scope="col">Variable</th>
<th id="en0002" class="align-left valign-top" colspan="3" scope="col">Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td id="en0003" class="align-left valign-top"></td>
<td id="en0004" class="align-left valign-top">EC<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#tb1fn2" name="btb1fn2">*</a></td>
<td id="en0005" class="align-left valign-top">Control<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#tb1fn2" name="btb1fn2">*</a></td>
<td id="en0006" class="align-left valign-top">P value</td>
</tr>
<tr>
<td id="en0007" class="align-left valign-top">Expression of estrus%, (n/n)</td>
<td id="en0008" class="align-left valign-top">85.7% (12/14)</td>
<td id="en0009" class="align-left valign-top">0% (0/14)</td>
<td id="en0010" class="align-left valign-top"><em>P</em>&nbsp;&lt; 0,001</td>
</tr>
<tr>
<td id="en0011" class="align-left valign-top">Interval to estrus (h)<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#tb1fn1" name="btb1fn1"><sup>a</sup></a></td>
<td id="en0012" class="align-left valign-top">46&nbsp;±&nbsp;3.7</td>
<td id="en0013" class="align-left valign-top">–</td>
<td id="en0014" class="align-left valign-top"></td>
</tr>
</tbody>
</table>
</div>
<dl class="footnotes">
<dd>
<p id="notep0001">Interval from CIDR® device removal to estrus detection.</p>
</dd>
<dt id="tb1fn2">⁎</dt>
<dd>
<p id="notep0002">All cows received a CIDR device plus 2&nbsp;mg of estradiol benzoate on Day 0 and 12.5&nbsp;mg of PGF analogue (Dinoprost) on Day 7. On Day 9, the CIDR devices were removed and cows were assigned to two treatment groups in a cross-over design to receive 0.5&nbsp;mL of canola oil (Control Group,&nbsp;<em>n</em>&nbsp;=&nbsp;14) or 1&nbsp;mg of estradiol cypionate (EC Group,&nbsp;<em>n</em>&nbsp;=&nbsp;14; E.C.P®).</p>
</dd>
</dl>
</div>
</div>
<div bis_skin_checked="1">
<p id="para0017">The distribution and percentage of ovariectomized cows showing estrus after CIDR removal in the EC group are shown in&nbsp;Fig.&nbsp;1.</p>
<p><img class="alignnone size-full wp-image-4989" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20386%20255'%3E%3C/svg%3E" alt="" width="386" height="255" data-lazy-srcset="/../../../../wp-content/uploads/2020/07/Interval.jpg 386w, //ikigaicorporation.com/wp-content/uploads/2020/07/Interval-320x211.jpg 320w" data-lazy-sizes="(max-width: 386px) 100vw, 386px" data-lazy-src="/../../../../wp-content/uploads/2020/07/Interval.jpg"><noscript><img class="alignnone size-full wp-image-4989" src="/../../../../wp-content/uploads/2020/07/Interval.jpg" alt="" width="386" height="255" srcset="/../../../../wp-content/uploads/2020/07/Interval.jpg 386w, //ikigaicorporation.com/wp-content/uploads/2020/07/Interval-320x211.jpg 320w" sizes="(max-width: 386px) 100vw, 386px" /></noscript></p>
<figure id="fig0001" class="figure text-xs">
<p id="spara001"><span class="label">Fig. 1</span>.&nbsp;Distribution and percentage of ovariectomized cows showing estrus after CIDR removal in the EC group.</p>
</figure>
</div>
</section>
<section id="sec0008">
<h6 id="cesectitle0011" class="u-h4 u-margin-m-top u-margin-xs-bottom">3.2.&nbsp;Experiment 2</h6>
<div bis_skin_checked="1">
<p id="para0018">Ovarian and estrus responses and P/AI in Experiment 2 are summarized in&nbsp;Tables&nbsp;2&nbsp;and&nbsp;<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#tbl0003" name="btbl0003">3</a>. The P/AI did not differ among the groups (<em>P</em>&nbsp;=&nbsp;0.87).</p>
<div id="tbl0002" class="tables colsep-0 frame-topbot rowsep-0" bis_skin_checked="1">
<p id="spara004"><span class="label">Table 2</span>.&nbsp;Diameter of preovulatory follicles, proportion of cows in estrus, and pregnancy per AI of cows treated with EC, EC-GnRH or Estrus-GnRH in Experiment 2.</p>
<div class="groups" bis_skin_checked="1">
<table>
<thead>
<tr class="rowsep-1">
<th id="en0015" class="align-left valign-top" scope="col"></th>
<th id="en0016" class="align-left valign-top" colspan="3" scope="col">Group</th>
<th id="en0017" class="align-left valign-top" scope="col"></th>
</tr>
</thead>
<tbody>
<tr>
<th id="en0018" class="align-left valign-top" scope="row"></th>
<td id="en0019" class="align-left valign-top">EC</td>
<td id="en0020" class="align-left valign-top">EC-GnRH</td>
<td id="en0021" class="align-left valign-top">Estrus-GnRH</td>
<td id="en0022" class="align-left valign-top">P value</td>
</tr>
<tr>
<th id="en0023" class="align-left valign-top" scope="row">Preovulatory follicle at TAI, mm (n)<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#tb2fn1" name="btb2fn1">*</a></th>
<td id="en0024" class="align-left valign-top">13.7&nbsp;±&nbsp;0.3 (47)</td>
<td id="en0025" class="align-left valign-top">12.8&nbsp;±&nbsp;0.3 (43)</td>
<td id="en0026" class="align-left valign-top">13.7&nbsp;±&nbsp;0.3 (48)</td>
<td id="en0027" class="align-left valign-top">0.12</td>
</tr>
<tr>
<th id="en0028" class="align-left valign-top" scope="row">Proportion of cows that showed estrus,% (n/total)</th>
<td id="en0029" class="align-left valign-top">68.7<sup>A</sup>&nbsp;(185/269)</td>
<td id="en0030" class="align-left valign-top">57.2<sup>B</sup>&nbsp;(154/269)</td>
<td id="en0031" class="align-left valign-top">35.7<sup>C</sup>&nbsp;(95/266)</td>
<td id="en0032" class="align-left valign-top">&lt; 0.001</td>
</tr>
<tr>
<th id="en0033" class="align-left valign-top" scope="row">Pregnancy per AI,% (n/total)</th>
<td id="en0034" class="align-left valign-top">58.7 (158/269)</td>
<td id="en0035" class="align-left valign-top">59.8 (161/269)</td>
<td id="en0036" class="align-left valign-top">57.1 (152/266)</td>
<td id="en0037" class="align-left valign-top">0.87</td>
</tr>
</tbody>
</table>
</div>
<p id="spara005">Within row, different superscripts indicate differences among groups (<em>P</em>&nbsp;&lt; 0.05).</p>
<dl class="footnotes">
<dt id="tb2fn1">⁎</dt>
<dd>
<p id="notep0004">Number of cows evaluated in each group.</p>
</dd>
</dl>
</div>
<div id="tbl0003" class="tables colsep-0 frame-topbot rowsep-0" bis_skin_checked="1">
<p id="spara006"><span class="label">Table 3</span>.&nbsp;Pregnancy per AI (P/AI) based on expression of estrus in cows treated with EC, EC-GnRH, or Estrus-GnRH. .</p>
<div class="groups" bis_skin_checked="1">
<table>
<thead>
<tr class="rowsep-1">
<th id="en0038" class="align-left valign-top" scope="col"></th>
<th id="en0039" class="align-left valign-top" colspan="3" scope="col">Group</th>
<th id="en0040" class="align-left valign-top" scope="col"></th>
</tr>
</thead>
<tbody>
<tr>
<th id="en0041" class="align-left valign-top" scope="row"></th>
<td id="en0042" class="align-left valign-top">EC</td>
<td id="en0043" class="align-left valign-top">EC-GnRH</td>
<td id="en0044" class="align-left valign-top">Estrus-GnRH</td>
<td id="en0045" class="align-left valign-top">P value<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#tb3fn1" name="btb3fn1">*</a></td>
</tr>
<tr>
<th id="en0046" class="align-left valign-top" scope="row">P/AI in cows that showed estrus,% (n/total)</th>
<td id="en0047" class="align-left valign-top">61.6 (114/185)</td>
<td id="en0048" class="align-left valign-top">68.2 (105/154)</td>
<td id="en0049" class="align-left valign-top">63.3 (60/95)</td>
<td id="en0050" class="align-left valign-top">0.44</td>
</tr>
<tr>
<th id="en0051" class="align-left valign-top" scope="row">P/AI in cows that did not display estrus,% (n/total)</th>
<td id="en0052" class="align-left valign-top">52.4 (44/84)</td>
<td id="en0053" class="align-left valign-top">48.7 (56/115)</td>
<td id="en0054" class="align-left valign-top">53.8 (92/171)</td>
<td id="en0055" class="align-left valign-top">0.69</td>
</tr>
<tr>
<th id="en0056" class="align-left valign-top" scope="row">P value<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#tb3fn2" name="btb3fn2"><sup>⁎⁎</sup></a></th>
<td id="en0057" class="align-left valign-top">0.15</td>
<td id="en0058" class="align-left valign-top">&lt;0.01</td>
<td id="en0059" class="align-left valign-top">0.13</td>
<td id="en0060" class="align-left valign-top"></td>
</tr>
</tbody>
</table>
</div>
<dl class="footnotes">
<dt id="tb3fn1">⁎</dt>
<dd>
<p id="notep0005">Comparison among groups.</p>
</dd>
<dt id="tb3fn2">⁎⁎</dt>
<dd>
<p id="notep0006">Comparison between cows that showed estrus and cows that did not show estrus.</p>
</dd>
</dl>
</div>
</div>
<p id="para0019">The proportion of cows that showed estrus during the interval from CIDR device removal to TAI was greater in EC and EC-GnRH groups than in the Estrus-GnRH group (<em>P</em>&nbsp;&lt; 0.001;&nbsp;Table&nbsp;2). Cows that showed estrus had a greater (<em>P</em>&nbsp;=&nbsp;0.04) follicular diameter at TAI (13.8&nbsp;±&nbsp;0.3&nbsp;vs. 13.0&nbsp;±&nbsp;0.3&nbsp;mm), and greater (<em>P</em>&nbsp;&lt; 0.001) P/AI than those that did not display estrus (64.3%, 279/434&nbsp;vs. 51.9%, 192/370).</p>
<p id="para0020">Considering only the cows that showed estrus within each group, there was no difference in P/AI among the groups (<em>P</em>&nbsp;=&nbsp;0.44). Similarly, in cows that did not show estrus, P/AI did not differ among groups (<em>P</em>&nbsp;=&nbsp;0.69;&nbsp;Table&nbsp;3).</p>
<div bis_skin_checked="1">
<p id="para0021">The diameter of the POF at TAI did not differ among the groups (<em>P</em>&nbsp;=&nbsp;0.12). However, the probability of cows showing estrus increased with increasing POF diameter (<em>P</em>&nbsp;=&nbsp;0.04;&nbsp;Fig.&nbsp;2).</p>
<p><img class="alignnone size-full wp-image-4990" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20391%20276'%3E%3C/svg%3E" alt="" width="391" height="276" data-lazy-srcset="/../../../../wp-content/uploads/2020/07/Diametr.jpg 391w, //ikigaicorporation.com/wp-content/uploads/2020/07/Diametr-320x226.jpg 320w" data-lazy-sizes="(max-width: 391px) 100vw, 391px" data-lazy-src="/../../../../wp-content/uploads/2020/07/Diametr.jpg"><noscript><img class="alignnone size-full wp-image-4990" src="/../../../../wp-content/uploads/2020/07/Diametr.jpg" alt="" width="391" height="276" srcset="/../../../../wp-content/uploads/2020/07/Diametr.jpg 391w, //ikigaicorporation.com/wp-content/uploads/2020/07/Diametr-320x226.jpg 320w" sizes="(max-width: 391px) 100vw, 391px" /></noscript></p>
<figure id="fig0002" class="figure text-xs">
<p id="spara002"><span class="label">Fig. 2</span>.&nbsp;Probability of estrus occurrence in suckled&nbsp;<em>Bos indicus</em>&nbsp;cows according to the diameter of the largest follicle (LF) at FTAI in Experiment 2 [probability of estrus occurrence =exp(0.031+0.0374&nbsp;×&nbsp;diameter of the LF/1&nbsp;+&nbsp;exp(0.031+0.0374&nbsp;×&nbsp;diameter of the LF);&nbsp;<em>P</em>&nbsp;=&nbsp;0.04)].</p>
</figure>
</div>
</section>
</section>
<section id="sec0009">
<h3 id="cesectitle0012" class="u-h3 u-margin-l-top u-margin-xs-bottom">4.&nbsp;Discussion</h3>
<hr>
<p>&nbsp;</p>
<p id="para0022">The results of the current study supported the hypothesis that EC is able to induce estrus in ovariectomized cows. However, the hypothesis that cows that exhibit estrus following EC administration will have lower P/AI compared to those that do not receive EC was not supported.</p>
<p id="para0023">The use of ovariectomized cows in Experiment 1 clearly showed that EC induces behavioral estrus in ovariectomized cows as has been previously described (Katz&nbsp;et&nbsp;al., 1980). Different doses of estradiol-17β (200, 400, and 800&nbsp;µg), administered to ovariectomized nulliparous cattle, induced a full repertoire of sexual behavioral patterns associated with the female in estrus (Katz&nbsp;et&nbsp;al., 1980). In Experiment 1, EC administration induced estrus in 64% (9/14) of the cows within 48&nbsp;h after treatment, which indicates that, in a conventional TAI protocol which included the administration of EC, most of the cows would have exhibited estrus before TAI. However, when nulliparous ovariectomized cattle were treated with estradiol-17β, the interval from treatment to the first stand to be mounted is 25.4&nbsp;±&nbsp;0.8&nbsp;h (Katz&nbsp;et&nbsp;al., 1980). Prior exposure to progesterone has also been shown to affect the interval to estrus after EC administration in intact dairy cows. In dairy cows subjected to the Heatsynch protocol, administration of 1&nbsp;mg of EC resulted in the expression of estrus in 19&nbsp;±&nbsp;5&nbsp;h when CIDR insert was given between GnRH and PGF treatment while the interval was 33&nbsp;±&nbsp;4&nbsp;h when the CIDR was not given (Stevenson&nbsp;et&nbsp;al., 2004). Moreover, when 0.25&nbsp;mg of EC was given concurrent with GnRH in the Ovsynch protocol, cows had higher serum estradiol concentrations at 6 and 12&nbsp;h after treatment, than when cows did not receive EC (Sellars&nbsp;et&nbsp;al., 2006). Collectively, these results demonstrate that EC is able to induce estrus in ovariectomized and intact cows.</p>
<p id="para0024">Estradiol esters are commonly used at the end of estradiol-progesterone-based TAI protocols to induce LH release and synchronize ovulation. A rise in circulating LH concentration has been reported to occur 40&nbsp;h after EC treatment in ovariectomized beef heifers submitted to an estradiol-progesterone-based protocol (Sales&nbsp;et&nbsp;al., 2012). However, administration of EC increased the proportion of Nelore cows showing estrus after progesterone device removal, compared to the administration of only GnRH as an ovulatory stimulus (Sa&nbsp;Filho&nbsp;et&nbsp;al., 2011). As observed in the present study, the proportion of cows that showed estrus was greater in EC-treated cows. In contrast, an unexpected difference in estrus manifestation between the EC and EC-GnRH groups was observed. Although not different, the diameter of the POF in the EC-GnRH group was ~ 1&nbsp;mm smaller than cows in the EC group. This could explain the difference in estrus rate between these experimental groups.</p>
<p id="para0025">Previous reports (Sa&nbsp;Filho&nbsp;et&nbsp;al., 2011;&nbsp;Pfeifer&nbsp;et&nbsp;al., 2018;&nbsp;Rodrigues&nbsp;et&nbsp;al., 2019), have indicated that cows that show estrus behavioral were more likely to become pregnant when TAI protocols are used. However, this effect was not detected in the present study when P/AI was compared between cows that displayed estrus and cows that did not display estrus within group. The failure to show a differences may be due to insufficient numbers of cows in the treatment groups. However, it has been reported that cows showing estrus had larger follicular diameters at TAI, and greater P/AI than those that did not show estrus (Sa&nbsp;Filho&nbsp;et&nbsp;al., 2011). The occurrence of standing estrus has been reported to be associated with peak circulating estradiol concentrations (Allrich,&nbsp;1994), which may influence fertilization by altering the uterine environment (Hawk,&nbsp;1983). Following the occurrence of standing estrus, the uterine environment has been shown to be modified to enhance sperm motility and longevity (Acott&nbsp;and Carr,&nbsp;1984;&nbsp;Jones&nbsp;and Bavister,&nbsp;2000). Thus, elevated estradiol levels from either endogenous or exogenous sources may play an important role in sperm transport and the sustained viability of sperm prior to ovulation and fertilization (Sa&nbsp;Filho&nbsp;et&nbsp;al., 2011) explaining the greater P/AI observed in cows that displayed estrus.</p>
<p id="para0026">More recently, alternatives have been developed to take advantage of the expression of estrus to improve fertility in TAI protocols. One such alternative, split-time artificial insemination (STAI), involves delaying AI by 20–24&nbsp;h for females failing to show estrus prior to the standard time of TAI. This approach has been shown to be an effective means of optimizing pregnancy rates while utilizing TAI (Thomas&nbsp;et&nbsp;al., 2014).</p>
<p id="para0027">In cows that were examined by ultrasound (<em>n</em>&nbsp;=&nbsp;138), in Experiment 2, 3 cows that showed estrus had a follicle ≤ 8&nbsp;mm in the ovary at the time of TAI. When the cows in this study were categorized based on the diameter of the POF, as described previously (Pfeifer et&nbsp;al., 2015,&nbsp;Pfeifer et&nbsp;al., 2019), 46% (28/61) of the cows with small follicles (&lt;13&nbsp;mm) exhibited estrus. Moreover, in cows that had POF ≤ 10&nbsp;mm at TAI, 27% showed behavioral estrus between progesterone device removal and TAI. In contrast, none of the cows with POF ≤ 11.5&nbsp;mm in the Estrus-GnRH group showed estrus. However, if a POF diameter of 11.5&nbsp;mm is used as a cut-off, 40% and 44% of the cows in the EC and EC-GnRH groups respectively, exhibited estrus. These results support our hypothesis that EC treatment can induce estrus in beef cows independently of the ovarian response.</p>
<p id="para0028">Cows in Experiment 2 were treated with 300 IU of eCG on Day 9 of the TAI protocol. Previous studies have demonstrated that eCG treatment of anestrus cows under nutritional stress increased follicular growth rate, the diameter of the dominant follicle at TAI, and pregnancy rates (Baruselli&nbsp;et&nbsp;al., 2004;&nbsp;Sa&nbsp;Filho et&nbsp;al., 2009). Thus, one could speculate that the use of eCG in Experiment 2 of the present study may have affected estrus response of treated cows. Nevertheless, Experiment 2 was performed at commercial beef operations and thus, we used standard TAI protocol for suckled beef cows which typically includes the use of eCG. Indeed, cows treated with eCG and EC, at progesterone insert removal, exhibited a greater occurrence of estrus than cows only treated with EC (Pessoa&nbsp;et&nbsp;al., 2016). Differences in protocols between Experiments 1 and 2 were mitigated because eCG was distributed equally among groups in Experiment 2. However, further studies are needed to determine if eCG could affect the proportion of EC-treated cows showing estrus.</p>
<p id="para0029">GnRH has been used as an alternative in cows that do not exhibit estrus between progesterone device removal and TAI. Interestingly, 35.7% of the cows from the Estrus-GnRH cohort underwent TAI without receiving GnRH to induce ovulation, and these cows achieved 63% of P/AI. In contrast, the remaining 64% of cows from this group were treated with GnRH at the time of TAI to induce ovulation. As compared to cows treated with EC (i.e. EC vs. EC-GnRH) in this study, GnRH did not improve pregnancy rates in cows that did not show estrus. In addition, it has been shown that GnRH administration is unnecessary in cows exhibiting estrus prior to TAI (Hill&nbsp;et&nbsp;al., 2016;&nbsp;Bishop&nbsp;et&nbsp;al., 2017). In contrast, others have observed that the administration of GnRH in estradiol progesterone-based protocols can be used as an alternative to improve conception rates in&nbsp;<em>Bos indicus</em>&nbsp;beef cows, particularly those with no or little evidence of behavioral estrus (Rodrigues&nbsp;et&nbsp;al., 2019), and Sa&nbsp;Filho&nbsp;et&nbsp;al.&nbsp;(2010)&nbsp;reported that the administration of GnRH at TAI avoided delayed ovulations, improving synchronization of ovulation and pregnancy rates. GnRH treatment at the time of TAI may induce a preovulatory LH surge and ovulation in cows that would have had delayed ovulation. Nonetheless,&nbsp;Shephard&nbsp;et&nbsp;al.&nbsp;(2014)&nbsp;suggests that the results of GnRH administration at the time of AI are limited, and that the positive effect in lactating dairy cows may be mediated through the improved oocyte maturation and/or improved luteal function, rather than by reducing AI-to-ovulation intervals. Finally, although a large study, performed with 937 beef cows revealed that GnRH increases P/AI in cows categorized as having low or no expression of behavioral estrus (Rodrigues&nbsp;et&nbsp;al., 2019), more research is necessary to determine the need for GnRH in cows that do not show estrus in an estradiol progesterone-based TAI protocols.</p>
<p id="para0030">Earlier, Sa&nbsp;Filho&nbsp;et&nbsp;al.&nbsp;(2010), observed that 57% of the cows treated with EC were detected in estrus between the P4 device removal and TAI. In contrast, considering only cows treated with EC in the present study (e.g. EC and EC-GnRH groups), 63% of the cows exhibited estrus. This effect may be due to the use of different doses of EC between studies (0.6&nbsp;mg vs. 1&nbsp;mg). More recently,&nbsp;Nogueira&nbsp;et&nbsp;al.&nbsp;(2019)&nbsp;observed that 41% of the cows treated EC using the same dose as described in the present study were detected in estrus. We, therefore, infer that the greater estrus rate observed in the present study was probably due to the adequate BCS of the cows; 82% (659/804) of the cows had a BCS &gt;2.75 (scale 1 – 5;&nbsp;Pfeifer&nbsp;et&nbsp;al., 2017) whereas cows raised in the Brazilian wetlands (Pantanal region) usually have low BCS (only 58% of the cows had BCS &gt;2.75). These evidence may explain why, in the present study, a greater proportion of cows were detected in estrus between P4 device removal and TAI compared to other studies.</p>
</section>
<section id="sec0010">
<h3 id="cesectitle0013" class="u-h3 u-margin-l-top u-margin-xs-bottom">5.&nbsp;Conclusions</h3>
<hr>
<p>&nbsp;</p>
<p id="para0031">In summary, EC used as a means of inducing ovulation in estradiol-progesterone-based TAI protocols has also been shown to induce estrus in ovariectomized cows. The results from Experiment 2 showed that EC could be removed from the TAI protocol when a combination of estrus detection and GnRH administration was used. In the present study, behavioral estrus without the use of EC treatment was used to increase pregnancy rates in cattle subjected to TAI. However, P/AI among groups was similar. Perhaps AI in cows that displayed estrus should be postponed in order to time AI in relation to ovulation more precisely. Therefore, more studies aiming to better understand the factors influencing the occurrence of estrus, ovulation and pregnancy, following estradiol-progesterone-based synchronization protocols that included the use of eCG, are necessary before concluding that the removal of EC from the protocol is beneficial for postpartum beef cows subjected to TAI.</p>
</section>
</div>
<section id="coi0001">
<h5 id="cesectitle0015" class="u-h3 u-margin-l-top u-margin-xs-bottom">Declaration of Competing Interest</h5>
<p id="para0033">We declare that there are no conflicts of interests in this study.</p>
</section>
<section id="ack0001">
<h5 id="cesectitle0016" class="u-h3 u-margin-l-top u-margin-xs-bottom">Acknowledgments</h5>
<p id="para0034">This study received funding support from&nbsp;<span id="gs0001">Embrapa</span>&nbsp;(MP1/PC3 Project n.&nbsp;<a href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#gs0001">01.03.14.011.00.00</a>) and from&nbsp;<span id="gs0002">CNPq</span>&nbsp;(Universal Project n:&nbsp;<a href="https://www.sciencedirect.com/science/article/pii/S1871141319312211#gs0002">407307/2016-8</a>). We thank Dr. Reuben Mapletoft for kindly editing the manuscript.</p>
</section>
<h5 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">References</h5>
<ol>
<li>Acott and Carr, 1984</li>
</ol>
<p>T.S. Acott, D.W. Carr</p>
<p>Inhibition of bovine spermatozoa by caudal epididymal fluid: II. Interaction of pH and a quiescence factor</p>
<p>Biol. Reprod., 30 (1984), pp. 926-935</p>
<p>&nbsp;</p>
<p>2. Allrich, 1994</p>
<p>R.D. Allrich</p>
<p>Endocrine and neural control of estrus in dairy cows</p>
<p>J. Dairy Sci., 77 (1994), pp. 2738-2744</p>
<p>&nbsp;</p>
<p>3. Ayres et al., 2008</p>
<p>J. Ayres, C.M. Martins, R.M. Ferreira, J.E. Mello, J.H. Dominguez, A.H. Souza, R. Valentin, I.C. Santos, P.S. Baruselli</p>
<p>Effect of timing of estradiol benzoate administration upon synchronization of ovulation in suckling nelore cows (Bos indicus) treated with a progesterone-releasing intravaginal device</p>
<p>Anim. Reprod. Sci., 109 (2008), pp. 77-87</p>
<p>&nbsp;</p>
<p>4. Baruselli et al., 2004</p>
<p>P.S. Baruselli, E.L. Reis, M.O. Marques, L.F. Nasser, G.A. Bo</p>
<p>The use of hormonal treatments to improve reproductive performance of anestrous beef cattle in tropical climates</p>
<p>Anim. Reprod. Sci., 82-83 (2004), pp. 479-486</p>
<p>&nbsp;</p>
<p>5. Baruselli et al., 2012</p>
<p>P.S. Baruselli, J.N. Sales, R.V. Sala, L.M. Vieira, M.F. Sa Filho</p>
<p>History, evolution and perspectives of timed artificial insemination programs in brazil</p>
<p>Anim. Reprod., 9 (2012), pp. 139-152</p>
<p>&nbsp;</p>
<p>6. Bishop et al., 2017</p>
<p>B.E. Bishop, J.M. Thomas, J.M. Abel, S.E. Poock, M.R. Ellersieck, M.F. Smith, D.J. Patterson</p>
<p>Split-time artificial insemination in beef cattle: III. comparing fixed-time artificial insemination to split-time artificial insemination with delayed administration of gnrh in postpartum cows</p>
<p>Theriogenology, 99 (2017), pp. 48-52</p>
<p>7. Bo et al., 2003</p>
<p>G.A. Bo, P.S. Baruselli, M.F. Martinez</p>
<p>Pattern and manipulation of follicular development in bos indicus cattle</p>
<p>Anim. Reprod. Sci., 78 (2003), pp. 307-326</p>
<p>&nbsp;</p>
<p>8. Colazo et al., 2003</p>
<p>M.G. Colazo, J.P. Kastelic, R.J. Mapletoft</p>
<p>Effects of estradiol cypionate (ECP) on ovarian follicular dynamics, synchrony of ovulation, and fertility in CIDR-based, fixed-time ai programs in beef heifers</p>
<p>Theriogenology, 60 (2003), pp. 855-865</p>
<p>&nbsp;</p>
<p>9. Hawk, 1983</p>
<p>H.W. Hawk</p>
<p>Sperm survival and transport in the female reproductive tract</p>
<ol>
<li>Dairy Sci., 66 (1983)</li>
</ol>
<p>2645–2460</p>
<p>&nbsp;</p>
<p>10. Hill et al., 2016</p>
<p>S.L. Hill, D.M. Grieger, K.C. Olson, J.R. Jaeger, C.R. Dahlen, M.R. Crosswhite, N.N. Pereira, S.R. Underdahl, B.W. Neville, J. Ahola, M.C. Fischer, G.E. Seidel, J.S. Stevenson</p>
<p>Gonadotropin-releasing hormone increased pregnancy risk in suckled beef cows not detected in estrus and subjected to a split-time artificial insemination program</p>
<p>J. Anim. Sci., 94 (2016), pp. 3722-3728</p>
<p>&nbsp;</p>
<p>11. Jones and Bavister, 2000</p>
<p>J.M. Jones, B.D. Bavister</p>
<p>Acidification of intracellular pH in bovine spermatozoa suppresses motility and extends viable life</p>
<p>J. Androl., 21 (2000), pp. 616-624</p>
<p>&nbsp;</p>
<p>12. Katz et al., 1980</p>
<p>L.S. Katz, E.A. Oltenacu, R.H. Foote</p>
<p>The behavioral responses in ovariectomized cattle to either estradiol, testosterone, androstenedione, or dihydrotestosterone</p>
<p>Horm. Behav., 14 (1980), pp. 224-235</p>
<p>&nbsp;</p>
<p>12. Lowman et al., 1976</p>
<p>B.G. Lowman, N.A. Scott, S.H. Somervalle</p>
<p>Condition scoring of cattle</p>
<p>Edinburgh, 6 (1976), pp. 1-31</p>
<p>&nbsp;</p>
<p>13. Nogueira et al., 2019</p>
<ol>
<li>Nogueira, M.R. Silva, J.C.B. Silva, U.P.G. Abreu, N.A. Anache, K.C. Silva, C.J.T. Cardoso, P. Sutovsky, W.B. Rodrigues</li>
</ol>
<p>Timed artificial insemination plus heat I: effect of estrus expression scores on pregnancy of cows subjected to progesterone-estradiol-based protocols</p>
<p>Animal (2019), pp. 1-8</p>
<p>&nbsp;</p>
<p>14. Pessoa et al., 2016</p>
<p>G.A. Pessoa, A.P. Martini, G.W. Carloto, M.C.C. Rodrigues, I. Claro Junior, P.S. Baruselli, C.C. Brauner, M.I.B Rubin, M.N Correa, F.G. Leivas, M.F. Sa Filho</p>
<p>Different doses of equine chorionic gonadotropin on ovarian follicular growth and pregnancy rate of suckled BOS taurus beef cows subjected to timed artificial insemination protocol</p>
<p>Theriogenology, 85 (2016), pp. 792-799</p>
<p>&nbsp;</p>
<p>15. Pfeifer et al., 2015</p>
<p>L.F.M. Pfeifer, N.A. Castro, V.T. Melo, P.M. Neves, J.P. Cestaro, A. Schneider</p>
<p>Timed artificial insemination in blocks: a new alternative to improve fertility in lactating beef cows</p>
<p>Anim. Reprod. Sci., 163 (2015), pp. 89-96</p>
<p>&nbsp;</p>
<p>16. Pfeifer et al., 2017</p>
<p>L.F. Pfeifer, N.A. Castro, P.M. Neves, J.P. Cestaro, L.G. Siqueira</p>
<p>Development and validation of an objective method for the assessment of body condition scores and selection of beef cows for timed artificial insemination</p>
<p>Liv. Sci., 197 (2017), pp. 82-87</p>
<p>&nbsp;</p>
<p>17. Pfeifer et al., 2018</p>
<p>Casanova da</p>
<p>L.F.M. Pfeifer, W.B. Rodrigues, K. Silva, N.A. Anache, N.A. Castro, E.M. Castilho, E. Nogueira</p>
<p>Different protocols using PGF2alpha as ovulation inducer in nelore cows subjected to estradiol-progesterone timed AI based protocols</p>
<p>Theriogenology, 120 (2018), pp. 56-60</p>
<p>&nbsp;</p>
<p>18. Pfeifer et al., 2019</p>
<p>L.F.M. Pfeifer, J.S.O. Junior, J.R. Potiens</p>
<p>Effect of sperm kinematics and size of follicle at ovulation on pregnancy rate after timed ai of beef cows</p>
<p>Anim. Reprod. Sci., 201 (2019), pp. 55-62</p>
<p>&nbsp;</p>
<p>19. Richardson et al., 2016</p>
<p>B.N. Richardson, S.L. Hill, J.S. Stevenson, G.D. Djira, G.A. Perry</p>
<p>Expression of estrus before fixed-time AI affects conception rates and factors that impact expression of estrus and the repeatability of expression of estrus in sequential breeding seasons</p>
<p>Anim. Reprod. Sci., 166 (2016), pp. 133-140</p>
<p>&nbsp;</p>
<p>20. Rodrigues et al., 2019</p>
<p>W.B. Rodrigues, A.S. Silva, J.C.B. Silva, N.A. Anache, K.C. Silva, C.J.T. Cardoso, W.R. Garcia, P. Sutovsky, E. Nogueira</p>
<p>Timed artificial insemination plus heat II: gonadorelin injection in cows with low estrus expression scores increased pregnancy in progesterone/estradiol-based protocol</p>
<p>Animal (2019), pp. 1-6</p>
<p>&nbsp;</p>
<p>21. Filho et al., 2010</p>
<p>Sa Filho, M. F., A.M. Crespilho, J.E. Santos, G.A. Perry, P.S. Baruselli</p>
<p>Ovarian follicle diameter at timed insemination and estrous response influence likelihood of ovulation and pregnancy after estrous synchronization with progesterone or progestin-based protocols in suckled BOS indicus cows</p>
<p>Anim. Reprod. Sci., 120 (2010), pp. 23-30</p>
<p>&nbsp;</p>
<p>22. Filho et al., 2011</p>
<p>Sa Filho, M. F., J.E. Santos, R.M. Ferreira, J.N. Sales, P.S. Baruselli</p>
<p>Importance of estrus on pregnancy per insemination in suckled BOS indicus cows submitted to estradiol/progesterone-based timed insemination protocols</p>
<p>Theriogenology, 76 (2011), pp. 455-463</p>
<p>&nbsp;</p>
<p>23. Sa Filho et al., 2013</p>
<p>M.F. Sa Filho, L. Penteado, E.L. Reis, T.A. Reis, K.N. Galvão, P.S. Baruselli</p>
<p>Timed artificial insemination early in the breeding season improves the reproductive performance of suckled beef cows</p>
<p>Theriogenology, 79 (2013), pp. 625-632</p>
<p>&nbsp;</p>
<p>24. Sa Filho et al., 2009</p>
<p>O.G. Sa Filho, M. Meneghetti, R.F. Peres, G.C. Lamb, J.L. Vasconcelos</p>
<p>Fixed-time artificial insemination with estradiol and progesterone for BOS indicus cows II: strategies and factors affecting fertility</p>
<p>Theriogenology, 72 (2009), pp. 210-218</p>
<p>&nbsp;</p>
<p>25. Sales et al., 2012</p>
<p>J.N. Sales, J.B. Carvalho, G.A. Crepaldi, R.S. Cipriano, J.O. Jacomini, J.R. Maio, J.C. Souza, G.P. Nogueira, P.S. Baruselli</p>
<p>Effects of two estradiol esters (benzoate and cypionate) on the induction of synchronized ovulations in bos indicus cows submitted to a timed artificial insemination protocol</p>
<p>Theriogenology, 78 (2012), pp. 510-516</p>
<p>&nbsp;</p>
<p>26. Sellars et al., 2006</p>
<p>C.B. Sellars, J.C. Dalton, R. Manzo, J. Day, A. Ahmadzadeh</p>
<p>Time and incidence of ovulation and conception rates after incorporating estradiol cypionate into a timed artificial insemination protocol</p>
<p>J. Dairy Sci., 89 (2006), pp. 620-626</p>
<p>&nbsp;</p>
<p>27. Shephard et al., 2014</p>
<p>R.W. Shephard, J.M. Morton, S.T. Norman</p>
<p>Effects of administration of gonadotropin-releasing hormone at artificial insemination on conception rates in dairy cows</p>
<p>Anim. Reprod. Sci., 144 (2014), pp. 14-21</p>
<p>&nbsp;</p>
<p>28. Stevenson et al., 2004</p>
<p>J.S. Stevenson, S.M. Tiffany, M.C. Lucy</p>
<p>Use of estradiol cypionate as a substitute for gnrh in protocols for synchronizing ovulation in dairy cattle</p>
<p>J. Dairy Sci., 87 (2004), pp. 3298-3305</p>
<p>&nbsp;</p>
<p>29. Thomas et al., 2014</p>
<p>J.M. Thomas, S.L. Lock, S.E. Poock, M.R. Ellersieck, M.F. Smith, D.J. Patterson</p>
<p>Delayed insemination of nonestrous cows improves pregnancy rates when using sex-sorted semen in timed artificial insemination of suckled beef cows</p>
<p>J. Anim. Sci., 92 (2014), pp. 1747-1752</p>
<h3>Source</h3>
<hr>
</section>
<p>&nbsp;</p>
<p>https://www.sciencedirect.com/science/article/pii/S1871141319312211</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2020/07/27/effect-of-estradiol-cypionate-on-estrus-expression-and-pregnancy-in-timed-artificially-inseminated-beef-cows/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2020/07/27/effect-of-estradiol-cypionate-on-estrus-expression-and-pregnancy-in-timed-artificially-inseminated-beef-cows/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-4717 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>20.05.2020</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2020/05/20/17%ce%b2-hydroxyestra-4911-trien-3-one-trenbolone-exhibits-tissue-selective-anabolic-activity-effects-on-muscle-bone-adiposity-hemoglobin-and-prostate/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2020/05/20/17%ce%b2-hydroxyestra-4911-trien-3-one-trenbolone-exhibits-tissue-selective-anabolic-activity-effects-on-muscle-bone-adiposity-hemoglobin-and-prostate/">17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p>&nbsp;</p>
<div class="pmc-page-banner whole_rhythm" bis_skin_checked="1">
<div bis_skin_checked="1">
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Logo of ajpendo" usemap="#logo-imagemap" data-lazy-src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/logo-ajpendo.gif"><noscript><img src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/logo-ajpendo.gif" alt="Logo of ajpendo" usemap="#logo-imagemap" /></noscript></p>
<map id="logo-imagemap" name="logo-imagemap">
<area title="Published Article" alt="Published Article" coords="406,0,500,21" shape="rect" href="http://ajpendo.physiology.org/cgi/reprint/300/4/E650" target="pmc_ext">
<area title="Archives" alt="Archives" coords="406,21,500,33" shape="rect" href="http://ajpendo.physiology.org/content/by/year" target="pmc_ext">
<area title="Subscriptions" alt="Subscriptions" coords="406,33,500,45" shape="rect" href="http://www.the-aps.org/mm/Publications/Purchasing" target="pmc_ext">
<area title="Submissions" alt="Submissions" coords="406,45,500,57" shape="rect" href="http://ajpendo.msubmit.net/" target="pmc_ext">
<area title="Contact Us" alt="Contact Us" coords="406,57,500,75" shape="rect" href="mailto:ajpendo@the-aps.org" target="pmc_ext">
<area title="AJP - Endocrinology and Metabolism" alt="AJP - Endocrinology and Metabolism" coords="141,0,405,75" shape="rect" href="http://ajpendo.physiology.org/" target="pmc_ext">
<area title="American Physiological Society" alt="American Physiological Society" coords="0,0,140,75" shape="rect" href="http://www.the-aps.org/" target="pmc_ext"></map>
</div>
</div>
<div class="" bis_skin_checked="1">
<div class="hide-overflow article lit-style content pmc-wm slang-all page-box" bis_skin_checked="1">
<div id="ui-ncbiinpagenav-1" class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" bis_skin_checked="1">
<div class="fm-sec half_rhythm no_top_margin" bis_skin_checked="1">
<div class="fm-citation half_rhythm no_top_margin clearfix" bis_skin_checked="1">
<div class="inline_block eight_col va_top" bis_skin_checked="1">
<div bis_skin_checked="1">
<div bis_skin_checked="1"><span class="cit"><span role="menubar"><a role="menuitem" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#" aria-expanded="false" aria-haspopup="true">Am J Physiol Endocrinol Metab</a></span>. 2011 Apr; 300(4): E650–E660.</span></div>
<div bis_skin_checked="1"><span class="fm-vol-iss-date">Published online 2011 Jan 25.&nbsp;</span><span class="doi">doi:&nbsp;<a href="https://dx.doi.org/10.1152%2Fajpendo.00440.2010" target="pmc_ext" rel="noopener noreferrer">10.1152/ajpendo.00440.2010</a></span></div>
</div>
</div>
<div class="inline_block four_col va_top show-overflow align_right" bis_skin_checked="1">
<div class="fm-citation-ids" bis_skin_checked="1">
<div class="fm-citation-pmcid" bis_skin_checked="1"><span class="fm-citation-ids-label">PMCID:&nbsp;</span>PMC6189634</div>
<div class="fm-citation-pmid" bis_skin_checked="1">PMID:&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/21266670">21266670</a></div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<p>&nbsp;</p>
<p><a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Yarrow%20JF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Joshua F. Yarrow</a>,<sup><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="corresponding author" data-lazy-src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/corrauth.gif"><noscript><img src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></noscript></sup><sup>1,</sup><sup>2</sup>&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Conover%20CF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Christine F. Conover</a>,<sup>1</sup>&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=McCoy%20SC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Sean C. McCoy</a>,<sup>1,</sup><sup>2</sup>&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Lipinska%20JA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Judyta A. Lipinska</a>,<sup>1</sup>&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Santillana%20CA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Cesar A. Santillana</a>,<sup>1</sup>&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Hance%20JM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">John M. Hance</a>,<sup>1</sup>&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Cannady%20DF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Darryl F. Cannady</a>,<sup>1</sup>&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=VanPelt%20TD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Tisha D. VanPelt</a>,<sup>1</sup>&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Sanchez%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Joshua Sanchez</a>,<sup>1</sup>&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Conrad%20BP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Bryan P. Conrad</a>,<sup>3</sup>&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Pingel%20JE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Jennifer E. Pingel</a>,<sup>4</sup>&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Wronski%20TJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Thomas J. Wronski</a>,<sup>4</sup>&nbsp;and&nbsp;<a class="affpopup" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Borst%20SE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21266670">Stephen E. Borst</a><sup>1,</sup><sup>2</sup></p>
<p><a class="pmctoggle" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#">Author information</a>&nbsp;<a class="pmctoggle" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#">Article notes</a>&nbsp;<a class="pmctoggle" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#">Copyright and License information</a>&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/about/disclaimer/">Disclaimer</a></p>
<pre>This article has been&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/citedby/">cited by</a>&nbsp;other articles in PMC.</pre>
<h2 id="idm139797871679920title" class="head no_bottom_margin ui-helper-clearfix">Abstract</h2>
<hr>
<div bis_skin_checked="1">
<p id="__p1" class="p p-first-last">Selective androgen receptor modulators (SARMs) now under development can protect against muscle and bone loss without causing prostate growth or polycythemia. 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone), a potent testosterone analog, may have SARM-like actions because, unlike testosterone, trenbolone does not undergo tissue-specific 5α-reduction to form more potent androgens. We tested the hypothesis that trenbolone-enanthate (TREN) might prevent orchiectomy-induced losses in muscle and bone and visceral fat accumulation without increasing prostate mass or resulting in adverse hemoglobin elevations. Male F344 rats aged 3 mo underwent orchiectomy or remained intact and were administered graded doses of TREN, supraphysiological testosterone-enanthate, or vehicle for 29 days. In both intact and orchiectomized animals, all TREN doses and supraphysiological testosterone-enanthate augmented androgen-sensitive levator ani/bulbocavernosus muscle mass by 35–40% above shams (<em>P</em>&nbsp;≤ 0.001) and produced a dose-dependent partial protection against orchiectomy-induced total and trabecular bone mineral density losses (<em>P</em>&nbsp;&lt; 0.05) and visceral fat accumulation (<em>P</em>&nbsp;&lt; 0.05). The lowest doses of TREN successfully maintained prostate mass and hemoglobin concentrations at sham levels in both intact and orchiectomized animals, whereas supraphysiological testosterone-enanthate and high-dose TREN elevated prostate mass by 84 and 68%, respectively (<em>P</em>&nbsp;&lt; 0.01). In summary, low-dose administration of the non-5α-reducible androgen TREN maintains prostate mass and hemoglobin concentrations near the level of shams while producing potent myotrophic actions in skeletal muscle and partial protection against orchiectomy-induced bone loss and visceral fat accumulation. Our findings indicate that TREN has advantages over supraphysiological testosterone and supports the need for future preclinical studies examining the viability of TREN as an option for androgen replacement therapy.</p>
</div>
<div class="sec" bis_skin_checked="1"><strong class="kwd-title">Keywords:&nbsp;</strong><span class="kwd-text">androgen, 5α-reductase, steroid, testosterone, selective androgen receptor modulator</span></div>
<div bis_skin_checked="1">
<hr>
<p id="__p2" class="p p-first"><span class="small-caps">in men, hypogonadism</span>&nbsp;(i.e., reduced circulating testosterone) results in a variety of detrimental effects, including the loss of skeletal muscle mass and bone mineral density (BMD) and increased visceral adiposity (<a id="__tag_729447887" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B52" aria-expanded="false" aria-haspopup="true">52</a>). Testosterone replacement therapy has been proposed as a means of reducing these unfavorable changes (<a id="__tag_729447853" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B6" aria-expanded="false" aria-haspopup="true">6</a>). However, replacement doses of testosterone result in only minor improvements in muscle strength (<a id="__tag_729447905" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B39" aria-expanded="false" aria-haspopup="true">39</a>) and BMD (<a id="__tag_729447906" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B61" aria-expanded="false" aria-haspopup="true">61</a>) and only small reductions in adiposity (<a id="__tag_729702443" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B27" aria-expanded="false" aria-haspopup="true">27</a>). In contrast, supraphysiological testosterone effectively augments skeletal muscle mass (<a id="__tag_729447859" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B7" aria-expanded="false" aria-haspopup="true">7</a>,&nbsp;<a id="__tag_729702441" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B8" aria-expanded="false" aria-haspopup="true">8</a>,&nbsp;<a id="__tag_729447858" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B57" aria-expanded="false" aria-haspopup="true">57</a>), reduces adiposity (<a id="__tag_729447868" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B65" aria-expanded="false" aria-haspopup="true">65</a>), and increases BMD (<a id="__tag_729447855" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B2" aria-expanded="false" aria-haspopup="true">2</a>) in men and in orchiectomized animal models (<a id="__tag_729447902" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B10" aria-expanded="false" aria-haspopup="true">10</a>,&nbsp;<a id="__tag_729447901" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B66" aria-expanded="false" aria-haspopup="true">66</a>) but also increases the risk for a variety of side effects, of which polycythemia, prostate enlargement, and increased incidence of prostate biopsy occur most frequently (<a id="__tag_729447884" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B13" aria-expanded="false" aria-haspopup="true">13</a>). Selective androgen receptor (AR) modulators (SARMs) are currently under development with the aim of producing anabolic effects in skeletal muscle and bone without prostate enlargement, polycythemia, or other androgenic side effects (<a id="__tag_729447882" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B33" aria-expanded="false" aria-haspopup="true">33</a>).</p>
<p id="__p3">17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) is a potent synthetic testosterone analog (<a id="__tag_729447914" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B67" aria-expanded="false" aria-haspopup="true">67</a>) that does not undergo 5α-reduction to more potent metabolites (<a id="__tag_729447861" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B46" aria-expanded="false" aria-haspopup="true">46</a>). As such, trenbolone may induce less growth in prostate and other androgenic tissues that highly express 5α-reductase. This is in contrast to testosterone, which has approximately threefold greater potency in androgenic tissues that highly express 5α-reductase (<a id="__tag_729447900" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B63" aria-expanded="false" aria-haspopup="true">63</a>) due to its conversion to dihydrotestosterone (DHT).</p>
<p id="__p4" class="p">The primary purpose of this study was to determine the effects of trenbolone-enanthate (TREN; a slowly released trenbolone ester) on a variety of androgen-sensitive tissues, including skeletal muscle, bone, visceral adiposity, hemoglobin (Hb), and the prostate of rodents. Because trenbolone is selectively metabolized to weaker androgens in vivo, we hypothesized that TREN will produce dose-dependent anabolic effects in skeletal muscle, bone, and fat that are at least equal to those of supraphysiological testosterone while producing a smaller increase in Hb and less growth of the prostate.</p>
<h2 id="__sec1title" class="head no_bottom_margin ui-helper-clearfix">METHODS</h2>
<hr>
<div id="__sec2" class="sec sec-first" bis_skin_checked="1">
<h3 id="__sec2title">Animal Care</h3>
<p id="__p5" class="p p-first-last">Barrier-raised and viral pathogen-free Fischer F344 male rats aged 3 mo were obtained from Charles River Laboratories (Wilmington, MA). Animals were housed individually in a temperature- and light-controlled room on a 12:12-h light-dark cycle. Rats were fed an ad libitum diet of Purina rodent chow containing 3.3 kcal/g distributed as 58.9% carbohydrate, 12.4% fat, and 28.7% protein (no. 5001; Purina Mills, St. Louis, MO) and tap water. All experimental procedures conformed to the Institute for Laboratory Animal Research&nbsp;<em>Guide to the Care and Use of Experimental Animals</em>&nbsp;and were approved by the Institutional Animal Care and Use Committee at the Gainesville Veterans Affairs Medical Center.</p>
</div>
<div id="__sec3" class="sec" bis_skin_checked="1">
<h3 id="__sec3title">Pilot Study Experiment Design: Verify Hormone Delivery and Suppression of Endogenous Sex Hormones</h3>
<p id="__p6" class="p p-first-last">A pilot study was performed to verify delivery of TREN (Steraloids, Newport, RI) following intramuscular administration and to evaluate the suppressive effects of TREN administration on circulating testosterone and DHT concentrations. For this experiment, intact 3-mo-old male Fisher F344 rats received intramuscular injections of either TREN (7.0 mg·wk<sup>−1</sup>·animal<sup>−1</sup>) or vehicle (sesame oil) at baseline and 7 days later (<em>n</em>&nbsp;= 5/group). Blood was sampled via tail tip amputation at baseline and every 2 days thereafter. Ten days following the initial injection, the rats were euthanized by an intraperitoneal injection of 120 mg/kg pentobarbital sodium, and blood was collected via cardiac puncture for the measurement of serum androgen concentrations.</p>
</div>
<div id="__sec4" class="sec" bis_skin_checked="1">
<h3 id="__sec4title">Experimental Design Study 1: Muscle, Bone, Adipose, and Prostate Tissue Responses to Trenbolone Administration in Gonadectomized Male Rats</h3>
<p id="__p7" class="p p-first">Male Fisher 344 rats, aged 3 mo, were divided into six groups (<em>n</em>&nbsp;= 10/group), including sham surgery plus vehicle (SHAM), orchiectomy (ORX) plus vehicle, ORX plus low-dose TREN (ORX + low TREN; 1.0 mg/wk), ORX plus moderate-dose TREN (ORX + mod TREN; 3.5 mg/wk), ORX plus high-dose TREN (ORX + high TREN; 7.0 mg/wk), or ORX plus supraphysiological testosterone-enanthate (ORX + TE; 7.0 mg/wk). We have reported previously that ORX induces catabolic effects in muscle, bone, and kidney and increases visceral fat accumulation (<a id="__tag_729447889" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B9" aria-expanded="false" aria-haspopup="true">9</a>), whereas supraphysiological TE administration prevents those effects but results in significant prostate enlargement (<a id="__tag_729447876" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B10" aria-expanded="false" aria-haspopup="true">10</a>,&nbsp;<a id="__tag_729447877" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B11" aria-expanded="false" aria-haspopup="true">11</a>,&nbsp;<a id="__tag_729447870" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B66" aria-expanded="false" aria-haspopup="true">66</a>). Blood was sampled via tail tip amputation prior to surgery and weekly thereafter. Food consumption was measured weekly. On&nbsp;<em>day 29</em>, rats were euthanized via intraperitoneal pentobarbital sodium (120 mg/kg) injection, and blood was collected via cardiac puncture for Hb analysis and hormone analyses. The levator ani/bulbocavernosus (LABC) muscle complex (an androgen-responsive skeletal muscle complex in rodents), soleus, plantaris, semimembranosus, retroperitoneal fat pads, left and right femurs and tibiae, kidney, and prostate were excised and weighed. With the exception of the femora, all tissues were snap-frozen in liquid nitrogen and stored at −80°C until further analysis. After weighing, the femora were measured using a digital caliper (Mitutoyo, Aurora, IL), wrapped in saline-soaked gauze, and stored at −20°C to maintain the mechanical properties of the bone (<a id="__tag_729447873" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B44" aria-expanded="false" aria-haspopup="true">44</a>).</p>
<div id="__sec5" class="sec" bis_skin_checked="1">
<h4 id="__sec5title" class="inline">Surgery.</h4>
<p id="__p8" class="p p-first-last">Animals received sham surgery or bilateral closed ORX, which involved removal of testes, epididymis, and epididymal fat. All surgeries were performed aseptically under isoflurane anesthesia. After surgery, rats received a nutritional supplement (Jell-O plus protein and fat) daily for 2 days to promote weight maintenance.</p>
</div>
<div id="__sec6" class="sec" bis_skin_checked="1">
<h4 id="__sec6title" class="inline">Hormone delivery.</h4>
<p id="__p9" class="p p-first-last">TREN and TE (Savient Pharmaceutical, East Brunswick, NJ) were dissolved in sesame oil prior to intramuscular injection. Once weekly injections were alternated between the right and left quadriceps musculature and administered under brief isoflurane anesthesia. Sham surgery animals received vehicle sesame oil injections, where orchiectomized rats received either low (1.0 mg/wk), moderate (3.5 mg/wk), or high doses (7.0 mg/wk) of TREN, TE (7.0 mg/wk), or vehicle immediately following surgery and once every 7 days thereafter.</p>
</div>
<div id="__sec7" class="sec" bis_skin_checked="1">
<h4 id="__sec7title" class="inline">Hb and serum hormone analyses.</h4>
<p id="__p10" class="p p-first-last">Whole blood Hb was analyzed in duplicate immediately upon euthanization using the Hb Pro Professional Hemoglobin Testing System (ITC, Edison, NJ), which has a sensitivity of 4.0 g/dl and an intra-assay coefficient of variation (CV) of &lt;3.3%. Serum was subsequently separated and stored at −80°C for further analysis. All hormones were assayed in duplicate using commercially available kits. Serum trenbolone was evaluated using qualitative enzyme-linked immunosorbent assay, which has a sensitivity of 0.1 ng/ml and an intra-assay CV of 3.76% (Neogen, Lexington, KY), and a standard curve was developed using trenbolone (Sigma-Aldrich, St. Louis, MO). Testosterone was assayed using a quantitative EIA kit (Diagnostic Systems Laboratories, Webster, TX) with a sensitivity of 0.04 ng/ml and an intra-assay covariance of 5.7%. DHT was assayed using a quantitative EIA kit (Alpco Diagnostics, Salem, NH) with a sensitivity of 6 pg/ml and an intra-assay covariance of 5.4%. Osteocalcin (a marker of bone formation) was determined with a Rat-Mid EIA, which has a sensitivity of 50 ng/ml and an intra-assay CV of &lt;8% (Immunodiagnostic Systems, Fountain Hills, AZ). Bone resorption was measured by evaluating tartrate-resistant acid phosphatase form 5b (TRAP5b; an early marker of bone resorption) (<a id="__tag_729447895" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B1" aria-expanded="false" aria-haspopup="true">1</a>) with a RatTrap EIA (Immunodiagnostic systems), which has a sensitivity of 0.1 U/l and an intra-assay CV &lt;5.8%, and by evaluating COOH-terminal telopeptide a1 chain of type 1 collagen (a late marker of bone resorption) with a RatLaps EIA (Immunodiagnostic Systems), which has a sensitivity of 2.0 ng/ml and an intra-assay CV &lt;9.2%.</p>
</div>
<div id="__sec8" class="sec sec-last" bis_skin_checked="1">
<h4 id="__sec8title" class="inline">Bone morphometry and mechanical strength.</h4>
<p id="__p11" class="p p-first">Prior to peripheral quantitative computerized tomography (pQCT), the femurs were thawed to room temperature and were kept in saline-soaked gauze except during measurement. The left femoral diaphysis and metaphysis were scanned by pQCT with a Stratec XCT Research M Instrument (Norland Medical Systems, Fort Atkinson, WI). Scans were performed at a distance of 5 (metaphysis) and 15 mm (diaphysis) proximal to the distal end of the femur for measurements of cancellous and cortical bone structure, respectively. The structural variables that were measured include total, trabecular, and cortical bone area (mm<sup>2</sup>), content (mg/mm), and density (mg/cm<sup>3</sup>).</p>
<p id="__p12" class="p p-last">Subsequent to pQCT, the midshaft of the left femora was subjected to a medial/lateral three-point bending test, using an MTS material testing machine (MTS Systems, Erden Prairie, MN) with methods we have reported previously (<a id="__tag_729447913" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B66" aria-expanded="false" aria-haspopup="true">66</a>). Before mechanical testing, a preload (10 N) was applied on the medial surface of the femur using a steel cross-bar fixture. The bending load was applied at 1.0 mm/s until failure. From the load-deformation curve, the following parameters were determined for the femoral shaft: breaking load, yield load, stiffness, and displacement. Bone mechanical strength is expressed as both force (measured in N) and stress (measured in Mpa).</p>
</div>
</div>
<div id="__sec9" class="sec" bis_skin_checked="1">
<h3 id="__sec9title">Experimental Design Study 2: Prostate and LABC Responses to Trenbolone Administration in Intact Male Rats</h3>
<p id="__p13" class="p p-first-last">Twenty male Fisher 344 rats, aged 3 mo, remained intact and were divided into the following four groups (<em>n</em>&nbsp;= 5/group): vehicle injection (SHAM), supraphysiological testosterone-enanthate (TE; 7.0 mg/wk), low-dose TREN (low TREN; 1.0 mg/wk), and one-half the low-dose TREN (half-Low TREN; 0.5 mg/wk). Animals remained intact to determine the effects of TREN on prostate and LABC masses and Hb concentrations when administered in the presence of endogenous sex hormones, a situation that simulates humans undergoing androgen replacement therapy. Once weekly intramuscular injections were delivered in a manner identical to that described in&nbsp;<em>experiment 1</em>. On&nbsp;<em>day 29</em>, rats were euthanized via intraperitoneal pentobarbital (120 mg/kg) injection, and blood was collected via cardiac puncture. The LABC muscle complex and prostate were excised and weighed. Whole blood Hb and serum testosterone, DHT, and trenbolone were analyzed using the methods and commercially available kits discussed previously (see&nbsp;<em>experiment 1</em>). For this experiment, the low TREN was a dose identical to that administered in&nbsp;<em>experiment 1</em>, a dose that produced robust muscle growth and preservation of BMD in ORX rats while maintaining prostate mass at the level of SHAMs. Additionally, TREN was administered in a dose lower than what was administered in&nbsp;<em>experiment 1</em>&nbsp;(i.e., half-low TREN) to further evaluate the dose-response effects of TREN within skeletal muscle and prostate.</p>
</div>
<div id="__sec10" class="sec sec-last" bis_skin_checked="1">
<h3 id="__sec10title">Statistical Analysis</h3>
<p id="__p14" class="p p-first-last">Results are reported as means ± SE, and&nbsp;<em>P</em>&nbsp;&lt; 0.05 was defined as the threshold of significance. One-Way ANOVAs (for normally distributed data) were used to separately analyze dependent variables, and Tukey’s post hoc test was performed for multiple comparisons among groups when appropriate. The Kruskal-Wallis and Mann-Whitney tests were performed when data were not normally distributed. Hormone values that were below the lowest detectable standard are reported as such and were assigned a value equal to the sensitivity of each individual assay for the purposes of statistical analysis. Data were analyzed with the SPSS version 15.0.0 statistical software package.</p>
<h2 id="__sec11title" class="head no_bottom_margin ui-helper-clearfix">RESULTS</h2>
<hr>
<h3 id="__sec12title">Pilot Experiment: Verification of Hormone Delivery and Suppression of Endogenous Sex Hormones</h3>
<p id="__p15" class="p p-first">Intramuscular TREN administration elevated serum trenbolone concentrations throughout the 7 days following injection (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F1/" target="figure" rel="noopener noreferrer">Fig. 1</a>). On&nbsp;<em>day 7</em>, rats received an additional TREN injection, which resulted in peak trenbolone concentrations (46.0 ± 5.6 ng/ml) occurring on&nbsp;<em>day 9</em>. Thus, once weekly TREN injections resulted in a sustained elevation of serum trenbolone, with peak concentrations occurring within 48 h. Within 10 days of administration, TREN also suppressed serum testosterone of intact animals by 80% (2.55 ± 0.46 vs. 0.49 ± 0.07,&nbsp;<em>P</em>&nbsp;≤ 0.05) and serum DHT by 70% (644 ± 99 vs. 187 ± 7,&nbsp;<em>P</em>&nbsp;≤ 0.05) compared with intact vehicle-treated animals.</p>
<pre class="figure" data-largeobj-link-rid="largeobj_idm139797877812448"><a class="inline_block ts_canvas" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6189634_zh10041161960001.jpg" target="tileshopwindow" rel="noopener noreferrer" bis_size="{&quot;x&quot;:51,&quot;y&quot;:266427,&quot;w&quot;:273,&quot;h&quot;:16,&quot;abs_x&quot;:51,&quot;abs_y&quot;:266427}"><img class="tileshop" title="Click on image to zoom" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960001.jpg" data-lazy-src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960001.jpg" bis_size="{&quot;x&quot;:51,&quot;y&quot;:266290,&quot;w&quot;:273,&quot;h&quot;:150,&quot;abs_x&quot;:51,&quot;abs_y&quot;:266290}" bis_id="bn_mbaqaob0o7pk1xw9z9wuie"><noscript><img class="tileshop" title="Click on image to zoom" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960001.jpg" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960001.jpg" /></noscript></a></pre>
<div id="lgnd_F1" class="icnblk_cntnt" bis_skin_checked="1">
<pre><a class="figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F1/" target="figure" rel="noopener noreferrer">Fig. 1.</a>

Weekly intramuscular injections of trenbolone-enanthate (TREN) elevate serum trenbolone in a sustainable manner. Intact male F344 rats were injected with 7.0 mg of TREN or vehicle under isoflurane anesthesia at baseline and 7 days later (as indicated by arrow). Blood samples were obtained by tail tip prior to injection and every 2 days thereafter for 10 days. Values are means ± SE;&nbsp;<em>n</em>&nbsp;= 5. Some error bars are within the width of the symbol.</pre>
</div>
</div>
</div>
<h3 id="__sec13title">Experiment 1: Study on Muscle, Bone, Adipose, and Prostate Tissue Responses to Trenbolone Administration in Gonadectomized Male Rats</h3>
<div id="__sec14" class="sec sec-first" bis_skin_checked="1">
<h4 id="__sec14title" class="inline">Serum androgen concentrations.</h4>
<p id="__p17" class="p p-first">Increasing doses of TREN resulted in a progressive increase in serum trenbolone (<em>P</em>&nbsp;≤ 0.001;&nbsp;<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F2/" target="figure" rel="noopener noreferrer">Fig. 2<em>A</em></a>). Serum testosterone was 1.9 ± 0.1 ng/ml in SHAMs (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F2/" target="figure" rel="noopener noreferrer">Fig. 2<em>B</em></a>) and was elevated 18-fold following TE administration (34.7 ± 2.5,&nbsp;<em>P</em>&nbsp;≤ 0.01). Testosterone was low to undetectable following ORX (0.04 ng/ml) and in all TREN treatment groups (ORX + low TREN: 0.04 ng/ml; ORX + mod TREN: 0.07 ± 0.03 ng/ml; ORX + high TREN: 0.06 ± 0.02 ng/ml). Serum DHT was 284 ± 33 pg/ml in SHAMs (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F2/" target="figure" rel="noopener noreferrer">Fig. 2<em>C</em></a>) and was elevated 34-fold by TE administration (9,774 ± 522 pg/ml,&nbsp;<em>P</em>&nbsp;≤ 0.001). DHT was reduced 70% with ORX compared with SHAMs (86 ± 7 pg/ml,&nbsp;<em>P</em>&nbsp;≤ 0.001) and remained reduced following all TREN treatments (ORX + low TREN: 93 ± 5 pg/ml; ORX + mod TREN: 150 ± 5 pg/ml; ORX + high TREN: 182 ± 6 pg/ml).</p>
<pre class="figure" data-largeobj-link-rid="largeobj_idm139797874633760"><img class="fig-image" title="An external file that holds a picture, illustration, etc. Object name is zh10041161960002.jpg" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960002.jpg" data-lazy-src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960002.jpg"><noscript><img class="fig-image" title="An external file that holds a picture, illustration, etc. Object name is zh10041161960002.jpg" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960002.jpg" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960002.jpg" /></noscript>

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F2/?report=objectonly" target="object" rel="noopener noreferrer">Open in a separate window</a></pre>
<div id="lgnd_F2" class="icnblk_cntnt" bis_skin_checked="1">
<pre><a class="figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F2/" target="figure" rel="noopener noreferrer">Fig. 2.</a>

Effects of orchiectomy (ORX), testosterone-enanthate (TE), or graded doses of TREN on serum trenbolone (<em>A</em>), testosterone (<em>B</em>), and dihydrotestosterone (DHT;&nbsp;<em>C</em>) at euthanization. Values are means ± SE;&nbsp;<em>n</em>&nbsp;= 9–10/group for trenbolone and DHT and 6/group for testosterone. Letters indicate differences from respectively labeled groups at&nbsp;<em>P</em>&nbsp;&lt; 0.05 or *<em>P</em>&nbsp;&lt; 0.01 [<sup>a</sup>vs. vehicle (SHAM);&nbsp;<sup>b</sup>vs. ORX;&nbsp;<sup>c</sup>vs. ORX + TE;&nbsp;<sup>d</sup>vs. ORX + low-dose TREN (low TREN);&nbsp;<sup>e</sup>vs. ORX + moderate-dose TREN (mod TREN)]. High TREN, high-dose TREN.</pre>
</div>
</div>
<h4 id="__sec15title" class="inline">Weight gain, food consumption, and adiposity.</h4>
<p id="__p19" class="p p-first">During the first 3 days following surgery, ORX animals experienced a 75% reduction in weight gain compared with SHAMs, and weight gain remained lower than SHAMs throughout the duration of the study (<em>P</em>&nbsp;≤ 0.01;&nbsp;<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F3/" target="figure" rel="noopener noreferrer">Fig. 3<em>A</em></a>). Both TE and TREN (at all doses) restored weight gain during the first 3 days following ORX. However, after the initial 3-day post-surgery period, total weight gain was gradually reduced in the TE- and TREN-treated groups such that at euthanization the weight gain in all androgen-treated groups was 30–50% lower than in SHAMs (<em>P</em>&nbsp;≤ 0.001) and not different from ORX (SHAM: 41.6 ± 2.5 g; ORX: 27.6 ± 1.9 g; ORX + TE: 25.7 ± 2.8 g; ORX + low TREN: 29.7 ± 1.5 g; ORX + mod TREN: 25.1 ± 1.1 g; ORX + high TREN: 20.7 ± 1.8 g). No differences in total weight gain were present between the TE and low and mod TREN treatments, although weight gain was 30% lower following high TREN treatment compared with low TREN (<em>P</em>&nbsp;≤ 0.05).</p>
<pre class="figure" data-largeobj-link-rid="largeobj_idm139797876127248"><a class="inline_block ts_canvas" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6189634_zh10041161960003.jpg" target="tileshopwindow" rel="noopener noreferrer" bis_size="{&quot;x&quot;:51,&quot;y&quot;:269656,&quot;w&quot;:273,&quot;h&quot;:16,&quot;abs_x&quot;:51,&quot;abs_y&quot;:269656}"><img class="tileshop" title="Click on image to zoom" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960003.jpg" data-lazy-src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960003.jpg" bis_size="{&quot;x&quot;:51,&quot;y&quot;:269519,&quot;w&quot;:273,&quot;h&quot;:150,&quot;abs_x&quot;:51,&quot;abs_y&quot;:269519}" bis_id="bn_yvs21hp6b1e3e6vajtva7f"><noscript><img class="tileshop" title="Click on image to zoom" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960003.jpg" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960003.jpg" /></noscript></a>

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F3/?report=objectonly" target="object" rel="noopener noreferrer">Open in a separate window</a>

<a class="figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F3/" target="figure" rel="noopener noreferrer">Fig. 3.</a>

Effects of ORX, TE, or graded doses of TREN on weekly body weight (BW) change (<em>A</em>) and total BW change (<em>B</em>) corrected for food consumption. Rats received ORX vs. sham surgery and were treated with intramuscular injections of vehicle, TE (7.0 mg/wk), or TREN (1.0, 3.5, or 7.0 mg/wk) for a period of 29 days. BW gain was reduced by ORX on&nbsp;<em>day 3</em>, and this reduction was initially prevented by all drug treatment groups. At euthanization, the BW change corrected for food intake was similarly reduced in all ORX groups compared with SHAM. Values are means ± SE;&nbsp;<em>n</em>&nbsp;= 9–10/group. Letters indicate differences from respectively labeled groups at&nbsp;<em>P</em>&nbsp;&lt; 0.05 or *<em>P</em>&nbsp;&lt; 0.01 (<sup>a</sup>vs. SHAM;&nbsp;<sup>b</sup>vs. ORX;&nbsp;<sup>c</sup>vs.ORX + TE;&nbsp;<sup>d</sup>vs. ORX + low TREN;&nbsp;<sup>e</sup>vs. ORX + mod TREN).</pre>
<p id="__p21">ORX also reduced total food consumption throughout the experiment by 14% when compared with SHAMs (<em>P</em>&nbsp;≤ 0.01), and this reduction was not prevented by any androgen treatment (data not shown). Change in body mass was subsequently corrected for total food consumption to determine whether food consumption influenced the observed differences in weight gain. Following this correction, the change in body mass gain corrected for food intake for the ORX and for the androgen treatments remained 20–40% below that of SHAMs (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F3/" target="figure" rel="noopener noreferrer">Fig. 3<em>B</em></a>). Thus, it appeared that reduced food intake only partially accounted for the reductions in body mass gain following ORX.</p>
<p id="__p22" class="p">ORX induced a nonsignificant 18% increase in retroperitoneal (retro) fat mass compared with SHAMs (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F4/" target="figure" rel="noopener noreferrer">Fig. 4<em>A</em></a>). Conversely, TE administration reduced retro fat mass by 27% compared with ORX (<em>P</em>&nbsp;≤ 0.01). TREN treatment also resulted in a dose-dependent reduction in retro fat mass. Specifically, low TREN restored retro fat mass to the level of SHAMs, moderate TREN reduced retro fat mass by 35% compared with ORX (<em>P</em>&nbsp;≤ 0.001) and by 23% compared with low TREN (<em>P</em>&nbsp;≤ 0.05), and high TREN reduced retro fat mass by 43–51% compared with SHAMs, low TREN, and ORX animals (<em>P</em>&nbsp;≤ 0.001) and also by 34% compared with TE treatment (<em>P</em>&nbsp;≤ 0.05).</p>
<pre class="figure" data-largeobj-link-rid="largeobj_idm139797881159904"><img class="fig-image" title="An external file that holds a picture, illustration, etc. Object name is zh10041161960004.jpg" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960004.jpg" data-lazy-src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960004.jpg"><noscript><img class="fig-image" title="An external file that holds a picture, illustration, etc. Object name is zh10041161960004.jpg" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960004.jpg" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960004.jpg" /></noscript>

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F4/?report=objectonly" target="object" rel="noopener noreferrer">Open in a separate window</a>

<a class="figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F4/" target="figure" rel="noopener noreferrer">Fig. 4.</a>

Effects of ORX, TE, or graded doses of TREN on retroperitoneal (retro) fat (<em>A</em>), levator ani/bulbocavernosus (LABC) muscle complex (<em>B</em>), and prostate masses (<em>C</em>). Rats received ORX vs. sham surgery and were treated with intramuscular injections of vehicle, TE (7.0 mg/wk), or TREN (1.0, 3.5, or 7.0 mg/wk) for a period of 29 days. Values are means ± SE;&nbsp;<em>n</em>&nbsp;= 9–10/group. Letters indicate differences from respectively labeled groups at&nbsp;<em>P</em>&nbsp;&lt; 0.05 or *<em>P</em>&nbsp;&lt; 0.01 (<sup>a</sup>vs. SHAM;&nbsp;<sup>b</sup>vs. ORX;&nbsp;<sup>c</sup>vs. ORX + TE;&nbsp;<sup>d</sup>vs. ORX + low TREN;&nbsp;<sup>e</sup>vs. ORX + mod TREN).</pre>
<div id="__sec16" class="sec" bis_skin_checked="1">
<p id="__sec16title" class="inline">Muscle.ORX resulted in a 59% reduction in the mass of the LABC muscle complex compared with SHAMs (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F4/" target="figure" rel="noopener noreferrer">Fig. 4<em>B</em></a>). All androgen treatments completely prevented this reduction and resulted in an additional 35–40% augmentation of the LABC above SHAMs (<em>P</em>&nbsp;≤ 0.001). Ultimately, the LABC mass was ∼3.3-fold greater than the ORX group in all androgen treatment groups (<em>P</em>&nbsp;≤ 0.001). The masses of the plantaris, soleus, and semimembranosus were unaltered by any treatment (data not shown).</p>
</div>
<div id="__sec17" class="sec" bis_skin_checked="1">
<p id="__sec17title" class="inline">Prostate.ORX resulted in an 80% reduction in prostate mass compared with SHAMs (<em>P</em>&nbsp;≤ 0.001;&nbsp;<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F4/" target="figure" rel="noopener noreferrer">Fig. 4<em>C</em></a>). TE and high TREN administrations increased prostate mass by 84 (<em>P</em>&nbsp;≤ 0.001) and 68% (<em>P</em>&nbsp;≤ 0.01), respectively, compared with SHAMs, whereas, neither low nor mod TREN elevated prostate mass above SHAMs. Ultimately, the low TREN resulted in a prostate that was 34% smaller than TE treatment (<em>P</em>&nbsp;≤ 0.05). No differences in prostate mass were present between the high TREN and TE treatments.</p>
</div>
<div id="__sec18" class="sec" bis_skin_checked="1">
<p id="__sec18title" class="inline">Kidney and Hb.ORX reduced kidney mass by 10% compared with SHAMs (<em>P</em>&nbsp;≤ 0.001;&nbsp;<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/table/T1/" target="table" rel="noopener noreferrer">Table 1</a>). TE administration prevented this reduction and further increased kidney mass by 14% compared with SHAMs (<em>P</em>&nbsp;≤ 0.001). Similarly, low TREN completely prevented the ORX-induced loss of kidney mass (<em>P</em>&nbsp;≤ 0.001), whereas both mod and high TREN increased kidney mass by ∼19% compared with SHAMs (<em>P</em>&nbsp;≤ 0.001).</p>
</div>
<pre>Table 1.

Effects of ORX, TE, or graded doses of TREN on kidney mass and Hb concentrations

</pre>
<table class="rendered small default_table" frame="hsides" rules="groups">
<thead valign="bottom">
<tr>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1" align="center">SHAM</th>
<th colspan="1" rowspan="1" align="center">ORX</th>
<th colspan="1" rowspan="1" align="center">ORX + TE</th>
<th colspan="1" rowspan="1" align="center">ORX + Low TREN</th>
<th colspan="1" rowspan="1" align="center">ORX + Mod TREN</th>
<th colspan="1" rowspan="1" align="center">ORX + High TREN</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td colspan="1" rowspan="1" align="left">Kidney, g</td>
<td colspan="1" rowspan="1" align="center">0.89 ± 0.01</td>
<td colspan="1" rowspan="1" align="center">0.79 ± 0.01<sup>a</sup>*</td>
<td colspan="1" rowspan="1" align="center">1.00 ± 0.01<sup>a</sup>*<sup>,b</sup>*</td>
<td colspan="1" rowspan="1" align="center">0.95 ± 0.01<sup>b</sup>*</td>
<td colspan="1" rowspan="1" align="center">1.05 ± 0.02<sup>a</sup>*<sup>,b</sup>*<sup>,d</sup>*</td>
<td colspan="1" rowspan="1" align="center">1.06 ± 0.02<sup>a</sup>*<sup>,b</sup>*<sup>,d</sup>*</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Hb, mg/dl</td>
<td colspan="1" rowspan="1" align="center">15.6 ± 0.2</td>
<td colspan="1" rowspan="1" align="center">15.7 ± 0.2</td>
<td colspan="1" rowspan="1" align="center">16.6 ± 0.2</td>
<td colspan="1" rowspan="1" align="center">16.7 ± 0.3</td>
<td colspan="1" rowspan="1" align="center">17.3 ± 0.4<sup>a</sup>*<sup>,b</sup>*</td>
<td colspan="1" rowspan="1" align="center">17.0 ± 0.3<sup>a,b</sup></td>
</tr>
</tbody>
</table>
<div class="tblwrap-foot" bis_skin_checked="1">
<p id="__p28" class="p p-first-last">Values are means ± SE;&nbsp;<em>n</em> = 9–10/group.</p>
<p id="__p29" class="p p-first-last">ORX, orchiectomy; TE, testosterone-enanthate; TREN, trenbolone-enanthate; SHAM, vehicle group; low, mod, and high TREN, low-, moderate- and high-dose TREN groups, respectively.</p>
<p class="p p-first-last">Letters indicate differences from respectively labeled groups at <em>P</em>&nbsp;&lt; 0.05 or *<em>P</em>&nbsp;&lt; 0.01 (<sup>a</sup>vs. SHAM;&nbsp;<sup>b</sup>vs. ORX;&nbsp;<sup>c</sup>vs. ORX + TE;&nbsp;<sup>d</sup>vs. ORX + low TREN).</p>
<div id="__sec18" class="sec" bis_skin_checked="1">
<p id="__p31" class="p p-last">No differences in whole blood Hb concentrations were observed between the SHAM, ORX, ORX + TE, or ORX + low TREN animals (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/table/T1/" target="table" rel="noopener noreferrer">Table 1</a>). However, both mod and high TREN administration elevated Hb by ∼8–10% compared with SHAMs and ORX (<em>P</em>&nbsp;≤ 0.05).</p>
</div>
<div id="__sec19" class="sec" bis_skin_checked="1">
<h4 id="__sec19title" class="inline">BMD and bone mechanical strength.</h4>
<p id="__p32" class="p p-first">ORX resulted in a 12–14% reduction in total bone mineral content (BMC) and total BMD and also reduced trabecular (t)BMC and tBMD by ∼50% at the distal femoral metaphysis compared with shams (<em>P</em>&nbsp;≤ 0.001;&nbsp;<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/table/T2/" target="table" rel="noopener noreferrer">Table 2</a>). Conversely, TE administration prevented the ORX-induced reductions at this skeletal site, ultimately resulting in an 11–12% increase in total BMC (<em>P</em>&nbsp;&lt; 0.05) and total BMD (<em>P</em>&nbsp;≤ 0.001) and a 62% increase in tBMC and tBMD (<em>P</em>&nbsp;≤ 0.001). Additionally, all TREN treatments ameliorated the ORX-induced reductions at this skeletal site in a dose-dependent manner, with low TREN treatment increasing total BMD by 6% and tBMD by 37% (<em>P</em>&nbsp;&lt; 0.05), mod TREN treatment increasing total BMD by 9% and tBMC and tBMD by 45% (<em>P</em>&nbsp;≤ 0.01), and high TREN treatment increasing total BMD by 9% and tBMC and tBMD by 55% (<em>P</em>&nbsp;≤ 0.001) compared with ORX. No differences were present between TE and any TREN treatments for the bone mineral measurements at this skeletal site, although TREN treatment did not completely restore tBMC and tBMD to SHAM values (<em>P</em>&nbsp;&lt; 0.05). The total and trabecular tissue areas remained unaltered at the distal femoral metaphysis, and no differences were present at the femoral diaphysis for any measurement (data not shown). Additionally, the femoral mass and length remained unaltered by all treatments, and no statistically significant differences were present between any bone mechanical measurements at the femoral midshaft (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/table/T2/" target="table" rel="noopener noreferrer">Table 2</a>).</p>
<pre>Table 2.

Effects of ORX, TE, or graded doses of TREN on femoral anthropometric measurements, metaphyseal BMC and BMD, and midshaft bone mechanical characteristics</pre>
<table class="rendered small default_table" frame="hsides" rules="groups">
<thead valign="bottom">
<tr>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1" align="center">SHAM</th>
<th colspan="1" rowspan="1" align="center">ORX</th>
<th colspan="1" rowspan="1" align="center">ORX + TE</th>
<th colspan="1" rowspan="1" align="center">ORX + Low TREN</th>
<th colspan="1" rowspan="1" align="center">ORX + Mod TREN</th>
<th colspan="1" rowspan="1" align="center">ORX + High TREN</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td colspan="1" rowspan="1" align="left">Femoral mass, g</td>
<td colspan="1" rowspan="1" align="center">0.78 ± 0.01</td>
<td colspan="1" rowspan="1" align="center">0.75 ± 0.01</td>
<td colspan="1" rowspan="1" align="center">0.78 ± 0.01</td>
<td colspan="1" rowspan="1" align="center">0.77 ± 0.01</td>
<td colspan="1" rowspan="1" align="center">0.77 ± 0.01</td>
<td colspan="1" rowspan="1" align="center">0.77 ± 0.01</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Femoral length, mm</td>
<td colspan="1" rowspan="1" align="center">37.1 ± 0.1</td>
<td colspan="1" rowspan="1" align="center">36.4 ± 0.2</td>
<td colspan="1" rowspan="1" align="center">36.8 ± 0.2</td>
<td colspan="1" rowspan="1" align="center">36.9 ± 0.1</td>
<td colspan="1" rowspan="1" align="center">36.8 ± 0.1</td>
<td colspan="1" rowspan="1" align="center">36.7 ± 0.2</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="center">Total BMC, mg/mm</td>
<td colspan="1" rowspan="1" align="center">12.7 ± 0.3</td>
<td colspan="1" rowspan="1" align="center">10.9 ± 0.3<sup>a</sup>*</td>
<td colspan="1" rowspan="1" align="center">12.1 ± 0.4<sup>b</sup></td>
<td colspan="1" rowspan="1" align="center">11.5 ± 0.3<sup>a</sup></td>
<td colspan="1" rowspan="1" align="center">11.9 ± 0.3</td>
<td colspan="1" rowspan="1" align="left">11.9 ± 0.2</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Total BMD, mg/cm<sup>3</sup></td>
<td colspan="1" rowspan="1" align="center">668 ± 6</td>
<td colspan="1" rowspan="1" align="center">587 ± 8<sup>a</sup>*</td>
<td colspan="1" rowspan="1" align="center">657 ± 10<sup>b</sup>*</td>
<td colspan="1" rowspan="1" align="center">624 ± 7<sup>a</sup>*<sup>,b</sup></td>
<td colspan="1" rowspan="1" align="center">632 ± 8<sup>a,b</sup>*</td>
<td colspan="1" rowspan="1" align="center">641 ± 9<sup>b</sup>*</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Trabecular BMC, mg/mm</td>
<td colspan="1" rowspan="1" align="center">2.0 ± 0.1</td>
<td colspan="1" rowspan="1" align="center">1.0 ± 0.1<sup>a</sup>*</td>
<td colspan="1" rowspan="1" align="center">1.6 ± 0.1<sup>b</sup>*</td>
<td colspan="1" rowspan="1" align="center">1.4 ± 0.1<sup>a</sup>*</td>
<td colspan="1" rowspan="1" align="center">1.5 ± 0.1<sup>a</sup>*<sup>,b</sup></td>
<td colspan="1" rowspan="1" align="center">1.5 ± 0.1<sup>a,b</sup>*</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Trabecular BMD, mg/cm<sup>3</sup></td>
<td colspan="1" rowspan="1" align="center">344 ± 16</td>
<td colspan="1" rowspan="1" align="center">177 ± 13<sup>a</sup>*</td>
<td colspan="1" rowspan="1" align="center">288 ± 17<sup>b</sup>*</td>
<td colspan="1" rowspan="1" align="center">243 ± 15<sup>a</sup>*<sup>,b</sup></td>
<td colspan="1" rowspan="1" align="center">257 ± 14<sup>a</sup>*<sup>,b</sup>*</td>
<td colspan="1" rowspan="1" align="center">274 ± 16<sup>a,b</sup>*</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Breaking load, N</td>
<td colspan="1" rowspan="1" align="center">136 ± 12</td>
<td colspan="1" rowspan="1" align="center">134 ± 11</td>
<td colspan="1" rowspan="1" align="center">138 ± 7</td>
<td colspan="1" rowspan="1" align="center">139 ± 11</td>
<td colspan="1" rowspan="1" align="center">139 ± 10</td>
<td colspan="1" rowspan="1" align="center">137 ± 10</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Yield load, N</td>
<td colspan="1" rowspan="1" align="center">93 ± 17</td>
<td colspan="1" rowspan="1" align="center">90 ± 20</td>
<td colspan="1" rowspan="1" align="center">93 ± 12</td>
<td colspan="1" rowspan="1" align="center">90 ± 17</td>
<td colspan="1" rowspan="1" align="center">116 ± 16</td>
<td colspan="1" rowspan="1" align="center">98 ± 20</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Stiffness, N/mm</td>
<td colspan="1" rowspan="1" align="center">245 ± 32</td>
<td colspan="1" rowspan="1" align="center">227 ± 30</td>
<td colspan="1" rowspan="1" align="center">270 ± 25</td>
<td colspan="1" rowspan="1" align="center">257 ± 30</td>
<td colspan="1" rowspan="1" align="center">253 ± 26</td>
<td colspan="1" rowspan="1" align="center">256 ± 34</td>
</tr>
</tbody>
</table>
<div class="tblwrap-foot" bis_skin_checked="1">
<p id="__p34" class="p p-first-last">Values are means ± SE;&nbsp;<em>n</em>&nbsp;= 9–10/group.</p>
<p id="__p35" class="p p-first-last">BMC, bone mineral content; BMD, bone mineral density.</p>
<p class="p p-first-last">Letters indicate differences from respectively labeled groups at <em>P</em>&nbsp;&lt; 0.05 or *<em>P</em>&nbsp;&lt; 0.01 (<sup>a</sup>vs. SHAM;&nbsp;<sup>b</sup>vs. ORX;&nbsp;<sup>c</sup>vs. ORX + TE;&nbsp;<sup>d</sup>vs. ORX + low TREN).</p>
</div>
</div>
</div>
<h4 id="__sec20title" class="inline">Systemic markers of bone remodeling.</h4>
<p id="__p37" class="p p-first">One week following surgery, serum Trap5b [an early marker of bone resorption (<a id="__tag_729447880" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B1" aria-expanded="false" aria-haspopup="true">1</a>)] was 9.4 ± 0.6 (SHAM), 11.7 ± 0.9 (ORX), 10.2 ± 0.4 (ORX + low TREN), 8.2 ± 0.4 (ORX + mod TREN), 7.6 ± 0.4 (ORX + high TREN), and 9.4 ± 0.8 (ORX + TE) (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F5/" target="figure" rel="noopener noreferrer">Fig. 5<em>A</em></a>). ORX resulted in a nonsignificant 25% increase in Trap5b, which was completely prevented by TE. Low TREN also resulted in a nonsignificant 15% reduction in Trap5b compared with ORX, whereas both mod TREN and high TREN reduced Trap5b by 30% compared with ORX (<em>P</em>&nbsp;&lt; 0.01). At euthanization, serum C-telopeptide (a late marker of bone resorption) was 33.3 ± 2.6 (SHAM), 36.3 ± 2.3 (ORX), 30.0 ± 2.2 (ORX + low TREN), 32.0 ± 2.6 (ORX + mod TREN), 26.5 ± 2.7 (ORX + high TREN), and 33.7 ± 2.2 (ORX + TE). High TREN reduced serum C-telopeptide by 27% compared with ORX (<em>P</em>&nbsp;≤ 0.05), with no other significant differences present between groups (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F5/" target="figure" rel="noopener noreferrer">Fig. 5<em>B</em></a>). At euthanization, serum osteocalcin (a marker of bone formation) was 679 ± 56 (SHAM), 892 ± 95 (ORX), 435 ± 42 (ORX + low TREN), 320 ± 30 (ORX + mod TREN), 282 ± 26 (ORX + high TREN), and 380 ± 48 (ORX + TE) (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F5/" target="figure" rel="noopener noreferrer">Fig. 5<em>C</em></a>). ORX resulted in a nonsignificant 31% increase in serum osteocalcin compared with SHAMs. All androgen treatment groups reduced serum osteocalcin by 36–58% compared with SHAMs (<em>P</em>&nbsp;≤ 0.01) and by 51–68% compared with ORX (<em>P</em>&nbsp;≤ 0.001). No differences were present between TREN- and TE-treated groups. In addition, serum osteocalcin was 26% lower in mod TREN (<em>P</em>&nbsp;= 0.063, trend) and 35% lower in high TREN (<em>P</em>&nbsp;≤ 0.05) groups compared with the low TREN.</p>
<pre class="figure" data-largeobj-link-rid="largeobj_idm139797883030768"><img class="fig-image" title="An external file that holds a picture, illustration, etc. Object name is zh10041161960005.jpg" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960005.jpg" data-lazy-src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960005.jpg"><noscript><img class="fig-image" title="An external file that holds a picture, illustration, etc. Object name is zh10041161960005.jpg" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960005.jpg" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960005.jpg" /></noscript>

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F5/?report=objectonly" target="object" rel="noopener noreferrer">Open in a separate window</a></pre>
<div id="lgnd_F5" class="icnblk_cntnt" bis_skin_checked="1">
<pre><a class="figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F5/" target="figure" rel="noopener noreferrer">Fig. 5.</a>

Effects of ORX, TE, or graded doses of TREN on serum tartrate-resistant acid phosphatase form 5b (Trap5b, an early marker of bone resorption;&nbsp;<em>A</em>), C-telopeptide (a later marker of bone resorption;&nbsp;<em>B</em>), and osteocalcin (<em>C</em>) at euthanization. Rats received ORX vs. sham surgery and were treated with intramuscular injections of vehicle, TE (7.0 mg/wk), or TREN (1.0, 3.5, or 7.0 mg/wk) for a period of 29 days. Values are means ± SE;&nbsp;<em>n</em>&nbsp;= 9–10/group. Letters indicate differences from respectively labeled groups at&nbsp;<em>P</em>&nbsp;&lt; 0.05 or *<em>P</em>&nbsp;&lt; 0.01 (<sup>a</sup>vs. SHAM;&nbsp;<sup>b</sup>vs. ORX;&nbsp;<sup>c</sup>vs.ORX + TE;&nbsp;<sup>d</sup>vs. ORX + low TREN;&nbsp;<sup>e</sup>vs. ORX + mod TREN).</pre>
</div>
<h3 id="__sec21title">Experiment 2: Study on Prostate and LABC Responses to Trenbolone Administration in Intact Male Rats</h3>
<div id="__sec22" class="sec sec-first" bis_skin_checked="1">
<h4 id="__sec22title" class="inline">Hormone responses.</h4>
<p id="__p39" class="p p-first">At euthanization, serum trenbolone was 13.7 ± 0.6 ng/ml in intact low TREN-treated animals and 4.8 ± 0.3 ng/ml in half-low TREN-treated animals (<em>P</em>&nbsp;&lt; 0.01;&nbsp;<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F6/" target="figure" rel="noopener noreferrer">Fig. 6<em>A</em></a>). Serum testosterone was 5.7 ± 1.5 ng/ml in SHAM animals and was increased ninefold by TE administration (53.0 ± 4.5 ng/ml,&nbsp;<em>P</em>&nbsp;&lt; 0.01;&nbsp;<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F6/" target="figure" rel="noopener noreferrer">Fig. 6<em>B</em></a>). Serum testosterone was reduced to nearly undetectable concentrations by both low TREN (0.4 ± 0.1 ng/ml) and half-low TREN (0.3 ± 0.1 ng/ml) treatments (<em>P</em>&nbsp;&lt; 0.01). Serum DHT was 962 ± 198 pg/ml in SHAM animals and was increased ∼13-fold in TE-treated animals (12,288 ± 1,037 pg/ml,&nbsp;<em>P</em>&nbsp;&lt; 0.01), whereas DHT was reduced below SHAM values by low TREN treatment (126 ± 4 pg/ml,&nbsp;<em>P</em>&nbsp;&lt; 0.01) and below both sham and low TREN treatment values by the half-Low TREN treatment (88 ± 2 pg/ml,&nbsp;<em>P</em>&nbsp;&lt; 0.01) (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F6/" target="figure" rel="noopener noreferrer">Fig. 6<em>C</em></a>).</p>
</div>
<pre class="figure" data-largeobj-link-rid="largeobj_idm139797870905728"><img class="fig-image" title="An external file that holds a picture, illustration, etc. Object name is zh10041161960006.jpg" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960006.jpg" data-lazy-src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960006.jpg"><noscript><img class="fig-image" title="An external file that holds a picture, illustration, etc. Object name is zh10041161960006.jpg" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960006.jpg" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960006.jpg" /></noscript>

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F6/?report=objectonly" target="object" rel="noopener noreferrer">Open in a separate window</a></pre>
<div id="lgnd_F6" class="icnblk_cntnt" bis_skin_checked="1">
<pre><a class="figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F6/" target="figure" rel="noopener noreferrer">Fig. 6.</a>

Effects of supraphysiological TE and graded doses of TREN on serum trenbolone (<em>A</em>), testosterone (<em>B</em>), and DHT (<em>C</em>) at euthanization. Intact male rats received intramuscular injections of vehicle, TE (7.0 mg/wk), or TREN (0.5 or 1.0 mg/wk) for a period of 29 days. Values are means ± SE;&nbsp;<em>n</em>&nbsp;= 5/group. Letters indicate differences from respectively labeled groups at&nbsp;<em>P</em>&nbsp;&lt; 0.05 or *<em>P</em>&nbsp;&lt; 0.01 (<sup>a</sup>vs. SHAM;&nbsp;<sup>b</sup>vs. TE;&nbsp;<sup>c</sup>vs. low TREN).</pre>
</div>
<h4 id="__sec23title" class="inline">Weight gain.</h4>
<p id="__p41" class="p p-first">At baseline, body mass was similar among all groups (SHAM: 270.7 ± 2.6 g; TE: 270.7 ± 3.7 g; low TREN: 271.6 ± 2.2 g; half-Low TREN: 271.4 ± 4.9 g). Body mass gain was reduced to a similar degree by all androgen treatments, which became significant on&nbsp;<em>day 21</em>&nbsp;of the experiment (<em>P</em>&nbsp;&lt; 0.05;&nbsp;<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F7/" target="figure" rel="noopener noreferrer">Fig. 7<em>A</em></a>). Combined retroperitoneal and perirenal (visceral) fat mass was also reduced 25% by TE treatment (<em>P</em>&nbsp;&lt; 0.05) and was nonsignificantly reduced 13–16% by both the low and half-low TREN treatments (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F7/" target="figure" rel="noopener noreferrer">Fig. 7<em>B</em></a>).</p>
<div id="__sec23" class="sec" bis_skin_checked="1">
<div id="F7" class="fig iconblock whole_rhythm clearfix" bis_skin_checked="1">
<pre class="figure" data-largeobj-link-rid="largeobj_idm139797874087072"><img class="fig-image" title="An external file that holds a picture, illustration, etc. Object name is zh10041161960007.jpg" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960007.jpg" data-lazy-src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960007.jpg"><noscript><img class="fig-image" title="An external file that holds a picture, illustration, etc. Object name is zh10041161960007.jpg" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/bin/zh10041161960007.jpg" alt="An external file that holds a picture, illustration, etc. Object name is zh10041161960007.jpg" /></noscript>

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F7/?report=objectonly" target="object" rel="noopener noreferrer">Open in a separate window</a>

</pre>
<div bis_skin_checked="1"><a class="figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F7/" target="figure" rel="noopener noreferrer">Fig. 7.</a></div>
<div class="caption" bis_skin_checked="1">
<p id="__p42">Effects of supraphysiological TE and graded doses of TREN on body mass change (<em>A</em>) and visceral fat pad mass (<em>B</em>). Intact male rats received intramuscular injections of vehicle, TE (7.0 mg/wk), or TREN (0.5 or 1.0 mg/wk) for a period of 29 days. Values are means ± SE;&nbsp;<em>n</em>&nbsp;= 5/group. Letters indicate differences from respectively labeled groups at&nbsp;<em>P</em>&nbsp;&lt; 0.05 or *<em>P</em>&nbsp;&lt; 0.01 (<sup>a</sup>vs. SHAM;&nbsp;<sup>b</sup>vs. TE;&nbsp;<sup>c</sup>vs. low TREN).</p>
</div>
</div>
</div>
<p>Prostate and LABC.<br>
In intact animals, TE treatment increased prostate mass by 59% compared with SHAMs (P &lt; 0.001; Fig. 8A). Low TREN maintained prostate mass at the level of SHAMs, ultimately resulting in a prostate that was 31% smaller than following TE treatment (P &lt; 0.001). Half-low TREN treatment resulted in a nonsignificant 22% reduction in prostate mass compared with SHAMs, a 29% reduction in prostate mass compared with low TREN treatment (P &lt; 0.01), and a 51% reduction compared with TE treatment (P &lt; 0.001).</p>
<pre>Fig. 8.
<img class="alignnone size-full wp-image-4718" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20510%201280'%3E%3C/svg%3E" alt="" width="510" height="1280" data-lazy-srcset="/../../../../wp-content/uploads/2020/05/zh10041161960008-1.jpg 510w, //ikigaicorporation.com/wp-content/uploads/2020/05/zh10041161960008-1-320x803.jpg 320w" data-lazy-sizes="(max-width: 510px) 100vw, 510px" data-lazy-src="/../../../../wp-content/uploads/2020/05/zh10041161960008-1.jpg"><noscript><img class="alignnone size-full wp-image-4718" src="/../../../../wp-content/uploads/2020/05/zh10041161960008-1.jpg" alt="" width="510" height="1280" srcset="/../../../../wp-content/uploads/2020/05/zh10041161960008-1.jpg 510w, //ikigaicorporation.com/wp-content/uploads/2020/05/zh10041161960008-1-320x803.jpg 320w" sizes="(max-width: 510px) 100vw, 510px" /></noscript>
Effects of supraphysiological TE and graded doses of TREN on prostate mass (A), LABC muscle complex mass (B), and LABC/prostate ratio (C). Intact male rats received intramuscular injections of vehicle, TE (7.0 mg/wk), or TREN (0.5 or 1.0 mg/wk) for a period of 29 days. Values are means ± SE; n = 5/group. Letters indicate differences from respectively labeled groups at P &lt; 0.05 or *P &lt; 0.01 (avs. SHAM; bvs. TE; cvs. low TREN).</pre>
<div id="__sec24" class="sec" bis_skin_checked="1">
<p id="__p45" class="p p-last">Mass of the LABC muscle complex was increased by 21–38% in TE- and TREN-treated animals (<em>P</em>&nbsp;&lt; 0.01;&nbsp;<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F8/" target="figure" rel="noopener noreferrer">Fig. 8<em>B</em></a>), with no differences present between any androgen treatment. The LABC/prostate ratio, which illustrates the anabolic/androgenic ratio of androgens, was unaltered by TE treatment (<a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/figure/F8/" target="figure" rel="noopener noreferrer">Fig. 8<em>C</em></a>). Following Low TREN treatment, the LABC/prostate ratio was increased by 12% compared with SHAMs (<em>P</em>&nbsp;&lt; 0.05) and by 25% compared with TE treatment (<em>P</em>&nbsp;&lt; 0.01). Ultimately, half-low TREN treatment resulted in the highest LABC/prostate ratio, a value that was 53% higher than low TREN treatment (<em>P</em>&nbsp;&lt; 0.05), 72% higher than SHAMs (<em>P</em>&nbsp;&lt; 0.01), and 92% higher than TE treatment (<em>P</em>&nbsp;&lt; 0.01).</p>
</div>
<div id="__sec25" class="sec sec-last" bis_skin_checked="1">
<p id="__sec25title" class="inline">Kidney and Hb. No differences in kidney mass (sham: 0.93 ± 0.02 g; TE: 1.01 ± 0.01 g; low TREN: 0.98 ± 0.02 g; half-low TREN: 0.94 ± 0.04 g) or Hb concentrations (sham: 14.6 ± 0.2 mg/dl; TE: 15.7 ± 0.2 mg/dl; low TREN: 15.5 ± 0.4 mg/dl; half-low TREN: 15.4 ± 0.4 mg/dl) were observed between groups.</p>
<h2 id="__sec26title" class="head no_bottom_margin ui-helper-clearfix">DISCUSSION</h2>
<hr>
</div>
<p>&nbsp;</p>
<p id="__p47" class="p p-first">Our results demonstrate that TREN prevents the deleterious alterations in body composition associated with ORX to the same extent as supraphysiological TE. Specifically, we observed that&nbsp;<em>1</em>) regardless of dose, TREN and supraphysiological TE produced equally myotrophic responses in the androgen-sensitive LABC muscle complex in both intact and ORX animals,&nbsp;<em>2</em>) TREN partially prevented ORX-induced bone loss to roughly the same extent as supraphysiological TE, and&nbsp;<em>3</em>) at equal doses, TREN was somewhat more lipolytic than TE in visceral fat. In contrast, the lowest doses of TREN maintained prostate mass and Hb concentrations at the level of shams in both intact and orchiectomized animals, whereas supraphysiological TE and high-dose TREN produced prostate enlargement and/or elevations in Hb. Thus, at the lowest doses administered, TREN appears to have a higher and more clinically favorable anabolic/androgenic ratio than supraphysiological TE.</p>
<p id="__p48">Skeletal muscle expresses ARs to varying degrees among specific muscle groups and among species. For example, humans respond robustly to androgenic stimuli due to the high percentages of AR-positive myonuclei (<a id="__tag_729447883" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B54" aria-expanded="false" aria-haspopup="true">54</a>). Conversely, certain rodent peripheral muscles respond poorly to androgenic stimuli due to the their low concentrations of AR-positive myonuclei (e.g., extensor digitorum longus with 7% AR-positive myonuclei) (<a id="__tag_729702439" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B34" aria-expanded="false" aria-haspopup="true">34</a>), whereas the rodent LABC muscle complex contains ∼74% AR-positive myonuclei and experiences a substantial atrophic response to androgen ablation and a robust myotrophic response to androgen administration (<a id="__tag_729702433" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B34" aria-expanded="false" aria-haspopup="true">34</a>). In our study, the lower limb muscles were insensitive to androgen status; however, ORX reduced LABC muscle mass, whereas TREN and TE robustly augmented LABC muscle mass. These results demonstrate clearly that TREN is at least as myotrophic as supraphysiological TE within androgen-sensitive skeletal muscle because even the lowest TREN doses produced equal growth of the LABC muscle in intact and ORX animals compared with supraphysiological TE. The mechanism(s) underlying the TREN-induced augmentation of skeletal muscle mass requires further clarification (<a id="__tag_729447890" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B67" aria-expanded="false" aria-haspopup="true">67</a>), although it is suspected that TREN acts via&nbsp;<em>1</em>) AR activation, since trenbolone possesses three times the affinity of testosterone for the AR (<a id="__tag_729447857" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B5" aria-expanded="false" aria-haspopup="true">5</a>),&nbsp;<em>2</em>) upregulation of endogenous growth factors (e.g., IGF-I or fibroblast growth factor) and/or increased responsiveness of skeletal muscle to such growth factors (<a id="__tag_729447869" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B29" aria-expanded="false" aria-haspopup="true">29</a>,&nbsp;<a id="__tag_729447865" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B60" aria-expanded="false" aria-haspopup="true">60</a>), and/or&nbsp;<em>3</em>) anticatabolic mechanisms associated with reductions in endogenous glucocorticoid activity (<a id="__tag_729447891" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B48" aria-expanded="false" aria-haspopup="true">48</a>,&nbsp;<a id="__tag_729447910" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B49" aria-expanded="false" aria-haspopup="true">49</a>).</p>
<p id="__p49">In our study, androgen treatment [either TE or TREN (at all doses)] prevented the initial weight reduction associated with surgical ORX to a similar extent. However, at euthanization, body weight gain was similarly reduced among all ORX groups compared with SHAMs, regardless of androgen treatment. Similarly, all intact androgen-treated animals experienced a reduced body weight gain compared with SHAMs. It remains unclear why TE did not maintain body weight gain throughout these studies, as we have reported previously (<a id="__tag_729447872" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B66" aria-expanded="false" aria-haspopup="true">66</a>). The reduced weight accrual may be at least partially explained by the lower food consumption within all ORX groups throughout the duration of&nbsp;<em>experiment 1</em>. However, the reduced food consumption did not cause a measurable loss of lower limb skeletal muscle mass. Conversely, we observed that ORX increased retroperitoneal fat mass, albeit nonsignificantly, and that visceral fat mass was reduced by TREN in a dose-dependent manner. Furthermore, at equal doses, TREN induced a greater magnitude of fat loss than TE. These results are somewhat surprising considering that all androgen treatments produced similar myotrophic growth of the androgen-sensitive LABC muscle complex and induced a substantial and roughly equivalent prevention of the ORX-induced BMD loss. Thus, it appears that TREN is capable of preventing the initial catabolic responses associated with ORX while inducing more potent lipolytic effects within visceral adiposity than endogenous androgens, at least on a dose-to-dose equivalent. Future research examining the mechanisms underlying the lipolytic effects of TREN is appealing considering the preponderance of health decrements associated with central adiposity (<a id="__tag_729447874" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B15" aria-expanded="false" aria-haspopup="true">15</a>).</p>
<p id="__p50">Clearly, androgens influence the development of male secondary sexual characteristics, skeletal muscle, bone, and fat, among other tissues (<a id="__tag_729447896" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B59" aria-expanded="false" aria-haspopup="true">59</a>). Testosterone is the primary circulating endogenous androgen that produces biological responses following nuclear interactions with ARs or through nongenomic signaling pathways (<a id="__tag_729447856" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B19" aria-expanded="false" aria-haspopup="true">19</a>). However, in tissues that highly express 5α-reductase (e.g., prostate), testosterone is transformed to its more potent metabolite DHT, which increases its androgenic potency within these tissues (<a id="__tag_729447864" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B63" aria-expanded="false" aria-haspopup="true">63</a>). As such, prostate enlargement is a concern associated with testosterone replacement therapy in hypogonadal men (<a id="__tag_729447879" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B13" aria-expanded="false" aria-haspopup="true">13</a>). In our studies, the lowest doses of TREN did not induce prostate enlargement in ORX or intact animals, whereas supraphysiological TE and the highest TREN dose increased prostate mass to a similar magnitude. These results are interesting considering that TREN binds to ARs with approximately three times the affinity of TE and an affinity roughly equal to that of DHT, the most potent endogenous androgen. In contrast to testosterone, certain anabolic steroids (e.g., 19-nortestosterone) are transformed to less potent metabolites by 5α-reductase or are not substrates for 5α-reductase (e.g., 7α-methyl-19-nortestosterone) due to slight variations in the structures of these compounds (<a id="__tag_729447897" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B58" aria-expanded="false" aria-haspopup="true">58</a>). Similarly, the reduced prostate enlargement associated with TREN appears to result from the presence of a 3-oxotriene structure that prevents A-ring reduction of this steroid (<a id="__tag_729447899" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B46" aria-expanded="false" aria-haspopup="true">46</a>), ultimately limiting its ability to undergo 5α-reduction or aromatization. As a result, trenbolone is primarily metabolized to its less potent 17α-isoform (epitrenbolone) or trendione in humans (<a id="__tag_729702445" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B55" aria-expanded="false" aria-haspopup="true">55</a>) and in other mammalian species (<a id="__tag_729447917" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B17" aria-expanded="false" aria-haspopup="true">17</a>,&nbsp;<a id="__tag_729702447" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B31" aria-expanded="false" aria-haspopup="true">31</a>,&nbsp;<a id="__tag_729447867" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B45" aria-expanded="false" aria-haspopup="true">45</a>,&nbsp;<a id="__tag_729447904" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B46" aria-expanded="false" aria-haspopup="true">46</a>), underlying its equal potency in tissues that highly express 5α-reductase (e.g., prostate) vs. those that do not (e.g., skeletal muscle) (<a id="__tag_729447892" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B67" aria-expanded="false" aria-haspopup="true">67</a>).</p>
<p id="__p51">Another concern with androgen replacement therapy is the potential to initiate or accelerate the growth of undiagnosed prostate cancer, although several recent meta-analyses have failed to detect an increased risk of prostate cancer following testosterone replacement in hypogonadal men (<a id="__tag_729447903" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B13" aria-expanded="false" aria-haspopup="true">13</a>,&nbsp;<a id="__tag_729447871" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B18" aria-expanded="false" aria-haspopup="true">18</a>). In our studies, TREN administration resulted in a nearly complete ablation of circulating testosterone and DHT, the primary endogenous androgens implicated in prostate growth, through mechanisms apparently associated with feedback inhibition; however, we did not directly evaluate the possibility that TREN may initiate or accelerate prostate cancer growth. Several previous reports indicate that trenbolone appears to produce little genotoxic activity and is not an initiator of cancer in various in vitro models (<a id="__tag_729447866" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B47" aria-expanded="false" aria-haspopup="true">47</a>,&nbsp;<a id="__tag_729447888" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B51" aria-expanded="false" aria-haspopup="true">51</a>), although trenbolone has been shown capable of inducing morphological changes in the Syrian hamster embryo cell transformation assay (an in vitro mutagenicity model) (<a id="__tag_729447911" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B50" aria-expanded="false" aria-haspopup="true">50</a>,&nbsp;<a id="__tag_729447860" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B51" aria-expanded="false" aria-haspopup="true">51</a>). As such, future research examining the effects of TREN and other androgens using in vitro and/or in vivo xenograft models of androgen-responsive prostate cancer is warranted and should be conducted prior to this agent being advanced to clinical testing.</p>
<p id="__p52">Certain androgens also undergo in vivo aromatization (e.g., the conversion of testosterone to estradiol) and subsequently exert systemic or tissue-specific estrogen receptor-mediated effects (<a id="__tag_729447852" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B28" aria-expanded="false" aria-haspopup="true">28</a>). The aromatization of testosterone appears to be essential for bone development in men (<a id="__tag_729447912" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B62" aria-expanded="false" aria-haspopup="true">62</a>), as demonstrated by the identification of several men who suffer from congenital aromatase deficiency resulting in osteopenia, which is treatable with estradiol but not testosterone (<a id="__tag_729447907" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B28" aria-expanded="false" aria-haspopup="true">28</a>). Similarly, male aromatase knockout mice develop severe osteopenia and adverse skeletal development, which is reversible with estradiol administration (<a id="__tag_729702437" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B37" aria-expanded="false" aria-haspopup="true">37</a>,&nbsp;<a id="__tag_729702444" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B41" aria-expanded="false" aria-haspopup="true">41</a>,&nbsp;<a id="__tag_729447881" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B43" aria-expanded="false" aria-haspopup="true">43</a>). Conversely, a number of side effects commonly associated with supraphysiological androgen administration are influenced by excessive systemic or tissue-specific aromatization of androgens, including gyncecomastia (<a id="__tag_729447886" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B12" aria-expanded="false" aria-haspopup="true">12</a>), prostate cancer (<a id="__tag_729447920" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B14" aria-expanded="false" aria-haspopup="true">14</a>), fluid retention (<a id="__tag_729447878" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B56" aria-expanded="false" aria-haspopup="true">56</a>), and premature epiphyseal closure (<a id="__tag_729702434" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B42" aria-expanded="false" aria-haspopup="true">42</a>). We were unable to measure circulating estrogens in our study, since the currently available methods lack the sensitivity required for this analysis in orchiectomized male rodents. However, in vitro evidence indicates that trenbolone and its primary metabolites are relatively nonestrogenic (<a id="__tag_729447854" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B30" aria-expanded="false" aria-haspopup="true">30</a>), and in vivo evidence demonstrates that trenbolone induces antiestrogenic effects in oviparous species (<a id="__tag_729447908" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B3" aria-expanded="false" aria-haspopup="true">3</a>,&nbsp;<a id="__tag_729702446" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B16" aria-expanded="false" aria-haspopup="true">16</a>,&nbsp;<a id="__tag_729702436" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B23" aria-expanded="false" aria-haspopup="true">23</a>,&nbsp;<a id="__tag_729702435" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B32" aria-expanded="false" aria-haspopup="true">32</a>,&nbsp;<a id="__tag_729447909" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B38" aria-expanded="false" aria-haspopup="true">38</a>,&nbsp;<a id="__tag_729447916" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B53" aria-expanded="false" aria-haspopup="true">53</a>). Additionally, it has been reported that trenbolone does not undergo aromatization due to its 3-oxotriene structure (<a id="__tag_729447863" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B46" aria-expanded="false" aria-haspopup="true">46</a>), although conflicting reports exist regarding the influence of trenbolone on circulating estrogens in mammalian species (<a id="__tag_729447919" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B24" aria-expanded="false" aria-haspopup="true">24</a>,&nbsp;<a id="__tag_729447918" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B26" aria-expanded="false" aria-haspopup="true">26</a>). It is plausible that the antiestrogenic effects and apparently nonaromatizable aspects of trenbolone partially underlie the slightly diminished bone-protective effects and the apparent adynamic bone state (i.e., reduced markers of bone resorption and bone formation) that we observed following TREN treatment of ORX animals. These results may provide further evidence indicating that the bone-protective effects of androgens are at least partially mediated by the systemic and/or tissue-specific aromatization to estrogens. Clearly, future research examining bone histomorphometry would provide further insight into the effects of TREN on bone turnover. Regardless, our findings indicate that androgens are capable of exerting direct bone protection, as evidenced by the TREN-induced partial prevention of BMD loss and the reversal of ORX-induced increases in serum markers of bone resorption and formation, results that ultimately assisted in the maintenance of bone strength. As such, future research evaluating the mechanism(s) underlying the bone-protective effects of TREN and other nonaromatizable androgens are warranted, especially considering the influence of estrogens on bone health and on the side effects associated with excessive androgen administration.</p>
<p id="__p53">Recently, SARMs that produce anabolic responses within muscle and bone without inducing prostate enlargement or other androgenic side effects have been developed (<a id="__tag_729447893" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B33" aria-expanded="false" aria-haspopup="true">33</a>). The mechanism(s) through which steroidal and nonsteroidal SARMs produce selective tissue-specific anabolic responses has not been fully elucidated, although it has been postulated that their reduced activity within the prostate and other androgenic tissues may result from their inability to undergo tissue-specific 5α-reduction to more potent metabolites (<a id="__tag_729447915" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B22" aria-expanded="false" aria-haspopup="true">22</a>). Our results demonstrate that TREN, a non-5α-reducible testosterone analog, exhibits SARM-like properties since it prevented the ORX-induced reductions in muscle and bone and also reduced fat mass while maintaining prostate mass and Hb at the level of intact animals. In fact, the half-low TREN treatment reduced prostate mass in intact animals, albeit nonsignificantly, whereas it increased LABC muscle mass, which corroborates previous work indicating that TREN remains myotrophic when administered at doses lower than in our current study (<a id="__tag_729447875" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B4" aria-expanded="false" aria-haspopup="true">4</a>,&nbsp;<a id="__tag_729702442" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B20" aria-expanded="false" aria-haspopup="true">20</a>,&nbsp;<a id="__tag_729447885" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B21" aria-expanded="false" aria-haspopup="true">21</a>,&nbsp;<a id="__tag_729447898" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B35" aria-expanded="false" aria-haspopup="true">35</a>,&nbsp;<a id="__tag_729702438" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B36" aria-expanded="false" aria-haspopup="true">36</a>,&nbsp;<a id="__tag_729447894" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B40" aria-expanded="false" aria-haspopup="true">40</a>), and may also be capable of reducing prostate mass in developing animals (<a id="__tag_729447862" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B25" aria-expanded="false" aria-haspopup="true">25</a>,&nbsp;<a id="__tag_729702440" class=" bibr popnode tag_hotlink tag_tooltip" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/#B64" aria-expanded="false" aria-haspopup="true">64</a>). The likely mechanisms underlying these findings are that&nbsp;<em>1</em>) TREN ablates circulating testosterone and DHT in intact animals and&nbsp;<em>2</em>) TREN undergoes tissue-specific biotransformation to less potent androgens in vivo. The long-term SARM-like potential of TREN remains to be determined, as does its anabolic/androgenic effects within older hypogonadal rodents, a model that may more appropriately mimic the effects of aging and/or hypogonadism in men.</p>
<p id="__p54" class="p p-last">In conclusion, administration of TREN, a potent non-5α-reducible and nonestrogenic synthetic testosterone analog, produces robust myotrophic effects, partial inhibition of bone loss, prevention of visceral fat accumulation, and maintenance of Hb and prostate mass at the level of intact animals, at least at the lowest dose administered. These results suggest that lower-dose TREN induces favorable SARM-like effects on musculoskeletal tissue and adiposity and within specific accessory sex organs. Future research examining the safety and efficacy of this androgen in preclinical settings appears to be appropriate because the anabolic/androgenic ratio appears to be higher and because the risk/benefit ratio appears to be less than that of supraphysiological TE, at least in regard to prostate enlargement, although evaluating TREN and other SARMs in models of androgen-responsive prostate cancer is necessary prior to these agents being recommended for clinical testing.</p>
<p>&nbsp;</p>
<h2 id="__sec27title" class="head no_bottom_margin ui-helper-clearfix">GRANTS</h2>
<hr>
<p>This work was supported by a Veterans Department Merit Award to S. E. Borst.</p>
<h2 id="__sec28title" class="head no_bottom_margin ui-helper-clearfix">DISCLOSURES</h2>
<hr>
<p>No conflicts of interest, financial or otherwise, are declared by the authors.</p>
<h2 id="idm139797874138608title" class="head no_bottom_margin ui-helper-clearfix">REFERENCES</h2>
<hr>
<p>&nbsp;</p>
<div id="ui-ncbiinpagenav-1" class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" bis_skin_checked="1">
<div id="idm139797874138608" class="tsec sec" bis_skin_checked="1">
<div id="reference-list" class="ref-list-sec sec" bis_skin_checked="1">
<div id="B1" class="ref-cit-blk half_rhythm" bis_skin_checked="1">1.&nbsp;<span class="mixed-citation">Alatalo SL, Peng Z, Janckila AJ, Kaija H, Vihko P, Vaananen HK, Halleen JM.&nbsp;<span class="ref-title">A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum</span>.&nbsp;<span class="ref-journal"><em>J Bone Miner Res</em></span>&nbsp;: 134–139, 2003. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/12510815" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Bone+Miner+Res&amp;title=A+novel+immunoassay+for+the+determination+of+tartrate-resistant+acid+phosphatase+5b+from+rat+serum&amp;author=SL+Alatalo&amp;author=Z+Peng&amp;author=AJ+Janckila&amp;author=H+Kaija&amp;author=P+Vihko&amp;publication_year=2003&amp;pages=134-139&amp;pmid=12510815&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B2" class="ref-cit-blk half_rhythm" bis_skin_checked="1">2.&nbsp;<span class="mixed-citation">Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL.&nbsp;<span class="ref-title">Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone</span>.&nbsp;<span class="ref-journal"><em>J Clin Endocrinol Metab</em></span>&nbsp;: 503–510, 2004. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/14764753" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Endocrinol+Metab&amp;title=Exogenous+testosterone+or+testosterone+with+finasteride+increases+bone+mineral+density+in+older+men+with+low+serum+testosterone&amp;author=JK+Amory&amp;author=NB+Watts&amp;author=KA+Easley&amp;author=PR+Sutton&amp;author=BD+Anawalt&amp;publication_year=2004&amp;pages=503-510&amp;pmid=14764753&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B3" class="ref-cit-blk half_rhythm" bis_skin_checked="1">3.&nbsp;<span class="mixed-citation">Ankley GT, Defoe DL, Kahl MD, Jensen KM, Makynen EA, Miracle A, Hartig P, Gray LE, Cardon M, Wilson V.&nbsp;<span class="ref-title">Evaluation of the model anti-androgen flutamide for assessing the mechanistic basis of responses to an androgen in the fathead minnow (Pimephales promelas)</span>.&nbsp;<span class="ref-journal"><em>Environ Sci Technol</em></span>&nbsp;: 6322–6327, 2004. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/15597888" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Environ+Sci+Technol&amp;title=Evaluation+of+the+model+anti-androgen+flutamide+for+assessing+the+mechanistic+basis+of+responses+to+an+androgen+in+the+fathead+minnow+(Pimephales+promelas)&amp;author=GT+Ankley&amp;author=DL+Defoe&amp;author=MD+Kahl&amp;author=KM+Jensen&amp;author=EA+Makynen&amp;publication_year=2004&amp;pages=6322-6327&amp;pmid=15597888&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B4" class="ref-cit-blk half_rhythm" bis_skin_checked="1">4.&nbsp;<span class="mixed-citation">Ashby J, Lefevre PA, Tinwell H, Odum J, Owens W.&nbsp;<span class="ref-title">Testosterone-stimulated weanlings as an alternative to castrated male rats in the Hershberger anti-androgen assay</span>.&nbsp;<span class="ref-journal"><em>Regul Toxicol Pharmacol</em></span>&nbsp;: 229–238, 2004. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/15041151" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Regul+Toxicol+Pharmacol&amp;title=Testosterone-stimulated+weanlings+as+an+alternative+to+castrated+male+rats+in+the+Hershberger+anti-androgen+assay&amp;author=J+Ashby&amp;author=PA+Lefevre&amp;author=H+Tinwell&amp;author=J+Odum&amp;author=W+Owens&amp;publication_year=2004&amp;pages=229-238&amp;pmid=15041151&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B5" class="ref-cit-blk half_rhythm" bis_skin_checked="1">5.&nbsp;<span class="mixed-citation">Bauer ER, Daxenberger A, Petri T, Sauerwein H, Meyer HH.&nbsp;<span class="ref-title">Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor</span>.&nbsp;<span class="ref-journal"><em>Apmis</em></span>&nbsp;: 838–846, 2000. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/11252818" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Apmis&amp;title=Characterisation+of+the+affinity+of+different+anabolics+and+synthetic+hormones+to+the+human+androgen+receptor,+human+sex+hormone+binding+globulin+and+to+the+bovine+progestin+receptor&amp;author=ER+Bauer&amp;author=A+Daxenberger&amp;author=T+Petri&amp;author=H+Sauerwein&amp;author=HH+Meyer&amp;publication_year=2000&amp;pages=838-846&amp;pmid=11252818&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B6" class="ref-cit-blk half_rhythm" bis_skin_checked="1">6.&nbsp;<span class="mixed-citation">Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT.&nbsp;<span class="ref-title">Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging</span>.&nbsp;<span class="ref-journal"><em>Nat Clin Pract Endocrinol Metab</em></span>&nbsp;: 146–159, 2006.&nbsp;<span class="nowrap">[<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072878/">PMC free article</a>]</span>&nbsp;[<a href="https://www.ncbi.nlm.nih.gov/pubmed/16932274" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Nat+Clin+Pract+Endocrinol+Metab&amp;title=Drug+insight:+Testosterone+and+selective+androgen+receptor+modulators+as+anabolic+therapies+for+chronic+illness+and+aging&amp;author=S+Bhasin&amp;author=OM+Calof&amp;author=TW+Storer&amp;author=ML+Lee&amp;author=NA+Mazer&amp;publication_year=2006&amp;pages=146-159&amp;pmid=16932274&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B7" class="ref-cit-blk half_rhythm" bis_skin_checked="1">7.&nbsp;<span class="mixed-citation">Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW.&nbsp;<span class="ref-title">Testosterone dose-response relationships in healthy young men</span>.&nbsp;<span class="ref-journal"><em>Am J Physiol Endocrinol Metab</em></span>&nbsp;: E1172–E1181, 2001. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/11701431" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Am+J+Physiol+Endocrinol+Metab&amp;title=Testosterone+dose-response+relationships+in+healthy+young+men&amp;author=S+Bhasin&amp;author=L+Woodhouse&amp;author=R+Casaburi&amp;author=AB+Singh&amp;author=D+Bhasin&amp;publication_year=2001&amp;pages=E1172-E1181&amp;pmid=11701431&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B8" class="ref-cit-blk half_rhythm" bis_skin_checked="1">8.&nbsp;<span class="mixed-citation">Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW.&nbsp;<span class="ref-title">Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle</span>.&nbsp;<span class="ref-journal"><em>J Clin Endocrinol Metab</em></span>&nbsp;: 678–688, 2005. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/15562020" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Endocrinol+Metab&amp;title=Older+men+are+as+responsive+as+young+men+to+the+anabolic+effects+of+graded+doses+of+testosterone+on+the+skeletal+muscle&amp;author=S+Bhasin&amp;author=L+Woodhouse&amp;author=R+Casaburi&amp;author=AB+Singh&amp;author=RP+Mac&amp;publication_year=2005&amp;pages=678-688&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B9" class="ref-cit-blk half_rhythm" bis_skin_checked="1">9.&nbsp;<span class="mixed-citation">Borst SE, Conover CF.&nbsp;<span class="ref-title">Orchiectomized Fischer 344 male rat models body composition in hypogonadal state</span>.&nbsp;<span class="ref-journal"><em>Life Sci</em></span>&nbsp;: 411–415, 2006. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/16507309" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Life+Sci&amp;title=Orchiectomized+Fischer+344+male+rat+models+body+composition+in+hypogonadal+state&amp;author=SE+Borst&amp;author=CF+Conover&amp;publication_year=2006&amp;pages=411-415&amp;pmid=16507309&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B10" class="ref-cit-blk half_rhythm" bis_skin_checked="1">10.&nbsp;<span class="mixed-citation">Borst SE, Conover CF, Carter CS, Gregory CM, Marzetti E, Leeuwenburgh C, Vandenborne K, Wronski TJ.&nbsp;<span class="ref-title">Anabolic effects of testosterone are preserved during inhibition of 5α-reductase</span>.&nbsp;<span class="ref-journal"><em>Am J Physiol Endocrinol Metab</em></span>&nbsp;: E507–E514, 2007. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/17488806" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Am+J+Physiol+Endocrinol+Metab&amp;title=Anabolic+effects+of+testosterone+are+preserved+during+inhibition+of+5%CE%B1-reductase&amp;author=SE+Borst&amp;author=CF+Conover&amp;author=CS+Carter&amp;author=CM+Gregory&amp;author=E+Marzetti&amp;publication_year=2007&amp;pages=E507-E514&amp;pmid=17488806&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B11" class="ref-cit-blk half_rhythm" bis_skin_checked="1">11.&nbsp;<span class="mixed-citation">Borst SE, Lee JH, Conover CF.&nbsp;<span class="ref-title">Inhibition of 5α-reductase blocks prostate effects of testosterone without blocking anabolic effects</span>.&nbsp;<span class="ref-journal"><em>Am J Physiol Endocrinol Metab</em></span>&nbsp;: E222–E227, 2005. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/15367394" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Am+J+Physiol+Endocrinol+Metab&amp;title=Inhibition+of+5%CE%B1-reductase+blocks+prostate+effects+of+testosterone+without+blocking+anabolic+effects&amp;author=SE+Borst&amp;author=JH+Lee&amp;author=CF+Conover&amp;publication_year=2005&amp;pages=E222-E227&amp;pmid=15367394&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B12" class="ref-cit-blk half_rhythm" bis_skin_checked="1">12.&nbsp;<span class="mixed-citation">Braunstein GD.&nbsp;<span class="ref-title">Aromatase and gynecomastia</span>.&nbsp;<span class="ref-journal"><em>Endocr Relat Cancer</em></span>&nbsp;: 315–324, 1999. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/10731125" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Endocr+Relat+Cancer&amp;title=Aromatase+and+gynecomastia&amp;author=GD+Braunstein&amp;publication_year=1999&amp;pages=315-324&amp;pmid=10731125&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B13" class="ref-cit-blk half_rhythm" bis_skin_checked="1">13.&nbsp;<span class="mixed-citation">Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S.&nbsp;<span class="ref-title">Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials</span>.&nbsp;<span class="ref-journal"><em>J Gerontol A Biol Sci Med Sci</em></span>&nbsp;: 1451–1457, 2005. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/16339333" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Gerontol+A+Biol+Sci+Med+Sci&amp;title=Adverse+events+associated+with+testosterone+replacement+in+middle-aged+and+older+men:+a+meta-analysis+of+randomized,+placebo-controlled+trials&amp;author=OM+Calof&amp;author=AB+Singh&amp;author=ML+Lee&amp;author=AM+Kenny&amp;author=RJ+Urban&amp;publication_year=2005&amp;pages=1451-1457&amp;pmid=16339333&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B14" class="ref-cit-blk half_rhythm" bis_skin_checked="1">14.&nbsp;<span class="mixed-citation">Carruba G.&nbsp;<span class="ref-title">Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario</span>.&nbsp;<span class="ref-journal"><em>J Cell Biochem</em></span>&nbsp;: 899–911, 2007. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/17786930" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Cell+Biochem&amp;title=Estrogen+and+prostate+cancer:+an+eclipsed+truth+in+an+androgen-dominated+scenario&amp;author=G+Carruba&amp;publication_year=2007&amp;pages=899-911&amp;pmid=17786930&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B15" class="ref-cit-blk half_rhythm" bis_skin_checked="1">15.&nbsp;<span class="mixed-citation">Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH.&nbsp;<span class="ref-title">The metabolic syndrome</span>.&nbsp;<span class="ref-journal"><em>Endocr Rev</em></span>&nbsp;: 777–822, 2008.&nbsp;<span class="nowrap">[<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393149/">PMC free article</a>]</span>&nbsp;[<a href="https://www.ncbi.nlm.nih.gov/pubmed/18971485" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Endocr+Rev&amp;title=The+metabolic+syndrome&amp;author=MA+Cornier&amp;author=D+Dabelea&amp;author=TL+Hernandez&amp;author=RC+Lindstrom&amp;author=AJ+Steig&amp;publication_year=2008&amp;pages=777-822&amp;pmid=18971485&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B16" class="ref-cit-blk half_rhythm" bis_skin_checked="1">16.&nbsp;<span class="mixed-citation">Dorts J, Richter CA, Wright-Osment MK, Ellersieck MR, Carter BJ, Tillitt DE.&nbsp;<span class="ref-title">The genomic transcriptional response of female fathead minnows (Pimephales promelas) to an acute exposure to the androgen, 17beta-trenbolone</span>.&nbsp;<span class="ref-journal"><em>Aquat Toxicol</em></span>&nbsp;: 44–53, 2009.&nbsp;<span class="nowrap">[<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747603/">PMC free article</a>]</span>&nbsp;[<a href="https://www.ncbi.nlm.nih.gov/pubmed/19019464" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Aquat+Toxicol&amp;title=The+genomic+transcriptional+response+of+female+fathead+minnows+(Pimephales+promelas)+to+an+acute+exposure+to+the+androgen,+17beta-trenbolone&amp;author=J+Dorts&amp;author=CA+Richter&amp;author=MK+Wright-Osment&amp;author=MR+Ellersieck&amp;author=BJ+Carter&amp;publication_year=2009&amp;pages=44-53&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B17" class="ref-cit-blk half_rhythm" bis_skin_checked="1">17.&nbsp;<span class="mixed-citation">Evrard P, Maghuin-Rogister G, Rico AG.&nbsp;<span class="ref-title">Fate and residues of trenbolone acetate in edible tissues from sheep amd calves implanted with tritium-labeled trenbolone acetate</span>.&nbsp;<span class="ref-journal"><em>J Anim Sci</em></span>&nbsp;: 1489–1496, 1989. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/2768105" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Anim+Sci&amp;title=Fate+and+residues+of+trenbolone+acetate+in+edible+tissues+from+sheep+amd+calves+implanted+with+tritium-labeled+trenbolone+acetate&amp;author=P+Evrard&amp;author=G+Maghuin-Rogister&amp;author=AG+Rico&amp;publication_year=1989&amp;pages=1489-1496&amp;pmid=2768105&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B18" class="ref-cit-blk half_rhythm" bis_skin_checked="1">18.&nbsp;<span class="mixed-citation">Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM.&nbsp;<span class="ref-title">Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis</span>.&nbsp;<span class="ref-journal"><em>J Clin Endocrinol Metab</em></span>&nbsp;: 2560–2575, 2010. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/20525906" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Endocrinol+Metab&amp;title=Clinical+review+1:+Adverse+effects+of+testosterone+therapy+in+adult+men:+a+systematic+review+and+meta-analysis&amp;author=MM+Fern%C3%A1ndez-Balsells&amp;author=MH+Murad&amp;author=M+Lane&amp;author=JF+Lampropulos&amp;author=F+Albuquerque&amp;publication_year=2010&amp;pages=2560-2575&amp;pmid=20525906&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B19" class="ref-cit-blk half_rhythm" bis_skin_checked="1">19.&nbsp;<span class="mixed-citation">Foradori CD, Weiser MJ, Handa RJ.&nbsp;<span class="ref-title">Non-genomic actions of androgens</span>.&nbsp;<span class="ref-journal"><em>Front Neuroendocrinol</em></span>&nbsp;: 169–181, 2008.&nbsp;<span class="nowrap">[<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386261/">PMC free article</a>]</span>&nbsp;[<a href="https://www.ncbi.nlm.nih.gov/pubmed/18093638" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Front+Neuroendocrinol&amp;title=Non-genomic+actions+of+androgens&amp;author=CD+Foradori&amp;author=MJ+Weiser&amp;author=RJ+Handa&amp;publication_year=2008&amp;pages=169-181&amp;pmid=18093638&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B20" class="ref-cit-blk half_rhythm" bis_skin_checked="1">20.&nbsp;<span class="mixed-citation">Freyberger A, Ellinger-Ziegelbauer H, Krotlinger F.&nbsp;<span class="ref-title">Evaluation of the rodent Hershberger bioassay: testing of coded chemicals and supplementary molecular-biological and biochemical investigations</span>.&nbsp;<span class="ref-journal"><em>Toxicology</em></span>&nbsp;: 77–88, 2007. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/17688994" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Toxicology&amp;title=Evaluation+of+the+rodent+Hershberger+bioassay:+testing+of+coded+chemicals+and+supplementary+molecular-biological+and+biochemical+investigations&amp;author=A+Freyberger&amp;author=H+Ellinger-Ziegelbauer&amp;author=F+Krotlinger&amp;publication_year=2007&amp;pages=77-88&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B21" class="ref-cit-blk half_rhythm" bis_skin_checked="1">21.&nbsp;<span class="mixed-citation">Freyberger A, Hartmann E, Krötlinger F.&nbsp;<span class="ref-title">Evaluation of the rodent Hershberger bioassay using three reference (anti)androgens</span>.&nbsp;<span class="ref-journal"><em>Arh Hig Rada Toksikol</em></span>&nbsp;: 131–139, 2005. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/15968828" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Arh+Hig+Rada+Toksikol&amp;title=Evaluation+of+the+rodent+Hershberger+bioassay+using+three+reference+(anti)androgens&amp;author=A+Freyberger&amp;author=E+Hartmann&amp;author=F+Kr%C3%B6tlinger&amp;publication_year=2005&amp;pages=131-139&amp;pmid=15968828&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B22" class="ref-cit-blk half_rhythm" bis_skin_checked="1">22.&nbsp;<span class="mixed-citation">Gao W, Dalton JT.&nbsp;<span class="ref-title">Ockham’s razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?</span>&nbsp;<span class="ref-journal"><em>Mol Interv</em></span>&nbsp;: 10–13, 2007.&nbsp;<span class="nowrap">[<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040232/">PMC free article</a>]</span>&nbsp;[<a href="https://www.ncbi.nlm.nih.gov/pubmed/17339601" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Mol+Interv&amp;title=Ockham%27s+razor+and+selective+androgen+receptor+modulators+(SARMs):+are+we+overlooking+the+role+of+5alpha-reductase?&amp;author=W+Gao&amp;author=JT+Dalton&amp;publication_year=2007&amp;pages=10-13&amp;pmid=17339601&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B23" class="ref-cit-blk half_rhythm" bis_skin_checked="1">23.&nbsp;<span class="mixed-citation">Hemmer MJ, Cripe GM, Hemmer BL, Goodman LR, Salinas KA, Fournie JW, Walker CC.&nbsp;<span class="ref-title">Comparison of estrogen-responsive plasma protein biomarkers and reproductive endpoints in sheepshead minnows exposed to 17beta-trenbolone</span>.&nbsp;<span class="ref-journal"><em>Aquat Toxicol</em></span>&nbsp;: 128–136, 2008. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/18495259" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Aquat+Toxicol&amp;title=Comparison+of+estrogen-responsive+plasma+protein+biomarkers+and+reproductive+endpoints+in+sheepshead+minnows+exposed+to+17beta-trenbolone&amp;author=MJ+Hemmer&amp;author=GM+Cripe&amp;author=BL+Hemmer&amp;author=LR+Goodman&amp;author=KA+Salinas&amp;publication_year=2008&amp;pages=128-136&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B24" class="ref-cit-blk half_rhythm" bis_skin_checked="1">24.&nbsp;<span class="mixed-citation">Henricks DM, Edwards RL, Champe KA, Gettys TW, Skelley GC, Gimenez T.&nbsp;<span class="ref-title">Trenbolone, estradiol-17 beta and estrone levels in plasma and tissues and live weight gains of heifers implanted with trenbolone acetate</span>.&nbsp;<span class="ref-journal"><em>J Anim Sci</em></span>&nbsp;: 1048–1056, 1982. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/7174549" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Anim+Sci&amp;title=Trenbolone,+estradiol-17+beta+and+estrone+levels+in+plasma+and+tissues+and+live+weight+gains+of+heifers+implanted+with+trenbolone+acetate&amp;author=DM+Henricks&amp;author=RL+Edwards&amp;author=KA+Champe&amp;author=TW+Gettys&amp;author=GC+Skelley&amp;publication_year=1982&amp;pages=1048-1056&amp;pmid=7174549&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B25" class="ref-cit-blk half_rhythm" bis_skin_checked="1">25.&nbsp;<span class="mixed-citation">Hotchkiss AK, Nelson RJ.&nbsp;<span class="ref-title">An environmental androgen, 17beta-trenbolone, affects delayed-type hypersensitivity and reproductive tissues in male mice</span>.&nbsp;<span class="ref-journal"><em>J Toxicol Environ Health A</em></span>&nbsp;: 138–140, 2007. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/17365574" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Toxicol+Environ+Health+A&amp;title=An+environmental+androgen,+17beta-trenbolone,+affects+delayed-type+hypersensitivity+and+reproductive+tissues+in+male+mice&amp;author=AK+Hotchkiss&amp;author=RJ+Nelson&amp;publication_year=2007&amp;pages=138-140&amp;pmid=17365574&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B26" class="ref-cit-blk half_rhythm" bis_skin_checked="1">26.&nbsp;<span class="mixed-citation">Hunt DW, Henricks DM, Skelley GC, Grimes LW.&nbsp;<span class="ref-title">Use of trenbolone acetate and estradiol in intact and castrate male cattle: effects on growth, serum hormones, and carcass characteristics</span>.&nbsp;<span class="ref-journal"><em>J Anim Sci</em></span>&nbsp;: 2452–2462, 1991. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/1885362" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Anim+Sci&amp;title=Use+of+trenbolone+acetate+and+estradiol+in+intact+and+castrate+male+cattle:+effects+on+growth,+serum+hormones,+and+carcass+characteristics&amp;author=DW+Hunt&amp;author=DM+Henricks&amp;author=GC+Skelley&amp;author=LW+Grimes&amp;publication_year=1991&amp;pages=2452-2462&amp;pmid=1885362&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B27" class="ref-cit-blk half_rhythm" bis_skin_checked="1">27.&nbsp;<span class="mixed-citation">Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A.&nbsp;<span class="ref-title">Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis</span>.&nbsp;<span class="ref-journal"><em>Clin Endocrinol</em></span>&nbsp;: 280–293, 2005. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/16117815" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Clin+Endocrinol&amp;title=Effects+of+testosterone+on+body+composition,+bone+metabolism+and+serum+lipid+profile+in+middle-aged+men:+a+meta-analysis&amp;author=AM+Isidori&amp;author=E+Giannetta&amp;author=EA+Greco&amp;author=D+Gianfrilli&amp;author=V+Bonifacio&amp;publication_year=2005&amp;pages=280-293&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B28" class="ref-cit-blk half_rhythm" bis_skin_checked="1">28.&nbsp;<span class="mixed-citation">Jones ME, Boon WC, Proietto J, Simpson ER.&nbsp;<span class="ref-title">Of mice and men: the evolving phenotype of aromatase deficiency</span>.&nbsp;<span class="ref-journal"><em>Trends Endocrinol Metab</em></span>&nbsp;: 55–64, 2006. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/16480891" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Trends+Endocrinol+Metab&amp;title=Of+mice+and+men:+the+evolving+phenotype+of+aromatase+deficiency&amp;author=ME+Jones&amp;author=WC+Boon&amp;author=J+Proietto&amp;author=ER+Simpson&amp;publication_year=2006&amp;pages=55-64&amp;pmid=16480891&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B29" class="ref-cit-blk half_rhythm" bis_skin_checked="1">29.&nbsp;<span class="mixed-citation">Kamanga-Sollo E, White ME, Hathaway MR, Chung KY, Johnson BJ, Dayton WR.&nbsp;<span class="ref-title">Roles of IGF-I and the estrogen, androgen and IGF-I receptors in estradiol-17beta- and trenbolone acetate-stimulated proliferation of cultured bovine satellite cells</span>.&nbsp;<span class="ref-journal"><em>Domest Anim Endocrinol</em></span>&nbsp;: 88–97, 2008. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/18403176" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Domest+Anim+Endocrinol&amp;title=Roles+of+IGF-I+and+the+estrogen,+androgen+and+IGF-I+receptors+in+estradiol-17beta-+and+trenbolone+acetate-stimulated+proliferation+of+cultured+bovine+satellite+cells&amp;author=E+Kamanga-Sollo&amp;author=ME+White&amp;author=MR+Hathaway&amp;author=KY+Chung&amp;author=BJ+Johnson&amp;publication_year=2008&amp;pages=88-97&amp;pmid=18403176&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B30" class="ref-cit-blk half_rhythm" bis_skin_checked="1">30.&nbsp;<span class="mixed-citation">Le Guevel R, Pakdel F.&nbsp;<span class="ref-title">Assessment of oestrogenic potency of chemicals used as growth promoter by in-vitro methods</span>.&nbsp;<span class="ref-journal"><em>Hum Reprod</em></span>&nbsp;: 1030–1036, 2001. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/11331656" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Hum+Reprod&amp;title=Assessment+of+oestrogenic+potency+of+chemicals+used+as+growth+promoter+by+in-vitro+methods&amp;author=R+Le+Guevel&amp;author=F+Pakdel&amp;publication_year=2001&amp;pages=1030-1036&amp;pmid=11331656&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B31" class="ref-cit-blk half_rhythm" bis_skin_checked="1">31.&nbsp;<span class="mixed-citation">Metzler M.&nbsp;<span class="ref-title">Metabolism of some anabolic agents: toxicological and analytical aspects</span>.&nbsp;<span class="ref-journal"><em>J Chromatograph</em></span>&nbsp;: 11–21, 1989. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/2745641" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Chromatograph&amp;title=Metabolism+of+some+anabolic+agents:+toxicological+and+analytical+aspects&amp;author=M+Metzler&amp;publication_year=1989&amp;pages=11-21&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B32" class="ref-cit-blk half_rhythm" bis_skin_checked="1">32.&nbsp;<span class="mixed-citation">Miracle A, Ankley G, Lattier D.&nbsp;<span class="ref-title">Expression of two vitellogenin genes (vg1 and vg3) in fathead minnow (Pimephales promelas) liver in response to exposure to steroidal estrogens and androgens</span>.&nbsp;<span class="ref-journal"><em>Ecotoxicol Environ Saf</em></span>&nbsp;: 337–342, 2006. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/16464498" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Ecotoxicol+Environ+Saf&amp;title=Expression+of+two+vitellogenin+genes+(vg1+and+vg3)+in+fathead+minnow+(Pimephales+promelas)+liver+in+response+to+exposure+to+steroidal+estrogens+and+androgens&amp;author=A+Miracle&amp;author=G+Ankley&amp;author=D+Lattier&amp;publication_year=2006&amp;pages=337-342&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B33" class="ref-cit-blk half_rhythm" bis_skin_checked="1">33.&nbsp;<span class="mixed-citation">Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD.&nbsp;<span class="ref-title">Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit</span>.&nbsp;<span class="ref-journal"><em>J Med Chem</em></span>&nbsp;: 3597–3617, 2009. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/19432422" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;title=Nonsteroidal+selective+androgen+receptor+modulators+(SARMs):+dissociating+the+anabolic+and+androgenic+activities+of+the+androgen+receptor+for+therapeutic+benefit&amp;author=ML+Mohler&amp;author=CE+Bohl&amp;author=A+Jones&amp;author=CC+Coss&amp;author=R+Narayanan&amp;publication_year=2009&amp;pages=3597-3617&amp;pmid=19432422&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B34" class="ref-cit-blk half_rhythm" bis_skin_checked="1">34.&nbsp;<span class="mixed-citation">Monks DA, O’Bryant EL, Jordan CL.&nbsp;<span class="ref-title">Androgen receptor immunoreactivity in skeletal muscle: enrichment at the neuromuscular junction</span>.&nbsp;<span class="ref-journal"><em>J Comp Neurol</em></span>&nbsp;: 59–72, 2004. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/15067718" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Comp+Neurol&amp;title=Androgen+receptor+immunoreactivity+in+skeletal+muscle:+enrichment+at+the+neuromuscular+junction&amp;author=DA+Monks&amp;author=EL+O%27Bryant&amp;author=CL+Jordan&amp;publication_year=2004&amp;pages=59-72&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B35" class="ref-cit-blk half_rhythm" bis_skin_checked="1">35.&nbsp;<span class="mixed-citation">Moon HJ, Kang TS, Kim TS, Kang IH, Ki HY, Kim SH, Han SY.&nbsp;<span class="ref-title">OECD validation of phase 3 Hershberger assay in Korea using surgically castrated male rats with coded chemicals</span>.&nbsp;<span class="ref-journal"><em>J Appl Toxicol</em></span>&nbsp;: 350–355, 2009. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/19241440" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Appl+Toxicol&amp;title=OECD+validation+of+phase+3+Hershberger+assay+in+Korea+using+surgically+castrated+male+rats+with+coded+chemicals&amp;author=HJ+Moon&amp;author=TS+Kang&amp;author=TS+Kim&amp;author=IH+Kang&amp;author=HY+Ki&amp;publication_year=2009&amp;pages=350-355&amp;pmid=19241440&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B36" class="ref-cit-blk half_rhythm" bis_skin_checked="1">36.&nbsp;<span class="mixed-citation">Moon HJ, Kang TS, Kim TS, Kang IH, Kim SH, Han SY.&nbsp;<span class="ref-title">OECD validation of phase-3 Hershberger assay using the stimulated weanling male rat in Korea</span>.&nbsp;<span class="ref-journal"><em>J Appl Toxicol</em></span>&nbsp;2010. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/20082360" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Appl+Toxicol&amp;title=OECD+validation+of+phase-3+Hershberger+assay+using+the+stimulated+weanling+male+rat+in+Korea&amp;author=HJ+Moon&amp;author=TS+Kang&amp;author=TS+Kim&amp;author=IH+Kang&amp;author=SH+Kim&amp;publication_year=2010&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B37" class="ref-cit-blk half_rhythm" bis_skin_checked="1">37.&nbsp;<span class="mixed-citation">Murata Y, Robertson KM, Jones ME, Simpson ER.&nbsp;<span class="ref-title">Effect of estrogen deficiency in the male: the ArKO mouse model</span>.&nbsp;<span class="ref-journal"><em>Mol Cell Endocrinol</em></span>&nbsp;: 7–12, 2002. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/12160996" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Endocrinol&amp;title=Effect+of+estrogen+deficiency+in+the+male:+the+ArKO+mouse+model&amp;author=Y+Murata&amp;author=KM+Robertson&amp;author=ME+Jones&amp;author=ER+Simpson&amp;publication_year=2002&amp;pages=7-12&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B38" class="ref-cit-blk half_rhythm" bis_skin_checked="1">38.&nbsp;<span class="mixed-citation">Orn S, Yamani S, Norrgren L.&nbsp;<span class="ref-title">Comparison of vitellogenin induction, sex ratio, and gonad morphology between zebrafish and Japanese medaka after exposure to 17alpha-ethinylestradiol and 17beta-trenbolone</span>.&nbsp;<span class="ref-journal"><em>Arch Environ Contam Toxicol</em></span>&nbsp;: 237–243, 2006. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/16783621" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Arch+Environ+Contam+Toxicol&amp;title=Comparison+of+vitellogenin+induction,+sex+ratio,+and+gonad+morphology+between+zebrafish+and+Japanese+medaka+after+exposure+to+17alpha-ethinylestradiol+and+17beta-trenbolone&amp;author=S+Orn&amp;author=S+Yamani&amp;author=L+Norrgren&amp;publication_year=2006&amp;pages=237-243&amp;pmid=16783621&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B39" class="ref-cit-blk half_rhythm" bis_skin_checked="1">39.&nbsp;<span class="mixed-citation">Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, Acha AA, Ostir GV.&nbsp;<span class="ref-title">Androgen treatment and muscle strength in elderly men: A meta-analysis</span>.&nbsp;<span class="ref-journal"><em>J Am Geriatr Soc</em></span>&nbsp;: 1666–1673, 2006.&nbsp;<span class="nowrap">[<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1752197/">PMC free article</a>]</span>&nbsp;[<a href="https://www.ncbi.nlm.nih.gov/pubmed/17087692" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Am+Geriatr+Soc&amp;title=Androgen+treatment+and+muscle+strength+in+elderly+men:+A+meta-analysis&amp;author=KJ+Ottenbacher&amp;author=ME+Ottenbacher&amp;author=AJ+Ottenbacher&amp;author=AA+Acha&amp;author=GV+Ostir&amp;publication_year=2006&amp;pages=1666-1673&amp;pmid=17087692&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B40" class="ref-cit-blk half_rhythm" bis_skin_checked="1">40.&nbsp;<span class="mixed-citation">Owens W, Gray LE, Zeiger E, Walker M, Yamasaki K, Ashby J, Jacob E.&nbsp;<span class="ref-title">The OECD program to validate the rat Hershberger bioassay to screen compounds for in vivo androgen and antiandrogen responses: phase 2 dose-response studies</span>.&nbsp;<span class="ref-journal"><em>Environ Health Perspect</em></span>&nbsp;: 671–678, 2007.&nbsp;<span class="nowrap">[<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1867976/">PMC free article</a>]</span>&nbsp;[<a href="https://www.ncbi.nlm.nih.gov/pubmed/17520051" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Environ+Health+Perspect&amp;title=The+OECD+program+to+validate+the+rat+Hershberger+bioassay+to+screen+compounds+for+in+vivo+androgen+and+antiandrogen+responses:+phase+2+dose-response+studies&amp;author=W+Owens&amp;author=LE+Gray&amp;author=E+Zeiger&amp;author=M+Walker&amp;author=K+Yamasaki&amp;publication_year=2007&amp;pages=671-678&amp;pmid=17520051&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B41" class="ref-cit-blk half_rhythm" bis_skin_checked="1">41.&nbsp;<span class="mixed-citation">Oz OK, Hirasawa G, Lawson J, Nanu L, Constantinescu A, Antich PP, Mason RP, Tsyganov E, Parkey RW, Zerwekh JE, Simpson ER.&nbsp;<span class="ref-title">Bone phenotype of the aromatase deficient mouse</span>.&nbsp;<span class="ref-journal"><em>J Steroid Biochem Mol Biol</em></span>&nbsp;: 49–59, 2001. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/11850207" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Steroid+Biochem+Mol+Biol&amp;title=Bone+phenotype+of+the+aromatase+deficient+mouse&amp;author=OK+Oz&amp;author=G+Hirasawa&amp;author=J+Lawson&amp;author=L+Nanu&amp;author=A+Constantinescu&amp;publication_year=2001&amp;pages=49-59&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B42" class="ref-cit-blk half_rhythm" bis_skin_checked="1">42.&nbsp;<span class="mixed-citation">Oz OK, Millsaps R, Welch R, Birch J, Zerwekh JE.&nbsp;<span class="ref-title">Expression of aromatase in the human growth plate</span>.&nbsp;<span class="ref-journal"><em>J Mol Endocrinol</em></span>&nbsp;: 249–253, 2001. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/11564607" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Mol+Endocrinol&amp;title=Expression+of+aromatase+in+the+human+growth+plate&amp;author=OK+Oz&amp;author=R+Millsaps&amp;author=R+Welch&amp;author=J+Birch&amp;author=JE+Zerwekh&amp;publication_year=2001&amp;pages=249-253&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B43" class="ref-cit-blk half_rhythm" bis_skin_checked="1">43.&nbsp;<span class="mixed-citation">Oz OK, Zerwekh JE, Fisher C, Graves K, Nanu L, Millsaps R, Simpson ER.&nbsp;<span class="ref-title">Bone has a sexually dimorphic response to aromatase deficiency</span>.&nbsp;<span class="ref-journal"><em>J Bone Miner Res</em></span>&nbsp;: 507–514, 2000. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/10750565" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Bone+Miner+Res&amp;title=Bone+has+a+sexually+dimorphic+response+to+aromatase+deficiency&amp;author=OK+Oz&amp;author=JE+Zerwekh&amp;author=C+Fisher&amp;author=K+Graves&amp;author=L+Nanu&amp;publication_year=2000&amp;pages=507-514&amp;pmid=10750565&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B44" class="ref-cit-blk half_rhythm" bis_skin_checked="1">44.&nbsp;<span class="mixed-citation">Pelker RR, Friedlaender GE, Markham TC, Panjabi MM, Moen CJ.&nbsp;<span class="ref-title">Effects of freezing and freeze-drying on the biomechanical properties of rat bone</span>.&nbsp;<span class="ref-journal"><em>J Orthop Res</em></span>&nbsp;: 405–411, 1984. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/6387075" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Orthop+Res&amp;title=Effects+of+freezing+and+freeze-drying+on+the+biomechanical+properties+of+rat+bone&amp;author=RR+Pelker&amp;author=GE+Friedlaender&amp;author=TC+Markham&amp;author=MM+Panjabi&amp;author=CJ+Moen&amp;publication_year=1984&amp;pages=405-411&amp;pmid=6387075&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B45" class="ref-cit-blk half_rhythm" bis_skin_checked="1">45.&nbsp;<span class="mixed-citation">Pottier J, Busigny M, Grandadam JA.&nbsp;<span class="ref-title">Plasma kinetics, excretion in mild and tissue levels in the cow following implantation of trenbolone acetate</span>.&nbsp;<span class="ref-journal"><em>J Anim Sci</em></span>&nbsp;: 962–968, 1975. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/1171859" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Anim+Sci&amp;title=Plasma+kinetics,+excretion+in+mild+and+tissue+levels+in+the+cow+following+implantation+of+trenbolone+acetate&amp;author=J+Pottier&amp;author=M+Busigny&amp;author=JA+Grandadam&amp;publication_year=1975&amp;pages=962-968&amp;pmid=1171859&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B46" class="ref-cit-blk half_rhythm" bis_skin_checked="1">46.&nbsp;<span class="mixed-citation">Pottier J, Cousty C, Heitzman RJ, Reynolds IP.&nbsp;<span class="ref-title">Differences in the biotransformation of a 17 beta-hydroxylated steroid, trenbolone acetate, in rat and cow</span>.&nbsp;<span class="ref-journal"><em>Xenobiotica</em></span>&nbsp;: 489–500, 1981. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/7293236" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Xenobiotica&amp;title=Differences+in+the+biotransformation+of+a+17+beta-hydroxylated+steroid,+trenbolone+acetate,+in+rat+and+cow&amp;author=J+Pottier&amp;author=C+Cousty&amp;author=RJ+Heitzman&amp;author=IP+Reynolds&amp;publication_year=1981&amp;pages=489-500&amp;pmid=7293236&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B47" class="ref-cit-blk half_rhythm" bis_skin_checked="1">47.&nbsp;<span class="mixed-citation">Richold M.&nbsp;<span class="ref-title">The genotoxicity of trenbolone, a synthetic steroid</span>.&nbsp;<span class="ref-journal"><em>Arch Toxicol</em></span>&nbsp;: 249–258, 1988. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/3288174" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Arch+Toxicol&amp;title=The+genotoxicity+of+trenbolone,+a+synthetic+steroid&amp;author=M+Richold&amp;publication_year=1988&amp;pages=249-258&amp;pmid=3288174&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B48" class="ref-cit-blk half_rhythm" bis_skin_checked="1">48.&nbsp;<span class="mixed-citation">Santidrian S, Thompson JR.&nbsp;<span class="ref-title">Effect of sex, testosterone propionate and trienbolone acetate on the rate of growth and myofibrillar protein degradation in growing young rats</span>.&nbsp;<span class="ref-journal"><em>Reproduccion</em></span>&nbsp;: 33–41, 1982. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/7117687" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Reproduccion&amp;title=Effect+of+sex,+testosterone+propionate+and+trienbolone+acetate+on+the+rate+of+growth+and+myofibrillar+protein+degradation+in+growing+young+rats&amp;author=S+Santidrian&amp;author=JR+Thompson&amp;publication_year=1982&amp;pages=33-41&amp;pmid=7117687&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B49" class="ref-cit-blk half_rhythm" bis_skin_checked="1">49.&nbsp;<span class="mixed-citation">Santidrián S, Thompson JR, Young VR.&nbsp;<span class="ref-title">Effect of trienbolone acetate on the rate of myofibrillar protein breakdown in young adrenalectomized male rate treated with corticosterone</span>.&nbsp;<span class="ref-journal"><em>Arch Farmacol Toxicol</em></span>&nbsp;: 333–340, 1981. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/7337472" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Arch+Farmacol+Toxicol&amp;title=Effect+of+trienbolone+acetate+on+the+rate+of+myofibrillar+protein+breakdown+in+young+adrenalectomized+male+rate+treated+with+corticosterone&amp;author=S+Santidri%C3%A1n&amp;author=JR+Thompson&amp;author=VR+Young&amp;publication_year=1981&amp;pages=333-340&amp;pmid=7337472&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B50" class="ref-cit-blk half_rhythm" bis_skin_checked="1">50.&nbsp;<span class="mixed-citation">Schiffmann D, Hieber L, Schmuck G, Pechan R, Metzler M, Henschler D.&nbsp;<span class="ref-title">Trenbolone induces micronucleus formation and neoplastic transformation in Syrian hamster embryo fibroblasts but not in mouse C3H10T1/2 cells</span>.&nbsp;<span class="ref-journal"><em>Arch Toxicol</em></span>&nbsp;: 49–53, 1988. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/3190456" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Arch+Toxicol&amp;title=Trenbolone+induces+micronucleus+formation+and+neoplastic+transformation+in+Syrian+hamster+embryo+fibroblasts+but+not+in+mouse+C3H10T1/2+cells&amp;author=D+Schiffmann&amp;author=L+Hieber&amp;author=G+Schmuck&amp;author=R+Pechan&amp;author=M+Metzler&amp;publication_year=1988&amp;pages=49-53&amp;pmid=3190456&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B51" class="ref-cit-blk half_rhythm" bis_skin_checked="1">51.&nbsp;<span class="mixed-citation">Schiffmann D, Metzler M, Neudecker T, Henschler D.&nbsp;<span class="ref-title">Morphological transformation of Syrian hamster embryo fibroblasts by the anabolic agent trenbolone</span>.&nbsp;<span class="ref-journal"><em>Arch Toxicol</em></span>&nbsp;: 59–63, 1985. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/3907591" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Arch+Toxicol&amp;title=Morphological+transformation+of+Syrian+hamster+embryo+fibroblasts+by+the+anabolic+agent+trenbolone&amp;author=D+Schiffmann&amp;author=M+Metzler&amp;author=T+Neudecker&amp;author=D+Henschler&amp;publication_year=1985&amp;pages=59-63&amp;pmid=3907591&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B52" class="ref-cit-blk half_rhythm" bis_skin_checked="1">52.&nbsp;<span class="mixed-citation">Seftel A.&nbsp;<span class="ref-title">Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis</span>.&nbsp;<span class="ref-journal"><em>Int J Impot Res</em></span>&nbsp;: 223–228, 2006. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/16094414" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Int+J+Impot+Res&amp;title=Male+hypogonadism.+Part+II:+etiology,+pathophysiology,+and+diagnosis&amp;author=A+Seftel&amp;publication_year=2006&amp;pages=223-228&amp;pmid=16094414&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B53" class="ref-cit-blk half_rhythm" bis_skin_checked="1">53.&nbsp;<span class="mixed-citation">Seki M, Fujishima S, Nozaka T, Maeda M, Kobayashi K.&nbsp;<span class="ref-title">Comparison of response to 17 beta-estradiol and 17 beta-trenbolone among three small fish species</span>.&nbsp;<span class="ref-journal"><em>Environ Toxicol Chem</em></span>&nbsp;: 2742–2752, 2006. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/17022416" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Environ+Toxicol+Chem&amp;title=Comparison+of+response+to+17+beta-estradiol+and+17+beta-trenbolone+among+three+small+fish+species&amp;author=M+Seki&amp;author=S+Fujishima&amp;author=T+Nozaka&amp;author=M+Maeda&amp;author=K+Kobayashi&amp;publication_year=2006&amp;pages=2742-2752&amp;pmid=17022416&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B54" class="ref-cit-blk half_rhythm" bis_skin_checked="1">54.&nbsp;<span class="mixed-citation">Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S.&nbsp;<span class="ref-title">Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment</span>.&nbsp;<span class="ref-journal"><em>J Clin Endocrinol Metab</em></span>&nbsp;: 5245–5255, 2004. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/15472231" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Endocrinol+Metab&amp;title=Androgen+receptor+in+human+skeletal+muscle+and+cultured+muscle+satellite+cells:+up-regulation+by+androgen+treatment&amp;author=I+Sinha-Hikim&amp;author=WE+Taylor&amp;author=NF+Gonzalez-Cadavid&amp;author=W+Zheng&amp;author=S+Bhasin&amp;publication_year=2004&amp;pages=5245-5255&amp;pmid=15472231&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B55" class="ref-cit-blk half_rhythm" bis_skin_checked="1">55.&nbsp;<span class="mixed-citation">Spranger B, Metzler M.&nbsp;<span class="ref-title">Disposition of 17 beta-trenbolone in humans</span>.&nbsp;<span class="ref-journal"><em>J Chromatograph</em></span>&nbsp;: 485–492, 1991. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/1874853" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Chromatograph&amp;title=Disposition+of+17+beta-trenbolone+in+humans&amp;author=B+Spranger&amp;author=M+Metzler&amp;publication_year=1991&amp;pages=485-492&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B56" class="ref-cit-blk half_rhythm" bis_skin_checked="1">56.&nbsp;<span class="mixed-citation">Stachenfeld NS, Taylor HS.&nbsp;<span class="ref-title">Effects of estrogen and progesterone administration on extracellular fluid</span>.&nbsp;<span class="ref-journal"><em>J Appl Physiol</em></span>&nbsp;: 1011–1018, 2004. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/14660504" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Appl+Physiol&amp;title=Effects+of+estrogen+and+progesterone+administration+on+extracellular+fluid&amp;author=NS+Stachenfeld&amp;author=HS+Taylor&amp;publication_year=2004&amp;pages=1011-1018&amp;pmid=14660504&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B57" class="ref-cit-blk half_rhythm" bis_skin_checked="1">57.&nbsp;<span class="mixed-citation">Storer TW, Woodhouse L, Magliano L, Singh AB, Dzekov C, Dzekov J, Bhasin S.&nbsp;<span class="ref-title">Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men</span>.&nbsp;<span class="ref-journal"><em>J Am Geriatr Soc</em></span>&nbsp;: 1991–1999, 2008.&nbsp;<span class="nowrap">[<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585153/">PMC free article</a>]</span>&nbsp;[<a href="https://www.ncbi.nlm.nih.gov/pubmed/18795988" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Am+Geriatr+Soc&amp;title=Changes+in+muscle+mass,+muscle+strength,+and+power+but+not+physical+function+are+related+to+testosterone+dose+in+healthy+older+men&amp;author=TW+Storer&amp;author=L+Woodhouse&amp;author=L+Magliano&amp;author=AB+Singh&amp;author=C+Dzekov&amp;publication_year=2008&amp;pages=1991-1999&amp;pmid=18795988&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B58" class="ref-cit-blk half_rhythm" bis_skin_checked="1">58.&nbsp;<span class="mixed-citation">Sundaram K, Kumar N, Monder C, Bardin CW.&nbsp;<span class="ref-title">Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens</span>.&nbsp;<span class="ref-journal"><em>J Steroid Biochem Mol Biol</em></span>&nbsp;: 253–257, 1995. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/7626464" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Steroid+Biochem+Mol+Biol&amp;title=Different+patterns+of+metabolism+determine+the+relative+anabolic+activity+of+19-norandrogens&amp;author=K+Sundaram&amp;author=N+Kumar&amp;author=C+Monder&amp;author=CW+Bardin&amp;publication_year=1995&amp;pages=253-257&amp;pmid=7626464&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B59" class="ref-cit-blk half_rhythm" bis_skin_checked="1">59.&nbsp;<span class="mixed-citation">Swerdloff RS, Wang C, Hines M, Gorski R.&nbsp;<span class="ref-title">Effect of androgens on the brain and other organs during development and aging</span>.&nbsp;<span class="ref-journal"><em>Psychoneuroendocrinology</em></span>&nbsp;: 375–383, 1992. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/1279738" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Psychoneuroendocrinology&amp;title=Effect+of+androgens+on+the+brain+and+other+organs+during+development+and+aging&amp;author=RS+Swerdloff&amp;author=C+Wang&amp;author=M+Hines&amp;author=R+Gorski&amp;publication_year=1992&amp;pages=375-383&amp;pmid=1279738&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B60" class="ref-cit-blk half_rhythm" bis_skin_checked="1">60.&nbsp;<span class="mixed-citation">Thompson SH, Boxhorn LK, Kong WY, Allen RE.&nbsp;<span class="ref-title">Trenbolone alters the responsiveness of skeletal muscle satellite cells to fibroblast growth factor and insulin-like growth factor I</span>.&nbsp;<span class="ref-journal"><em>Endocrinology</em></span>&nbsp;: 2110–2117, 1989. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/2707149" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Endocrinology&amp;title=Trenbolone+alters+the+responsiveness+of+skeletal+muscle+satellite+cells+to+fibroblast+growth+factor+and+insulin-like+growth+factor+I&amp;author=SH+Thompson&amp;author=LK+Boxhorn&amp;author=WY+Kong&amp;author=RE+Allen&amp;publication_year=1989&amp;pages=2110-2117&amp;pmid=2707149&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B61" class="ref-cit-blk half_rhythm" bis_skin_checked="1">61.&nbsp;<span class="mixed-citation">Tracz MJ, Sideras K, Boloña ER, Haddad RM, Kennedy CC, Uraga MV, Caples SM, Erwin PJ, Montori VM.&nbsp;<span class="ref-title">Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials</span>.&nbsp;<span class="ref-journal"><em>J Clin Endocrinol Metab</em></span>&nbsp;: 2011–2016, 2006. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/16720668" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Endocrinol+Metab&amp;title=Testosterone+use+in+men+and+its+effects+on+bone+health.+A+systematic+review+and+meta-analysis+of+randomized+placebo-controlled+trials&amp;author=MJ+Tracz&amp;author=K+Sideras&amp;author=ER+Bolo%C3%B1a&amp;author=RM+Haddad&amp;author=CC+Kennedy&amp;publication_year=2006&amp;pages=2011-2016&amp;pmid=16720668&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B62" class="ref-cit-blk half_rhythm" bis_skin_checked="1">62.&nbsp;<span class="mixed-citation">Vandenput L, Ohlsson C.&nbsp;<span class="ref-title">Estrogens as regulators of bone health in men</span>.&nbsp;<span class="ref-journal"><em>Nat Rev Endocrinol</em></span>&nbsp;: 437–443, 2009. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/19528961" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Endocrinol&amp;title=Estrogens+as+regulators+of+bone+health+in+men&amp;author=L+Vandenput&amp;author=C+Ohlsson&amp;publication_year=2009&amp;pages=437-443&amp;pmid=19528961&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B63" class="ref-cit-blk half_rhythm" bis_skin_checked="1">63.&nbsp;<span class="mixed-citation">Wilson JD.&nbsp;<span class="ref-title">The role of 5alpha-reduction in steroid hormone physiology</span>.&nbsp;<span class="ref-journal"><em>Reprod Fertil Dev</em></span>&nbsp;: 673–678, 2001. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/11999320" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Reprod+Fertil+Dev&amp;title=The+role+of+5alpha-reduction+in+steroid+hormone+physiology&amp;author=JD+Wilson&amp;publication_year=2001&amp;pages=673-678&amp;pmid=11999320&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B64" class="ref-cit-blk half_rhythm" bis_skin_checked="1">64.&nbsp;<span class="mixed-citation">Wilson VS, Lambright C, Ostby J, Gray LE.&nbsp;<span class="ref-title">In vitro and in vivo effects of 17beta-trenbolone: a feedlot effluent contaminant</span>.&nbsp;<span class="ref-journal"><em>Toxicol Sci</em></span>&nbsp;: 202–211, 2002. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/12441365" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Toxicol+Sci&amp;title=In+vitro+and+in+vivo+effects+of+17beta-trenbolone:+a+feedlot+effluent+contaminant&amp;author=VS+Wilson&amp;author=C+Lambright&amp;author=J+Ostby&amp;author=LE+Gray&amp;publication_year=2002&amp;pages=202-211&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B65" class="ref-cit-blk half_rhythm" bis_skin_checked="1">65.&nbsp;<span class="mixed-citation">Woodhouse LJ, Gupta N, Bhasin M, Singh AB, Ross R, Phillips J, Bhasin S.&nbsp;<span class="ref-title">Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men</span>.&nbsp;<span class="ref-journal"><em>J Clin Endocrinol Metab</em></span>&nbsp;: 718–726, 2004. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/14764787" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Endocrinol+Metab&amp;title=Dose-dependent+effects+of+testosterone+on+regional+adipose+tissue+distribution+in+healthy+young+men&amp;author=LJ+Woodhouse&amp;author=N+Gupta&amp;author=M+Bhasin&amp;author=AB+Singh&amp;author=R+Ross&amp;publication_year=2004&amp;pages=718-726&amp;pmid=14764787&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B66" class="ref-cit-blk half_rhythm" bis_skin_checked="1">66.&nbsp;<span class="mixed-citation">Yarrow JF, Conover CF, Purandare AV, Bhakta AM, Zheng N, Conrad B, Altman MK, Franz SE, Wronski TJ, Borst SE.&nbsp;<span class="ref-title">Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female rats</span>.&nbsp;<span class="ref-journal"><em>Am J Physiol Endocrinol Metab</em></span>&nbsp;: E1213–E1222, 2008. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/18780767" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Am+J+Physiol+Endocrinol+Metab&amp;title=Supraphysiological+testosterone+enanthate+administration+prevents+bone+loss+and+augments+bone+strength+in+gonadectomized+male+and+female+rats&amp;author=JF+Yarrow&amp;author=CF+Conover&amp;author=AV+Purandare&amp;author=AM+Bhakta&amp;author=N+Zheng&amp;publication_year=2008&amp;pages=E1213-E1222&amp;pmid=18780767&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div id="B67" class="ref-cit-blk half_rhythm" bis_skin_checked="1">67.&nbsp;<span class="mixed-citation">Yarrow JF, McCoy SC, Borst SE.&nbsp;<span class="ref-title">Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity</span>.&nbsp;<span class="ref-journal"><em>Steroids</em></span>&nbsp;: 377–389, 2010. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/20138077" target="pmc_ext" rel="noopener noreferrer">PubMed</a>]&nbsp;<span class="nowrap">[<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Steroids&amp;title=Tissue+selectivity+and+potential+clinical+applications+of+trenbolone+(17beta-hydroxyestra-4,9,11-trien-3-one):+A+potent+anabolic+steroid+with+reduced+androgenic+and+estrogenic+activity&amp;author=JF+Yarrow&amp;author=SC+McCoy&amp;author=SE+Borst&amp;publication_year=2010&amp;pages=377-389&amp;pmid=20138077&amp;" target="pmc_ext" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div>
<div bis_skin_checked="1"></div>
</div>
</div>
<div bis_skin_checked="1">
<h2 id="idm139797874138608title" class="head no_bottom_margin ui-helper-clearfix">SOURCE</h2>
<hr>
<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189634/</p>
</div>
</div>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2020/05/20/17%ce%b2-hydroxyestra-4911-trien-3-one-trenbolone-exhibits-tissue-selective-anabolic-activity-effects-on-muscle-bone-adiposity-hemoglobin-and-prostate/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2020/05/20/17%ce%b2-hydroxyestra-4911-trien-3-one-trenbolone-exhibits-tissue-selective-anabolic-activity-effects-on-muscle-bone-adiposity-hemoglobin-and-prostate/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><div class="btPagination boldSection gutter" bis_skin_checked="1"><div class="port" bis_skin_checked="1"><div class="paging onLeft" bis_skin_checked="1"><p class="pagePrev"><a href="/../../../../category/articles/page/3/">Newer Posts</a></p></div></div></div>
</div>
</div>
</div>
<!--PAGE-CONTENT-END-HERE-->

<div class="bt_bb_wrapper"><section id="bt_section610e3a31c4f1c" data-parallax="0.7" data-parallax-offset="0" class="boldSection btDivider topSpaced bottomSemiSpaced btDarkSkin gutter boxed inherit btParallax" style="background-color:#1a86d3  !important;"><div class="port"><div class="boldCell"><div class="boldCellInner"><div class="boldRow "><div class="boldRowInner">
<div class="rowItem col-md-3 col-sm-6 col-ms-12 btTextLeft" data-width="3"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>HONG KONG</span></div>
<div class="dash"><h4><span class="headline">Headquarter</span></h4></div></header><span class="btIco btIcoDefaultType btIcoSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../index.html" target="no_target" data-ico-es="&#xe964;" class="btIcoHolder"><span>+852 3575 9046 </span></a></span><div class="btClear btSeparator noBorder"><hr></div>
<span class="btIco btIcoDefaultType btIcoSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../index.html" target="_self" data-ico-fa="&#xf0c1;" class="btIcoHolder"><span>www.ikigaicorporation.com</span></a></span><div class="btClear btSeparator noBorder"><hr></div>
<div class="bpgPhoto btDefaultHoverType">
<a href="./../../../../index.html" target="_self" title=""></a>
<div class="boldPhotoBox"><div class="bpbItem"><div class="btImage">
<img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="" title="" data-lazy-src="./../../../../wp-content/uploads/2020/05/HK-e1588760431256.png"><noscript><img src="./../../../../wp-content/uploads/2020/05/HK-e1588760431256.png" alt="" title=""></noscript>
</div></div></div>
<div class="captionPane btDarkSkin btTextCenter">
<div class="captionTable">
<div class="captionCell">
<div class="captionTxt"></div>
</div>
</div>
</div>
</div>
</div></div>
<div class="rowItem col-md-6 col-sm-12 btTextLeft" data-width="6"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>LOCATIONS</span></div>
<div class="dash"><h4><span class="headline">Our network</span></h4></div></header><div class="btClear btSeparator bottomSmallSpaced noBorder"><hr></div>
<div class="boldRow "><div class="boldRowInner">
<div class="rowItem rowInnerItem col-sm-6  btTextLeft"><div class="rowItemContent">
<div class="bpgPhoto btDefaultHoverType"><div class="btImage">
<img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="" title="						" data-lazy-src="./../../../../wp-content/uploads/2016/10/world-dot-map-gray-320x156.png"><noscript><img src="./../../../../wp-content/uploads/2016/10/world-dot-map-gray-320x156.png" alt="" title="						"></noscript>
</div></div>
<div class="btClear btSeparator topSmallSpaced noBorder"><hr></div>
</div></div>
<div class="rowItem rowInnerItem col-sm-6  btTextLeft"><div class="rowItemContent">
<header class="header btClear small  "><div class="btSuperTitle"><span>OUR NETWORK</span></div></header><div class="btClear btSeparator bottomExtraSmallSpaced noBorder"><hr></div>
<span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Asia</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Americas</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Middle East</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Europe</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Africa</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Oceania</span></a></span>
</div></div>
</div></div>
<div class="btClear btSeparator bottomExtraSmallSpaced noBorder"><hr></div>
<div class="btClear btSeparator bottomSemiSpaced noBorder"><hr></div>
</div></div>
<div class="rowItem col-md-3 col-sm-6 col-ms-12 btTextLeft" data-width="3"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>GET IN TOUCH</span></div>
<div class="dash"><h4><span class="headline">Follow us</span></h4></div></header><div class="btClear btSeparator bottomSmallSpaced noBorder"><hr></div>
<span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.facebook.com/ikigaicorporationcom" target="no_target" data-ico-fa="&#xf09a;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.instagram.com/ikigaicorporation" target="no_target" data-ico-fa="&#xf16d;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.google.com/maps/place/IKIGAI+CORPORATION+LTD/@22.3937048,113.9694348,17z/data=!3m1!4b1!4m5!3m4!1s0x3403fb18add189e3:0xccf4eec041856f0d!8m2!3d22.3936999!4d113.9716288" target="no_target" data-ico-fa="&#xf1a0;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://wa.me/message/UZHAWI3JZQDVB1" target="no_target" data-ico-fa="&#xf232;" class="btIcoHolder"></a></span><div class="btClear btSeparator bottomSemiSpaced noBorder"><hr></div>
</div></div>
</div></div></div></div></div></section></div>
<footer>
  <section class="boldSection gutter btSiteFooter btGutter">
<div class="port">
<div class="boldRow">
<div class="rowItem btFooterCopy col-md-6 col-sm-12 btTextLeft">
<p class="copyLine">Ikigai Corporation Company is a leading pharmaceutical contract development and manufacturing organisation (CDMO) for both APIs and finished dose forms.</p> </div>
<div class="rowItem btFooterMenu col-md-6 col-sm-12 btTextRight">
<ul id="menu-primary-menu-1" class="menu">
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-3253"><a title="						" href="./../index.html">Home</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3403"><a href="./../about-us/index.html">About us</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-3451 current_page_item menu-item-3459"><a href="./index.html" aria-current="page">Our Technology</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3256"><a title="						" href="./../services/index.html">Product Portfolio</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3872"><a href="./../policies/index.html">Policies</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3594"><a href="./../services/partner_with_us/index.html">Partner with us</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3494"><a href="./../careers/index.html">Careers</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4734"><a href="./../library/index.html">Library</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3438"><a href="./../contact/index.html">Contact</a></li>
</ul> </div>
</div>
</div>
</section>
</footer>
</div>
<script >window.addEventListener('DOMContentLoaded', function() {
				(function( $ ) {
					$( document ).ready(function() {
						
						var time_notation = '24';
						
						var time = function() {
							
							if ( time_notation == '12' ) {
								var time = moment().tz( 'Asia/Hong_Kong' ).format( 'h:mm A' );
							} else {
								var time = moment().tz( 'Asia/Hong_Kong' ).format( 'H:mm' );
							}

							$( '#time610e3a31c10e7 .btIconWidgetText' ).html( time );
						}
						setInterval( function() {
							time();
						}, 1000 );
						time();
					});
				})( jQuery );
			});</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/comment-reply.min.js?ver=5.8" id="comment-reply-js" defer></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="buttonizer_frontend_javascript-js-extra">
/* <![CDATA[ */
var buttonizer_ajax = {"ajaxurl":".\/wp-admin\/admin-ajax.php","version":"2.4.3","buttonizer_path":".\/wp-content\/plugins\/buttonizer-multifunctional-button","buttonizer_assets":".\/wp-content\/plugins\/buttonizer-multifunctional-button\/assets\/","base_url":".","current":[],"in_preview":"","is_admin":"","cache":"ec7e88ea4f3f1891d22d4075828b5b63","enable_ga_clicks":"1"};
/* ]]> */
</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/buttonizer-multifunctional-button/assets/frontend.min.js?v=7ab4fd8a7cd8bd136942183145de39a0&#038;ver=5.8" id="buttonizer_frontend_javascript-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/bootstrap.js?ver=1620657753" id="bootstrap-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/popup.js?ver=1620657753" id="modal-popup-js-js" defer></script>
<script  data-rocket-type="text/javascript" id="rocket-browser-checker-js-after">
"use strict";var _createClass=function(){function defineProperties(target,props){for(var i=0;i<props.length;i++){var descriptor=props[i];descriptor.enumerable=descriptor.enumerable||!1,descriptor.configurable=!0,"value"in descriptor&&(descriptor.writable=!0),Object.defineProperty(target,descriptor.key,descriptor)}}return function(Constructor,protoProps,staticProps){return protoProps&&defineProperties(Constructor.prototype,protoProps),staticProps&&defineProperties(Constructor,staticProps),Constructor}}();function _classCallCheck(instance,Constructor){if(!(instance instanceof Constructor))throw new TypeError("Cannot call a class as a function")}var RocketBrowserCompatibilityChecker=function(){function RocketBrowserCompatibilityChecker(options){_classCallCheck(this,RocketBrowserCompatibilityChecker),this.passiveSupported=!1,this._checkPassiveOption(this),this.options=!!this.passiveSupported&&options}return _createClass(RocketBrowserCompatibilityChecker,[{key:"_checkPassiveOption",value:function(self){try{var options={get passive(){return!(self.passiveSupported=!0)}};window.addEventListener("test",null,options),window.removeEventListener("test",null,options)}catch(err){self.passiveSupported=!1}}},{key:"initRequestIdleCallback",value:function(){!1 in window&&(window.requestIdleCallback=function(cb){var start=Date.now();return setTimeout(function(){cb({didTimeout:!1,timeRemaining:function(){return Math.max(0,50-(Date.now()-start))}})},1)}),!1 in window&&(window.cancelIdleCallback=function(id){return clearTimeout(id)})}},{key:"isDataSaverModeOn",value:function(){return"connection"in navigator&&!0===navigator.connection.saveData}},{key:"supportsLinkPrefetch",value:function(){var elem=document.createElement("link");return elem.relList&&elem.relList.supports&&elem.relList.supports("prefetch")&&window.IntersectionObserver&&"isIntersecting"in IntersectionObserverEntry.prototype}},{key:"isSlowConnection",value:function(){return"connection"in navigator&&"effectiveType"in navigator.connection&&("2g"===navigator.connection.effectiveType||"slow-2g"===navigator.connection.effectiveType)}}]),RocketBrowserCompatibilityChecker}();
</script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="rocket-preload-links-js-extra">
/* <![CDATA[ */
var RocketPreloadLinksConfig = {"excludeUris":"\/(.+\/)?feed\/?.+\/?|\/(?:.+\/)?embed\/|\/(index\\.php\/)?wp\\-json(\/.*|$)|\/wp-admin\/|\/logout\/|\/pudra\/","usesTrailingSlash":"1","imageExt":"jpg|jpeg|gif|png|tiff|bmp|webp|avif","fileExt":"jpg|jpeg|gif|png|tiff|bmp|webp|avif|php|pdf|html|htm","siteUrl":".","onHoverDelay":"100","rateThrottle":"3"};
/* ]]> */
</script>
<script  data-rocket-type="text/javascript" id="rocket-preload-links-js-after">
(function() {
"use strict";var r="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},e=function(){function i(e,t){for(var n=0;n<t.length;n++){var i=t[n];i.enumerable=i.enumerable||!1,i.configurable=!0,"value"in i&&(i.writable=!0),Object.defineProperty(e,i.key,i)}}return function(e,t,n){return t&&i(e.prototype,t),n&&i(e,n),e}}();function i(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}var t=function(){function n(e,t){i(this,n),this.browser=e,this.config=t,this.options=this.browser.options,this.prefetched=new Set,this.eventTime=null,this.threshold=1111,this.numOnHover=0}return e(n,[{key:"init",value:function(){!this.browser.supportsLinkPrefetch()||this.browser.isDataSaverModeOn()||this.browser.isSlowConnection()||(this.regex={excludeUris:RegExp(this.config.excludeUris,"i"),images:RegExp(".("+this.config.imageExt+")$","i"),fileExt:RegExp(".("+this.config.fileExt+")$","i")},this._initListeners(this))}},{key:"_initListeners",value:function(e){-1<this.config.onHoverDelay&&document.addEventListener("mouseover",e.listener.bind(e),e.listenerOptions),document.addEventListener("mousedown",e.listener.bind(e),e.listenerOptions),document.addEventListener("touchstart",e.listener.bind(e),e.listenerOptions)}},{key:"listener",value:function(e){var t=e.target.closest("a"),n=this._prepareUrl(t);if(null!==n)switch(e.type){case"mousedown":case"touchstart":this._addPrefetchLink(n);break;case"mouseover":this._earlyPrefetch(t,n,"mouseout")}}},{key:"_earlyPrefetch",value:function(t,e,n){var i=this,r=setTimeout(function(){if(r=null,0===i.numOnHover)setTimeout(function(){return i.numOnHover=0},1e3);else if(i.numOnHover>i.config.rateThrottle)return;i.numOnHover++,i._addPrefetchLink(e)},this.config.onHoverDelay);t.addEventListener(n,function e(){t.removeEventListener(n,e,{passive:!0}),null!==r&&(clearTimeout(r),r=null)},{passive:!0})}},{key:"_addPrefetchLink",value:function(i){return this.prefetched.add(i.href),new Promise(function(e,t){var n=document.createElement("link");n.rel="prefetch",n.href=i.href,n.onload=e,n.onerror=t,document.head.appendChild(n)}).catch(function(){})}},{key:"_prepareUrl",value:function(e){if(null===e||"object"!==(void 0===e?"undefined":r(e))||!1 in e||-1===["http:","https:"].indexOf(e.protocol))return null;var t=e.href.substring(0,this.config.siteUrl.length),n=this._getPathname(e.href,t),i={original:e.href,protocol:e.protocol,origin:t,pathname:n,href:t+n};return this._isLinkOk(i)?i:null}},{key:"_getPathname",value:function(e,t){var n=t?e.substring(this.config.siteUrl.length):e;return n.startsWith("/")||(n="/"+n),this._shouldAddTrailingSlash(n)?n+"/":n}},{key:"_shouldAddTrailingSlash",value:function(e){return this.config.usesTrailingSlash&&!e.endsWith("/")&&!this.regex.fileExt.test(e)}},{key:"_isLinkOk",value:function(e){return null!==e&&"object"===(void 0===e?"undefined":r(e))&&(!this.prefetched.has(e.href)&&e.origin===this.config.siteUrl&&-1===e.href.indexOf("?")&&-1===e.href.indexOf("#")&&!this.regex.excludeUris.test(e.href)&&!this.regex.images.test(e.href))}}],[{key:"run",value:function(){"undefined"!=typeof RocketPreloadLinksConfig&&new n(new RocketBrowserCompatibilityChecker({capture:!0,passive:!0}),RocketPreloadLinksConfig).init()}}]),n}();t.run();
}());
</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/slick.min.js?ver=5.8" id="slick-min-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/jquery.magnific-popup.min.js?ver=5.8" id="jquery-magnific-popup-min-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/iscroll.js?ver=1620657753" id="iscroll-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/fancySelect.js?ver=1620657753" id="fancySelect-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/misc.js?ver=1620657753" id="industrial-misc-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/dir.hover.js?ver=1620657753" id="industrial-dir-hover-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/sliders.js?ver=1620657753" id="industrial-sliders-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/bt_parallax.js?ver=1620657753" id="industrial-bt-parallax-js" defer></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="cookie-notice-front-js-extra">
/* <![CDATA[ */
var cnArgs = {"ajaxUrl":".\/wp-admin\/admin-ajax.php","nonce":"870ef1de7b","hideEffect":"fade","position":"bottom","onScroll":"1","onScrollOffset":"100","onClick":"0","cookieName":"cookie_notice_accepted","cookieTime":"604800","cookieTimeRejected":"604800","cookiePath":"\/","cookieDomain":"","redirection":"0","cache":"1","refuse":"0","revokeCookies":"0","revokeCookiesOpt":"automatic","secure":"1"};
/* ]]> */
</script>
<script  async data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/cookie-notice/includes/../js/front.min.js?ver=2.1.0" id="cookie-notice-front-js"></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" src="./../../../../wp-includes/js/wp-embed.min.js?ver=5.8" id="wp-embed-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/moment.js?ver=1620657753" id="bt_moment-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/moment-timezone-with-data.js?ver=1620657753" id="bt_moment_timezone-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/industrial/imagesloaded.pkgd.min.js?ver=5.8" id="boldthemes_imagesloaded-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/industrial/packery.pkgd.min.js?ver=5.8" id="boldthemes_packery-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_grid_tweak.js?ver=1620658021" id="boldthemes_grid_tweak-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_grid.js?ver=1620658021" id="boldthemes_grid-js" defer></script>

<div id="cookie-notice" role="banner" class="cookie-notice-hidden cookie-revoke-hidden cn-position-bottom" aria-label="Cookie Notice" style="background-color: rgba(0,0,0,1);">
<div class="cookie-notice-container" style="color: #fff;">
<span id="cn-notice-text" class="cn-text-container">We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.</span><span id="cn-notice-buttons" class="cn-buttons-container"><a href="#" id="cn-accept-cookie" data-cookie-set="accept" class="cn-set-cookie cn-button bootstrap" aria-label="I AGREE, thank you.">I AGREE, thank you.</a><a href="./../../../../services/privacy-policy/index.html" target="_blank" id="cn-more-info" class="cn-more-info cn-button bootstrap" aria-label="Privacy policy">Privacy policy</a></span><a href="javascript:void(0);" id="cn-close-notice" data-cookie-set="accept" class="cn-close-icon" aria-label="I AGREE, thank you."></a>
</div>
</div>
 <script  data-rocket-type="text/javascript">window.addEventListener('DOMContentLoaded', function() {
        jQuery(document).ready(function ($) {
            //$( document ).ajaxStart(function() {
            //});

			
            for (var i = 0; i < document.forms.length; ++i) {
                var form = document.forms[i];
				if ($(form).attr("method") != "get") { $(form).append('<input type="hidden" name="kNEuIGs" value="ToGFEeP2A" />'); }
if ($(form).attr("method") != "get") { $(form).append('<input type="hidden" name="-rgtSF" value="PeoHbQdFwGR2kU" />'); }
            }

			
            $(document).on('submit', 'form', function () {
				if ($(this).attr("method") != "get") { $(this).append('<input type="hidden" name="kNEuIGs" value="ToGFEeP2A" />'); }
if ($(this).attr("method") != "get") { $(this).append('<input type="hidden" name="-rgtSF" value="PeoHbQdFwGR2kU" />'); }
                return true;
            });

			
            jQuery.ajaxSetup({
                beforeSend: function (e, data) {

                    //console.log(Object.getOwnPropertyNames(data).sort());
                    //console.log(data.type);

                    if (data.type !== 'POST') return;

                    if (typeof data.data === 'object' && data.data !== null) {
						data.data.append("kNEuIGs", "ToGFEeP2A");
data.data.append("-rgtSF", "PeoHbQdFwGR2kU");
                    }
                    else {
                        data.data =  data.data + '&kNEuIGs=ToGFEeP2A&-rgtSF=PeoHbQdFwGR2kU';
                    }
                }
            });

        });
	});</script>
<script src="./../../../../live_search.js"></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript">window.lazyLoadOptions={elements_selector:"img[data-lazy-src],.rocket-lazyload",data_src:"lazy-src",data_srcset:"lazy-srcset",data_sizes:"lazy-sizes",class_loading:"lazyloading",class_loaded:"lazyloaded",threshold:300,callback_loaded:function(element){if(element.tagName==="IFRAME"&&element.dataset.rocketLazyload=="fitvidscompatible"){if(element.classList.contains("lazyloaded")){if(typeof window.jQuery!="undefined"){if(jQuery.fn.fitVids){jQuery(element).parent().fitVids()}}}}}};window.addEventListener('LazyLoad::Initialized',function(e){var lazyLoadInstance=e.detail.instance;if(window.MutationObserver){var observer=new MutationObserver(function(mutations){var image_count=0;var iframe_count=0;var rocketlazy_count=0;mutations.forEach(function(mutation){for(i=0;i<mutation.addedNodes.length;i++){if(typeof mutation.addedNodes[i].getElementsByTagName!=='function'){continue}
if(typeof mutation.addedNodes[i].getElementsByClassName!=='function'){continue}
images=mutation.addedNodes[i].getElementsByTagName('img');is_image=mutation.addedNodes[i].tagName=="IMG";iframes=mutation.addedNodes[i].getElementsByTagName('iframe');is_iframe=mutation.addedNodes[i].tagName=="IFRAME";rocket_lazy=mutation.addedNodes[i].getElementsByClassName('rocket-lazyload');image_count+=images.length;iframe_count+=iframes.length;rocketlazy_count+=rocket_lazy.length;if(is_image){image_count+=1}
if(is_iframe){iframe_count+=1}}});if(image_count>0||iframe_count>0||rocketlazy_count>0){lazyLoadInstance.update()}});var b=document.getElementsByTagName("body")[0];var config={childList:!0,subtree:!0};observer.observe(b,config)}},!1)</script><script data-no-minify="1" async src="./../../../../wp-content/plugins/wp-rocket/assets/js/lazyload/16.1/lazyload.min.js" type="06cd7e663a0e46d4271fe72d-text/javascript"></script><script src="./../../../../cdn-cgi/scripts/7d0fa10a/cloudflare-static/rocket-loader.min.js" data-cf-settings="06cd7e663a0e46d4271fe72d-|49" defer></script><script type="text/javascript">(function(){window['__CF$cv$params']={r:'67b14aa0bd2192f8',m:'43df34172ca0f4f68ebbecbcf9a5a00029aba502-1628347556-1800-AVTlhDW4t9yA80xF5UdjoXKJiq7B7xNjRkAuPvixBxFixLosCDHCFG2h63XgOhBwRiCIDj2P9TKIHYBnV4kRgrcIoT5BrroyHzIFxwvjgkVmd115AGEcIIJPkP66qAQCQm/6tYO8Bkqd31TIv3OlW/z8inBUFtnaZsPjnH1RBzcf',s:[0xc47a4f690a,0xb1c6885590],}})();</script><script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67b14aa0bd2192f8","version":"2021.7.0","r":1,"token":"e3b748a178054eff95051ca851daefa1","si":10}'></script>
</body>
</html>